CA2677046A1 - Indenoisoquinolinone analogs and methods of use thereof - Google Patents

Indenoisoquinolinone analogs and methods of use thereof Download PDF

Info

Publication number
CA2677046A1
CA2677046A1 CA002677046A CA2677046A CA2677046A1 CA 2677046 A1 CA2677046 A1 CA 2677046A1 CA 002677046 A CA002677046 A CA 002677046A CA 2677046 A CA2677046 A CA 2677046A CA 2677046 A1 CA2677046 A1 CA 2677046A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
chz
alkylene
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002677046A
Other languages
French (fr)
Inventor
Prakash Jagtap
Duy-Phong Pham-Huu
Fred Cohen
Xiaojing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rocket Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2677046A1 publication Critical patent/CA2677046A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
    • A01N43/38—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)

Abstract

The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.

Description

DEMANDE OU BREVET VOLUMINEUX

LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:

NOTE POUR LE TOME / VOLUME NOTE:

INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF
1. REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No.
60/904,393, filed on February 28, 2007, the disclosure of which is incorporated by reference herein in its entirety.
2. FIELD OF THE INVENTION

The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.
3. BACKGROUND OF THE INVENTION

Erectile dysfunction ("ED") is a significant male-health issue. While estimating its prevalence is difficult, estimates range from about 15 million to 30 million sufferers worldwide.
The etiology of erectile dysfunction can be multiple, and can include mechanical trauma to the nerves (such as during prostatectomy), or it can be due to diabetes mellitus, cardiovascular diseases, induced by radiation, certain drugs, or advanced age.
Urinary incontinence affects people of all ages and levels of physical health, both in health care settings and in the community at large. Persons suffering from urinary incontinence can be predisposed to also having urinary-tract infections, pressure ulcers, perineal rashes and urosepsis. Psychosocially, urinary incontinence can be associated with embarrassment, social stigmatization, depression and a risk of institutionalization (Herzo et al., Annu. Rev. Gerontol. Geriatr. 9:74 (1989)).
An inflammatory disease, such as arthritis, colitis, and autoimmune diabetes, typically manifests itself as a disorder distinct from that associated with a reperfusion injury, e.g., stroke and heart attack, and can clinically manifest itself as a different entity.
However, there can be common underlying mechanisms between these two types of disorders. Specifically, inflammatory disease and reperfusion injury can induce proinflammatory cytokine and chemokine synthesis which can, in turn, result in production of cytotoxic free radicals such as nitric oxide and superoxide. NO
and superoxide can react to form peroxynitrite (ONOO-) (Szab6 et al., Shock 6:79-88, 1996).
The ONOO--induced cell necrosis observed in inflammatory disease and in reperfusion injury involves the activation of the nuclear enzyme poly (ADP-ribose) polymerase (PARP). Activation of PARP is thought to be an important step in the cell-mediated death observed in inflammation and reperfusion injury (Szab6 et al., Trends Pharmacol. Sci. 19:287-98, 1998).
A number of PARP inhibitors have been described in the art. See, e.g., Banasik et al., J. Biol. Chem., 267:1569-75, 1992, and Banasik et al., Mol. Cell.
Biochem., 138:185-97, 1994; WO 00/39104; WO 00/39070; WO 99/59975; WO 99/59973; WO
99/11649; WO 99/11645; WO 99/11644; WO 99/11628; WO 99/11623; WO 99/11311;
WO 00/42040; Zhang et al., Biochem. Biophys. Res. Commun., 278:590-98,2000;
White et al., J. Med. Chem., 43:4084-4097, 2000; Griffin et al., J. Med. Chem., 41:5247-5256, 1998; Shinkwin et al., Bioorg. Med. Chem., 7:297-308, 1999; and Soriano et at., Nature Medicine, 7:108-113, 2001. Adverse effects associated with administration of PARP
inhibitors have been discussed in Milan et al., Science, 223:589-591, 1984.
Indenoisoquinolinone compounds have been previously discussed in the art. For example, cytotoxic non-camptothecin topoisomerase I inhibitors are reported in Cushman et al., J. Med. Chem., 43:3688-3698, 2300 and Cushman et al., J. Med. Chem.
42:446-57, 1999; indeno[1,2-c]isoquinolines are reported as antineoplastic agents in Cushman et al., WO 00/21537; and as neoplasm inhibitors in Hrbata et al., WO 93/05023.
Syntheses of indenoisoquinolinone compounds have been reported. For example, see Wawzonek et al., Org. Prep. Proc. Int., 14:163-8, 1982; Wawzonek et al., Can. J.
Chem., 59:2833, 1981; Andoi et al., Bull. Chem. Soc. Japan, 47:1014-17, 1974;
Dusemund et al., Arch. Pharm (Weinheim, Ger.), 3 17:381-2, 1984; and Lal et al., Indian J. Chem., Sect. B, 38B:33-39, 1999.
There remains, however, a need in the art for compounds useful for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence.
Citation of any reference in Section 3 of this application is not an admission that the reference is prior art.
4. SUMMARY OF THE INVENTION

In one aspect the invention provides a compound of Formula (Ia) NH
X

R' (Ia) and pharmaceutically acceptable salts thereof, wherein X is N(Ci-C4 alkyl)-, -CH(OH)-, -N(C(O)N(H)-(CHz)p-Z)- or -N((CHz)q Z)-;
Ri is -(CHz)ri N(R2)(R2) or -O-(CH2)õ-N(R2)(R);
each R2 is independently -H, -Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, -C1-alkylene phenyl, phenyl, an N-terminal alpha amino acid residue, an N-terminal alpha amino hydroxymethyl residue, a Ci-C6 alkyl ester of an N-terminal alpha amino acid residue, or a nitrogen-containing 3- to 7-membered monocyclic heterocycle, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)zOH, -Ci-C6 alkyl, -O-Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -(Ci-C6 alkyl-substituted) 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -Ci-CS alkyl, -(Ci-CS alkylene)-O-Ci-CS alkyl, benzyl, or -C3-C8 monocyclic cycloalkyl, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -N(Ra)z, -(Ci-CS alkylene)-O-Ci-CS alkyl, -NH2, a nitrogen-containing 3-to 7- membered monocyclic heterocycle, or a-(Ci-alkyl-substituted) nitrogen-containing 3- to 7- membered monocyclic heterocycle, wherein each occurrence of R' is independently -H, benzyl, or -Ci-Cio alkyl;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one or more of -Ci-CS
alkyl, phenyl, -(phenyl-substituted) Ci-CS alkyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-Cs alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(Ci-CS alkylene)-N(Ra)z, -(Ci-CS alkylene)-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(Ci-CS alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(Ci-CS alkylene)-OP(O)(OH)2, -(Ci-CS alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(Ci-CS alkylene)-C(O)O-Ci-CS alkyl, -(Ci-CS
alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, benzyl, or -Ci-Cio alkyl; or N and both Ra groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle or a nitrogen-containing 7- to 10-membered bicyclic heterocycle, each of which is unsubstituted or substituted with one or more of -Ci-CS
alkyl, -C3-C8 monocyclic cycloalkyl, phenyl, a nitrogen-containing 3- to 7-membered monocyclic heterocycle, -(phenyl-substituted) Ci-CS alkyl, -(hydroxy-substituted) Ci-CS
alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(Ci-C5 alkylene)-N(Ra)z, -Ci-C5 alkylene-C(O)O-(Ci-C5 alkylene)-N(Ra)z, -COOH, -(Ci-C5 alkylene)-O-Ci-CS alkyl, -(Ci-CS alkylene)-C3-C8 monocyclic cycloalkyl, -(Ci-CS
alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(Ci-CS alkylene)-OP(O)(OH)2, -(Ci-CS
alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(Ci-CS
alkylene)-C(O)O-Ci-CS alkyl, -(Ci-CS alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, -Ci-Cio alkyl; or N
and both R' groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

Z is -CF3, -F, -OH or -O-CH3;

n is an integer ranging from 1 to 10;
m is an integer ranging from 2 to 10;
p is an integer ranging from 1 to 5; and q is an integer ranging from 1 to 5.
In one aspect the invention provides a compound of Formula (Ib) NH

X

R' (Ib) and pharmaceutically acceptable salts thereof, wherein X is N(Ci-C4 alkyl)-, -CH(OH)-, -N(C(O)N(H)-(CHz)p-Z)- or -N((CHz)q Z)-;
Ri is -(CHz)ri N(R2)(R2) or -O-(CH2)õ-N(R2)(R);
each R2 is independently -H, -Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, -Ci-alkylene phenyl, phenyl, an N-terminal alpha amino acid residue, an N-terminal alpha amino hydroxymethyl residue, a Ci-C6 alkyl ester of an N-terminal alpha amino acid residue, or a nitrogen-containing 3- to 7-membered monocyclic heterocycle, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)zOH, -Ci-C6 alkyl, -O-Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -(Ci-C6 alkyl-substituted) 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -Ci-CS alkyl, -(Ci-CS alkylene)-O-Ci-CS alkyl, benzyl, or -C3-C8 monocyclic cycloalkyl, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -N(Ra)z, -(Ci-CS alkylene)-O-Ci-CS alkyl, -NH2, a nitrogen-containing 3-to 7- membered monocyclic heterocycle, or a-(Ci-alkyl-substituted) nitrogen-containing 3- to 7- membered monocyclic heterocycle, wherein each occurrence of R' is independently -H, benzyl, or -Ci-Cio alkyl;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one or more of -Ci-CS
alkyl, phenyl, -(phenyl-substituted) Ci-CS alkyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(Ci-CS alkylene)-N(Ra)z, -(Ci-CS alkylene)-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(Ci-CS alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(Ci-CS alkylene)-OP(O)(OH)2, -(Ci-CS alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(Ci-CS alkylene)-C(O)O-Ci-CS alkyl, -(Ci-CS
alkylene)-C(O)NH-Ci-Cs alkyl, -C(O)NH2, or -NO2, wherein each occurrence of Ra is independently -H, benzyl, or -Ci-Cio alkyl; or N and both Ra groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle or a nitrogen-containing 7- to 10-membered bicyclic heterocycle, each of which is unsubstituted or substituted with one or more of -Ci-CS
alkyl, -C3-C8 monocyclic cycloalkyl, phenyl, a nitrogen-containing 3- to 7-membered monocyclic heterocycle, -(phenyl-substituted) Ci-C5 alkyl, -(hydroxy-substituted) Ci-C5 alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(Ci-CS alkylene)-N(Ra)z, -Ci-CS alkylene-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(Ci-C5 alkylene)-O-Ci-CS alkyl, -(Ci-CS alkylene)-C3-C8 monocyclic cycloalkyl, -(Ci-CS
alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(Ci-CS alkylene)-OP(O)(OH)2, -(Ci-CS
alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(Ci-CS
alkylene)-C(O)O-Ci-CS alkyl, -(Ci-CS alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NO2, wherein each occurrence of Ra is independently -H, -benzyl, -Ci-Cio alkyl; or N
and both R' groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

Z is -CF3, -F, -OH or -O-CH3;
n is an integer ranging from 1 to 10;
m is an integer ranging from 2 to 10;
p is an integer ranging from 1 to 5; and q is an integer ranging from 1 to 5.
In one aspect the invention provides a compound of Formula (Ic) NH
X Rt (Ic) and pharmaceutically acceptable salts thereof, wherein X is N(Ci-C4 alkyl)-, -CH(OH)-, -N(C(O)N(H)-(CHz)p-Z)- or -N((CHz)q Z)-;
Ri is -(CHz)ri N(R2)(R2) or -O-(CH2)õ-N(R2)(R);
each R2 is independently -H, -Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, -Ci-alkylene phenyl, phenyl, an N-terminal alpha amino acid residue, an N-terminal alpha amino hydroxymethyl residue, a Ci-C6 alkyl ester of an N-terminal alpha amino acid residue, or a nitrogen-containing 3- to 7-membered monocyclic heterocycle, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)zOH, -Ci-C6 alkyl, -O-Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -(Ci-C6 alkyl-substituted) 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -Ci-CS alkyl, -(Ci-CS alkylene)-O-Ci-CS alkyl, benzyl, or -C3-C8 monocyclic cycloalkyl, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -N(Ra)z, -(Ci-C5 alkylene)-O-Ci-C5 alkyl, -NH2, a nitrogen-containing 3-to 7- membered monocyclic heterocycle, or a-(Ci-alkyl-substituted) nitrogen-containing 3- to 7- membered monocyclic heterocycle, wherein each occurrence of R' is independently -H, benzyl, or -Ci-Cio alkyl;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one or more of -Ci-CS
alkyl, phenyl, -(phenyl-substituted) Ci-CS alkyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(Ci-CS alkylene)-N(Ra)z, -(Ci-CS alkylene)-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(Ci-CS alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(Ci-CS alkylene)-OP(O)(OH)2, -(Ci-CS alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(Ci-CS alkylene)-C(O)O-Ci-CS alkyl, -(Ci-CS
alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, benzyl, or -Ci-Cio alkyl; or N and both Ra groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle or a nitrogen-containing 7- to 10-membered bicyclic heterocycle, each of which is unsubstituted or substituted with one or more of -Ci-C5 alkyl, -C3-C8 monocyclic cycloalkyl, phenyl, a nitrogen-containing 3- to 7-membered monocyclic heterocycle, -(phenyl-substituted) Ci-CS alkyl, -(hydroxy-substituted) Ci-CS
alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(Ci-CS alkylene)-N(Ra)z, -Ci-CS alkylene-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(Ci-C5 alkylene)-O-Ci-CS alkyl, -(Ci-CS alkylene)-C3-C8 monocyclic cycloalkyl, -(Ci-CS
alkylene)-COOH, -OP(O)(OH)2, -OS(O)20H, -(Ci-Cs alkylene)-OP(O)(OH)2, -(Ci-Cs alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(Ci-CS
alkylene)-C(O)O-Ci-CS alkyl, -(Ci-CS alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, -Ci-Cio alkyl; or N
and both R' groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

Z is -CF3, -F, -OH or -O-CH3;
n is an integer ranging from 1 to 10;
m is an integer ranging from 2 to 10;
p is an integer ranging from 1 to 5; and q is an integer ranging from 1 to 5.

In another aspect the invention provides a compound of Formula (IIa) NH
X

R' (IIa) and pharmaceutically acceptable salts thereof, wherein X is -CH2-, -0-, -C(O)-, -CH(OH)-, -NH-, -N(Ci-C4 alkyl)- or -S-;
O_~
-O

Rl is -(CHZ)ri N(RZ)(R3) or n R2 is -H, -Ci-C6 alkyl, or -C3-C8 monocyclic cycloalkyl;
R3 is -C(O)-(Ci-C6 alkylene)-(3- to 7-membered monocyclic heterocycle), a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one or more of -C(0)0-Ci-C6 alkyl, or -C3-C8 monocyclic cycloalkyl which is substituted with one or more of (hydroxy-substituted) Ci-C5 alkyl groups;

or N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with one or more of -C2-alkenyl, -C(0)-Ci-C6 alkyl, -(Ci-C4 alkylene)-C(O)-(C3-C8 monocyclic cycloalkyl), -C7-Cio alkyl, -(Ci-CS alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-CS
alkyl, -(Ci-CS alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or -(Ci-CS alkylene)-(3- to 7-membered monocyclic heterocycle) groups; and an n is an integer ranging from 1 to 10.

In another aspect the invention provides a compound of Formula (IIb) NH
X

R' (IIb) and pharmaceutically acceptable salts thereof, wherein X is -CH2-, -0-, -C(O)-, -CH(OH)-, -NH-, -N(Ci-C4 alkyl)- or -S-;
O-) -O

Rl is -(CHZ)ri N(RZ)(R3) or n R2 is -H, -Ci-C6 alkyl, or -C3-C8 monocyclic cycloalkyl;
R3 is -C(0)-(C1-C6 alkylene)-(3- to 7-membered monocyclic heterocycle), a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one or more of -C(0)0-C1-C6 alkyl, or -C3-C8 monocyclic cycloalkyl which is substituted with one or more of (hydroxy-substituted) Ci-CS alkyl groups;

or N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with one or more of -C2-alkenyl, -C(0)-C1-C6 alkyl, -(Ci-C4 alkylene)-C(0)-(C3-C8 monocyclic cycloalkyl), -C7-Cio alkyl, -(Ci-C5 alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-C5 alkyl, -(Ci-CS alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or -(Ci-CS alkylene)-(3- to 7-membered monocyclic heterocycle) groups; and an n is an integer ranging from 1 to 10.

In another aspect the invention provides a compound of Formula (IIc) NH

R' X

(IIc) and pharmaceutically acceptable salts thereof, wherein X is -CH2-, -0-, -C(O)-, -CH(OH)-, -NH-, -N(Ci-C4 alkyl)- or -S-;
O~
-O
Rl is -(CHZ)ri N(RZ)(R3) or R2 is -H, -Ci-C6 alkyl, or -C3-C8 monocyclic cycloalkyl;
R3 is -C(0)-(C1-C6 alkylene)-(3- to 7-membered monocyclic heterocycle), a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one or more of -C(0)0-C1-C6 alkyl, or -C3-C8 monocyclic cycloalkyl which is substituted with one or more of (hydroxy-substituted) Ci-CS alkyl groups;

or N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with one or more of -C2-alkenyl, -C(0)-C1-C6 alkyl, -(Ci-C4 alkylene)-C(0)-(C3-C8 monocyclic cycloalkyl), -C7-Cio alkyl, -(Ci-C5 alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-C5 alkyl, -(Ci-CS alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or -(Ci-CS alkylene)-(3- to 7-membered monocyclic heterocycle) groups; and an n is an integer ranging from 1 to 10.

In one aspect, the invention provides the following Indenoisoquinolinone Analogs according to Formula (IIIa) as set forth below:
NH

R' (IIIa) Compound - Rl IIIa-1 e N Me N
IIIa-2 r NMe N
IIIa-3 r' N
N
IIIa-4 H
NH
IIIa-5 H

IIIa-6 N
r N
NI ~~~
IIIa-7 Me H
IIIa-8 N
ON) IIIa-9 rJ
N
IIIa-10 N~
~N
'-~OEt IIIa-11 NU
IIIa-12 No, IIIa-13 N

~N, IIIa-14 /--ON "
IIIa-15 Na F
IIIa-16 ON, tBOC

IIIa-17 IIIa-18 "~ON Me I-lk OH
Me IIIa-19 rO
N--, N

Me IIIa-20 HN-CNH
IIIa-21 N
La CF3 IIIa-22 /--N

IIIa-23 ON, CH2 3'OH
IIIa-24 Me NH

Me (cis dimethyl) and pharmaceutically acceptable salts thereof.
In another aspect, the invention provides the following Indenoisoquinolinone Analogs according to Formula (IIIb) as set forth below:

NH

R' (IIIb) Compound - Rl IIIb-1 e N Me N
IIIb-2 r NMe N
IIIb-3 r' N
N
IIIb-4 H
H
IIIb-5 H

IIIb-6 N
r N
NI ~~~

IIIb-7 N, Me H
IIIb-8 N

ON) IIIb-9 rJ
N
IIIb-10 N~
~N
'-~OEt IIIb-11 NU
IIIb-12 No, IIIb-13 N

~N, IIIb-14 /--ON "
IIIb-15 Na F
IIIb-16 ON, tBOC

IIIb-17 IIIb-18 '~N ~ Me ~NI-lk OH
Me IIIb-19 rO
N--, N

IIIb-20 Me HN-CNH
IIIb-21 N
La CF3 IIIb-22 /--N

IIIb-23 ON, CH2 3'OH
IIIb-24 Me NH

Me (cis dimethyl) and pharmaceutically acceptable salts thereof.

In one aspect the invention provides a compound of Formula (IVa) NH
X

R' (IVa) and pharmaceutically acceptable salts thereof, wherein X is -0-, -CH2-, -C(O)-, -NH-, -S-, -N(Ci-C4 alkyl)-, -CH(OH)-, -N(C(O)N(H)-(CHz)p-Z)- or -N((CHz)q Z)-;
RI is -O-C(CI-C3 alkyl)z-(CHz)ri N(R2)(R2);
each R2 is independently -H, -Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, -Ci-alkylene phenyl, phenyl, an N-terminal alpha amino acid residue, an N-terminal alpha amino hydroxymethyl residue, a Ci-C6 alkyl ester of an N-terminal alpha amino acid residue, or a nitrogen-containing 3- to 7-membered monocyclic heterocycle, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)zOH, -Ci-C6 alkyl, -O-Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -(Ci-C6 alkyl-substituted) 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -Ci-CS alkyl, -(Ci-CS alkylene)-O-Ci-CS alkyl, benzyl, or -C3-C8 monocyclic cycloalkyl, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -N(Ra)z, -(Ci-CS alkylene)-O-Ci-CS alkyl, -NH2, a nitrogen-containing 3-to 7- membered monocyclic heterocycle, or a-(Ci-alkyl-substituted) nitrogen-containing 3- to 7- membered monocyclic heterocycle, wherein each occurrence of R' is independently -H, benzyl, or -Ci-Cio alkyl;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one or more of -Ci-CS
alkyl, phenyl, -(phenyl-substituted) Ci-CS alkyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(Ci-CS alkylene)-N(Ra)z, -(Ci-CS alkylene)-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(Ci-CS alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(Ci-CS alkylene)-OP(O)(OH)2, -(Ci-CS alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(Ci-CS alkylene)-C(O)O-Ci-CS alkyl, -(Ci-CS
alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, benzyl, or -Ci-Cio alkyl; or N and both Ra groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle or a nitrogen-containing 7- to 10-membered bicyclic heterocycle, each of which is unsubstituted or substituted with one or more of -Ci-CS
alkyl, -C3-C8 monocyclic cycloalkyl, phenyl, a nitrogen-containing 3- to 7-membered monocyclic heterocycle, -(phenyl-substituted) Ci-CS alkyl, -(hydroxy-substituted) Ci-CS
alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(Ci-CS alkylene)-N(Ra)z, -Ci-CS alkylene-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(Ci-CS alkylene)-O-Ci-CS alkyl, -(CI-C5 alkylene)-C3-C8 monocyclic cycloalkyl, -(CI-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)20H, -(CI-C5 alkylene)-OP(O)(OH)2, -(CI-C5 alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)O-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, -Ci-Cio alkyl; or N
and both R' groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

Z is -CF3, -F, -OH or -O-CH3;
n is an integer ranging from 1 to 10;
p is an integer ranging from 1 to 5; and q is an integer ranging from 1 to 5.

In one aspect the invention provides a compound of Formula (IVb) NH

X

R' (IVb) and pharmaceutically acceptable salts thereof, wherein X is -0-, -CH2-, -C(O)-, -NH-, -S-, -N(Ci-C4 alkyl)-, -CH(OH)-, -N(C(O)N(H)-(CHz)p-Z)- or -N((CHz)q Z)-;
R' is -O-C(CI-C3 alkyl)z-(CHz)ri N(R2)(R2);
each R2 is independently -H, -Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, -Ci-alkylene phenyl, phenyl, an N-terminal alpha amino acid residue, an N-terminal alpha amino hydroxymethyl residue, a Ci-C6 alkyl ester of an N-terminal alpha amino acid residue, or a nitrogen-containing 3- to 7-membered monocyclic heterocycle, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)zOH, -Ci-C6 alkyl, -O-Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -(Ci-C6 alkyl-substituted) 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -Ci-CS alkyl, -(Ci-CS alkylene)-O-Ci-CS alkyl, benzyl, or -C3-C8 monocyclic cycloalkyl, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -N(Ra)z, -(Ci-CS alkylene)-O-Ci-CS alkyl, -NH2, a nitrogen-containing 3-to 7- membered monocyclic heterocycle, or a-(Ci-alkyl-substituted) nitrogen-containing 3- to 7- membered monocyclic heterocycle, wherein each occurrence of R' is independently -H, benzyl, or -Ci-Cio alkyl;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one or more of -Ci-CS
alkyl, phenyl, -(phenyl-substituted) Ci-CS alkyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(Ci-CS alkylene)-N(Ra)z, -(Ci-CS alkylene)-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(Ci-CS alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(Ci-CS alkylene)-OP(O)(OH)2, -(Ci-CS alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(Ci-CS alkylene)-C(O)O-Ci-CS alkyl, -(Ci-CS
alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, benzyl, or -Ci-Cio alkyl; or N and both Ra groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle or a nitrogen-containing 7- to 10-membered bicyclic heterocycle, each of which is unsubstituted or substituted with one or more of -Ci-CS
alkyl, -C3-C8 monocyclic cycloalkyl, phenyl, a nitrogen-containing 3- to 7-membered monocyclic heterocycle, -(phenyl-substituted) Ci-CS alkyl, -(hydroxy-substituted) Ci-CS

alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(Ci-CS alkylene)-N(Ra)z, -Ci-CS alkylene-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(Ci-CS alkylene)-O-Ci-CS alkyl, -(Ci-CS alkylene)-C3-C8 monocyclic cycloalkyl, -(Ci-CS
alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(Ci-CS alkylene)-OP(O)(OH)2, -(Ci-CS
alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(Ci-CS
alkylene)-C(O)O-Ci-CS alkyl, -(Ci-CS alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, -Ci-Cio alkyl; or N
and both R' groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

Z is -CF3, -F, -OH or -O-CH3;
n is an integer ranging from 1 to 10;
p is an integer ranging from 1 to 5; and q is an integer ranging from 1 to 5.
In one aspect the invention provides a compound of Formula (IVc) NH

X Rt (IVC) and pharmaceutically acceptable salts thereof, wherein X is -0-, -CH2-, -C(O)-, -NH-, -S-, -N(Ci-C4 alkyl)-, -CH(OH)-, -N(C(O)N(H)-(CHz)p-Z)- or -N((CHz)q Z)-;
R' is -O-C(CI-C3 alkyl)z-(CHz)ri N(R2)(R2);
each R2 is independently -H, -Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, -Ci-alkylene phenyl, phenyl, an N-terminal alpha amino acid residue, an N-terminal alpha amino hydroxymethyl residue, a Ci-C6 alkyl ester of an N-terminal alpha amino acid residue, or a nitrogen-containing 3- to 7-membered monocyclic heterocycle, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)zOH, -Ci-C6 alkyl, -O-Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -(Ci-C6 alkyl-substituted) 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -Ci-CS alkyl, -(CI-C5 alkylene)-O-Ci-CS alkyl, benzyl, or -C3-C8 monocyclic cycloalkyl, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -N(Ra)z, -(CI-C5 alkylene)-O-Ci-CS alkyl, -NH2, a nitrogen-containing 3-to 7- membered monocyclic heterocycle, or a-(Ci-alkyl-substituted) nitrogen-containing 3- to 7- membered monocyclic heterocycle, wherein each occurrence of R' is independently -H, benzyl, or -Ci-Cio alkyl;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one or more of -Ci-CS
alkyl, phenyl, -(phenyl-substituted) Ci-CS alkyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-C5 alkyl, -N(Ra)z, -(CI-C5 alkylene)-N(Ra)z, -(Ci-CS alkylene)-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(CI-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(CI-C5 alkylene)-OP(O)(OH)2, -(CI-C5 alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)O-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, benzyl, or -Ci-Cio alkyl; or N and both Ra groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle or a nitrogen-containing 7- to 10-membered bicyclic heterocycle, each of which is unsubstituted or substituted with one or more of -Ci-CS
alkyl, -C3-C8 monocyclic cycloalkyl, phenyl, a nitrogen-containing 3- to 7-membered monocyclic heterocycle, -(phenyl-substituted) Ci-CS alkyl, -(hydroxy-substituted) Ci-CS
alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(Ci-CS alkylene)-N(Ra)z, -Ci-CS alkylene-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(Ci-C5 alkylene)-O-Ci-Cs alkyl, -(Ci-Cs alkylene)-C3-Cs monocyclic cycloalkyl, -(Ci-Cs alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(CI-C5 alkylene)-OP(O)(OH)2, -(CI-C5 alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(Ci-CS
alkylene)-C(O)O-Ci-CS alkyl, -(Ci-CS alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, -Ci-Cio alkyl; or N
and both R' groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

Z is -CF3, -F, -OH or -O-CH3;
n is an integer ranging from 1 to 10;
p is an integer ranging from 1 to 5; and q is an integer ranging from 1 to 5.

In one aspect, the invention provides a compound of Formula (Va) NH
X I

yY' R' (Va) and pharmaceutically acceptable salts thereof, wherein Ri is -CH2NH-R2;

R2 is a-C3-C8 monocyclic cycloalkyl which is unsubstituted or substituted with one or more of -(hydroxy-substituted) Ci-CS alkyl; or a 3- to 7-membered monocyclic heterocycle;

X is halo or -H; and Y' is halo or -H, wherein at least one of X and Y' is halo.

The invention provides compositions comprising an effective amount of a compound of Formula (Ia), (Ib), (Ic), (IIa), (IIb), (IIc), (IIIa), (IIIb), (IVa), (IVb), (IVc), (Va), or a pharmaceutically acceptable salt thereof and a physiologically acceptable carrier or vehicle.
The invention further provides methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence (each being a "Condition"), comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog of Formula (Ia), (Ib), (Ic), (IIa), (IIb), (IIc), (IIIa), (IIIb), (IVa), (IVb), (IVc), (Va), or a pharmaceutically acceptable salt thereof.
A compound of Formula (Ia), Formula (Ib), Formula (Ic), Formula (IIa), Formula (IIb), Formula (IIc), Formula (IIIa), Formula (IIIb), Formula (IVa), Formula (IVb), Formula (IVc), Formula (Va), or a pharmaceutically acceptable salt thereof (an "Indenoisoquinolinone Analog") is useful for treating or preventing a Condition.
A composition comprising an effective amount of an Indenoisoquinolinone Analog and a physiologically acceptable carrier or vehicle is useful for treating or preventing a Condition.
The details of the invention are set forth in the accompanying description below.
All patents and publications cited in this specification are incorporated by reference in their entirety.

5. DETAILED DESCRIPTION OF THE INVENTION
5.1 Definitions and Abbreviations The following definitions are used in connection with the Indenoisoquinolinone Analogs:
The term "-Ci-C3 alkyl" as used herein, refers to a straight chain or branched non-cyclic hydrocarbon having from 1 to 3 carbon atoms, wherein one of the hydrocarbon's hydrogen atoms has been replaced by a single bond.
Representative straight chain -Ci-C3 alkyls include -methyl, -ethyl, and -n-propyl.
Representative branched -Ci-C3 alkyls include -isopropyl.
The term "-Ci-C4 alkyl" as used herein, refers to a straight chain or branched non-cyclic hydrocarbon having from 1 to 4 carbon atoms, wherein one of the hydrocarbon's hydrogen atoms has been replaced by a single bond.
Representative straight chain -Ci-C4 alkyls include -methyl, -ethyl, -n-propyl, and -n-butyl.
Representative branched -Ci-C4 alkyls include -isopropyl, -sec-butyl, -isobutyl and -tert-butyl. In one embodiment, the -Ci-C4 alkyl is substituted with one or more of -halo, -OH, -N(Ra)z, -(Ci-CS alkylene)-O-Ci-CS alkyl, -NH2, a nitrogen-containing 3-to 7-membered monocyclic heterocycle, or an -(Ci-C6 alkyl-substituted) nitrogen-containing 3- to 7- membered monocyclic heterocycle. Unless otherwise indicated, the -Ci-C4 alkyl is unsubstituted.
A"Ci-C4 alkylene" refers to a Ci-C4 alkyl group, as defined above, wherein one of the Ci-C4 alkyl group's hydrogen atoms has been replaced with a bond.
A"Cz-C4 alkylene" refers to a straight or branched chain saturated hydrocarbon containing 2-4 carbon atoms, wherein two of the hydrocarbon's hydrogen atoms have been replaced by a single a bond. Representative C2-C4 alkylene groups include, ethylene, n-propylene, isopropylene, n-butylene and isobutylene.
The term "-Ci-C5 alkyl" as used herein, refers to a straight chain or branched non-cyclic hydrocarbon having from 1 to 5 carbon atoms, wherein one of the hydrocarbon's hydrogen atoms has been replaced by a single bond.
Representative straight chain -Ci-CS alkyls include -methyl, -ethyl, -n-propyl, -n-butyl and -n-pentyl.
Representative branched -Ci-CS alkyls include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, -neopentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl and 1,2-dimethylpropyl. In one embodiment, the -Ci-CS alkyl is substituted with one or more of -halo, -OH, -N(Ra)z, -Ci-CS alkylene-O-Ci-CS
alkyl, -NH2, a nitrogen-containing 3-to 7- membered monocyclic heterocycle, or an -Ci-alkyl-substituted nitrogen-containing 3- to 7- membered monocyclic heterocycle. Unless otherwise indicated, the -Ci-CS alkyl is unsubstituted.
A"Ci-CS alkylene" refers to a Ci-CS alkyl group, as defined above, wherein one of the Ci-CS alkyl group's hydrogen atoms has been replaced with a bond.
The term "-phenyl-substituted Ci-CS alkyl" as used herein, refers to a"-Ci-CS
alkyl" wherein one of the its hydrogen atoms has been replaced by a phenyl group.
The term "-Ci-C6 alkyl" as used herein, refers to a straight chain or branched non-cyclic hydrocarbon having from 1 to 6 carbon atoms, wherein one of the hydrocarbon's hydrogen atoms has been replaced by a single bond.
Representative straight chain -Ci-C6 alkyls include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl and -n-hexyl. Representative branched -Ci-C6 alkyls include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, -neopentyl, -1-methylbutyl, -isohexyl, -neohexyl, -2-methylbutyl, -3-methylbutyl, -1,1-dimethylpropyl and -1,2-dimethylpropyl. In one embodiment, the -Ci-C6 alkyl is substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)zOH, -Ci-C6 alkyl, -O-Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -(Ci-C6 alkyl-substituted) 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4). Unless otherwise indicated, the -Ci-C6 alkyl is unsubstituted.
A"Ci-C6 alkylene" refers to a Ci-C6 alkyl group, as defined above, wherein one of the Ci-C6 alkyl group's hydrogen atoms has been replaced with a bond.
The term "-C2-C6 alkenyl" refers to a straight or branched chain hydrocarbon containing 2-6 carbon atoms and at least one double bond. Representative C2-C6 alkenyl groups include, but are not limited to, ethylene, propylene, 1-butylene, 2-butylene, isobutylene, sec-butylene, 1-pentene, 2-pentene, isopentene, 1-hexene, 2-hexene, 3-hexene and isohexene.
The term "-Ci-C9 alkyl" as used herein, refers to a straight chain or branched non-cyclic hydrocarbon having from 1 to 9 carbon atoms, wherein one of the hydrocarbon's hydrogen atoms has been replaced by a single bond.
Representative -Ci-C9 alkyls include, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -nonyl, isopropyl, isobutyl, sec-butyl and tert-butyl, isopentyl, neopentyl, isohexyl, isoheptyl, isooctyl and isononyl.
The term "-C7-Cio alkyl" as used herein, refers to a straight chain or branched non-cyclic hydrocarbon having from 7 to 10 carbon atoms, wherein one of the hydrocarbon's hydrogen atoms has been replaced by a single bond.
Representative -C7-Cio alkyls include, but are not limited to, heptyl, octyl, nonyl, isohexyl, isoheptyl, isooctyl and isononyl, decyl, and isodecyl.
The term "-Ci-Cio alkyl" as used herein, refers to a straight chain or branched non-cyclic hydrocarbon having from 1 to 10 carbon atoms, wherein one of the hydrocarbon's hydrogen atoms has been replaced by a single bond.
Representative -Ci-Cio alkyls include, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -nonyl, decyl, isopropyl, isobutyl, sec-butyl and tert-butyl, isopentyl, neopentyl, isohexyl, isoheptyl, isooctyl, isononyl and isodecyl.
The term "-C3-C8 monocyclic cycloalkyl" as used herein, refers to a saturated cyclic hydrocarbon having from 3 to 8 carbon atoms. Representative -C3-C8 monocyclic cycloalkyls include -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclohexyl, -cycloheptyl and -cyclooctyl. In one embodiment, the -C3-C8 monocyclic cycloalkyl is substuted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)zOH, -Ci-C6 alkyl, -O-Ci-C6 alkyl, -monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -Ci-C6 alkyl-substituted 3- to 7- membered monocyclic heterocycle. In another embodiment, the -C3-C8 monocyclic cycloalkyl is substituted with one or more of -N(Ra)z, -Ci-CS
alkylene-O-Ci-CS alkyl, or -NHz. Unless otherwise indicated, the -C3-C8 monocyclic cycloalkyl is unsubstituted.
A "nitrogen containing 3- to 7-membered monocyclic heterocycle" refers to a monocyclic 3- to 7-membered aromatic or non-aromatic monocyclic cycloalkyl group in which one of the cycloalkyl group's ring carbon atoms has been replaced with a nitrogen atom and 0-4 of the cycloalkyl group's remaining ring carbon atoms are independently replaced with a N, 0 or S atom. The nitrogen containing 3- to 7-membered monocyclic heterocycles can be attached via a nitrogen, sulfur, or carbon atom.
Representative examples of nitrogen-containing-3- to 7-membered monocyclic heterocycles include, but are not limited to, piperidinyl, piperazinyl, pyrrolyl, piperidonyl, oxazinyl, thiazinyl, diazinyl, triazinyl, tetrazinyl, imidazolyl, tetrazolyl, pyrrolidinyl, isoxazolyl, pyridinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, pyrimidinyl, morpholinyl, furuzanyl, pyrrolinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, pyrazolidinyl, and thiomorpholinyl.
In one embodiment, the nitrogen-containing 3- to 7-membered monocyclic heterocycle is fully saturated or partially saturated.
In another embodiment, the nitrogen-containing 3- to 7-membered monocyclic heterocycle is substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)zOH, -Ci-C6 alkyl, -O-Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -(Ci-C6 alkyl-substituted) 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4). Unless otherwise indicated, the nitrogen-containing 3- to 7-membered monocyclic heterocycle is unsubstituted.
A "nitrogen-containing 7- to 10-membered bicyclic heterocycle" refers to a 7-to 10-membered bicyclic ring system that contains at least one ring nitrogen atom. The nitrogen-containing 7- to 10-membered bicyclic heterocycles can be attached via a nitrogen, sulfur, or carbon atom. Representative nitrogen-containing 7- to 10-membered bicyclic heterocycles include -quinolinyl, -isoquinolinyl, -chromonyl, -indolyl, -isoindolyl,-indolinyl, indolizinyl, -indazolyl, -purinyl, -4H-quinolizinyl, -isoquinolyl, -quinolyl, -phthalazinyl, -naphthyridinyl, benzimidazolyl, benzthiazolyl, dihydroquinolyl, dihydroisoquinolyl, cinnolyl, phthalazyl, quinazolyl, quinoxalyl, and pteridyl.
In one embodiment, the nitrogen-containing 7- to 10-membered bicyclic heterocycle is saturated or partially saturated.
A "3- to 7-membered monocyclic heterocycle" refers to a monocyclic 3- to 7-membered aromatic or non-aromatic monocyclic cycloalkyl in which 1-4 of the ring carbon atoms have been independently replaced with a N, 0 or S atom. The 3- to membered monocyclic heterocycles can be attached via a nitrogen, sulfur, or carbon atom. Representative examples of a 3- to 7-membered monocyclic heterocycle group include, but are not limited to, nitrogen-containing 3- to 7-membered monocyclic heterocycles discussed above, tetrahydrofuranyl, dihydrofuranyl, pyranyl, dihydropyranyl, tetrahydropyranyl, thiopyranyl, dihydrothiopyranyl, tetrahydrothiopyranyl, dioxanyl, dithianyl, trithianyl, dioxolanyl, furanyl, and thiophenyl.
In one embodiment, the 3- to 7-membered monocyclic heterocycle is a nitrogen-containing 3- to 7-membered monocyclic heterocycle. In another embodiment, the 3- to 7-membered monocyclic heterocycle is saturated or partially saturated.
A"Ci-C6 alkyl-substituted 3- to 7-membered monocyclic heterocycle" refers to to a "3- to 7-membered monocyclic heterocycle," as defined above, wherein one or more of the heterocycle's hydrogen atoms has been replaced by a Ci-C6 alkyl, as defined above.
"Halo" is -F, -Cl, -Br or -I.
"Halo-substituted Ci-CS alkyl" refers to a Ci-CS alkyl group, as defined above, wherein one or more of the Ci-CS alkyl group's hydrogen atoms has been replaced with -F, -Cl, -Br or -I. Representative examples of a halo-substituted Ci-CS alkyl include, but are not limited to, -CH2F, -CC13, -CF3, -CH2C1, -CH2CH2Br, -CHzCHzI, -CH2CH2CH2F, -CH2CH2CH2C1, -CH2CH2CH2CH2Br, -CH2CH2CH2CH2I, -CH2CH2CH2CH2CH2Br, -CH2CH2CH2CH2CH2I, -CH2CH(Br)CH3, -CH2CH(Cl)CH2CH3, -CH(F)CH2CH3 and -C(CH3)2(CH2C1).
"Halo-substituted phenyl" refers to a phenyl group, wherein one or more of the phenyl group's hydrogen atoms has been replaced with -F, Cl, -Br or -I.
"Cyano-substituted phenyl" refers to a phenyl group, wherein one or more of the phenyl group's hydrogen atoms has been replaced with -CN.
"Cyano-substituted Ci-CS alkyl" refers to a Ci-CS alkyl group, as defined above, wherein one or more of the Ci-CS alkyl group's hydrogen atoms has been replaced with -CN. Representative examples of a cyano-substituted Ci-CS alkyl include, but are not limited to, -CH2CN, -CH2CH2CN, -CH2CH2CH2CN, -CH2CH2CH2CH2CN, -CH2CH2CH2CH2CH2CN, -CH2CH(CN)CH3, -CH2CH(CN)CH2CH3, -CH(CN)CH2CH3 and -C(CH3)2(CH2CN).
A"Ci-C6 alkylene phenyl" refers to a Ci-C6 alkyl group, as defined above, wherein one of the Ci-C6 alkyl group's hydrogen atoms has been replaced with phenyl.
"Hydroxy-substituted Ci-C5 alkyl" refers to a Ci-C5 alkyl group, as defined above, wherein one or more of the Ci-CS alkyl group's hydrogen atoms has been replaced with -OH. Representative examples of a hydroxy-substituted Ci-CS alkyl include, but are not limited to, -CHzOH, -CHzCHzOH, -CHzCHzCHzOH, -CHzCHzCHzCHzOH, -CHzCHzCHzCHzCHzOH, -CH2CH(OH)CH3, -CH2CH(OH)CH2CH3, -CH(OH)CH2CH3 and -C(CH3)2(CH2OH).
A "C-terminal alpha amino acid residue" refers to an L-, D- or racemic natural or unnatural alpha amino acid, less the hydroxyl group of the alpha amino acid's carboxyl group. Representative examples of a C-terminal alpha amino acid residue include, but are not limited to, CH3-CH(NH2)-C(O)-, HN=C(NH2)-NH-(CH2)3-CH(NH2)-C(O)-, H2N-C(O)-CH2-CH(NH2)-C(O)-, HOOC-CH2-CH(NH2)-C(O)-, HS-CH2-CH(NH2)-C(O)-, H2N-C(O)-(CH2)2-CH(NH2)-C(O)-, HOOC-(CH2)2-CH(NH2)-C(O)-, H2N-CH2-C(O)-, CH3-CH2-CH(CH3)-CH(NH2)-C(O)-, (CH3)2-CH-CH2-CH(NH2)-C(O)-, H2N-(CH2)4-CH(NH2)-C(O)-, CH3-S-(CH2)2-CH(NH2)-C(O)-, HO-CH2-CH(NH2)-C(O)-, CH3-CH(OH)-CH(NH2)-C(O)-, (CH3)2-CH-CH(NH2)-C(O)-, O

NHZ
</N
HN NHZ
0 I ~
c and NHZ OH
HZN
N
H
In one embodiment, the C-terminal alpha amino acid is a natural amino acid.
In another embodiment, the C-terminal alpha amino acid is an unnatural amino acid.
In one embodiment, the C-terminal alpha amino acid is an L amino acid.
An "N-terminal alpha amino acid residue" refers to an L-, D- or racemic natural or unnatural alpha amino acid, less the alpha amino acid's N-terminal amino group.
Representative examples of an N-terminal alpha amino acid residue include, but are not limited to, -CH2-COOH, -CH(CH3)COOH, -CH(CH(CH3)2)COOH, -CH(CH2CH(CH3)2)COOH, -CH(CH(CH3)(CH2CH3))COOH, -CH((CH2)4-NH2)COOH, -CH((CH2)3NH(C=NH2)-NH2)COOH, -CH(CH2-OH)COOH, -CH(CH((CH3)(OH)))COOH, -CH(CH2-COOH)COOH, -CH((CHz)zCOOH)COOH, -CH((CH2)(CONH2))COOH, -CH((CH2)2(CONH2))COOH, -CH(CH2-SH)COOH, -CH((CH2)2-S-CH3)COOH, O OH
O
O

<~\ VYVVI nnn~
OH
HN

O

OH
and OH
N
H
In one embodiment, the N-terminal alpha amino acid residue is substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)zOH, -Ci-C6 alkyl, -O-Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -Ci-C6 alkyl-substituted 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4). Unless otherwise indicated, the N-terminal alpha amino acid residue is unsubstituted.
An "N-terminal alpha amino hydroxymethyl residue" refers to an "N-terminal alpha amino acid residue," wherein its C-terminal carboxyl group, a side chain's carboxyl group, or both have been replaced with a hydroxymethyl group. In one embodiment, the N-terminal alpha amino hydroxymethyl residue is substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)zOH, -Ci-C6 alkyl, -O-Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -Ci-C6 alkyl-substituted 3- to 7-membered monocyclic heterocycle, or -N(Z3)(Z4). In another embodiment, the hydroxyl group of the hydroxymethyl residue is substituted with -P03H2, -P206H3, -P309H4, -SO3H, -C(O)-C1-C9 alkyl, (3-D-glucuronyl, or a C-terminal alpha amino acid residue.
Unless otherwise indicated, the N-terminal alpha amino hydroxymethyl residue is unsubstituted.
A"Ci-C6 alkyl ester of an N-terminal alpha amino acid residue" refers to an "N-terminal alpha amino acid residue," wherein the hydrogen atom of the amino acid's C-terminal carboxyl group, a side chain's carboxyl group, or both have been replaced by a-Ci-C6 alkyl group. In one embodiment, the Ci-C6 alkyl ester of an N-terminal alpha amino acid residue is a methyl, an ethyl, an n-propyl or an iso-propyl ester of an N-terminal alpha amino acid residue. In another embodiment, the Ci-C6 alkyl ester of an N-terminal alpha amino acid residue is substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)zOH, -Ci-C6 alkyl, -O-Ci-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -Ci-C6 alkyl-substituted 3- to 7-membered monocyclic heterocycle, or -N(Z3)(Z4). Unless otherwise indicated, the Ci-C6 alkyl ester of an N-terminal alpha amino acid residue is unsubstituted.
In one embodiment, the N-terminal alpha amino acid is a natural amino acid.
In another embodiment, the N-terminal alpha amino acid is an unnatural amino acid.
In one embodiment, the N-terminal alpha amino acid is an L amino acid.
A"(3-D-glucuronyl" refers to a group having the formula:

O OH

HO~~~~ ,""OH
OH
A"subject" is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus. In one embodiment, the subject is a human.
The phrase "pharmaceutically acceptable salt," as used herein, is a salt of an acid and a basic nitrogen atom of an Indenoisoquinolinone Analog. Illustrative salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts.
The term "pharmaceutically acceptable salt" also refers to a salt of an Indenoisoquinolinone Analog having an acidic functional group, such as a carboxylic acid functional group, and a base. Suitable bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metal such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc;
ammonia, and organic amines, such as unsubstituted or hydroxy-substituted mono-, di-, or tri-alkylamines, dicyclohexylamine; tributyl amine; pyridine; N-methyl, N-ethylamine;
diethylamine; triethylamine; mono-, bis-, or tris-(2-OH-lower alkylamines), such as mono-; bis-, or tris-(2-hydroxyethyl)amine, 2-hydroxy-tert-butylamine, or tris-(hydroxymethyl)methylamine, N,N-di-lower alkyl-N-(hydroxyl-lower alkyl)-amines, such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl)amine;
N-methyl-D-glucamine; and amino acids such as arginine, lysine, and the like.
The term "pharmaceutically acceptable salt" also includes a hydrate of a compound of the invention.
In one embodiment, the pharmaceutically acceptable salt is a mesylate salt.
In another embodiment, the pharmaceutically acceptable salt is a camphorsulfonate salt.
An "effective amount" when used in connection with an Indenoisoquinolinone Analog is an amount that is effective for treating or preventing a Condition.
An "effective amount" when used in connection with another anticancer agent is an amount that is effective for treating or preventing cancer alone or in combination with an Indenoisoquinolinone Analog. "In combination with" includes administration within the same composition and via separate compositions. In the latter instance, the other anticancer agent is administered during a time when the Indenoisoquinolinone Analog exerts its prophylactic or therapeutic effect, or vice versa.
The following abbreviations are used herein and have the indicated definitions:
DMF is N,N-dimethylformamide, THF is tetrahydrofuran, DMAC is dimethylacetamide.
DMSO is dimethylsulfoxide, Et is ethyl, Pr is n-propyl, i-Pr is isopropyl, EtOAc is ethyl acetate, EtOH is ethanol, Me is methyl, MS is mass spectrometry, Ts is tosylate, Tf is triflate, Ph is phenyl, NMR is Nuclear Magnetic Resonance, Ms is mesylate, LAH
is lithium aluminum hydride and tBoc is t-butyloxycarbonyl.
5.2 The Indenoisoquinolinone Analogs of Formula (Ia) The present invention provides Indenoisoquinolinone Analogs according to Formula (Ia), below:

NH
X

R' (Ia) and pharmaceutically acceptable salts thereof, wherein X and Ri are as defined above for the Indenoisoquinolinone Analogs of Formula (Ia).
In one embodiment, X is N(CH3)-. In another embodiment, X is is -N(CH2CH3)-. In another embodiment, X is -N(CH2CH2CH3)-. In another embodiment, X is -N(CH2 CH2CH2CH3)-. In another embodiment, X is -N(C(H)(CH3)(CH2CH3))-.
In another embodiment, X is -N(C(H)(CH3)2)-. In another embodiment, X is -N(CH2C(H)(CH3)2)-. In another embodiment, X is -N(C(CH3)3)-.
In one embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(CH3)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(CH2CH3)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(CH2CH2CH3)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2) and X is -N(CH2 CH2CH2CH3)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(C(H)(CH3)(CH2CH3))-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(C(H)(CH3)2)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(CH2C(H)(CH3)2)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(C(CH3)3)-.
In one embodiment, Ri is -O-(CH2)õ-N(R2)(R2) and X is -N(CH3)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(CH2CH3)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is N(CH2CH2CH3)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(CH2 CHzCHzCH3)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(C(H)(CH3)(CH2CH3))-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(C(H)(CH3)z)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(CHzC(H)(CH3)z)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2)(R2 ) and X is -N(C(CH3)3)-.
In one embodiment, one R2 is -H, and the other R2 is -Ci-C6 alkyl.
In another embodiment, each R2 is -Ci-C6 alkyl.
In another embodiment, each R2 is -methyl.
In one embodiment, X is -CH(OH)-.
In another embodiment, X is -CH(OH)- and Ri is -(CHz)ri N(R2)(R).
In yet another embodiment, X is -CH(OH)- and Ri is -(CH2)-N(R2 )(R2).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)2-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-Z)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p Z)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)-Z)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q Z)-.
In another embodiment, X is -N((CHz)-Z)-.
In another embodiment, X is -N((CHz)z-Z)-.
In another embodiment, X is -N((CHz)q Z)- and Ri is -(CHz)ri N(R2 )(R2).
In yet another embodiment, X is -N((CHz)q Z)- and Ri is -(CH2)-N(R2)(R 2).
In still another embodiment, X is -N((CH2)-Z)- and Ri is -(CH2)-N(R2)(R2).
In one embodiment, Z is -CF3.
In another embodiment, Z is -F.
In yet another embodiment, Z is -OH.
In still another embodiment, Z is -O-CH3.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OH)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OH)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p OH)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q OH)-.
In another embodiment, X is -N((CH2)2-OH)-.
In another embodiment, X is -N((CHz)q OH)- and Ri is -(CHz)ri N(R2)(R).
In yet another embodiment, X is -N((CHz)q OH)- and Ri is -(CH2)-N(R2)(R).
In still another embodiment, X is -N((CH2)2-OH)- and Ri is -(CH2)-N(R2)(R).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-F)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)-F)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-F)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p F)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)-F)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q F)-.
In another embodiment, X is -N((CH2)-F)-.
In another embodiment, X is -N((CHz)q F)- and Ri is -(CHz)ri N(R2 )(R2).
In yet another embodiment, X is -N((CHz)q F)- and Ri is -(CH2)-N(R2)(R).
In still another embodiment, X is -N((CH2)-F)- and Ri is -(CH2)-N(R2)(R2).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OMe)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)2-OMe)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OMe)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p OMe)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OMe)- and Ri is -(CH2)-N(R2 )(R2 ).

In one embodiment, X is -N((CHz)q OMe)-.
In another embodiment, X is -N((CH2)2-OMe)-.
In another embodiment, X is -N((CHz)q OMe)- and Ri is -(CHz)ri N(R2)(R).
In yet another embodiment, X is -N((CHz)q OMe)- and Ri is -(CH2)-N(R2 )(R2).
In still another embodiment, X is -N((CH2)2-OMe)- and Ri is -(CH2)-N(R2 )(R2).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)p-CF3)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p CF3)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)-CF3)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q CF3)-.
In another embodiment, X is -N((CH2)-CF3)-.
In another embodiment, X is -N((CHz)q CF3)- and Ri is -(CHz)ri N(R2)(R2).
In yet another embodiment, X is -N((CHz)q CF3)- and Ri is -(CH2)-N(R2)(R).
In still another embodiment, X is -N((CH2)-CF3)- and Ri is -(CH2)-N(R2)(R2).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)- CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p- CF3)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p CF3)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)-CF3)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q CF3)-.
In another embodiment, X is -N((CH2)-CF3)-.
In another embodiment, X is -N((CHz)q CF3)- and Ri is -(CHz)ri N(R2 )(R2).
In yet another embodiment, X is -N((CHz)q CF3)- and Ri is -(CH2)-N(R2)(R).
In still another embodiment, X is -N((CH2)-CF3)- and Ri is -(CH2)-N(R2)(R2).
In one embodiment, n is 1.
In another embodiment, n is 2.
In yet another embodiment, n is 3.
In a further embodiment, n is 4, 5, or 6.
In yet a further embodiment, n is 7, 8, or 9.
In still a further embodiment, n is 10.
In one embodiment, m is 2.
In another embodiment, m is 3.
In yet another embodiment, m is 4, 5, or 6.
In a further embodiment, m is 7, 8, or 9.
In yet a further embodiment, m is 10.
In one embodiment, p is 1.
In another embodiment, p is 2.
In yet another embodiment, p is an integer ranging from 2 to 5.
In one embodiment, q is 1.
In another embodiment, q is 2.
In yet another embodiment, q is an integer ranging from 2 to 5.
In various embodiments, -N(R2)(R2) is:

/ v / \ CH3 -N 0 ~-NaOH ~-NN-CH3 ~-N~N-/
~-N/-\ H 2-N ~-N ~N--//--N(CHs)2 ~-N / \ N~O N N~Ph C(O)OH C(O)OCH2CH3 H - ~-N\ N~ ~-N\ N~
~ / \N--"~NH

HgC/~CHs where X = -H -OMe -CN -F
-Cl, -Br, or -I

N(CH3)2 OH

-N N -N N ~-N\CH3 ~-N\CH2CH3 /CH2CH2OH /CH2CH2N(CH3)2 /CH2Ph /CH2CH2OCH3 ~-N\CH2CH2OH ~-N\CH2CH2N(CH3)2 ~-N\CH3 ~-N\CH2CH2OCH3 CH3 CH2N(CH3)2 ~_N`CH3 N~CH3 I_N~CH3 ~-N' CH2N(CH3)2 ~-N\-7 I-NaOH N CH3 CH3 CH3 ~- -I-N
-CH3 ~-N

H N~/~N~ ~O N.CH3 ~O NH ~
N~ NN
~ ~~ -37-NN,CH3 , NN=/

/ \ I-Na OH - OP(O)(OH)2 N or I- NNCH2CH2OP(O)(OH)2 OP(O)(OH)2 In other embodiments, -N(R2)(R2) is:

/~rN ) ~\ I-N/~rN I /~
\N
~-N
~/ ~/ ~/ ~J
/ I- I-N
~ , HON O
`N OH OMe ~-N -N 0 I-No I-N`~
\~ ao N3 Hp_ ~
1 N OH I-NH ,CH2CH3 I-NH I-N I-NH

D, /-\ s I-NH CHs N ~/ ' H CH3 N

I_N ~_CH3 i-NH H3C
_O
I-NEH I-N N

OH

i-N - CH
~ NON, N Z ~~
I-N H N ' 'I-NN-\iOH
_ -1- ~~N~iCH3 -1-N~OEt , -i-NN-NIIiOMe ' -1-N

_ ~\ 0 CH3 OH
~ N~OEt ~-N~ OH ~-N CH3 ~-N CH3 H3C\
~-N-CH3 ' -1-N-CH2CH3 ~-N-CH2CH2CH3 -HrCH3 H3 N ~-N
O Me >--CH3 -N-CHZCHZOH , 0 , H3C -~-N ~ or \ --IQ

~-N ~N

In some embodiments, -N(R2)(R2) is N
I V
F F
~-N\~ N Q~aF
NMe2 NMe2 F
N -N N
or In still other embodiments, -N(R2)(R2) is -N(CH2CH3)(CH3), -N(CH2CH2CH3)(CH3), -N(CH2CH2CH2CH3)(CH3), -NH-CH2CH2CH2CH3, or -NH-CH2CH2-O-CH3.
In some embodiments, -N(R2)(R2) is aOPO(OH)2 ~-N N OPO(OH)2 OPO(OH)2 , _ CH3 _ H

~ N IN i-N
or OPO(OH)2 OPO(OH)2 OPO(OH)2 In various embodiments, -N(Z3)(Z4) is:

/ \ / \ CH3 -N 0 ~-NaOH ~-N\ N-CH3 ~-N\ N~
-N NH -N ~-N \ N_/-N(CH3)2 ~-N/ N \ / F

~-N NO N N-/Ph C(O)OH C(O)OCH2CH3 H~ ~-N / N _/ ~-N/ \N~
~

O HO
HgC CHs where X = -H, -OMe, -CN, -F, -Cl, -Br, or -I
N(CH3)2 OH

-N N -N N / N ~-N\CH3 ~-N'CH2CH3 I-N\CH2CH2OH ~-N\CH2CH2N(CH3)2 I-N\CH2Ph I-N\CH2CH2OCH3 CH2CH2OH CH2CH2N(CH3)2 CH3 CH2CH2OCH3 ~ Hs C -H2N(CH3)2 I_N`CH3 N~CH3 ~-NQH3 ~-N~ H2N(CH3)2 CH3 ~CH3 ~-N\-7 ~-N~
`~\OH

~- -I-N -CH3 ~-N

N~\N^ 0 H N.CH3 N ( ~ H N,/~ N-~~N

NN,CH3 , NN=/
~OH ~-N`~
OP(O)(OH)2 ~-N or NCH2CH2OP(O)(OH)2 OP(O)(OH)2 In other embodiments, -N(Z3)(Z4) is:

õ~.
I
CCN) I NO-Nb I NO-Nb I N I-HO O

N .OH }_No OMe N
I_N Z
N
`~
~ HO_ O
~
~N OH I-NH t-NH i-N, CH2CH3 -NH
V

I-N\_jS ' 1-NIC~-\0 H I-N

I-N OH
0 , OH

i-N CHs }-N ~ / N CH 2 ON, , ~~

N Z ~~
-NH N I-NN--",,iOH
/~
I-N~j ~iCH3 -1-N, rOEt 'i-N

N N~ O ,CH3 OH
I 'OEt ~-N I-N I-N_ rCH3 OH kCH3 ~/

H3C\
~-N-CH3 =}-N-CH2CH3 '~-N-CH2CH2CH3 HrCHs ~-CH3 TNH
CH3 or v/

In some embodiments, -N(Z3)(Z4) is A N
NI

vsF F
N\~ N
Q aF
NMe2 NMe2 F
N N
or Q -In still other embodiments, -N(Z3)(Z4) is -N(CH2CH3)(CH3), -N(CH2CH2CH3)(CH3), -N(CH2CH2CH2CH3)(CH3), -NH-CH2CH2CH2CH3, or -NH-CHzCHz-O-CH3.
In some embodiments, -N(Z3)(Z4) is N ~-N ~-N OPO(OH)2 OPO(OH)2 OPO(OH)2 or ~

In one embodiment, X is N(CH3)- N(CHzCH3)- -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-;
Ri is -(CHz)ri N(R2)(R2) or -O-(CH2)õ-N(R2)(R);
each R2 is independently -H, -Ci-C6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(Ci-C6 alkylene)-phenyl or phenyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)z, -OS(O)zOH or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -Ci-CS alkyl, or -(CI-C5 alkylene)-O-Ci-CS alkyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH or -NH2;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -Ci-CS
alkyl, -phenyl, -(CI-C5 alkylene)-phenyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(CI-C5 alkylene)-N(Ra)z, -Ci-CS alkylene-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(CI-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)20H, -(CI-C5 alkylene)-OP(O)(OH)2, -(CI-C5 alkylene)-OS(O)20H, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)O-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, or -Ci-Cio alkyl;
or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -Ci-CS alkyl, -phenyl, -(CI-C5 alkylene) -phenyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(CI-C5 alkylene)-N(Ra)z, -(CI-C5 alkylene)-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(CI-alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(CI-C5 alkylene)-OP(O)(OH)2, -(CI-C5 alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)O-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, or -Ci-Cio alkyl;
n is an integer ranging from 1 to 10; and m is an integer ranging from 2 to 10.
In one embodiment, X is N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; Ri is -CH2-N(R2)(R 2); and at least one R2 is methyl.
In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; Ri is -CH2-N(R2)(R2 ); and at least one R2 is ethyl.
In yet another embodiment, X is -N(CH3)- -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; Ri is -CH2-N(R 2)(R2); and at least one R2 is propyl.
In one embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; Ri is -CH2-N(R2)(R 2); and at least one R2 is -C3-C8 monocyclic cycloalkyl.
In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; Ri is -CH2-N(R2 )(R2); and at least one R2 is cyclohexyl.
In yet another embodiment, X is -N(CH3)- -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; and Ri is -CH2-N(R2)(R2), wherein N and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle.
In one embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; and Ri is -CH2-N(R2)(R2), wherein N and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with a hydroxyl.
In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; and Ri is -CH2-N(R2)(R2), wherein N and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with a nitrogen-containing 3- to 7-membered monocyclic heterocycle.

Illustrative examples of the Indenoisoquinolinone Analogs include the compounds of Formula (Ia) as set forth below:

NH
X

R' (Ia) Compound n - R X
Ia-1 1 -(CHz)ri N(CH3)z N(CH3)-Ia-2 2 -(CHz)ri N(CH3)z N(CH3)-Ia-3 3 -(CHz)ri N(CH3)z N(CH3)-Ia-4 4 -(CHz)ri N(CH3)z N(CH3)-Ia-5 5 -(CHz)ri N(CH3)z N(CH3)-Ia-6 6 -(CHz)ri N(CH3)z N(CH3)-Ia-7 1 CHz ri N CH3 z -N CHzCH3 -Ia-8 2 CHz ri N CH3 z -N CHzCH3 -Ia-9 3 CHz ri N CH3 z -N CHzCH3 -Ia-10 4 CHz ri N CH3 z -N CHzCH3 -Ia-11 5 CHz ri N CH3 z -N CHzCH3 -Ia-12 6 CHz ri N CH3 z -N CHzCH3 -Ia-13 1 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ia-14 2 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ia-15 3 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ia-16 4 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ia-17 5 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ia-18 6 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ia-19 1 -(CHz)ri N(CH3)z -N(CH2 CH2CH2CH3)-Ia-20 2 -(CHz)ri N(CH3)z -N(CH2 CH2CH2CH3)-Ia-21 3 CHz ri N CH3 z -N(CH2 CH2CH2CH3 -Ia-22 4 CHz ri N CH3 z -N(CH2 CH2CH2CH3 -Ia-23 5 CHz ri N CH3 z -N(CH2 CH2CH2CH3 -Ia-24 6 CHz ri N CH3 z -N(CH2 CH2CH2CH3 -Ia-25 1 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ia-26 2 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ia-27 3 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ia-28 4 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ia-29 5 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ia-30 6 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ia-31 1 CHz ri N CH3 z -N C H CH3 z-Ia-32 2 -(CHz)ri N(CH3)z -N(C(H)(CH3)2)-Ia-33 3 CH2riNCH32 -NCH CH3z-Ia-34 4 CH2riNCH32 -NCH CH3z-Ia-35 5 CH2riNCH32 -NCH CH3z-Ia-36 6 CH2riNCH32 -NCH CH3z-Ia-37 1 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ia-38 2 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ia-39 3 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ia-40 4 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ia-41 5 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ia-42 6 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ia-43 1 CHz ri N CH3 z -N C CH3 3-Ia-44 2 CHz ri N CH3 z -N C CH3 3-Ia-45 3 -(CHz)ri N(CH3)z -N(C(CH3)3)-Ia-46 4 -(CHz)ri N(CH3)z -N(C(CH3)3)-Ia-47 5 -(CHz)ri N(CH3)z -N(C(CH3)3)-Ia-48 6 -(CHz)ri N(CH3)z -N(C(CH3)3)-Ia-49 1 N(CH3)--(CH2)n N 0 Ia-50 2 N(CH3)--(CH2)n N 0 Ia-51 3 N(CH3)--(CH2)n N 0 Ia-52 4 N(CH3)--(CH2)n N 0 Ia-53 5 N(CH3)--(CH2)n N 0 Ia-54 6 N(CH3)--(CH2)n N 0 Ia-55 1 -N(CH2CH3)--(CH2)n N 0 Ia-56 2 -N(CH2CH3)--(CH2)n N 0 Ia-57 3 -N(CH2CH3)--(CH2)n N 0 Ia-58 4 -N(CH2CH3)--(CH2)n N 0 Ia-59 5 -N(CH2CH3)--(CH2)n N 0 Ia-60 6 -N(CH2CH3)--(CH2)n N 0 Ia-61 1 N(CH2CH2CH3)--(CH2)n N 0 Ia-62 2 N(CH2CH2CH3)--(CH2)n N 0 Ia-63 3 N(CH2CH2CH3)--(CH2)n N 0 Ia-64 4 N(CH2CH2CH3)--(CH2)n N 0 Ia-65 5 N(CH2CH2CH3)--(CH2)n N 0 Ia-66 6 N(CH2CH2CH3)--(CH2)n N 0 Ia-67 1 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ia-68 2 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ia-69 3 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ia-70 4 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ia-71 5 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ia-72 6 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ia-73 1 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ia-74 2 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ia-75 3 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ia-76 4 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ia-77 5 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ia-78 6 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ia-79 1 -N(C(H)(CH3)2)--(CH2)n N 0 Ia-80 2 -N(C(H)(CH3)2)--(CH2)n N 0 Ia-81 3 -N(C(H)(CH3)2)--(CH2)n N 0 Ia-82 4 -N(C(H)(CH3)2)--(CH2)n N 0 Ia-83 5 -N(C(H)(CH3)2)--(CH2)n N 0 Ia-84 6 -N(C(H)(CH3)2)--(CH2)n N 0 Ia-85 1 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ia-86 2 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ia-87 3 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ia-88 4 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ia-89 5 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ia-90 6 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ia-91 1 -N(C(CH3)3)--(CH2)n N 0 Ia-92 2 -N(C(CH3)3)--(CH2)n N 0 Ia-93 3 -N(C(CH3)3)--(CH2)n N 0 Ia-94 4 -N(C(CH3)3)--(CH2)n N 0 Ia-95 5 -N(C(CH3)3)--(CH2)n N 0 Ia-96 6 -N(C(CH3)3)--(CH2)n N 0 Compound m - R X
Ia-146 2 -O-(CHz)m N(CH3)z N(CH3)-Ia-147 3 -O-(CHz)m N(CH3)z N(CH3)-Ia-148 4 -O-(CHz)m N(CH3)z N(CH3)-Ia-149 5 -O-(CHz)m N(CH3)z N(CH3)-Ia-150 6 -O-(CHz)m N(CH3)z N(CH3)-Ia-151 2 -O CHz m N CH3 z N CH3 -Ia-152 3 -O CHz õ-N CH3 z -N CHzCH3 -Ia-153 4 -O CHz õ-N CH3 z -N CHzCH3 -Ia-154 5 -O CHz õ-N CH3 z -N CHzCH3 -Ia-155 6 -O CHz õ-N CH3 z -N CHzCH3 -Ia-156 2 -O-(CHz)m N(CH3)z -N(CH2CH3)-Ia-157 3 -O-(CHz)m N(CH3)z -N(CH2CH3)-Ia-158 4 -O-(CHz)m N(CH3)z -N(CH2CH2CH3)-Ia-159 5 -O-(CHz)m N(CH3)z -N(CH2CH2CH3)-Ia-160 6 -O-(CH2)õ-N(CH3)2 -N(CH2CH2CH3)-Ia-161 2 -O CHz õ-N CH3 z -N CHzCHzCH3 -Ia-162 3 -O CHz õ-N CH3 z -N CHzCHzCH3 -Ia-163 4 -O CHz õ-N CH3 z -N CHzCHzCH3 -Ia-164 5 -O CHz õ-N CH3 z -N CHzCHzCHzCH3 -Ia-165 6 -O CHz õ-N CH3 z -N CHzCHzCHzCH3 -Ia-166 2 -O-(CHz)m N(CH3)z -N(CH2CH2CH2CH3)-Ia-167 3 -O-(CHz)m N(CH3)z -N(CH2CH2CH2CH3)-Ia-168 4 -O-(CHz)m N(CH3)z -N(CH2CH2CH2CH3)-Ia-169 5 -O-(CHz)m N(CH3)z -N(CH2CH2CH2CH3)-Ia-170 6 -O-(CHz)m N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ia-171 2 -O CHz õ-N CH3 z -N C H CH3 CHzCH3 -Ia-172 3 -O CHz õ-N CH3 z -N C H CH3 CHzCH3 -Ia-173 4 -O CHz õ-N CH3 z -N C H CH3 CHzCH3 -Ia-174 5 -O CHz õ-N CH3 z -N C H CH3 CHzCH3 -Ia-175 6 -O CHz õ-N CH3 z -N C H CH3 CHzCH3 -Ia-176 2 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ia-178 3 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ia-179 4 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ia-180 5 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ia-181 6 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ia-182 2 -O CHz õ-N CH3 z -N C H CH3 z-Ia-183 3 -O CHz õ-N CH3 z -N CHzC H CH3 z-Ia-184 4 -O-(CHz)m N(CH3)z -N(CH2C(H)(CH3)2)-Ia-185 5 -O CHz õ-N CH3 z -N CHzC H CH3 2-Ia-186 6 -O CHz õ-N CH3 z -N CHzC H CH3 z-Ia-187 2 N(CH3)--0(cH2)m N 0 Ia-188 3 N(CH3)--0(cH2)m N j Ia-189 4 N(CH3)--0(cH2)m N 0 Ia-190 5 N(CH3)--0(cH2)m N %

Ia-191 6 N(CH3)--0(cH2)m N 0 \ N(CH3)-Ia-192 2 /--o (cH2)m N~

Ia-193 3 -N(CH2CH3)--0(cH2)m N j Ia-194 4 -N(CH2CH3)--0(cH2)m N 0 Ia-195 5 -N(CH2CH3)--0 (CH2)m N 0 Ia-196 6 -N(CH2CH3)--0 (CH2)m N 0 Ia-197 2 -N(CH2CH3)--0 (CH2)m N 0 Ia-198 3 -N(CH2CH3)--0 (CH2)m N 0 Ia-199 4 N(CH2CH2CH3)--0 (CH2)m N 0 Ia-200 5 N(CH2CH2CH3)--0 (CH2)m N 0 Ia-201 6 N(CH2CH2CH3)--0 (CH2)m N 0 Ia-202 2 N(CH2CH2CH3)--0 (CH2)m N 0 Ia-203 3 N(CH2CH2CH3)--0 (CH2)m N 0 Ia-204 4 N(CH2CH2CH3)--0 (CH2)m N 0 Ia-205 5 -0 (CH2) \ -N(CHzCHzCHzCH3)-m~% ~

Ia-206 6 -N(CH2CH2CH2CH3)--0 (CH2)m N 0 Ia-207 2 -N(CH2CH2CH2CH3)--0 (CH2)m N j Ia-208 3 -0 (CH \ -N(CHzCHzCHzCH3)-2)m~~ ~

Ia-209 4 -N(CH2CH2CH2CH3)--0 (CH2)m N j Ia-210 5 -N(CH2CH2CH2CH3)--0 (CH2)m N 0 Ia-211 6 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ia-212 2 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ia-213 3 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ia-214 4 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ia-215 5 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ia-216 6 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ia-217 2 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ia-218 3 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ia-219 4 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ia-220 s -0 (CH2)/~ -N(C(H)(CH3)z)-m~%

Ia-221 6 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ia-222 2 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ia-223 3 -0 (CH \ -N(CHzC(H)(CH3)z)-2)m~~ ~

Ia-224 4 -N(CH2C(H)(CH3)2)--0 (CH2)m N 0 Ia-225 5 -N(CH2C(H)(CH3)2)--0(CH2)m N j Ia-226 6 -N(CH2C(H)(CH3)2)--0(CH2)m N 0 Compound - Rl X
Ia-267 -CH2-N(CH2-CH3)2 -N(CH3)-Ia-268 -CH2-N(CH2-CH3)2 -N(CH2CH3)-Ia-269 -CH2-N(CH2-CH3)2 -N(CH2CH2CH3)-Ia-270 -CH2-N(CH2-CH3)2 -N(CH2CH2CH2CH3)-Ia-271 -CH2-N(CH2-CH3)2 -N(C(H)(CH3)(CH2CH3))-Ia-272 -CH2-N(CH2-CH3)2 -N(C(H)(CH3)2)-Ia-273 -CH2-N(CH2-CH3)2 -N(CH2C(H)(CH3)2)-Ia-274 -CH2-N(CH2-CH3)2 -N(C(CH3)3)-Ia-275 -CHz-N CHz-CHz-CH3 z -N CH3 -Ia-276 -CHz-N CHz-CHz-CH3 z -N CHzCH3 -Ia-277 -CHz-N CHz-CHz-CH3 z -N CHzCHzCH3 -Ia-278 -CHz-N CHz-CHz-CH3 z -N CHzCHzCHzCH3 -Ia-279 -CHz-N CHz-CHz-CH3 z -N C H CH3 CHzCH3 -Ia-280 -CHz-N CHz-CHz-CH3 z -N C H CH3 z-Ia-281 -CHz-N CHz-CHz-CH3 z -N CHzC H CH3 z-Ia-282 -CHz-N CHz-CHz-CH3 z -N C CH3 3-Ia-283 -CHz-N CHz-CHzOH z -N CH3 -Ia-284 -CHz-N CHz-CHzOH z -N CHzCH3 -Ia-285 -CHz-N(CHz-CHzOH)z -N(CH2CH2CH3)-Ia-286 -CHz-N(CHz-CHzOH)z -N(CH2CH2CH2CH3)-Ia-287 -CHz-N CHz-CHzOH z -N C H CH3 CHzCH3 -Ia-288 -CHz-N CHz-CHzOH z -N C H CH3 z-Ia-289 -CHz-N(CHz-CHzOH)z -N(CH2C(H)(CH3)2)-Ia-290 -CHz-N CHz-CHzOH z -N C CH3 3-Ia-291 -CHz-N(CHz-CHz-N(CH3)1)1 N CH3 -Ia-292 -CHz-N(CHz-CHz-N(CH3)1)1 -N CHzCH3 -Ia-293 -CHz-N(CHz-CHz-N(CH3)1)1 N CHzCHzCH3 -Ia-294 -CHz-N(CHz-CHz-N(CH3)1)1 -N CHzCHzCHzCH3 -Ia-295 -CHz-N(CHz-CHz-N(CH3)1)1 -N C H CH3 CHzCH3 -Ia-296 -CHz-N(CHz-CHz-N(CH3)1)1 -N C H CH3 z-Ia-297 -CHz-N(CHz-CHz-N(CH3)1)1 -N CHzC H CH3 z-Ia-298 -CHz-N(CHz-CHz-N(CH3)1)1 -N C CH3 3 -Ia-299 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N CH3 -Ia-300 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N CHzCH3 -Ia-3U1 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N(CH2CH2CH3)-Ia-302 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N CHzCHzCHzCH3 -Ia-303 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C H CH3 CHzCH3 -Ia-304 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N(C(H)(CH3)2)-Ia-305 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N CHzC H CH3 z-Ia-306 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C CH3 3 -Ia-307 -CHz-N~ N(CH3)-Ia-308 -CH2-N~ -N(CH2CH3)-Ia-309 -CH2-N N(CH2CH2CH3)-Ia-310 -CHz-N~ -N(CH2CH2CH2CH3)-Ia-311 -CH2-N~ -N(C(H)(CH3)(CH2CH3))-Ia-312 -CH2-N~ -N(C(H)(CH3)2)-Ia-313 -CHz-N~ -N(CH2C(H)(CH3)2)-Ia-314 -CH2-N~ -N(C(CH3)3)-Ia-315 -CH2-N~> -N(CH3)-Ia-316 -CH2-N~> -N(CH2CH3)-Ia-317 -CH2-Nc> -N(CH2CH2CH3)-Ia-318 -CH2-Nc> -N(CH2CH2CH2CH3)-Ia-319 -CH2-<> -N(C(H)(CH3)(CH2CH3))-Ia-320 -CH2-<> -N(C(H)(CH3)2)-Ia-321 -CH2-N~> -N(CH2C(H)(CH3)2)-Ia-322 -CH2-Nc> -N(C(CH3)3)-Ia-323 -CHz-NC) N(CH3)-Ia-324 -CH2-No -N(CH2CH3)-Ia-325 -CH2-No -N(CH2CH2CH3)-Ia-326 -CHz-No -N(CH2CH2CH2CH3)-Ia-327 -CH2-No -N(C(H)(CH3)(CH2CH3))-Ia-328 -CHz-No -N(C(H)(CH3)2)-Ia-329 -CH2-No -N(CH2C(H)(CH3)2)-Ia-330 -CH2-NC) -N(C(CH3)3)-Ia-331 -CHz-Na N(CH3)-OH

Ia-332 -CHz-N~ -N(CH2CH3)-Ia-333 -CH2-NaN(CHzCHzCH3)-OH
Ia-334 -CH2-Na -N(CH2CH2CH2CH3)-Ia-335 -CH2-Na -N(C(H)(CH3)(CH2CH3))-Ia-336 -CH2-Na -N(C(H)(CH3)2)-Ia-337 -CH2-Na -N(CH2C(H)(CH3)2)-Ia-338 -CHz-Na -N(C(CH3)3)-Ia-339 -CHz_N -N(CH3)-Ia-340 -CHz_N -N(CH2CH3)-OH
Ia-341 -CHz-N -N(CH2CH2CH3)-Ia-342 -CHz-N -N(CH2CH2CH2CH3)-Ia-343 -CHz-N -N(C(H)(CH3)(CH2CH3))-OH
Ia-344 -CHz_N -N(C(H)(CH3)2)-Ia-345 -CHz_N -N(CH2C(H)(CH3)2)-Ia-346 -CHz_N -N(C(CH3)3)-OH
Ia-347 -CH2-ND N(CH3)-Ia-348 -CH2-N_ ) -N(CH2CH3)-Ia-349 -CH2-N ) - - N(CHzCHzCH3)-Ia-350 -CH2-N -, )- -N(CH2CH2CH2CH3)-Ia-351 -CH2-N - )- -N(C(H)(CH3)(CH2CH3))-Ia-352 -CH2-N-- ~ -N(C(H)(CH3)2)-Ia-353 -CHz-N --D -N(CH2C(H)(CH3)2)-Ia-354 -CH2-N-- ~ -N(C(CH3)3)-Ia-355 -CH2-N~ --N-CH3 -N(CH3)-Ia-356 -CH2-N/-\ N-CH3 -N(CH2CH3)-Ia-357 -CH2-N/-\ N-CH3 -N(CH2CH2CH3)-Ia-358 -CH2-N/-\ N-CH3 -N(CH2CH2CH2CH3)-Ia-359 -CH2-N/-\ N-CH3 -N(C(H)(CH3)(CH2CH3))-Ia-360 -CH2-N/-\ N-CH3 -N(C(H)(CH3)2)-Ia-361 -CH2-N/-\ N-CH3 -N(CH2C(H)(CH3)2)-Ia-362 -CH2-N/-\ N-CH3 -N(C(CH3)3)-Ia-363 --CH2-N /CH3 N(CH3)-Ia-364 -CH2-N /cH3 -N(CH2CH3)-Ia-365 -CH2-N /cH3 N(CH2CH2CH3)-Ia-366 --CH2-N /cH3 -N(CH2CH2CH2CH3)-Ia-367 -CH2-N /cH3 -N(C(H)(CH3)(CH2CH3))-Ia-368 -CH2-N /cH3 -N(C(H)(CH3)2)-Ia-369 -CH2-N /cH3 -N(CH2C(H)(CH3)2)-Ia-370 --CH2-N /CH3 -N(C(CH3)3)-~ ~
Ia-371 -CH2-N CH3 N(CH3)->-CH3 Ia-372 -CH2 -N CH3 -N(CH2CH3)->-CH3 Ia-373 -CH2-N CH3 N(CH2CH2CH3)->-CH3 H C
Ia-374 -CH2-N CH3 -N(CH2CH2CH2CH3)->-CH3 H C
Ia-375 -CH2 -N CH3 -N(C(H)(CH3)(CH2CH3))->-CH3 H C
Ia-376 -CH2-N CH3 -N(C(H)(CH3)2)->-CH3 H C
Ia-377 -CH2-N CH3 -N(CH2C(H)(CH3)2)->-CH3 H C
Ia-378 -CH2-N CH3 -N(C(CH3)3)->-CH3 H C
Ia-379 -CH2-N CH3 N(CH3)-Ia-380 -CH2-N CH3 -N(CH2CH3)-Ia-381 -CH2-N CH3 N(CH2CH2CH3)-Ia-382 ~H2-N CH3 -N(CH2CH2CH2CH3)-Ia-383 -CH2-N CH3 -N(C(H)(CH3)(CH2CH3))-Ia-384 -CH2-N /QH3 -N(C(H)(CH3)2)-Ia-385 -CH2-N CH3 -N(CH2C(H)(CH3)2)-Ia-386 -CH2-N CH3 -N(C(CH3)3)-Ia-387 ~ H -N(CH3)-Ia-388 ~ H N~ -N(CH2CH3)--CH2 ~O
Ia-389 ~ H N(CH2CH2CH3)-Ia-390 ~N-N(CH2CH2CH2CH3)-Ia-391 N-N(C(H)(CH3)(CH2CH3))-Ia-392 H -N(C(H)(CH3)2)-Ia-393 N-N(CH2C(H)(CH3)2)-Ia-394 " H -N(C(CH3)3)-Ia-395 ~O N(CH3)-H N~/
\
CH / N
Ia-396 ~O -N(CHzCH3)-H N~/
\
CH / N
Ia-397 ~O -N(CHzCHzCH3)-H N~/
\
CH / N

Ia-398 O -N(CH2CH2CH2CH3)-N
CH/
Ia-399 (--O -N(C(H)(CH3)(CH2CH3))-~NN~
CH
Ia-400 -N(C(H)(CH3)2)-/NN~/
CH
Ia-401 ("-- O -N(CH2C(H)(CH3)2)-H N-/
CH -' N
Ia-402 ~O -N(C(CH3)3)-H
CH
Ia-403 ~N CH3 N(CH3)-H
\CH2 "I N,,/---,/

Ia-404 ~N CH3 -N(CH2CH3)-H
\CH2 "I N,,/---,/

Ia-405 ~N CH3 N(CH2CH2CH3)-H
\CH2 "I N,,/---,/

Ia-406 ~N CH3 -N(CH2CH2CH2CH3)-H
\CH2 "I N,,/---,/

Ia-407 ~N CH3 -N(C(H)(CH3)(CH2CH3))-H /NZ~N~/

Ia-408 ~N CH3 -N(C(H)(CH3)2)-H N-/
\CH2 ~N,,/---,/

Ia-409 ~ N ,CH3 -N(CH2C(H)(CH3)2)-H N-/
\CH2~

Ia-410 ~N CH3 -N(C(CH3)3)-H
\ ~NZ~N~

Ia-411 H3C N(CH3)-CH NN`CH3 Ia-412 H3C -N(CHzCH3)-CH N, Ia-413 H3C -N(CH2CH2CH3)-H

Ia-414 H3C -N(CHzCHzCHzCH3)-H
CH ~N~/N`CH3 Ia-415 H3C -N(C(H)(CH3)(CHzCH3))-CH N, Ia-416 H3~ -N(C(H)(CH3)2)-Ia-417 H3C -N(CH2C(H)(CH3)2)-H

Ia-418 H3C -N(C(CH3)3)-CH NN`CH3 Ia-419 N N(CH3)-\CH ~N
N
Ia-420 N -N(CH2CH3)-N
\CH "I N
Ia-421 N -N(CHzCHzCH3)-/
\CH N

Ia-422 ~ N -N(CH2CH2CH2CH3)-/
\CH ~N
N

Ia-423 ~N -N(C(H)(CH3)(CHzCH3))-/
N
\CH "I
Ia-424 N -N(C(H)(CH3)2)-N
\CH ~N

Ia-425 ~ N -N(CH2C(H)(CH3)2)-/
H N
\CH ~N
Ia-426 N -N(C(CH3)3)-H N
\CH "I N
Ia-427 ~ ~ N(CH3)-~
-CH2-N~/N
Ia-428 ~ ~ -N(CHzCH3)-~
-CH2-N~/N

Ia-429 ~ ~ N(CHzCHzCH3)-~
-CH2-N~/ N
Ia-430 ~ ~ -N(CHzCHzCHzCH3)-/
-CH2-N~/N
Ia-431 ~ ~ -N(C(H)(CH3)(CHzCH3))-~
-CH2-N~/N
Ia-432 ~ ~ -N(C(H)(CH3)z)-~
-CH2-N~/ N
Ia-433 ~ ~ -N(CHzC(H)(CH3)z)-~
-CH2-N~/ N
Ia-434 ~ ~ -N(C(CH3)3)-~
-CH2-N~/ N

Ia-435 -CH2iV/-\ N F -N(CH3)-~/ -Ia-436 -CH2iV /-\ N F -N(CH2CH3)-~/ -Ia-437 -CH2iV /-\ N F -N(CH2CH2CH3)-~/ -Ia-438 -CH2iV /-\ N F -N(CH2CH2CH2CH3)-~/ -Ia-439 -CH2iV/-\ N ~ F -N(C(H)(CH3)(CH2CH3))--Ia-440 -CH2iV/-\ N F -N(C(H)(CH3)2)-~/ -Ia-441 -CH2iV/-\ N F -N(CH2C(H)(CH3)2)-~/ -Ia-442 -CH2iV/-\ N F -N(C(CH3)3)-~/
Ia-443 -CH2-N ~F N(CH3)-Ia-444 -CH2-N ~F -N(CH2CH3)-Ia-445 -CH2-N ~F N(CH2CH2CH3)-Ia-446 -CH2-N ~F -N(CH2CH2CH2CH3)-Ia-447 -CH2-N ~F -N(C(H)(CH3)(CH2CH3))-Ia-448 -CH2-N 3-&F -N(C(H)(CH3)2)-Ia-449 -CH2-N ~F -N(CH2C(H)(CH3)2)-Ia-450 -CH2-N ~F -N(C(CH3)3)-Ia-451 -CH2-N o -N(CH3)-Ia-452 -CH2-N ~ -N(CH2CH3)-Ia-453 -CH2-N O N(CH2CH2CH3)-Ia-454 -CH2-N O -N(CH2CH2CH2CH3)-Ia-455 -CH2-N ~ -N(C(H)(CH3)(CH2CH3))-Ia-456 -CH2-N 0 -N(C(H)(CH3)2)-Ia-457 -CH2-N ~ -N(CH2C(H)(CH3)2)-Ia-458 -CH2-N ~ -N(C(CH3)3)-Ia-459 -CH2-N \ / \ c N(CH3)-Ia-460 -cHz-N \ / \ c -N(CH2CH3)-Ia-461 -CH2-N CI N(CH2CH2CH3)-Ia-462 -CH2-N CI -N(CH2CH2CH2CH3)-Ia-463 -CH2-10--aCI -N(C(H)(CH3)(CH2CH3))-Ia-464 -cHz_N \ / \ ci -N(C(H)(CH3)2)-Ia-465 -CH2-N 0--&cl -N(CH2C(H)(CH3)2)-Ia-466 -cHz-N \ / \ ci -N(C(CH3)3)-Ia-467 -cHz-N \ / \ N(CH3)-Ia-468 -cHz_N \ / \ -N(CH2CH3)-Ia-469 -CHz_N \ / \ N(CH2CH2CH3)-Ia-470 -CHz_N \ / \ -N(CH2CH2CH2CH3)-Ia-471 -CHz_N \ / \ -N(C(H)(CH3)(CH2CH3))-Ia-472 _cHz_N D Q -N(C(H)(CH3)2)-Ia-473 -cHz_N \ / \ -N(CH2C(H)(CH3)2)-Ia-474 -cHz_N \ / \ -N(C(CH3)3)-Ia-475 -cHz_N / \ N(CH3)-Ia-476 -cHz_N / \ -N(CH2CH3)-Ia-477 -CHz_N / \ N(CH2CH2CH3)-Ia-478 -CHz_N / \ -N(CH2CH2CH2CH3)-Ia-479 -CHz_N / \ -N(C(H)(CH3)(CH2CH3))-Ia-480 -CHz-N -N(C(H)(CH3)2)-OH
Ia-481 -cHz-N ~/~\ -N(CH2C(H)(CH3)2)-Ia-482 _cHz_N -N(C(CH3)3)-OH -Ia-483 -CH2-N NCH2CH2OP(O)(OH)2 N(CH3)-Ia-484 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(CH2CH3)-Ia-485 -CH2-N /-\ NCH2CH2OP(O)(OH)2 N(CH2CH2CH3)-Ia-486 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(CH2CH2CH2CH3)-Ia-487 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(C(H)(CH3)(CH2CH3))-Ia-488 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(C(H)(CH3)2)-Ia-489 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(CH2C(H)(CH3)2)-Ia-490 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(C(CH3)3)-Ia-491 -CH2-CH2-CH2-OP(O)(OH)2 N CH3 -Ia-492 -CH2-CH2-CH2-OP(O)(OH)2 -N CH2CH3 -Ia-493 -CH2-CH2-CH2-OP(O)(OH)2 N CH2CH2CH3 -Ia-494 -CH2-CH2-CH2-OP(O)(OH)2 -N CH2CH2CH2CH3 -Ia-495 -CH2-CH2-CH2-OP(O)(OH)2 -N C H CH3 CH2CH3 -Ia-496 -CH2-CH2-CH2-OP(O)(OH)2 -N C H CH3 2-Ia-497 -CH2-CH2-CH2-OP(O)(OH)2 -N CH2C H CH3 2-Ia-498 -CH2-CH2-CH2-OP(O)(OH)2 -N C CH3 3 -Ia-499 -CHz-CHz-CHz-OS(O)zOH N CH3 -Ia-500 -CHz-CHz-CHz-OS(O)zOH -N CH2CH3 -Ia-501 -CHz-CHz-CHz-OS(O)zOH N CH2CH2CH3 -Ia-502 -CHz-CHz-CHz-OS(O)zOH -N CH2CH2CH2CH3 -Ia-503 -CHz-CHz-CHz-OS(O)zOH -N C H CH3 CH2CH3 -Ia-504 -CHz-CHz-CHz-OS(O)zOH -N C H CH3 2-Ia-505 -CHz-CHz-CHz-OS(O)zOH -N(CH2C(H)(CH3)2)-Ia-506 -CHz-CHz-CHz-OS(O)zOH -N C CH3 3 -Ia-507 -CH2-Na -N(CH3)-OP O OH
Ia-508 -CHz-Na -N(CH2CH3)-OP O OH
Ia-509 -CH2-Na -N(CH2CH2CH3)-OP O OH
Ia-510 -CH2-NC( -N(CH2CH2CH2CH3)-OP O OH

Ia-511 -CH2-Na -N(C(H)(CH3)(CH2CH3))-OP O OH
Ia-512 -CH2-Na -N(C(H)(CH3)2)-OP O OH
Ia-513 -CH2-NC( -N(CH2C(H)(CH3)2)-OP O OH
Ia-514 -CH2-NC( -N(C(CH3)3)-OP O OH
Ia-515 -CH2-N N(CH3)-OP O OH
Ia-516 -CH2-N -N(CH2CH3)-OP O OH
Ia-517 -CHz-N N(CH2CH2CH3)-OP O OH
Ia-518 -CH2-N -N(CH2CH2CH2CH3)-OP O OH
Ia-519 -CH2-N -N(C(H)(CH3)(CH2CH3))-OP O OH
Ia-520 -CH2-N -N(C(H)(CH3)2)-OP O OH
Ia-521 -CH2-N -N(CH2C(H)(CH3)2)-OP O OH
Ia-522 -CH2-N -N(C(CH3)3)-OP O OH
Ia-523 -(CH2)io-N(CH2-CH2-O-CH3)2 N CH3 -Ia-524 -(CH2)io-N(CH2-CH2-0-CH3)2 -N CHzCH3 -Ia-525 -(CH2),o-N(CH2-CH2-0-CH3)2 N CHzCHzCH3 -Ia-526 -(CH2),o-N(CH2-CH2-O-CH3)2 -N CHzCHzCHzCH3 -Ia-527 -(CH2),o-N(CH2-CH2-O-CH3)2 -N C H CH3 CHzCH3 -Ia-528 -(CH2)io-N(CH2-CH2-O-CH3)2 -N C H CH3 z-Ia-529 -(CH2)io-N(CH2-CH2-O-CH3)2 -N CHzC H CH3 z-Ia-530 -(CH2)io-N(CH2-CH2-0-CH3)2 -N(C(CH3)3)-Ia-531 -CH2-N(CH2-CH2-O-CH3)2 N CH3 -Ia-532 -CH2-N(CH2-CH2-O-CH3)2 -N CHzCH3 -Ia-533 -CH2-N(CH2-CH2-O-CH3)2 -N(CH2CH2CH3)-Ia-534 -CH2-N(CH2-CH2-O-CH3)2 -N CHzCHzCHzCH3 -Ia-535 -CH2-N(CH2-CH2-0-CH3)2 -N C H CH3 CHzCH3 -Ia-536 -CH2-N(CH2-CH2-O-CH3)2 -N C H CH3 z-Ia-537 -CH2-N(CH2-CH2-O-CH3)2 -N CHzC H CH3 z-Ia-538 -CH2-N(CH2-CH2-O-CH3)2 -N C CH3 3 -Ia-539 -N(CH3)-N

Ia-540 -N(CH2CH3)-Ia-541 -N N(CH2CH2CH3)-Ia-542 -N(CH2CH2CH2CH3)-Ia-543 -N --~z -N(C(H)(CH3)(CH2CH3))-Ia-544 -N(C(H)(CH3)2)-~N

Ia-545 -N(CH2C(H)(CH3)2)--N

Ia-546 -N -N(C(CH3)3)-Ia-547 -N(CH3)-OH
Ia-548 -N(CH2CH3)-OH
Ia-549 N(CH2CH2CH3)-OH
Ia-550 /-Na -N(CH2CH2CH2CH3)-OH
Ia-551 /-Na -N(C(H)(CH3)(CH2CH3))-OH
Ia-552 /-Na -N(C(H)(CH3)2)-OH
Ia-553 /-Na -N(CH2C(H)(CH3)2)-OH

Ia-554 /-Na -N(C(CH3)3)-OH
Ia-555 lqlo- No N(CH3)-Ia-556 ~lqlo- No -N(CH2CH3)-Ia-557 N(CH2CH2CH3)-Ia-558 -N(CH2CH2CH2CH3)-Ia-559 -N(C(H)(CH3)(CH2CH3))-Ia-560 -N(C(H)(CH3)2)-Ia-561 -N(CH2C(H)(CH3)2)-Ia-562 -N(C(CH3)3)-Ia-563 r N -N(CH3)-N
Ia-564 v r N -N(CH2CH3)-N
Ia-565 v r N N -N(CH2CH2CH3)-Ia-566 v -N(CH2CH2CH2CH3)-~N N~

Ia-567 v -N(C(H)(CH3)(CH2CH3))-~N N~
Ia-568 v r N -N(c(H)(cH3)2)-N
Ia-569 v r N -N(cH2c(H)(cH3)2)-N
Ia-570 v r N N -N(C(CH3)3)-Ia-571 v N(CH3)-N
/-HO

Ia-572 -N(CH2CH3)-N
/-HO
Ia-573 N(CH2CH2CH3)-N
/-HO
Ia-574 -N(CH2CH2CH2CH3)-N
/-HO
Ia-575 -N(C(H)(CH3)(CH2CH3))-/-HON
Ia-576 -N(C(H)(CH3)2)-N
/-HO
Ia-577 -N(CH2C(H)(CH3)2)-N
/-HO
Ia-578 -N(C(CH3)3)-N
/-HO
Ia-579 N(CH3)-xl-N

O
OMe Ia-580 -N(CH2CH3)-N

O
O Me Ia-581 N(CH2CH2CH3)-N

O
O Me Ia-582 -N(CH2CH2CH2CH3)-N

O
O Me Ia-583 -N(C(H)(CH3)(CH2CH3))-xl-N

O
O Me Ia-584 -N(C(H)(CH3)2)-N

O
O Me Ia-585 -N(CH2C(H)(CH3)2)-N

O
O Me Ia-586 -N(C(CH3)3)-N

O
O Me Ia-587 N N(CH3)-~ /

Ia-588 N -N(CH2CH3)-~

Ia-589 N N(CH2CH2CH3)-~

Ia-590 N -N(CH2CH2CH2CH3)-~

Ia-591 N -N(C(H)(CH3)(CH2CH3))-~

Ia-592 -N(C(H)(CH3)2)-~

Ia-593 N -N(CHzC(H)(CH3)z)-~ /

Ia-594 N -N(C(CH3)3)-~

Ia-595 N(CH3)-No Ia-596 -N(CHzCH3)-No Ia-597 N(CHzCHzCH3)-No Ia-598 -N(CHzCHzCHzCH3)-No Ia-599 -N(C(H)(CH3)(CHzCH3))-No Ia-600 -N(C(H)(CH3)z)-No Ia-601 -N(CHzC(H)(CH3)z)-No Ia-602 -N(C(CH3)3)-No Ia-603 N(CH3)-I-N\-/ N--\\_,,N(CHa) Ia-604 -N(CHzCH3)-[-N~N--\_,-N(CHa) Ia-605 N(CHzCHzCH3)-[-N\__/N--\_,,-N(CHa) Ia-606 -N(CHzCHzCHzCH3)-[-N\__/N--\\,,-N(CHa) Ia-607 -N(C(H)(CH3)(CHzCH3))-[-N\__/N--\\,,-N(CHa) Ia-608 -N(C(H)(CH3)z)-[-N\__/N--\_,-N(CHa) Ia-609 -N(CHzC(H)(CH3)z)-[-N\__/N--\\,,-N(CHa) Ia-610 -N(C(CH3)3)-[-N\_/N--\,,N(CHa) Ia-611 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N CH3 -Ia-612 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N CHZCH3 -Ia-613 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N CHzCHzCH3 -Ia-614 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N CHzCHzCHzCH3 -Ia-615 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N(C(H)(CH3)(CH2CH3))-Ia-616 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C H CH3 Z-Ia-617 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N CHzC H CH3 z-Ia-618 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C CH3 3 -Ia-619 0 N(CH3)-~NC I

Ia-620 0 -N(CHzCH3)-~NC I

Ia-621 0 N(CH2CH2CH3)-~N~ I ~

Ia-622 0 -N(CH2CH2CH2CH3)-~N~ I ~

Ia-623 0 -N(C(H)(CH3)(CH2CH3))-~N~

Ia-624 0 -N(C(H)(CH3)z)-~NCI ~

Ia-625 0 -N(cH2c(H)(cH3)2) Ia-626 O -N(C(CH3)3)-~NC I ~

Ia-627 i-No,,OH N(CH3)-Ia-628 i-No .,OH -N(CH2CH3)-Ia-629 i-No .,OH N(CH2CH2CH3)-Ia-630 i-No .,OH -N(CH2CH2CH2CH3)-Ia-631 /~',OH -N(C(H)(CH3)(CHzCH3))-~N, Ia-632 v/~',OH -N(C(H)(CH3)z)-~N, Ia-633 v/~',OH -N(CHzC(H)(CH3)z)-~N, Ia-634 v/~',OH -N(C(CH3)3)-~N, Ia-635 /-No -N(CH3)-HO-I
Ia-636 /-No -N(CH2CH3)-HO
Ia-637 ~ N(CH2CH2CH3)-~
HO-.~
Ia-638 /-No -N(CH2CH2CH2CH3)-HO

Ia-639 ~ -N(C(H)(CH3)(CH2CH3))-~

HO
Ia-640 ~ -N(C(H)(CH3)2)-~

HO
Ia-641 ~ -N(CH2C(H)(CH3)2)-~

HO
Ia-642 ~ -N(C(CH3)3)-~

HO
Ia-643 ,CH3 N(CH3)-~N
~CH3 Ia-644 ,C H3 -N(CH2CH3)-/-N
/-;;~-CH3 \

Ia-645 ,CH3 N(CH2CH2CH3)-~N
~CH3 Ia-646 ,CH3 -N(CH2CH2CH2CH3)-/-N
/.7CH3 \

Ia-647 ,CH3 -N(C(H)(CH3)(CH2CH3))-/-N
/11;~-CH3 \

Ia-648 ,C H3 -N(C(H)(CH3)2)-/~,-N

\

Ia-649 ,C H3 -N(CH2C(H)(CH3)2)-~N

Ia-650 ,CH3 -N(C(CH3)3)-~N
/\-CH3 Ia-651 -N(CH3)-Ia-652 -N(CH2CH3)-Ia-653 N(CH2CH2CH3)-Ia-654 N -N(CH2CH2CH2CH3)-O
Ia-655 -N(C(H)(CH3)(CH2CH3))-Ia-656 -N(C(H)(CH3)2)-Ia-657 -N(CH2C(H)(CH3)2)-Ia-658 -N(C(CH3)3)-Ia-659 \-N oH N(CH3)-Ia-660 \-N OH -N(CH2CH3)-Ia-661 \-N OH N(CH2CH2CH3)-Ia-662 \\_N OH -N(CH2CH2CH2CH3)-Ia-663 \\_N oH -N(C(H)(CH3)(CH2CH3))-Ia-664 \-N oH -N(C(H)(CH3)2)-Ia-665 \-N oH -N(CH2C(H)(CH3)2)-Ia-666 \-N oH -N(C(CH3)3)-Ia-667 a OH N(CH3)-Ia-668 a OH -N(CH2CH3)-Ia-669 N OH N(CH2CH2CH3)-Ia-670 OH -N(CH2CH2CH2CH3)-Ia-671 a OH -N(C(H)(CH3)(CH2CH3))-Ia-672 a OH -N(C(H)(CH3)2)-Ia-673 a OH -N(CH2C(H)(CH3)2)-Ia-674 a OH -N(C(CH3)3)-Ia-675 NH -N(CH3)-Ia-676 NH -N(CH2CH3)-Ia-677 NH -N(CH2CH2CH3)-Ia-678 NH -N(CH2CH2CH2CH3)-Ia-679 NH -N(C(H)(CH3)(CH2CH3))-Ia-680 NH -N(C(H)(CH3)2)-Ia-681 NH -N(CH2C(H)(CH3)2)-Ia-682 NH -N(C(CH3)3)-Ia-683 /-NH N(CH3)-Ia-684 //-NH -N(CH2CH3)-Ia-685 /-NH N(CH2CH2CH3)-Ia-686 //-NH -N(CH2CH2CH2CH3)-Ia-687 //-NH -N(C(H)(CH3)(CH2CH3))-Ia-688 Ilo---NH -N(C(H)(CH3)2)-Ia-689 Ilo---NH -N(CH2C(H)(CH3)2)-Ia-690 //-NH -N(C(CH3)3)-Ia-691 /-NH N(CH3)-Ia-692 /cH2CH3 -N(CH2CH3)-Ia-693 /cH2CH3 N(CH2CH2CH3)-Ia-694 /cH2CH3 -N(CH2CH2CH2CH3)-Ia-695 /cH2CH3 -N(C(H)(CH3)(CH2CH3))-Ia-696 / CH2CH3 -N(C(H)(CH3)2)-Ia-697 /CH2CH3 -N(CH2C(H)(CH3)2)-Ia-698 ,CH2CH3 -N(C(CH3)3)-Ia-699 / CH2CH3 N(CH3)-Ia-700 /-NH -N(CH2CH3)-D Ia-701 /-NH N(CH2CH2CH3)-D Ia-702 /-NH -N(CH2CH2CH2CH3)-D Ia-703 /-NH -N(C(H)(CH3)(CH2CH3))-D Ia-704 /-NH
N(C(H)(CH3)2) D

Ia-705 /-NH -N(CH2C(H)(CH3)2)-D Ia-706 /-NH -N(C(CH3)3)-D Ia-707 /-NH N(CH3)-D
Ia-708 /-NH -N(CH2CH3)-D Ia-709 /-NH N(CH2CH2CH3)-D 80-Ia-710 /-NN -N(CH2CH2CH2CH3)-D Ia-711 /-NN -N(C(H)(CH3)(CH2CH3))-D Ia-712 /-NH
N(c(H)(cH3)2) D

Ia-713 /-NN -N(CH2C(H)(CH3)2)-D Ia-714 /-NN -N(C(CH3)3)-D Ia-715 ~/-\ N(CH3)--N(CHzCH3)-Ia-716 -\N% ~

Ia-717 ~/-\ S N(CH2CH2CH3)-Ia-718 -N /-\ -N(CH2CH2CH2CH3)-Ia-719 -N /-\ -N(C(H)(CH3)(CH2CH3))-Ia-720 -N /-\ -N(C(H)(CH3)2)-Ia-721 ~~ ~ -N(CHzC(H)(CH3)z)-~/Ia-722 -N /-\ -N(C(CH3)3)-Ia-723 N\~ N(CH3)-Ia-724 -N(CH2CH3)-Ia-725 N(CH2CH2CH3)-Ia-726 ~OH -N(CH2CH2CH2CH3)-Ia-727 N\~ -N(C(H)(CH3)(CH2 CH3))-Ia-728 N(C(H)(CH3)2) ~
Ia-729 -N(CH2C(H)(CH3)2)-~
Ia-730 N\~ -N(C(CH3)3)-~
Ia-731 /-NH N(CH3)-Ia-732 /-NH -N(CH2CH3)-Ia-733 /-NH N(CHzCHzCH3)-Ia-734 /-NH -N(CH2CH2CH2CH3)-Ia-735 /-NH -N(C(H)(CH3)(CH2CH3))-Ia-736 /-NH -N(C(H)(CH3)2)-Ia-737 /-NH -N(CH2C(H)(CH3)2)-Ia-738 /-NH -N(C(CH3)3)-H C
Ia-739 CH3 -N(CH3)-N

Ia-740 CH3 -N(CH2CH3)-N

Ia-741 CH3 -N(CHzCHzCH3)-~N N

Ia-742 CH3 -N(CH2CH2CH2CH3)-N

Ia-743 CH3 -N(C(H)(CH3)(CHzCH3))-~N N

Ia-744 CH3 -N(C(H)(CH3)2)-N

Ia-745 CH3 -N(CHzC(H)(CH3)z)-~N N

Ia-746 CH3 -N(C(CH3)3)-N

Ia-747 CH3 N(CH3)-~N

Ia-748 CH3 -N(CH2CH3)-~N

Ia-749 CH3 N(CH2CH2CH3)-~N
Ia-750 CH3 -N(CH2CH2CH2CH3)-N
Ia-751 CH3 -N(C(H)(CH3)(CH2CH3))-N
Ia-752 CH3 -N(C(H)(CH3)2)-~N
Ia-753 CH3 -N(CH2C(H)(CH3)2)-N
Ia-754 CH3 -N(C(CH3)3)-N

Ia-755 NH -N(CH3)-0 Ia-756 NH -N(CH2CH3)-0 OH

Ia-757 NH -N(CH2CH2CH3)-0 -84-Ia-758 ~NH -N(CH2CH2CH2CH3)-0 OH

Ia-759 NH -N(C(H)(CH3)(CH2CH3))-0 Ia-760 NH -N(C(H)(CH3)2)-0 Ia-761 NH -N(CH2C(H)(CH3)2)-0 Ia-762 NH -N(C(CH3)3)-0 Ia-763 NOH N(CH3)-Ia-764 /-N-*,-~ OH -N(CH2CH3)-Ia-765 //--N-*,-~ OH N(CH2CH2CH3)-Ia-766 //--N--~ OH -N(CH2CH2CH2CH3)-Ia-767 OH -N(C(H)(CH3)(CH2CH3))-Ia-768 NOH -N(C(H)(CH3)2) Ia-769 /-N-,-~ OH -N(CH2C(H)(CH3)2)-Ia-770 OH -N(C(CH3)3)-Ia-771 /-ND-CH3 N(CH3) Ia-772 /-NCH -N(CHzCH3)-Ia-773 /-N rCH N(CHzCHzCH3)-~--/ 3 Ia-774 /-N~ rCH -N(CHzCHzCHzCH3)-~/ 3 Ia-775 /-N--rCH3 -N(C(H)(CH3)(CH2CH3))-Ia-776 /-N D-CH3 -N(C(H)(CH3)2)-Ia-777 /-ND-CH3 -N(CH2C(H)(CH3)2)-Ia-778 /-NCH -N(C(CH3)3)-Ia-779 -CH2-NH-CH3 -N CH3 -Ia-780 -CH2-NH-CH3 N CHzCH3 -Ia-781 -CH2-NH-CH3 -N CHzCHzCH3 -Ia-782 -CH2-NH-CH3 -N CHzCHzCHzCH3 -Ia-783 -CH2-NH-CH3 -N C H CH3 CHzCH3 -Ia-784 -CH2-NH-CH3 -N C H CH3 z-Ia-785 -CH2-NH-CH3 -N CHzC H CH3 z-Ia-786 -CH2-NH-CH3 -N C CH3 3 -Ia-787 -CH2-NH-CH2-CH3 -N CH3 -Ia-788 -CH2-NH-CH2-CH3 -N(CH2CH3)-Ia-789 -CH2-NH-CH2-CH3 -N(CH2CH2CH3)-Ia-790 -CH2-NH-CH2-CH3 -N(CH2CH2CH2CH3)-Ia-791 -CH2-NH-CH2-CH3 -N(C(H)(CH3)(CH2CH3))-Ia-792 -CH2-NH-CH2-CH3 -N C H CH3 z-Ia-793 -CH2-NH-CH2-CH3 -N CHzC H CH3 z-Ia-794 -CH2-NH-CH2-CH3 -N C CH3 3 -Ia-795 -CH2-NH-CH2-CH2-CH3 -N CH3 -Ia-796 -CH2-NH-CH2-CH2-CH3 -N CHzCH3 -Ia-797 -CH2-NH-CHz-CHz-CH3 -N CHzCHzCH3 -Ia-798 -CH2-NH-CH2-CH2-CH3 -N CHzCHzCHzCH3 -Ia-799 -CH2-NH-CH2-CH2-CH3 -N C H CH3 CHzCH3 -Ia-800 -CH2-NH-CH2-CH2-CH3 -N C H CH3 z-Ia-801 -CH2-NH-CH2-CH2-CH3 -N CHzC H CH3 z-Ia-802 -CH2-NH-CH2-CH2-CH3 -N C CH3 3 -Ia-803 H3C N(CH3)-\-NCH3 Ia-804 ~~~CH -N(CHzCH3)-H
Ia-805 ~~CH N(CHzCHzCH3)-Ia-806 ~~CH -N(CHzCHzCHzCH3)-H
Ia-807 H3C\ -N(C(H)(CH3)(CHzCH3))-~NrCH3 Ia-808 H3C\ -N(C(H)(CH3)z)-~NrCH3 H
Ia-809 ~~cH -N(CHzC(H)(CH3)z)-Ia-810 ~~CH -N(C(CH3)3)-H
Ia-811 H3C -N(CH3)-H
I-N
OMe Ia-812 H3C -N(CH2CH3)-H
I-N
OMe Ia-813 H3C -N(CH2CH2CH3)-H
I-N
OMe Ia-814 H3C -N(CH2CH2CH2CH3)-H
I-N
OMe Ia-815 H3C -N(C(H)(CH3)(CH2CH3))-H
I-N
OMe Ia-816 H3C -N(C(H)(CH3)2)-H
I-N
OMe Ia-817 H3C -N(CH2C(H)(CH3)2)-H
I-N
OMe Ia-818 H3C -N(C(CH3)3)-H
I-N
OMe O
Ia-819 H3C N(CH3)-~-CH3 /-N
>--,H3 H C
Ia-820 H3C -N(CH2CH3)-~-CH3 >---CH3 H C
Ia-821 H3C N(CH2CH2CH3)-~-CH3 >---CH3 H C
Ia-822 H3C -N(CH2CH2CH2CH3)-~-CH3 >---CH3 H C

Ia-823 H3C -N(C(H)(CH3)(CH2CH3))-~-CH3 >---CH3 H C
Ia-824 H3C -N(C(H)(CH3)2)-~-CH3 >---CH3 H C
Ia-825 H3C -N(CH2C(H)(CH3)2)-~-CH3 ZI-N
>---CH3 H C
Ia-826 H3C -N(C(CH3)3)-~-CH3 ZI-N

>---CH3 H C
Ia-827 ~ H3 N N(CH3)-N
Ia-828 ~ H3 N -N(CH2CH3)-N
Ia-829 ~ H3 N N(CHzCHzCH3)-N
Ia-830 ~ H3 N -N(CH2CH2CH2CH3)-N
Ia-831 -N(C(H)(CH3)(CH2CH3))-N
Ia-832 ~ H3 N r -N(C(H)(CH3)2)-N
Ia-833 -N(CH2C(H)(CH3)2)-N
Ia-834 -N(C(CH3)3)-N
Ia-835 CH3CH22 // N -N(CH3)-N ~

Ia-836 CH3CH2i N -N(CH2CH3)-Ia-837 CH3CH2 N(CHzCHzCH3)-, N
Ia-838 CH3CH2 N -N(CH2CH2CH2CH3)-, N(C(H)(CH3)(CH2 CH3))-Ia-839 CH3CH~~-j N Ia -840 CH3CH2 -N(C(H)(CH3)2)---/ N -~
Ia-841 CH3CH2 N -N(CH2C(H)(CH3)2)-, N
Ia-842 CH3CH2 N -N(C(CH3)3)-i --/ N
Ia-843 ~ CH3 -N(CH3)--CH CH OH
Ia-844 ~ CH3 -N(CH2CH3)--CH CH OH
Ia-845 ~ CH3 -N(CH2CH2CH3)--CH CH OH
Ia-846 ~ CH3 -N(CH2CH2CH2CH3)--CH CH OH
Ia-847 CH3 -N(C(H)(CH3)(CH2CH3))-~N-CH CH OH
Ia-848 CH3 -N(C(H)(CH3)2)-~N-CH CH OH
Ia-849 CH3 -N(CH2C(H)(CH3)2)-~N-CH CH OH
Ia-850 ~ CH3 -N(C(CH3)3)--CH CH OH

Ia-851 -N(CH3)-Ia-852 -N(CH2CH3)-Ia-853 -N(CH2CH2CH3)-Ia-854 -N(CH2CH2CH2CH3)-Ia-855 -N(C(H)(CH3)(CH2CH3))-Ia-856 /-NaNo -N(C(H)(CH3)2)-Ia-857 //-NaNo -N(CH2C(H)(CH3)2)-Ia-858 //-NaNo -N(C(CH3)3)-Ia-859 N(CH3)-/-N_/N
Ia-860 -N(CH2CH3)-/-N_/0 Ia-861 N(CH2CH2CH3)-//-N~
N
Ia-862 N(CH2CH2CH2CH3)-Ia-863 -N(C(H)(CH3)(CH2CH3))-~N ~N
Ia-864 -N(C(H)(CH3)2)-~N ~N
Ia-865 -N(CH2C(H)(CH3)2)-Ia-866 N(C(CH3)3)-N
Ia-867 C N(CH3)-CDI
CH
Ia-868 C -N(CHzCH3)-N\CH~
Ia-869 C N(CHzCHzCH3)-N\~ /
CH
Ia-870 C -N(CHzCHzCHzCH3)-N\CH~
Ia-871 \-N~ -N(c(H)(cH3)(CHzCH3))-`cH
Ia-872 \-N/-N(C(H)(CH3)z)-`CH )/, Ia-873 \-N~ -N(cHzc(H)(CH3)z)-`CH /
Ia-874 \-N~ -N(C(CH3)3)-\CH3 Ia-875 N(CH3)-,/-NH N

Ia-876 -N(CH2CH3)-,/-NH N

Ia-877 N(CH2CH2CH3)-,/~---NH N

Ia-878 -N(CH2CH2CH2CH3)-//---NH N

Ia-879 -N(C(H)(CH3)(CH2CH3))-//---NH N

Ia-880 -N(C(H)(CH3)2)-//---NH N

Ia-881 -N(CH2C(H)(CH3)2)-//-NH N

Ia-882 -N(C(CH3)3)-,/~---NH N

Ia-883 ~ H3 -N(CH3)-NH N

Ia-884 ~ H3 -N(CH2CH3)-NH N

Ia-885 ~ H3 -N(CH2CH2CH3)-NH N

Ia-886 ~ H3 -N(CH2CH2CH2CH3)-NH N

Ia-887 ~ H3 -N(C(H)(CH3)(CH2CH3))-NH N

Ia-888 ~ H3 -N(C(H)(CH3)2)-NH N

Ia-889 ~ H3 -N(CH2C(H)(CH3)2)-NH N

Ia-890 ~ H3 -N(C(CH3)3)-NH N

Ia-891 -N(CH3)-/-N\ N H

Ia-892 -N(CH2CH3)-/-N\ /N H

Ia-893 N(CH2CH2CH3)-/-N\ N H
Ia-894 -N(CH2CH2CH2CH3)-/-N\ N H

Ia-895 -N(C(H)(CH3)(CH2CH3))-/-N\ N H
Ia-896 -N(C(H)(CH3)2)-/-N\ N H
Ia-897 -N(CH2C(H)(CH3)2)-/-N\ /N H

Ia-898 -N(C(CH3)3)-/-N\ N H
Ia-899 CH3 -N(CH3)-Ia-900 ~N~\NCH3 -N(CH2CH3)-Ia-901 CH3 N(CH2CH2CH3)-~N\

Ia-902 CH3 -N(CH2CH2CH2CH3)-Ia-903 ~N~\NCH3 -N(C(H)(CH3)(CH2CH3))-Ia-904 ~N~\NCH3 -N(C(H)(CH3)2)-Ia-905 CH3 -N(CH2C(H)(CH3)2)-~N\

Ia-906 CH3 -N(C(CH3)3)-Ia-907 Z/-N H -N(CH3)-Ia-908 //-N H -N(CH2CH3)-Ia-909 -N(CH2CH2CH3)-Ia-910 //-N H -N(CH2CH2CH2CH3)-Ia-911 /,--N V H -N(C(H)(CH3)(CH2CH3))-Ia-912 //-N ~ -N(C(H)(CH3)2)-Ia-913 //-N ~ -N(CH2C(H)(CH3)2)-Ia-914 /,,--N ~ -N(C(CH3)3)-Ia-915 \-v ~\ -N(CH3)-oH
Ia-916 \-\ -N(CHzCH3)-~~ ~~ OH

Ia-917 \-N /-\ -N(CH2CH2CH3)-N ~~ OH

Ia-918 \-v ~\ -N(CHzCHzCHzCH3)-oH
Ia-919 \-\ -N(C(H)(CH3)(CHzCH3))-~~ ~~ OH

Ia-920 -N(C(H)(CH3)2)-~~ ~/OH
Ia-921 \-v ~\ -N(CHzC(H)(CH3)z)-oH
Ia-922 \-\ -N(C(CH3)3)-~~ ~~/OH

Ia-923 ~ \ N(CH3)-~j ~~ioH3 Ia-924 ~ \ -N(CHzCH3)-~j ~~ioH3 Ia-925 N - \ N N(CHzCHzCH3)-~ ~~CH3 Ia-926 ~ \ -N(CHzCHzCHzCH3)-~j ~ ~i~"3 Ia-927 //---N -N(C(H)(CH3)(CH2CH3))-N ~CH3 Ia-928 //---N -N(C(H)(CH3)2)-N ~CH3 Ia-929 //-N \ N ~CH3 -N(CH2C(H)(CH3)2)-~ ~~

Ia-930 ~ \ -N(C(CH3)3)-~j ~~i~"3 Ia-931 -N(CH3)-\-N N

Ia-932 -N(CH2CH3)-\-N/--N N

Ia-933 -N(CH2CH2CH3)-\-N/--N N

Ia-934 -N(CH2CH2CH2CH3)-\-N N

Ia-935 -N(C(H)(CH3)(CH2CH3))-\-N N
v Ia-936 -N(C(H)(CH3)2)-\-N N
v Ia-937 -N(CH2C(H)(CH3)2)-\-N/--N N

Ia-938 -N(C(CH3)3)-\-N/,-N N

Ia-939 \-ND-OEt N(CH3)-Ia-940 \-ND-OEt -N(CH2CH3)-Ia-941 \-NaOEt N(CH2CH2CH3)-Ia-942 \\-NaOEt -N(CH2CH2CH2CH3)-Ia-943 \\-NaOEt -N(C(H)(CH3)(CH2CH3))-Ia-944 \\-NaOEt -N(C(H)(CH3)2)-Ia-945 \-NaOEt -N(CH2C(H)(CH3)2)-Ia-946 \-ND-OEt -N(C(CH3)3)-Ia-947 N(CH3)-/- Q~ H
N -N(CH2CH3)-Ia-948 /-OH
Ia-949 N(CH2CH2CH3)-/,- Q~ H
Ia-950 -N(CH2CH2CH2CH3)-/- Q~ H
N -N(C(H)(CH3)(CH2CH3))-Ia-951 /-OH
Ia-952 -N(C(H)(CH3)2)-/,- Q~ H
Ia-953 -N(CH2C(H)(CH3)2)-/,- Q~ H
Ia-954 -N(C(CH3)3)-/- Q~ H
Ia-955 - N / O N(CH3) OEt Ia-956 - N/O -N(CH2CH3)-OEt Ia-957 O -N(CH2CH2CH3) N N~
OEt Ia-958 O -N(CHzCHzCHzCH3)-N
OEt Ia-959 N(C(H)(CH3)(CH2CH3))-OEt Ia-960 0 N(C(H)(CH3)2) OFt Ia-961 -N N/0 -N(CH2C(H)(CH3)2)-OEt Ia-962 - N / vo N(C(CH3)3) OEt Ia-963 -CHz-N CHzCH3 CH3 N CH3 -Ia-964 -CHz-N CHzCH3 CH3 N CHzCH3 -Ia-965 -CHz-N CHzCH3 CH3 N CHzCHzCH3 -Ia-966 -CHz-N CHzCH3 CH3 -N CHzCHzCHzCH3 -Ia-967 -CHz-N CHzCH3 CH3 -N C H CH3 CHzCH3 -Ia-968 -CHz-N CHzCH3 CH3 -N C H CH3 z-Ia-969 -CHz-N CHzCH3 CH3 N CHzC H CH3 z-Ia-970 -CHz-N CHzCH3 CH3 -N C CH3 3-Ia-971 -CHz-N CHzCHzCH3 CH3 N CH3 -Ia-972 -CHz-N CHzCHzCH3 CH3 -N CHzCH3 -Ia-973 -CHz-N CHzCHzCH3 CH3 N CHzCHzCH3 -Ia-974 -CHz-N CHzCHzCH3 CH3 -N CHzCHzCHzCH3 -Ia-975 -CHz-N CHzCHzCH3 CH3 -N C H CH3 CHzCH3 -Ia-976 -CHz-N CHzCHzCH3 CH3 -N C H CH3 z-Ia-977 -CHz-N CHzCHzCH3 CH3 -N CHzC H CH3 z-Ia-978 -CH2-N(CH2CH2CH3)(CH3) -N(C(CH3)3)-Ia-979 -CH2-N(CH2CH2CH2CH3)(CH3) N(CH3)-Ia-980 -CH2-N(CH2CH2CH2CH3)(CH3) N(CH2CH3)-Ia-981 -CH2-N(CH2CH2CH2CH3)(CH3) N(CH2CH2CH3)-Ia-982 -CH2-N(CH2CH2CH2CH3)(CH3) -N CHzCHzCHzCH3 -Ia-983 -CH2-N(CH2CH2CH2CH3)(CH3) -N C H CH3 CHzCH3 -Ia-984 -CH2-N(CH2CH2CH2CH3)(CH3) -N C H CH3 z-Ia-985 -CH2-N(CH2CH2CH2CH3)(CH3) N CHzC H CH3 z-Ia-986 -CH2-N(CH2CH2CH2CH3)(CH3) -N C CH3 3 -Ia-987 -CH2-NH-CH2CH2CH2CH3 N CH3 -Ia-988 -CH2-NH-CH2CH2CH2CH3 -N CHzCH3 -Ia-989 -CH2-NH-CH2CH2CH2CH3 N CHzCHzCH3 -Ia-990 -CH2-NH-CH2CH2CH2CH3 -N CHzCHzCHzCH3 -Ia-991 -CH2-NH-CH2CH2CH2CH3 -N C H CH3 CHzCH3 -Ia-992 -CH2-NH-CH2CH2CH2CH3 -N C H CH3 z-Ia-993 -CH2-NH-CH2CH2CH2CH3 -N CHzC H CH3 z-Ia-994 -CH2-NH-CH2CH2CH2CH3 -N C CH3 3 -Ia-995 -CH2-NH-CH2CH2-O-CH3 N CH3 -Ia-996 -CH2-NH-CH2CH2-O-CH3 -N CHzCH3 -Ia-997 -CH2-NH-CH2CH2-O-CH3 N(CH2CH2CH3)-Ia-998 -CH2-NH-CH2CH2-O-CH3 -N(CH2CH2CH2CH3)-Ia-999 -CH2-NH-CH2CH2-O-CH3 -N(C(H)(CH3)(CH2CH3))-Ia-1000 -CH2-NH-CH2CH2-O-CH3 -N C H CH3 z-Ia-1001 -CH2-NH-CH2CH2-O-CH3 -N(CH2C(H)(CH3)2)-Ia-1002 -CH2-NH-CH2CH2-O-CH3 -N C CH3 3 -Ia-1003 /-N N--\,OMe N(CH3)-Ia-1004 /-N /-\ N--\,OMe N(CH2CH3)-Ia-1005 /-N /-\ N--\,OMe N(CH2CH2CH3)-Ia-1006 -N --\ N -N(CHzCHzCHzCH3)-~~OMe Ia-1007 /-N N--,\,OMe -N(C(H)(CH3)(CH2CH3))-Ia-1008 /-N N-NOMe -N(C(H)(CH3)2)-Ia-1009 /-N N--\,OMe N(CH2C(H)(CH3)2)-Ia-1010 /-N/-\ N--\,OMe -N(C(CH3)3)-Ia-1011 N(CH3)-N OPO OH
Ia-1012 N(CH2CH3)-N OPO OH
Ia-1013 N(CH2CH2CH3)-N OPO OH
Ia-1014 N -N(CH2CH2CH2CH3)-OPO OH
Ia-1015 N -N(C(H)(CH3)(CH2CH3))-OPO OH
Ia-1016 -N(C(H)(CH3)2)-N OPO OH
Ia-1017 N(CH2C(H)(CH3)2)-N OPO OH
Ia-1018 -N(C(CH3)3)-N OPO OH
Ia-1019 N(CH3)-OPO(OH)Z
Ia-1020 N(CHzCH3)-OPO(OH)Z

Ia-1021 N(CHzCHzCH3)-OPO(OH)Z
Ia-1022 -N(CHzCHzCHzCH3)-OPO(OH)Z
Ia-1023 -N(C(H)(CH3)(CHzCH3))-OPO(OH)Z
Ia-1024 -N(C(H)(CH3)z)-OPO(OH)Z
Ia-i025 N N(CHzC(H)(CH3)z)-OPO(OH)Z
Ia-i026 N -N(C(CH3)3)-OPO(OH)Z
Ia-1027 N OPO(OH)z N(CH3)-Ia-1028 N OPO(OH)z N(CH2CH3)-Ia-1029 N OPO(OH)z N(CH2CH2CH3)-Ia-1030 N OPO(OH)z -N(CH2CH2CH2CH3)-Ia-1031 N OPO(OH)z -N(C(H)(CH3)(CH2CH3))-Ia-1032 N OPO(OH)z -N(C(H)(CH3)2)-Ia-1033 N OPO(OH)z N(CH2C(H)(CH3)2)-Ia-1034 N OPO(OH)z -N(C(CH3)3)-Ia-1035 /--NCH3 N(CH3)-OPO OH
Ia-1036 CH3 N(CH2CH3)-OPO OH

Ia-1037 CH3 N(CH2CH2CH3)-OPO OH
Ia-1038 /--NCH3 -N(CH2CH2CH2CH3)-OPO OH
Ia-1039 /--NCH3 -N(C(H)(CH3)(CH2CH3))-OPO OH
Ia-1040 NCH3 -N(C(H)(CH3)2)-OPO OH
Ia-1041 N/CH3 N(CH2C(H)(CH3)2)-OPO OH
Ia-1042 NCH3 -N(C(CH3)3)-OPO OH
Ia-1043 N(CH3)-OPO OH
Ia-1044 N(CH2CH3)-OPO OH
Ia-1045 N(CH2CH2CH3)-OPO OH
Ia-1046 -N(CH2CH2CH2CH3)-OPO OH

Ia-1047 -N(C(H)(CH3)(CH2CH3))-OPO OH
Ia-1048 -N(C(H)(CH3)2)-OPO OH
Ia-1049 N(CH2C(H)(CH3)2)-OPO OH
Ia-1050 -N(C(CH3)3)-/-N

OPO OH
Ia-1051 \\--H -N(CH3)-N

OPO OH
Ia-1052 \\__H N(CH2CH3)-N

OPO OH
Ia-1053 N(CH2CH2CH3)-N

OPO OH
Ia-1054 \\--H -N(CH2CH2CH2CH3)-N

OPO OH
Ia-1055 H -N(C(H)(CH3)(CH2CH3))-OPO OH

Ia-1056 -N(C(H)(CH3)2)-OPO OH
Ia-1057 \\__~ N(CHzC(H)(CH3)z)-OPO OH
Ia-1058 -N(C(CH3)3)-N

)aOPO(OH), Compound n - Rl X
Ia-al 1 -(CHz)ri N(CH3)z -CH(OH)-Ia-a2 2 -(CHz)ri N(CH3)z -CH(OH)-Ia-a3 3 -(CHz)ri N(CH3)z -CH(OH)-Ia-a4 4 -(CHz)ri N(CH3)z -CH(OH)-Ia-a5 5 -(CHz)ri N(CH3)z -CH(OH)-Ia-a6 6 -(CHz)ri N(CH3)z -CH(OH)-Ia-a7 1 CHz ri N CH3 z N C O N H-CHz-CHz-OH -Ia-a8 2 CHz ri N CH3 z N C O N H-CHz-CHz-OH -Ia-a9 3 CHz ri N CH3 z N C O N H-CHz-CHz-OH -Ia-a10 4 CHz ri N CH3 z N C O N H-CHz-CHz-OH -Ia-all 5 CHz ri N CH3 z N C O N H-CHz-CHz-OH -Ia-a12 6 CHz ri N CH3 z N C O N H-CHz-CHz-OH -Ia-a13 1 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ia-a14 2 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ia-a15 3 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ia-a16 4 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ia-a17 5 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ia-a18 6 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ia-a19 1 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ia-a20 2 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ia-a21 3 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ia-a22 4 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ia-a23 5 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ia-a24 6 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a25 1 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ia-a26 2 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ia-a27 3 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ia-a28 4 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ia-a29 5 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ia-a30 6 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ia-a31 1 CHz ri N CH3 z -N CHz-CHz-OH -Ia-a32 2 CHz ri N CH3 z -N CHz-CHz-OH -Ia-a33 3 CHz ri N CH3 z -N CHz-CHz-OH -Ia-a34 4 CHz ri N CH3 z -N CHz-CHz-OH -Ia-a35 5 CHz ri N CH3 z -N CHz-CHz-OH -Ia-a36 6 CHz ri N CH3 z -N CHz-CHz-OH -Ia-a37 1 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ia-a38 2 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ia-a39 3 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ia-a40 4 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ia-a41 5 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ia-a42 6 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ia-a43 1 CHz ri N CH3 z N CHz-CHz-OCH3 -Ia-a44 2 CHz ri N CH3 z N CHz-CHz-OCH3 -Ia-a45 3 CHz ri N CH3 z N CHz-CHz-OCH3 -Ia-a46 4 CHz ri N CH3 z N CHz-CHz-OCH3 -Ia-a47 5 CHz ri N CH3 z N CHz-CHz-OCH3 -Ia-a48 6 CHz ri N CH3 z N CHz-CHz-OCH3 -Ia-a49 1 -CH(OH)--(CH2)n N 0 Ia-a50 2 -CH(OH)--(CH2)n N 0 Ia-a51 3 -CH(OH)--(CH2)n N 0 Ia-a52 4 -CH(OH)--(CH2)n N 0 Ia-a53 5 -CH(OH)--(CH2)n N 0 Ia-a54 6 -CH(OH)--(CH2)n N 0 Ia-a55 1 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ia-a56 2 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ia-a57 3 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ia-a58 4 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ia-a59 5 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ia-a60 6 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ia-a61 1 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ia-a62 2 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ia-a63 3 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ia-a64 4 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ia-a65 5 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ia-a66 6 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ia-a67 1 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ia-a68 2 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ia-a69 3 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ia-a70 4 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ia-a71 5 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ia-a72 6 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ia-a73 1 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ia-a74 2 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ia-a75 3 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ia-a76 4 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ia-a77 5 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ia-a78 6 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ia-a79 1 N(CH2-CH2-OH)--(CH2)n N 0 Ia-a80 2 N(CH2-CH2-OH)--(CH2)n N 0 Ia-a81 3 N(CH2-CH2-OH)--(CH2)n N 0 Ia-a82 4 N(CH2-CH2-OH)--(CH2)n N 0 Ia-a83 5 N(CH2-CH2-OH)--(CH2)n N 0 Ia-a84 6 N(CH2-CH2-OH)--(CH2)n N 0 Ia-a85 1 -N(CH2-CH2-F)--(CH2)n N 0 Ia-a86 2 -N(CH2-CH2-F)--(CH2)n N 0 Ia-a87 3 -N(CH2-CH2-F)--(CH2)n N 0 Ia-a88 4 -N(CH2-CH2-F)--(CH2)n N 0 Ia-a89 5 -N(CH2-CH2-F)--(CH2)n N 0 Ia-a90 6 -N(CH2-CH2-F)--(CH2)n N 0 Ia-a91 1 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ia-a92 2 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ia-a93 3 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ia-a94 4 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ia-a95 5 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ia-a96 6 -N(CH2-CH2-OCH3)--(CH2)n N 0 Compound m - Rl X
Ia-a146 2 -O-(CHz)m N(CH3)z -CH(OH)-Ia-a147 3 -O-(CHz)m N(CH3)z -CH(OH)-Ia-a148 4 -O-(CHz)m N(CH3)z -CH(OH)-Ia-a149 5 -O-(CHz)m N(CH3)z -CH(OH)-Ia-a150 6 -O-(CHz)m N(CH3)z -CH(OH)-Ia-a151 2 -O-(CHz)m N(CH3)z N(C(O)N(H)-CH2-CH2-OH)-Ia-a152 3 -O CHz õ-N CH3 z N C O N H-CHz-CHz-OH -Ia-a153 4 -O CHz õ-N CH3 z N C O N H-CHz-CHz-OH -Ia-a154 5 -O CHz õ-N CH3 z N C O N H-CHz-CHz-OH -Ia-a155 6 -O CHz õ-N CH3 z N C O N H-CHz-CHz-OH -Ia-a156 2 -O-(CHz)m N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ia-a157 3 -O-(CHz)m N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ia-a158 4 -O-(CHz)m N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ia-a159 5 -O-(CHz)m N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ia-a160 6 -O-(CHz)m N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ia-a161 2 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ia-a162 3 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ia-a163 4 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ia-a164 5 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ia-a165 6 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ia-a166 2 -O-(CHz)m N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ia-a167 3 -O-(CHz)m N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ia-a168 4 -O-(CHz)m N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ia-a169 5 -O-(CHz)m N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ia-a170 6 -O-(CHz)m N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ia-a171 2 -O-(CHz)m N(CH3)z -N(CH2-CH2-OH)-Ia-a172 3 -O CHz m N CH3 z -N CHz-CHz-OH -Ia-a173 4 -O CHz õ-N CH3 z -N CHz-CHz-OH -Ia-a174 5 -O CHz õ-N CH3 z -N CHz-CHz-OH -Ia-a175 6 -O-(CHz)m N(CH3)z -N(CH2-CH2-OH)-Ia-a176 2 -O-(CHz)m N(CH3)z -N(CH2-CH2-F)-Ia-a178 3 -O-(CHz)m N(CH3)z -N(CH2-CH2-F)-Ia-a179 4 -O-(CHz)m N(CH3)z -N(CH2-CH2-F)-Ia-a180 5 -O-(CHz)m N(CH3)z -N(CH2-CH2-F)-Ia-a181 6 -O-(CHz)m N(CH3)z -N(CH2-CH2-F)-Ia-a182 2 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ia-a183 3 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ia-a184 4 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ia-a185 5 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ia-a186 6 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ia-a187 2 -CH(OH)--o (cH2)m N 0 Ia-a188 3 ~\ -CH(OH)--o (cH2)m N~

Ia-a189 4 -CH(OH)--o (cH2)m N j Ia-a190 5 -CH(OH)--o (cH2)m N 0 Ia-a191 6 -CH(OH)--o (cH2)m N %

Ia-a192 2 N(C(O)N(H)-CHz-CHz-OH)--o (cH2)m N 0 Ia-a193 3 N(C(O)N(H)-CHz-CHz-OH)--o (cH2)m N 0 Ia-a194 4 N(C(O)N(H)-CHz-CHz-OH)--o (cH2)m N 0 Ia-a195 5 N(C(O)N(H)-CHz-CHz-OH)--o (cH2)m N 0 Ia-a196 6 -o (cH2) \ N(C(O)N(H)-CHz-CHz-OH)-m~% ~- 108 -Ia-a197 2 N(C(O)N(H)-CH2-CH2-F)--0 (CH2)m N j Ia-a198 3 N(C(O)N(H)-CH2-CH2-F)--0 (CH2)m N 0 Ia-a199 4 N(C(O)N(H)-CH2-CH2-F)--0 (CH2)m N %

Ia-a200 5 N(C(O)N(H)-CH2-CH2-F)--0 (CH2)m N j Ia-a201 6 N(C(O)N(H)-CH2-CH2-F)--0 (CH2)m N 0 Ia-a202 2 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N %

Ia-a203 3 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N 0 Ia-a204 4 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N 0 Ia-a205 5 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N j Ia-a206 6 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N 0 Ia-a207 2 -0 (CH \ N(C(O)N(H)-CHz-CHz-CF3)-2)m~%

Ia-a208 3 N(C(O)N(H)-CH2-CH2-CF3)--0 (CH2)m N %

Ia-a209 4 N(C(O)N(H)-CH2-CH2-CF3)--0 (CH2)m N j Ia-a210 5 -0 (CH2)~\ N(C(O)N(H)-CHz-CHz-CF3)-m~~

Ia-a211 6 N(C(O)N(H)-CH2-CH2-CF3)--0 (CH2)m N j Ia-a212 2 N(CH2-CH2-OH)--0 (CH2)m N 0 Ia-a213 3 N(CH2-CH2-OH)--0 (CH2)m N 0 Ia-a214 4 N(CH2-CH2-OH)--0 (CH2)m N 0 Ia-a215 5 N(CH2-CH2-OH)--0 (CH2)m N 0 Ia-a216 6 N(CH2-CH2-OH)--0 (CH2)m N 0 Ia-a217 2 -N(CH2-CH2-F)--0 (CH2)m N 0 Ia-a218 3 -N(CH2-CH2-F)--0 (CH2)m N 0 Ia-a219 4 -N(CH2-CH2-F)--0 (CH2)m N 0 Ia-a220 5 -N(CH2-CH2-F)--0 (CH2)m N 0 Ia-a221 6 -N(CH2-CH2-F)--0 (CH2)m N 0 Ia-a222 2 -0 (CH2) \ -N(CHz-CHz-OCH3)-m~% ~

Ia-a223 3 -N(CH2-CH2-OCH3)--0 (CH2)m N 0 Ia-a224 4 -N(CH2-CH2-OCH3)--0 (CH2)m N j Ia-a225 5 -0 (CH \ -N(CHz-CHz-OCH3)-2)m~~ ~

Ia-a226 6 -N(CH2-CH2-OCH3)--0 (CH2)m N j Compound - Rl X
Ia-a267 -CH2-N(CH2-CH3)2 -CH(OH)-Ia-a268 -CH2-N(CH2-CH3)2 N(C(O)N(H)-CH2-CH2-OH)-Ia-a269 -CH2-N(CH2-CH3)2 -N(C(O)N(H)-CH2-CH2-F)-Ia-a270 -CH2-N(CH2-CH3)2 -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a271 -CH2-N(CH2-CH3)2 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a275 -CHz-N CHz-CHz-CH3 z -CH OH -Ia-a276 -CHz-N CHz-CHz-CH3 z N C O N H-CHz-CHz-OH -Ia-a277 -CHz-N CHz-CHz-CH3 z -N C O N H-CHz-CHz-F -Ia-a278 -CHz-N CHz-CHz-CH3 z -N C O N H-CHz-CHz-OCH3 -Ia-a279 -CHz-N CHz-CHz-CH3 z N C O N H-CHz-CHz-CF3 -Ia-a283 -CHz-N CHz-CHzOH z -CH OH -Ia-a284 -CHz-N CHz-CHzOH z N C O N H-CHz-CHz-OH -Ia-a285 -CHz-N CHz-CHzOH z -N C O N H-CHz-CHz-F -Ia-a286 -CHz-N CHz-CHzOH z -N C O N H-CHz-CHz-OCH3 -Ia-a291 -CHz-N(CHz-CHz-N(CH3)1)1 -CH OH -Ia-a292 -CHz-N(CHz-CHz-N(CH3)1)1 N C O N H-CHz-CHz-OH -Ia-a293 -CHz-N(CHz-CHz-N(CH3)1)1 -N C O N H-CHz-CHz-F -Ia-a294 -CHz-N(CHz-CHz-N(CH3)1)1 -N C O N H-CHz-CHz-OCH3 -Ia-a295 -CHz-N(CHz-CHz-N(CH3)1)1 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a296 -CHz-N(CHz-CHz-N(CH3)1)1 N C O N H-CHz-CHz-CF3 -Ia-a297 -CHz-N(CHz-CHz-N(CH3)1)1 -N C O N H-CHz-CF3 -Ia-a298 -CHz-N(CHz-CHz-N(CH3)1)1 -N C O N H CHz 3-OH -Ia-a299 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -CH OH -Ia-a300 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N C O N H-CHz-CHz-OH -Ia-a301 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C O N H-CHz-CHz-F -Ia-a302 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C O N H-CHz-CHz-OCH3 -Ia-a303 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N C O N H-CHz-CHz-CF3 -Ia-a304 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N C O N H-CHz-CHz-CF3 -Ia-a305 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C O N H-CHz-CF3 -Ia-a306 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C O N H CHz 3-OH -Ia-a307 -CH2-N,-] -CH(OH)-Ia-a308 -CH2-N7 -] N(C(O)N(H)-CH2-CH2-OH)-Ia-a309 -CH2-N- -N(C(O)N(H)-CH2-CH2-F)-Ia-a310 -CH2-N,-] -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a311 -CH2-Nq N(C(O)N(H)-CH2-CH2-CF3)-Ia-a312 -CH2-Nq N(C(O)N(H)-CH2-CH2-CF3)-Ia-a313 -CH2-Nq -N(C(O)N(H)-CH2-CF3)-Ia-a314 -CH2-Nq -N(C(O)N(H)-(CH2)3-OH)-Ia-a315 -CH2-Nc> -CH(OH)-Ia-a316 -CH2-N~> N(C(O)N(H)-CH2-CH2-OH)-Ia-a317 -CH2-N~> -N(C(O)N(H)-CH2-CH2-F)-Ia-a318 -CH2-Nc> -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a319 -CH2-Nc> N(C(O)N(H)-CH2-CH2-CF3)-Ia-a320 -CH2-<> N(C(O)N(H)-CH2-CH2-CF3)-Ia-a321 -CH2-<> -N(C(O)N(H)-CH2-CF3)-Ia-a322 -CH2-N~> -N(C(O)N(H)-(CH2)3-OH)-Ia-a323 -CHz-NC) -CH(OH)-Ia-a324 -CHz-NC) N(C(O)N(H)-CH2-CH2-OH)-Ia-a325 -CH2-No -N(C(O)N(H)-CH2-CH2-F)-Ia-a326 -CH2-No -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a327 -CH2-No N(C(O)N(H)-CH2-CH2-CF3)-Ia-a328 -CH2-No N(C(O)N(H)-CH2-CH2-CF3)-Ia-a329 -CH2-No -N(C(O)N(H)-CH2-CF3)-Ia-a330 -CH2-No -N(C(O)N(H)-(CH2)3-OH)-Ia-a331 -CHz-Na -CH(OH)-Ia-a332 -CHz-NaN(C(O)N(H)-CHz-CHz-OH)-OH
Ia-a333 -CH2-Na -N(C(O)N(H)-CH2-CH2-F)-Ia-a334 -CH2-Na -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a335 -CH2-Na N(C(O)N(H)-CH2-CH2-CF3)-Ia-a336 -CH2-Na N(C(O)N(H)-CH2-CH2-CF3)-Ia-a337 -CH2- -N(C(O)N(H)-CH2-CF3)-Ia-a338 -CH2-N~ -N(C(O)N(H)-(CH2)3-OH)-Ia-a339 -CHz_N -CH(OH)-Ia-a340 -CHz-N N(C(O)N(H)-CH2-CH2-OH)-Ia-a341 -CHz-N -N(C(O)N(H)-CH2-CH2-F)-Ia-a342 -CHz-N -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a343 -CHz-N N(C(O)N(H)-CH2-CH2-CF3)-Ia-a344 -CHz_N N(C(O)N(H)-CH2-CH2-CF3)-Ia-a345 -CHz_N -N(C(O)N(H)-CH2-CF3)-Ia-a346 -CHz_N -N(C(O)N(H)-(CH2)3-OH)-Ia-a347 -CH2-N_ ) -CH(OH)-Ia-a348 -CH2-N-- ~ N(C(O)N(H)-CHz-CHz-OH)-Ia-a349 -CHz-N --D -N(C(O)N(H)-CH2-CH2-F)-Ia-a350 -CHz-ND -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a351 -CHz-ND N(C(O)N(H)-CH2-CH2-CF3)-Ia-a352 -CH2-N-- ~ N(C(O)N(H)-CHz-CHz-CF3)-Ia-a353 -CH2-N --~ -N(C(O)N(H)-CH2-CF3)-Ia-a354 -CHz-N --D -- -N(C(O)N(H)-(CH2)3-OH)-Ia-a355 -CH2-N/-\ N-CH3 -CH(OH)-Ia-a356 -CH2-N/-\ N-CH3 N(C(O)N(H)-CH2-CH2-OH)-Ia-a357 -CH2-N/-\ N-CH3 -N(C(O)N(H)-CH2-CH2-F)-Ia-a358 -CH2-N/-\ N-CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a359 -CH2-N/-\ N-CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a360 -CH2-N/-\ N-CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a361 -CH2-N/-\ N-CH3 -N(C(O)N(H)-CH2-CF3)-Ia-a362 -CH2-N/-\ N-CH3 -N(C(O)N(H)-(CH2)3-OH)-Ia-a363 -CH2-N /CH3 -CH(OH)-Ia-a364 -CH2-N /cH3 N(C(O)N(H)-CHz-CHz-OH)-Ia-a365 -CH2-N /cH3 -N(C(O)N(H)-CHz-CHz-F)-Ia-a366 -CH2-N /cH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a367 --CH2-N /cH3 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a368 -CH2-N /cH3 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a369 -CH2-N /cH3 -N(C(O)N(H)-CH2-CF3)-Ia-a370 --CH2-N /cH3 -N(C(O)N(H)-(CH2)3-OH)-Ia-a371 -CH2-N CH3 -CH(OH)->-CH3 H C
Ia-a372 -CH2-N CH3 N(C(O)N(H)-CHz-CHz-OH)->-CH3 H C
Ia-a373 -CH2-N CH3 -N(C(O)N(H)-CHz-CHz-F)->-CH3 Ia-a374 -CH2-N CH3 -N(C(O)N(H)-CH2-CH2-OCH3)->-CH3 H C

Ia-a375 -CH2 -N CH3 N(C(O)N(H)-CH2-CH2-CF3)->-CH3 Ia-a376 -CH2 -N CH3 N(C(O)N(H)-CH2-CH2-CF3)->-CH3 Ia-a377 -CH2 -N CH3 -N(C(O)N(H)-CH2-CF3)->-CH3 H C
Ia-a378 -CH2-N CH3 -N(C(O)N(H)-(CH2)3-OH)->-CH3 Ia-a379 -CH2-N CH3 -CH(OH)-Ia-a380 -CH2-N CH3 N(C(O)N(H)-CHz-CHz-OH)-Ia-a381 -CH2-N /QH3 -N(C(O)N(H)-CHz-CHz-F)-Ia-a382 -CH2-N CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a383 -CH2-N CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a384 -CH2-N CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a385 -CH2-N CH3 -N(C(O)N(H)-CH2-CF3)-Ia-a386 -CH2-N /QH3 -N(C(O)N(H)-(CH2)3-OH)-Ia-a387 ~N~~N~ -CH(OH)-Ia-a388 NN(C(O)N(H)-CH2-CH2-OH)-Ia-a389 N-N(C(O)N(H)-CH2-CH2-F)-Ia-a390 "N-N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a391 "NN(C(O)N(H)-CH2-CH2-CF3)-Ia-a392 -'NN(C(O)N(H)-CH2-CH2-CF3)-Ia-a393 N-N(C(O)N(H)-CH2-CF3)-Ia-a394 NN~ -N(C(O)N(H)-(CH2)3-OH)--CH2 ~O
Ia-a395 ~O -CH(OH)-H N~/
\
CH / N
Ia-a396 N(C(O)N(H)-CHz-CHz-OH)-/N-/
CH
Ia-a397 (--O -N(C(O)N(H)-CH2-CH2-F)-H
CH
Ia-a398 -N(C(O)N(H)-CH2-CH2-OCH3)-/NN~/
CH
Ia-a399 O -N(C(O)N(H)-CH2-CH2-CF3)-H N-/
CH -' N
Ia-a400 O N(C(O)N(H)-CH2-CH2-CF3)-\ N-/
CH
Ia-a401 CO -N(C(O)N(H)-CH2-CF3)-H
CH
Ia-a402 ("--O -N(C(O)N(H)-(CH2)3-OH)-/NN~/
CH
Ia-a403 ~N CH3 -CH(OH)-H

Ia-a404 N .CHs -N(C(O)N(H)-CH2-CH2-OH)-H N-_/
\CH2~

Ia-a405 N CH3 -N(C(O)N(H)-CH2-CH2-F)-H \CH2 "I N,,/---,/

Ia-a406 N CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-H \CH2 "I N,,/---,/

Ia-a407 N CH3 -N(C(O)N(H)-CH2-CH2-CF3)-H \CH2 "I N,,/---,/

Ia-a408 N CH3 -N(C(O)N(H)-CH2-CH2-CF3)-H \CH2 "I N,,/---,/

Ia-a409 N CH3 -N(C(O)N(H)-CH2-CF3)-H \CH2 "I N,,/---,/

Ia-a410 N CH3 -N(C(O)N(H)-(CH2)3-OH)-H
/NZ~

Ia-a411 H3C -CH(OH)-CH ~NN`CH3 Ia-a412 H3C -N(C(O)N(H)-CH2-CH2-OH)-H
N, Ia-a413 H3C -N(C(O)N(H)-CHz-CHz-F)-CH 'N-CH3 Ia-a414 H3C -N(C(O)N(H)-CH2-CH2-OCH3)-CH -'N`CH3 Ia-a415 H3C N(C(O)N(H)-CHz-CHz-CF3)-CH ~N~/N`CH3 Ia-a416 H3C N(C(O)N(H)-CHz-CHz-CF3)-CH N`

Ia-a417 H3C -N(C(O)N(H)-CH2-CF3)-CH 'NN-CH3 Ia-a418 H3C -N(C(O)N(H)-(CH2)3-OH)-CH -'NN`H3 Ia-a419 N -CH(OH)-H N
\CH "I N
Ia-a420 N -N(C(O)N(H)-CH2-CH2-OH)-H N
\CH 'IN
Ia-a421 N -N(C(O)N(H)-CH2-CH2-F)-H N
\CH /N

Ia-a422 N -N(C(O)N(H)-CH2-CH2-OCH3)-N
\CH /N

Ia-a423 N N(C(O)N(H)-CH2-CH2-CF3)-N
\CH ~N
Ia-a424 N -N(C(O)N(H)-CH2-CH2-CF3)-H N
\CH "I N
Ia-a425 N -N(C(O)N(H)-CH2-CF3)-N
\CH 'IN
Ia-a426 N -N(C(O)N(H)-(CH2)3-OH)-N
\CH ~N
Ia-a427 ~ -CH(OH)-/
-CH2-N~/ N
Ia-a428 ~ N(C(O)N(H)-CHz-CHz-OH)-~
-CH2-N~/N

Ia-a429 -N(C(O)N(H)-CH2-CH2-F)--CH2-N -CH2-N~/N
Ia-a430 -N(C(O)N(H)-CH2-CH2-OCH3)--CH2-N -CH2-N ~\ N

Ia-a431 -N(C(O)N(H)-CH2-CH2-CF3)--CH2-N -CH2-N~/N
Ia-a432 N(C(O)N(H)-CHz-CHz-CF3)-/
~

Ia-a433 -N(C(O)N(H)-CH2-CF3)--CH2-N -CH2-N~/N
Ia-a434 -N(C(O)N(H)-(CH2)3-OH)--CH2-N -CH2-N~/ N

Ia-a435 -CH2iV/-\ N F -CH(OH)-~/
Ia-a436 -CH2iv/-\ N F N(C(O)N(H)-CHz-CHz-OH)-~/
Ia-a437 -CH2iV/-\ N F -N(C(O)N(H)-CHz-CHz-F)-~/ -Ia-a438 -CH2iv/-\ N ~ F -N(C(O)N(H)-CH2-CH2-OCH3)--Ia-a439 -CH2iv/-\ N ~ F N(C(O)N(H)-CHz-CHz-CF3)--Ia-a440 -CH2iv/-\ N F N(C(O)N(H)-CH2-CH2-CF3)-~/ -Ia-a441 -CH2iV/-\ N F -N(C(O)N(H)-CH2-CF3)-~/
Ia-a442 -CH2iv/-\ N F -N(C(O)N(H)-(CH2)3-OH)-~/ -Ia-a443 -CH2-N a-aF -CH(OH)-Ia-a444 -CH2-N ~F N(C(O)N(H)-CH2-CH2-OH)-Ia-a445 -CH2-N ~F -N(C(O)N(H)-CHz-CHz-F)-Ia-a446 -CH2-N ~F -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a447 -CH2-N ~F N(C(O)N(H)-CH2-CH2-CF3)-Ia-a448 -CH2-N ~F N(C(O)N(H)-CH2-CH2-CF3)-Ia-a449 -CH2-N ~F -N(C(O)N(H)-CH2-CF3)-Ia-a450 -CH2-N 3-&F -N(C(O)N(H)-(CH2)3-OH)-Ia-a451 -CH2-N o -CH(OH)-Ia-a452 -CH2-N o N(C(O)N(H)-CH2-CH2-OH)-Ia-a453 -CH2-N O -N(C(O)N(H)-CH2-CH2-F)-Ia-a454 -CH2-N -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a455 -CH2-N N(C(O)N(H)-CH2-CH2-CF3)-Ia-a456 -CHz-N N(C(O)N(H)-CH2-CH2-CF3)-Ia-a457 -CH2-N O -N(C(O)N(H)-CH2-CF3)-Ia-a458 -CHz-N O -N(C(O)N(H)-(CH2)3-OH)-Ia-a459 -CHz-N \ &cl -CH(OH)-Ia-a460 -CHz-N ~cl N(C(O)N(H)-CH2-CH2-OH)-Ia-a461 -CHz-N \ CI -N(C(O)N(H)-CH2-CH2-F)-Ia-a462 -CHz-N ~cl -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a463 -CHz-N ~cl N(C(O)N(H)-CH2-CH2-CF3)-Ia-a464 -cHz-N \ N(C(O)N(H)-CH2-CH2-CF3)-Ia-a465 -cHz-N \ / \ c -N(C(O)N(H)-CH2-CF3)-Ia-a466 -cHz-N \ / \ c -N(C(O)N(H)-(CH2)3-OH)-Ia-a467 -CHz-N \ / \ -CH(OH)-Ia-a468 -CHz-N \ / \ N(C(O)N(H)-CHz-CHz-OH)-Ia-a469 _CHz-N \ / \ -N(C(O)N(H)-CH2-CH2-F)-Ia-a470 _CHz_N \ / \ -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a471 _CHz_N \ / \ N(C(O)N(H)-CH2-CH2-CF3)-Ia-a472 _CHz_N \ / \ N(C(O)N(H)-CH2-CH2-CF3)-Ia-a473 _CHz_N \ / \ -N(C(O)N(H)-CH2-CF3)-Ia-a474 _CHz_N \ / \ -N(C(O)N(H)-(CH2)3-OH)-Ia-a475 _CHz-N / \ -CH(OH)-Ia-a476 _CHz-N / \ N(C(O)N(H)-CH2-CH2-OH)-Ia-a477 _CHz-N / \ -N(C(O)N(H)-CH2-CH2-F)-Ia-a478 _CHz-N / \ -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a479 _CHz-N / \ N(C(O)N(H)-CH2-CH2-CF3)-Ia-a480 _CHz-N / \ N(C(O)N(H)-CH2-CH2-CF3)-Ia-a481 _CHz-N / \ -N(C(O)N(H)-CH2-CF3)-Ia-a482 _CHz-N -N(C(O)N(H)-(CH2)3-OH)-OH
Ia-a483 -CH2-N NCH2CH2OP(O)(OH)2 -CH(OH)-Ia-a484 -CH2-N /-\ NCHzCHzOP(o)(oH)z N(C(O)N(H)-CH2-CH2-OH)-Ia-a485 -CH2-N /-\ NCHzCHzOP(o)(oH)z -N(C(O)N(H)-CH2-CH2-F)-Ia-a486 -CH2-N /-\ NCHzCHzOP(o)(oH)z -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a487 -CH2-N NCH2CH2OP(O)(OH)2 N(C(0)N(H)-CH2-CH2-CF3)-Ia-a488 -CH2-N NCH2CH2OP(O)(OH)2 N(C(0)N(H)-CH2-CH2-CF3)-Ia-a489 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(C(0)N(H)-CH2-CF3)-Ia-a490 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(C(0)N(H)-(CH2)3-OH)-Ia-a491 -CH2-CH2-CH2-OP(O)(OH)2 -CH OH -Ia-a492 -CHz-CHz-CHz-OP(O)(OH)z N C O N H-CHz-CHz-OH -Ia-a493 -CH2-CH2-CH2-OP(O)(OH)2 -N C O N H-CHz-CHz-F -Ia-a494 -CH2-CH2-CH2-OP(O)(OH)2 -N C O N H-CHz-CHz-OCH3 -Ia-a495 -CH2-CH2-CH2-OP(O)(OH)2 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a496 -CH2-CH2-CH2-OP(O)(OH)2 N C O N H-CHz-CHz-CF3 -Ia-a497 -CH2-CH2-CH2-OP(O)(OH)2 -N C O N H-CHz-CF3 -Ia-a498 -CH2-CH2-CH2-OP(O)(OH)2 -N(C(O)N(H)-(CH2)3-OH)-Ia-a499 -CHz-CHz-CHz-OS(O)zOH -CH OH -Ia-a500 -CHz-CHz-CHz-OS(O)zOH N C O N H-CHz-CHz-OH -Ia-a501 -CHz-CHz-CHz-OS(O)zOH -N C O N H-CHz-CHz-F -Ia-a502 -CHz-CHz-CHz-OS(O)zOH -N C O N H-CH2-CH2-OCH3 -Ia-a503 -CHz-CHz-CHz-OS(O)zOH N C O N H-CHz-CHz-CF3 -Ia-a504 -CHz-CHz-CHz-OS(O)zOH N C O N H-CHz-CHz-CF3 -Ia-a505 -CHz-CHz-CHz-OS(O)zOH -N C O N H-CHz-CF3 -Ia-a506 -CHz-CHz-CHz-OS(O)zOH -N C O N H CHz 3-OH -Ia-a507 -CH2-NC( -CH(OH)-OP O OH
Ia-a508 -CHz-NC( N(C(O)N(H)-CHz-CHz-OH)-OP O OH
Ia-a509 -CHz-Na -N(C(O)N(H)-CHz-CHz-F)-OP O OH
Ia-a510 -CH2-Na -N(C(O)N(H)-CH2-CH2-OCH3)-OP O OH
Ia-a511 -CH2-Na N(C(O)N(H)-CH2-CH2-CF3)-OP O OH
Ia-a512 -CH2-NC( N(C(O)N(H)-CH2-CH2-CF3)-OP O OH
Ia-a513 -CHz-NC( -N(C(O)N(H)-CH2-CF3)-OP O OH
Ia-a514 -CH2-Na -N(C(O)N(H)-(CH2)3-OH)-OP O OH
Ia-a515 -CH2-N -CH(OH)-OP O OH
Ia-a516 -CH2-N N(C(O)N(H)-CHz-CHz-OH)-OP O OH
Ia-a517 -CH2-N -N(C(O)N(H)-CHz-CHz-F)-OP O OH

Ia-a518 -CHz-N -N(C(O)N(H)-CH2-CH2-OCH3)-OP O OH
Ia-a519 -CH2-N N(C(O)N(H)-CH2-CH2-CF3)-OP O OH
Ia-a520 -CHz-N N(C(O)N(H)-CH2-CH2-CF3)-OP O OH
Ia-a521 -CH2-N -N(C(O)N(H)-CH2-CF3)-OP O OH
Ia-a522 -CH2-N -N(C(O)N(H)-(CH2)3-OH)-OP O OH
Ia-a523 -(CH2),o-N(CH2-CH2-O-CH3)2 -CH(OH)-Ia-a524 -(CH2),o-N(CH2-CH2-O-CH3)2 N C O N H-CHz-CHz-OH -Ia-a525 -(CH2),o-N(CH2-CH2-O-CH3)2 -N C O N H-CHz-CHz-F -Ia-a526 -(CH2),o-N(CH2-CH2-0-CH3)2 -N C O N H-CHz-CHz-OCH3 -Ia-a527 -(CH2),o-N(CH2-CH2-0-CH3)2 N C O N H-CHz-CHz-CF3 -Ia-a528 -(CH2),o-N(CH2-CH2-0-CH3)2 N C O N H-CHz-CHz-CF3 -Ia-a529 -(CH2),o-N(CH2-CH2-O-CH3)2 -N C O N H-CHz-CF3 -Ia-a530 -(CH2),o-N(CH2-CH2-O-CH3)2 -N C O N H CHz 3-OH -Ia-a531 -CH2-N(CH2-CH2-O-CH3)2 -CH OH -Ia-a532 -CH2-N(CH2-CH2-O-CH3)2 N C O N H-CHz-CHz-OH -Ia-a533 -CH2-N(CH2-CH2-O-CH3)2 -N C O N H-CHz-CHz-F -Ia-a534 -CH2-N(CH2-CH2-O-CH3)2 -N C O N H-CHz-CHz-OCH3 -Ia-a535 -CH2-N(CH2-CH2-O-CH3)2 N C O N H-CHz-CHz-CF3 -Ia-a536 -CH2-N(CH2-CH2-O-CH3)2 N C O N H-CHz-CHz-CF3 -Ia-a537 -CH2-N(CH2-CH2-O-CH3)2 -N C O N H-CHz-CF3 -Ia-a538 -CH2-N(CH2-CH2-O-CH3)2 -N C O N H CHz 3-OH -Ia-a539 -N -CH(OH)-Ia-a540 -N N(C(O)N(H)-CHz-CHz-OH)-Ia-a541 -N(C(O)N(H)-CHz-CHz-F)-~N

Ia-a542 N -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a543 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a544 ~ N(C(O)N(H)-CH2-CH2-CF3)-~N
~
Ia-a545 -N -N(C(O)N(H)-CH2-CF3)-Ia-a546 -N(C(O)N(H)-(CH2)3-OH)-~N

Ia-a547 /-Na -CH(OH)-OH
Ia-a548 /-NaN(C(O)N(H)-CHz-CHz-OH)-OH
Ia-a549 /-Na -N(C(O)N(H)-CHz-CHz-F)-OH
Ia-a550 /-Na -N(C(O)N(H)-CH2-CH2-OCH3)-OH
Ia-a551 /-NaN(C(O)N(H)-CHz-CHz-CF3)-OH
Ia-a552 /-NaN(C(O)N(H)-CHz-CHz-CF3)-OH
Ia-a553 /-Na -N(C(O)N(H)-CH2-CF3)-OH
Ia-a554 /-Na -N(C(O)N(H)-(CH2)3-OH)-OH
Ia-a555 lqla No -CH(OH)-Ia-a556 ~lqla No N(C(O)N(H)-CH2-CH2-OH)-Ia-a557 -N(C(O)N(H)-CH2-CH2-F)-Ia-a558 lqlo- No -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a559 lqla No N(C(O)N(H)-CH2-CH2-CF3)-Ia-a560 lqla No N(C(O)N(H)-CH2-CH2-CF3)-Ia-a561 -N(C(O)N(H)-CH2-CF3)-Ia-a562 -N(C(O)N(H)-(CH2)3-OH)-Ia-a563 -CH(OH)-~N N~

Ia-a564 v N(C(O)N(H)-CHz-CHz-OH)-~N

Ia-a565 N -N(C(O)N(H)-CHz-CHz-F)-N

Ia-a566 v N -N(C(O)N(H)-CH2-CH2-OCH3)-~ N

Ia-a567 v N Nv N(C(O)N(H)-CHz-CHz-CF3)-~~

Ia-a568 N Nv N(C(O)N(H)-CHz-CHz-CF3)-~~

Ia-a569 -N(C(O)N(H)-CH2-CF3)-~N N~

Ia-a570 v N -N(C(O)N(H)-(CH2)3-OH)-~ N

Ia-a571 v -CH(OH)-N
/-HO
Ia-a572 N(C(O)N(H)-CHz-CHz-OH)-/-N
HO
Ia-a573 -N(C(O)N(H)-CHz-CHz-F)-N
/-HO
Ia-a574 -N(C(O)N(H)-CH2-CH2-OCH3)-N
/-HO
Ia-a575 N(C(O)N(H)-CH2-CH2-CF3)-N
/-HO
Ia-a576 N(C(O)N(H)-CH2-CH2-CF3)-N
/-HO
Ia-a577 -N(C(O)N(H)-CH2-CF3)-N
/-HO

Ia-a578 -N(C(O)N(H)-(CH2)3-OH)-/-N
HO
Ia-a579 -CH(OH)-X/-N

O
O Me Ia-a580 N(C(O)N(H)-CHz-CHz-OH)-//-N

O
O Me Ia-a581 -N(C(O)N(H)-CHz-CHz-F)-//-N

O
O Me Ia-a582 -N(C(O)N(H)-CH2-CH2-OCH3)-N

O
O Me Ia-a583 N(C(O)N(H)-CH2-CH2-CF3)-N

O
O Me Ia-a584 N(C(O)N(H)-CH2-CH2-CF3)-N

O
O Me Ia-a585 -N(C(O)N(H)-CH2-CF3)-N

O
O Me Ia-a586 -N(C(O)N(H)-(CH2)3-OH)-//-N

O
O Me Ia-a587 N -CH(OH)-~ /

Ia-a588 N N(C(O)N(H)-CHz-CHz-OH)-~

Ia-a589 N -N(C(O)N(H)-CHz-CHz-F)-~

Ia-a590 N -N(C(O)N(H)-CH2-CH2-OCH3)-~

Ia-a591 N N(C(O)N(H)-CH2-CH2-CF3)-~

Ia-a592 N N(C(O)N(H)-CH2-CH2-CF3)-~

Ia-a593 N -N(C(O)N(H)-CH2-CF3)-~

Ia-a594 N -N(C(O)N(H)-(CH2)3-OH)-~

Ia-a595 -CH(OH)-~

No Ia-a596 N(C(O)N(H)-CHz-CHz-OH)-No Ia-a597 -N(C(O)N(H)-CHz-CHz-F)-No Ia-a598 -N(C(O)N(H)-CHz-CHz-OCH3)-~

No Ia-a599 N(C(O)N(H)-CHz-CHz-CF3)-~

No Ia-a600 N(C(O)N(H)-CHz-CHz-CF3)-No Ia-a601 -N(C(O)N(H)-CHz-CF3)-No Ia-a602 -N(C(O)N(H)-(CHz)3-OH)-No Ia-a603 -CH(OH)-[-N~N--\_,-N(CHs) Ia-a604 N(C(O)N(H)-CHz-CHz-OH)-[-N\__/N--\,,N(CHs) Ia-a605 -N(C(O)N(H)-CHz-CHz-F)-I-N\-/ N--\\_,,N(CHs) Ia-a606 -N(C(O)N(H)-CH2-CH2-OCH3)-[-N\__/N--\,,N(CH3) Ia-a607 N(C(O)N(H)-CH2-CH2-CF3)-[-N\__/N--\_.,-N(CHs) Ia-a608 N(C(O)N(H)-CH2-CH2-CF3)-[-N\__/N--\\,,-N(CHs) Ia-a609 -N(C(O)N(H)-CH2-CF3)-[-N\__/N--\_,-N(CHs) Ia-a610 -N(C(O)N(H)-(CH2)3-OH)-[-N\__/N--\_,,-N(CHs) Ia-a611 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -CH OH -Ia-a612 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N C O N H-CHz-CHz-OH -Ia-a613 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C O N H-CHz-CHz-F -Ia-a614 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C O N H-CHz-CHz-OCH3 -Ia-a615 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a616 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N C p N H-CHz-CHz-CF3 -Ia-a617 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C p N H-CHz-CF3 -Ia-a618 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N(C(O)N(H)-(CH2)3-OH)-Ia-a619 0 -CH(OH)-~NC I

Ia-a620 0 N(C(O)N(H)-CHz-CHz-OH)-~NC I

Ia-a621 0 -N(C(O)N(H)-CHz-CHz-F)-~NC I

Ia-a622 O -N(C(O)N(H)-CHz-CHz-OCH3)-~NC I

Ia-a623 O N(C(O)N(H)-CHz-CHz-CF3)-~NC I

Ia-a624 0 N(C(O)N(H)-CH2-CH2-CF3)-~N~

Ia-a625 0 -N(C(O)N(H)-CH2-CF3)-~N~

Ia-a626 0 -N(C(O)N(H) (CHz)3 OH) Ia-a627 /-No,,OH -CH(OH)-Ia-a628 /-No,,OH N(C(O)N(H)-CHz-CHz-OH)-Ia-a629 /-No,,OH -N(C(O)N(H)-CHz-CHz-F)-Ia-a630 /-No,,OH -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a631 /~",OH N(C(O)N(H)-CHz-CHz-CF3)-~N, I

Ia-a632 v /-No,,OH N(C(O)N(H)-CH2-CH2-CF3)-Ia-a633 /-No ,,OH -N(C(O)N(H)-CH2-CF3)-Ia-a634 /-No,,OH -N(C(O)N(H)-(CH2)3-OH)-Ia-a635 -CH(OH)-HO
Ia-a636 ~ N(C(O)N(H)-CHz-CHz-OH)-~

HO
Ia-a637 ~ -N(C(O)N(H)-CHz-CHz-F)-~

HO
Ia-a638 ~ -N(C(O)N(H)-CH2-CH2-OCH3)-~

HO
Ia-a639 ~ N(C(O)N(H)-CH2-CH2-CF3)-~

HO
Ia-a640 ~ N(C(O)N(H)-CH2-CH2-CF3)-~

HO
Ia-a641 ~ -N(C(O)N(H)-CH2-CF3)-~

HO
Ia-a642 ~ -N(C(O)N(H)-(CH2)3-OH)-~

HO
Ia-a643 ,CH3 -CH(OH)-~N
/\-,CH3 Ia-a644 ,CHa N(C(O)N(H)-CHz-CHz-OH)-~N

Ia-a645 ,CH3 -N(C(O)N(H)-CHz-CHz-F)-~N
/\-,CH3 Ia-a646 ,CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-~N

Ia-a647 ,CN3 N(C(O)N(H)-CH2-CH2-CF3)-//-N

Ia-a648 ,CN3 N(C(O)N(H)-CH2-CH2-CF3)-/-N
/.VCH3 \

Ia-a649 ,CN3 -N(C(O)N(H)-CH2-CF3)-~N
~CH3 Ia-a650 ,CN3 -N(C(O)N(H)-(CH2)3-OH)-/-N
/.VCH3 \

Ia-a651 -CH(OH)-Ia-a652 N N(C(O)N(H)-CHz-CHz-OH)-O
Ia-a653 -N(C(O)N(H)-CH2-CH2-F)-Ia-a654 -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a655 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a656 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a657 -N(C(O)N(H)-CH2-CF3)-Ia-a658 -N(C(O)N(H)-(CH2)3-OH)-Ia-a659 \-N OH -CH(OH)-Ia-a660 \_N OH N(C(O)N(H)-CHz-CHz-OH)-Ia-a661 \_N OH -N(C(O)N(H)-CHz-CHz-F)-Ia-a662 \_N OH -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a663 \\_N OH N(C(O)N(H)-CH2-CH2-CF3)-Ia-a664 \\_N OH N(C(O)N(H)-CH2-CH2-CF3)-Ia-a665 \\_N OH -N(C(O)N(H)-CH2-CF3)-Ia-a666 \\_N OH -N(C(O)N(H)-(CH2)3-OH)-Ia-a667 a OH -CH(OH)-Ia-a668 a OH N(C(O)N(H)-CH2-CH2-OH)-Ia-a669 a OH -N(C(O)N(H)-CH2-CH2-F)-Ia-a670 a OH -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a671 a OH N(C(O)N(H)-CH2-CH2-CF3)-Ia-a672 a OH N(C(O)N(H)-CH2-CH2-CF3)-Ia-a673 a OH -N(C(O)N(H)-CH2-CF3)-Ia-a674 a OH -N(C(O)N(H)-(CH2)3-OH)-Ia-a675 ~NH -CH(OH)-Ia-a676 NH N(C(O)N(H)-CH2-CH2-OH)-Ia-a677 NH -N(C(O)N(H)-CH2-CH2-F)-Ia-a678 NH -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a679 NH N(C(O)N(H)-CH2-CH2-CF3)-Ia-a680 NH N(C(O)N(H)-CH2-CH2-CF3)-Ia-a681 NH -N(C(O)N(H)-CH2-CF3)-Ia-a682 NH -N(C(O)N(H)-(CH2)3-OH)-Ia-a683 /-NH -CH(OH)-Ia-a684 //-NH N(C(O)N(H)-CH2-CH2-OH)-Ia-a685 //-NH -N(C(O)N(H)-CH2-CH2-F)-Ia-a686 //-NH -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a687 //-NH N(C(O)N(H)-CH2-CH2-CF3)-Ia-a688 Ilo---NH N(C(O)N(H)-CH2-CH2-CF3)-Ia-a689 //-NH -N(C(O)N(H)-CH2-CF3)-Ia-a690 Ilo---NH -N(C(O)N(H)-(CH2)3-OH)-Ia-a691 /-NH -CH(OH)-Ia-a692 /cH2CH3 N(C(O)N(H)-CHz-CHz-OH)-Ia-a693 "CH2CH3 -N(C(O)N(H)-CHz-CHz-F)-Ia-a694 / CH2CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a695 /cH2CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a696 /cH2CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a697 / CH2CH3 -N(C(O)N(H)-CH2-CF3)-Ia-a698 /cH2CH3 -N(C(O)N(H)-(CH2)3-OH)-Ia-a699 /cH2CH3 -CH(OH)-Ia-a700 /-NH N(C(O)N(H)-CH2-CH2-OH)-D Ia-a701 /-NH -N(C(O)N(H) CHz CHz F) D

Ia-a702 /-NH -N(C(O)N(H)-CH2-CH2-OCH3)-D Ia-a703 /-NH N(C(O)N(H)-CH2-CH2-CF3)-Ia-a704 /-NN N(C(O)N(H)-CH2-CH2-CF3)-D Ia-a705 /-NH -N(C(O)N(H)-CH2-CF3)-D Ia-a706 /-NH -N(C(O)N(H)-(CH2)3-OH)-D Ia-a707 /-NH -CH(OH)-D Ia-a708 /-NH
N(C(O)N(H)-CH2-CH2-OH)-D Ia-a709 /-NH -N(C(O)N(H)-CH2-CH2-F)-D Ia-a710 /-NH -N(C(O)N(H)-CH2-CH2-OCH3)-D Ia-a711 /-NN N(C(O)N(H)-CH2-CH2-CF3)-D Ia-a712 /-NH
N(C(O)N(H)-CH2-CH2-CF3)-D Ia-a713 /-NH -N(C(O)N(H)-CH2-CF3)-D Ia-a714 /-NH -N(C(O)N(H)-(CH2)3-OH)-D Ia-a715 -CH(OH)-~
Ia-a716 N(C(O)N(H)-CHz-CHz-OH)-Ia-a717 -N(C(O)N(H)-CHz-CHz-F)-Ia-a718 ~N S -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a719 -N /-S N(C(O)N(H)-CH2-CH2-CF3)-Ia-a720 -N /-S N(C(O)N(H)-CH2-CH2-CF3)-Ia-a721 -N /-\ -N(C(O)N(H)-CH2-CF3)-Ia-a722 -N /-\ -N(C(O)N(H)-(CH2)3-OH)-Ia-a723 -CH(OH)-Ia-a724 N(C(O)N(H)-CHz-CHz-OH)-Ia-a725 N\~ -N(C(O)N(H)-CHz-CHz-F)-Ia-a726 -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a727 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a728 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a729 -N(C(O)N(H)-CH2-CF3)-Ia-a730 N\~ -N(C(O)N(H)-(CH2)3-OH)-Ia-a731 /-NH -CH(OH)-Ia-a732 /-NH N(C(O)N(H)-CHz-CHz-OH)-H C
Ia-a733 /-NH -N(C(O)N(H)-CH2-CH2-F)-H C

Ia-a734 /-NH -N(C(O)N(H)-CH2-CH2-OCH3)-H C
Ia-a735 /-NH N(C(O)N(H)-CHz-CHz-CF3)-H C
Ia-a736 /-NH N(C(O)N(H)-CHz-CHz-CF3)-H C
Ia-a737 /-NH -N(C(O)N(H)-CH2-CF3)-Ia-a738 /-NH -N(C(O)N(H)-(CH2)3-OH)-H C
Ia-a739 CH3 -CH(OH)-N

Ia-a740 CH3 N(C(O)N(H)-CHz-CHz-OH)-N

Ia-a741 CH3 -N(C(O)N(H)-CHz-CHz-F)-~N N

Ia-a742 CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-/-N_/ N

Ia-a743 CH3 N(C(O)N(H)-CHz-CHz-CF3)-~N N

Ia-a744 CHs N(C(O)N(H)-CH2-CH2-CF3)-N
Ia-a745 CH3 -N(C(O)N(H)-CH2-CF3)-N

Ia-a746 CH3 -N(C(O)N(H)-(CHz)3-OH)-~N N

Ia-a747 CH3 -CH(OH)-N

Ia-a748 CH3 N(C(O)N(H)-CH2-CH2-OH)-~N
Ia-a749 CH3 -N(C(O)N(H)-CH2-CH2-F)-~N
Ia-a750 CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-N
Ia-a751 CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N
Ia-a752 CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N

Ia-a753 CH3 -N(C(O)N(H)-CH2-CF3)-~N
Ia-a754 CH3 -N(C(O)N(H)-(CH2)3-OH)-N
Ia-a755 NH -CH(OH)-0 Ia-a756 NH 0 N(C(O)N(H)-CH2-CH2-OH)-Ia-a757 NH -N(C(O)N(H)-CH2-CH2-F)-0 Ia-a758 NH -N(C(O)N(H)-CH2-CH2-OCH3)-0 Ia-a759 NH 0 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a760 NH 0 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a761 NH -N(C(O)N(H)-CH2-CF3)-0 OH

Ia-a762 /-NH -N(C(O)N(H)-(CH2)3-OH)-0 OH

Ia-a763 /-N--~ OH -CH(OH)-Ia-a764 OH N(C(O)N(H)-CH2-CH2-OH)-Ia-a765 //-N-1-~ OH -N(C(O)N(H)-CH2-CH2-F)-Ia-a766 //--N--~ OH -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a767 //--N--~ OH N(C(O)N(H)-CH2-CH2-CF3)-Ia-a768 OH N(C(O)N(H)-CH2-CH2-CF3)-Ia-a769 OH -N(C(O)N(H)-CH2-CF3)-Ia-a770 OH -N(C(O)N(H)-(CH2)3-OH)-Ia-a771 /-ND-CH3 -CH(OH)-Ia-a772 /-ND-CH3 N(C(O)N(H)-CH2-CH2-OH)-Ia-a773 /-N--rCH3 -N(C(O)N(H)-CH2-CH2-F)-Ia-a774 /-N D-CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a775 /-ND-CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a776 /-ND-CH3 N(C(O)N(H)-CH2-CH2-CF3)-~ rCH3 -N(C(O)N(H)-CH2-CF3)-Ia-a777 /-N--Ia-a778 /-N D-CH3 -N(C(O)N(H)-(CH2)3-OH)-Ia-a779 -CH2-NH-CH3 -CH(OH)-Ia-a780 -CH2-NH-CH3 N C O N H-CHz-CHz-OH -Ia-a781 -CH2-NH-CH3 -N C O N H-CHz-CHz-F -Ia-a782 -CH2-NH-CH3 -N C O N H-CHz-CHz-OCH3 -Ia-a783 -CH2-NH-CH3 N C O N H-CHz-CHz-CF3 -Ia-a784 -CH2-NH-CH3 N C O N H-CHz-CHz-CF3 -Ia-a785 -CH2-NH-CH3 -N C O N H-CHz-CF3 -Ia-a786 -CH2-NH-CH3 -N C O N H CHz 3-OH -Ia-a787 -CH2-NH-CH2-CH3 -CH OH -Ia-a788 -CH2-NH-CH2-CH3 N C O N H-CHz-CHz-OH -Ia-a789 -CH2-NH-CH2-CH3 -N C O N H-CHz-CHz-F -Ia-a790 -CH2-NH-CH2-CH3 -N C O N H-CHz-CHz-OCH3 -Ia-a791 -CH2-NH-CH2-CH3 N C O N H-CHz-CHz-CF3 -Ia-a792 -CH2-NH-CH2-CH3 N C O N H-CHz-CHz-CF3 -Ia-a793 -CH2-NH-CH2-CH3 -N C O N H-CHz-CF3 -Ia-a794 -CH2-NH-CH2-CH3 -N C O N H CHz 3-OH -Ia-a795 -CH2-NH-CH2-CH2-CH3 -CH(OH)-Ia-a796 -CH2-NH-CH2-CH2-CH3 N C O N H-CHz-CHz-OH -Ia-a797 -CH2-NH-CH2-CH2-CH3 -N(C(O)N(H)-CH2-CH2-F)-Ia-a798 -CH2-NH-CH2-CH2-CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a799 -CH2-NH-CH2-CH2-CH3 N C O N H-CHz-CHz-CF3 -Ia-a800 -CH2-NH-CH2-CH2-CH3 N C O N H-CHz-CHz-CF3 -Ia-a801 -CH2-NH-CHz-CHz-CH3 -N C O N H-CHz-CF3 -Ia-a802 -CH2-NH-CH2-CH2-CH3 -N C O N H CHz 3-OH -Ia-a803 H3C\ -CH(OH)-~NrCH3 Ia-a804 H3C\ N(C(O)N(H)-CHz-CHz-OH)-~NrCH3 H
Ia-a805 H3C\ -N(C(O)N(H)-CHz-CHz-F)-~NrCH3 Ia-a806 H3C\ -N(C(O)N(H)-CHz-CHz-OCH3)-~NrCH3 H
Ia-a807 ~~~CH N(C(O)N(H)-CHz-CHz-CF3)-Ia-a808 ~~~CH N(C(O)N(H)-CHz-CHz-CF3)-Ia-a809 ~~~CH -N(C(O)N(H)-CHz-CF3)-H

Ia-a810 H3C -N(C(O)N(H)-(CH2)3-OH)-\-NCH3 Ia-a811 H3C -CH(OH)-H
/-N

OMe Ia-a812 H3C N(C(O)N(H)-CH2-CH2-OH)-H
I-N
OMe Ia-a813 H3C -N(C(O)N(H)-CH2-CH2-F)-H
I-N
OMe Ia-a814 H3C -N(C(O)N(H)-CH2-CH2-OCH3)-H
I-N
OMe Ia-a815 H3C N(C(O)N(H)-CH2-CH2-CF3)-H
I-N
OMe Ia-a816 H3C N(C(O)N(H)-CH2-CH2-CF3)-H
I-N
OMe Ia-a817 H3C -N(C(O)N(H)-CH2-CF3)-H
I-N
OMe Ia-a818 H3C -N(C(O)N(H)-(CH2)3-OH)-H
I-N
OMe Ia-a819 H3C -CH(OH)-~-CH3 >---CH3 H C
Ia-a820 H3C N(C(O)N(H)-CH2-CH2-OH)-~-CH3 //-N
>---cH3 H C
Ia-a821 H3C -N(C(O)N(H)-CH2-CH2-F)-~-CH3 >---CH3 H C
Ia-a822 H3C -N(C(O)N(H)-CH2-CH2-OCH3)-~-CH3 >---CH3 H C
Ia-a823 H3C N(C(O)N(H)-CH2-CH2-CF3)-~-CH3 >---CH3 H C
Ia-a824 H3C N(C(O)N(H)-CH2-CH2-CF3)-~-CH3 >---CH3 H C
Ia-a825 H3C -N(C(O)N(H)-CH2-CF3)-~-CH3 //-N
>---cfl3 H C
Ia-a826 H3C -N(C(O)N(H)-(CH2)3-OH)-~-CH3 >---CH3 Ia-a827 -CH(OH)-Ia-a828 N(C(O)N(H)-CHz-CHz-OH)-N
Ia-a829 -N(C(O)N(H)-CHz-CHz-F)-N
Ia-a830 -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a831 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a832 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a833 -N(C(O)N(H)-CH2-CF3)-N
Ia-a834 -N(C(O)N(H)-(CH2)3-OH)-N
Ia-a835 CH3CHi2 N -CH(OH)-N
Ia-a836 CH3CH2 N N(C(O)N(H)-CHz-CHz-OH)-~
--/ N
Ia-a837 CH3CH22 N -N(C(O)N(H)-CHz-CHz-F)-N
Ia-a838 CH3CH2 N -N(C(O)N(H)-CH2-CH2-OCH3)-, N
Ia-a839 CH3CH2 N N(C(O)N(H)-CHz-CHz-CF3)-i --/ N
Ia-a840 CH3CH2 N N(C(O)N(H)-CH2-CH2-CF3)-, N
Ia-a841 CH3CH22 N -N(C(O)N(H)-CH2-CF3)-N
Ia-a842 CH3CH2 N -N(C(O)N(H) (CHz)3 OH) --/ N --:z Ia-a843 ~ CH3 -CH(OH)--CH CH OH
Ia-a844 ~ H3 N(C(O)N(H)-CHz-CHz-OH)-~N-CH CH OH

Ia-a845 CH3 -N(C(O)N(H)-CHz-CHz-F)-~N-CH CH OH
Ia-a846 CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-~N-CH CH OH
Ia-a847 CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N-CH CH OH
Ia-a848 CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N-CH CH OH
Ia-a849 CH3 -N(C(O)N(H)-CH2-CF3)-~N-CH CH OH
Ia-a850 CH3 -N(C(O)N(H)-(CH2)3-OH)-~N-CH CH OH

Ia-a851 -CH(OH) Ia-a852 N(C(O)N(H)-CH2-CH2-OH)-Ia-a853 -N(C(O)N(H)-CH2-CH2-F)-Ia-a854 -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a855 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a856 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a857 -N(C(O)N(H)-CH2-CF3)-Ia-a858 -N(C(O)N(H)-(CH2)3-OH)-Ia-a859 -CH(OH)-~N
Ia-a860 N(C(O)N(H)-CHz-CHz-OH)-Ia-a861 -N(C(O)N(H)-CHz-CHz-F)-Ia-a862 -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a863 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a864 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a865 -N(C(O)N(H)-CH2-CF3)-,/-NN-/0 Ia-a866 -N(C(O)N(H)-(CH2)3-OH)-/-N_/0 Ia-a867 --- C -CH(OH)-N\ CHD/
Ia-a868 \-N~ N(C(O)N(H)-CHz-CHz-OH)-\CH /
Ia-a869 N -N(C(O)N(H)-CHz-CHz-F)-\CH /
Ia-a870 -N(C(O)N(H)-CHz-CHz-OCH3)-Ia-a871 N N(C(O)N(H)-CHz-CHz-CF3)-\CH /
Ia-a872 N(C(O)N(H)-CHz-CHz-CF3)-Ia-a873 ~ C -N(C(O)N(H)-CHz-CF3)-N\CH I
Ia-a874 -N(C(O)N(H)-(CHz)3-OH)-Ia-a875 -CH(OH)-//-NH N,~, Ia-a876 N(C(O)N(H)-CHz-CHz-OH)-//---NH N\

Ia-a877 -N(C(O)N(H)-CHz-CHz-F)-/,/--NH N

Ia-a878 -N(C(O)N(H)-CH2-CH2-OCH3)-/,/--NH N

Ia-a879 N(C(O)N(H)-CH2-CH2-CF3)-//-NH N~

Ia-a880 N(C(O)N(H)-CH2-CH2-CF3)-,/-NH N

Ia-a881 -N(C(O)N(H)-CH2-CF3)-,/-NH N

Ia-a882 -N(C(O)N(H)-(CH2)3-OH)-,/~---NH N

Ia-a883 ~ H3 -CH(OH)-NH N

Ia-a884 ~ H3 N(C(O)N(H)-CHz-CHz-OH)-NH N

Ia-a885 ~ H3 -N(C(O)N(H)-CHz-CHz-F)-NH N

Ia-a886 ~ H3 -N(C(O)N(H)-CH2-CH2-OCH3)-NH N

Ia-a887 ~ H3 N(C(O)N(H)-CHz-CHz-CF3)-NH N

Ia-a888 ~ H3 N(C(O)N(H)-CHz-CHz-CF3)-NH N

Ia-a889 ~ H3 -N(C(O)N(H)-CH2-CF3)-NH N

Ia-a890 ~ H3 -N(C(O)N(H)-(CH2)3-OH)-NH N

Ia-a891 -CH(OH)-/-N\ N H
Ia-a892 N(C(O)N(H)-CHz-CHz-OH)-/-N\ /N H
Ia-a893 -N(C(O)N(H)-CHz-CHz-F)-/-N\ N H

Ia-a894 -N(C(O)N(H)-CH2-CH2-OCH3)-/-N\ /N H
Ia-a895 N(C(O)N(H)-CH2-CH2-CF3)-/-N\ N H
Ia-a896 N(C(O)N(H)-CH2-CH2-CF3)-/-N\ /N H
Ia-a897 -N(C(O)N(H)-CH2-CF3)-/-N\ N H
Ia-a898 -N(C(O)N(H)-(CH2)3-OH)-/-N\ N H
Ia-a899 CH3 -CH(OH)-~N\

Ia-a900 CH3 N(C(O)N(H)-CHz-CHz-OH)-~N\

Ia-a901 CH3 -N(C(O)N(H)-CHz-CHz-F)-~N\

Ia-a902 ~N~\NCH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a903 CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a904 ~N~\NCH3 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a905 CH3 -N(C(O)N(H)-CH2-CF3)-~N\

Ia-a906 CH3 -N(C(O)N(H)-(CH2)3-OH)-~N\

Ia-a907 -CH(OH)-Ia-a908 //-N H N(C(O)N(H)-CH2-CH2-OH)-Ia-a909 //-N ~ -N(C(O)N(H)-CH2-CH2-F)-Ia-a910 /,,--N H -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a911 //-N H N(C(O)N(H)-CH2-CH2-CF3)-Ia-a912 /,---N H N(C(O)N(H)-CH2-CH2-CF3)-Ia-a913 //-N H -N(C(O)N(H)-CH2-CF3)-Ia-a914 //-N ~ -N(C(O)N(H)-(CH2)3-OH)-Ia-a915 \-\ -CH(OH)-~~ ~~ OH

Ia-a916 N(C(O)N(H)-CHz-CHz-OH)-N N OH

Ia-a917 ~ v ~\ -N(C(O)N(H)-CHz-CHz-F)-oH
Ia-a918 \-\ -N(C(O)N(H)-CHz-CHz-OCH3)-~~ ~~ OH

Ia-a919 N(C(O)N(H)-CHz-CHz-CF3)-N N OH
Ia-a920 ~ v ~\ N(C(O)N(H)-CHz-CHz-CF3)-oH
Ia-a921 \-\ -N(C(O)N(H)-CHz-CF3)-~~ ~~ OH

Ia-a922 -N(C(O)N(H)-(CH2)3-OH)-N N OH

~
Ia-a923 /,--N \ N ~CH3 -CH(OH)-Ia-a924 /,--N \ N ~CH3 N(C(O)N(H)-CHz-CHz-OH)-~~

~
Ia-a925 /,--N \ N ~CH3 -N(C(O)N(H)-CHz-CHz-F)-Ia-a926 ~ \ -N(C(O)N(H)-CHz-CHz-OCH3)-~j ~~ioH3 Ia-a927 ~ \ N(C(O)N(H)-CHz-CHz-CF3)-~j ~ ~ioH3 Ia-a928 //---N N(C(O)N(H)-CHz-CHz-CF3)-N ~CH3 Ia-a929 ~ \ -N(C(O)N(H)-CHz-CF3)-~j ~ioH3 Ia-a930 //---N -N(C(O)N(H)-(CH2)3-OH)-N ~CH3 Ia-a931 -CH(OH)-\-Nr-\ N

Ia-a932 N(C(O)N(H)-CHz-CHz-OH)-\-Nr-\ N
v Ia-a933 -N(C(O)N(H)-CHz-CHz-F)-\-N/--N N

Ia-a934 -N(C(O)N(H)-CH2-CH2-OCH3)-\-N N

Ia-a935 N(C(O)N(H)-CH2-CH2-CF3)-\-N N

Ia-a936 N(C(O)N(H)-CH2-CH2-CF3)-\-N N

Ia-a937 -N(C(O)N(H)-CH2-CF3)-\-N N

Ia-a938 -N(C(O)N(H)-(CH2)3-OH)-\-N/--N N

Ia-a939 \-NaOEt -CH(OH)-Ia-a940 \_NaOEt N(C(O)N(H)-CH2-CH2-OH)-Ia-a941 \\-NaOEt -N(C(O)N(H)-CH2-CH2-F)-Ia-a942 \\_NaOEt -N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a943 \_NaOEt N(C(O)N(H)-CH2-CH2-CF3)-Ia-a944 \_NaOEt N(C(O)N(H)-CH2-CH2-CF3)-Ia-a945 \\-NaOEt -N(C(O)N(H)-CH2-CF3)-Ia-a946 \-NaOEt -N(C(O)N(H)-(CH2)3-OH)-Ia-a947 -CH(OH)-/,-N Q~ H

Ia-a948 N
N(C(O)N(H)-CHz-CHz-OH)-~
Q~ H

Ia-a949 ~
-N(C(O)N(H)-CHz-CHz-F)-~
Q~ H
Ia-a950 N
-N(C(O)N(H)-CH2-CH2-OCH3)-~
Q~ H
Ia-a951 ~
N(C(O)N(H)-CH2-CH2-CF3)-~
Q~ H
Ia-a952 /-N N(C(O)N(H)-CH2-CH2-CF3)-Ia-a953 N -N(C(O)N(H)-CH2-CF3)-/- Q~ H
Ia-a954 ~
-N(C(O)N(H)-(CH2)3-OH)-~
Q~ H
Ia-a955 O -CH(OH) OEt Ia-a956 - N/0 N(C(O)N(H)-CHz-CHz-OH)-OEt Ia-a957 - N/0 -N(C(O)N(H)-CHz-CHz-F)-OEt Ia-a958 -N(C(O)N(H)-CH2-CH2-OCH3)-OEt Ia-a959 N(C(O)N(H)-CH2-CH2-CF3)-OEt Ia-a960 - N/0 N(C(O)N(H)-CH2-CH2-CF3)-OEt Ia-a961 - N/0 -N(C(O)N(H)-CH2-CF3)-OEt Ia-a962 - N/0 -N(C(O)N(H)-(CH2)3-OH)-OEt Ia-a963 -CHz-N CHzCH3 CH3 -CH OH -Ia-a964 -CH2-N(CH2CH3)(CH3) N(C(O)N(H)-CH2-CH2-OH)-Ia-a965 -CHz-N CHzCH3 CH3 N C O N H-CHz-CHz-F -Ia-a966 -CHz-N CHzCH3 CH3 N C O N H-CHz-CHz-OCH3 -Ia-a967 -CHz-N CHzCH3 CH3 N C O N H-CHz-CHz-CF3 -Ia-a968 -CHz-N CHzCH3 CH3 N C O N H-CHz-CHz-CF3 -Ia-a969 -CHz-N CHzCH3 CH3 N C O N H-CHz-CF3 -Ia-a970 -CHz-N CHzCH3 CH3 N C O N H CHz 3-OH -Ia-a971 -CHz-N CHzCHzCH3 CH3 -CH OH -Ia-a972 -CH2-N(CH2CH2CH3)(CH3) N(C(O)N(H)-CH2-CH2-OH)-Ia-a973 -CHz-N CHzCHzCH3 CH3 -N C O N H-CHz-CHz-F -Ia-a974 -CHz-N CHzCHzCH3 CH3 -N C O N H-CHz-CHz-OCH3 -Ia-a975 -CH2-N(CH2CH2CH3)(CH3) N(C(O)N(H)-CH2-CH2-CF3)-Ia-a976 -CHz-N CHzCHzCH3 CH3 N C O N H-CHz-CHz-CF3 -Ia-a977 -CHz-N CHzCHzCH3 CH3 -N C O N H-CHz-CF3 -Ia-a978 -CHz-N CHzCHzCH3 CH3 -N C O N H CHz 3-OH -Ia-a979 -CH2-N(CH2CH2CH2CH3)(CH3) -CH OH -Ia-a980 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-OH -Ia-a981 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-F -Ia-a982 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-OCH3 -Ia-a983 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-CF3 -Ia-a984 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-CF3 -Ia-a985 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CF3 -Ia-a986 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H CHz 3-OH -Ia-a987 -CH2-NH-CH2CH2CH2CH3 -CH OH -Ia-a988 -CH2-NH-CH2CH2CH2CH3 N C O N H-CHz-CHz-OH -Ia-a989 -CH2-NH-CH2CH2CH2CH3 -N C O N H-CHz-CHz-F -Ia-a990 -CH2-NH-CH2CH2CH2CH3 -N C O N H-CHz-CHz-OCH3 -Ia-a991 -CH2-NH-CH2CH2CH2CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a992 -CH2-NH-CH2CH2CH2CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ia-a993 -CH2-NH-CH2CH2CH2CH3 -N(C(O)N(H)-CH2-CF3)-Ia-a994 -CH2-NH-CH2CH2CH2CH3 -N(C(O)N(H)-(CH2)3-OH)-Ia-a995 -CH2-NH-CH2CH2-O-CH3 -CH OH -Ia-a996 -CH2-NH-CH2CH2-O-CH3 N C O N H-CHz-CHz-OH -Ia-a997 -CH2-NH-CH2CH2-O-CH3 -N C O N H-CHz-CHz-F -Ia-a998 -CH2-NH-CH2CH2-O-CH3 -N C O N H-CHz-CHz-OCH3 -Ia-a999 -CH2-NH-CH2CH2-O-CH3 N C O N H-CHz-CHz-CF3 -Ia-a1000 -CH2-NH-CH2CH2-O-CH3 N C O N H-CHz-CHz-CF3 -Ia-a1001 -CH2-NH-CH2CH2-O-CH3 -N C O N H-CHz-CF3 -Ia-a1002 -CH2-NH-CH2CH2-O-CH3 -N C O N H CHz 3-OH -Ia-a1003 /-N/--\ N--,\,OMe -CH(OH)-Ia-a1004 /-N N--,\,OMe N(C(O)N(H)-CH2-CH2-OH)-Ia-a1005 /-N N-NOMe N(C(O)N(H)-CH2-CH2-F)-Ia-a1006 /-N N--\,OMe N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a1007 /-N N--\,OMe N(C(O)N(H)-CH2-CH2-CF3)-Ia-a1008 /-N N--\,OMe N(C(O)N(H)-CH2-CH2-CF3)-Ia-a1009 /-N N--,\,OMe N(C(O)N(H)-CH2-CF3)-Ia-a1010 /-N/--\ N--,\,OMe N(C(O)N(H)-(CH2)3-OH)-Ia-a1011 -CH(OH)-N OPO OH
Ia-a1012 N(C(O)N(H)-CHz-CHz-OH)-N OPO OH
Ia-a1013 -N(C(O)N(H)-CHz-CHz-F)-N OPO OH
Ia-a1014 N(C(O)N(H)-CH2-CH2-OCH3)-N OPO OH
Ia-a1015 N(C(O)N(H)-CH2-CH2-CF3)-N OPO OH
Ia-a1016 N(C(O)N(H)-CH2-CH2-CF3)-N OPO OH
Ia-a1017 N(C(O)N(H)-CH2-CF3)-N OPO OH
Ia-a1018 N(C(O)N(H)-(CH2)3-OH)-N OPO OH
Ia-a1019 -CH(OH)-OPO(OH)Z
Ia-a1020 N(C(O)N(H)-CHz-CHz-OH)-OPO(OH)Z
Ia-a1021 N(C(O)N(H)-CHz-CHz-F)-OPO(OH)Z
Ia-a1022 N(C(O)N(H)-CHz-CHz-OCH3)-OPO(OH)Z
Ia-a1023 N(C(O)N(H)-CHz-CHz-CF3)-OPO(OH)Z
Ia-a1024 N(C(O)N(H)-CHz-CHz-CF3)-OPO(OH)Z
Ia-a1025 N(C(O)N(H)-CHz-CF3)-OPO(OH)Z
Ia-a1026 N(C(O)N(H)-(CHz)3-OH)-OPO(OH)Z

Ia-a1027 /\N OPO(OH)z -CH(OH)-Ia-a1028 /\N OPO(OH)z N(C(O)N(H)-CH2-CH2-OH)-Ia-a1029 /\N OPO(OH)z -N(C(O)N(H)-CH2-CH2-F)-Ia-a1030 /\N OPO(OH)z N(C(O)N(H)-CH2-CH2-OCH3)-Ia-a1031 /\N OPO(OH)z N(C(O)N(H)-CH2-CH2-CF3)-Ia-a1032 /\N OPO(OH)z N(C(O)N(H)-CH2-CH2-CF3)-Ia-a1033 /\N OPO(OH)z N(C(O)N(H)-CH2-CF3)-Ia-a1034 /\N OPO(OH)z N(C(O)N(H)-(CH2)3-OH)-Ia-a1035 CH3 -CH(OH)-OPO OH
Ia-a1036 /--N/CH3 N(C(O)N(H)-CHz-CHz-OH)-OPO OH
Ia-a1037 CH3 -N(C(O)N(H)-CHz-CHz-F)-OPO OH
Ia-a1038 CH3 N(C(O)N(H)-CH2-CH2-OCH3)-OPO OH
Ia-a1039 /--N/CH3 N(C(O)N(H)-CH2-CH2-CF3)-OPO OH
Ia-a1040 /--NCH3 N(C(O)N(H)-CH2-CH2-CF3)-OPO OH

Ia-a1041 CH3 N(C(O)N(H)-CH2-CF3)-OPO OH
Ia-a1042 /--N1-1 CH3 N(C(O)N(H)-(CH2)3-OH)-OPO OH
Ia-a1043 -CH(OH)-/-N

OPO OH
Ia-a1044 N(C(O)N(H)-CHz-CHz-OH)-OPO OH
Ia-a1045 -N(C(O)N(H)-CHz-CHz-F)-OPO OH
Ia-a1046 N(C(O)N(H)-CH2-CH2-OCH3)-OPO OH
Ia-a1047 N(C(O)N(H)-CH2-CH2-CF3)-OPO OH
Ia-a1048 N(C(O)N(H)-CH2-CH2-CF3)-OPO OH

Ia-a1049 N(C(O)N(H)-CH2-CF3)-OPO OH
Ia-a1050 N(C(O)N(H)-(CH2)3-OH)-OPO OH
Ia-a1051 \--H -CH(OH)-N

OPO OH )a2 Ia-a1052 \\__H N(C(O)N(H)-CHz-CHz-OH)-N

OPO OH
Ia-a1053 N(C(O)N(H)-CHz-CHz-F)-N

OPO OH
Ia-a1054 \\--H N(C(O)N(H)-CH2-CH2-OCH3)-N

OPO OH
Ia-a1055 \\__H N(C(O)N(H)-CH2-CH2-CF3)-N

OPO OH
Ia-a1056 H N(C(O)N(H)-CH2-CH2-CF3)-N

OPO OH
Ia-a1057 \\__H N(C(O)N(H)-CH2-CF3)-N

OPO OH

Ia-a1058 N -N(C(O)N(H)-(CH2)3-OH)-)aOPO(OH)2 and pharmaceutically acceptable salts thereof.

5.3 The Indenoisoquinolinone Analogs of Formula (IIa) The present invention provides Indenoisoquinolinone Analogs according to Formula (Ib), below:

NH
X

R' (Ib) and pharmaceutically acceptable salts thereof, wherein X and Ri are as defined above for the Indenoisoquinolinone Analogs of Formula (Ib).
In one embodiment, X is -N(CH3)-. In another embodiment, X is is -N(CH2CH3)-. In another embodiment, X is -N(CH2CH2CH3)-. In another embodiment, X is -N(CH2 CH2CH2CH3)-. In another embodiment, X is -N(C(H)(CH3)(CH2CH3))-.
In another embodiment, X is -N(C(H)(CH3)2)-. In another embodiment, X is -N(CH2C(H)(CH3)2)-. In another embodiment, X is -N(C(CH3)3)-.
In one embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(CH3)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(CH2CH3)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(CH2CH2CH3)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2) and X is -N(CH2 CH2CH2CH3)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(C(H)(CH3)(CHzCH3))-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(C(H)(CH3)2)-.

In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(CHzC(H)(CH3)z)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(C(CH3)3)-.
In one embodiment, Ri is -O-(CH2)õ-N(R2)(R2) and X is -N(CH3)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(CH2CH3)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is N(CHzCHzCH3)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(CH2 CHzCHzCH3)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(C(H)(CH3)(CH2CH3))-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(C(H)(CH3)z)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(CHzC(H)(CH3)z)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2)(R2 ) and X is -N(C(CH3)3)-.
In one embodiment, one R2 is -H, and the other R2 is -Ci-C6 alkyl.
In another embodiment, each R2 is -Ci-C6 alkyl.
In another embodiment, each R2 is -methyl.
In one embodiment, X is -CH(OH)-.
In another embodiment, X is -CH(OH)- and Ri is -(CHz)ri N(R2)(R).
In yet another embodiment, X is -CH(OH)- and Ri is -(CH2)-N(R2 )(R2).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)2-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-Z)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p Z)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)-Z)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q Z)-.
In another embodiment, X is -N((CHz)-Z)-.
In another embodiment, X is -N((CH2)2-Z)-.
In another embodiment, X is -N((CHz)q Z)- and Ri is -(CHz)ri N(R2 )(R2).
In yet another embodiment, X is -N((CHz)q Z)- and Ri is -(CH2)-N(R2)(R 2).

In still another embodiment, X is -N((CH2)-Z)- and Ri is -(CH2)-N(R2)(R2).
In one embodiment, Z is -CF3.
In another embodiment, Z is -F.
In yet another embodiment, Z is -OH.
In still another embodiment, Z is -O-CH3.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OH)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OH)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p OH)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q OH)-.
In another embodiment, X is -N((CH2)2-OH)-.
In another embodiment, X is -N((CHz)q OH)- and Ri is -(CHz)ri N(R2)(R).
In yet another embodiment, X is -N((CHz)q OH)- and Ri is -(CH2)-N(R2)(R).
In still another embodiment, X is -N((CH2)2-OH)- and Ri is -(CH2)-N(R2)(R).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-F)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)-F)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-F)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p F)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)-F)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q F)-.
In another embodiment, X is -N((CH2)-F)-.
In another embodiment, X is -N((CHz)q F)- and Ri is -(CHz)ri N(R2 )(R2).
In yet another embodiment, X is -N((CHz)q F)- and Ri is -(CH2)-N(R2)(R2).
In still another embodiment, X is -N((CH2)-F)- and Ri is -(CH2)-N(R2)(R2).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OMe)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)2-OMe)-.

In another embodiment, X is -N(C(O)N(H)-(CHz)p-OMe)- and Ri is -(CHz)ri N(R2 )(R2 ).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p OMe)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OMe)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q OMe)-.
In another embodiment, X is -N((CH2)2-OMe)-.
In another embodiment, X is -N((CHz)q OMe)- and Ri is -(CHz)ri N(R2)(R).
In yet another embodiment, X is -N((CHz)q OMe)- and Ri is -(CH2)-N(R2 )(R2).
In still another embodiment, X is -N((CH2)2-OMe)- and Ri is -(CH2)-N(R2 )(R2).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)p-CF3)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p CF3)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)-CF3)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q CF3)-.
In another embodiment, X is -N((CHz)-CF3)-.
In another embodiment, X is -N((CHz)q CF3)- and Ri is -(CHz)ri N(R2 )(R2).
In yet another embodiment, X is -N((CHz)q CF3)- and Ri is -(CH2)-N(R2)(R2).
In still another embodiment, X is -N((CH2)-CF3)- and Ri is -(CH2)-N(R2)(R2).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)- CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p- CF3)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p CF3)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)-CF3)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q CF3)-.

In another embodiment, X is -N((CHz)-CF3)-.
In another embodiment, X is -N((CHz)q CF3)- and Ri is -(CHz)ri N(R2 )(R2).
In yet another embodiment, X is -N((CHz)q CF3)- and Ri is -(CH2)-N(R2)(R).
In still another embodiment, X is -N((CH2)-CF3)- and Ri is -(CH2)-N(R2)(R2).
In one embodiment, n is 1.
In another embodiment, n is 2.
In yet another embodiment, n is 3.
In a further embodiment, n is 4, 5, or 6.
In yet a further embodiment, n is 7, 8, or 9.
In still a further embodiment, n is 10.
In one embodiment, m is 2.
In another embodiment, m is 3.
In yet another embodiment, m is 4, 5, or 6.
In a further embodiment, m is 7, 8, or 9.
In yet a further embodiment, m is 10.
In one embodiment, p is 1.
In another embodiment, p is 2.
In yet another embodiment, p is an integer ranging from 2 to 5.
In one embodiment, q is 1.
In another embodiment, q is 2.
In yet another embodiment, q is an integer ranging from 2 to 5.
In various embodiments, -N(R2)(R2) is:

/ v / \ / \ CH3 0 No ~-NaOH ~-NN-CH3 ~-N/-\ H ~-N ~-N ~N-/-N(CHs)2 ~~N//~ N0 N N~Ph C(O)OH C(O)OCHZCH3 H ~-N\ N-/ ~-N/ N-/

~ / \N---"INH

H3C~CH3 where X = -H -OMe -CN -F
-Cl, -Br, or -I

N(CH3)2 OH

-N~ N~ -N N ~-N\CH3 ~-N\CH2CH3 F/CH2CH2OH /CH2CH2N(CH3)2 /CH2Ph /CH2CH2OCH3 N\CH2CH2OH ~-N\CH2CH2N(CH3)2 ~-N\CH3 ~-N\CH2CH2OCH3 ~ Hs ~ H2N(CHs)2 I_N`CH3 N~CH3 ~-NCH3 I-NCH2N(CH3)2 CH3 \-CH3 I , ~-N\-7 ~-N~
`~\OH

~- -I-N
-CH3 ~-N

N~\N^ O H N.CH3 N~
~ H N,/~ N

NN,CH3 , NN=/

/ \ I-Na OH - OP(O)(OH)2 N or I- NNCH2CH2OP(O)(OH)2 OP(O)(OH)2 In other embodiments, -N(R2)(R2) is:

/~rN ) ~\ I-N/~rN I /~
\N
~-N
~/ ~/ ~/ ~J
/ I- I-N
~ , HON O
`N OH OMe ~-N -N 0 I-No I-N`~
\~ ao N3 Hp_ ~
1 N OH I-NH ,CH2CH3 I-NH I-N I-NH

D, /-\ s I-NH CHs N ~/ ' H CH3 N

I_N ~_CH3 i-NH H3C
_O
I-NEH I-N N

OH

i-N - CH
~ NON, N Z ~~
I-N H N ' 'I-NN-\iOH
_ -1- ~~N~iCH3 -1-N~OEt , -i-NN-NIIiOMe ' -1-N

_ ~\ 0 CH3 OH
~ N~OEt ~-N~ OH ~-N CH3 ~-N CH3 H3C\
N-CH3 ' -1-N-CH2CH3 ~-N-CH2CH2CH3 -HrCH3 H3 H~-CH3 O Me >--CH3 -N-CH2CH2OH , 0 , H3C -~-N ~ or \ --IQ

~-N ~N

In some embodiments, -N(R2)(R2) is AN
I V
F F
~-N\~ N Q~aF
NMe2 NMe2 F
N
-N N
or In still other embodiments, -N(R2)(R2) is -N(CH2CH3)(CH3), -N(CH2CH2CH3)(CH3), -N(CH2CH2CH2CH3)(CH3), -NH-CH2CH2CH2CH3, or -NH-CH2CH2-O-CH3.
In some embodiments, -N(R2)(R2) is aOPO(OH)2 ~-N N OPO(OH)2 OPO(OH)2 , _ CH3 _ H

~ N IN i-N
or OPO(OH)2 OPO(OH)2 OPO(OH)2 In various embodiments, -N(Z3)(Z4) is:

/ \ / \ CH3 -N 0 ~-NaOH ~-N\ N-CH3 ~-N\ N~
-N NH -N ~-N \ N_/-N(CH3)2 ~-N/ N \ / F

~-N NO N N-/Ph C(O)OH C(O)OCH2CH3 H~ ~-N / N _/ ~-N/ \N~
~

O HO
H3C CH3 where X = -H, -OMe, -CN, -F, -Cl, -Br, or -I
N(CH3)2 OH

-N N -N N / N ~-N\CH3 ~-N\CH2CH3 I-N\CH2CH2OH ~-N\CH2CH2N(CH3)2 I-N\CH2Ph I-N\CH2CH2OCH3 CH2CH2OH CH2CH2N(CH3)2 CH3 CH2CH2OCH3 ~ Hs ~-H2N(CHs)2 I_N`CH3 N~CH3 ~-NQH3 ~-N~ H2N(CH3)2 CH3 ~CH3 ~-N\-7 ~-N~
`~\OH

~- -I-N -CH3 ~-N

N~\N^ O H N.CH3 N~
~ H N,/~ N-~~N

NN,CH3 , NN=/
~OH ~-N`~
OP(O)(OH)2 ~-N or NCH2CH2OP(O)(OH)2 OP(O)(OH)2 In other embodiments, -N(Z3)(Z4) is:

õ~.
I
\ N) I-NO-Nb I-NO-Nb I N I-HO O
I-N .OH }_No OMe N
I_N Z
N
`~
~ HO_ ~ O
~
~N OH I-NH t-NH i-N, CH2CH3 ~-NH
~

I-N\_jS ' 1-NIC~-\0 H I-N

I-N OH
0 , OH

i-N CHs N~ , ~~
}-N ~ / N ~N`CH3 2 CH3CH2 }-NH N CH3 Z
-NH N I-N\_/ N--\iOH
/~
I-N~j ~iCH3 -1-N, rOEt 'i-N

N N~ O ,CH3 OH
I 'OEt ~-N~ I-N I-N_ rCH3 OH kCH3 ~/

H3C\
~-N-CH3 =}-N-CH2CH3 '~-N-CH2CH2CH3 HrCHs ~H3 ~-CH3 TNH
CH3 or \
~/

In some embodiments, -N(Z3)(Z4) is A N
I
F F
N\~ ~\N N
v F
NMe2 NMe2 F Q -N N
or In still other embodiments, -N(Z3)(Z4) is -N(CH2CH3)(CH3), -N(CH2CH2CH3)(CH3), -N(CH2CH2CH2CH3)(CH3), -NH-CH2CH2CH2CH3, or -NH-CHzCHz-O-CH3.
In some embodiments, -N(Z3)(Z4) is N ~-N ~- N OPO(OH)2 OPO(OH)2 OPO(OH)2 or ~

In one embodiment, X is N(CH3)- N(CHzCH3)- -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;
Ri is -(CHz)ri N(R2)(R2) or -O-(CH2)õ-N(R2)(R);
each R2 is independently -H, -Ci-C6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(Ci-C6 alkylene)-phenyl or phenyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)z, -OS(O)zOH or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -Ci-CS alkyl, or -(CI-C5 alkylene)-O-Ci-CS alkyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH or -NH2;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -Ci-CS
alkyl, -phenyl, -(CI-C5 alkylene)-phenyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(CI-C5 alkylene)-N(Ra)z, -Ci-CS alkylene-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(CI-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(CI-C5 alkylene)-OP(O)(OH)2, -(CI-C5 alkylene)-OS(O)zOH, -C(O)O-Ci-Cs alkyl, -OC(O)-Ci-Cs alkyl, -(Ci-Cs alkylene)-C(O)O-Ci-Cs alkyl, -(CI-C5 alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, or -Ci-Cio alkyl;
or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -Ci-CS alkyl, -phenyl, -(CI-C5 alkylene) -phenyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(CI-C5 alkylene)-N(Ra)z, -(CI-C5 alkylene)-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(CI-alkylene)-COOH, -OP(O)(OH)z, -OS(O)zOH, -(CI-C5 alkylene)-OP(O)(OH)2, -(CI-C5 alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)O-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, or -Ci-Cio alkyl;
n is an integer ranging from 1 to 10; and m is an integer ranging from 2 to 10.
In one embodiment, X is N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; Ri is -CH2-N(R2)(R 2); and at least one R2 is methyl.

In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;Ri is -CH2-N(R 2)(R2); and at least one R2 is ethyl.
In yet another embodiment, X is -N(CH3)- -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; Ri is -CH2-N(R2)(R2); and at least one R2 is propyl.
In one embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;Ri is -CH2-N(R 2)(R2); and at least one R2 is monocyclic cycloalkyl.
In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;Ri is -CH2-N(R2)(R2 ); and at least one R2 is cyclohexyl.
In yet another embodiment, X is -N(CH3)- -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; and Ri is -CH2-N(R2)(R 2), wherein N and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle.
In one embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; and Ri is -CH2-N(R2)(R 2), wherein N and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with a hydroxyl.
In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; and Ri is -CH2-N(R2)(R 2), wherein N and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with a nitrogen-containing 3- to 7-membered monocyclic heterocycle.

Illustrative examples of the Indenoisoquinolinone Analogs include the compounds of Formula (Ib) as set forth below:

NH
X

R' (m) Compound n - R X
Ib-1 1 -(CHz)ri N(CH3)z N(CH3)-Ib-2 2 -(CHz)ri N(CH3)z N(CH3)-Ib-3 3 -(CHz)ri N(CH3)z N(CH3)-Ib-4 4 -(CHz)ri N(CH3)z N(CH3)-Ib-5 5 -(CHz)ri N(CH3)z N(CH3)-Ib-6 6 -(CHz)ri N(CH3)z N(CH3)-Ib-7 1 CHz ri N CH3 z -N CHzCH3 -Ib-8 2 CHz ri N CH3 z -N CHzCH3 -Ib-9 3 CHz ri N CH3 z -N CHzCH3 -Ib-10 4 CHz ri N CH3 z -N CHzCH3 -Ib-11 5 CHz ri N CH3 z -N CHzCH3 -Ib-12 6 CHz ri N CH3 z -N CHzCH3 -Ib-13 1 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ib-14 2 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ib-15 3 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ib-16 4 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ib-17 5 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ib-18 6 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ib-19 1 -(CHz)ri N(CH3)z -N(CH2 CH2CH2CH3)-Ib-20 2 -(CHz)ri N(CH3)z -N(CH2 CH2CH2CH3)-Ib-21 3 -(CHz)ri N(CH3)z -N(CH2 CH2CH2CH3)-Ib-22 4 CHz ri N CH3 z -N(CH2 CH2CH2CH3 -Ib-23 5 -(CHz)ri N(CH3)z -N(CH2 CH2CH2CH3)-Ib-24 6 CHz ri N CH3 z -N(CH2 CH2CH2CH3 -Ib-25 1 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ib-26 2 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ib-27 3 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ib-28 4 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ib-29 5 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ib-30 6 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ib-31 1 CH2riNCH32 -NCH CH32-Ib-32 2 CHz ri N CH3 z -N C H CH3 z-Ib-33 3 CHz ri N CH3 z -N C H CH3 z-Ib-34 4 CHz ri N CH3 z -N C H CH3 z-Ib-35 5 CHz ri N CH3 z -N C H CH3 z-Ib-36 6 CHz ri N CH3 z -N C H CH3 z-Ib-37 1 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ib-38 2 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ib-39 3 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ib-40 4 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ib-41 5 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ib-42 6 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ib-43 1 CHz ri N CH3 z -N C CH3 3-Ib-44 2 CHz ri N CH3 z -N C CH3 3-Ib-45 3 CH2riNCH32 -NCCH33-Ib-46 4 CH2riNCH32 -NCCH33-Ib-47 5 CHz ri N CH3 z -N C CH3 3-Ib-48 6 CHz ri N CH3 z -N C CH3 3-Ib-49 1 N(CH3)--(CH2)n N 0 Ib-50 2 N(CH3)--(CH2)n N 0 Ib-51 3 N(CH3)--(CH2)n N 0 Ib-52 4 N(CH3)--(CH2)n N 0 Ib-53 5 N(CH3)--(CH2)n N 0 Ib-54 6 N(CH3)--(CH2)n N 0 Ib-55 1 -N(CH2CH3)--(CH2)n N 0 Ib-56 2 -N(CH2CH3)--(CH2)n N 0 Ib-57 3 -N(CH2CH3)--(CH2)n N 0 Ib-58 4 -N(CH2CH3)--(CH2)n N 0 Ib-59 5 -N(CH2CH3)--(CH2)n N 0 Ib-60 6 -N(CH2CH3)--(CH2)n N 0 Ib-61 1 N(CH2CH2CH3)--(CH2)n N 0 Ib-62 2 N(CH2CH2CH3)--(CH2)n N 0 Ib-63 3 N(CH2CH2CH3)--(CH2)n N 0 Ib-64 4 N(CH2CH2CH3)--(CH2)n N 0 Ib-65 5 N(CH2CH2CH3)--(CH2)n N 0 Ib-66 6 N(CH2CH2CH3)--(CH2)n N 0 Ib-67 1 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ib-68 2 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ib-69 3 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ib-70 4 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ib-71 5 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ib-72 6 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ib-73 1 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ib-74 2 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ib-75 3 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ib-76 4 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ib-77 5 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ib-78 6 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ib-79 1 -N(C(H)(CH3)2)--(CH2)n N 0 Ib-80 2 -N(C(H)(CH3)2)--(CH2)n N 0 Ib-81 3 -N(C(H)(CH3)2)--(CH2)n N 0 Ib-82 4 -N(C(H)(CH3)2)--(CH2)n N 0 Ib-83 5 -N(C(H)(CH3)2)--(CH2)n N 0 Ib-84 6 -N(C(H)(CH3)2)--(CH2)n N 0 Ib-85 1 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ib-86 2 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ib-87 3 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ib-88 4 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ib-89 5 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ib-90 6 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ib-91 1 -N(C(CH3)3)--(CH2)n N 0 Ib-92 2 -N(C(CH3)3)--(CH2)n N 0 Ib-93 3 -N(C(CH3)3)--(CH2)n N 0 Ib-94 4 -N(C(CH3)3)--(CH2)n N 0 Ib-95 5 -N(C(CH3)3)--(CH2)n N 0 Ib-96 6 -N(C(CH3)3)--(CH2)n N 0 Compound m - Rl X
Ib-146 2 -O-(CHz)m N(CH3)z N(CH3)-Ib-147 3 -O-(CHz)m N(CH3)z N(CH3)-Ib-148 4 -O-(CHz)m N(CH3)z N(CH3)-Ib-149 5 -O-(CHz)m N(CH3)z N(CH3)-Ib-150 6 -O-(CHz)m N(CH3)z N(CH3)-Ib-151 2 -O-(CHz)m N(CH3)z N(CH3)-Ib-152 3 -O CHz õ-N CH3 z -N CHzCH3 -Ib-153 4 -O CHz õ-N CH3 z -N CHzCH3 -Ib-154 5 -O CHz õ-N CH3 z -N CHzCH3 -Ib-155 6 -O CHz õ-N CH3 z -N CHzCH3 -Ib-156 2 -O-(CHz)m N(CH3)z -N(CH2CH3)-Ib-157 3 -O-(CHz)m N(CH3)z -N(CH2CH3)-Ib-158 4 -O-(CHz)m N(CH3)z -N(CH2CH2CH3)-Ib-159 5 -O-(CHz)m N(CH3)z -N(CH2CH2CH3)-Ib-160 6 -O-(CH2)õ-N(CH3)2 -N(CH2CH2CH3)-Ib-161 2 -O CHz õ-N CH3 z -N CHzCHzCH3 -Ib-162 3 -O CHz õ-N CH3 z -N CHzCHzCH3 -Ib-163 4 -O CHz õ-N CH3 z -N CHzCHzCH3 -Ib-164 5 -O CHz õ-N CH3 z -N CHzCHzCHzCH3 -Ib-165 6 -O CHz õ-N CH3 z -N CHzCHzCHzCH3 -Ib-166 2 -O-(CHz)m N(CH3)z -N(CH2CH2CH2CH3)-Ib-167 3 -O-(CHz)m N(CH3)z -N(CH2CH2CH2CH3)-Ib-168 4 -O-(CHz)m N(CH3)z -N(CH2CH2CH2CH3)-Ib-169 5 -O-(CHz)m N(CH3)z -N(CH2CH2CH2CH3)-Ib-170 6 -O-(CHz)m N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ib-171 2 -O-(CHz)m N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ib-172 3 -O CHz õ-N CH3 z -N C H CH3 CHzCH3 -Ib-173 4 -O CHz õ-N CH3 z -N C H CH3 CHzCH3 -Ib-174 5 -O CHz õ-N CH3 z -N C H CH3 CHzCH3 -Ib-175 6 -O-(CHz)m N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ib-176 2 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ib-178 3 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ib-179 4 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ib-180 5 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ib-181 6 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ib-182 2 -O CHz õ-N CH3 z -N C H CH3 z-Ib-183 3 -O CHz õ-N CH3 z -N CHzC H CH3 z-Ib-184 4 -O CHz õ-N CH3 z -N CHzC H CH3 z-Ib-185 5 -O CHz õ-N CH3 z -N CHzC H CH3 z-Ib-186 6 -O CHz õ-N CH3 z -N CHzC H CH3 z-Ib-187 2 N(CH3)--0(cH2)m N 0 Ib-188 3 ~\ N(CH3)--o (cH2)m N~

Ib-189 4 N(CH3)--0(cH2)m N j Ib-190 5 N(CH3)--0(cH2)m N 0 Ib-191 6 N(CH3)--0(cH2)m N %

Ib-192 2 N(CH3)--0(cH2)m N 0 Ib-193 3 -N(CH2CH3)--0(cH2)m N 0 Ib-194 4 -N(CH2CH3)--0(cH2)m N j Ib-195 5 -N(CH2CH3)--0(cH2)m N 0 Ib-196 6 -o (cH \ -N(CHzCH3)-2)m~% ~- 178 -Ib-197 2 -N(CH2CH3)--0 (CH2)m N 0 Ib-198 3 -N(CH2CH3)--0 (CH2)m N 0 Ib-199 4 N(CH2CH2CH3)--0 (CH2)m N 0 Ib-200 5 N(CH2CH2CH3)--0 (CH2)m N 0 Ib-201 6 N(CH2CH2CH3)--0 (CH2)m N 0 Ib-202 2 N(CH2CH2CH3)--0 (CH2)m N 0 Ib-203 3 N(CH2CH2CH3)--0 (CH2)m N 0 Ib-204 4 N(CH2CH2CH3)--0 (CH2)m N 0 Ib-205 5 -N(CH2CH2CH2CH3)--0 (CH2)m N 0 Ib-206 6 -N(CH2CH2CH2CH3)--0 (CH2)m N 0 Ib-207 2 -0 (CH \ -N(CHzCHzCHzCH3)-2)m~% ~

Ib-208 3 -N(CH2CH2CH2CH3)--0 (CH2)m N 0 Ib-209 4 -N(CH2CH2CH2CH3)--0 (CH2)m N j Ib-210 5 -0 (CH \ -N(CHzCHzCHzCH3)-2)m~~ ~

Ib-211 6 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N j Ib-212 2 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ib-213 3 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ib-214 4 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ib-215 5 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ib-216 6 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ib-217 2 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ib-218 3 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ib-219 4 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ib-220 5 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ib-221 6 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ib-222 2 -0 (CH2) \ -N(C(H)(CH3)z)-m~% ~

Ib-223 3 -N(CH2C(H)(CH3)2)--0 (CH2)m N 0 Ib-224 4 -N(CH2C(H)(CH3)2)--0 (CH2)m N 0 Ib-225 5 -0 (CH \ -N(CHzC(H)(CH3)z)-2)m~~ ~

Ib-226 6 -N(CH2C(H)(CH3)2)--0 (CH2)m N 0 Compound - Rl X
Ib-267 -CH2-N(CH2-CH3)2 -N(CH3)-Ib-268 -CH2-N(CH2-CH3)2 -N(CH2CH3)-Ib-269 -CH2-N(CH2-CH3)2 -N(CH2CH2CH3)-Ib-270 -CH2-N(CH2-CH3)2 -N(CH2CH2CH2CH3)-Ib-271 -CH2-N(CH2-CH3)2 -N(C(H)(CH3)(CH2CH3))-Ib-272 -CH2-N(CH2-CH3)2 -N(C(H)(CH3)2)-Ib-273 -CH2-N(CH2-CH3)2 -N(CH2C(H)(CH3)2)-Ib-274 -CH2-N(CH2-CH3)2 -N(C(CH3)3)-Ib-275 -CH2-N(CH2-CH2-CH3)2 -N(CH3)-Ib-276 -CHz-N CHz-CHz-CH3 z -N CHzCH3 -Ib-277 -CHz-N CHz-CHz-CH3 z -N CHzCHzCH3 -Ib-278 -CHz-N CHz-CHz-CH3 z -N CHzCHzCHzCH3 -Ib-279 -CHz-N CHz-CHz-CH3 z -N C H CH3 CHzCH3 -Ib-280 -CHz-N CHz-CHz-CH3 z -N C H CH3 z-Ib-281 -CHz-N CHz-CHz-CH3 z -N CHzC H CH3 z-Ib-282 -CHz-N CHz-CHz-CH3 z -N C CH3 3-Ib-283 -CHz-N CHz-CHzOH z -N CH3 -Ib-284 -CHz-N CHz-CHzOH z -N CHzCH3 -Ib-285 -CHz-N CHz-CHzOH z -N CHzCHzCH3 -Ib-286 -CHz-N CHz-CHzOH z -N CHzCHzCHzCH3 -Ib-287 -CHz-N CHz-CHzOH z -N C H CH3 CHzCH3 -Ib-288 -CHz-N CHz-CHzOH z -N C H CH3 z-Ib-289 -CHz-N CHz-CHzOH z -N CHzC H CH3 z-Ib-290 -CHz-N CHz-CHzOH z -N C CH3 3-Ib-291 -CHz-N(CHz-CHz-N(CH3)1)1 N(CH3)-Ib-292 -CHz-N(CHz-CHz-N(CH3)1)1 -N(CH2CH3)-Ib-293 -CHz-N(CHz-CHz-N(CH3)1)1 N(CH2CH2CH3)-Ib-294 -CHz-N(CHz-CHz-N(CH3)1)1 -N(CH2CH2CH2CH3)-Ib-295 -CHz-N(CHz-CHz-N(CH3)1)1 -N C H CH3 CHzCH3 -Ib-296 -CHz-N(CHz-CHz-N(CH3)1)1 -N C H CH3 z-Ib-297 -CHz-N(CHz-CHz-N(CH3)1)1 -N CHzC H CH3 z-Ib-298 -CHz-N(CHz-CHz-N(CH3)1)1 -N C CH3 3 -Ib-299 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N CH3 -Ib-3UU -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N CHzCH3 -Ib-3U1 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N CHzCHzCH3 -Ib-302 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N CHzCHzCHzCH3 -Ib-303 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C H CH3 CHzCH3 -Ib-3U4 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C H CH3 z-Ib-3U5 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N CHzC H CH3 z-Ib-3U6 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C CH3 3 -Ib-307 -CH2-N~ N(CH3)-Ib-308 -CH2-N -N(CH2CH3)-Ib-309 -CH2-N~ N(CH2CH2CH3)-Ib-310 -CH2-N~ -N(CH2CH2CH2CH3)-Ib-311 -CH2-N~ -N(C(H)(CH3)(CH2CH3))-Ib-312 -CHz-N~ -N(C(H)(CH3)2)-Ib-313 -CH2-N~ -N(CH2C(H)(CH3)2)-Ib-314 -CH2-N~ -N(C(CH3)3)-Ib-315 -CHz-<> -N(CH3)-Ib-316 -CH2-<> -N(CH2CH3)-Ib-317 -CH2-Nc> -N(CH2CH2CH3)-Ib-318 -CH2-Nc> -N(CH2CH2CH2CH3)-Ib-319 -CH2-Nc> -N(C(H)(CH3)(CH2CH3))-Ib-320 -CHz-<> -N(C(H)(CH3)2)-Ib-321 -CHz-<> -N(CH2C(H)(CH3)2)-Ib-322 -CH2-N~> -N(C(CH3)3)-Ib-323 -CHz-NC) N(CH3)-Ib-324 -CHz-No -N(CH2CH3)-Ib-325 -CHz-No -N(CH2CH2CH3)-Ib-326 -CH2-No -N(CH2CH2CH2CH3)-Ib-327 -CH2-No -N(C(H)(CH3)(CH2CH3))-Ib-328 -CHz-No -N(C(H)(CH3)2)-Ib-329 -CHz-No -N(CH2C(H)(CH3)2)-Ib-330 -CHz-No -N(C(CH3)3)-Ib-331 -CHz-Na N(CH3)-Ib-332 -CHz-Na -N(CH2CH3)-Ib-333 -CH2-Na N(CH2CH2CH3)-Ib-334 -CH2-Na -N(CH2CH2CH2CH3)-OH

Ib-335 -CH2-N~ -N(C(H)(CH3)(CH2CH3))-Ib-336 -CHz-Na -N(C(H)(CH3)2)-OH
Ib-337 -CHz-Na -N(CH2C(H)(CH3)2)-Ib-338 -CHz-Na -N(C(CH3)3)-Ib-339 -CHz-N -N(CH3)-OH
Ib-340 -CHz-N -N(CH2CH3)-Ib-341 -CHz-N -N(CH2CH2CH3)-Ib-342 -CHz-N -N(CH2CH2CH2CH3)-OH
Ib-343 -CHz-N -N(C(H)(CH3)(CH2CH3))-Ib-344 -CHz-N -N(C(H)(CH3)2)-Ib-345 -CHz-N -N(CH2C(H)(CH3)2)-Ib-346 -CHz-N -N(C(CH3)3)-Ib-347 -CHz-N, ) N(CH3)-Ib-348 -CHz-N --, )-- -N(CH2CH3)-Ib-349 -CH2-N -- )-- N(CH2CH2CH3)-Ib-350 -CH2-N_ ) -N(CH2CH2CH2CH3)-Ib-351 -CH2-N_ ) -N(C(H)(CH3)(CH2CH3))-Ib-352 -CHz-N_ ) -N(C(H)(CH3)2)-Ib-353 -CHz-N --D -- -N(CH2C(H)(CH3)2)-Ib-354 -CHz-N, ) -N(C(CH3)3)-Ib-355 -CH2-N~--N---CH3 -N(CH3)-Ib-356 -CH2-N/-\ N-CH3 -N(CH2CH3)-Ib-357 -CH2-N/-\ N-CH3 -N(CH2CH2CH3)-Ib-358 -CH2-N/-\ N-CH3 -N(CH2CH2CH2CH3)-Ib-359 -CH2-N/-\ N-CH3 -N(C(H)(CH3)(CH2CH3))-Ib-360 -CH2-N/-\ N-CH3 -N(C(H)(CH3)2)-Ib-361 -CH2-N/-\ N-CH3 -N(CH2C(H)(CH3)2)-Ib-362 -CH2-N/-\ N-CH3 -N(C(CH3)3)-Ib-363 -CH2-N /CH3 N(CH3)-Ib-364 --CH2-N /cH3 -N(CH2CH3)-Ib-365 -CH2-N /cH3 N(CH2CH2CH3)-Ib-366 -CH2-N /cH3 -N(CH2CH2CH2CH3)-Ib-367 --CH2-N /cH3 -N(C(H)(CH3)(CH2CH3))-Ib-368 -CH2-N /cH3 -N(C(H)(CH3)2)-Ib-369 -CH2-N /cH3 -N(CH2C(H)(CH3)2)-Ib-370 --CH2-N /cH3 -N(C(CH3)3)-Ib-371 -CH2-N /cHs N(CH3)->-CH3 H C

Ib-372 -CH2 -N CH3 -N(CH2CH3)->-CH3 Ib-373 -CH2 -N /QH3 N(CH2CH2CH3)->-CH3 Ib-374 -CH2 -N CH3 -N(CH2CH2CH2CH3)->-CH3 H C
Ib-375 -CH2 -N CH3 -N(C(H)(CH3)(CH2CH3))->-CH3 Ib-376 -CH2 -N /CH3 -N(C(H)(CH3)2)->-CH3 H C
Ib-377 -CH2-N /CH3 -N(CH2C(H)(CH3)2)->-CH3 H C
Ib-378 -CH2-N /QH3 -N(C(CH3)3)->-CH3 H C
Ib-379 -CH2-N /CH3 N(CH3)-Ib-380 -CH2-N /CH3 -N(CH2CH3)-Ib-381 -CH2-N CH3 N(CH2CH2CH3)-Ib-382 -CH2-N CH3 -N(CH2CH2CH2CH3)-Ib-383 -CH2-N CH3 -N(C(H)(CH3)(CH2CH3))-Ib-384 ~H2-N CH3 -N(C(H)(CH3)2)-Ib-385 -CH2-N /QH3 -N(CH2C(H)(CH3)2)-Ib-386 -CH2-N /CH3 -N(C(CH3)3)-Ib-387 ~ N -N(CH3)-Ib-388 ~ N ~~ N~ -N(CH2CH3)--CH2 ~O
Ib-389 ~ N ~~ N~ N(CHzCHzCH3) -CH2 ~O
Ib-390 "N-N(CH2CH2CH2CH3)-Ib-391 N-N(C(H)(CH3)(CH2CH3))-Ib-392 N -N(C(H)(CH3)2)-Ib-393 N-N(CH2C(H)(CH3)2)-Ib-394 N -N(C(CH3)3)-Ib-395 ~
O N(CH3)-H N~/
CH -' N

Ib-396 iii:5 -N(CHzCH3)-H N~/
\
CH
Ib-397 ~O -N(CHzCHzCH3)-H N~/
\
CH / N

Ib-398 (--O -N(CH2CH2CH2CH3)-/NN,/
CH
Ib-399 ("-- O -N(C(H)(CH3)(CH2CH3))-H N-/
CH -' N
Ib-400 (/--O -N(C(H)(CH3)2)-/NN~/
CH

Ib-401 ~O -N(CH2C(H)(CH3)2)-H
CH/
Ib-402 ~O -N(C(CH3)3)-H N~
~
CH -' N
Ib-403 N CH3 -N(CH3)-H
/N

Ib-404 ~N CH3 -N(CHzCH3)-\ /N~~N~/

Ib-405 ~N CH3 N(CHzCHzCH3)-\ ~NN~/

Ib-406 ~N CH3 -N(CHzCHzCHzCH3)-\ N-/

Ib-407 N CH3 -N(C(H)(CH3)(CHzCH3))-\ N-/

Ib-408 ~N CH3 -N(C(H)(CH3)2)-H

Ib-409 ~N CH3 -N(CH2C(H)(CH3)2)-H

Ib-410 ~N CH3 -N(C(CH3)3)-H

Ib-411 H3~ N(CH3)-CH 'N-CH3 Ib-412 H3C -N(CHzCH3)-H
CH ~N~/N`CH3 Ib-413 H3~ N(CHzCHzCH3)-CH N`

Ib-414 H3~ -N(CH2CH2CH2CH3)-CH 'NN-CH3 Ib-415 H3~ -N(C(H)(CH3)(CH2CH3))-H
CH -'NN`CH3 Ib-416 H3~ -N(C(H)(CH3)2)-Ib-417 H3~ -N(CH2C(H)(CH3)2)-Ib-418 H3~ -N(C(CH3)3)-H

Ib-419 N -N(CH3)-/
H N
\CH N
Ib-420 ~ N -N(CH2CH3)-/
N
\CH N
Ib-421 ~ N -N(CHzCHzCH3)-/
\CH N

Ib-422 ~ N -N(CH2CH2CH2CH3)-/
N
\CH ~N
Ib-423 ~N -N(C(H)(CH3)(CH2CH3))-N
\CH "I N
Ib-424 ~ N -N(C(H)(CH3)2)-/
H N
\CH N
Ib-425 ~ N -N(CH2C(H)(CH3)2)-H N
\CH N
Ib-426 N -N(C(CH3)3)-H N
\CH N

Ib-427 ~ ~ N(CH3)-~
-CH2-N~/N
Ib-428 ~ ~ -N(CHzCH3)-~
-CH2-N ~\ N

Ib-429 ~ ~ N(CHzCHzCH3)-~
-CH2-N~/N
Ib-430 ~ ~ -N(CHzCHzCHzCH3)-/
~

Ib-431 ~ ~ -N(C(H)(CH3)(CHzCH3))-~
-CH2-N~/N
Ib-432 ~ ~ -N(C(H)(CH3)z)-~
-CH2-N~/ N
Ib-433 ~ ~ -N(CHzC(H)(CH3)z)-~
~

Ib-434 ~ ~ -N(C(CH3)3)-~
-CH2-N~/N

Ib-435 -CH2iv/-\ N F -N(CH3)-~/
Ib-436 -CH2iv/-\ N F -N(CH2CH3)-~/ -Ib-437 -CH2iv /-\ N F -N(CH2CH2CH3)-~/
Ib-438 -CH iV/-\ N F -N(CH2CH2CH2CH3)-2 ~/ -Ib-439 -CHzfv/-\ N ~ F -N(C(H)(CH3)(CH2CH3))--Ib-440 -CH2iv/-\ N F -N(C(H)(CH3)2)-~/
Ib-441 -CH2iv/-\ N F -N(CH2C(H)(CH3)2)-~/
Ib-442 -CH2iv/-\ N F -N(C(CH3)3)-~/

Ib-443 -CH2-N ~F N(CH3)-Ib-444 -CH2-N ~F -N(CH2CH3)-Ib-445 -CH2-N ~F N(CH2CH2CH3)-Ib-446 -CH2-N ~F -N(CH2CH2CH2CH3)-Ib-447 -CH2-N ~F -N(C(H)(CH3)(CH2CH3))-Ib-448 -CHz-N ~F -N(C(H)(CH3)2)-Ib-449 -CH2-N ~F -N(CH2C(H)(CH3)2)-Ib-450 -CHz-N ~F -N(C(CH3)3)-Ib-451 -CH2-N ~ -N(CH3)-Ib-452 -CH2-N ~ -N(CH2CH3)-Ib-453 -CHz-N O N(CH2CH2CH3)-Ib-454 -CHz-N O -N(CH2CH2CH2CH3)-Ib-455 -CH2-N ~ -N(C(H)(CH3)(CH2CH3))-Ib-456 -CH2-N O -N(C(H)(CH3)2)-Ib-457 -CH2-N ~ -N(CH2C(H)(CH3)2)-Ib-458 -CH2-N o -N(C(CH3)3)-Ib-459 -cHz-N \ / \ c N(CH3)-Ib-460 -cHz-N \ / \ c -N(CH2CH3)-Ib-461 -cHz-N \ / \ c N(CH2CH2CH3)-Ib-462 -CHz-N ~cl -N(CH2CH2CH2CH3)-Ib-463 -CHz-N cl -N(C(H)(CH3)(CH2CH3))-Ib-464 -cH2-N 0--acl -N(C(H)(CH3)2)-Ib-465 -cH2-N \ / \ c -N(CH2C(H)(CH3)2)-Ib-466 -cH2-N \ / \ c -N(C(CH3)3)-Ib-467 -cH2-N \ / \ N(CH3)-Ib-468 -cH2_N \ / \ -N(CH2CH3)-Ib-469 -cH2_N \ / \ N(CH2CH2CH3)-Ib-470 -CH2_N \ / \ -N(CH2CH2CH2CH3)-Ib-471 -CH2_N \ / \ -N(C(H)(CH3)(CH2CH3))-Ib-472 -cH2_N \ / \ -N(C(H)(CH3)2)-Ib-473 -cH2_N \ / \ -N(CH2C(H)(CH3)2)-Ib-474 -cH2_N \ / \ -N(C(CH3)3)-Ib-475 -cH2_N / \ N(CH3)-Ib-476 -cH2_N / \ -N(CH2CH3)-Ib-477 -cH2_N N(CH2CH2CH3)-OH -Ib-478 -CH2_N / \ -N(CH2CH2CH2CH3)-Ib-479 -CH2_N / \ -N(C(H)(CH3)(CH2CH3))-Ib-480 -CH2-N ~ -N(C(H)(CH3)2)-Ib-481 -cH2_N o -N(CH2C(H)(CH3)2)-Ib-482 -cH2_N / \ -N(C(CH3)3)-Ib-483 -CH2-N /-\ NCH2CH2OP(O)(OH)2 N(CH3)-Ib-484 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(CH2CH3)-Ib-485 -CH2-N /-\ NCH2CH2OP(O)(OH)2 N(CH2CH2CH3)-Ib-486 -CH2-N NCH2CH2OP(O)(OH)2 -N(CH2CH2CH2CH3)-Ib-487 -CH2-N NCH2CH2OP(O)(OH)2 -N(C(H)(CH3)(CH2CH3))-Ib-488 -CH2- N/'-NNCH2CH2OP(O)(OH)2 -N(C(H)(CH3)2)-Ib-489 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(CH2C(H)(CH3)2)-Ib-490 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(C(CH3)3)-Ib-491 -CH2-CH2-CH2-OP(O)(OH)2 N CH3 -Ib-492 -CH2-CH2-CH2-OP(O)(OH)2 -N CH2CH3 -Ib-493 -CH2-CH2-CH2-OP(O)(OH)2 N CH2CH2CH3 -Ib-494 -CH2-CH2-CH2-OP(O)(OH)2 -N CH2CH2CH2CH3 -Ib-495 -CH2-CH2-CH2-OP(O)(OH)2 -N C H CH3 CH2CH3 -Ib-496 -CH2-CH2-CH2-OP(O)(OH)2 -N C H CH3 2-Ib-497 -CH2-CH2-CH2-OP(O)(OH)2 -N CH2C H CH3 2-Ib-498 -CH2-CH2-CH2-OP(O)(OH)2 -N C CH3 3 -Ib-499 -CHz-CHz-CHz-OS(O)zOH N CH3 -Ib-500 -CHz-CHz-CHz-OS(O)zOH -N(CH2CH3)-Ib-501 -CHz-CHz-CHz-OS(O)zOH N(CH2CH2CH3)-Ib-502 -CHz-CHz-CHz-OS(O)zOH -N(CH2CH2CH2CH3)-Ib-503 -CHz-CHz-CHz-OS(O)zOH -N(C(H)(CH3)(CH2CH3))-Ib-504 -CHz-CHz-CHz-OS(O)zOH -N(C(H)(CH3)2)-Ib-505 -CHz-CHz-CHz-OS(O)zOH -N CH2C H CH3 2-Ib-506 -CHz-CHz-CHz-OS(O)zOH -N C CH3 3 -Ib-507 -CHz-Na -N(CH3)-OP O OH
Ib-508 -CHz-Na -N(CH2CH3)-OP O OH
Ib-509 -CHz-Na -N(CH2CH2CH3)-OP O OH
Ib-510 -CH2-NC( -N(CH2CH2CH2CH3)-OP O OH
Ib-511 -CHz-NC( -N(C(H)(CH3)(CH2CH3))-OP O OH
Ib-512 -CHz-NC( -N(C(H)(CH3)2)-OP O OH
Ib-513 -CH2-Na -N(CH2C(H)(CH3)2)-OP O OH
Ib-514 -CH2-NC( -N(C(CH3)3)-OP O OH
Ib-515 -CH2-N N(CH3)-OP O OH

Ib-516 -CHz-N -N(CH2CH3)-OP O OH
Ib-517 -CH2-N N(CH2CH2CH3)-OP O OH
Ib-518 -CH2-N -N(CH2CH2CH2CH3)-OP O OH
Ib-519 -CH2-N -N(C(H)(CH3)(CH2CH3))-OP O OH
Ib-520 -CHz-N -N(C(H)(CH3)2)-OP O OH
Ib-521 -CHz-N -N(CH2C(H)(CH3)2)-OP O OH
Ib-522 -CH2-N -N(C(CH3)3)-OP O OH
Ib-523 -(CH2)io-N(CH2-CH2-O-CH3)2 N(CH3)-Ib-524 -(CH2)io-N(CH2-CH2-O-CH3)2 -N(CH2CH3)-Ib-525 -(CH2),o-N(CH2-CH2-O-CH3)2 N(CH2CH2CH3)-Ib-526 -(CH2),o-N(CH2-CH2-O-CH3)2 -N(CH2CH2CH2CH3)-Ib-527 -(CH2),o-N(CH2-CH2-O-CH3)2 -N C H CH3 CHzCH3 -Ib-528 -(CH2)io-N(CH2-CH2-O-CH3)2 -N C H CH3 z-Ib-529 -(CH2)io-N(CH2-CH2-O-CH3)2 -N CHzC H CH3 z-Ib-53U -(CH2)io-N(CH2-CH2-O-CH3)2 -N C CH3 3 -Ib-531 -CH2-N(CH2-CH2-O-CH3)2 N CH3 -Ib-532 -CH2-N(CH2-CH2-O-CH3)2 -N CHzCH3 -Ib-533 -CH2-N(CH2-CH2-O-CH3)2 -N CHzCHzCH3 -Ib-534 -CH2-N(CH2-CH2-O-CH3)2 -N CHzCHzCHzCH3 -Ib-535 -CH2-N(CH2-CH2-O-CH3)2 -N C H CH3 CHzCH3 -Ib-536 -CH2-N(CH2-CH2-O-CH3)2 -N C H CH3 z-Ib-537 -CH2-N(CH2-CH2-O-CH3)2 -N CHzC H CH3 z-Ib-538 -CH2-N(CH2-CH2-O-CH3)2 -N C CH3 3 -Ib-539 N N(CH3)-~
Ib-540 ~ -N -N(CH2CH3)-Ib-541 ~ N(CH2CH2CH3)-~N _ Ib-542 -N -N(CH2CH2CH2CH3)-~

Ib-543 -N(C(H)(CH3)(CH2CH3))-~N

Ib-544 -N(C(H)(CH3)2)-~N
~
Ib-545 -N(CH2C(H)(CH3)2)-~N

Ib-546 N~ -N(C(CH3)3)-~
~
Ib-547 /-Na -N(CH3)-OH
Ib-548 /-Na -N(CH2CH3)-OH
Ib-549 /-NaN(CHzCHzCH3)-OH
Ib-550 /-Na -N(CH2CH2CH2CH3)-OH
Ib-551 /-Na -N(C(H)(CH3)(CH2CH3))-OH
Ib-552 /-Na -N(C(H)(CH3)2)-OH
Ib-553 /-Na -N(CH2C(H)(CH3)2)-OH
Ib-554 /-Na -N(C(CH3)3)-OH
Ib-555 lqlo- No N(CH3)-Ib-556 ~lqlo- No -N(CH2CH3)-Ib-557 ~lqlo- No N(CH2CH2CH3)-Ib-558 -N(CH2CH2CH2CH3)-Ib-559 lqlo- No -N(C(H)(CH3)(CH2CH3))-Ib-560 lqlo- No -N(C(H)(CH3)2)-Ib-561 ~lqlo- No -N(CH2C(H)(CH3)2)-Ib-562 -N(C(CH3)3)-Ib-563 r N Nv -N(CH3)-~

Ib-564 r N -N(CH2CH3)-N~
Ib-565 r ~ ~ -N(CHzCHzCH3)-N N

Ib-566 -N(CH2CH2CH2CH3)-~N

Ib-567 -N(C(H)(CH3)(CH2CH3))-~N N~

Ib-568 v -N(C(H)(CH3)2)-~N

Ib-s69 r N -N(cH2c(H)(cH3)2)-N

Ib-570 v r N N -N(C(CH3)3)-Ib-571 v N(CH3)-/-N
HO
Ib-572 -N(CH2CH3)-N
/-HO
Ib-573 N(CH2CH2CH3)-N
/-HO
Ib-574 -N(CH2CH2CH2CH3)-/-N
HO
Ib-575 -N(C(H)(CH3)(CHzCH3))-/-N
HO

Ib-576 -N(C(H)(CH3)2)-N
/-HO
Ib-577 -N(CHzC(H)(CH3)z)-~N
HO
Ib-578 -N(C(CH3)3)-N
/-HO
Ib-579 N(CH3)-X/-N
O
O Me Ib-580 -N(CH2CH3)-N

O
O Me Ib-581 N(CH2CH2CH3)-N

O
O Me Ib-582 -N(CH2CH2CH2CH3)-N

O
O Me Ib-583 -N(C(H)(CH3)(CH2CH3))-N

O
O Me Ib-584 -N(C(H)(CH3)2)-N

O
O Me Ib-585 -N(CH2C(H)(CH3)2)-N

O
O Me Ib-586 -N(C(CH3)3)-X/-N

O
O Me Ib-587 N N(CH3)-~ /

Ib-588 N -N(CHzCH3)-~ /

Ib-589 N N(CHzCHzCH3)-~ /

Ib-590 N -N(CH2CH2CH2CH3)-~

Ib-591 N -N(C(H)(CH3)(CH2CH3))-~

Ib-592 N -N(C(H)(CH3)2)-~

Ib-593 N -N(CHzC(H)(CH3)z)-~ /

Ib-594 N -N(C(CH3)3)-~ /

Ib-595 N(CH3)-No Ib-596 -N(CHzCH3)-No Ib-597 N(CHzCHzCH3)-No Ib-598 -N(CHzCHzCHzCH3)-No Ib-599 -N(C(H)(CH3)(CHzCH3))-No Ib-600 -N(C(H)(CH3)z)-No Ib-601 -N(CHzC(H)(CH3)z)-No Ib-602 -N(C(CH3)3)-No Ib-603 N(CH3)-[-N\__/N--\\,,-N(CHa) Ib-604 -N(CHzCH3)-[-N\_/N--\\,,N(CHa) Ib-605 N(CHzCHzCH3)-[-N\__/N--\_,-N(CHa) Ib-606 -N(CHzCHzCHzCH3)-[-N\_/N--\,,N(CHa) Ib-607 -N(C(H)(CH3)(CHzCH3))-[-N\__/N--\\,,-N(CHa) Ib-608 -N(C(H)(CH3)z)-[-N\_/N--\\,,N(CHa) Ib-609 -N(CHzC(H)(CH3)z)-[-N~N--\_,-N(CHa) Ib-610 -N(C(CH3)3)-[-N\__/N--\_,-N(CHa) Ib-611 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N CH3 -Ib-612 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N CHzCH3 -Ib-613 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N CHzCHzCH3 -Ib-614 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N CHzCHzCHzCH3 -Ib-615 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C H CH3 CHzCH3 -Ib-616 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C H CH3 Z-Ib-617 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N CHzC H CH3 z-Ib-618 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C CH3 3 -Ib-619 O N(CH3)-~N~

Ib-620 O -N(CHzCH3)-~N~

Ib-621 0 N(CH2CH2CH3) - NC DII/

Ib-622 0 N(CH2CH2CH2CH3) Ib-623 0 -N(C(H)(CH3)(CHzCH3))-~NC I ~

Ib-624 0 -N(C(H)(CH3)z)-~NC I ~

Ib-625 0 -N(CHzC(H)(CH3)z)-~NC I

Ib-626 0 -N(C(CH3)3)-~NC I

Ib-627 /~",OH N(CH3)-~N, I

Ib-628 v/~ OH -N(CHzCH3)-~N, I199-Ib-629 /-No,,OH N(CH2CH2CH3)-Ib-630 /-No,,OH -N(CH2CH2CH2CH3)-Ib-631 /-No,,OH -N(C(H)(CH3)(CH2CH3))-Ib-632 /-No,,OH -N(C(H)(CH3)2)-Ib-633 i-No,,OH -N(CH2C(H)(CH3)2)-Ib-634 /-No,,OH -N(C(CH3)3)-Ib-635 /-No -N(CH3)-HO
Ib-636 /-No -N(CH2CH3)-HO
Ib-637 ~ N(CH2CH2CH3)-~

HO
Ib-638 ~ -N(CH2CH2CH2CH3)-~

HO
Ib-639 -N(C(H)(CH3)(CH2CH3))-HO-$
Ib-640 -N(C(H)(CH3)2)-HO
Ib-641 ~ -N(CH2C(H)(CH3)2)-~

HO
Ib-642 ~ -N(C(CH3)3)-~

HO
Ib-643 ,CH3 N(CH3)-~N
~CH3 Ib-644 ,C N3 -N(CH2CH3)-//-N

Ib-645 ,CN3 N(CH2CH2CH3)-/-N
/.VCH3 \

Ib-646 ,CH3 -N(CH2CH2CH2CH3)-~N
~CH3 Ib-647 ,CH3 -N(C(H)(CH3)(CH2CH3))-/-N
/.VCH3 \

Ib-648 ,CN3 -N(C(H)(CH3)2)-/-N
/-\- C H 3 \

Ib-649 ,CN3 -N(CH2C(H)(CH3)2)-/~,-N
/-\- C H 3 \

Ib-650 ,CN3 -N(C(CH3)3)-/-N
/-;;~-CH3 \

Ib-651 N(CH3)-Ib-652 -N(CH2CH3)-Ib-653 N(CH2CH2CH3) Ib-654 N(CH2CH2CH2CH3) Ib-655 N(C(H)(CH3)(CH2CH3)) Ib-656 -N(C(H)(CH3)2)-Ib-657 -N(CH2C(H)(CH3)2)-Ib-658 N(C(CH3)3) O

Ib-659 \-N OH N(CH3)-Ib-660 \-N OH -N(CH2CH3)-Ib-661 \-N OH N(CH2CH2CH3)-Ib-662 \\_N OH -N(CH2CH2CH2CH3)-Ib-663 \\_N oH -N(C(H)(CH3)(CH2CH3))-Ib-664 \-N oH -N(C(H)(CH3)2)-Ib-665 \-N oH -N(CH2C(H)(CH3)2)-Ib-666 \-N oH -N(C(CH3)3)-Ib-667 a OH N(CH3)-Ib-668 a OH -N(CH2CH3)-Ib-669 a OH N(CH2CH2CH3)-Ib-670 a N OH -N(CH2CH2CH2CH3)-Ib-671 a OH -N(C(H)(CH3)(CH2CH3))-Ib-672 a OH -N(C(H)(CH3)2)-Ib-673 a OH -N(CH2C(H)(CH3)2)-Ib-674 a OH -N(C(CH3)3)-Ib-675 ~NH -N(CH3)-Ib-676 NH -N(CH2CH3)-Ib-677 NH -N(CH2CH2CH3)-Ib-678 NH -N(CH2CH2CH2CH3)-Ib-679 NH -N(C(H)(CH3)(CH2CH3))-Ib-680 NH -N(C(H)(CH3)2)-Ib-681 NH -N(CH2C(H)(CH3)2)-Ib-682 NH -N(C(CH3)3)-Ib-683 ZI-NH N(CH3)-Ib-684 //-NH -N(CH2CH3)-Ib-685 /-NH N(CH2CH2CH3)-Ib-686 //-NH -N(CH2CH2CH2CH3)-Ib-687 //-NH -N(C(H)(CH3)(CH2CH3))-Ib-688 /,,--NH -N(C(H)(CH3)2)-Ib-689 //-NH -N(CH2C(H)(CH3)2)-Ib-690 /-NH -N(C(CH3)3)-Ib-691 /-NH N(CH3)-Ib-692 / CH2CH3 -N(CH2CH3)-Ib-693 /cH2CH3 N(CH2CH2CH3)-Ib-694 /cH2CH3 -N(CH2CH2CH2CH3)-Ib-695 / CH2CH3 -N(C(H)(CH3)(CH2CH3))-Ib-696 / CH2CH3 -N(C(H)(CH3)2)-Ib-697 /cH2CH3 -N(CH2C(H)(CH3)2)-Ib-698 /cH2CH3 -N(C(CH3)3)-Ib-699 / CH2CH3 N(CH3)-Ib-700 /-NH -N(CH2CH3)-D Ib-701 /-NH N(CH2CH2CH3)-D - 204 -Ib-702 /-NN -N(CH2CH2CH2CH3)-D Ib-703 /-NN -N(C(H)(CH3)(CH2CH3))-D Ib-704 /-NN
N(C(H)(CH3)2) D

Ib-705 /-NH -N(CH2C(H)(CH3)2)-D Ib-706 /-NN -N(C(CH3)3)-D Ib-707 /-NH N(CH3)-D
Ib-708 /-NN -N(CH2CH3)-D Ib-709 /-NN N(CH2CH2CH3)-D Ib-710 /-NN -N(CH2CH2CH2CH3)-D Ib-711 /-NH -N(C(H)(CH3)(CH2CH3))-D Ib-712 /-NH
N(c(H)(cH3)2) D
Ib-713 :IIIII:ii/-NN -N(CH2C(H)(CH3)2)-Ib-714 /-NH -N(C(CH3)3)-D Ib-715 XI-N /-\ N(CH3)-Ib-716 -N /-\ -N(CH2CH3)-N(CH2CH2CH3)-Ib-717 -\N% ~

-N(CH2CH2CH2CH3)-Ib-718 -\N% ~

Ib-719 -N /-\ -N(C(H)(CH3)(CH2CH3))-Ib-720 -N /-\ -N(C(H)(CH3)2)-Ib-721 -N /-\ -N(CH2C(H)(CH3)2)-Ib-722 -N /-\ -N(C(CH3)3)-Ib-723 N\~ N(CH3)-~ OH
Ib-724 N\~ -N(CH2CH3)-Ib-725 N(CH2CH2CH3)-Ib-726 -N(CH2CH2CH2CH3)-Ib-727 ~QH -N(C(H)(CH3)(CH2CH3))-Ib-72s ~ N(c(H)(cH3)z) Ib-729 N~~ -N(cHzc(H)(CH3)z)-Ib-730 N\~ -N(C(CH3)3)-Ib-731 /-NH N(CH3)-Ib-732 /-NH -N(CH2CH3)-H C
Ib-733 /-NH N(CHzCHzCH3)-H C
Ib-734 /-NH -N(CH2CH2CH2CH3)-H C
Ib-735 /-NH -N(C(H)(CH3)(CH2CH3))-Ib-736 /-NH -N(C(H)(CH3)2)-H C
Ib-737 /-NH -N(CH2C(H)(CH3)2)-H C
Ib-738 /-NH -N(C(CH3)3)-H C
Ib-739 CH3 -N(CH3)-N

Ib-740 CH3 -N(CH2CH3)-N

Ib-741 CH3 -N(CHzCHzCH3)-~N N

Ib-742 CH3 -N(CH2CH2CH2CH3)-N
Ib-743 CH3 -N(C(H)(CH3)(CH2CH3))-N

Ib-744 CH3 -N(C(H)(CH3)z)-~N N

Ib-745 CH3 -N(CH2C(H)(CH3)2)-N

Ib-746 CH3 -N(C(CH3)3)-~N N

Ib-747 CH3 N(CH3)-N

Ib-748 CH3 -N(CH2CH3)-~N

Ib-749 CH3 N(CH2CH2CH3)-~N
Ib-750 CH3 -N(CH2CH2CH2CH3)-N
Ib-751 CH3 -N(C(H)(CH3)(CH2CH3))-~N

Ib-752 CH3 -N(C(H)(CH3)2)-~N
Ib-753 CH3 -N(CH2C(H)(CH3)2)-N
Ib-754 CH3 -N(C(CH3)3)-N

Ib-755 NH -N(CH3)-0 Ib-756 NH -N(CH2CH3)-0 OH

Ib-757 NH -N(CH2CH2CH3)-0 Ib-758 NH -N(CH2CH2CH2CH3)-0 Ib-759 NH -N(C(H)(CH3)(CH2CH3))-0 Ib-760 NH -N(C(H)(CH3)2)-0 - 209 -Ib-761 NH -N(CH2C(H)(CH3)2)-0 OH

Ib-762 NH -N(C(CH3)3)-0 Ib-763 /-N--~ OH N(CH3)-Ib-764 OH -N(CH2CH3)-Ib-765 //-N-1-~ OH N(CH2CH2CH3)-Ib-766 //-N-*,-~ OH -N(CH2CH2CH2CH3)-Ib-767 OH -N(C(H)(CH3)(CH2CH3))-Ib-768 //--N--~ OH -N(C(H)(CH3)2) Ib-769 //-N-*,-~ OH -N(CH2C(H)(CH3)2)-Ib-770 //-N-*,-~ OH -N(C(CH3)3)-Ib-771 /-N~ rCH3 N(CH3) ~--/

Ib-772 /-ND-CH3 -N(CH2CH3)-Ib-773 /-N~ rCH -N(CH2CH2CH3)-Ib-774 /-N~ rCH -N(CHzCHzCHzCH3)-~--/ 3 Ib-775 /-ND-CH3 -N(C(H)(CH3)(CH2CH3))-Ib-776 /-ND-CH3 -N(C(H)(CH3)2)-~ rCH3 -N(CH2C(H)(CH3)2)-Ib-777 /-N--Ib-778 /-N D-CH3 -N(C(CH3)3)-Ib-779 -CH2-NH-CH3 -N(CH3)-Ib-780 -CH2-NH-CH3 N CHzCH3 -Ib-781 -CH2-NH-CH3 -N CHzCHzCH3 -Ib-782 -CH2-NH-CH3 -N CHzCHzCHzCH3 -Ib-783 -CH2-NH-CH3 -N C H CH3 CHzCH3 -Ib-784 -CH2-NH-CH3 -N C H CH3 z-Ib-785 -CH2-NH-CH3 -N CHzC H CH3 z-Ib-786 -CH2-NH-CH3 -N C CH3 3 -Ib-787 -CH2-NH-CH2-CH3 -N CH3 -Ib-788 -CH2-NH-CH2-CH3 -N CHzCH3 -Ib-789 -CH2-NH-CH2-CH3 -N CHzCHzCH3 -Ib-790 -CH2-NH-CH2-CH3 -N CHzCHzCHzCH3 -Ib-791 -CH2-NH-CH2-CH3 -N C H CH3 CHzCH3 -Ib-792 -CH2-NH-CH2-CH3 -N C H CH3 z-Ib-793 -CH2-NH-CH2-CH3 -N CHzC H CH3 z-Ib-794 -CH2-NH-CH2-CH3 -N C CH3 3 -Ib-795 -CH2-NH-CH2-CH2-CH3 -N(CH3)-Ib-796 -CH2-NH-CH2-CH2-CH3 -N(CH2CH3)-Ib-797 -CH2-NH-CH2-CH2-CH3 -N(CH2CH2CH3)-Ib-798 -CH2-NH-CH2-CH2-CH3 -N(CH2CH2CH2CH3)-Ib-799 -CH2-NH-CH2-CH2-CH3 -N C H CH3 CHzCH3 -Ib-800 -CHz-NH-CHz-CHz-CH3 -N C H CH3 z-Ib-801 -CHz-NH-CHz-CHz-CH3 -N CHzC H CH3 z-Ib-802 -CH2-NH-CH2-CH2-CH3 -N C CH3 3 -Ib-803 ~~~CH N(CH3)-Ib-804 ~~~CH -N(CHzCH3)-Ib-805 ~~~CH N(CHzCHzCH3)-Ib-806 ~~~CH -N(CHzCHzCHzCH3)-Ib-807 H3C\ -N(C(H)(CH3)(CHzCH3))-~NrCH3 Ib-808 H3C \ -N(C(H)(CH3)z)-~NrCH3 Ib-809 H3C \ -N(CHzC(H)(CH3)z)-~NrCH3 H
Ib-810 ~~~CH -N(C(CH3)3)-Ib-811 H3C -N(CH3)-H
/-N

OMe Ib-812 H3C -N(CH2CH3)-H
I-N
OMe Ib-813 H3C -N(CH2CH2CH3)-H
I-N
OMe Ib-814 H3C -N(CH2CH2CH2CH3)-H
I-N
OMe Ib-815 H3C -N(C(H)(CH3)(CH2CH3))-H
I-N
OMe Ib-816 H3C -N(C(H)(CH3)2)-H
I-N
OMe Ib-817 H3C -N(CH2C(H)(CH3)2)-H
I-N
OMe Ib-818 H3C -N(C(CH3)3)-H
I-N
OMe Ib-819 H3C N(CH3)-~-CH3 >---CH3 H C
Ib-820 H3C -N(CH2CH3)-~-CH3 >---CH3 H C
Ib-821 H3C N(CH2CH2CH3)-~-CH3 ZI-N
>---CH3 H C
Ib-822 H3C -N(CH2CH2CH2CH3)-~-CH3 //-N
>---cfl3 H C
Ib-823 H3C -N(C(H)(CH3)(CH2CH3))-~-CH3 >---CH3 H C
Ib-824 H3C -N(C(H)(CH3)2)-~-CH3 ZI-N
>---CH3 H C
Ib-825 H3C -N(CH2C(H)(CH3)2)-~-CH3 ZI-N
>---CH3 Ib-826 H3C -N(C(CH3)3)-~-CH3 >---CH3 H C
Ib-827 N(CH3)-N
Ib-828 -N(CH2CH3)-Ib-829 N(CH2CH2CH3)-Ib-830 -N(CH2CH2CH2CH3)-Ib-831 -N(C(H)(CH3)(CH2CH3))-N
Ib-832 -N(C(H)(CH3)2)-N
Ib-833 -N(CH2C(H)(CH3)2)-N
Ib-834 -N(C(CH3)3)-N

Ib-835 CH3CH,2 N -N(CH3)-N
Ib-836 CH3CHi2 ~ N -N(CH2CH3)-N ~
Ib-837 CH3CH2 ~ N N(CHzCHzCH3)-~
--/ N ~
Ib-838 CH3CH2 // N -N(CH2CH2CH2CH3)-, N
Ib-839 CH3CH2 ~ N -N(C(H)(CH3)(CH2CH3))---/ N ~
Ib-840 CH3CH,2 // N -N(C(H)(CH3)2)-N ~
Ib-841 CH3CH2 ~ N -N(CH2C(H)(CH3)2)-i N N(C(CH3)3) Ib-842 CH3CH2 Ib-843 ~ ~ H3 -N(CH3)-N-CH CH OH
Ib-844 ~ CH3 -N(CH2CH3)--CH CH OH
Ib-845 ~ CH3 -N(CH2CH2CH3)--CH CH OH
Ib-846 ~ CH3 -N(CH2CH2CH2CH3)--CH CH OH
Ib-847 CH3 -N(C(H)(CH3)(CH2CH3))-L-CH CH OH
Ib-848 CH3 -N(C(H)(CH3)2)-L-CH CH OH
Ib-849 CH3 -N(CH2C(H)(CH3)2)-L-CH CH OH
Ib-850 L CH3 -N(C(CH3)3)--CH CH OH

Ib-851 /-Iqlo-No -N(CH3)-Ib-852 -N(CH2CH3)-Ib-853 -N(CH2CH2CH3)-Ib-854 -N(CH2CH2CH2CH3)-Ib-855 -N(C(H)(CH3)(CH2CH3))-Ib-856 -N(C(H)(CH3)2)-Ib-857 -N(CH2C(H)(CH3)2)-Ib-858 -N(C(CH3)3)-Ib-859 N(CH3)-Ib-860 -N(CH2CH3)-Ib-861 N(CH2CH2CH3)-Ib-862 N(CH2CH2CH2CH3)-,/-NN
Ib-863 -N(C(H)(CH3)(CH2CH3))-Ib-864 -N(C(H)(CH3)2)-N
Ib-865 -N(CH2C(H)(CH3)2)-Ib-866 -N(C(CH3)3)-Ib-867 N(CH3)-cH
Ib-868 C -N(CH2CH3)-N\ ~
CH
Ib-869 C N(CHzCHzCH3)-N`CH I
Ib-870 C -N(CHzCHzCHzCH3)-N\CH~
Ib-871 N1C -N(C(H)(CH3)(CHzCH3))-`CHl~j Ib-872 \-N~ -N(c(H)(cH3)z)-`cH /
Ib-873 -N(CHzC(H)(CH3)z)-CH /
Ib-874 \-N~ N(C(CH3)3) `cH
Ib-875 N(CH3)-//-NH N

Ib-876 -N(CH2CH3)-//-NH N

Ib-877 N(CH2CH2CH3)-ZI-NH N~

Ib-878 -N(CH2CH2CH2CH3)-,/-NH N

Ib-879 -N(C(H)(CH3)(CH2CH3))-,/-NH N

Ib-880 -N(C(H)(CH3)2)-,/~---NH N

Ib-881 -N(CH2C(H)(CH3)2)-//---NH N

Ib-882 -N(C(CH3)3)-//---NH N

Ib-883 ~ H3 -N(CH3)-NH N

Ib-884 ~ H3 -N(CH2CH3)-NH N

Ib-885 ~ H3 -N(CH2CH2CH3)-NH N

Ib-886 ~ H3 -N(CH2CH2CH2CH3)-NH N

Ib-887 ~ H3 -N(C(H)(CH3)(CH2CH3))-NH N

Ib-888 ~ H3 -N(C(H)(CH3)2)-NH N

Ib-889 ~ H3 -N(CH2C(H)(CH3)2)-NH N

Ib-890 ~ H3 -N(C(CH3)3)-NH N

Ib-891 -N(CH3)-/-N\ /N H

Ib-892 -N(CH2CH3)-/-N\ N H

Ib-893 N(CH2CH2CH3)-/-N\ /N H

Ib-894 -N(CH2CH2CH2CH3)-/-N\ N H

Ib-895 -N(C(H)(CH3)(CH2CH3))-/-N\ N H
Ib-896 -N(C(H)(CH3)2)-/-N\ N H
Ib-897 -N(CH2C(H)(CH3)2)-/-N\ N H
Ib-898 -N(C(CH3)3)-/-N\ /N H
Ib-899 CH3 -N(CH3)-~N\

Ib-900 CH3 -N(CH2CH3)-~N\

Ib-901 CH3 N(CH2CH2CH3)-Ib-902 ~N~\NCH3 -N(CH2CH2CH2CH3)-Ib-903 CH3 -N(C(H)(CH3)(CH2CH3))-Ib-904 ~N~\NCH3 -N(C(H)(CH3)2)-Ib-905 ~N~\NCH3 -N(CH2C(H)(CH3)2)-Ib-906 ~N~\NCH3 -N(C(CH3)3)-Ib-907 /,--N H -N(CH3)-Ib-908 z,,--N H -N(CH2CH3)-Ib-909 //-N H -N(CH2CH2CH3)-Ib-910 /,--N H -N(CH2CH2CH2CH3)-Ib-911 //-N ~ -N(C(H)(CH3)(CH2CH3))-Ib-912 Z/-N v H -N(C(H)(CH3)2)-Ib-913 ZI-N v H -N(CH2C(H)(CH3)2)-Ib-914 /-N v H -N(C(CH3)3)-Ib-915 \-\ -N(CH3)-~~ ~~ OH

Ib-916 \-\ -N(CHzCH3)-~~ ~~ OH

Ib-917 -N(CH2CH2CH3)-N N OH

Ib-918 \-\ -N(CHzCHzCHzCH3)-~~ ~~ OH

Ib-919 \-\ -N(C(H)(CH3)(CHzCH3))-~~ ~~ OH

Ib-920 N N -N(C(H)(CH3)2)-OH
Ib-921 \-\ -N(CHzC(H)(CH3)z)-~~ ~~ OH

Ib-922 \-\ -N(C(CH3)3)-~~ ~~ OH

Ib-923 ~ \ N(CH3)-~% ~~CH3 Ib-924 //-N /-\ -N(CHzCH3)-N~~CH3 Ib-925 ~/-\ N(CHzCHzCH3)-~/CH3 Ib-926 \ -N(CHzCHzCHzCH3)-~~% ~ ~/CH3 Ib-927 ~ \ -N(C(H)(CH3)(CHzCH3))-~% ~/CH3 Ib-928 ~ \ -N(C(H)(CH3)2)-~% ~CH3 Ib-929 ~ \ -N(CH2C(H)(CH3)2)-~% ~~CH3 Ib-930 \ -N(C(CH3)3)-~~% ~CH3 Ib-931 -N(CH3)-\-N N

Ib-932 -N(CH2CH3)-\-N/--N N

Ib-933 -N(CH2CH2CH3)-\-N N

Ib-934 -N(CH2CH2CH2CH3)-\-N N

Ib-935 -N(C(H)(CH3)(CH2CH3))-\-N N

Ib-936 -N(C(H)(CH3)2)-\-N N

Ib-937 -N(CH2C(H)(CH3)2)-\-N/--N N

Ib-938 -N(C(CH3)3)-\-N N

Ib-939 \-ND-OEt N(CH3)-Ib-940 \-ND-OEt -N(CH2CH3)-Ib-941 \-NaOEt N(CH2CH2CH3)-Ib-942 \\-NaOEt -N(CH2CH2CH2CH3)-Ib-943 \\-NaOEt -N(C(H)(CH3)(CH2CH3))-Ib-944 \\-NaOEt -N(C(H)(CH3)2)-Ib-945 \-NaOEt -N(CH2C(H)(CH3)2)-Ib-946 \-ND-OEt -N(C(CH3)3)-Ib-947 N(CH3)-H

Ib-948 N
-N(CH2CH3)-~
Q~ H
Ib-949 N
N(CH2CH2CH3)-~
Q~ H
Ib-950 N
-N(CH2CH2CH2CH3)-~
Q~ H
Ib-951 /-N -N(C(H)(CH3)(CH2CH3))-Ib-952 -N(C(H)(CH3)2)-H
Ib-953 N -N(CH2C(H)(CH3)2)-~
H
Ib-954 N -N(C(CH3)3)-~

Ib-955 N(CH3) OEt Ib-956 O -N(CH2CH3)-OFt Ib-957 - N/O -N(CH2CH2CH3)-OEt Ib-958 0 -N(CHzCHzCHzCH3)-N
OEt Ib-959 N(C(H)(CH3)(CH2CH3))-OFt Ib-960 N(C(H)(CH3)2) OEt Ib-961 -N N/0 -N(CH2C(H)(CH3)2)-OEt Ib-962 - N" o N(c(cH3)3) OEt Ib-963 -CHz-N CHzCH3 CH3 N CH3 -Ib-964 -CHz-N CHzCH3 CH3 N CHzCH3 -Ib-965 -CHz-N CHzCH3 CH3 N CHzCHzCH3 -Ib-966 -CHz-N CHzCH3 CH3 -N CHzCHzCHzCH3 -Ib-967 -CHz-N CHzCH3 CH3 -N C H CH3 CHzCH3 -Ib-968 -CHz-N CHzCH3 CH3 -N C H CH3 z-Ib-969 -CH2-N(CH2CH3)(CH3) N(CH2C(H)(CH3)2)-Ib-970 -CHz-N CHzCH3 CH3 -N C CH3 3-Ib-971 -CHz-N CHzCHzCH3 CH3 N CH3 -Ib-972 -CH2-N(CH2CH2CH3)(CH3) -N(CH2CH3)-Ib-973 -CHz-N CHzCHzCH3 CH3 N CHzCHzCH3 -Ib-974 -CHz-N CHzCHzCH3 CH3 -N CHzCHzCHzCH3 -Ib-975 -CHz-N CHzCHzCH3 CH3 -N C H CH3 CHzCH3 -Ib-976 -CHz-N CHzCHzCH3 CH3 -N C H CH3 z-Ib-977 -CHz-N CHzCHzCH3 CH3 -N CHzC H CH3 z-Ib-978 -CHz-N CHzCHzCH3 CH3 -N C CH3 3-Ib-979 -CH2-N(CH2CH2CH2CH3)(CH3) N CH3 -Ib-980 -CH2-N(CH2CH2CH2CH3)(CH3) N CHzCH3 -Ib-981 -CH2-N(CH2CH2CH2CH3)(CH3) N CHzCHzCH3 -Ib-982 -CH2-N(CH2CH2CH2CH3)(CH3) -N CHzCHzCHzCH3 -Ib-983 -CH2-N(CH2CH2CH2CH3)(CH3) -N C H CH3 CHzCH3 -Ib-984 -CH2-N(CH2CH2CH2CH3)(CH3) -N C H CH3 z-Ib-985 -CH2-N(CH2CH2CH2CH3)(CH3) N CHzC H CH3 z-Ib-986 -CH2-N(CH2CH2CH2CH3)(CH3) -N C CH3 3 -Ib-987 -CH2-NH-CH2CH2CH2CH3 N CH3 -Ib-988 -CH2-NH-CH2CH2CH2CH3 -N(CH2CH3)-Ib-989 -CH2-NH-CH2CH2CH2CH3 N(CH2CH2CH3)-Ib-990 -CH2-NH-CH2CH2CH2CH3 -N(CH2CH2CH2CH3)-Ib-991 -CH2-NH-CH2CH2CH2CH3 -N(C(H)(CH3)(CH2CH3))-Ib-992 -CH2-NH-CH2CH2CH2CH3 -N C H CH3 z-Ib-993 -CH2-NH-CH2CH2CH2CH3 -N CHzC H CH3 z-Ib-994 -CH2-NH-CH2CH2CH2CH3 -N C CH3 3 -Ib-995 -CH2-NH-CH2CH2-O-CH3 N CH3 -Ib-996 -CH2-NH-CH2CH2-O-CH3 -N CHzCH3 -Ib-997 -CH2-NH-CH2CH2-O-CH3 N CHzCHzCH3 -Ib-998 -CH2-NH-CH2CH2-O-CH3 -N CHzCHzCHzCH3 -Ib-999 -CH2-NH-CH2CH2-O-CH3 -N C H CH3 CHzCH3 -Ib-1000 -CH2-NH-CH2CH2-O-CH3 -N C H CH3 z-Ib-1001 -CH2-NH-CH2CH2-O-CH3 -N CHzC H CH3 z-Ib-1002 -CH2-NH-CH2CH2-O-CH3 -N C CH3 3 -Ib-1003 /-N N--\,OMe N(CH3)-Ib-1004 /-N N--,\,OMe N(CH2CH3)-N N(CHzCHzCH3)-Ib-1005 /-N --\
~~OMe Ib-1006 /-N /-\ N-N\,OMe -N(CH2CH2CH2CH3)-Ib-1007 /-N N--\,OMe -N(C(H)(CH3)(CH2CH3))-Ib-1008 /-N N--\,OMe -N(C(H)(CH3)2)-Ib-1009 /-N N--\,OMe N(CH2C(H)(CH3)2)-Ib-1010 /-N N--\,OMe -N(C(CH3)3)-Ib-1011 N(CH3)-N OPO OH
Ib-1012 N(CH2CH3)-N OPO OH
Ib-1013 N(CH2CH2CH3)-N OPO OH
Ib-1014 ag -N(CH2CH2CH2CH3)-OPO OH
Ib-1015 N -N(C(H)(CH3)(CH2CH3))-OPO OH
Ib-1016 -N(C(H)(CH3)2)-N OPO OH
Ib-1017 N(CH2C(H)(CH3)2)-N OPO OH
Ib-1018 -N(C(CH3)3)-N OPO OH
Ib-1019 N(CH3)-OPO(OH)Z
Ib-1020 N(CHzCH3)-OPO(OH)Z
Ib-1021 N(CHzCHzCH3)-OPO(OH)Z
Ib-1022 -N(CHzCHzCHzCH3)-OPO(OH)Z
Ib-1023 -N(C(H)(CH3)(CHzCH3))-OPO(OH)Z
Ib-1024 -N(C(H)(CH3)z)-OPO(OH)Z
Ib-1025 N N(CHzC(H)(CH3)z)-OPO(OH)Z

Ib-1026 -N(C(CH3)3)-OPO(OH)Z
Ib-1027 /\N OPO(OH)z N(CH3)-Ib-1028 /\N OPO(OH)z N(CH2CH3)-Ib-1029 /\N OPO(OH)z N(CH2CH2CH3)-Ib-1030 /\N OPO(OH)z -N(CH2CH2CH2CH3)-Ib-1031 /\N OPO(OH)z -N(C(H)(CH3)(CH2CH3))-Ib-1032 /\N OPO(OH)z -N(C(H)(CH3)2)-Ib-1033 /\N OPO(OH)z N(CH2C(H)(CH3)2)-Ib-1034 /\N OPO(OH)z -N(C(CH3)3)-Ib-1035 CH3 N(CH3)-OPO OH
Ib-1036 /--NiCH3 N(CH2CH3)-OPO OH
Ib-1037 CH3 N(CH2CH2CH3)-OPO OH
Ib-1038 CH3 -N(CH2CH2CH2CH3)-OPO OH
Ib-1039 N/CH3 -N(C(H)(CH3)(CH2CH3))-OPO OH

Ib-1040 CH3 -N(C(H)(CH3)2)-OPO OH
Ib-1041 /--NiCH3 N(CH2C(H)(CH3)2)-OPO OH
Ib-1042 /--NiCH3 -N(C(CH3)3)-OPO OH
Ib-1043 N(CH3)-OPO OH
Ib-1044 N(CH2CH3)-OPO OH
Ib-1045 N(CH2CH2CH3)-OPO OH
Ib-1046 -N(CH2CH2CH2CH3)-OPO OH
Ib-1047 -N(C(H)(CH3)(CH2CH3))-OPO OH
Ib-1048 -N(C(H)(CH3)2)-/-N

OPO OH

Ib-1049 N(CH2C(H)(CH3)2)-OPO OH
Ib-1050 -N(C(CH3)3)-OPO OH
Ib-1051 \\--H -N(CH3)-N

OPO OH )a2 Ib-1052 \\__H N(CH2CH3)-N

OPO OH
Ib-1053 -N(CH2CH2CH3)-N

OPO OH
Ib-1054 \\--H -N(CH2CH2CH2CH3)-N

OPO OH
Ib-1055 \--H -N(C(H)(CH3)(CH2CH3))-N

OPO OH
Ib-1056 H -N(C(H)(CH3)2)-N

OPO OH
Ib-1057 \\__H -N(CH2C(H)(CH3)2)-N

OPO OH

Ib-1058 N -N(C(CH3)3)-)aOPO(OH)2 Compound n - Rl X
Ib-bl 1 -(CHz)ri N(CH3)z -CH(OH)-Ib-b2 2 -(CHz)ri N(CH3)z -CH(OH)-Ib-b3 3 -(CHz)ri N(CH3)z -CH(OH)-Ib-b4 4 -(CHz)ri N(CH3)z -CH(OH)-Ib-b5 5 -(CHz)ri N(CH3)z -CH(OH)-Ib-b6 6 -(CHz)ri N(CH3)z -CH(OH)-Ib-b7 1 CHz ri N CH3 z N C O N H-CHz-CHz-OH -Ib-b8 2 CHz ri N CH3 z N C O N H-CHz-CHz-OH -Ib-b9 3 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-OH)-Ib-b10 4 CHz ri N CH3 z N C O N H-CHz-CHz-OH -Ib-bll 5 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-OH)-Ib-b12 6 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-OH)-Ib-b13 1 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ib-b14 2 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ib-b15 3 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ib-b16 4 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ib-b17 5 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ib-b18 6 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ib-b19 1 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ib-b20 2 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ib-b21 3 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b22 4 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ib-b23 5 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ib-b24 6 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ib-b25 1 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ib-b26 2 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ib-b27 3 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ib-b28 4 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ib-b29 5 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ib-b30 6 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ib-b31 1 CHz ri N CH3 z -N CHz-CHz-OH -Ib-b32 2 CHz ri N CH3 z -N CHz-CHz-OH -Ib-b33 3 CHz ri N CH3 z -N CHz-CHz-OH -Ib-b34 4 CHz ri N CH3 z -N CHz-CHz-OH -Ib-b35 5 CHz ri N CH3 z -N CHz-CHz-OH -Ib-b36 6 CHz ri N CH3 z -N CHz-CHz-OH -Ib-b37 1 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ib-b38 2 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ib-b39 3 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ib-b40 4 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ib-b41 5 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ib-b42 6 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ib-b43 1 CHz ri N CH3 z N CHz-CHz-OCH3 -Ib-b44 2 CHz ri N CH3 z N CHz-CHz-OCH3 -Ib-b45 3 CHz ri N CH3 z N CHz-CHz-OCH3 -Ib-b46 4 CHz ri N CH3 z N CHz-CHz-OCH3 -Ib-b47 5 CHz ri N CH3 z N CHz-CHz-OCH3 -Ib-b48 6 CHz ri N CH3 z N CHz-CHz-OCH3 -Ib-b49 1 -CH(OH)--(CH2)n N 0 Ib-b50 2 -CH(OH)--(CH2)n N 0 Ib-b51 3 -CH(OH)--(CH2)n N 0 Ib-b52 4 -CH(OH)--(CH2)n N 0 Ib-b53 5 -CH(OH)--(CH2)n N 0 Ib-b54 6 -CH(OH)--(CH2)n N 0 Ib-b55 1 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ib-b56 2 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ib-b57 3 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ib-b58 4 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ib-b59 5 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ib-b60 6 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ib-b61 1 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ib-b62 2 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ib-b63 3 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ib-b64 4 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ib-b65 5 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ib-b66 6 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ib-b67 1 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ib-b68 2 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ib-b69 3 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ib-b70 4 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ib-b71 5 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ib-b72 6 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ib-b73 1 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ib-b74 2 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ib-b75 3 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ib-b76 4 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ib-b77 5 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ib-b78 6 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ib-b79 1 N(CH2-CH2-OH)--(CH2)n N 0 Ib-b80 2 N(CH2-CH2-OH)--(CH2)n N 0 Ib-b81 3 N(CH2-CH2-OH)--(CH2)n N 0 Ib-b82 4 N(CH2-CH2-OH)--(CH2)n N 0 Ib-b83 5 N(CH2-CH2-OH)--(CH2)n N 0 Ib-b84 6 N(CH2-CH2-OH)--(CH2)n N 0 Ib-b85 1 -N(CH2-CH2-F)--(CH2)n N 0 Ib-b86 2 -N(CH2-CH2-F)--(CH2)n N 0 Ib-b87 3 -N(CH2-CH2-F)--(CH2)n N 0 Ib-b88 4 -N(CH2-CH2-F)--(CH2)n N 0 Ib-b89 5 -N(CH2-CH2-F)--(CH2)n N 0 Ib-b90 6 -N(CH2-CH2-F)--(CH2)n N 0 Ib-b91 1 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ib-b92 2 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ib-b93 3 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ib-b94 4 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ib-b95 5 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ib-b96 6 -N(CH2-CH2-OCH3)--(CH2)n N 0 Compound m - Rl X
Ib-b146 2 -O-(CHz)m N(CH3)z -CH(OH)-Ib-b147 3 -O-(CHz)m N(CH3)z -CH(OH)-Ib-b148 4 -O-(CHz)m N(CH3)z -CH(OH)-Ib-b149 5 -O-(CHz)m N(CH3)z -CH(OH)-Ib-b150 6 -O-(CH2)õ-N(CH3)2 -CH(OH)-Ib-b151 2 -O CHz õ-N CH3 z N C O N H-CHz-CHz-OH -Ib-b152 3 -O CHz õ-N CH3 z N C O N H-CHz-CHz-OH -Ib-b153 4 -O CHz õ-N CH3 z N C O N H-CHz-CHz-OH -Ib-b154 5 -O CHz õ-N CH3 z N C O N H-CHz-CHz-OH -Ib-b155 6 -O CHz õ-N CH3 z N C O N H-CHz-CHz-OH -Ib-b156 2 -O-(CHz)m N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ib-b157 3 -O-(CHz)m N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ib-b158 4 -O-(CHz)m N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ib-b159 5 -O-(CHz)m N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ib-b160 6 -O-(CH2)õ-N(CH3)2 -N(C(O)N(H)-CH2-CH2-F)-Ib-b161 2 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ib-b162 3 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ib-b163 4 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ib-b164 5 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ib-b165 6 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ib-b166 2 -O-(CH2)õ-N(CH3)2 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b167 3 -O-(CH2)õ-N(CH3)2 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b168 4 -O-(CH2)õ-N(CH3)2 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b169 5 -O-(CH2)õ-N(CH3)2 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b170 6 -O-(CH2)õ-N(CH3)2 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b171 2 -O CHz õ-N CH3 z -N CHz-CHz-OH -Ib-b172 3 -O CHz õ-N CH3 z -N CHz-CHz-OH -Ib-b173 4 -O CHz õ-N CH3 z -N CHz-CHz-OH -Ib-b174 5 -O CHz õ-N CH3 z -N CHz-CHz-OH -Ib-b175 6 -O CHz õ-N CH3 z -N CHz-CHz-OH -Ib-b176 2 -O-(CHz)m N(CH3)z -N(CH2-CH2-F)-Ib-b178 3 -O-(CH2)õ-N(CH3)2 -N(CH2-CH2-F)-Ib-b179 4 -O-(CHz)m N(CH3)z -N(CHz-CHz-F)-Ib-b180 5 -O-(CH2)õ-N(CH3)2 -N(CH2-CH2-F)-Ib-b181 6 -O-(CH2)õ-N(CH3)2 -N(CH2-CH2-F)-Ib-b182 2 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ib-b183 3 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ib-b184 4 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ib-b185 5 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ib-b186 6 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ib-b187 2 -CH(OH)--o (cH2)m N 0 Ib-b188 3 -CH(OH)--o (cH2)m N 0 Ib-b189 4 -CH(OH)--o (cH2)m N j Ib-b190 5 -CH(OH)--o (cH2)m N 0 Ib-b191 6 -CH(OH)--o (cH2)m N %

Ib-b192 2 N(C(O)N(H)-CHz-CHz-OH)--o (cH2)m N 0 Ib-b193 3 N(C(O)N(H)-CHz-CHz-OH)--o (cH2)m N 0 Ib-b194 4 -o (cH2) \ N(C(O)N(H)-CHz-CHz-OH)-m~~ ~

Ib-b195 5 N(C(O)N(H)-CHz-CHz-OH)--o (cH2)m N 0 Ib-b196 6 N(C(O)N(H)-CHz-CHz-OH)--o (cH2)m N 0 Ib-b197 2 N(C(O)N(H)-CHz-CHz-F)--o (cH2)m N 0 Ib-b198 3 N(C(O)N(H)-CHz-CHz-F)--o (cH2)m N 0 Ib-b199 4 N(C(O)N(H)-CH2-CH2-F)--0 (CH2)m N j Ib-b200 5 N(C(O)N(H)-CH2-CH2-F)--0 (CH2)m N 0 Ib-b201 6 N(C(O)N(H)-CH2-CH2-F)--0 (CH2)m N %

Ib-b202 2 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N j Ib-b203 3 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N 0 Ib-b204 4 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N %

Ib-b205 5 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N 0 Ib-b206 6 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N 0 Ib-b207 2 N(C(O)N(H)-CH2-CH2-CF3)--0 (CH2)m N j Ib-b208 3 -N(C(O)N(H)-CH2-CH2-CF3)--0 (CH2)m N 0 Ib-b209 4 -0 (CH2)~\ N(C(O)N(H)-CHz-CHz-CF3)-m~%

Ib-b210 5 N(C(O)N(H)-CH2-CH2-CF3)--0 (CH2)m N %

Ib-b211 6 N(C(O)N(H)-CH2-CH2-CF3)--0 (CH2)m N j Ib-b212 2 -0 (CH \ N(CHz-CHz-OH)-2)m~~ ~

Ib-b213 3 N(CH2-CH2-OH)--0 (CH2)m N j Ib-b214 4 N(CHz-CHz-OH)--o (cH2)m N 0 Ib-b215 5 N(CHz-CHz-OH)--o (cH2)m N 0 Ib-b216 6 N(CHz-CHz-OH)--o (cH2)m N 0 Ib-b217 2 -N(CHz-CHz-F)--o (cH2)m N 0 Ib-b218 3 -N(CHz-CHz-F)--o (cH2)m N 0 Ib-b219 4 -N(CHz-CHz-F)--o (cH2)m N 0 Ib-b220 5 -N(CHz-CHz-F)--o (cH2)m N 0 Ib-b221 6 -N(CHz-CHz-F)--o (cH2)m N 0 Ib-b222 2 -N(CH2-CH2-OCH3)--0(cH2)m N 0 Ib-b223 3 -N(CH2-CH2-OCH3)--0(cH2)m N 0 Ib-b224 4 -o (cH \ -N(CHz-CHz-OCH3)-2)m~% ~

Ib-b225 5 -N(CH2-CH2-OCH3)--0(cH2)m N 0 Ib-b226 6 -N(CH2-CH2-OCH3)--0(cH2)m N 0 Compound - Rl X
Ib-b267 -CH2-N(CH2-CH3)2 -CH(OH)-Ib-b268 -CH2-N(CH2-CH3)2 N(C(O)N(H)-CHz-CHz-OH)-Ib-b269 -CH2-N(CH2-CH3)2 -N(C(O)N(H)-CH2-CH2-F)-Ib-b270 -CH2-N(CH2-CH3)2 -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b271 -CH2-N(CH2-CH3)2 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b275 -CHz-N CHz-CHz-CH3 z -CH OH -Ib-b276 -CHz-N CHz-CHz-CH3 z N C O N H-CHz-CHz-OH -Ib-b277 -CHz-N CHz-CHz-CH3 z -N C O N H-CHz-CHz-F -Ib-b278 -CHz-N CHz-CHz-CH3 z -N C O N H-CHz-CHz-OCH3 -Ib-b279 -CHz-N CHz-CHz-CH3 z N C O N H-CHz-CHz-CF3 -Ib-b283 -CHz-N CHz-CHzOH z -CH OH -Ib-b284 -CHz-N CHz-CHzOH z N C O N H-CHz-CHz-OH -Ib-b285 -CHz-N(CHz-CHzOH)z -N(C(O)N(H)-CH2-CH2-F)-Ib-b286 -CHz-N CHz-CHzOH z -N C O N H-CHz-CHz-OCH3 -Ib-b291 -CHz-N(CHz-CHz-N(CH3)1)1 -CH OH -Ib-b292 -CHz-N(CHz-CHz-N(CH3)1)1 N C O N H-CHz-CHz-OH -Ib-b293 -CHz-N(CHz-CHz-N(CH3)1)1 -N(C(O)N(H)-CH2-CH2-F)-Ib-b294 -CHz-N(CHz-CHz-N(CH3)1)1 -N C O N H-CHz-CHz-OCH3 -Ib-b295 -CHz-N(CHz-CHz-N(CH3)1)1 N C O N H-CHz-CHz-CF3 -Ib-b296 -CHz-N(CHz-CHz-N(CH3)2)2N C O N H-CHz-CHz-CF3 -Ib-b297 -CH2-N(CH2-CH2-N(CH3)2)2 -N C O N H-CHz-CF3 -Ib-b298 -CH2-N(CH2-CH2-N(CH3)2)2 -N C O N H CHz 3-OH -Ib-b299 -CHz-N(CH2-CH2-CH2-N(CH3)2)2 -CH OH -Ib-b300 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N C O N H-CHz-CHz-OH -Ib-b301 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C O N H-CHz-CHz-F -Ib-b302 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C O N H-CHz-CHz-OCH3 -Ib-b303 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N C O N H-CHz-CHz-CF3 -Ib-b304 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N C O N H-CHz-CHz-CF3 -Ib-b305 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C O N H-CHz-CF3 -Ib-b306 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C O N H CHz 3-OH -Ib-b307 -CH2-N-7 -CH(OH)-Ib-b308 -CH2-N-7 N(C(O)N(H)-CH2-CH2-OH)-Ib-b309 -CHz-N- -N(C(O)N(H)-CH2-CH2-F)-Ib-b310 -CHz-N~ -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b311 -CHz-N~ N(C(O)N(H)-CH2-CH2-CF3)-Ib-b312 -CH2-N N(C(O)N(H)-CH2-CH2-CF3)-Ib-b313 -CHz-N~ -N(C(O)N(H)-CH2-CF3)-Ib-b314 -CH2-N~ -N(C(O)N(H)-(CH2)3-OH)-Ib-b315 -CH2-N~ -CH(OH)-Ib-b316 -CHz-N~ N(C(O)N(H)-CH2-CH2-OH)-Ib-b317 -CH2-<> -N(C(O)N(H)-CH2-CH2-F)-Ib-b318 -CHz-Nc> -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b319 -CHz-Nc> -N(C(O)N(H)-CH2-CH2-CF3)-Ib-b320 -CHz-N~> N(C(O)N(H)-CH2-CH2-CF3)-Ib-b321 -CH2-N~> -N(C(O)N(H)-CH2-CF3)-Ib-b322 -CHz-NC> -N(C(O)N(H)-(CH2)3-OH)-Ib-b323 -CHz-NC) -CH(OH)-Ib-b324 -CHz-NC) N(C(O)N(H)-CH2-CH2-OH)-Ib-b325 -CHz-No -N(C(O)N(H)-CH2-CH2-F)-Ib-b326 -CHz-No -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b327 -CHz-No N(C(O)N(H)-CH2-CH2-CF3)-Ib-b328 -CHz-No N(C(O)N(H)-CH2-CH2-CF3)-Ib-b329 -CHz-No -N(C(O)N(H)-CH2-CF3)-Ib-b330 -CHz-No -N(C(O)N(H)-(CH2)3-OH)-Ib-b331 -CHz-Na -CH(OH)-Ib-b332 -CHz-Na N(C(O)N(H)-CH2-CH2-OH)-Ib-b333 -CHz-Na -N(C(O)N(H)-CH2-CH2-F)-Ib-b334 -CHz-Na -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b335 -CHz-N~ N(C(O)N(H)-CH2-CH2-CF3)-Ib-b336 -CHz-Na N(C(O)N(H)-CH2-CH2-CF3)-Ib-b337 -CHz-Na -N(C(O)N(H)-CH2-CF3)-OH
Ib-b338 -CHz-Na -N(C(O)N(H)-(CH2)3-OH)-OH
Ib-b339 -CHz-N -CH(OH)-Ib-b340 -CHz-N N(C(O)N(H)-CHz-CHz-OH)-Ib-b341 -CHz_N -N(C(O)N(H)-CH2-CH2-F)-Ib-b342 -CHz_N -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b343 -CHz_N N(C(O)N(H)-CH2-CH2-CF3)-Ib-b344 -CHz_N N(C(O)N(H)-CH2-CH2-CF3)-Ib-b345 -CHz_N -N(C(O)N(H)-CH2-CF3)-Ib-b346 -CHz_N -N(C(O)N(H)-(CH2)3-OH)-Ib-b347 -CHz-N_ ) -CH(OH)-Ib-b348 -CHz-N --D -- N(C(O)N(H)-CH2-CH2-OH)-Ib-b349 -CHz-ND -N(C(O)N(H)-CH2-CH2-F)-Ib-b350 -CHz-N--- ~ -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b351 -CH2-N ) --- N(C(O)N(H)-CHz-CHz-CF3)-Ib-b352 -CHz-N ) -- -- N(C(O)N(H)-CHz-CHz-CF3)-Ib-b353 -CHz-N --D -- -N(C(O)N(H)-CH2-CF3)-Ib-b354 -CHz-N, ) -N(C(O)N(H)-(CH2)3-OH)-Ib-b355 -CH2-N~--N---CH3 -CH(OH)-Ib-b356 -CH2-N/-\ N-CH3 N(C(O)N(H)-CH2-CH2-OH)-Ib-b357 -CH2-N/-\ N-CH3 -N(C(O)N(H)-CH2-CH2-F)-Ib-b358 -CH2-N/-\ N-CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b359 -CH2-N/-\ N-CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b360 -CH2-N/-\ N-CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b361 -CH2-N/-\ N-CH3 -N(C(O)N(H)-CH2-CF3)-Ib-b362 -CH2-N/-\ N-CH3 -N(C(O)N(H)-(CH2)3-OH)-Ib-b363 -CH2-N /CH3 -CH(OH)-Ib-b364 -CH2-N /cH3 N(C(O)N(H)-CHz-CHz-OH)-Ib-b365 --CH2-N /cH3 -N(C(O)N(H)-CHz-CHz-F)-Ib-b366 -CH2-N /cH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b367 -CH2-N /cH3 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b368 -CH2-N /cH3 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b369 -CH2-N /cH3 -N(C(O)N(H)-CH2-CF3)-Ib-b370 -CH2-N /cH3 -N(C(O)N(H)-(CH2)3-OH)-Ib-b371 -CH2-N /cH3 -CH(OH)->-CH3 Ib-b372 -CH2-N /CH3 N(C(O)N(H)-CHz-CHz-OH)->-CH3 Ib-b373 -CH2-N /CH3 -N(C(O)N(H)-CHz-CHz-F)->-CH3 H C
Ib-b374 -CH2-N CH3 -N(C(O)N(H)-CH2-CH2-OCH3)->-CH3 H C
Ib-b375 -CH2-N /QH3 N(C(O)N(H)-CH2-CH2-CF3)->-CH3 H C
Ib-b376 -CH2-N /QH3 N(C(O)N(H)-CH2-CH2-CF3)->-CH3 H C

Ib-b377 -CH2 -N /CH3 -N(C(O)N(H)-CH2-CF3)->-CH3 Ib-b378 -CH2 -N /QH3 -N(C(O)N(H)-(CH2)3-OH)->-CH3 Ib-b379 -CH2-N /CH3 -CH(OH)-Ib-b380 -CH2-N /CH3 N(C(O)N(H)-CHz-CHz-OH)-Ib-b381 -CH2-N /CH3 -N(C(O)N(H)-CHz-CHz-F)-Ib-b382 -CH2-N CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b383 -CH2-N /CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b384 -CH2-N /CHs N(C(O)N(H)-CH2-CH2-CF3)-Ib-b385 -CH2-N /CH3 -N(C(O)N(H)-CH2-CF3)-Ib-b386 -CH2-N /CH3 -N(C(O)N(H)-(CH2)3-OH)-Ib-b387 ~N~~N~ -CH(OH)--CH2 ~0 Ib-b388 NN(C(O)N(H)-CH2-CH2-OH)--CH2 ~0 Ib-b389 N-N(C(O)N(H)-CH2-CH2-F)-Ib-b390 N-N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b391 NN(C(O)N(H)-CH2-CH2-CF3)-Ib-b392 NN(C(O)N(H)-CH2-CH2-CF3)-Ib-b393 N-N(C(O)N(H)-CH2-CF3)-Ib-b394 NN~ -N(C(O)N(H)-(CHz)3-OH)--CH2 ~O
Ib-b395 ~O -CH(OH)-H N~/
N
CH /
Ib-b396 (/--O N(C(O)N(H)-CHz-CHz-OH)-/NN~/
CH
Ib-b397 CO -N(C(O)N(H)-CH2-CH2-F)-H
CH
Ib-b398 CO -N(C(O)N(H)-CH2-CH2-OCH3)-\ N,/
CH
Ib-b399 (--O -N(C(O)N(H)-CH2-CH2-CF3)-H
CH
Ib-b400 ("--O N(C(O)N(H)-CH2-CH2-CF3)-/NN~/
CH
Ib-b401 O -N(C(O)N(H)-CH2-CF3)-H N-/
CH -' N
Ib-b402 CO -N(C(O)N(H)-(CH2)3-OH)-\ N,/
CH
Ib-b403 ~N CH3 -CH(OH)-H

Ib-b404 N CH3 -N(C(O)N(H)-CH2-CH2-OH)-H N--/
\CH2 "I N,,/---,/

Ib-b405 N .cH3 -N(C(O)N(H)-CH2-CH2-F)-H N-/
\CH2 "I N,,/---,/

Ib-b406 N .cH3 -N(C(O)N(H)-CH2-CH2-OCH3)-H
\ /NZ~

Ib-b407 N CH3 -N(C(O)N(H)-CH2-CH2-CF3)-H /NZ~N~/

Ib-b408 N CH3 -N(C(O)N(H)-CH2-CH2-CF3)-H /NZ~N~/

Ib-b409 N CH3 -N(C(O)N(H)-CH2-CF3)-H N-/
\CH2 "I N,,/---,/

Ib-b410 N CH3 -N(C(O)N(H)-(CH2)3-OH)-H N--/
\CH2 "I N,,/---,/

Ib-b411 H3C -CH(OH)-CH ~NN,CH3 Ib-b412 H3~ -N(C(O)N(H)-CH2-CH2-OH)-H
N, Ib-b413 H3~ -N(C(O)N(H)-CHz-CHz-F)-CH 'N-CH3 Ib-b414 H3~ -N(C(O)N(H)-CHz-CHz-OCH3)-CH ~N~/N`CH3 Ib-b415 H3~ N(C(O)N(H)-CH2-CH2-CF3)-CH ~NN`CH3 Ib-b416 H3~ -N(C(O)N(H)-CH2-CH2-CF3)-H
N, Ib-b417 H3~ -N(C(O)N(H)-CHz-CF3)-CH ~N~/N`CH3 Ib-b418 H3~ -N(C(O)N(H)-(CH2)3-OH)-H N`

Ib-b419 N -CH(OH)-/
H N
\CH /N

Ib-b420 N -N(C(O)N(H)-CH2-CH2-OH)-H N
\CH ~N
Ib-b421 N -N(C(O)N(H)-CH2-CH2-F)-H N
\CH "I N
Ib-b422 N -N(C(O)N(H)-CH2-CH2-OCH3)-N
\CH "I N
Ib-b423 N N(C(O)N(H)-CH2-CH2-CF3)-N
\CH /N

Ib-b424 N N(C(O)N(H)-CH2-CH2-CF3)-N
\CH ~N
Ib-b425 N -N(C(O)N(H)-CH2-CF3)-H N
\CH "I N
Ib-b426 N -N(C(O)N(H)-(CH2)3-OH)-N
\CH 'IN
Ib-b427 -CH(OH)-~
-CH2-N~/ N
Ib-b428 N(C(O)N(H)-CHz-CHz-OH)-~
-CH2-N~/N
Ib-b429 -N(C(O)N(H)-CHz-CHz-F)-~
-CH2-N ~\ N

Ib-b430 -N(C(O)N(H)-CHz-CHz-OCH3)-~
-CH2-N~/ N

Ib-b431 N(C(O)N(H)-CHz-CHz-CF3)-~
-CH2-N~/N
Ib-b432 N(C(O)N(H)-CHz-CHz-CF3)-~
-CH2-N ~\ N

Ib-b433 -N(C(O)N(H)-CHz-CF3)-~
-CH2-N~/N
Ib-b434 -N(C(O)N(H)-(CHz)3-OH)-~
~

Ib-b435 -CH2iv/-\ N F -CH(OH)-~/ -Ib-b436 -CHzfv/-\ N ~ F N(C(O)N(H)-CHz-CHz-OH)-~/ -Ib-b437 -CH2iV/-\ N ~ F -N(C(O)N(H)-CHz-CHz-F)--Ib-b438 -CHziv/-\ N F -N(C(O)N(H)-CH2-CH2-OCH3)-~/
Ib-b439 -CHziv/-\ N F N(C(O)N(H)-CH2-CH2-CF3)-~/
Ib-b440 -CH2iv/-\ N F N(C(O)N(H)-CH2-CH2-CF3)-~/
Ib-b441 -CH2iv/-\ N F -N(C(O)N(H)-CH2-CF3)-~/
Ib-b442 -CH2iv/-\ N ~ F -N(C(O)N(H)-(CH2)3-OH)--Ib-b443 -CH2-N 3-&F -CH(OH)-Ib-b444 -CH2-N ~F N(C(O)N(H)-CH2-CH2-OH)-Ib-b445 -CH2-N ~F -N(C(O)N(H)-CH2-CH2-F)-Ib-b446 -CHz-N ~F -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b447 -CH2-N ~F N(C(O)N(H)-CH2-CH2-CF3)-Ib-b448 -CH2-N ~F N(C(O)N(H)-CH2-CH2-CF3)-Ib-b449 -CH2-N ~F -N(C(O)N(H)-CH2-CF3)-Ib-b450 -CH2-N ~F -N(C(O)N(H)-(CH2)3-OH)--CH(OH)-Ib-b451 -CH2-N / \

Ib-b452 -CHz-N ~ N(C(O)N(H)-CH2-CH2-OH)-Ib-b453 -CH2-N -N(C(O)N(H)-CH2-CH2-F)-Ib-b454 -CH2-N -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b455 -CH2-N ~ N(C(O)N(H)-CH2-CH2-CF3)-Ib-b456 -CHz-N N(C(O)N(H)-CH2-CH2-CF3)-Ib-b457 -CHz-N O -N(C(O)N(H)-CH2-CF3)-Ib-b458 -CH2-N o -N(C(O)N(H)-(CH2)3-OH)-Ib-b459 _cHz-N \ / \ c -CH(OH)-Ib-b460 _cHz_N \ / \ c N(C(O)N(H)-CH2-CH2-OH)-Ib-b461 _cHz-N \ / \ c -N(C(O)N(H)-CH2-CH2-F)-Ib-b462 _cHz-N \ / \ c -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b463 _cHz-N \ / \ c N(C(O)N(H)-CH2-CH2-CF3)-Ib-b464 _cHz-N \ / \ c N(C(O)N(H)-CH2-CH2-CF3)-Ib-b465 _cHz-N \ / \ c -N(C(O)N(H)-CH2-CF3)-Ib-b466 _cHz-N \ / \ c -N(C(O)N(H)-(CH2)3-OH)-Ib-b467 _cHz-N \ / \ -CH(OH)-Ib-b468 _cHz_N \ / \ N(C(O)N(H)-CH2-CH2-OH)-Ib-b469 _cHz_N \ / \ -N(C(O)N(H)-CH2-CH2-F)-Ib-b470 _cHz_N \ / \ -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b471 _cHz_N \ / \ N(C(O)N(H)-CH2-CH2-CF3)-Ib-b472 _cHz_N \ / \ N(C(O)N(H)-CH2-CH2-CF3)-Ib-b473 _cHz_N \ / \ -N(C(O)N(H)-CH2-CF3)-Ib-b474 _CHz-N \ / \ -N(C(O)N(H)-(CH2)3-OH)-Ib-b475 _CHz_N O -CH(OH)-DSH Ib-b476 _CHz-N / \ N(C(O)N(H)-CH2-CH2-OH)-Ib-b477 _CHz-N / \ -N(C(O)N(H)-CH2-CH2-F)-Ib-b478 _CHz-N / \ -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b479 _CHz-N / \ N(C(O)N(H)-CH2-CH2-CF3)-Ib-b480 _CHz-N / \ N(C(O)N(H)-CH2-CH2-CF3)-Ib-b481 _CHz_N / \ -N(C(O)N(H)-CH2-CF3)-Ib-b482 _CHz_N / \ -N(C(O)N(H)-(CH2)3-OH)-Ib-b483 -CH2-N /-\ NCH2CH20P(O)(OH)2 -CH(OH)-Ib-b484 -CH2-N /-\ NCH2CH20P(O)(OH)2 N(C(O)N(H)-CH2-CH2-OH)-Ib-b485 -CH2-N NCH2CH20P(O)(OH)2 -N(C(O)N(H)-CHz-CHz-F)-Ib-b486 -CH2-N NCH2CH20P(O)(OH)2 -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b487 -CH2-N /-\ NCH2CH20P(O)(OH)2 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b488 -CH2-N /-\ NCH2CH20P(O)(OH)2 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b489 -CH2-N /-\ NCH2CH20P(O)(OH)2 -N(C(O)N(H)-CH2-CF3)-Ib-b490 -CH2-N NCH2CH20P(O)(OH)2 -N(C(O)N(H)-(CH2)3-OH)-Ib-b491 -CH2-CH2-CH2-OP(O)(OH)2 -CH OH -Ib-b492 -CH2-CH2-CH2-OP(O)(OH)2 N C O N H-CHz-CHz-OH -Ib-b493 -CH2-CH2-CH2-OP(O)(OH)2 -N(C(O)N(H)-CH2-CH2-F)-Ib-b494 -CH2-CH2-CH2-OP(O)(OH)2 -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b495 -CH2-CH2-CH2-OP(O)(OH)2 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b496 -CH2-CH2-CH2-OP(O)(OH)2 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b497 -CH2-CH2-CH2-OP(O)(OH)2 -N C O N H-CHz-CF3 -Ib-b498 -CH2-CH2-CH2-OP(O)(OH)2 -N C O N H CHz 3-OH -Ib-b499 -CHz-CHz-CHz-OS(O)zOH -CH OH -Ib-b500 -CHz-CHz-CHz-OS(O)zOH N C O N H-CHz-CHz-OH -Ib-b501 -CHz-CHz-CHz-OS(O)zOH -N C O N H-CHz-CHz-F -Ib-b502 -CHz-CHz-CHz-OS(O)zOH -N C O N H-CHz-CHz-OCH3 -Ib-b503 -CHz-CHz-CHz-OS(O)zOH N(C(O)N(H)-CH2-CH2-CF3)-Ib-b504 -CHz-CHz-CHz-OS(O)zOH N C O N H-CHz-CHz-CF3 -Ib-b505 -CHz-CHz-CHz-OS(O)zOH -N C O N H-CHz-CF3 -Ib-b506 -CHz-CHz-CHz-OS(O)zOH -N(C(O)N(H)-(CH2)3-OH)-Ib-b507 -CHz-Na -CH(OH)-OP O OH
Ib-b508 -CHz-Na N(C(O)N(H)-CHz-CHz-OH)-OP O OH
Ib-b509 -CHz-Na -N(C(O)N(H)-CHz-CHz-F)-OP O OH
Ib-b510 -CHz-NC( -N(C(O)N(H)-CH2-CH2-OCH3)-OP O OH
Ib-b511 -CHz-Na N(C(O)N(H)-CH2-CH2-CF3)-OP O OH
Ib-b512 -CHz-Na N(C(O)N(H)-CH2-CH2-CF3)-OP O OH
Ib-b513 -CH2-Na -N(C(O)N(H)-CH2-CF3)-OP O OH
Ib-b514 -CH2-NC( -N(C(O)N(H)-(CH2)3-OH)-OP O OH
Ib-b515 -CH2-N -CH(OH)-OP O OH
Ib-b516 -CHz-N N(C(O)N(H)-CHz-CHz-OH)-OP O OH
Ib-b517 -CHz-N -N(C(O)N(H)-CHz-CHz-F)-OP O OH
Ib-b518 -CHz-N -N(C(O)N(H)-CH2-CH2-OCH3)-OP O OH
Ib-b519 -CHz-N N(C(O)N(H)-CH2-CH2-CF3)-OP O OH

Ib-b520 -CHz-N N(C(O)N(H)-CH2-CH2-CF3)-OP O OH
Ib-b521 -CH2-N -N(C(O)N(H)-CH2-CF3)-OP O OH
Ib-b522 -CHz-N -N(C(O)N(H)-(CH2)3-OH)-OP O OH
Ib-b523 -(CH2)io-IV(CH2-CH2-0-CH3)2 -CH(OH)-Ib-b524 -(CH2)io-IV(CH2-CH2-0-CH3)2 N C O N H-CHz-CHz-OH -Ib-b525 -(CH2)io-IV(CH2-CH2-0-CH3)2 -N C O N H-CHz-CHz-F -Ib-b526 -(CH2)io-IV(CH2-CH2-0-CH3)2 -N C O N H-CHz-CHz-OCH3 -Ib-b527 -(CH2)io-IV(CH2-CH2-0-CH3)2 N C O N H-CHz-CHz-CF3 -Ib-b528 -(CH2)io-IV(CH2-CH2-0-CH3)2 N C O N H-CHz-CHz-CF3 -Ib-b529 -(CH2)io-IV(CH2-CH2-0-CH3)2 -N C O N H-CHz-CF3 -Ib-b530 -(CH2)io-IV(CH2-CH2-0-CH3)2 -N C O N H CHz 3-OH -Ib-b531 -CH2-rr(CH2-CH2-0-CH3)2 -CH OH -Ib-b532 -CH2-rr(CH2-CH2-0-CH3)2 N C O N H-CHz-CHz-OH -Ib-b533 -CH2-rr(CH2-CH2-0-CH3)2 -N C O N H-CHz-CHz-F -Ib-b534 -CH2-rr(CH2-CH2-0-CH3)2 -N C O N H-CHz-CHz-OCH3 -Ib-b535 -CH2-rr(CH2-CH2-0-CH3)2 N C O N H-CHz-CHz-CF3 -Ib-b536 -CH2-rr(CH2-CH2-0-CH3)2 N C O N H-CHz-CHz-CF3 -Ib-b537 -CH2-rr(CH2-CH2-0-CH3)2 -N C O N H-CHz-CF3 -Ib-b538 -CH2-rr(CH2-CH2-0-CH3)2 -N C O N H CHz 3-OH -Ib-b539 /- N~ -CH(OH)-Ib-b540 -N N(C(O)N(H)-CHz-CHz-OH)-Ib-b541 -N(C(O)N(H)-CHz-CHz-F)-~N
~
Ib-b542 N~ -N(C(O)N(H)-CH2-CH2-OCH3)-~

Ib-b543 N~ N(C(O)N(H)-CHz-CHz-CF3)-~
~
(C(O)N(H)-CHz-CHz-CF3)-Ib-b544 0:: N

Ib-b545 N~ -N(C(O)N(H)-CH2-CF3)-~
~
Ib-b546 -N(C(O)N(H)-(CH2)3-OH)-~N

Ib-b547 /-Na -CH(OH)-OH
Ib-b548 /-NaN(C(O)N(H)-CHz-CHz-OH)-OH
Ib-b549 /-Na -N(C(O)N(H)-CHz-CHz-F)-OH
Ib-b550 /-Na -N(C(O)N(H)-CH2-CH2-OCH3)-OH
Ib-b551 /-NaN(C(O)N(H)-CHz-CHz-CF3)-OH
Ib-b552 /-NaN(C(O)N(H)-CHz-CHz-CF3)-OH
Ib-b553 /-Na -N(C(O)N(H)-CH2-CF3)-OH
Ib-b554 /-Na -N(C(O)N(H)-(CH2)3-OH)-OH
Ib-b555 ~lqlo- No -CH(OH)-Ib-b556 lqlo- No N(C(O)N(H)-CH2-CH2-OH)-Ib-b557 lqlo- No -N(C(O)N(H)-CH2-CH2-F)-Ib-b558 ~lqlo- No -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b559 ~lqlo- No N(C(O)N(H)-CH2-CH2-CF3)-Ib-b560 ~lqlo- No N(C(O)N(H)-CH2-CH2-CF3)-Ib-b561 -N(C(O)N(H)-CH2-CF3)-Ib-b562 -N(C(O)N(H)-(CH2)3-OH)-Ib-b563 -CH(OH)-~N N~

Ib-b564 v N(C(O)N(H)-CHz-CHz-OH)-~N N~

Ib-b565 v -N(C(O)N(H)-CHz-CHz-F)-~N N~

Ib-b566 N Nv -N(C(O)N(H)-CHz-CHz-OCH3)-~

Ib-b567 N N N(C(O)N(H)-CHz-CHz-CF3)-Ib-b568 v N N(C(O)N(H)-CHz-CHz-CF3)-N
Ib-b569 v N -N(C(O)N(H)-CH2-CF3)-~ N

Ib-b570 v N Nv -N(C(O)N(H)-(CHz)3-OH)-~~

Ib-b571 -CH(OH)-~N

HO
Ib-b572 N(C(O)N(H)-CHz-CHz-OH)-N
/-HO
Ib-b573 -N(C(O)N(H)-CHz-CHz-F)-N
/-HO
Ib-b574 -N(C(O)N(H)-CH2-CH2-OCH3)-N
/-HO
Ib-b575 N(C(O)N(H)-CHz-CHz-CF3)-~N
HO
Ib-b576 N(C(O)N(H)-CH2-CH2-CF3)-N
/-HO
Ib-b577 -N(C(O)N(H)-CHz-CF3)-~N
HO
Ib-b578 -N(C(O)N(H)-(CH2)3-OH)-/-N
HO
Ib-b579 -CH(OH)-N

O
O Me Ib-b580 N(C(O)N(H)-CHz-CHz-OH)-X/-N

O
O Me Ib-b581 -N(C(O)N(H)-CHz-CHz-F)-N

O
O Me Ib-b582 -N(C(O)N(H)-CH2-CH2-OCH3)-N

O
O Me Ib-b583 N(C(O)N(H)-CH2-CH2-CF3)-N

O
O Me Ib-b584 N(C(O)N(H)-CH2-CH2-CF3)-N

O
O Me Ib-b585 -N(C(O)N(H)-CH2-CF3)-N

O
O Me Ib-b586 -N(C(O)N(H)-(CH2)3-OH)-N

O
O Me Ib-b587 N -CH(OH)-~ /

Ib-b588 N N(C(O)N(H)-CHz-CHz-OH)-~

Ib-b589 N -N(C(O)N(H)-CHz-CHz-F)-~

Ib-b590 N -N(C(O)N(H)-CH2-CH2-OCH3)-~

Ib-b591 N(C(O)N(H)-CH2-CH2-CF3)-~

Ib-b592 N N(C(O)N(H)-CH2-CH2-CF3)-~

Ib-b593 N -N(C(O)N(H)-CH2-CF3)-~

Ib-b594 N -N(C(O)N(H)-(CH2)3-OH)-~

Ib-b595 -CH(OH)-No Ib-b596 N(C(O)N(H)-CHz-CHz-OH)-~

No Ib-b597 -N(C(O)N(H)-CHz-CHz-F)-~

No Ib-b598 -N(C(O)N(H)-CHz-CHz-OCH3)-No Ib-b599 N(C(O)N(H)-CHz-CHz-CF3)-No Ib-b600 N(C(O)N(H)-CHz-CHz-CF3)-No Ib-b601 -N(C(O)N(H)-CHz-CF3)-No Ib-b602 -N(C(O)N(H)-(CHz)3-OH)-No Ib-b603 -CH(OH)-I-N\-/ N--\\_,,N(CHa) Ib-b604 N(C(O)N(H)-CHz-CHz-OH)-[-N\_/N--\,_,N(CHa) Ib-b605 -N(C(O)N(H)-CHz-CHz-F)-[-N\__/N--\\,,-N(CHa) Ib-b606 -N(C(O)N(H)-CHz-CHz-OCH3)-[-N\_/N--\,,N(CHa) Ib-b607 N(C(O)N(H)-CH2-CH2-CF3)-I-N\-/ N--\\_,,N(CHa) Ib-b608 N(C(O)N(H)-CHz-CHz-CF3)-[-N\__/N--\_,-N(CHa) Ib-b609 -N(C(O)N(H)-CHz-CF3)-[-N\__/N--\\,,-N(CHa) Ib-b610 -N(C(O)N(H)-(CHz)3-OH)-[-N\__/N--\\,,,N(CHa) Ib-b611 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -CH OH -Ib-b612 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N(C(O)N(H)-CH2-CH2-OH)-Ib-b613 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N(C(O)N(H)-CH2-CH2-F)-Ib-b614 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C O N H-CHz-CHz-OCH3 -Ib-b615 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b616 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N C O N H-CHz-CHz-CF3 -Ib-b617 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C O N H-CHz-CF3 -Ib-b618 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C O N H CHz 3-OH -Ib-b619 0 -CH(OH)-NCO

Ib-b620 0 N(C(O)N(H)-CHz-CHz-OH)-~NC I ~

Ib-b621 0 -N(C(O)N(H)-CHz-CHz-F)-~NCI ~

Ib-b622 0 -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b623 0 N(C(O)N(H)-CHz-CHz-CF3)-NCO

Ib-b624 0 N(C(O)N(H)-CHz-CHz-CF3)-NCO

Ib-b625 0 -N(C(O)N(H)-CH2-CF3)-~NC I

Ib-b626 0 -N(C(O)N(H)-(CH2)3-OH)-~N~ I

Ib-b627 /~",OH -CH(OH)-~N, Ib-b628 v/~",OH N(C(O)N(H)-CHz-CHz-OH)-~N, Ib-b629 v/~",OH -N(C(O)N(H)-CHz-CHz-F)-~N, Ib-b630 v/~",OH -N(C(O)N(H)-CHz-CHz-OCH3)-~N, Ib-b631 v/~",OH N(C(O)N(H)-CHz-CHz-CF3)-~N, Ib-b632 v/~",OH N(C(O)N(H)-CHz-CHz-CF3)-~N, Ib-b633 v/~",OH -N(C(O)N(H)-CHz-CF3)-~N, Ib-b634 v/~",OH -N(C(O)N(H)-(CHz)3-OH)-~N, Ib-b635 -CH(OH)-HO
Ib-b636 N(C(O)N(H)-CHz-CHz-OH)-Ib-b637 -N(C(O)N(H)-CHz-CHz-F)-HO
Ib-b638 -N(C(O)N(H)-CH2-CH2-OCH3)-HO
Ib-b639 N(C(O)N(H)-CH2-CH2-CF3)-HO
Ib-b640 N(C(O)N(H)-CH2-CH2-CF3)-HO
Ib-b641 -N(C(O)N(H)-CH2-CF3)-HO
Ib-b642 -N(C(O)N(H)-(CH2)3-OH)-HO
Ib-b643 ,CH3 -CH(OH)-~N
~CH3 Ib-b644 ,C H3 N(C(O)N(H)-CHz-CHz-OH)-/~,-N
/-\- C H 3 \

Ib-b645 ,CH3 -N(C(O)N(H)-CHz-CHz-F)-/-N

Ib-b646 ,CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-/~,-N
/\- C H 3 Ib-b647 ,CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N

Ib-b648 ,CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N
/\-CH3 Ib-b649 ,CH3 -N(C(O)N(H)-CH2-CF3)-/\-CH3 Ib-b650 ,CH3 -N(C(O)N(H)-(CH2)3-OH)-//-N

Ib-b651 -CH(OH)-Ib-b652 N(C(O)N(H)-CH2-CH2-OH)-Ib-b653 -N(C(O)N(H)-CH2-CH2-F)-Ib-b654 -N(C(O)N(H) CHz CHz-OCH3)-O
Ib-b655 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b656 N(C(O)N(H) CHz-CHz-CF3)-Ib-b657 -N(C(O)N(H) CHz CF3) Ib-b658 -N(C(O)N(H) (CHz)3-OH)-Ib-b659 \-N OH -CH(OH)-Ib-b660 \_N OH N(C(O)N(H)-CHz-CHz-OH)-Ib-b661 \_N OH -N(C(O)N(H)-CHz-CHz-F)-Ib-b662 \_N OH -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b663 \\_N OH N(C(O)N(H)-CH2-CH2-CF3)-Ib-b664 \\_N OH N(C(O)N(H)-CH2-CH2-CF3)-Ib-b665 \\_N OH -N(C(O)N(H)-CH2-CF3)-Ib-b666 \\_N oH -N(C(O)N(H)-(CH2)3-OH)-Ib-b667 N OH -CH(OH)-Ib-b668 a OH N(C(O)N(H)-CH2-CH2-OH)-Ib-b669 cr OH -N(C(O)N(H)-CH2-CH2-F)-Ib-b670 a OH -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b671 a OH N(C(O)N(H)-CH2-CH2-CF3)-Ib-b672 a OH N(C(O)N(H)-CH2-CH2-CF3)-Ib-b673 a OH -N(C(O)N(H)-CH2-CF3)-Ib-b674 a OH -N(C(O)N(H)-(CH2)3-OH)-Ib-b675 ~NH -CH(OH)-Ib-b676 NH N(C(O)N(H)-CH2-CH2-OH)-Ib-b677 NH -N(C(O)N(H)-CH2-CH2-F)-Ib-b678 NH -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b679 NH N(C(O)N(H)-CH2-CH2-CF3)-Ib-b680 NH N(C(O)N(H)-CH2-CH2-CF3)-Ib-b681 NH -N(C(O)N(H)-CH2-CF3)-Ib-b682 NH -N(C(O)N(H)-(CH2)3-OH)-Ib-b683 /-NH -CH(OH)-Ib-b684 //-NH N(C(O)N(H)-CH2-CH2-OH)-Ib-b685 //-NH -N(C(O)N(H)-CH2-CH2-F)-Ib-b686 Ilo---NH -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b687 Ilo---NH N(C(O)N(H)-CH2-CH2-CF3)-Ib-b688 //-NH N(C(O)N(H)-CH2-CH2-CF3)-Ib-b689 Ilo---NH -N(C(O)N(H)-CH2-CF3)-Ib-b690 //-NH -N(C(O)N(H)-(CH2)3-OH)-Ib-b691 /-NH -CH(OH)-Ib-b692 /cH2CH3 N(C(O)N(H)-CHz-CHz-OH)-Ib-b693 /cH2CH3 -N(C(O)N(H)-CHz-CHz-F)-Ib-b694 /CH2CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b695 /cH2CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b696 "CH2CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b697 / CH2CH3 -N(C(O)N(H)-CH2-CF3)-Ib-b698 /cH2CH3 -N(C(O)N(H)-(CH2)3-OH)-Ib-b699 /cH2CH3 -CH(OH)-Ib-b700 /-NH N(C(O)N(H)-CH2-CH2-OH)-D Ib-b701 /-NH -N(C(O)N(H) CHz CHz F) D

Ib-b702 /-NH -N(C(O)N(H)-CH2-CH2-OCH3)-D Ib-b703 /-NH N(C(O)N(H)-CH2-CH2-CF3)-D Ib-b704 /-NH N(C(O)N(H)-CH2-CH2-CF3)-D Ib-b705 /-NH -N(C(O)N(H)-CH2-CF3)-D
Ib-b706 /-NH -N(C(O)N(H)-(CH2)3-OH)-D 259-Ib-b707 /-NH -CH(OH)-D Ib-b708 /-NH N(C(O)N(H)-CH2-CH2-OH)-D Ib-b709 /-NH -N(C(O)N(H)-CH2-CH2-F)-D Ib-b710 /-NH -N(C(O)N(H)-CH2-CH2-OCH3)-D Ib-b711 /-NH
N(C(O)N(H)-CH2-CH2-CF3)-D Ib-b712 /-NH N(C(O)N(H)-CH2-CH2-CF3)-D Ib-b713 /-NH -N(C(O)N(H)-CH2-CF3)-D Ib-b714 /-NH -N(C(O)N(H)-(CH2)3-OH)-D Ib-b715 -CH(OH)-Ib-b716 N(C(O)N(H)-CHz-CHz-OH)-Ib-b717 ~/-\ S -N(C(O)N(H)-CHz-CHz-F)-Ib-b718 -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b719 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b720 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b721 -N(C(O)N(H)-CH2-CF3)-Ib-b722 -N /-\ -N(C(O)N(H)-(CH2)3-OH)-Ib-b723 N\~ -CH(OH)-Ib-b724 N\~ N(C(O)N(H)-CHz-CHz-OH)-Ib-b725 N\~ -N(C(O)N(H)-CHz-CHz-F)-Ib-b726 -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b727 N\~ N(C(O)N(H)-CH2-CH2-CF3)-Ib-b728 N\~ N(C(O)N(H)-CH2-CH2-CF3)-Ib-b729 N\~ -N(C(O)N(H)-CH2-CF3)-Ib-b730 -N(C(O)N(H)-(CH2)3 OH) Ib-b731 /-NH -CH(OH)-Ib-b732 /-NH N(C(O)N(H)-CHz-CHz-OH)-Ib-b733 /-NH -N(C(O)N(H)-CH2-CH2-F)-Ib-b734 /-NH -N(C(O)N(H)-CH2-CH2-OCH3)-H C
Ib-b735 /-NH N(C(O)N(H)-CHz-CHz-CF3)-Ib-b736 /-NH N(C(O)N(H)-CHz-CHz-CF3)-H C
Ib-b737 /-NH -N(C(O)N(H)-CH2-CF3)-H C
Ib-b738 /-NH -N(C(O)N(H)-(CH2)3-OH)-H C
Ib-b739 CH3 -CH(OH)-N

Ib-b740 CH3 N(C(O)N(H)-CHz-CHz-OH)-~N N

Ib-b741 CH3 -N(C(O)N(H)-CHz-CHz-F)-N

Ib-b742 CH3 -N(C(O)N(H)-CHz-CHz-OCH3)-~N N

Ib-b743 CH3 N(C(O)N(H)-CH2-CH2-CF3)-N

Ib-b744 CH3 N(C(O)N(H)-CHz-CHz-CF3)-~N N

Ib-b745 CH3 -N(C(O)N(H)-CH2-CF3)-N

Ib-b746 CH3 -N(C(O)N(H)-(CHz)3-OH)-~N N

Ib-b747 CH3 -CH(OH)-~N
Ib-b748 CH3 N(C(O)N(H)-CH2-CH2-OH)-N
Ib-b749 CH3 -N(C(O)N(H)-CH2-CH2-F)-N
Ib-b750 CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-~N
Ib-b751 CH3 N(C(O)N(H)-CH2-CH2-CF3)-N
Ib-b752 CH3 N(C(O)N(H)-CH2-CH2-CF3)-N
Ib-b753 CH3 -N(C(O)N(H)-CH2-CF3)-~N
Ib-b754 CH3 -N(C(O)N(H)-(CH2)3-OH)-~N

Ib-b755 NH -CH(OH)-0 OH

Ib-b756 NH 0 N(C(O)N(H)-CH2-CH2-OH)-Ib-b757 NH -N(C(O)N(H)-CH2-CH2-F)-0 Ib-b758 NH -N(C(O)N(H)-CH2-CH2-OCH3)-0 Ib-b759 ~NH 0 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b760 NH 0 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b761 NH -N(C(O)N(H)-CH2-CF3)-0 Ib-b762 NH -N(C(O)N(H)-(CH2)3-OH)-0 Ib-b763 /-N-*,-~ OH -CH(OH)-Ib-b764 //--N--~ OH N(C(O)N(H)-CH2-CH2-OH)-Ib-b765 /-N-,-~ OH -N(C(O)N(H)-CH2-CH2-F)-Ib-b766 OH -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b767 OH N(C(O)N(H)-CH2-CH2-CF3)-Ib-b768 OH N(C(O)N(H)-CH2-CH2-CF3)-Ib-b769 //-N-*,-~ OH -N(C(O)N(H)-CH2-CF3)-Ib-b770 OH -N(C(O)N(H)-(CH2)3-OH)-Ib-b771 /-ND-CH3 -CH(OH)-~ rCH3 N(C(O)N(H)-CH2-CH2-OH)-Ib-b772 /-N--Ib-b773 /-N D-CH3 -N(C(O)N(H)-CH2-CH2-F)-Ib-b774 /-ND-CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-~ rCH3 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b775 /-N--Ib-b776 /-N D-CH3 N(C(O)N(H)-CH2-CH2-CF3)-~ rCH3 -N(C(O)N(H)-CH2-CF3)-Ib-b777 /-N--Ib-b778 /-N D-CH3 -N(C(O)N(H)-(CH2)3-OH)-Ib-b779 -CH2-NH-CH3 -CH OH -Ib-b780 -CH2-NH-CH3 N C O N H-CHz-CHz-OH -Ib-b781 -CH2-NH-CH3 -N C O N H-CHz-CHz-F -Ib-b782 -CH2-NH-CH3 -N C O N H-CHz-CHz-OCH3 -Ib-b783 -CH2-NH-CH3 N C O N H-CHz-CHz-CF3 -Ib-b784 -CH2-NH-CH3 N C O N H-CHz-CHz-CF3 -Ib-b785 -CH2-NH-CH3 -N C O N H-CHz-CF3 -Ib-b786 -CH2-NH-CH3 -N C O N H CHz 3-OH -Ib-b787 -CH2-NH-CH2-CH3 -CH OH -Ib-b788 -CH2-NH-CH2-CH3 N C O N H-CHz-CHz-OH -Ib-b789 -CH2-NH-CH2-CH3 -N(C(O)N(H)-CH2-CH2-F)-Ib-b790 -CH2-NH-CH2-CH3 -N C O N H-CHz-CHz-OCH3 -Ib-b791 -CH2-NH-CH2-CH3 N C O N H-CHz-CHz-CF3 -Ib-b792 -CH2-NH-CH2-CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b793 -CH2-NH-CH2-CH3 -N C O N H-CHz-CF3 -Ib-b794 -CH2-NH-CH2-CH3 -N C O N H CHz 3-OH -Ib-b795 -CHz-NH-CHz-CHz-CH3 -CH OH -Ib-b796 -CH2-NH-CH2-CH2-CH3 N C O N H-CHz-CHz-OH -Ib-b797 -CH2-NH-CH2-CH2-CH3 -N C O N H-CHz-CHz-F -Ib-b798 -CH2-NH-CH2-CH2-CH3 -N C O N H-CHz-CHz-OCH3 -Ib-b799 -CH2-NH-CHz-CHz-CH3 N C O N H-CHz-CHz-CF3 -Ib-b800 -CH2-NH-CH2-CH2-CH3 N C O N H-CHz-CHz-CF3 -Ib-b801 -CH2-NH-CH2-CH2-CH3 -N C O N H-CHz-CF3 -Ib-b802 -CH2-NH-CH2-CH2-CH3 -N C O N H CHz 3-OH -Ib-b803 H3C -CH(OH)-\-N \rCH3 Ib-b804 H3C\ N(C(O)N(H)-CHz-CHz-OH)-~NrCH3 Ib-b805 H3C \ -N(C(O)N(H)-CHz-CHz-F)-~NrCH3 H
Ib-b806 H3C -N(C(O)N(H)-CH2-CH2-OCH3)-_NrCH3 Ib-b807 H3C \ N(C(O)N(H)-CHz-CHz-CF3)-~NrCH3 Ib-b808 H3C \ N(C(O)N(H)-CHz-CHz-CF3)-~NrCH3 Ib-b809 H3C \ -N(C(O)N(H)-CHz-CF3)-~NrCH3 Ib-b810 H3C \ -N(C(O)N(H)-(CHz)3-OH)-~NrCH3 H
Ib-b811 H3C -CH(OH)-H
I-N
OMe Ib-b812 H3C N(C(O)N(H)-CH2-CH2-OH)-H
I-N
OMe Ib-b813 H3C -N(C(O)N(H)-CH2-CH2-F)-H
I-N
OMe Ib-b814 H3C -N(C(O)N(H)-CH2-CH2-OCH3)-H
I-N
OMe Ib-b815 H3C N(C(O)N(H)-CH2-CH2-CF3)-H
I-N
OMe Ib-b816 H3C N(C(O)N(H)-CH2-CH2-CF3)-H
I-N
OMe O
Ib-b817 H3C -N(C(O)N(H)-CH2-CF3)-H
I-N
OMe O
Ib-b818 H3C -N(C(O)N(H)-(CH2)3-OH)-H
I-N
OMe O
Ib-b819 H3C -CH(OH)-~-CH3 ZI-N

>---CH3 H C
Ib-b820 H3C N(C(O)N(H)-CH2-CH2-OH)-~-CH3 ZI-N
>---CH3 H C

Ib-b821 H3C -N(C(O)N(H)-CH2-CH2-F)-~-CH3 >---CH3 H C
Ib-b822 H3C -N(C(O)N(H)-CH2-CH2-OCH3)-~-CH3 >---CH3 H C
Ib-b823 H3C N(C(O)N(H)-CH2-CH2-CF3)-~-CH3 ZI-N
~H3 H C
Ib-b824 H3C N(C(O)N(H)-CH2-CH2-CF3)-~-CH3 ZI-N
>---CH3 H C
Ib-b825 H3C -N(C(O)N(H)-CH2-CF3)-~-CH3 ZI-N
~H3 H C
Ib-b826 H3C -N(C(O)N(H)-(CH2)3-OH)-~-CH3 ZI-N
>---CH3 H C
Ib-b827 -CH(OH)-N
Ib-b828 N(C(O)N(H)-CHz-CHz-OH)-N
Ib-b829 -N(C(O)N(H)-CHz-CHz-F)-N
Ib-b830 -N(C(O)N(H)-CH2-CH2-OCH3)-N
Ib-b831 N(C(O)N(H)-CH2-CH2-CF3)-N
Ib-b832 N(C(O)N(H)-CH2-CH2-CF3)-N

Ib-b833 -N(C(O)N(H)-CH2-CF3)-N
Ib-b834 -N(C(O)N(H)-(CH2)3-OH)-N
Ib-b835 CH3CH,2 N -CH(OH)-N
Ib-b836 CH3CHz N N(C(O)N(H)-CHz-CHz-OH)-~
--/ N
Ib-b837 CH3CH2 // N -N(C(O)N(H)-CHz-CHz-F)-N ~
Ib-b838 CH3CHi2 N -N(C(O)N(H)-CH2-CH2-OCH3)---/ N
Ib-b839 CH3CH,2 N N(C(O)N(H)-CH2-CH2-CF3)-N
Ib-b840 CH3CH2 N N(C(O)N(H)-CH2-CH2-CF3)-N
Ib-b841 CH3CH2 N -N(C(O)N(H)-CH2-CF3)---/ N
Ib-b842 CH3CH,2 // N -N(C(O)N(H)-(CH2)3-OH)-N
Ib-b843 CH3 -CH(OH)-~N-CH CH OH
Ib-b844 CH3 N(C(O)N(H)-CHz-CHz-OH)-~N-CH CH OH
Ib-b845 CH3 -N(C(O)N(H)-CHz-CHz-F)-~N-CH CH OH
Ib-b846 CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-~N-CH CH OH
Ib-b847 CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N-CH CH OH
Ib-b848 CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N-CH CH OH
Ib-b849 CH3 -N(C(O)N(H)-CH2-CF3)-~N-CH CH OH
Ib-b850 CH3 -N(C(O)N(H)-(CH2)3-OH)-~N-CH CH OH

Ib-b851 -CH(OH)-Ib-b852 /-HaHo N(C(O)N(H)-CH2-CH2-OH)-Ib-b853 //-HaHo -N(C(O)N(H)-CH2-CH2-F)-Ib-b854 -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b855 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b856 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b857 -N(C(O)N(H)-CH2-CF3)-Ib-b858 -N(C(O)N(H)-(CH2)3-OH)-Ib-b859 -CH(OH)-Ib-b860 N(C(O)N(H)-CHz-CHz-OH)-Ib-b861 -N(C(O)N(H)-CHz-CHz-F)-Ib-b862 -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b863 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b864 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b865 -N(C(O)N(H)-CH2-CF3)-Ib-b866 -N(C(O)N(H)-(CH2)3-OH)-//-N~
N
Ib-b867 \,--H~ -CH(OH)-\CH3 ~
Ib-b868 \-H~ N(C(O)N(H)-CHz-CHz-OH)-\cH ~
Ib-b869 ~ C -N(C(O)N(H)-CHz-CHz-F)-N\CH I /, Ib-b870 -N(C(O)N(H)-CHz-CHz-OCH3)-CH D/, Ib-b871 N~ N(C(O)N(H)-CHz-CHz-CF3)-~CH
Ib-b872 N1 N(C(O)N(H)-CH2-CH2-CF3)-\cH /
Ib-b873 \-N,~ -N(C(O)N(H) CHz CF3) \CH /
Ib-b874 N -N(C(O)N(H)-(CH2)3-OH)-\CH
Ib-b875 -CH(OH)-//-NH N

Ib-b876 N(C(O)N(H)-CHz-CHz-OH)-//-NH N

Ib-b877 -N(C(O)N(H)-CHz-CHz-F)-~NH

Ib-b878 -N(C(O)N(H)-CH2-CH2-OCH3)-/,---NH N,, Ib-b879 N(C(O)N(H)-CH2-CH2-CF3)-//-NH N

Ib-b880 N(C(O)N(H)-CH2-CH2-CF3)-//-NH N~

Ib-b881 -N(C(O)N(H)-CH2-CF3)-//-NH N~

Ib-b882 -N(C(O)N(H)-(CH2)3-OH)-//-NH N

Ib-b883 ~ ~ H3 -CH(OH)-NH N

Ib-b884 ~ Hs N(C(O)N(H)-CHz-CHz-OH)-NH N

Ib-b885 ~ H3 -N(C(O)N(H)-CHz-CHz-F)-NH N

Ib-b886 ~ H3 -N(C(O)N(H)-CH2-CH2-OCH3)-NH N

Ib-b887 ~ H3 N(C(O)N(H)-CHz-CHz-CF3)-NH N

Ib-b888 ~ H3 N(C(O)N(H)-CHz-CHz-CF3)-NH N

Ib-b889 ~ H3 -N(C(O)N(H)-CH2-CF3)-NH N

Ib-b890 ~ H3 -N(C(O)N(H)-(CH2)3-OH)-NH N

Ib-b891 -CH(OH)-/-N\ /N H
Ib-b892 N(C(O)N(H)-CHz-CHz-OH)-/-N\ N H
Ib-b893 -N(C(O)N(H)-CHz-CHz-F)-/-N\ N H
Ib-b894 -N(C(O)N(H)-CH2-CH2-OCH3)-/-N\ N H
Ib-b895 N(C(O)N(H)-CH2-CH2-CF3)-/-N\ N H
Ib-b896 N(C(O)N(H)-CH2-CH2-CF3)-/-N\ /N H
Ib-b897 -N(C(O)N(H)-CH2-CF3)-/-N\ N H
Ib-b898 -N(C(O)N(H)-(CH2)3-OH)-/-N\ N H
Ib-b899 CH3 -CH(OH)-~N\

Ib-b900 CH3 N(C(O)N(H)-CHz-CHz-OH)-~N\

Ib-b901 CH3 -N(C(O)N(H)-CHz-CHz-F)-~N\

Ib-b902 CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-~N\

Ib-b903 CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N\

Ib-b904 CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N\

Ib-b905 CH3 -N(C(O)N(H)-CH2-CF3)-~N\

Ib-b906 CH3 -N(C(O)N(H)-(CH2)3-OH)-~N\

Ib-b907 //-N H -CH(OH)-Ib-b908 N(C(O)N(H)-CH2-CH2-OH)-Ib-b909 //-N V H -N(C(O)N(H)-CH2-CH2-F)-Ib-b910 /,---N H -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b911 //-N ~ N(C(O)N(H)-CHz-CHz-CF3)-Ib-b912 //-N N(C(O)N(H)-CHz-CHz-CF3)-Ib-b913 /,--N ~ -N(C(O)N(H)-CH2-CF3)-Ib-b914 //-N -N(C(O)N(H)-(CH2)3-OH)-Ib-b915 \-\ -CH(OH)-~~ ~~ OH

Ib-b916 \-v ~\ N(C(O)N(H)-CHz-CHz-OH)-oH
Ib-b917 \-\ -N(C(O)N(H)-CHz-CHz-F)-~~ ~~ OH

Ib-b918 \-\ -N(C(O)N(H)-CHz-CHz-OCH3)-~~ ~~ OH

Ib-b919 \-v ~\ N(C(O)N(H)-CHz-CHz-CF3)-oH
Ib-b920 \-\ N(C(O)N(H)-CHz-CHz-CF3)-~~ ~~ OH

Ib-b921 \-\ -N(C(O)N(H)-CHz-CF3)-~~ ~~ OH

Ib-b922 \-\ -N(C(O)N(H)-(CHz)3-OH)-~~ ~~ OH

Ib-b923 ~ \ -CH(OH)-~% ~~CH3 Ib-b924 //-N /-\ N(C(O)N(H)-CHz-CHz-OH)-N~~CH3 Ib-b925 //-N /-\ -N(C(O)N(H)-CHz-CHz-F)-N~~CH3 Ib-b926 ~ \ -N(C(O)N(H)-CHz-CHz-OCH3)-~% ~~/CH3 Ib-b927 //-N /-\ N(C(O)N(H)-CHz-CHz-CF3)-N~~CH3 Ib-b928 ~ \ N(C(O)N(H)-CHz-CHz-CF3)-~% ~~CH3 Ib-b929 ~ \ -N(C(O)N(H)-CH2-CF3)-~% ~~CH3 Ib-b930 //-N /-\ -N(C(O)N(H)-(CHz)3-OH)-N~~CH3 Ib-b931 -CH(OH)-N N
Ib-b932 N(C(O)N(H)-CHz-CHz-OH)-~N N
Ib-b933 -N(C(O)N(H)-CHz-CHz-F)-~N N
Ib-b934 -N(C(O)N(H)-CH2-CH2-OCH3)-~ N/--N N

Ib-b935 N(C(O)N(H)-CH2-CH2-CF3)-~ Nr-\ N
v Ib-b936 N(C(O)N(H)-CH2-CH2-CF3)-~N N
v Ib-b937 -N(C(O)N(H)-CH2-CF3)-~N N
v Ib-b938 -N(C(O)N(H)-(CH2)3-OH)-\-N/--N N

Ib-b939 \~NO-OEt -CH(OH)-Ib-b940 \_ND_OEt N(C(O)N(H)-CH2-CH2-OH)-Ib-b941 \\-NaOEt -N(C(O)N(H)-CH2-CH2-F)-Ib-b942 \_NaOEt -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b943 \_NaOEt N(C(O)N(H)-CH2-CH2-CF3)-Ib-b944 \_NaOEt N(C(O)N(H)-CH2-CH2-CF3)-Ib-b945 \\-NaOEt -N(C(O)N(H)-CH2-CF3)-Ib-b946 \~NO-OEt -N(C(O)N(H)-(CH2)3-OH)-Ib-b947 N -CH(OH)-/- Q~ H
Ib-b948 N N(C(O)N(H)-CHz-CHz-OH)-/,- Q~ H
Ib-b949 N -N(C(O)N(H)-CHz-CHz-F)-/- Q~ H
N -N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b950 /-OH
Ib-b951 N(C(O)N(H)-CH2-CH2-CF3)-/- Q~ H
Ib-b952 N N(C(O)N(H)-CH2-CH2-CF3)-/,- Q~ H

Ib-b953 N OH -N(C(O)N(H)-CHz-CF3)-~

Ib-b954 -N(C(O)N(H)-(CH2)3-OH)-/- Q~ H
Ib-b955 ~N N / O -CH(OH)-OEt Ib-b956 N(C(O)N(H)-CHz-CHz-OH)-OEt Ib-b957 - N/0 -N(C(O)N(H)-CHz-CHz-F)-OEt Ib-b958 -N N/0 -N(C(O)N(H)-CH2-CH2-OCH3)-OEt Ib-b959 -N N/0 N(C(O)N(H)-CH2-CH2-CF3)-OEt Ib-b960 -N N/0 N(C(O)N(H)-CH2-CH2-CF3)-OEt Ib-b961 - N/0 -N(C(O)N(H)-CH2-CF3)-OEt Ib-b962 - N/0 -N(C(O)N(H)-(CH2)3-OH)-OEt Ib-b963 -CHz-N CHzCH3 CH3 -CH OH -Ib-b964 -CHz-N CHzCH3 CH3 N C O N H-CHz-CHz-OH -Ib-b965 -CHz-N CHzCH3 CH3 N C O N H-CHz-CHz-F -Ib-b966 -CHz-N CHzCH3 CH3 N C O N H-CHz-CHz-OCH3 -Ib-b967 -CHz-N CHzCH3 CH3 N C O N H-CHz-CHz-CF3 -Ib-b968 -CHz-N CHzCH3 CH3 N C O N H-CHz-CHz-CF3 -Ib-b969 -CH2-N(CH2CH3)(CH3) N(C(O)N(H)-CH2-CF3)-Ib-b970 -CH2-N(CH2CH3)(CH3) N(C(O)N(H)-(CH2)3-OH)-Ib-b971 -CHz-N CHzCHzCH3 CH3 -CH OH -Ib-b972 -CHz-N CHzCHzCH3 CH3 N C O N H-CHz-CHz-OH -Ib-b973 -CH2-N(CH2CH2CH3)(CH3) -N(C(O)N(H)-CH2-CH2-F)-Ib-b974 -CHz-N CHzCHzCH3 CH3 -N C O N H-CHz-CHz-OCH3 -Ib-b975 -CHz-N CHzCHzCH3 CH3 N C O N H-CHz-CHz-CF3 -Ib-b976 -CHz-N CHzCHzCH3 CH3 N C O N H-CHz-CHz-CF3 -Ib-b977 -CHz-N CHzCHzCH3 CH3 -N C O N H-CHz-CF3 -Ib-b978 -CHz-N CHzCHzCH3 CH3 -N C O N H CHz 3-OH -Ib-b979 -CH2-N(CH2CH2CH2CH3)(CH3) -CH OH -Ib-b980 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-OH -Ib-b981 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-F -Ib-b982 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-OCH3 -Ib-b983 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-CF3 -Ib-b984 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-CF3 -Ib-b985 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CF3 -Ib-b986 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H CHz 3-OH -Ib-b987 -CH2-NH-CH2CH2CH2CH3 -CH OH -Ib-b988 -CH2-NH-CH2CH2CH2CH3 N(C(O)N(H)-CH2-CH2-OH)-Ib-b989 -CH2-NH-CH2CH2CH2CH3 -N C O N H-CHz-CHz-F -Ib-b990 -CH2-NH-CH2CH2CH2CH3 -N C O N H-CHz-CHz-OCH3 -Ib-b991 -CH2-NH-CH2CH2CH2CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ib-b992 -CH2-NH-CH2CH2CH2CH3 N C O N H-CHz-CHz-CF3 -Ib-b993 -CH2-NH-CH2CH2CH2CH3 -N C O N H-CHz-CF3 -Ib-b994 -CH2-NH-CH2CH2CH2CH3 -N C O N H CHz 3-OH -Ib-b995 -CH2-NH-CH2CH2-O-CH3 -CH OH -Ib-b996 -CH2-NH-CH2CH2-O-CH3 N C O N H-CHz-CHz-OH -Ib-b997 -CH2-NH-CH2CH2-O-CH3 -N C O N H-CHz-CHz-F -Ib-b998 -CH2-NH-CH2CH2-O-CH3 -N C O N H-CHz-CHz-OCH3 -Ib-b999 -CH2-NH-CH2CH2-O-CH3 N C O N H-CHz-CHz-CF3 -Ib-b1000 -CH2-NH-CH2CH2-O-CH3 N C O N H-CHz-CHz-CF3 -Ib-b1001 -CH2-NH-CH2CH2-O-CH3 -N C O N H-CHz-CF3 -Ib-b1002 -CH2-NH-CH2CH2-O-CH3 -N C O N H CHz 3-OH -Ib-b1003 /-N N--\,OMe -CH(OH)-Ib-b1004 /-N N--,\,OMe N(C(O)N(H)-CH2-CH2-OH)-Ib-b1005 /-N N--,\,OMe N(C(O)N(H)-CH2-CH2-F)-Ib-b1006 /-N N-N\,OMe N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b1007 /-N N--\,OMe N(C(O)N(H)-CH2-CH2-CF3)-Ib-b1008 /-N N--\,OMe N(C(O)N(H)-CH2-CH2-CF3)-Ib-b1009 /-N N--\,OMe N(C(O)N(H)-CH2-CF3)-Ib-b1010 /-N N--\,OMe N(C(O)N(H)-(CH2)3-OH)-Ib-b1011 -CH(OH)-N OPO OH
Ib-b1012 N(C(O)N(H)-CHz-CHz-OH)-N OPO OH
Ib-b1013 -N(C(O)N(H)-CHz-CHz-F)-N OPO OH
Ib-b1014 N(C(O)N(H)-CH2-CH2-OCH3)-N OPO OH
Ib-b1015 N(C(O)N(H)-CH2-CH2-CF3)-N OPO OH

Ib-b1016 N(C(O)N(H)-CH2-CH2-CF3)-N OPO OH
Ib-b1017 N(C(O)N(H)-CH2-CF3)-N OPO OH
Ib-b1018 N(C(O)N(H)-(CH2)3-OH)-N OPO OH
Ib-b1019 -CH(OH)-OPO(OH)Z
Ib-b1020 N(C(O)N(H)-CHz-CHz-OH)-OPO(OH)Z
Ib-b1021 N(C(O)N(H)-CHz-CHz-F)-OPO(OH)Z
Ib-b1022 N(C(O)N(H)-CHz-CHz-OCH3)-OPO(OH)Z
Ib-b1023 N(C(O)N(H)-CHz-CHz-CF3)-OPO(OH)Z
Ib-b1024 N(C(O)N(H)-CHz-CHz-CF3)-OPO(OH)Z
Ib-b1025 N(C(O)N(H)-CHz-CF3)-OPO(OH)Z
Ib-b1026 N(C(O)N(H)-(CHz)3-OH)-OPO(OH)Z
Ib-b1027 N OPO(OH)z -CH(OH)-Ib-b1028 N OPO(OH)z N(C(O)N(H)-CH2-CH2-OH)-Ib-b1029 N OPO(OH)z -N(C(O)N(H)-CH2-CH2-F)-Ib-b1030 N OPO(OH)z N(C(O)N(H)-CH2-CH2-OCH3)-Ib-b1031 /\N OPO(OH)z N(C(O)N(H)-CH2-CH2-CF3)-Ib-b1032 N OPO(OH)z N(C(O)N(H)-CH2-CH2-CF3)-Ib-b1033 N OPO(OH)z N(C(O)N(H)-CH2-CF3)-Ib-b1034 N OPO(OH)z N(C(O)N(H)-(CH2)3-OH)-Ib-b1035 /--NiCH3 -CH(OH)-OPO OH
Ib-b1036 /--NiCH3 N(C(O)N(H)-CHz-CHz-OH)-OPO OH
Ib-b1037 /--NiCH3 -N(C(O)N(H)-CHz-CHz-F)-OPO OH
Ib-b1038 CH3 N(C(O)N(H)-CH2-CH2-OCH3)-OPO OH
Ib-b1039 iCH3 N(C(O)N(H)-CH2-CH2-CF3)-OPO OH
Ib-b1040 NiCH3 N(C(O)N(H)-CH2-CH2-CF3)-OPO OH
Ib-b1041 CH3 N(C(O)N(H)-CH2-CF3)-OPO OH
Ib-b1042 iCH3 N(C(O)N(H)-(CH2)3-OH)-OPO OH
Ib-b1043 -CH(OH)-/-N

OPO OH

Ib-b1044 N(C(O)N(H)-CHz-CHz-OH)-OPO OH
Ib-b1045 -N(C(O)N(H)-CHz-CHz-F)-OPO OH
Ib-b1046 N(C(O)N(H)-CH2-CH2-OCH3)-OPO OH
Ib-b1047 N(C(O)N(H)-CH2-CH2-CF3)-/-N

OPO OH
Ib-b1048 N(C(O)N(H)-CH2-CH2-CF3)-OPO OH
Ib-b1049 N(C(O)N(H)-CH2-CF3)-OPO OH
Ib-b1050 N(C(O)N(H)-(CH2)3-OH)-OPO OH
Ib-b1051 H -CH(OH)-N

OPO OH

Ib-b1052 N N(C(O)N(H)-CHz-CHz-OH)-OPO OH
Ib-b1053 \\__~ N(C(O)N(H)-CHz-CHz-F)-OPO OH )a, Ib-b1054 N(C(O)N(H)-CH2-CH2-OCH3)-N

OPO OH
Ib-b1055 \\--~ N(C(O)N(H)-CHz-CHz-CF3)-OPO OH )a2 Ib-b1056 \\__H N(C(O)N(H)-CH2-CH2-CF3)-N

OPO OH ~a2 Ib-b1057 N(C(O)N(H)-CH2-CF3)-N

OPO OH
Ib-b1058 \\--H -N(C(O)N(H)-(CH2)3-OH)-N

OPO OH

and pharmaceutically acceptable salts thereof.

5.4 The Indenoisoquinolinone Analogs of Formula (Ic) The present invention provides Indenoisoquinolinone Analogs according to Formula (Ic), below:

NH

R' X

(Ic) and pharmaceutically acceptable salts thereof, wherein X and Ri are as defined above for the Indenoisoquinolinone Analogs of Formula (Ic).
In one embodiment, X is N(CH3)-. In another embodiment, X is is -N(CH2CH3)-. In another embodiment, X is -N(CH2CH2CH3)-. In another embodiment, X is -N(CH2 CH2CH2CH3)-. In another embodiment, X is -N(C(H)(CH3)(CH2CH3))-.
In another embodiment, X is -N(C(H)(CH3)2)-. In another embodiment, X is -N(CH2C(H)(CH3)2)-. In another embodiment, X is -N(C(CH3)3)-.
In one embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(CH3)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(CHzCH3)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(CHzCHzCH3)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2) and X is -N(CH2 CH2CH2CH3)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(C(H)(CH3)(CHzCH3))-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(C(H)(CH3)z)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(CHzC(H)(CH3)z)-.
In another embodiment, Ri is -(CHz)ri N(R2)(R2 ) and X is -N(C(CH3)3)-.
In one embodiment, Ri is -O-(CH2)õ-N(R2)(R2) and X is -N(CH3)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(CHzCH3)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is N(CHzCHzCH3)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(CH2 CH2CH2CH3)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(C(H)(CH3)(CHzCH3))-.
In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(C(H)(CH3)2)-.

In another embodiment, Ri is -O-(CH2)õ-N(R2 )(R2) and X is -N(CHzC(H)(CH3)z)-.
In another embodiment, Ri is -O-(CH2)õ-N(R2)(R2 ) and X is -N(C(CH3)3)-.
In one embodiment, one R2 is -H, and the other R2 is -Ci-C6 alkyl.
In another embodiment, each R2 is -Ci-C6 alkyl.
In another embodiment, each R2 is -methyl.
In one embodiment, X is -CH(OH)-.
In another embodiment, X is -CH(OH)- and Ri is -(CHz)ri N(R2)(R).
In yet another embodiment, X is -CH(OH)- and Ri is -(CH2)-N(R2 )(R2).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)2-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-Z)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p Z)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)-Z)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q Z)-.
In another embodiment, X is -N((CHz)-Z)-.
In another embodiment, X is -N((CHz)z-Z)-.
In another embodiment, X is -N((CHz)q Z)- and Ri is -(CHz)ri N(R2 )(R2).
In yet another embodiment, X is -N((CHz)q Z)- and Ri is -(CH2)-N(R2 )(R2).
In still another embodiment, X is -N((CH2)-Z)- and Ri is -(CH2)-N(R2)(R2).
In one embodiment, Z is -CF3.
In another embodiment, Z is -F.
In yet another embodiment, Z is -OH.
In still another embodiment, Z is -O-CH3.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OH)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OH)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p OH)- and Ri is -(CHz)-N(R2 )(R2 ).

In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q OH)-.
In another embodiment, X is -N((CH2)2-OH)-.
In another embodiment, X is -N((CHz)q OH)- and Ri is -(CHz)ri N(R2)(R).
In yet another embodiment, X is -N((CHz)q OH)- and Ri is -(CH2)-N(R2)(R2).
In still another embodiment, X is -N((CH2)2-OH)- and Ri is -(CH2)-N(R2)(R2).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-F)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)-F)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-F)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p F)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)-F)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q F)-.
In another embodiment, X is -N((CH2)-F)-.
In another embodiment, X is -N((CHz)q F)- and Ri is -(CHz)ri N(R2)(R2).
In yet another embodiment, X is -N((CHz)q F)- and Ri is -(CH2)-N(R2)(R).
In still another embodiment, X is -N((CH2)-F)- and Ri is -(CH2)-N(R2)(R2).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OMe)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)2-OMe)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OMe)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p OMe)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OMe)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q OMe)-.
In another embodiment, X is -N((CH2)2-OMe)-.
In another embodiment, X is -N((CHz)q OMe)- and Ri is -(CHz)ri N(R2)(R).
In yet another embodiment, X is -N((CHz)q OMe)- and Ri is -(CH2)-N(R2)(R 2).

In still another embodiment, X is -N((CH2)2-OMe)- and Ri is -(CH2)-N(R2 )(R2).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)p-CF3)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p CF3)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)-CF3)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q CF3)-.
In another embodiment, X is -N((CHz)-CF3)-.
In another embodiment, X is -N((CHz)q CF3)- and Ri is -(CHz)ri N(R2)(R2).
In yet another embodiment, X is -N((CHz)q CF3)- and Ri is -(CH2)-N(R2)(R).
In still another embodiment, X is -N((CH2)-CF3)- and Ri is -(CH2)-N(R2)(R2).
In another embodiment, X is -N(C(O)N(H)-(CHz)p-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)- CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p- CF3)- and Ri is -(CHz)ri N(R2)(R).

In yet another embodiment, X is -N(C(O)N(H)-(CHz)p CF3)- and Ri is -(CH2)-N(R2)(R).

In still another embodiment, X is -N(C(O)N(H)-(CH2)-CF3)- and Ri is -(CH2)-N(R2)(R).

In one embodiment, X is -N((CHz)q CF3)-.
In another embodiment, X is -N((CH2)-CF3)-.
In another embodiment, X is -N((CHz)q CF3)- and Ri is -(CHz)ri N(R2)(R2).
In yet another embodiment, X is -N((CHz)q CF3)- and Ri is -(CH2)-N(R2)(R).
In still another embodiment, X is -N((CH2)-CF3)- and Ri is -(CH2)-N(R2)(R2).
In one embodiment, n is 1.
In another embodiment, n is 2.
In yet another embodiment, n is 3.
In a further embodiment, n is 4, 5, or 6.
In yet a further embodiment, n is 7, 8, or 9.
In still a further embodiment, n is 10.

In one embodiment, m is 2.
In another embodiment, m is 3.
In yet another embodiment, m is 4, 5, or 6.
In a further embodiment, m is 7, 8, or 9.
In yet a further embodiment, m is 10.
In one embodiment, p is 1.
In another embodiment, p is 2.
In yet another embodiment, p is an integer ranging from 2 to 5.
In one embodiment, q is 1.
In another embodiment, q is 2.
In yet another embodiment, q is an integer ranging from 2 to 5.
In various embodiments, -N(R2)(R2) is:

/ v / \ CH3 -N 0 ~-NaOH ~-NN-CH3 ~-NN~
-N/-\ NH -N ~-N ~N--/--N(CHs)2 ~\N / \ N~p N N~Ph C(O)OH C(O)OCH2CH3 H - ~-N\ N~ ~-N\ N-/

O HO
/ \N--"NH

H3C CH3 where X = -H, -OMe, -CN, -F, -Cl, -Br, or -I

N(CH3)2 OH

-N~ N~ -N \N -N N ~-N\CH3 ~-N\CH2CH3 ` I , , I-N\CH2CH2OH I-N\CH2CH2N(CH3)2 ~-N\CH2Ph I-N\CH2CH2OCH3 CH2CH2OH CH2CH2N(CH3)2 CH3 CH2CH2OCH3 CH3 CH2N(CH3)2 I-N`CH3 N~CH3 IN~ H3 _N~CH2N(CHs)2 CH3 CH3 I~/
~-N\-7 I-NC(OH

\-CH3 ~-N

N--//\N , 0 N=CH3 ~ H N H N
N --/~/ N ~~ v NN\CH3 NN=/

~OH ~-Na OP(O)(OH)2 N or ~- NCH2CH2OP(O)(OH)2 OP(O)(OH)2 In other embodiments, -N(R2)(R2) is:

I
/~
\ N/ I-N~N ) I-N~N/~
I I-N ~-N
U ~~// ~J
HO O
`N 0 OH OMe -N
\~ N
N-~ / I-N`~

Hp_ ' O
',s'_N OH I-NH ,CH2CH3 ~-NH ~-N 1-NH
N ~~ I-NH CH3 ~ ~~ ' ~-N~OH ' CH3 N

I_N ~CH3 ~-NH 3H3C
~\
I-NEH I-N r-\ N_) ~/
OH

N~
/ N } ~N`CH3 Z
I-N H N I-N\--/ N-\iOH
_ -1- ~/ N~iCH3 -1-N~OEt , -i-NN_N\iOMe -1-N
Q , --N /-\ O CH3 D OH 1 N~OEt ~-N~ I-N ~-N rCH3 OH kCH3 H3C CH3 H3C\
I-N-CH3 ' -1-H , ~-N-CH2CH2CH3 -HrCH3 H3 N ~-N
O Me >--CH3 1-N-CH2CH2OH , 0 , H3C - 288 --~-N H or ~\ ~-N N

In some embodiments, -N(R2)(R2) is A N
I
F F
No ~\N -N
F
NMe2 NMe2 F Q -N N
or In still other embodiments, -N(R2)(R2) is -N(CH2CH3)(CH3), -N(CH2CH2CH3)(CH3), -N(CH2CH2CH2CH3)(CH3), -NH-CH2CH2CH2CH3, or -NH-CHzCHz-O-CH3.
In some embodiments, -N(R2)(R2) is ~-aOPO(OH)2 ~N ~~N OPO(OH)2 OPO(OH)z H H3_or ~a OPO(OH)2 OPO(OH)2 OPO(OH)2 In various embodiments, -N(Z3)(Z4) is:

/ v / \ / \ CH3 0 No ~-NaOH ~-NN-CH3 ~-NN~
-N/-\ NH ~-N ~- N /--~ N--/--N(CHs)2 ~-N NO N N-/Ph C(O)OH C(O)OCHZCH3 H ~-N\ N~ ~-N\ N~

O HO
H3C/~CH3 where X = -H -OMe -CN -F
-Cl, -Br, or -I
N(CH3)2 OH

-N N -N N ~-N\CH3 ~-N\CH2CH3 /CH2CH2OH /CH2CH2N(CH3)2 /CH2Ph /CH2CH2OCH3 ~-N\CH2CH2OH ~-N\CH2CH2N(CH3)2 ~-N\CH3 ~-N\CH2CH2OCH3 ~ Hs ~-H2N(CHs)2 I_N`CH3 N~CH3 ~-NQH3 ~-N~ H2N(CH3)2 CH3 ~CH3 ~-N\-7 ~-N~
`~\OH

~- -I-N -CH3 ~-N

N~\N^ O H N.CH3 N~
~ H N,/~ N

NN,CH3 , NN=/
~OH ~-N`~
OP(O)(OH)2 ~-N or NCH2CH2OP(O)(OH)2 OP(O)(OH)2 In other embodiments, -N(Z3)(Z4) is:

õ~.
I
\ N) I-NO-Nb I-NO-Nb I N I-HO O
I-N .OH }_No OMe N
I_N Z
N
`~
~ HO_ ~ O
~
~N OH I-NH t-NH i-N, CH2CH3 ~-NH
~

I-N\_jS ' 1-NIC~-\0 H I-N

I-N OH
0 , OH

i-N CHs N~ , ~~
}-N ~ / N ~N`CH3 2 CH3CH2 }-NH N CH3 Z
-NH N I-N\_/ N--\iOH
/~
I-N~j ~iCH3 -1-N, rOEt 'i-N

N N~ O ,CH3 OH
I 'OEt ~-N~ I-N I-N_ rCH3 OH kCH3 ~/

H3C\
~-N-CH3 =}-N-CH2CH3 '~-N-CH2CH2CH3 HrCHs ~-CH3 TNH
CH3 or v/

In some embodiments, -N(Z3)(Z4) is A N
I
F F
N\~ ~\N N
v F
NMe2 NMe2 F Q -N N
or In still other embodiments, -N(Z3)(Z4) is -N(CH2CH3)(CH3), -N(CH2CH2CH3)(CH3), -N(CH2CH2CH2CH3)(CH3), -NH-CH2CH2CH2CH3, or -NH-CHzCHz-O-CH3.
In some embodiments, -N(Z3)(Z4) is N ~-N ~- N OPO(OH)2 OPO(OH)2 OPO(OH)2 or ~

In one embodiment, X is N(CH3)- N(CHzCH3)- -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;
Ri is -(CHz)ri N(R2)(R2) or -O-(CH2)õ-N(R2)(R);
each R2 is independently -H, -Ci-C6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(Ci-C6 alkylene)-phenyl or phenyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)z, -OS(O)zOH or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -Ci-CS alkyl, or -(CI-C5 alkylene)-O-Ci-CS alkyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH or -NH2;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -Ci-CS
alkyl, -phenyl, -(CI-C5 alkylene)-phenyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(CI-C5 alkylene)-N(Ra)z, -Ci-CS alkylene-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(CI-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(CI-C5 alkylene)-OP(O)(OH)2, -(CI-C5 alkylene)-OS(O)zOH, -C(O)O-Ci-Cs alkyl, -OC(O)-Ci-Cs alkyl, -(Ci-Cs alkylene)-C(O)O-Ci-Cs alkyl, -(CI-C5 alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, or -Ci-Cio alkyl;
or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -Ci-CS alkyl, -phenyl, -(CI-C5 alkylene) -phenyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(CI-C5 alkylene)-N(Ra)z, -(CI-C5 alkylene)-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(CI-alkylene)-COOH, -OP(O)(OH)z, -OS(O)zOH, -(CI-C5 alkylene)-OP(O)(OH)2, -(CI-C5 alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)O-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, or -Ci-Cio alkyl;
n is an integer ranging from 1 to 10; and m is an integer ranging from 2 to 10.
In one embodiment, X is N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; Ri is -CH2-N(R2)(R 2); and at least one R2 is methyl.

In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;Ri is -CH2-N(R 2)(R2); and at least one R2 is ethyl.
In yet another embodiment, X is -N(CH3)- -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; Ri is -CH2-N(R2)(R2); and at least one R2 is propyl.
In one embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; Ri is -CH2-N(R2)(R 2); and at least one R2 is -C3-C8 monocyclic cycloalkyl.
In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;Ri is -CH2-N(R2)(R2 ); and at least one R2 is cyclohexyl.
In yet another embodiment, X is -N(CH3)- -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; and Ri is -CH2-N(R2)(R 2), wherein N and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle.
In one embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; and Ri is -CH2-N(R2)(R2), wherein N and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with a hydroxyl.
In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; and Ri is -CH2-N(R2)(R 2), wherein N and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with a nitrogen-containing 3- to 7-membered monocyclic heterocycle.
Illustrative examples of the Indenoisoquinolinone Analogs include the compounds of Formula (Ic) as set forth below:

NH

R' X

(Ic) Compound n - Rl X
Ic-1 1 -(CHz)ri N(CH3)z -N(CH3)-Ic-2 2 -(CHz)ri N(CH3)z -N(CH3)-Ic-3 3 -(CHz)ri N(CH3)z -N(CH3)-Ic-4 4 -(CHz)ri N(CH3)z -N(CH3)-Ic-5 5 -(CHz)ri N(CH3)z -N(CH3)-Ic-6 6 -(CHz)ri N(CH3)z -N(CH3)-Ic-7 1 CHz ri N CH3 z -N CHzCH3 -Ic-8 2 CHz ri N CH3 z -N CHzCH3 -Ic-9 3 CHz ri N CH3 z -N CHzCH3 -Ic-10 4 -(CHz)ri N(CH3)z -N(CH2CH3)-Ic-11 5 CHz ri N CH3 z -N CHzCH3 -Ic-12 6 CHz ri N CH3 z -N CHzCH3 -Ic-13 1 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ic-14 2 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ic-15 3 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ic-16 4 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ic-17 5 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ic-18 6 -(CHz)ri N(CH3)z -N(CH2CH2CH3)-Ic-19 1 CHz ri N CH3 z -N(CH2 CH2CH2CH3 -Ic-20 2 CHz ri N CH3 z -N(CH2 CH2CH2CH3 -Ic-21 3 CHz ri N CH3 z -N(CH2 CH2CH2CH3 -Ic-22 4 -(CHz)ri N(CH3)z -N(CH2 CH2CH2CH3)-Ic-23 5 -(CHz)ri N(CH3)z -N(CH2 CH2CH2CH3)-Ic-24 6 -(CHz)ri N(CH3)z -N(CH2 CH2CH2CH3)-Ic-25 1 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ic-26 2 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ic-27 3 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ic-28 4 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ic-29 5 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ic-30 6 -(CHz)ri N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ic-31 1 CHz ri N CH3 z -N C H CH3 z-Ic-32 2 CHz ri N CH3 z -N C H CH3 z-Ic-33 3 CH2riNCH32 -N(C(H)(CH3)2)-Ic-34 4 CH2riNCH32 -N(C(H)(CH3)2)-Ic-35 5 CH2riNCH32 -N(C(H)(CH3)2)-Ic-36 6 CH2riNCH32 -N(C(H)(CH3)2)-Ic-37 1 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ic-38 2 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ic-39 3 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ic-40 4 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ic-41 5 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ic-42 6 -(CHz)ri N(CH3)z -N(CH2C(H)(CH3)2)-Ic-43 1 -(CHz)ri N(CH3)z -N(C(CH3)3)-Ic-44 2 -(CHz)ri N(CH3)z -N(C(CH3)3)-Ic-45 3 CHz ri N CH3 z -N C CH3 3-Ic-46 4 CHz ri N CH3 z -N C CH3 3-Ic-47 5 CH2riNCH32 -N(C(CH3)3)-Ic-48 6 CH2riNCH32 -N(C(CH3)3)-Ic-49 1 N(CH3)--(CH2)n N 0 Ic-50 2 N(CH3)--(CH2)n N 0 Ic-51 3 N(CH3)--(CH2)n N 0 Ic-52 4 N(CH3)--(CH2)n N 0 Ic-53 5 N(CH3)--(CH2)n N 0 Ic-54 6 N(CH3)--(CH2)n N 0 Ic-55 1 -N(CH2CH3)--(CH2)n N 0 Ic-56 2 -N(CH2CH3)--(CH2)n N 0 Ic-57 3 -N(CH2CH3)--(CH2)n N 0 Ic-58 4 -N(CH2CH3)--(CH2)n N 0 Ic-59 5 -N(CH2CH3)--(CH2)n N 0 Ic-60 6 -N(CH2CH3)--(CH2)n N 0 Ic-61 1 N(CH2CH2CH3)--(CH2)n N 0 Ic-62 2 N(CH2CH2CH3)--(CH2)n N 0 Ic-63 3 N(CH2CH2CH3)--(CH2)n N 0 Ic-64 4 N(CH2CH2CH3)--(CH2)n N 0 Ic-65 5 N(CH2CH2CH3)--(CH2)n N 0 Ic-66 6 N(CH2CH2CH3)--(CH2)n N 0 Ic-67 1 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ic-68 2 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ic-69 3 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ic-70 4 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ic-71 5 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ic-72 6 -N(CH2CH2CH2CH3)--(CH2)n N 0 Ic-73 1 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ic-74 2 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ic-75 3 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ic-76 4 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ic-77 5 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ic-78 6 -N(C(H)(CH3)(CH2CH3))--(CH2)n N 0 Ic-79 1 -N(C(H)(CH3)2)--(CH2)n N 0 Ic-80 2 -N(C(H)(CH3)2)--(CH2)n N 0 Ic-81 3 -N(C(H)(CH3)2)--(CH2)n N 0 Ic-82 4 -N(C(H)(CH3)2)--(CH2)n N 0 Ic-83 5 -N(C(H)(CH3)2)--(CH2)n N 0 Ic-84 6 -N(C(H)(CH3)2)--(CH2)n N 0 Ic-85 1 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ic-86 2 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ic-87 3 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ic-88 4 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ic-89 5 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ic-90 6 -N(CH2C(H)(CH3)2)--(CH2)n N 0 Ic-91 1 -N(C(CH3)3)--(CH2)n N 0 Ic-92 2 -N(C(CH3)3)--(CH2)n N 0 Ic-93 3 -N(C(CH3)3)--(CH2)n N 0 Ic-94 4 -N(C(CH3)3)--(CH2)n N 0 Ic-95 5 -N(C(CH3)3)--(CH2)n N 0 Ic-96 6 -N(C(CH3)3)--(CH2)n N 0 Compound m - Rl X
Ic-146 2 -O-(CHz)m N(CH3)z -N(CH3)-Ic-147 3 -O-(CHz)m N(CH3)z -N(CH3)-Ic-148 4 -O-(CHz)m N(CH3)z -N(CH3)-Ic-149 5 -O-(CHz)m N(CH3)z -N(CH3)-Ic-150 6 -O-(CHz)m N(CH3)z -N(CH3)-Ic-151 2 -O CHz m N CH3 z N CH3 -Ic-152 3 -O CHz õ-N CH3 z -N CHzCH3 -Ic-153 4 -O CHz õ-N CH3 z -N CHzCH3 -Ic-154 5 -O CHz õ-N CH3 z -N CHzCH3 -Ic-155 6 -O CHz õ-N CH3 z -N CHzCH3 -Ic-156 2 -O-(CHz)m N(CH3)z -N(CH2CH3)-Ic-157 3 -O-(CHz)m N(CH3)z -N(CH2CH3)-Ic-158 4 -O-(CHz)m N(CH3)z -N(CH2CH2CH3)-Ic-159 5 -O-(CHz)m N(CH3)z -N(CH2CH2CH3)-Ic-160 6 -O-(CH2)õ-N(CH3)2 -N(CH2CH2CH3)-Ic-161 2 -O CHz õ-N CH3 z -N CHzCHzCH3 -Ic-162 3 -O CHz õ-N CH3 z -N CHzCHzCH3 -Ic-163 4 -O CHz õ-N CH3 z -N CHzCHzCH3 -Ic-164 5 -O CHz õ-N CH3 z -N CHzCHzCHzCH3 -Ic-165 6 -O CHz õ-N CH3 z -N CHzCHzCHzCH3 -Ic-166 2 -O-(CHz)m N(CH3)z -N(CH2CH2CH2CH3)-Ic-167 3 -O-(CHz)m N(CH3)z -N(CH2CH2CH2CH3)-Ic-168 4 -O-(CHz)m N(CH3)z -N(CH2CH2CH2CH3)-Ic-169 5 -O-(CHz)m N(CH3)z -N(CH2CH2CH2CH3)-Ic-170 6 -O-(CHz)m N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ic-171 2 -O CHz õ-N CH3 z -N C H CH3 CHzCH3 -Ic-172 3 -O CHz õ-N CH3 z -N C H CH3 CHzCH3 -Ic-173 4 -O-(CHz)m N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ic-174 5 -O-(CHz)m N(CH3)z -N(C(H)(CH3)(CH2CH3))-Ic-175 6 -O CHz õ-N CH3 z -N C H CH3 CHzCH3 -Ic-176 2 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ic-178 3 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ic-179 4 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ic-180 5 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ic-181 6 -O-(CHz)m N(CH3)z -N(C(H)(CH3)2)-Ic-182 2 -O CHz õ-N CH3 z -N C H CH3 z-Ic-183 3 -O-(CHz)m N(CH3)z -N(CH2C(H)(CH3)2)-Ic-184 4 -O-(CHz)m N(CH3)z -N(CH2C(H)(CH3)2)-Ic-185 5 -O-(CHz)m N(CH3)z -N(CH2C(H)(CH3)2)-Ic-186 6 -O-(CHz)m N(CH3)z -N(CH2C(H)(CH3)2)-Ic-187 2 N(CH3)--0(cH2)m N 0 Ic-188 3 N(CH3)--0(cH2)m N 0 Ic-189 4 N(CH3)--0(cH2)m N 0 Ic-190 5 N(CH3)--0(cH2)m N 0 Ic-191 6 N(CH3)--0(cH2)m N 0 Ic-192 2 N(CH3)--0(cH2)m N 0 Ic-193 3 -N(CH2CH3)--0(cH2)m N 0 Ic-194 4 -N(CH2CH3)--0(cH2)m N 0 Ic-195 5 -N(CH2CH3)--0(cH2)m N 0 Ic-196 6 -N(CH2CH3)--0(cH2)m N 0 Ic-197 2 -N(CH2CH3)--0(cH2)m N 0 Ic-198 3 -N(CH2CH3)--0 (CH2)m N 0 Ic-199 4 N(CH2CH2CH3)--0 (CH2)m N 0 Ic-200 5 N(CH2CH2CH3)--0 (CH2)m N 0 Ic-201 6 N(CH2CH2CH3)--0 (CH2)m N 0 Ic-202 2 N(CH2CH2CH3)--0 (CH2)m N 0 Ic-203 3 N(CH2CH2CH3)--0 (CH2)m N 0 Ic-204 4 N(CH2CH2CH3)--0 (CH2)m N 0 Ic-205 5 -N(CH2CH2CH2CH3)--0 (CH2)m N 0 Ic-206 6 -N(CH2CH2CH2CH3)--0 (CH2)m N 0 Ic-207 2 -N(CH2CH2CH2CH3)--0 (CH2)m N 0 Ic-208 3 -0 (CH \ -N(CHzCHzCHzCH3)-2)m~% ~

Ic-209 4 -N(CH2CH2CH2CH3)--0 (CH2)m N 0 Ic-210 5 -N(CH2CH2CH2CH3)--0 (CH2)m N 0 Ic-211 6 -0 (CH \ -N(C(H)(CH3)(CHzCH3))-2)m~~ ~

Ic-212 2 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ic-213 3 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ic-214 4 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ic-215 5 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ic-216 6 -N(C(H)(CH3)(CH2CH3))--0 (CH2)m N 0 Ic-217 2 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ic-218 3 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ic-219 4 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ic-220 5 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ic-221 6 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ic-222 2 -N(C(H)(CH3)2)--0 (CH2)m N 0 Ic-223 3 -0 (CH \ -N(CHzC(H)(CH3)z)-2)m~% ~

Ic-224 4 -N(CH2C(H)(CH3)2)--0 (CH2)m N 0 Ic-225 5 -N(CH2C(H)(CH3)2)--0 (CH2)m N 0 Ic-226 6 -0 (CH2) \ -N(CHzC(H)(CH3)z)-m~~ ~

Com ound - Rl X

Ic-267 -CH2-N(CH2-CH3)2 -N(CH3)-Ic-268 -CH2-N(CH2-CH3)2 -N(CH2CH3)-Ic-269 -CH2-N(CH2-CH3)2 -N(CH2CH2CH3)-Ic-270 -CH2-N(CH2-CH3)2 -N(CH2CH2CH2CH3)-Ic-271 -CH2-N(CH2-CH3)2 -N(C(H)(CH3)(CH2CH3))-Ic-272 -CH2-N(CH2-CH3)2 -N(C(H)(CH3)2)-Ic-273 -CH2-N(CH2-CH3)2 -N(CH2C(H)(CH3)2)-Ic-274 -CH2-N(CH2-CH3)2 -N(C(CH3)3)-Ic-275 -CHz-N CHz-CHz-CH3 z -N CH3 -Ic-276 -CH2-N(CH2-CH2-CH3)2 -N(CH2CH3)-Ic-277 -CH2-N(CH2-CH2-CH3)2 -N(CH2CH2CH3)-Ic-278 -CH2-N(CH2-CH2-CH3)2 -N(CH2CH2CH2CH3)-Ic-279 -CH2-N(CH2-CH2-CH3)2 -N(C(H)(CH3)(CH2CH3))-Ic-280 -CHz-N CHz-CHz-CH3 z -N C H CH3 z-Ic-281 -CHz-N CHz-CHz-CH3 z -N CHzC H CH3 z-Ic-282 -CHz-N CHz-CHz-CH3 z -N C CH3 3-Ic-283 -CHz-N CHz-CHzOH z -N CH3 -Ic-284 -CHz-N CHz-CHzOH z -N CHzCH3 -Ic-285 -CHz-N CHz-CHzOH z -N CHzCHzCH3 -Ic-286 -CHz-N CHz-CHzOH z -N CHzCHzCHzCH3 -Ic-287 -CHz-N CHz-CHzOH z -N C H CH3 CHzCH3 -Ic-288 -CHz-N CHz-CHzOH z -N C H CH3 z-Ic-289 -CHz-N CHz-CHzOH z -N CHzC H CH3 z-Ic-290 -CHz-N CHz-CHzOH z -N C CH3 3-Ic-291 -CHz-N(CHz-CHz-N(CH3)1)1 N CH3 -Ic-292 -CH2-N(CH2-CH2-N(CH3)2)2 -N CHzCH3 -Ic-293 -CH2-N(CH2-CH2-N(CH3)2)2 N CHzCHzCH3 -Ic-294 -CH2-N(CH2-CH2-N(CH3)2)2 -N CHzCHzCHzCH3 -Ic-295 -CH2-N(CH2-CH2-N(CH3)2)2 -N(C(H)(CH3)(CH2CH3))-Ic-296 -CH2-N(CH2-CH2-N(CH3)2)2 -N C H CH3 z-Ic-297 -CH2-N(CH2-CH2-N(CH3)2)2 -N CHzC H CH3 z-Ic-298 -CH2-N(CH2-CH2-N(CH3)2)2 -N(C(CH3)3)-Ic-299 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N CH3 -Ic-3UU -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N CHzCH3 -Ic-301 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N CHzCHzCH3 -Ic-302 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N CHzCHzCHzCH3 -Ic-303 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C H CH3 CHzCH3 -Ic-3U4 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C H CH3 z-Ic-305 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N CHzC H CH3 z-Ic-306 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C CH3 3 -Ic-307 -CHz-N -N(CH3)-Ic-308 -CH2-N~ -N(CH2CH3)-Ic-309 -CH2-N- N(CH2CH2CH3)-Ic-310 -CH2-N -N(CH2CH2CH2CH3)-Ic-311 -CH2-N~ -N(C(H)(CH3)(CH2CH3))-Ic-312 -CH2-N~ -N(C(H)(CH3)2)-Ic-313 -CH2-N~ -N(CH2C(H)(CH3)2)-Ic-314 -CHz-N~ -N(C(CH3)3)-Ic-315 -CHz-Nc> -N(CH3)-Ic-316 -CH2-Nc> -N(CH2CH3)-Ic-317 -CH2-Nc> -N(CH2CH2CH3)-Ic-318 -CH2-<> -N(CH2CH2CH2CH3)-Ic-319 -CH2-<> -N(C(H)(CH3)(CH2CH3))-Ic-320 -CHz-Nc> -N(C(H)(CH3)2)-Ic-321 -CHz-Nc> -N(CH2C(H)(CH3)2)-Ic-322 -CHz-Nc> -N(C(CH3)3)-Ic-323 -CHz-NC) -N(CH3)-Ic-324 -CH2-No -N(CH2CH3)-Ic-325 -CH2-No -N(CH2CH2CH3)-Ic-326 -CH2-No -N(CH2CH2CH2CH3)-Ic-327 -CH2-No -N(C(H)(CH3)(CH2CH3))-Ic-328 -CHz-No -N(C(H)(CH3)2)-Ic-329 -CHz-No -N(CH2C(H)(CH3)2)-Ic-330 -CHz-No -N(C(CH3)3)-Ic-331 -CHz-Na N(CH3)-Ic-332 -CH2-Na -N(CH2CH3)-Ic-333 -CH2-N~ N(CH2CH2CH3)-Ic-334 -CH2-N~ -N(CH2CH2CH2CH3)-Ic-335 -CHz-N~ -N(C(H)(CH3)(CH2CH3))-Ic-336 -CHz-Na -N(C(H)(CH3)2)-Ic-337 -CHz-Na -N(CH2C(H)(CH3)2)-OH
Ic-338 -CHz-Na -N(C(CH3)3)-Ic-339 -CHz-N -N(CH3)-Ic-340 -CHz-N -N(CH2CH3)-Ic-341 -CHz-N -N(CH2CH2CH3)-Ic-342 -CHz-N -N(CH2CH2CH2CH3)-Ic-343 -CHz-N -N(C(H)(CH3)(CH2CH3))-Ic-344 -CHz-N -N(C(H)(CH3)2)-Ic-345 -CHz-N -N(CH2C(H)(CH3)2)-Ic-346 -CHz-N -N(C(CH3)3)-Ic-347 -CHz-N, ) -N(CH3)-Ic-348 -CH2-N --_ )-- -N(CH2CH3)-Ic-349 -CH2-N_ ) N(CH2CH2CH3)-Ic-350 -CH2-N_ ) -N(CH2CH2CH2CH3)-Ic-351 -CH2-N, ) -N(C(H)(CH3)(CH2CH3))-Ic-352 -CHz-N - )- -N(C(H)(CH3)2)-Ic-353 -CHz-ND -N(CH2C(H)(CH3)2)-Ic-354 -CHz-N, ) -N(C(CH3)3)-Ic-355 -CH2-N~--N---CH3 -N(CH3)-Ic-356 -CH2-N/-\ N-CH3 -N(CH2CH3)-Ic-357 -CH2-N/-\ N-CH3 -N(CH2CH2CH3)-Ic-358 -CH2-N/-\ N-CH3 -N(CH2CH2CH2CH3)-Ic-359 -CH2-N/-\ N-CH3 -N(C(H)(CH3)(CH2CH3))-Ic-360 -CH2-N/-\ N-CH3 -N(C(H)(CH3)2)-Ic-361 -CH2-N/-\ N-CH3 -N(CH2C(H)(CH3)2)-Ic-362 -CH2-N/-\ N-CH3 -N(C(CH3)3)-Ic-363 -CH2-N /CH3 N(CH3)-Ic-364 -CH2-N /cH3 -N(CH2CH3)-Ic-365 -CH2-N /cH3 N(CH2CH2CH3)-Ic-366 --CH2-N /cH3 -N(CH2CH2CH2CH3)-Ic-367 -CH2-N /cH3 -N(C(H)(CH3)(CH2CH3))-Ic-368 -CH2-N /cH3 -N(C(H)(CH3)2)-Ic-369 --CH2-N /cH3 -N(CH2C(H)(CH3)2)-Ic-370 -CH2-N /cH3 -N(C(CH3)3)-Ic-371 -CH2-N /cH3 N(CH3)->-CH3 H C
Ic-372 ~H2-N CH3 -N(CH2CH3)->-CH3 H C

Ic-373 -CH2 -N /CH3 N(CH2CH2CH3)->-CH3 Ic-374 -CH2 -N /QH3 -N(CH2CH2CH2CH3)->-CH3 Ic-375 -CH2 -N /QH3 -N(C(H)(CH3)(CH2CH3))->-CH3 Ic-376 -CH2-N CH3 -N(C(H)(CH3)2)->-CH3 Ic-377 -CH2 -N /CH3 -N(CH2C(H)(CH3)2)->-CH3 H C
Ic-378 -CH2-N /CH3 -N(C(CH3)3)->-CH3 H C
Ic-379 -CH2-N /CH3 N(CH3)-Ic-380 -CH2-N /CH3 -N(CH2CH3)-Ic-381 -CH2-N CH3 N(CH2CH2CH3)-Ic-382 -CH2-N /CH3 -N(CH2CH2CH2CH3)-Ic-383 -CH2-N CH3 -N(C(H)(CH3)(CH2CH3))-Ic-384 -CH2-N /CH3 -N(C(H)(CH3)2)-Ic-38s ~H2-N ~H3 -N(CH2C(H)(CH3)2)-Ic-386 -CH2-N /QH3 -N(C(CH3)3)-Ic-387 ~ H -N(CH3)-Ic-388 ~ H N~ -N(CH2CH3)--CH2 ~0 Ic-389 ~ N N~ N(CHzCHzCH3) -CH2 ~0 Ic-390 "N-N(CH2CH2CH2CH3)-Ic-391 N~"N~ -N(C(H)(CH3)(CH2CH3))-Ic-392 H -N(C(H)(CH3)2)-Ic-393 H -N(CH2C(H)(CH3)2)-Ic-394 ~ H -N(C(CH3)3)-Ic-395 ~ O N(CH3)-H N~/
\
CH / N
Ic-396 ~0 -N(CH2CH3)-H
\
N~/
CH
Ic-397 ~0 -N(CHzCHzCH3)-H N~/
\
CH / N

Ic-398 ("--0 -N(CH2CH2CH2CH3)-/NN-/
CH
Ic-399 ("--0 -N(C(H)(CH3)(CH2CH3))-/NN-/
CH
Ic-400 (-~ o -N(C(H)(CH3)2)-H N-/
CH -' N
Ic-401 ("--o -N(CH2C(H)(CH3)2)-~NN,/
CH

Ic-402 ~O -N(C(CH3)3)-H
\
N~/
CH /
Ic-403 N CH3 -N(CH3)-H /N~~N~/

Ic-404 N CH3 -N(CH2CH3)-\ /N~~N~/

Ic-405 N CH3 N(CH2CH2CH3)-H N-/
\CH2 "I N,,/---,/

Ic-406 N CH3 -N(CH2CH2CH2CH3)-H N-/
\CH2 "I N,,/---,/

Ic-407 N CH3 -N(C(H)(CH3)(CH2CH3))-H N-/
\CH2 "I N,,/---,/

Ic-408 N CH3 -N(C(H)(CH3)2)-H N-/
\CH2 "I N,,/---,/

Ic-409 N CH3 -N(CH2C(H)(CH3)2)-H /N~~N~/

Ic-410 N CH3 -N(C(CH3)3)-H N-/
\CH2 "I N,,/---,/

Ic-411 H3~ N(CH3)-CH ~N~/N`CH3 Ic-412 H3~ -N(CH2CH3)-CH ~NN`CH3 Ic-413 H3C N(CHzCHzCH3)-H
CH ~N~/N`CH3 Ic-414 H3C -N(CHzCHzCHzCH3)-CH N`

Ic-415 H3C -N(C(H)(CH3)(CH2CH3))-CH 'NN-CH3 Ic-416 H3~ -N(C(H)(CH3)2)-H

Ic-417 H3~ -N(CH2C(H)(CH3)2)-Ic-418 H3~ -N(C(CH3)3)-Ic-419 ~ N -N(CH3)-H N
\CH N
Ic-420 ~ N -N(CH2CH3)-/
N
\CH N
Ic-421 ~ N -N(CH2CH2CH3)-/
\CH ~N
Ic-422 N -N(CH2CH2CH2CH3)-N
\CH "I N
Ic-423 ~N -N(C(H)(CH3)(CH2CH3))-/
N
\CH N
Ic-424 N -N(C(H)(CH3)2)-N
\CH N
Ic-425 ~ N -N(CH2C(H)(CH3)2)-/
H N
\CH ~N
Ic-426 N -N(C(CH3)3)-H N
\CH "I N
Ic-427 ~ ~ N(CH3)-~
-CH2-N~/N

Ic-428 ~ ~ -N(CHzCH3)-~
-CH2-N~/N
Ic-429 ~ ~ N(CHzCHzCH3)-~
-CH2-N ~\ N

Ic-430 ~ ~ -N(CHzCHzCHzCH3)-~
-CH2-N~/N
Ic-431 ~ ~ -N(C(H)(CH3)(CHzCH3))-/
~

Ic-432 ~ ~ -N(C(H)(CH3)z)-~
-CH2-N~/N
Ic-433 ~ ~ -N(CHzC(H)(CH3)z)-~
-CH2-N~/ N
Ic-434 ~ ~ -N(C(CH3)3)-~
~

Ic-435 -CH2~V/-\ N F -N(CH3)-~/ -Ic-436 -CH iV /-\ N ~ ~ F -N(CH2CH3)-Ic-437 -CH2iV /-\ N 0 F -N(CH2CH2CH3)-Ic-438 -CH2iV /-\ N F -N(CH2CH2CH2CH3)-~/ -Ic-439 -CH2iV/-\ N F -N(C(H)(CH3)(CH2CH3))-~/ -Ic-440 -CH2iV/-\ N F -N(C(H)(CH3)2)-~/ -Ic-441 -CH2fV/-\ N ~ F -N(CH2C(H)(CH3)2)--Ic-442 -CH2iV/-\ N F -N(C(CH3)3)-~/
Ic-443 -CH2-N a-&F N(CH3)-Ic-444 -CH2-N ~F -N(CH2CH3)-Ic-445 -CH2-N ~F N(CH2CH2CH3)-Ic-446 -CH2-N ~F -N(CH2CH2CH2CH3)-Ic-447 -CH2-N ~F -N(C(H)(CH3)(CH2CH3))-Ic-448 -CH2-N ~F -N(C(H)(CH3)2)-Ic-449 -CH2-N ~F -N(CH2C(H)(CH3)2)-Ic-450 -CH2-N ~F -N(C(CH3)3)-Ic-451 -CH2-N ~ -N(CH3)-Ic-452 -CH2-N o -N(CH2CH3)-Ic-453 -CH2-N O -N(CH2CH2CH3)-Ic-454 -CH2-N O -N(CH2CH2CH2CH3)-Ic-455 -CH2-N ~ -N(C(H)(CH3)(CH2CH3))-Ic-456 -CHz-N O -N(C(H)(CH3)2)-Ic-457 -CHz-N ~ -N(CH2C(H)(CH3)2)-Ic-458 -CH2-N ~ -N(C(CH3)3)-Ic-459 -CHz-N \ / \ ci -N(CH3)-Ic-460 -CHz-N \ / \ ci -N(CH2CH3)-Ic-461 -CHz-N CI -N(CH2CH2CH3)-Ic-462 -CHz-N ~CI -N(CH2CH2CH2CH3)-Ic-463 -CHz-N ~CI -N(C(H)(CH3)(CH2CH3))-Ic-464 -CHz-N \ / \ cl -N(C(H)(CH3)2)-Ic-465 -CHz-N \ / \ cl -N(CH2C(H)(CH3)2)-Ic-466 -CHz-N \ / \ ci -N(C(CH3)3)-Ic-467 -CHz-N \ / \ -N(CH3)-Ic-468 -CH2-N \ / \ -N(CH2CH3)-Ic-469 -CH2-N \ / \ N(CH2CH2CH3)-Ic-470 -CH2-N \ / \ -N(CH2CH2CH2CH3)-Ic-471 -CH2-N \ / \ -N(C(H)(CH3)(CH2CH3))-Ic-472 -CH2-N \ / \ -N(C(H)(CH3)2)-Ic-473 -CH2-N \ / \ -N(CH2C(H)(CH3)2)-Ic-474 -CH2-N \ / \ -N(C(CH3)3)-Ic-475 -cH2_N / \ N(CH3)-Ic-476 -CH2-N -N(CH2CH3)-OH -Ic-477 -CH2-N N(CH2CH2CH3)-Ic-478 -CH2-N -N(CH2CH2CH2CH3)-Ic-479 -CH2-N
/ \ -N(C(H)(CH3)(CH2CH3))-OSH
Ic-480 -CH2-N
/ \ -N(C(H)(CH3)2)-OSH
Ic-481 -CH2-N / \ -N(CH2C(H)(CH3)2)-Ic-482 -CH2-N / \ -N(C(CH3)3)-Ic-483 -CH2-N NCH2CH2OP(O)(OH)2 -N(CH3)-Ic-484 Ic-484 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(CH2CH3)-Ic-485 -CH2-N /-\ NCH2CH2OP(O)(OH)2 N(CH2CH2CH3)-Ic-486 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(CH2CH2CH2CH3)-Ic-487 -CH2-N NCH2CH2OP(O)(OH)2 -N(C(H)(CH3)(CH2CH3))-Ic-488 -CH2-N NCH2CH2OP(O)(OH)2 -N(C(H)(CH3)2)-Ic-489 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(CH2C(H)(CH3)2)-Ic-490 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(C(CH3)3)-Ic-491 -CH2-CH2-CH2-OP(O)(OH)2 -N(CH3)-Ic-492 -CH2-CH2-CH2-OP(O)(OH)2 -N CHzCH3 -Ic-493 -CH2-CH2-CH2-OP(O)(OH)2 N CHzCHzCH3 -Ic-494 -CH2-CH2-CH2-OP(O)(OH)2 -N(CH2CH2CH2CH3)-Ic-495 -CH2-CH2-CH2-OP(O)(OH)2 -N C H CH3 CHzCH3 -Ic-496 -CH2-CH2-CH2-OP(O)(OH)2 -N C H CH3 z-Ic-497 -CH2-CH2-CH2-OP(O)(OH)2 -N CHzC H CH3 z-Ic-498 -CH2-CH2-CH2-OP(O)(OH)2 -N C CH3 3 -Ic-499 -CHz-CHz-CHz-OS(O)zOH N CH3 -Ic-500 -CHz-CHz-CHz-OS(O)zOH -N CHzCH3 -Ic-501 -CHz-CHz-CHz-OS(O)zOH N CHzCHzCH3 -Ic-502 -CHz-CHz-CHz-OS(O)zOH -N CHzCHzCHzCH3 -Ic-503 -CHz-CHz-CHz-OS(O)zOH -N C H CH3 CHzCH3 -Ic-504 -CHz-CHz-CHz-OS(O)zOH -N C H CH3 z-Ic-505 -CHz-CHz-CHz-OS(O)zOH -N CHzC H CH3 z-Ic-506 -CHz-CHz-CHz-OS(O)zOH -N C CH3 3 -Ic-507 -CH2-Na -N(CH3)-OP O OH
Ic-508 -CHz-NC( -N(CH2CH3)-OP O OH
Ic-509 -CHz-NC( -N(CH2CH2CH3)-OP O OH
Ic-510 -CH2-Na -N(CH2CH2CH2CH3)-OP O OH
Ic-511 -CH2-Na -N(C(H)(CH3)(CH2CH3))-OP O OH
Ic-512 -CH2-NC( -N(C(H)(CH3)2)-OP O OH
Ic-513 -CHz-NC( -N(CH2C(H)(CH3)2)-OP O OH
Ic-514 -CHz-NC( -N(C(CH3)3)-OP O OH
Ic-515 -CHz-N N(CH3)-OP O OH
Ic-516 -CH2-N -N(CH2CH3)-OP O OH

Ic-517 -CHz-N N(CH2CH2CH3)-OP O OH
Ic-518 -CH2-N -N(CH2CH2CH2CH3)-OP O OH
Ic-519 -CH2-N -N(C(H)(CH3)(CH2CH3))-OP O OH
Ic-520 -CH2-N -N(C(H)(CH3)2)-OP O OH
Ic-521 -CHz-N -N(CH2C(H)(CH3)2)-OP O OH
Ic-522 -CHz-N -N(C(CH3)3)-OP O OH
Ic-523 -(CH2)io-N(CH2-CH2-O-CH3)2 N CH3 -Ic-524 -(CH2)io-N(CH2-CH2-0-CH3)2 -N CHzCH3 -Ic-525 -(CH2),o-N(CH2-CH2-O-CH3)2 N CHzCHzCH3 -Ic-526 -(CH2),o-N(CH2-CH2-O-CH3)2 -N CHzCHzCHzCH3 -Ic-527 -(CH2),o-N(CH2-CH2-O-CH3)2 -N C H CH3 CHzCH3 -Ic-528 -(CH2)io-N(CH2-CH2-O-CH3)2 -N C H CH3 z-Ic-529 -(CH2)io-N(CH2-CH2-0-CH3)2 -N CHzC H CH3 z-Ic-530 -(CH2)io-N(CH2-CH2-O-CH3)2 -N C CH3 3 -Ic-531 -CH2-N(CH2-CH2-O-CH3)2 -N(CH3)-Ic-532 -CH2-N(CH2-CH2-O-CH3)2 -N(CH2CH3)-Ic-533 -CH2-N(CH2-CH2-O-CH3)2 -N(CH2CH2CH3)-Ic-534 -CH2-N(CH2-CH2-O-CH3)2 -N(CH2CH2CH2CH3)-Ic-535 -CH2-N(CH2-CH2-0-CH3)2 -N C H CH3 CHzCH3 -Ic-536 -CH2-N(CH2-CH2-O-CH3)2 -N C H CH3 z-Ic-537 -CH2-N(CH2-CH2-O-CH3)2 -N CHzC H CH3 z-Ic-538 -CH2-N(CH2-CH2-O-CH3)2 -N C CH3 3 -Ic-539 -N(CH3)-N

Ic-540 -N(CH2CH3)-Ic-541 -N N(CH2CH2CH3)-Ic-542 ~ -N(CH2CH2CH2CH3)-~N
~
Ic-543 -N --:z -N(C(H)(CH3)(CH2CH3))-Ic-544 -N(C(H)(CH3)2)-~N

Ic-545 -N(CH2C(H)(CH3)2)-~N _ Ic-546 -N(C(CH3)3)-Ic-547 -N(CH3)-OH
Ic-548 -N(CH2CH3)-OH
Ic-549 N(CH2CH2CH3)-OH
Ic-550 /-Na -N(CH2CH2CH2CH3)-OH
Ic-551 /-Na -N(C(H)(CH3)(CH2CH3))-OH
Ic-552 /-Na -N(C(H)(CH3)2)-OH
Ic-553 /-Na -N(CH2C(H)(CH3)2)-OH
Ic-554 /-Na -N(C(CH3)3)-OH
Ic-555 -N(CH3)-Ic-556 -N(CH2CH3)-Ic-557 N(CH2CH2CH3)-Ic-558 lqlo- No -N(CH2CH2CH2CH3)-Ic-559 -N(C(H)(CH3)(CH2CH3))-Ic-560 -N(C(H)(CH3)2)-Ic-561 lqlo- No -N(CH2C(H)(CH3)2)-Ic-562 ~lqlo- N~~/ ~\ -N(C(CH3)3)-Ic-563 r N N -N(CH3)-Ic-564 v r N N -N(CH2CH3)-Ic-565 v -N(CH2CH2CH3)-Ic-566 Ic-566 -N(CH2CH2CH2CH3)-Ic-567 Ic-567 -N(C(H)(CH3)(CH2CH3))-~N N~

Ic-568 v -N(C(H)(CH3)2)-~N N~

Ic-569 v -N(CH2C(H)(CH3)2)-Ic-570 Ic-570 N Nv -N(C(CH3)3)-~
Ic-571 N(CH3)-N
/-HO
Ic-572 -N(CH2CH3)-N
/-HO
Ic-573 N(CH2CH2CH3)-N
/-HO
Ic-574 -N(CH2CH2CH2CH3)-N
/-HO
Ic-575 -N(C(H)(CH3)(CH2CH3))-/-HON
Ic-576 -N(C(H)(CH3)2)-/-N
HO

Ic-577 -N(CH2C(H)(CH3)2)-N
/-HO
Ic-578 -N(C(CH3)3)-~N
HO
Ic-579 N(CH3)-X/-N

O
O Me Ic-580 -N(CH2CH3)-N

O
O Me Ic-581 N(CH2CH2CH3)-N

O
O Me Ic-582 -N(CH2CH2CH2CH3)-N

O
O Me Ic-583 -N(C(H)(CH3)(CH2CH3))-N

O
O Me Ic-584 -N(C(H)(CH3)2)-N

O
O Me Ic-585 -N(CH2C(H)(CH3)2)-N

O
O Me Ic-586 -N(C(CH3)3)-N

O
O Me Ic-587 N N(CH3)-~

Ic-588 N -N(CHzCH3)-~ /

Ic-589 N N(CHzCHzCH3)-~ /

Ic-590 N -N(CH2CH2CH2CH3)-Ic-591 Ic-591 N -N(C(H)(CH3)(CH2CH3))-~
Ic-592 N -N(C(H)(CH3)2)-Ic-593 Ic-593 N -N(CH2C(H)(CH3)2)-Ic-594 /
Ic-594 N -N(C(CH3)3)-Ic-595 /
Ic-595 N(CH3)-~

No Ic-596 -N(CHzCH3)-No Ic-597 N(CHzCHzCH3)-No Ic-598 -N(CHzCHzCHzCH3)-No Ic-599 -N(C(H)(CH3)(CHzCH3))-No Ic-600 -N(C(H)(CH3)z)-No Ic-601 -N(CHzC(H)(CH3)z)-No Ic-602 -N(C(CH3)3)-No Ic-603 N(CH3)-[-N\__/N--\\,,,N(CHa) Ic-604 -N(CHzCH3)-[-N\_/N--\\,,N(CHa) Ic-605 N(CHzCHzCH3)-[-N\__/N--\\,,-N(CHa) Ic-606 -N(CHzCHzCHzCH3)-[-N\_/N--\,,N(CHa) Ic-607 -N(C(H)(CH3)(CHzCH3))-[-N\__/N--\_,-N(CHa) Ic-608 -N(C(H)(CH3)z)-[-N\_/N--\\,,N(CHa) Ic-609 -N(CH2C(H)(CH3)2)-I-N\-/ N--\\_,,N(CHa) Ic-610 -N(C(CH3)3)-[-N~N--\_,-N(CHa) 1c-611 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N CH3 -Ic-612 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N CHZCH3 -Ic-613 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N CHzCHzCH3 -Ic-614 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N CHzCHzCHzCH3 -1c-615 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C H CH3 CHzCH3 -1c-616 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C H CH3 Z-Ic-617 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N CHzC H CH3 z-1c-618 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C CH3 3 -Ic-619 0 N(CH3)-NC DII/

Ic-620 O -N(CHzCH3)-~N~

N(CHzCHzCH3)-Ic-621 O

~NC CH3 -N(CHzCHzCHzCH3)-Ic-622 O

~NC CH3 Ic-623 O -N(C(H)(CH3)(CHzCH3))-~NC I

Ic-624 O -N(C(H)(CH3)z)-~NC I

Ic-625 0 -N(CH2C(H)(CH3)2)-~N~

Ic-626 0 -N(C(CH3)3)-~N~

Ic-627 /-No,,OH -N(CH3)-Ic-628 /-No,,OH -N(CH2CH3)-Ic-629 /~",OH N(CHzCHzCH3)-~N, I

Ic-630 v /-No ,,OH -N(CH2CH2CH2CH3)-Ic-631 /-No",OH -N(C(H)(CH3)(CH2CH3))-Ic-632 /-No",OH -N(C(H)(CH3)2)-Ic-633 /-No",OH -N(CH2C(H)(CH3)2)-Ic-634 /-No",OH -N(C(CH3)3)-Ic-635 /-No -N(CH3)-HO
Ic-636 ~ -N(CH2CH3)-~

HO
Ic-637 ~ N(CH2CH2CH3)-~

HO-$
Ic-638 ~ -N(CH2CH2CH2CH3)-~
HO-.~
Ic-639 /-No -N(C(H)(CH3)(CH2CH3))-HO
Ic-640 -N(C(H)(CH3)2)-HO
Ic-641 /-No -N(CH2C(H)(CH3)2)-HO-$
Ic-642 ~ -N(C(CH3)3)-~

HO
Ic-643 ,CH3 N(CH3)-~N
I'll-CH3 Ic-644 ,C H3 -N(CH2CH3)-~N

Ic-645 ,CH3 N(CH2CH2CH3)-//-N

Ic-646 ,CH3 -N(CH2CH2CH2CH3)-/-N
/.VCH3 \

Ic-647 ,CH3 -N(C(H)(CH3)(CH2CH3))-~N
~CH3 Ic-648 ,CN3 -N(C(H)(CH3)2)-/-N
/.VCH3 \

Ic-649 ,C H3 -N(CH2C(H)(CH3)2)-/-N
/-\- C H 3 \

Ic-650 ,CN3 -N(C(CH3)3)-~N

Ic-651 -N(CH3)-Ic-652 -N(CH2CH3)-Ic-653 N(CH2CH2CH3)-Ic-654 -N(CH2CH2CH2CH3)-Ic-655 -N(C(H)(CH3)(CH2CH3))-Ic-656 -N(C(H)(CH3)2)-Ic-657 -N(CH2C(H)(CH3)2) O
Ic-658 -N(C(CH3)3)-Ic-659 \-N oH N(CH3)-Ic-660 \-N OH -N(CH2CH3)-Ic-661 \-N OH N(CH2CH2CH3)-Ic-662 \\_N OH -N(CH2CH2CH2CH3)-Ic-663 \\_N oH -N(C(H)(CH3)(CH2CH3))-Ic-664 \-N oH -N(C(H)(CH3)2)-Ic-665 \-N oH -N(CH2C(H)(CH3)2)-Ic-666 \-N oH -N(C(CH3)3)-Ic-667 cr OH N(CH3)-Ic-668 a OH -N(CH2CH3)-Ic-669 N OH N(CH2CH2CH3)-Ic-670 OH -N(CH2CH2CH2CH3)-Ic-671 a OH -N(C(H)(CH3)(CH2CH3))-Ic-672 a OH -N(C(H)(CH3)2)-Ic-673 a OH -N(CH2C(H)(CH3)2)-Ic-674 a OH -N(C(CH3)3)-Ic-675 NH -N(CH3)-Ic-676 NH -N(CH2CH3)-Ic-677 NH -N(CH2CH2CH3)-Ic-678 NH -N(CH2CH2CH2CH3)-Ic-679 NH -N(C(H)(CH3)(CH2CH3))-Ic-680 ~NH -N(C(H)(CH3)2)-Ic-681 ~NH -N(CH2C(H)(CH3)2)-Ic-682 NH -N(C(CH3)3)-Ic-683 /-NH -N(CH3)-Ic-684 /-NH -N(CH2CH3)-Ic-685 //-NH N(CH2CH2CH3)-Ic-686 lo---NH -N(CH2CH2CH2CH3)-Ic-687 o---NH -N(C(H)(CH3)(CH2CH3))-Ic-688 //-NH -N(C(H)(CH3)2)-Ic-689 lo,--NH -N(CH2C(H)(CH3)2)-Ic-690 Ilo---NH -N(C(CH3)3)-Ic-691 ~NH N(CH3)-Ic-692 "CH2CH3 -N(CH2CH3)-Ic-693 / CH2CH3 N(CH2CH2CH3)-Ic-694 /cH2CH3 -N(CH2CH2CH2CH3)-Ic-695 /cH2CH3 -N(C(H)(CH3)(CH2CH3))-Ic-696 / CH2CH3 -N(C(H)(CH3)2)-Ic-697 /cH2CH3 -N(CH2C(H)(CH3)2)-Ic-698 /cH2CH3 -N(C(CH3)3)-Ic-699 /cH2CH3 N(CH3)-Ic-700 /-NH -N(CH2CH3)-D Ic-701 /-NH N(CH2CH2CH3) D

Ic-702 /-NH -N(CH2CH2CH2CH3)-D 328 -Ic-703 /-NN -N(C(H)(CH3)(CH2CH3))-D Ic-704 /-NN N(C(H)(CH3)2) D

Ic-705 /-NH -N(CH2C(H)(CH3)2)-D Ic-706 /-NH -N(C(CH3)3)-D Ic-707 /-NH N(CH3)-D
Ic-708 /-NH -N(CH2CH3)-D Ic-709 /-NN N(CH2CH2CH3)-D Ic-710 /-NH -N(CH2CH2CH2CH3)-D Ic-711 /-NN -N(C(H)(CH3)(CH2CH3))-D Ic-712 /-NH
N(c(H)(cH3)2) D

Ic-713 /-NN -N(CH2C(H)(CH3)2)-D Ic-714 IIIII:ii/-NN -N(C(CH3)3)-Ic-715 N(CH3)-Ic-716 ~/-\ S -N(CH2CH3)-Ic-717 -N /-\ N(CH2CH2CH3)-Ic-718 -N /-\ -N(CH2CH2CH2CH3)-Ic-719 -N /-\ -N(C(H)(CH3)(CH2CH3))-Ic-720 -N /-\ -N(C(H)(CH3)2)-Ic-721 -N /-\ -N(CH2C(H)(CH3)2)-Ic-722 -N /-\ -N(C(CH3)3)-Ic-723 N\~ N(CH3)-Ic-724 N\~ -N(CH2CH3)-Ic-725 N(CH2CH2CH3)-Ic-726 N\~ -N(CH2CH2CH2CH3)-Ic-727 N\~ -N(C(H)(CH3)(CH2CH3))-Ic-72s ~ N(c(H)(cH3)z) Ic-729 N~~ -N(cHzc(H)(CH3)z)-Ic-730 N\~ -N(C(CH3)3)-Ic-731 /-NH N(CH3)-Ic-732 /-NH -N(CH2CH3)-Ic-733 /-NH N(CHzCHzCH3)-Ic-734 /-NH -N(CH2CH2CH2CH3)-Ic-735 /-NH -N(C(H)(CH3)(CH2CH3))-Ic-736 /-NH -N(C(H)(CH3)2)-Ic-737 /-NH -N(CH2C(H)(CH3)2)-Ic-738 /-NH -N(C(CH3)3)-Ic-739 CH3 -N(CH3)-N

Ic-740 CH3 -N(CH2CH3)-N

Ic-741 CH3 -N(CHzCHzCH3)-~N N

Ic-742 CH3 -N(CH2CH2CH2CH3)-N

Ic-743 CH3 -N(C(H)(CH3)(CH2CH3))-N
Ic-744 CH3 -N(C(H)(CH3)z)-~N N

Ic-745 CH3 -N(CH2C(H)(CH3)2)-/-N_/ N

Ic-746 CH3 -N(C(CH3)3)-~N N

Ic-747 CH3 N(CH3)-~N

Ic-748 CH3 -N(CH2CH3)-N

Ic-749 CH3 N(CH2CH2CH3)-N
Ic-750 CH3 -N(CH2CH2CH2CH3)-~N
Ic-751 CH3 -N(C(H)(CH3)(CH2CH3))-N

Ic-752 CH3 -N(C(H)(CH3)2)-~N
Ic-753 CH3 -N(CH2C(H)(CH3)2)-N
Ic-754 CH3 -N(C(CH3)3)-N

Ic-755 NH -N(CH3)-0 Ic-756 NH -N(CH2CH3)-0 OH

Ic-757 NH -N(CH2CH2CH3)-0 Ic-758 NH -N(CH2CH2CH2CH3)-0 Ic-759 NH -N(C(H)(CH3)(CH2CH3))-0 Ic-760 NH -N(C(H)(CH3)2)-0 - 333 -Ic-761 NH -N(CH2C(H)(CH3)2)-0 OH

Ic-762 NH -N(C(CH3)3)-0 Ic-763 /-N--~ OH N(CH3)-Ic-764 OH -N(CH2CH3)-Ic-765 //-N-1-~ OH N(CH2CH2CH3)-Ic-766 //-N-*,-~ OH -N(CH2CH2CH2CH3)-Ic-767 OH -N(C(H)(CH3)(CH2CH3))-Ic-768 //--N--~ OH -N(C(H)(CH3)2) Ic-769 //-N-*,-~ OH -N(CH2C(H)(CH3)2)-Ic-770 //-N-*,-~ OH -N(C(CH3)3)-Ic-771 /-N~ rCH3 -N(CH3)-Ic-772 Ic-772 /-ND-CH3 -N(CH2CH3)-Ic-773 /-N~ rCH N(CHzCHzCH3)-~/ 3 Ic-774 /-N rCH -N(CHzCHzCHzCH3)-~--/ 3 Ic-775 /-ND-CH3 -N(C(H)(CH3)(CH2CH3))-Ic-776 /-ND-CH3 -N(C(H)(CH3)2)-~ rCH3 -N(CH2C(H)(CH3)2)-Ic-777 /-N--Ic-778 /-N D-CH3 -N(C(CH3)3)-Ic-779 -CH2-NH-CH3 -N(CH3)-Ic-780 -CH2-NH-CH3 N CHzCH3 -Ic-781 -CH2-NH-CH3 -N CHzCHzCH3 -Ic-782 -CH2-NH-CH3 -N CHzCHzCHzCH3 -Ic-783 -CH2-NH-CH3 -N C H CH3 CHzCH3 -Ic-784 -CH2-NH-CH3 -N C H CH3 z-Ic-785 -CH2-NH-CH3 -N CHzC H CH3 z-Ic-786 -CH2-NH-CH3 -N C CH3 3 -Ic-787 -CH2-NH-CH2-CH3 -N CH3 -Ic-788 -CH2-NH-CH2-CH3 -N CHzCH3 -Ic-789 -CH2-NH-CH2-CH3 -N CHzCHzCH3 -Ic-790 -CH2-NH-CH2-CH3 -N CHzCHzCHzCH3 -Ic-791 -CH2-NH-CH2-CH3 -N C H CH3 CHzCH3 -Ic-792 -CH2-NH-CH2-CH3 -N C H CH3 z-Ic-793 -CH2-NH-CH2-CH3 -N CHzC H CH3 z-Ic-794 -CH2-NH-CH2-CH3 -N C CH3 3 -Ic-795 -CH2-NH-CH2-CH2-CH3 -N(CH3)-Ic-796 -CH2-NH-CH2-CH2-CH3 -N(CH2CH3)-Ic-797 -CH2-NH-CH2-CH2-CH3 -N(CH2CH2CH3)-Ic-798 -CH2-NH-CH2-CH2-CH3 -N(CH2CH2CH2CH3)-Ic-799 -CH2-NH-CH2-CH2-CH3 -N C H CH3 CHzCH3 -Ic-800 -CHz-NH-CHz-CHz-CH3 -N C H CH3 z-Ic-801 -CHz-NH-CHz-CHz-CH3 -N CHzC H CH3 z-Ic-802 -CH2-NH-CH2-CH2-CH3 -N C CH3 3 -Ic-803 ~~~CH N(CH3)-Ic-804 ~~~CH -N(CHzCH3)-Ic-805 ~~~CH N(CHzCHzCH3)-Ic-806 ~~~CH -N(CHzCHzCHzCH3)-Ic-807 H3C\ -N(C(H)(CH3)(CHzCH3))-~NrCH3 Ic-808 H3C \ -N(C(H)(CH3)z)-~NrCH3 Ic-809 ~~~cH -N(CHzC(H)(CH3)z)-H
Ic-810 ~~~CH -N(C(CH3)3)-Ic-811 H3C -N(CH3)-H
/-N

OMe Ic-812 H3C -N(CH2CH3)-H
I-N
OMe Ic-813 H3C -N(CH2CH2CH3)-H
I-N
OMe Ic-814 H3C -N(CH2CH2CH2CH3)-H
I-N
OMe Ic-815 H3C -N(C(H)(CH3)(CH2CH3))-H
I-N
OMe Ic-816 H3C -N(C(H)(CH3)2)-H
I-N
OMe Ic-817 H3C -N(CH2C(H)(CH3)2)-H
I-N
OMe Ic-818 H3C -N(C(CH3)3)-H
I-N
OMe Ic-819 H3C N(CH3)-~-CH3 >---CH3 H C
Ic-820 H3C -N(CH2CH3)-~-CH3 >---CH3 H C
Ic-821 H3C N(CH2CH2CH3)-~-CH3 ZI-N
>---CH3 H C
Ic-822 H3C -N(CH2CH2CH2CH3)-~-CH3 //-N
>---cfl3 H C
Ic-823 H3C -N(C(H)(CH3)(CH2CH3))-~-CH3 >---CH3 H C
Ic-824 H3C -N(C(H)(CH3)2)-~-CH3 ZI-N
>---CH3 H C
Ic-825 H3C -N(CH2C(H)(CH3)2)-~-CH3 ZI-N
>---CH3 Ic-826 H3C -N(C(CH3)3)-~-CH3 >---CH3 H C
Ic-827 -N(CH3)-Ic-828 -N(CH2CH3)-Ic-829 Ic-829 -N(CH2CH2CH3)-Ic-830 Ic-830 -N(CH2CH2CH2CH3)-Ic-831 -N(C(H)(CH3)(CH2CH3))-N
Ic-832 -N(C(H)(CH3)2)-N
Ic-833 -N(CH2C(H)(CH3)2)-N
Ic-834 -N(C(CH3)3)-Ic-835 CH3CH,2 N -N(CH3)-N
Ic-836 CH3CHi2 ~ N -N(CH2CH3)-N ~
Ic-837 CH3CH2 ~ N N(CHzCHzCH3)-~
--/ N ~
Ic-838 CH3CH2 // N -N(CH2CH2CH2CH3)-, N
Ic-839 CH3CH2 ~ N -N(C(H)(CH3)(CH2CH3))---/ N ~
Ic-840 CH3CH,2 // N -N(C(H)(CH3)2)-N ~
Ic-841 CH3CHz ~ N -N(CH2C(H)(CH3)2)-, i N N(C(CH3)3) Ic-842 CH3CH2 Ic-843 ~ ~ H3 -N(CH3)-N-CH CH OH
Ic-844 ~ CH3 -N(CH2CH3)--CH CH OH
Ic-845 ~ CH3 -N(CH2CH2CH3)--CH CH OH
Ic-846 ~ CH3 -N(CH2CH2CH2CH3)--CH CH OH
Ic-847 CH3 -N(C(H)(CH3)(CH2CH3))-L-CH CH OH
Ic-848 CH3 -N(C(H)(CH3)2)-L-CH CH OH
Ic-849 CH3 -N(CH2C(H)(CH3)2)-L-CH CH OH
IC-85U L CH3 -N(C(CH3)3)--CH CH OH

Ic-851 /-Iqlo-No -N(CH3)-Ic-852 -N(CH2CH3)-Ic-853 -N(CH2CH2CH3)-Ic-854 -N(CH2CH2CH2CH3)-Ic-855 -N(C(H)(CH3)(CH2CH3))-Ic-856 -N(C(H)(CH3)2)-Ic-857 -N(CH2C(H)(CH3)2)-Ic-858 -N(C(CH3)3)-Ic-859 -N(CH3)-Ic-860 -N(CH2CH3)-Ic-861 N(CH2CH2CH3)-Ic-862 N(CH2CH2CH2CH3)-,/-NN
Ic-863 -N(C(H)(CH3)(CH2CH3))-Ic-864 -N(C(H)(CH3)2)-N
Ic-865 -N(CH2C(H)(CH3)2)-Ic-866 -N(C(CH3)3)-Ic-867 C N(CH3)-N\ C
CH
Ic-868 C -N(CH2CH3)-N\ ~
CH
Ic-869 C N(CH2CH2CH3)-N\ CH I
Ic-870 C -N(CHzCHzCHzCH3)-N\CH~
Ic-871 \-N~ -N(c(H)(cH3)(CHzCH3))-\CH /
Ic-872 \-N~ -N(C(H)(CH3)z)-\CH /
Ic-873 -N(CHzC(H)(CH3)z)-CH /
Ic-874 \-N~ N(C(CH3)3) \cH
Ic-875 N(CH3)-//-NH N

Ic-876 -N(CH2CH3)-//-NH N

Ic-877 N(CH2CH2CH3)-ZI-NH N~

Ic-878 -N(CH2CH2CH2CH3)-,/-NH N

Ic-879 -N(C(H)(CH3)(CH2CH3))-,/-NH N

Ic-880 -N(C(H)(CH3)2)-,/~---NH N

Ic-881 -N(CH2C(H)(CH3)2)-//---NH N

Ic-882 -N(C(CH3)3)-//---NH N

Ic-883 ~ H3 -N(CH3)-NH N

Ic-884 ~ H3 -N(CH2CH3)-NH N

Ic-885 ~ H3 -N(CH2CH2CH3)-NH N

Ic-886 ~ H3 -N(CH2CH2CH2CH3)-NH N

Ic-887 ~ H3 -N(C(H)(CH3)(CH2CH3))-NH N

Ic-888 ~ H3 -N(C(H)(CH3)2)-NH N

Ic-889 ~ H3 -N(CH2C(H)(CH3)2)-NH N

Ic-890 ~ H3 -N(C(CH3)3)-NH N

Ic-891 -N(CH3)-/-N\ /N H

Ic-892 -N(CH2CH3)-/-N\ N H

Ic-893 N(CH2CH2CH3)-/-N\ /N H

Ic-894 -N(CH2CH2CH2CH3)-/-N\ N H

Ic-895 -N(C(H)(CH3)(CH2CH3))-/-N\ N H
Ic-896 -N(C(H)(CH3)2)-/-N\ N H
Ic-897 -N(CH2C(H)(CH3)2)-/-N\ N H
Ic-898 -N(C(CH3)3)-/-N\ /N H
Ic-899 CH3 -N(CH3)-~N\

Ic-900 CH3 -N(CH2CH3)-~N\

Ic-901 CH3 N(CH2CH2CH3)-Ic-902 ~N~\NCH3 -N(CH2CH2CH2CH3)-Ic-903 CH3 -N(C(H)(CH3)(CH2CH3))-Ic-904 ~N~\NCH3 -N(C(H)(CH3)2)-Ic-905 ~N~\NCH3 -N(CH2C(H)(CH3)2)-Ic-906 ~N~\NCH3 -N(C(CH3)3)-Ic-907 /,--N H -N(CH3)-Ic-908 z,,--N H -N(CH2CH3)-Ic-909 //-N ~ -N(CH2CH2CH3)-Ic-910 /,--N ~ -N(CH2CH2CH2CH3)-Ic-911 //-N ~ -N(C(H)(CH3)(CH2CH3))-Ic-912 Z/-N v H -N(C(H)(CH3)2)-Ic-913 ZI-N v H -N(CH2C(H)(CH3)2)-Ic-914 /-N v H -N(C(CH3)3)-Ic-915 \-\ -N(CH3)-~~ ~~ OH

Ic-916 \-\ -N(CHzCH3)-~~ ~~ OH

Ic-917 -N(CH2CH2CH3)-N N OH

Ic-918 \-\ -N(CHzCHzCHzCH3)-~~ ~~ OH

Ic-919 \-\ -N(C(H)(CH3)(CHzCH3))-~~ ~~ OH

Ic-920 N N -N(C(H)(CH3)2)-OH
Ic-921 \-\ -N(CHzC(H)(CH3)z)-~~ ~~ OH

Ic-922 \-\ -N(C(CH3)3)-~~ ~~ OH

Ic-923 ~ \ N(CH3)-~% ~~CH3 Ic-924 //-N /-\ -N(CHzCH3)-N~~CH3 Ic-925 N - \ N N(CHzCHzCH3)-~~/CH3 Ic-926 \ -N(CHzCHzCHzCH3)-~~% ~ ~/CH3 Ic-927 ~ \ -N(C(H)(CH3)(CHzCH3))-~% ~~/CH3 Ic-928 ~ \ -N(C(H)(CH3)2)-~% ~~CH3 Ic-929 ~ \ -N(CH2C(H)(CH3)2)-Ic-930 ~~CH3 Ic-930 \ -N(C(CH3)3)-~~% ~~CH3 Ic-931 -N(CH3)-\-N N

Ic-932 -N(CH2CH3)-\-N/--N N

Ic-933 -N(CH2CH2CH3)-\-N N

Ic-934 -N(CH2CH2CH2CH3)-\-N N

Ic-935 -N(C(H)(CH3)(CH2CH3))-\-N N

Ic-936 -N(C(H)(CH3)2)-\-N N

Ic-937 -N(CH2C(H)(CH3)2)-\-N/--N N

Ic-938 -N(C(CH3)3)-\-N N

Ic-939 \-ND-OEt -N(CH3)-Ic-940 \-ND-OEt -N(CH2CH3)-Ic-941 \-NaOEt -N(CH2CH2CH3)-Ic-942 \\-NaOEt -N(CH2CH2CH2CH3)-Ic-943 \\-NaOEt -N(C(H)(CH3)(CH2CH3))-Ic-944 \\-NaOEt -N(C(H)(CH3)2)-Ic-945 \-NaOEt -N(CH2C(H)(CH3)2)-Ic-946 \-ND-OEt -N(C(CH3)3)-Ic-947 N(CH3)-H

Ic-948 N
-N(CH2CH3)-~
Q~ H
Ic-949 N
N(CH2CH2CH3)-~
Q~ H
Ic-950 N
-N(CH2CH2CH2CH3)-~
Q~ H
Ic-951 /-N -N(C(H)(CH3)(CH2CH3))-Ic-952 -N(C(H)(CH3)2)-H
Ic-953 N -N(CH2C(H)(CH3)2)-~
H
Ic-954 N -N(C(CH3)3)-~

Ic-955 N(CH3) OEt Ic-956 - N/O -N(CH2CH3)-OEt Ic-957 - N/O -N(CH2CH2CH3)-OEt Ic-958 0 -N(CHzCHzCHzCH3)-N
OEt Ic-959 N(C(H)(CH3)(CH2CH3))-OFt Ic-960 N(C(H)(CH3)2) OEt Ic-961 -N N/0 -N(CH2C(H)(CH3)2)-OEt Ic-962 - N / vo N(C(CH3)3) OEt Ic-963 -CHz-N CHzCH3 CH3 N CH3 -Ic-964 -CHz-N CHzCH3 CH3 N CHzCH3 -Ic-965 -CHz-N CHzCH3 CH3 N CHzCHzCH3 -Ic-966 -CHz-N CHzCH3 CH3 -N CHzCHzCHzCH3 -Ic-967 -CHz-N CHzCH3 CH3 -N C H CH3 CHzCH3 -Ic-968 -CHz-N CHzCH3 CH3 -N C H CH3 z-Ic-969 -CH2-N(CH2CH3)(CH3) -N(CH2C(H)(CH3)2)-Ic-970 -CHz-N CHzCH3 CH3 -N C CH3 3-Ic-971 -CHz-N CHzCHzCH3 CH3 N CH3 -Ic-972 -CH2-N(CH2CH2CH3)(CH3) -N(CH2CH3)-Ic-973 -CHz-N CHzCHzCH3 CH3 N CHzCHzCH3 -Ic-974 -CHz-N CHzCHzCH3 CH3 -N CHzCHzCHzCH3 -Ic-975 -CHz-N CHzCHzCH3 CH3 -N C H CH3 CHzCH3 -Ic-976 -CHz-N CHzCHzCH3 CH3 -N C H CH3 z-Ic-977 -CHz-N CHzCHzCH3 CH3 -N CHzC H CH3 z-Ic-978 -CHz-N CHzCHzCH3 CH3 -N C CH3 3-Ic-979 -CH2-N(CH2CH2CH2CH3)(CH3) N CH3 -Ic-980 -CH2-N(CH2CH2CH2CH3)(CH3) N CHzCH3 -Ic-981 -CH2-N(CH2CH2CH2CH3)(CH3) N CHzCHzCH3 -Ic-982 -CH2-N(CH2CH2CH2CH3)(CH3) -N CHzCHzCHzCH3 -Ic-983 -CH2-N(CH2CH2CH2CH3)(CH3) -N C H CH3 CHzCH3 -Ic-984 -CH2-N(CH2CH2CH2CH3)(CH3) -N C H CH3 z-Ic-985 -CH2-N(CH2CH2CH2CH3)(CH3) N CHzC H CH3 z-Ic-986 -CH2-N(CH2CH2CH2CH3)(CH3) -N C CH3 3 -Ic-987 -CH2-NH-CH2CH2CH2CH3 N CH3 -Ic-988 -CH2-NH-CH2CH2CH2CH3 -N(CH2CH3)-Ic-989 -CH2-NH-CH2CH2CH2CH3 N(CH2CH2CH3)-Ic-990 -CH2-NH-CH2CH2CH2CH3 -N(CH2CH2CH2CH3)-Ic-991 -CH2-NH-CH2CH2CH2CH3 -N(C(H)(CH3)(CH2CH3))-Ic-992 -CH2-NH-CH2CH2CH2CH3 -N C H CH3 z-Ic-993 -CH2-NH-CH2CH2CH2CH3 -N CHzC H CH3 z-Ic-994 -CH2-NH-CH2CH2CH2CH3 -N C CH3 3 -Ic-995 -CH2-NH-CH2CH2-O-CH3 N CH3 -Ic-996 -CH2-NH-CH2CH2-O-CH3 -N CHzCH3 -Ic-997 -CH2-NH-CH2CH2-O-CH3 N CHzCHzCH3 -Ic-998 -CH2-NH-CH2CH2-O-CH3 -N CHzCHzCHzCH3 -Ic-999 -CH2-NH-CH2CH2-O-CH3 -N C H CH3 CHzCH3 -Ic-1000 -CH2-NH-CH2CH2-O-CH3 -N C H CH3 z-Ic-1001 -CH2-NH-CH2CH2-O-CH3 -N CHzC H CH3 z-Ic-1002 -CH2-NH-CH2CH2-O-CH3 -N C CH3 3 -Ic-1003 /-N N--\,OMe N(CH3)-Ic-1004 /-N N--,\,OMe N(CH2CH3)-N N(CHzCHzCH3)-Ic-1005 /-N --\
~~OMe Ic-1006 /-N /-\ N-N\,OMe -N(CH2CH2CH2CH3)-Ic-1007 /-N N--\,OMe -N(C(H)(CH3)(CH2CH3))-Ic-1008 /-N N--\,OMe -N(C(H)(CH3)2)-Ic-1009 /-N/-\ N--\,OMe N(CH2C(H)(CH3)2)-Ic-1010 /-N/-\ N--\,OMe -N(C(CH3)3)-Ic-1011 N(CH3)-N OPO OH
Ic-1012 N(CH2CH3)-N OPO OH
Ic-1013 N(CH2CH2CH3)-N OPO OH
Ic-1014 ag -N(CH2CH2CH2CH3)-OPO OH
Ic-1015 N -N(C(H)(CH3)(CH2CH3))-OPO OH
Ic-1016 -N(C(H)(CH3)2)-N OPO OH
Ic-1017 N(CH2C(H)(CH3)2)-N OPO OH
Ic-1018 -N(C(CH3)3)-N OPO OH
Ic-1019 N(CH3)-OPO(OH)Z
Ic-1020 N(CHzCH3)-OPO(OH)Z
Ic-1021 N(CHzCHzCH3)-OPO(OH)Z
Ic-1022 -N(CHzCHzCHzCH3)-OPO(OH)Z
Ic-1023 -N(C(H)(CH3)(CHzCH3))-OPO(OH)Z
Ic-1024 -N(C(H)(CH3)z)-OPO(OH)Z
Ic-1025 N N(CHzC(H)(CH3)z)-OPO(OH)Z

Ic-1026 -N(C(CH3)3)-OPO(OH)Z
Ic-1027 /\N OPO(OH)z -N(CH3)-Ic-1028 /\N OPO(OH)z N(CH2CH3)-Ic-1029 /\N OPO(OH)z N(CH2CH2CH3)-Ic-1030 /\N OPO(OH)z -N(CH2CH2CH2CH3)-Ic-1031 /\N OPO(OH)z -N(C(H)(CH3)(CH2CH3))-Ic-1032 /\N OPO(OH)z -N(C(H)(CH3)2)-Ic-1033 /\N OPO(OH)z -N(CH2C(H)(CH3)2)-Ic-1034 /\N OPO(OH)z -N(C(CH3)3)-Ic-1035 CH3 N(CH3)-OPO OH
Ic-1036 /--NiCH3 N(CH2CH3)-OPO OH
Ic-1037 CH3 N(CH2CH2CH3)-OPO OH
Ic-1038 CH3 -N(CH2CH2CH2CH3)-OPO OH
Ic-1039 N/CH3 -N(C(H)(CH3)(CH2CH3))-OPO OH

Ic-1040 CH3 -N(C(H)(CH3)2)-OPO OH
Ic-1041 /--N/CH3 N(CH2C(H)(CH3)2)-OPO OH
Ic-1042 /--NiCH3 -N(C(CH3)3)-OPO OH
Ic-1043 N(CH3)-OPO OH
Ic-1044 N(CH2CH3)-OPO OH
Ic-1045 N(CH2CH2CH3)-OPO OH
Ic-1046 -N(CH2CH2CH2CH3)-OPO OH
Ic-1047 -N(C(H)(CH3)(CH2CH3))-OPO OH
Ic-1048 -N(C(H)(CH3)2)-/-N

OPO OH

Ic-1049 N(CH2C(H)(CH3)2)-OPO OH
Ic-1050 -N(C(CH3)3)-OPO OH
Ic-1051 \\--H -N(CH3)-N

OPO OH )a2 Ic-1052 \\__H N(CH2CH3)-N

OPO OH
Ic-1053 -N(CH2CH2CH3)-N

OPO OH
Ic-1054 \\--H -N(CH2CH2CH2CH3)-N

OPO OH
Ic-1055 \--H -N(C(H)(CH3)(CH2CH3))-N

OPO OH
Ic-1056 H -N(C(H)(CH3)2)-N

OPO OH
Ic-1057 \\__H -N(CH2C(H)(CH3)2)-N

OPO OH

Ic-1058 N -N(C(CH3)3)-)aOPO(OH)2 Compound n - Rl X
Ic-cl 1 -(CHz)ri N(CH3)z -CH(OH)-Ic-c2 2 -(CHz)ri N(CH3)z -CH(OH)-Ic-c3 3 -(CHz)ri N(CH3)z -CH(OH)-Ic-c4 4 -(CHz)ri N(CH3)z -CH(OH)-Ic-c5 5 -(CHz)ri N(CH3)z -CH(OH)-Ic-c6 6 -(CHz)ri N(CH3)z -CH(OH)-Ic-c7 1 CHz ri N CH3 z N C O N H-CHz-CHz-OH -Ic-c8 2 CHz ri N CH3 z N C O N H-CHz-CHz-OH -Ic-c9 3 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-OH)-Ic-c10 4 CHz ri N CH3 z N C O N H-CHz-CHz-OH -Ic-c11 5 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-OH)-Ic-c12 6 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-OH)-Ic-c13 1 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ic-c14 2 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ic-c15 3 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ic-c16 4 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ic-c17 5 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ic-c18 6 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ic-c19 1 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ic-c20 2 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ic-c21 3 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c22 4 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ic-c23 5 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ic-c24 6 CHz ri N CH3 z -N C O N H-CHz-CHz-OCH3 -Ic-c25 1 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c26 2 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c27 3 -(CHz)ri N(CH3)z -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c28 4 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ic-c29 5 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ic-c30 6 -(CHz)ri N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ic-c31 1 CHz ri N CH3 z -N CHz-CHz-OH -Ic-c32 2 CHz ri N CH3 z -N CHz-CHz-OH -Ic-c33 3 CHz ri N CH3 z -N CHz-CHz-OH -Ic-c34 4 CHz ri N CH3 z -N CHz-CHz-OH -Ic-c35 5 CHz ri N CH3 z -N CHz-CHz-OH -Ic-c36 6 CHz ri N CH3 z -N CHz-CHz-OH -Ic-c37 1 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ic-c38 2 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ic-c39 3 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ic-c40 4 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ic-c41 5 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ic-c42 6 -(CHz)ri N(CH3)z -N(CH2-CH2-F)-Ic-c43 1 CHz ri N CH3 z N CHz-CHz-OCH3 -Ic-c44 2 CHz ri N CH3 z N CHz-CHz-OCH3 -Ic-c45 3 CHz ri N CH3 z N CHz-CHz-OCH3 -Ic-c46 4 CHz ri N CH3 z N CHz-CHz-OCH3 -Ic-c47 5 CHz ri N CH3 z N CHz-CHz-OCH3 -Ic-c48 6 CHz ri N CH3 z N CHz-CHz-OCH3 -Ic-c49 1 -CH(OH)--(CH2)n N 0 Ic-c50 2 -CH(OH)--(CH2)n N 0 Ic-c51 3 -CH(OH)--(CH2)n N 0 Ic-c52 4 -CH(OH)--(CH2)n N 0 Ic-c53 5 -CH(OH)--(CH2)n N 0 Ic-c54 6 -CH(OH)--(CH2)n N 0 Ic-c55 1 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ic-c56 2 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ic-c57 3 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ic-c58 4 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ic-c59 5 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ic-c60 6 N(C(O)N(H)-CH2-CH2-OH)--(CH2)n N 0 Ic-c61 1 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ic-c62 2 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ic-c63 3 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ic-c64 4 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ic-c65 5 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ic-c66 6 N(C(O)N(H)-CH2-CH2-F)--(CH2)n N 0 Ic-c67 1 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ic-c68 2 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ic-c69 3 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ic-c70 4 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ic-c71 5 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ic-c72 6 -N(C(O)N(H)-CH2-CH2-OCH3)--(CH2)n N 0 Ic-c73 1 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ic-c74 2 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ic-c75 3 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ic-c76 4 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ic-c77 5 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ic-c78 6 N(C(O)N(H)-CH2-CH2-CF3)--(CH2)n N 0 Ic-c79 1 N(CH2-CH2-OH)--(CH2)n N 0 Ic-c80 2 N(CH2-CH2-OH)--(CH2)n N 0 Ic-c81 3 N(CH2-CH2-OH)--(CH2)n N 0 Ic-c82 4 N(CH2-CH2-OH)--(CH2)n N 0 Ic-c83 5 N(CH2-CH2-OH)--(CH2)n N 0 Ic-c84 6 N(CH2-CH2-OH)--(CH2)n N 0 Ic-c85 1 -N(CH2-CH2-F)--(CH2)n N 0 Ic-c86 2 -N(CH2-CH2-F)--(CH2)n N 0 Ic-c87 3 -N(CH2-CH2-F)--(CH2)n N 0 Ic-c88 4 -N(CH2-CH2-F)--(CH2)n N 0 Ic-c89 5 -N(CH2-CH2-F)--(CH2)n N 0 Ic-c90 6 -N(CH2-CH2-F)--(CH2)n N 0 Ic-c91 1 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ic-c92 2 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ic-c93 3 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ic-c94 4 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ic-c95 5 -N(CH2-CH2-OCH3)--(CH2)n N 0 Ic-c96 6 -N(CH2-CH2-OCH3)--(CH2)n N 0 Compound m - Rl X
Ic-c146 2 -O-(CHz)m N(CH3)z -CH(OH)-Ic-c147 3 -O-(CHz)m N(CH3)z -CH(OH)-Ic-c148 4 -O-(CHz)m N(CH3)z -CH(OH)-Ic-c149 5 -O-(CHz)m N(CH3)z -CH(OH)-Ic-c150 6 -O-(CHz)m N(CH3)z -CH(OH)-Ic-c151 2 -O CHz õ-N CH3 z N C O N H-CHz-CHz-OH -Ic-c152 3 -O CHz õ-N CH3 z N C O N H-CHz-CHz-OH -Ic-c153 4 -O CHz õ-N CH3 z N C O N H-CHz-CHz-OH -Ic-c154 5 -O CHz õ-N CH3 z N C O N H-CHz-CHz-OH -Ic-c155 6 -O CHz õ-N CH3 z N C O N H-CHz-CHz-OH -Ic-c156 2 -O-(CHz)m N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ic-c157 3 -O-(CHz)m N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ic-c158 4 -O-(CHz)m N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ic-c159 5 -O-(CHz)m N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ic-c160 6 -O-(CHz)m N(CH3)z -N(C(O)N(H)-CH2-CH2-F)-Ic-c161 2 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ic-c162 3 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ic-c163 4 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ic-c164 5 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ic-c165 6 -O CHz õ-N CH3 z -N C O N H-CHz-CHz-OCH3 -Ic-c166 2 -O-(CHz)m N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ic-c167 3 -O-(CHz)m N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ic-c168 4 -O-(CHz)m N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ic-c169 5 -O-(CHz)m N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ic-c170 6 -O-(CHz)m N(CH3)z N(C(O)N(H)-CH2-CH2-CF3)-Ic-c171 2 -O CHz m N CH3 z -N CHz-CHz-OH -Ic-c172 3 -O CHz m N CH3 z -N CHz-CHz-OH -Ic-c173 4 -O CHz m N CH3 z -N CHz-CHz-OH -Ic-c174 5 -O CHz m N CH3 z -N CHz-CHz-OH -Ic-c175 6 -O CHz m N CH3 z -N CHz-CHz-OH -Ic-c176 2 -O-(CHz)m N(CH3)z -N(CH2-CH2-F)-Ic-c178 3 -O-(CHz)m N(CH3)z -N(CH2-CH2-F)-Ic-c179 4 -O-(CHz)m N(CH3)z -N(CH2-CH2-F)-Ic-c180 5 -O-(CHz)m N(CH3)z -N(CH2-CH2-F)-Ic-c181 6 -O-(CHz)m N(CH3)z -N(CH2-CH2-F)-Ic-c182 2 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ic-c183 3 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ic-c184 4 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ic-c185 5 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ic-c186 6 -O CHz õ-N CH3 z N CHz-CHz-OCH3 -Ic-c187 2 -CH(OH)--0-(cH2)m N 0 Ic-c188 3 -CH(OH)--o (cH2)m N 0 Ic-c189 4 -CH(OH)--o (cH2)m N 0 Ic-c190 5 -CH(OH)--0-(cH2)m N 0 Ic-c191 6 -CH(OH)--o (cH2)m N 0 Ic-c192 2 N(C(O)N(H)-CHz-CHz-OH)--o (cH2)m N 0 Ic-c193 3 N(C(O)N(H)-CHz-CHz-OH)--o (cH2)m N 0 Ic-c194 4 -o (cH2) \ N(C(O)N(H)-CHz-CHz-OH)-m~~ ~

Ic-c195 5 N(C(O)N(H)-CHz-CHz-OH)--o (cH2)m N 0 Ic-c196 6 N(C(O)N(H)-CHz-CHz-OH)--o (cH2)m N 0 Ic-c197 2 N(C(O)N(H)-CHz-CHz-F)--o (cH2)m N 0 Ic-c198 3 N(C(O)N(H)-CHz-CHz-F)--o (cH2)m N 0 Ic-c199 4 N(C(O)N(H)-CH2-CH2-F)--0 (CH2)m N 0 Ic-c200 5 N(C(O)N(H)-CH2-CH2-F)--0 (CH2)m N 0 Ic-c201 6 N(C(O)N(H)-CH2-CH2-F)--0 (CH2)m N 0 Ic-c202 2 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N 0 Ic-c203 3 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N 0 Ic-c204 4 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N 0 Ic-c205 5 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N 0 Ic-c206 6 -N(C(O)N(H)-CH2-CH2-OCH3)--0 (CH2)m N 0 Ic-c207 2 N(C(O)N(H)-CH2-CH2-CF3)--0 (CH2)m N 0 Ic-c208 3 N(C(O)N(H)-CH2-CH2-CF3)--0 (CH2)m N 0 Ic-c209 4 -0 (CH \ N(C(O)N(H)-CHz-CHz-CF3)-2)m~% ~

Ic-c210 5 N(C(O)N(H)-CH2-CH2-CF3)--0 (CH2)m N 0 Ic-c211 6 N(C(O)N(H)-CH2-CH2-CF3)--0 (CH2)m N 0 Ic-c212 2 -0 (CH \ N(CHz-CHz-OH)-2)m~~ ~

Ic-c213 3 N(CH2-CH2-OH)--0 (CH2)m N 0 Ic-c214 4 N(CHz-CHz-OH)--o (cH2)m N 0 Ic-c215 5 N(CHz-CHz-OH)--o (cH2)m N 0 Ic-c216 6 N(CHz-CHz-OH)--o (cH2)m N 0 Ic-c217 2 -N(CHz-CHz-F)--o (cH2)m N 0 Ic-c218 3 -N(CHz-CHz-F)--o (cH2)m N 0 Ic-c219 4 -N(CHz-CHz-F)--o (cH2)m N 0 Ic-c220 5 -N(CHz-CHz-F)--o (cH2)m N 0 Ic-c221 6 -N(CHz-CHz-F)--o (cH2)m N 0 Ic-c222 2 -N(CH2-CH2-OCH3)--0(cH2)m N 0 Ic-c223 3 -N(CH2-CH2-OCH3)--0(cH2)m N 0 Ic-c224 4 -o (cH \ -N(CHz-CHz-OCH3)-2)m~% ~

Ic-c225 5 -N(CH2-CH2-OCH3)--0(cH2)m N 0 Ic-c226 6 -N(CH2-CH2-OCH3)--0(cH2)m N 0 Compound - Rl X
Ic-c267 -CH2-N(CH2-CH3)2 -CH(OH)-Ic-c268 -CH2-N(CH2-CH3)2 N(C(O)N(H)-CHz-CHz-OH)-Ic-c269 -CH2-N(CH2-CH3)2 -N(C(O)N(H)-CH2-CH2-F)-Ic-c270 -CH2-N(CH2-CH3)2 -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c271 -CH2-N(CH2-CH3)2 -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c275 -CHz-N CHz-CHz-CH3 z -CH OH -Ic-c276 -CHz-N CHz-CHz-CH3 z N C O N H-CHz-CHz-OH -Ic-c277 -CHz-N CHz-CHz-CH3 z -N C O N H-CHz-CHz-F -Ic-c278 -CHz-N CHz-CHz-CH3 z -N C O N H-CHz-CHz-OCH3 -Ic-c279 -CHz-N CHz-CHz-CH3 z N C O N H-CHz-CHz-CF3 -Ic-c283 -CHz-N CHz-CHzOH z -CH OH -Ic-c284 -CHz-N CHz-CHzOH z N C O N H-CHz-CHz-OH -Ic-c285 -CHz-N(CHz-CHzOH)z -N(C(O)N(H)-CH2-CH2-F)-Ic-c286 -CHz-N CHz-CHzOH z -N C O N H-CHz-CHz-OCH3 -Ic-c291 -CHz-N(CHz-CHz-N(CH3)1)1 -CH OH -Ic-c292 -CHz-N(CHz-CHz-N(CH3)1)1 N C O N H-CHz-CHz-OH -Ic-c293 -CHz-N(CHz-CHz-N(CH3)1)1 -N(C(O)N(H)-CH2-CH2-F)-Ic-c294 -CHz-N(CHz-CHz-N(CH3)1)1 -N C O N H-CHz-CHz-OCH3 -Ic-c295 -CHz-N(CHz-CHz-N(CH3)1)1 N C O N H-CHz-CHz-CF3 -Ic-c296 -CHz-N(CHz-CHz-N(CH3)2)2N C O N H-CHz-CHz-CF3 -Ic-c297 -CH2-N(CH2-CH2-N(CH3)2)2 -N C O N H-CHz-CF3 -Ic-c298 -CH2-N(CH2-CH2-N(CH3)2)2 -N C O N H CHz 3-OH -Ic-c299 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -CH OH -Ic-c300 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N C O N H-CHz-CHz-OH -Ic-c301 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C O N H-CHz-CHz-F -Ic-c302 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C O N H-CHz-CHz-OCH3 -Ic-c303 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N C O N H-CHz-CHz-CF3 -Ic-c304 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 N C O N H-CHz-CHz-CF3 -Ic-c305 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C O N H-CHz-CF3 -Ic-c306 -CH2-N(CH2-CH2-CH2-N(CH3)2)2 -N C O N H CHz 3-OH -Ic-c307 -CHz-N~ -CH(OH)-Ic-c308 -CH2-N-7 N(C(O)N(H)-CH2-CH2-OH)-Ic-c309 -CHz-N- -N(C(O)N(H)-CH2-CH2-F)-Ic-c310 -CHz-N~ -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c311 -CHz-N~ N(C(O)N(H)-CH2-CH2-CF3)-Ic-c312 -CHz-N N(C(O)N(H)-CH2-CH2-CF3)-Ic-c313 -CHz-N~ -N(C(O)N(H)-CH2-CF3)-Ic-c314 -CHz-N~ -N(C(O)N(H)-(CH2)3-OH)-Ic-c315 -CH2-<> -CH(OH)-Ic-c316 -CHz-<> N(C(O)N(H)-CH2-CH2-OH)-Ic-c317 -CH2-<> -N(C(O)N(H)-CH2-CH2-F)-Ic-c318 -CHz-NC> -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c319 -CHz-Nc> N(C(O)N(H)-CH2-CH2-CF3)-Ic-c320 -CHz-N~> -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c321 -CHz-N~> -N(C(O)N(H)-CH2-CF3)-Ic-c322 -CHz-NC> -N(C(O)N(H)-(CH2)3-OH)-Ic-c323 -CHz-NC) -CH(OH)-Ic-c324 -CHz-NC) -N(C(O)N(H)-CH2-CH2-OH)-Ic-c325 -CH2-No -N(C(O)N(H)-CH2-CH2-F)-Ic-c326 -CHz-No -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c327 -CHz-No -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c328 -CHz-No -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c329 -CHz-No -N(C(O)N(H)-CH2-CF3)-Ic-c330 -CHz-No -N(C(O)N(H)-(CH2)3-OH)-Ic-c331 -CHz-Na -CH(OH)-Ic-c332 -CHz-Na N(C(O)N(H)-CH2-CH2-OH)-Ic-c333 -CHz-Na -N(C(O)N(H)-CH2-CH2-F)-Ic-c334 -CHz-Na -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c335 -CHz-N~ N(C(O)N(H)-CH2-CH2-CF3)-Ic-c336 -CHz-Na N(C(O)N(H)-CH2-CH2-CF3)-Ic-c337 -CHz-Na -N(C(O)N(H)-CH2-CF3)-OH
Ic-c338 -CHz-Na -N(C(O)N(H)-(CH2)3-OH)-OH
Ic-c339 -CHz-N -CH(OH)-Ic-c340 -CHz-N N(C(O)N(H)-CHz-CHz-OH)-Ic-c341 -CHz-N -N(C(O)N(H)-CH2-CH2-F)-Ic-c342 -CHz-N -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c343 -CHz-N N(C(O)N(H)-CH2-CH2-CF3)-Ic-c344 -CHz_N N(C(O)N(H)-CH2-CH2-CF3)-Ic-c345 -CHz_N -N(C(O)N(H)-CH2-CF3)-Ic-c346 -CHz_N -N(C(O)N(H)-(CH2)3-OH)-Ic-c347 -CH2-N. ) -CH(OH)-Ic-c348 -CHz-ND -N(C(O)N(H)-CH2-CH2-OH)-Ic-c349 -CHz-ND -N(C(O)N(H)-CH2-CH2-F)-Ic-c350 -CHz-N--- ~ -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c351 -CHz-N ---~ -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c352 -CHz-N ---D --- -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c353 -CHz-ND -N(C(O)N(H)-CH2-CF3)-Ic-c354 -CHz-ND -N(C(O)N(H)-(CH2)3-OH)-Ic-c355 -CH2-N/-\ N-CH3 -CH(OH)-Ic-c356 -CH2-N/-\ N-CH3 N(C(O)N(H)-CH2-CH2-OH)-Ic-c357 -CH2-N/-\ N-CH3 -N(C(O)N(H)-CH2-CH2-F)-Ic-c358 -CH2-N/-\ N-CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c359 -CH2-N/-\ N-CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c360 -CH2-N/-\ N-CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c361 -CH2-N/-\ N-CH3 -N(C(O)N(H)-CH2-CF3)-Ic-c362 -CH2-N/-\ N-CH3 -N(C(O)N(H)-(CH2)3-OH)-Ic-c363 -CH2-N /CH3 -CH(OH)-Ic-c364 -CH2-N /cH3 N(C(O)N(H)-CHz-CHz-OH)-Ic-c365 --CH2-N /cH3 -N(C(O)N(H)-CHz-CHz-F)-Ic-c366 -CH2-N /cH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c367 -CH2-N /cH3 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c368 -CH2-N /cH3 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c369 -CH2-N /cH3 -N(C(O)N(H)-CH2-CF3)-Ic-c370 -CH2-N /cH3 -N(C(O)N(H)-(CH2)3-OH)-Ic-c371 -CH2-N /cH3 -CH(OH)->-CH3 Ic-c372 -CH2-N /CH3 N(C(O)N(H)-CHz-CHz-OH)->-CH3 Ic-c373 -CH2-N /CH3 -N(C(O)N(H)-CHz-CHz-F)->-CH3 H C
Ic-c374 -CH2-N /CH3 -N(C(O)N(H)-CH2-CH2-OCH3)->-CH3 H C
Ic-c375 -CH2-N /QH3 N(C(O)N(H)-CH2-CH2-CF3)->-CH3 H C
Ic-c376 -CH2-N /QH3 N(C(O)N(H)-CH2-CH2-CF3)->-CH3 H C

Ic-c377 -CH2 -N /CH3 -N(C(O)N(H)-CH2-CF3)->-CH3 Ic-c378 -CH2 -N /QH3 -N(C(O)N(H)-(CH2)3-OH)->-CH3 Ic-c379 -CH2-N /CH3 -CH(OH)-Ic-c380 -CH2-N /CH3 N(C(O)N(H)-CHz-CHz-OH)-Ic-c381 -CH2-N /CH3 -N(C(O)N(H)-CHz-CHz-F)-Ic-c382 -CH2-N /CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c383 -CH2-N /CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c384 -CH2-N /CHs N(C(O)N(H)-CH2-CH2-CF3)-Ic-c385 -CH2-N /CH3 -N(C(O)N(H)-CH2-CF3)-Ic-c386 -CH2-N /CH3 -N(C(O)N(H)-(CH2)3-OH)-Ic-c387 ~ H ~' N~ -CH(OH) -CH2 ~0 Ic-c388 NN(C(O)N(H)-CH2-CH2-OH)-Ic-c389 N-N(C(O)N(H)-CH2-CH2-F)-Ic-c390 ~N-N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c391 "NN(C(O)N(H)-CH2-CH2-CF3)-Ic-c392 ~NN(C(O)N(H)-CH2-CH2-CF3)-Ic-c393 N-N(C(O)N(H)-CH2-CF3)-Ic-c394 N~~N~ -N(C(O)N(H)-(CHz)3-OH)--CH2 ~O
Ic-c395 ~O -CH(OH)-H N~
~
CH -' N
Ic-c396 O N(C(O)N(H)-CHz-CHz-OH)-/NN~/
CH
Ic-c397 CO -N(C(O)N(H)-CH2-CH2-F)-H N,/
CH
Ic-c398 CO -N(C(O)N(H)-CH2-CH2-OCH3)-\ N,/
CH
Ic-c399 O N(C(O)N(H)-CH2-CH2-CF3)-~NN~
CH
Ic-c400 ("-- O N(C(O)N(H)-CH2-CH2-CF3)-~NN~
CH
Ic-c401 (-~ O -N(C(O)N(H)-CH2-CF3)-H N-/
CH -' N
Ic-c402 CO -N(C(O)N(H)-(CH2)3-OH)-\ N,/
CH
Ic-c403 N CH3 -CH(OH)-H

Ic-c404 N CH3 -N(C(O)N(H)-CH2-CH2-OH)-H N--/
\CH2 "I N,,/---,/

Ic-c405 N .cH3 -N(C(O)N(H)-CH2-CH2-F)-H N-/
\CH2~

Ic-c406 N CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-H
/NZ~

Ic-c407 N CH3 -N(C(O)N(H)-CH2-CH2-CF3)-H /NZ~N~/

Ic-c408 N CH3 -N(C(O)N(H)-CH2-CH2-CF3)-H /NZ~N~/

Ic-c409 N CH3 -N(C(O)N(H)-CH2-CF3)-H N-/
\CH2 "I N,,/---,/

Ic-c410 N CH3 -N(C(O)N(H)-(CH2)3-OH)-H N--/
\CH2 "I N,,/---,/

Ic-c411 H3~ -CH(OH)-CH ~NN,CH3 Ic-c412 H3~ -N(C(O)N(H)-CH2-CH2-OH)-H
N, Ic-c413 H3~ -N(C(O)N(H)-CHz-CHz-F)-CH 'N-CH3 Ic-c414 H3~ -N(C(O)N(H)-CHz-CHz-OCH3)-CH ~N~/N`CH3 Ic-c415 H3~ N(C(O)N(H)-CH2-CH2-CF3)-CH ~NN`CH3 Ic-c416 H3~ -N(C(O)N(H)-CH2-CH2-CF3)-H
N, Ic-c417 H3~ -N(C(O)N(H)-CHz-CF3)-CH ~N~/N`CH3 Ic-c418 H3~ -N(C(O)N(H)-(CH2)3-OH)-H N`

Ic-c419 ~ N -CH(OH)-/
H N
\CH /N

Ic-c420 N -N(C(O)N(H)-CH2-CH2-OH)-H N
\CH ~N
Ic-c421 N -N(C(O)N(H)-CH2-CH2-F)-H N
\CH "I N
Ic-c422 N -N(C(O)N(H)-CH2-CH2-OCH3)-N
\CH "I N
Ic-c423 N N(C(O)N(H)-CH2-CH2-CF3)-N
\CH /N

Ic-c424 N N(C(O)N(H)-CH2-CH2-CF3)-N
\CH ~N
Ic-c425 N -N(C(O)N(H)-CH2-CF3)-H N
\CH "I N
Ic-c426 N -N(C(O)N(H)-(CH2)3-OH)-N
\CH 'IN
Ic-c427 -CH(OH)-/
-CH2-N~/ N
Ic-c428 N(C(O)N(H)-CHz-CHz-OH)-/
-CH2-N~/N
Ic-c429 -N(C(O)N(H)-CHz-CHz-F)-~
-CH2-N ~\ N

Ic-c430 -N(C(O)N(H)-CHz-CHz-OCH3)-/
-CH2-N~/ N

Ic-c431 N(C(O)N(H)-CHz-CHz-CF3)-~
-CH2-N~/N
Ic-c432 N(C(O)N(H)-CHz-CHz-CF3)-~
-CH2-N ~\ N

Ic-c433 -N(C(O)N(H)-CHz-CF3)-~
-CH2-N~/N
Ic-c434 -N(C(O)N(H)-(CHz)3-OH)-~
~

Ic-c435 -CH2iV/-\ N F -CH(OH)-~/
Ic-c436 -CHziq /-\ N ~ F N(C(O)N(H)-CHz-CHz-OH)-~/ -Ic-c437 -CH2iV/-\ N ~ ~ F -N(C(O)N(H)-CHz-CHz-F)--Ic-c438 -CHziv/-\ N F -N(C(O)N(H)-CH2-CH2-OCH3)-~/
Ic-c439 -CHziv/-\ N F N(C(O)N(H)-CH2-CH2-CF3)-~/
Ic-c440 -CHziv/-\ N F N(C(O)N(H)-CH2-CH2-CF3)-~/
Ic-c441 -CH2iv/-\ N F -N(C(O)N(H)-CH2-CF3)-~/
Ic-c442 -CH2iv/-\ N ~ F -N(C(O)N(H)-(CH2)3-OH)--Ic-c443 -CH2-N 3-&F -CH(OH)-Ic-c444 -CH2-N ~F -N(C(O)N(H)-CH2-CH2-OH)-Ic-c445 -CH2-N ~F -N(C(O)N(H)-CH2-CH2-F)-Ic-c446 -CHz-N ~F -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c447 -CH2-N ~F N(C(O)N(H)-CH2-CH2-CF3)-Ic-c448 -CHz-N ~F N(C(O)N(H)-CH2-CH2-CF3)-Ic-c449 -CHz-N ~F -N(C(O)N(H)-CH2-CF3)-Ic-c450 -CHz-N ~F -N(C(O)N(H)-(CH2)3-OH)--CH(OH)-Ic-c451 -CH2-N / \

Ic-c452 -CHz-N ~ -N(C(O)N(H)-CH2-CH2-OH)-Ic-c453 -CH2-N -N(C(O)N(H)-CH2-CH2-F)-Ic-c454 -CHz-N -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c455 -CH2-N ~ -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c456 -CHz-N -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c457 -CHz-N O -N(C(O)N(H)-CH2-CF3)-Ic-c458 -CHz-N o -N(C(O)N(H)-(CH2)3-OH)-Ic-c459 -CHz-N CI -CH(OH)-Ic-c460 -CHz-N ~CI -N(C(O)N(H)-CH2-CH2-OH)-Ic-c461 -CHz-N ~CI -N(C(O)N(H)-CH2-CH2-F)-Ic-c462 -CHz-N 3-&CI -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c463 -CHz-N ~CI -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c464 -CHz-N \ / \ ci -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c465 -CHz-N \ / \ ci -N(C(O)N(H)-CH2-CF3)-Ic-c466 -CHz-N \ / \ ci -N(C(O)N(H)-(CH2)3-OH)-Ic-c467 -CHz-N \ / \ -CH(OH)-Ic-c468 -CHz_N \ / \ -N(C(O)N(H)-CH2-CH2-OH)-Ic-c469 -CHz_N \ / \ -N(C(O)N(H)-CH2-CH2-F)-Ic-c470 -CHz_N \ / \ -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c471 -CHz_N \ / \ -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c472 -CHz_N \ / \ -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c473 -CHz_N \ / \ -N(C(O)N(H)-CH2-CF3)-Ic-c474 -CHz-N \ / \ -N(C(O)N(H)-(CH2)3-OH)-Ic-c475 -CHz_N DSHO -CH(OH)-Ic-c476 -CHz-N ~ ~ N(C(O)N(H)-CHz-CHz-OH)-Ic-c477 -CHz-N o -N(C(O)N(H)-CH2-CH2-F)-Ic-c478 -CHz-N /~\ -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c479 -CHz-N ~/~\ N(C(O)N(H)-CH2-CH2-CF3)-Ic-c480 -CHz-N ~ N(C(O)N(H)-CH2-CH2-CF3)-Ic-c481 -CHz_N / \ -N(C(O)N(H)-CH2-CF3)-Ic-c482 -CHz_N / \ -N(C(O)N(H)-(CH2)3-OH)-Ic-c483 -CH2-N /-\ NCH2CH20P(O)(OH)2 -CH(OH)-Ic-c484 -CH2-N /-\ NCH2CH20P(O)(OH)2 -N(C(O)N(H)-CH2-CH2-OH)-Ic-c485 -CH2-N NCH2CH20P(O)(OH)2 -N(C(O)N(H)-CH2-CH2-F)-Ic-c486 -CH2-N NCH2CH2OP(O)(OH)2 -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c487 -CH2-N /-\ NCH2CH20P(O)(OH)2 -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c488 -CH2-N /-\ NCH2CH20P(O)(OH)2 -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c489 -CH2-N /-\ NCH2CH2OP(O)(OH)2 -N(C(O)N(H)-CH2-CF3)-Ic-c490 -CH2-N NCH2CH2OP(O)(OH)2 -N(C(O)N(H)-(CH2)3-OH)-Ic-c491 -CH2-CH2-CH2-OP(O)(OH)2 -CH OH -Ic-c492 -CH2-CH2-CH2-OP(O)(OH)2 N C O N H-CHz-CHz-OH -Ic-c493 -CH2-CH2-CH2-OP(O)(OH)2 -N(C(O)N(H)-CH2-CH2-F)-Ic-c494 -CH2-CH2-CH2-OP(O)(OH)2 -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c495 -CH2-CH2-CH2-OP(O)(OH)2 -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c496 -CH2-CH2-CH2-OP(O)(OH)2 -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c497 -CH2-CH2-CH2-OP(O)(OH)2 -N C O N H-CHz-CF3 -Ic-c498 -CH2-CH2-CH2-OP(O)(OH)2 -N C O N H CHz 3-OH -Ic-c499 -CHz-CHz-CHz-OS(O)zOH -CH OH -Ic-c500 -CHz-CHz-CHz-OS(O)zOH N C O N H-CHz-CHz-OH -Ic-c501 -CHz-CHz-CHz-OS(O)zOH -N C O N H-CHz-CHz-F -Ic-c502 -CHz-CHz-CHz-OS(O)zOH -N C O N H-CHz-CHz-OCH3 -Ic-c503 -CHz-CHz-CHz-OS(O)zOH N(C(O)N(H)-CH2-CH2-CF3)-Ic-c504 -CHz-CHz-CHz-OS(O)zOH N C O N H-CHz-CHz-CF3 -Ic-c505 -CHz-CHz-CHz-OS(O)zOH -N C O N H-CHz-CF3 -Ic-c506 -CHz-CHz-CHz-OS(O)zOH -N(C(O)N(H)-(CH2)3-OH)-Ic-c507 -CH2-Na -CH(OH)-OP O OH
Ic-c508 -CHz-Na N(C(O)N(H)-CHz-CHz-OH)-OP O OH
Ic-c509 -CHz-Na -N(C(O)N(H)-CHz-CHz-F)-OP O OH
Ic-c510 -CHz-NC( -N(C(O)N(H)-CH2-CH2-OCH3)-OP O OH
Ic-c511 -CHz-Na N(C(O)N(H)-CH2-CH2-CF3)-OP O OH
Ic-c512 -CHz-Na N(C(O)N(H)-CH2-CH2-CF3)-OP O OH
Ic-c513 -CHz-Na -N(C(O)N(H)-CH2-CF3)-OP O OH
Ic-c514 -CH2-NC( -N(C(O)N(H)-(CH2)3-OH)-OP O OH
Ic-c515 -CH2-N -CH(OH)-OP O OH
Ic-c516 -CHz-N N(C(O)N(H)-CHz-CHz-OH)-OP O OH
Ic-c517 -CH2-N -N(C(O)N(H)-CHz-CHz-F)-OP O OH
Ic-c518 -CH2-N -N(C(O)N(H)-CH2-CH2-OCH3)-OP O OH
Ic-c519 -CH2-N N(C(O)N(H)-CH2-CH2-CF3)-OP O OH

Ic-c520 -CHz-N N(C(O)N(H)-CH2-CH2-CF3)-OP O OH
Ic-c521 -CH2-N -N(C(O)N(H)-CH2-CF3)-OP O OH
Ic-c522 -CHz-N -N(C(O)N(H)-(CH2)3-OH)-OP O OH
Ic-c523 -(CH2)io-N(CH2-CH2-O-CH3)2 -CH(OH)-Ic-c524 -(CH2),o-N(CH2-CH2-O-CH3)2 N C O N H-CHz-CHz-OH -Ic-c525 -(CH2),o-N(CH2-CH2-O-CH3)2 -N C O N H-CHz-CHz-F -Ic-c526 -(CH2),o-N(CH2-CH2-0-CH3)2 -N C O N H-CHz-CHz-OCH3 -Ic-c527 -(CH2),o-N(CH2-CH2-0-CH3)2 N C O N H-CHz-CHz-CF3 -Ic-c528 -(CH2),o-N(CH2-CH2-0-CH3)2 N C O N H-CHz-CHz-CF3 -Ic-c529 -(CH2),o-N(CH2-CH2-O-CH3)2 -N C O N H-CHz-CF3 -Ic-c530 -(CH2),o-N(CH2-CH2-O-CH3)2 -N C O N H CHz 3-OH -Ic-c531 -CH2-N(CH2-CH2-O-CH3)2 -CH OH -Ic-c532 -CH2-N(CH2-CH2-O-CH3)2 N C O N H-CHz-CHz-OH -Ic-c533 -CH2-N(CH2-CH2-O-CH3)2 -N C O N H-CHz-CHz-F -Ic-c534 -CH2-N(CH2-CH2-O-CH3)2 -N C O N H-CHz-CHz-OCH3 -Ic-c535 -CH2-N(CH2-CH2-O-CH3)2 N C O N H-CHz-CHz-CF3 -Ic-c536 -CH2-N(CH2-CH2-0-CH3)2 N C O N H-CHz-CHz-CF3 -Ic-c537 -CH2-N(CH2-CH2-O-CH3)2 -N C O N H-CHz-CF3 -Ic-c538 -CH2-N(CH2-CH2-O-CH3)2 -N C O N H CHz 3-OH -Ic-c539 /-N~ -CH(OH)-Ic-c540 -N N(C(O)N(H)-CHz-CHz-OH)-Ic-c541 -N(C(O)N(H)-CHz-CHz-F)-~N _ Ic-c542 -N -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c543 N(C(O)N(H)-CH2-CH2-CF3)-~
Ic-c544 -N N(C(O)N(H)-CH2-CH2-CF3)-Ic-c545 -N(C(O)N(H)-CH2-CF3)-~N
~
Ic-c546 -N(C(O)N(H)-(CH2)3-OH)-~N

Ic-c547 /-Na -CH(OH)-OH
Ic-c548 /-NaN(C(O)N(H)-CHz-CHz-OH)-OH
Ic-c549 /-Na -N(C(O)N(H)-CHz-CHz-F)-OH
Ic-c550 /-Na -N(C(O)N(H)-CH2-CH2-OCH3)-OH
Ic-c551 /-NaN(C(O)N(H)-CHz-CHz-CF3)-OH
Ic-c552 /-NaN(C(O)N(H)-CHz-CHz-CF3)-OH
Ic-c553 /-Na -N(C(O)N(H)-CH2-CF3)-OH
Ic-c554 /-Na -N(C(O)N(H)-(CH2)3-OH)-OH
Ic-c555 ~lqlo- No -CH(OH)-Ic-c556 lqlo- No -N(C(O)N(H)-CH2-CH2-OH)-Ic-c557 lqlo- No -N(C(O)N(H)-CH2-CH2-F)-Ic-c558 ~lqlo- No -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c559 lqlo- No -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c560 ~lqlo- No -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c561 -N(C(O)N(H)-CH2-CF3)--N(C(O)N(H)-(CH2)3-OH)-Ic-c562 Ic-c563 -CH(OH)-Ic-c564 Ic-c564 v N(C(O)N(H)-CHz-CHz-OH)-~N N~

Ic-c565 v -N(C(O)N(H)-CHz-CHz-F)-~N N~

Ic-c566 N Nv -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c567 Ic-c567 -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c568 Ic-c568 N -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c569 Ic-c569 v N -N(C(O)N(H)-CH2-CF3)-~ N

Ic-c570 v N Nv -N(C(O)N(H)-(CH2)3-OH)-Ic-c571 Ic-c571 -CH(OH)-~N
HO
Ic-c572 N(C(O)N(H)-CHz-CHz-OH)-N
/-HO
Ic-c573 -N(C(O)N(H)-CHz-CHz-F)-N
/-HO
Ic-c574 -N(C(O)N(H)-CH2-CH2-OCH3)-N
/-HO
Ic-c575 N(C(O)N(H)-CHz-CHz-CF3)-~N
HO
Ic-c576 N(C(O)N(H)-CH2-CH2-CF3)-N
/-HO
Ic-c577 -N(C(O)N(H)-CHz-CF3)-~N
HO
Ic-c578 -N(C(O)N(H)-(CH2)3-OH)-/-N
HO
Ic-c579 -CH(OH)-X/-N

O
O Me Ic-c580 N(C(O)N(H)-CHz-CHz-OH)-X/-N

O
O Me Ic-c581 -N(C(O)N(H)-CHz-CHz-F)-N

O
O Me Ic-c582 -N(C(O)N(H)-CH2-CH2-OCH3)-N

O
O Me Ic-c583 N(C(O)N(H)-CH2-CH2-CF3)-N

O
O Me Ic-c584 N(C(O)N(H)-CH2-CH2-CF3)-N

O
O Me Ic-c585 -N(C(O)N(H)-CH2-CF3)-N

O
O Me Ic-c586 -N(C(O)N(H)-(CH2)3-OH)-N

O
O Me Ic-c587 N -CH(OH)-Ic-c588 /
Ic-c588 N -N(C(O)N(H)-CH2-CH2-OH)-Ic-c589 Ic-c589 N -N(C(O)N(H)-CH2-CH2-F)-Ic-c590 Ic-c590 N -N(C(O)N(H)-CH2-CH2-OCH3)-~
Ic-c591 N(C(O)N(H)-CH2-CH2-CF3)-~

Ic-c592 N -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c593 Ic-c593 N -N(C(O)N(H)-CH2-CF3)-Ic-c594 Ic-c594 N -N(C(O)N(H)-(CH2)3-OH)-Ic-c595 Ic-c595 -CH(OH)-No Ic-c596 N(C(O)N(H)-CHz-CHz-OH)-~

No Ic-c597 -N(C(O)N(H)-CHz-CHz-F)-~

No Ic-c598 -N(C(O)N(H)-CHz-CHz-OCH3)-No Ic-c599 N(C(O)N(H)-CHz-CHz-CF3)-No Ic-c600 N(C(O)N(H)-CHz-CHz-CF3)-No Ic-c601 -N(C(O)N(H)-CHz-CF3)-No Ic-c602 -N(C(O)N(H)-(CHz)3-OH)-No Ic-c603 -CH(OH)-I-N\-/ N--\\_,,N(CHa) Ic-c604 N(C(O)N(H)-CHz-CHz-OH)-[-N\__/N--\,_,N(CHa) Ic-c605 -N(C(O)N(H)-CHz-CHz-F)-[-N\__/N--\\,,-N(CHa) Ic-c606 -N(C(O)N(H)-CHz-CHz-OCH3)-[-N\_/N--\,,N(CHa) Ic-c607 N(C(O)N(H)-CH2-CH2-CF3)-I-N\-/ N--\\_,,N(CHa) Ic-c608 N(C(O)N(H)-CHz-CHz-CF3)-[-N\__/N--\_,-N(CHa) Ic-c609 -N(C(O)N(H)-CHz-CF3)-[-N\__/N--\\,,-N(CHa) Ic-c610 -N(C(O)N(H)-(CHz)3-OH)-[-N\__/N--\\,,,N(CHa) Ic-c611 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -CH OH -Ic-c612 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N(C(O)N(H)-CH2-CH2-OH)-Ic-c613 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N(C(O)N(H)-CH2-CH2-F)-Ic-c614 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C O N H-CHz-CHz-OCH3 -Ic-c615 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c616 -CH2-NH-CH2-CH2-CH2-N(CH3)2 N C O N H-CHz-CHz-CF3 -Ic-c617 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C O N H-CHz-CF3 -Ic-c618 -CH2-NH-CH2-CH2-CH2-N(CH3)2 -N C O N H CHz 3-OH -Ic-c619 0 -CH(OH)-NCO

Ic-c620 0 N(C(O)N(H)-CHz-CHz-OH)-~NC I ~

Ic-c621 0 -N(C(O)N(H)-CHz-CHz-F)-~NCI ~

Ic-c622 0 -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c623 O N(C(O)N(H)-CHz-CHz-CF3)-~NC I

Ic-c624 0 N(C(O)N(H)-CHz-CHz-CF3)-NCO

Ic-c625 0 -N(C(O)N(H)-CH2-CF3)-~NC I

Ic-c626 0 -N(C(O)N(H)-(CH2)3-OH)-~N~ I

Ic-c627 /~",OH -CH(OH)-~N, Ic-c628 v/~",OH N(C(O)N(H)-CHz-CHz-OH)-~N, Ic-c629 v/~",OH -N(C(O)N(H)-CHz-CHz-F)-~N, Ic-c630 v/~",OH -N(C(O)N(H)-CHz-CHz-OCH3)-~N, Ic-c631 v/~",OH N(C(O)N(H)-CHz-CHz-CF3)-~N, Ic-c632 v/~",OH N(C(O)N(H)-CHz-CHz-CF3)-~N, Ic-c633 v/~",OH -N(C(O)N(H)-CHz-CF3)-~N, Ic-c634 v/~",OH -N(C(O)N(H)-(CHz)3-OH)-~N, Ic-c635 -CH(OH)-HO
Ic-c636 N(C(O)N(H)-CHz-CHz-OH)-Ic-c637 -N(C(O)N(H)-CHz-CHz-F)-HO
Ic-c638 -N(C(O)N(H)-CH2-CH2-OCH3)-HO
Ic-c639 N(C(O)N(H)-CH2-CH2-CF3)-HO
Ic-c640 N(C(O)N(H)-CH2-CH2-CF3)-HO
Ic-c641 -N(C(O)N(H)-CH2-CF3)-HO
Ic-c642 -N(C(O)N(H)-(CH2)3-OH)-HO
Ic-c643 ,CH3 -CH(OH)-~N
~CH3 Ic-c644 ,CH3 N(C(O)N(H)-CHz-CHz-OH)-/~,-N
/-\- C H 3 \

Ic-c645 ,CH3 -N(C(O)N(H)-CHz-CHz-F)-/-N

Ic-c646 ,CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-/~,-N
/\- C H 3 Ic-c647 ,CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N

Ic-c648 ,CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N
/\-CH3 Ic-c649 ,CH3 -N(C(O)N(H)-CH2-CF3)-/\-CH3 Ic-c650 ,CH3 -N(C(O)N(H)-(CH2)3-OH)-//-N

Ic-c651 -CH(OH)-Ic-c652 -N(C(O)N(H)-CH2-CH2-OH)-Ic-c653 -N(C(O)N(H)-CH2-CH2-F)--N(C(O)N(H) CHz CHz-OCH3)-Ic-c654 O
Ic-c655 -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c656 -N(C(O)N(H)-CH2-CH2-CF3)--N(C(O)N(H) CHz CF3) Ic-c657 Ic-c658 -N(C(O)N(H)-(CH2)3-OH)-Ic-c659 \-N OH -CH(OH)-Ic-c660 \_N OH -N(C(O)N(H)-CH2-CH2-OH)-Ic-c661 \_N OH -N(C(O)N(H)-CH2-CH2-F)-Ic-c662 \_N OH -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c663 \\_N OH -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c664 \\_N OH -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c665 \\_N OH -N(C(O)N(H)-CH2-CF3)-Ic-c666 \\_N oH -N(C(O)N(H)-(CH2)3-OH)-Ic-c667 N OH -CH(OH)-Ic-c668 a OH N(C(O)N(H)-CH2-CH2-OH)-Ic-c669 cr OH -N(C(O)N(H)-CH2-CH2-F)-Ic-c670 a OH -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c671 a OH N(C(O)N(H)-CH2-CH2-CF3)-Ic-c672 a OH N(C(O)N(H)-CH2-CH2-CF3)-Ic-c673 a OH -N(C(O)N(H)-CH2-CF3)-Ic-c674 cJOH -N(C(O)N(H)-(CH2)3-OH)-Ic-c675 NH -CH(OH)-Ic-c676 NH -N(C(O)N(H)-CH2-CH2-OH)-Ic-c677 NH -N(C(O)N(H)-CH2-CH2-F)-Ic-c678 NH -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c679 NH -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c680 NH -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c681 NH -N(C(O)N(H)-CH2-CF3)-Ic-c682 NH -N(C(O)N(H)-(CH2)3-OH)-Ic-c683 /-NH -CH(OH)-Ic-c684 //-NH -N(C(O)N(H)-CH2-CH2-OH)-Ic-c685 //-NH -N(C(O)N(H)-CH2-CH2-F)-Ic-c686 Ilo---NH -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c687 Ilo---NH -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c688 //-NH -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c689 Ilo---NH -N(C(O)N(H)-CH2-CF3)-Ic-c690 //-NH -N(C(O)N(H)-(CH2)3-OH)-Ic-c691 /-NH -CH(OH)-Ic-c692 /cH2CH3 N(C(O)N(H)-CHz-CHz-OH)-Ic-c693 /cH2CH3 -N(C(O)N(H)-CHz-CHz-F)-Ic-c694 /CH2CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c695 /cH2CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c696 "CH2CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c697 / CH2CH3 -N(C(O)N(H)-CH2-CF3)-Ic-c698 /cH2CH3 -N(C(O)N(H)-(CH2)3-OH)-Ic-c699 /cH2CH3 -CH(OH)-Ic-c700 /-NH N(C(O)N(H)-CH2-CH2-OH)-D Ic-c701 /-NH -N(C(O)N(H) CHz CHz F) D

Ic-c702 /-NH -N(C(O)N(H)-CH2-CH2-OCH3)-D Ic-c703 /-NH N(C(O)N(H)-CH2-CH2-CF3)-D Ic-c704 /-NH N(C(O)N(H)-CH2-CH2-CF3)-D Ic-c705 /-NH -N(C(O)N(H)-CH2-CF3)-D
Ic-c706 /-NH -N(C(O)N(H)-(CH2)3-OH)-D 383 -Ic-c707 /-NH -CH(OH)-D Ic-c708 /-NH N(C(O)N(H)-CH2-CH2-OH)-D Ic-c709 /-NH -N(C(O)N(H)-CH2-CH2-F)-D Ic-c710 /-NH -N(C(O)N(H)-CH2-CH2-OCH3)-D Ic-c711 /-NH
N(C(O)N(H)-CH2-CH2-CF3)-D Ic-c712 /-NH N(C(O)N(H)-CH2-CH2-CF3)-D Ic-c713 /-NH -N(C(O)N(H)-CH2-CF3)-D Ic-c714 /-NH -N(C(O)N(H)-(CH2)3-OH)-D Ic-c715 -CH(OH)-Ic-c716 ~N 5 N(C(O)N(H)-CHz-CHz-OH)-Ic-c717 X/-N /-\ S -N(C(O)N(H)-CHz-CHz-F)-Ic-c718 -N 5 -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c719 -N 5 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c720 -N /-\ N(C(O)N(H)-CH2-CH2-CF3)-Ic-c721 -N /-\ s -N(C(O)N(H)-CH2-CF3)-Ic-c722 -N /-\ -N(C(O)N(H)-(CH2)3-OH)-Ic-c723 N\~ -CH(OH)-Ic-c724 -N(C(O)N(H)-CH2-CH2-OH)-N\~ -N(C(O)N(H)-CHz-CHz-F)-Ic-c725 Ic-c726 -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c727 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c728 -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c729 -N(C(O)N(H)-CH2-CF3)-N\~ -N(C(O)N(H)-(CH2)3-OH)-Ic-c730 Ic-c731 /-NH -CH(OH)-H C
Ic-c732 /-NH N(C(O)N(H)-CHz-CHz-OH)-H C
Ic-c733 /-NH -N(C(O)N(H)-CH2-CH2-F)-H C
Ic-c734 /-NH -N(C(O)N(H)-CH2-CH2-OCH3)-H C
Ic-c735 /-NH N(C(O)N(H)-CHz-CHz-CF3)-H C

Ic-c736 /-NH N(C(O)N(H)-CHz-CHz-CF3)-H C
Ic-c737 /-NH -N(C(O)N(H)-CH2-CF3)-H C
Ic-c738 /-NH -N(C(O)N(H)-(CH2)3-OH)-H C
Ic-c739 CH3 -CH(OH)-N

Ic-c740 CH3 N(C(O)N(H)-CHz-CHz-OH)-~N N

Ic-c741 CH3 -N(C(O)N(H)-CHz-CHz-F)-N

Ic-c742 CH3 -N(C(O)N(H)-CHz-CHz-OCH3)-~N N

Ic-c743 CH3 N(C(O)N(H)-CH2-CH2-CF3)-N

Ic-c744 CH3 N(C(O)N(H)-CHz-CHz-CF3)-~N N

Ic-c745 CH3 -N(C(O)N(H)-CH2-CF3)-N

Ic-c746 CH3 -N(C(O)N(H)-(CHz)3-OH)-~N N

Ic-c747 CH3 -CH(OH)-~N
Ic-c748 CH3 N(C(O)N(H)-CH2-CH2-OH)-N
Ic-c749 CH3 -N(C(O)N(H)-CH2-CH2-F)-N
Ic-c750 CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-~N
Ic-c751 CH3 N(C(O)N(H)-CH2-CH2-CF3)-N
Ic-c752 CH3 N(C(O)N(H)-CH2-CH2-CF3)-N
Ic-c753 CH3 -N(C(O)N(H)-CH2-CF3)-~N
Ic-c754 CH3 -N(C(O)N(H)-(CH2)3-OH)-~N

Ic-c755 NH -CH(OH)-0 OH

Ic-c756 NH 0 N(C(O)N(H)-CH2-CH2-OH)-Ic-c757 NH -N(C(O)N(H)-CH2-CH2-F)-0 Ic-c758 ~NH -N(C(O)N(H)-CH2-CH2-OCH3)-0 Ic-c759 ~NH 0 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c760 NH 0 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c761 NH -N(C(O)N(H)-CH2-CF3)-0 Ic-c762 NH -N(C(O)N(H)-(CH2)3-OH)-0 Ic-c763 /-N-*,-~ OH -CH(OH)-Ic-c764 //--N--~ OH N(C(O)N(H)-CH2-CH2-OH)-Ic-c765 /-N-,-~ OH -N(C(O)N(H)-CH2-CH2-F)-Ic-c766 OH -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c767 OH N(C(O)N(H)-CH2-CH2-CF3)-Ic-c768 OH N(C(O)N(H)-CH2-CH2-CF3)-Ic-c769 N-*,-~ OH -N(C(O)N(H)-CH2-CF3)-Ic-c770 OH -N(C(O)N(H)-(CH2)3-OH)-Ic-c771 /-ND-CH3 -CH(OH)-~ rCH3 -N(C(O)N(H)-CH2-CH2-OH)-Ic-c772 /-N--Ic-c773 /-N D-CH3 -N(C(O)N(H)-CH2-CH2-F)-Ic-c774 /-ND-CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c775 /-N~ rCH N(C(O)N(H)-CHz-CHz-CF3)-~--/ 3 Ic-c776 /-ND-CH3 -N(C(O)N(H)-CH2-CH2-CF3)-~ rCH3 -N(C(O)N(H)-CH2-CF3)-Ic-c777 /-N--Ic-c778 /-N D-CH3 -N(C(O)N(H)-(CH2)3-OH)-Ic-c779 -CH2-NH-CH3 -CH OH -Ic-c780 -CH2-NH-CH3 N C O N H-CHz-CHz-OH -Ic-c781 -CH2-NH-CH3 -N C O N H-CHz-CHz-F -Ic-c782 -CH2-NH-CH3 -N C O N H-CHz-CHz-OCH3 -Ic-c783 -CH2-NH-CH3 N C O N H-CHz-CHz-CF3 -Ic-c784 -CH2-NH-CH3 N C O N H-CHz-CHz-CF3 -Ic-c785 -CH2-NH-CH3 -N C O N H-CHz-CF3 -Ic-c786 -CH2-NH-CH3 -N C O N H CHz 3-OH -Ic-c787 -CH2-NH-CH2-CH3 -CH OH -Ic-c788 -CH2-NH-CH2-CH3 N C O N H-CHz-CHz-OH -Ic-c789 -CH2-NH-CH2-CH3 -N(C(O)N(H)-CH2-CH2-F)-Ic-c790 -CH2-NH-CH2-CH3 -N C O N H-CHz-CHz-OCH3 -Ic-c791 -CH2-NH-CH2-CH3 N C O N H-CHz-CHz-CF3 -Ic-c792 -CH2-NH-CH2-CH3 -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c793 -CH2-NH-CH2-CH3 -N C O N H-CHz-CF3 -Ic-c794 -CH2-NH-CH2-CH3 -N C O N H CHz 3-OH -Ic-c795 -CHz-NH-CHz-CHz-CH3 -CH OH -Ic-c796 -CH2-NH-CH2-CH2-CH3 N C O N H-CHz-CHz-OH -Ic-c797 -CH2-NH-CH2-CH2-CH3 -N C O N H-CHz-CHz-F -Ic-c798 -CH2-NH-CH2-CH2-CH3 -N C O N H-CHz-CHz-OCH3 -Ic-c799 -CH2-NH-CHz-CHz-CH3 N C O N H-CHz-CHz-CF3 -Ic-c800 -CH2-NH-CH2-CH2-CH3 N C O N H-CHz-CHz-CF3 -Ic-c801 -CH2-NH-CH2-CH2-CH3 -N C O N H-CHz-CF3 -Ic-c802 -CH2-NH-CH2-CH2-CH3 -N C O N H CHz 3-OH -Ic-c803 H3C -CH(OH)-\-N \rCH3 Ic-c804 H3C \ N(C(O)N(H)-CHz-CHz-OH)-~NrCH3 Ic-c805 H3C \ -N(C(O)N(H)-CHz-CHz-F)-~NrCH3 H
Ic-c806 ~~ CH -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c807 H3C \ N(C(O)N(H)-CHz-CHz-CF3)-~NrCH3 Ic-c808 ~~~CH N(C(O)N(H)-CHz-CHz-CF3)-Ic-c809 ~~~CH -N(C(O)N(H)-CHz-CF3)-Ic-c810 H3C \ -N(C(O)N(H)-(CHz)3-OH)-~NrCH3 H
Ic-c811 H3C -CH(OH)-H
I-N
OMe Ic-c812 H3C N(C(O)N(H)-CH2-CH2-OH)-H
I-N
OMe Ic-c813 H3C -N(C(O)N(H)-CH2-CH2-F)-H
I-N
OMe Ic-c814 H3C -N(C(O)N(H)-CH2-CH2-OCH3)-H
I-N
OMe Ic-c815 H3C N(C(O)N(H)-CH2-CH2-CF3)-H
I-N
OMe Ic-c816 H3C N(C(O)N(H)-CH2-CH2-CF3)-H
I-N
OMe O
Ic-c817 H3C -N(C(O)N(H)-CH2-CF3)-H
I-N
OMe O
Ic-c818 H3C -N(C(O)N(H)-(CH2)3-OH)-H
I-N
OMe O
Ic-c819 H3C -CH(OH)-~-CH3 ZI-N

>---CH3 H C
Ic-c820 H3C N(C(O)N(H)-CH2-CH2-OH)-~-CH3 ZI-N
>---CH3 H C

Ic-c821 H3C -N(C(O)N(H)-CH2-CH2-F)-~-CH3 >---CH3 H C
Ic-c822 H3C -N(C(O)N(H)-CH2-CH2-OCH3)-~-CH3 >---CH3 H C
Ic-c823 H3C N(C(O)N(H)-CH2-CH2-CF3)-~-CH3 ZI-N
~H3 H C
Ic-c824 H3C N(C(O)N(H)-CH2-CH2-CF3)-~-CH3 ZI-N
>---CH3 H C
Ic-c825 H3C -N(C(O)N(H)-CH2-CF3)-~-CH3 ZI-N
~H3 H C
Ic-c826 H3C -N(C(O)N(H)-(CH2)3-OH)-~-CH3 ZI-N
>---CH3 H C
Ic-c827 -CH(OH)-N
Ic-c828 N(C(O)N(H)-CHz-CHz-OH)-N
Ic-c829 -N(C(O)N(H)-CHz-CHz-F)-N
Ic-c830 -N(C(O)N(H)-CH2-CH2-OCH3)-N
Ic-c831 N(C(O)N(H)-CH2-CH2-CF3)-N
Ic-c832 N(C(O)N(H)-CH2-CH2-CF3)-N

Ic-c833 -N(C(O)N(H)-CH2-CF3)-Ic-c834 Ic-c834 -N(C(O)N(H)-(CH2)3-OH)-N
Ic-c835 CH3CH2 N -CH(OH)-N
Ic-c836 CH3CHz N N(C(O)N(H)-CHz-CHz-OH)-~
--/ N
Ic-c837 CH3CH,2 // N -N(C(O)N(H)-CHz-CHz-F)-N
Ic-c838 CH3CHi2 N -N(C(O)N(H)-CH2-CH2-OCH3)---/ N
Ic-c839 CH3CH,2 N N(C(O)N(H)-CH2-CH2-CF3)-N
Ic-c840 CH3CH2 N N(C(O)N(H)-CH2-CH2-CF3)-, N
Ic-c841 CH3CHz N -N(C(O)N(H)-CH2-CF3)-i --/ N
Ic-c842 CH3CH,2 // N -N(C(O)N(H)-(CH2)3-OH)-N
Ic-c843 ~ CH3 -CH(OH)--CH CH OH
Ic-c844 CH3 N(C(O)N(H)-CHz-CHz-OH)-~N-CH CH OH
Ic-c845 CH3 -N(C(O)N(H)-CHz-CHz-F)-~N-CH CH OH
Ic-c846 CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-~N-CH CH OH
Ic-c847 CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N-CH CH OH
Ic-c848 CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N-CH CH OH
Ic-c849 CH3 -N(C(O)N(H)-CH2-CF3)-~N-CH CH OH
FK CH3 -N(C(O)N(H)-(CHz)3-OH)-~-CH CH OH

Ic-c851 -CH(OH)-Ic-c852 /-NaNo N(C(O)N(H)-CH2-CH2-OH)-Ic-c853 //-NaNo -N(C(O)N(H)-CH2-CH2-F)-Ic-c854 -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c855 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c856 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c857 -N(C(O)N(H)-CH2-CF3)-Ic-c858 -N(C(O)N(H)-(CH2)3-OH)-Ic-c859 -CH(OH)-Ic-c860 -N(C(O)N(H)-CH2-CH2-OH)-Ic-c861 -N(C(O)N(H)-CH2-CH2-F)-Ic-c862 -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c863 -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c864 -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c865 -N(C(O)N(H)-CH2-CF3)-Ic-c866 -N(C(O)N(H)-(CH2)3-OH)-//-N~
N
Ic-c867 ~ C -CH(OH)-N\CH3~ ~
Ic-c868 \-N~ N(C(O)N(H)-CHz-CHz-OH)-\CH /
Ic-c869 ~ C -N(C(O)N(H)-CHz-CHz-F)-N\CH I ~

Ic-c870 -N(C(O)N(H)-CHz-CHz-OCH3)-CH D/, Ic-c871 N~'~C~ N(C(O)N(H)-CHz-CHz-CF3)-~CHII~~

Ic-c872 N1 N(C(O)N(H)-CH2-CH2-CF3)-\CH /
Ic-c873 \-N,~ -N(C(O)N(H) CHz CF3) \CH /
Ic-c874 N -N(C(O)N(H)-(CH2)3-OH)-\CH
Ic-c875 -CH(OH)-//-NH N

Ic-c876 N(C(O)N(H)-CHz-CHz-OH)-//-NH N

Ic-c877 -N(C(O)N(H)-CH2-CH2-F)-Ic-c878 Ic-c878 -N(C(O)N(H)-CH2-CH2-OCH3)-/,---NH N,, Ic-c879 N(C(O)N(H)-CH2-CH2-CF3)-//-NH N

Ic-c880 N(C(O)N(H)-CH2-CH2-CF3)-//-NH N~

Ic-c881 -N(C(O)N(H)-CH2-CF3)-//-NH N~

Ic-c882 -N(C(O)N(H)-(CH2)3-OH)-//-NH N

Ic-c883 ~ ~ H3 -CH(OH)-NH N

Ic-c884 ~ Hs N(C(O)N(H)-CHz-CHz-OH)-NH N

Ic-c885 ~ H3 -N(C(O)N(H)-CHz-CHz-F)-NH N

Ic-c886 ~ H3 -N(C(O)N(H)-CH2-CH2-OCH3)-NH N

Ic-c887 ~ H3 N(C(O)N(H)-CHz-CHz-CF3)-NH N

Ic-c888 ~ H3 N(C(O)N(H)-CHz-CHz-CF3)-NH N

Ic-c889 ~ H3 -N(C(O)N(H)-CH2-CF3)-NH N

Ic-c890 ~ H3 -N(C(O)N(H)-(CH2)3-OH)-NH N

Ic-c891 -CH(OH)-/-N\ /N H
Ic-c892 N(C(O)N(H)-CHz-CHz-OH)-/-N\ N H
Ic-c893 -N(C(O)N(H)-CHz-CHz-F)-/-N\ N H
Ic-c894 -N(C(O)N(H)-CH2-CH2-OCH3)-/-N\ N H
Ic-c895 N(C(O)N(H)-CH2-CH2-CF3)-/-N\ N H
Ic-c896 N(C(O)N(H)-CH2-CH2-CF3)-/-N\ /N H
Ic-c897 -N(C(O)N(H)-CH2-CF3)-/-N\ N H
Ic-c898 -N(C(O)N(H)-(CH2)3-OH)-/-N\ N H
Ic-c899 CH3 -CH(OH)-~N\

Ic-c900 CH3 N(C(O)N(H)-CHz-CHz-OH)-~N\

Ic-c901 CH3 -N(C(O)N(H)-CHz-CHz-F)-~N\

Ic-c902 CH3 -N(C(O)N(H)-CH2-CH2-OCH3)-~N\

Ic-c903 CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N\

Ic-c904 CH3 N(C(O)N(H)-CH2-CH2-CF3)-~N\

Ic-c905 CH3 -N(C(O)N(H)-CH2-CF3)-~N\

Ic-c906 CH3 -N(C(O)N(H)-(CH2)3-OH)-~N\

Ic-c907 //-N H -CH(OH)-Ic-c908 N(C(O)N(H)-CH2-CH2-OH)-Ic-c909 //-N V H -N(C(O)N(H)-CH2-CH2-F)-Ic-c910 /,---N H -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c911 //-N ~ N(C(O)N(H)-CHz-CHz-CF3)-Ic-c912 //-N N(C(O)N(H)-CHz-CHz-CF3)-Ic-c913 /,--N ~ -N(C(O)N(H)-CH2-CF3)-Ic-c914 //-N -N(C(O)N(H)-(CH2)3-OH)-Ic-c915 \-\ -CH(OH)-~~ ~~ OH

Ic-c916 \-\ N(C(O)N(H)-CHz-CHz-OH)-~~ ~~ OH

Ic-c917 \-\ -N(C(O)N(H)-CHz-CHz-F)-~~ ~~ OH

Ic-c918 \-\ -N(C(O)N(H)-CHz-CHz-OCH3)-~~ ~~ OH

Ic-c919 \-\ N(C(O)N(H)-CHz-CHz-CF3)-~~ ~~ OH

Ic-c920 \-\ N(C(O)N(H)-CHz-CHz-CF3)-~~ ~~ OH

Ic-c921 \-\ -N(C(O)N(H)-CHz-CF3)-~~ ~~ OH

Ic-c922 \-\ -N(C(O)N(H)-(CHz)3-OH)-~~ ~~ OH

Ic-c923 ~ \ -CH(OH)-~% ~~CH3 Ic-c924 ~ \ N(C(O)N(H)-CHz-CHz-OH)-~% ~~CH3 Ic-c925 ~ \ -N(C(O)N(H)-CHz-CHz-F)-~% ~ ~/CH3 Ic-c926 ~ \ -N(C(O)N(H)-CHz-CHz-OCH3)-~% ~/CH3 Ic-c927 ~ \ N(C(O)N(H)-CHz-CHz-CF3)-~% ~ ~/CH3 Ic-c928 ~ \ N(C(O)N(H)-CHz-CHz-CF3)-~% ~CH3 Ic-c929 ~ \ -N(C(O)N(H)-CH2-CF3)-~% ~~CH3 Ic-c930 ~ \ -N(C(O)N(H)-(CH2)3-OH)-~% ~CH3 Ic-c931 -CH(OH)-N N
Ic-c932 N(C(O)N(H)-CHz-CHz-OH)-~N N
Ic-c933 -N(C(O)N(H)-CHz-CHz-F)-~N N
Ic-c934 -N(C(O)N(H)-CH2-CH2-OCH3)-~ Nr-\ N

Ic-c935 N(C(O)N(H)-CH2-CH2-CF3)-~ Nr-\ N
v Ic-c936 N(C(O)N(H)-CH2-CH2-CF3)-~N N
v Ic-c937 -N(C(O)N(H)-CH2-CF3)-~N N
v Ic-c938 -N(C(O)N(H)-(CH2)3-OH)-\-N/--N N

Ic-c939 \~NO-OEt -CH(OH)-Ic-c940 \_ND_OEt -N(C(O)N(H)-CH2-CH2-OH)-Ic-c941 \\-NaOEt -N(C(O)N(H)-CH2-CH2-F)-Ic-c942 \_NaOEt -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c943 \_NaOEt -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c944 \_NaOEt -N(C(O)N(H)-CH2-CH2-CF3)-Ic-c945 \\-NaOEt -N(C(O)N(H)-CH2-CF3)-Ic-c946 \~NO-OEt -N(C(O)N(H)-(CH2)3-OH)-Ic-c947 -CH(OH)-/-N Q~ H
Ic-c948 N N(C(O)N(H)-CHz-CHz-OH)-/,- Q~ H
Ic-c949 N -N(C(O)N(H)-CHz-CHz-F)-/- Q~ H
N -N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c950 /-OH
Ic-c951 N(C(O)N(H)-CH2-CH2-CF3)-/- Q~ H
Ic-c952 N N(C(O)N(H)-CH2-CH2-CF3)-/,- Q~ H

Ic-c953 N OH -N(C(O)N(H)-CHz-CF3)-~

Ic-c954 -N(C(O)N(H)-(CH2)3-OH)-/- Q~ H
Ic-c955 - N / O -CH(OH)-OEt Ic-c956 N(C(O)N(H)-CHz-CHz-OH)-OFt Ic-c957 - N/0 -N(C(O)N(H)-CHz-CHz-F)-OEt Ic-c958 - N/0 -N(C(O)N(H)-CH2-CH2-OCH3)-OEt Ic-c959 - N/0 N(C(O)N(H)-CH2-CH2-CF3)-OEt Ic-c960 - N/0 N(C(O)N(H)-CH2-CH2-CF3)-OEt Ic-c961 - N/0 -N(C(O)N(H)-CH2-CF3)-OEt Ic-c962 - N/0 -N(C(O)N(H)-(CH2)3-OH)-OEt Ic-c963 -CHz-N CHzCH3 CH3 -CH OH -Ic-c964 -CHz-N CHzCH3 CH3 N C O N H-CHz-CHz-OH -Ic-c965 -CHz-N CHzCH3 CH3 N C O N H-CHz-CHz-F -Ic-c966 -CHz-N CHzCH3 CH3 N C O N H-CHz-CHz-OCH3 -Ic-c967 -CHz-N CHzCH3 CH3 N C O N H-CHz-CHz-CF3 -Ic-c968 -CHz-N CHzCH3 CH3 N C O N H-CHz-CHz-CF3 -Ic-c969 -CH2-N(CH2CH3)(CH3) -N(C(O)N(H)-CH2-CF3)-Ic-c970 -CH2-N(CH2CH3)(CH3) -N(C(O)N(H)-(CH2)3-OH)-Ic-c971 -CHz-N CHzCHzCH3 CH3 -CH OH -Ic-c972 -CHz-N CHzCHzCH3 CH3 N C O N H-CHz-CHz-OH -Ic-c973 -CH2-N(CH2CH2CH3)(CH3) -N(C(O)N(H)-CH2-CH2-F)-Ic-c974 -CHz-N CHzCHzCH3 CH3 -N C O N H-CHz-CHz-OCH3 -Ic-c975 -CHz-N CHzCHzCH3 CH3 N C O N H-CHz-CHz-CF3 -Ic-c976 -CHz-N CHzCHzCH3 CH3 N C O N H-CHz-CHz-CF3 -Ic-c977 -CHz-N CHzCHzCH3 CH3 -N C O N H-CHz-CF3 -Ic-c978 -CHz-N CHzCHzCH3 CH3 -N C O N H CHz 3-OH -Ic-c979 -CH2-N(CH2CH2CH2CH3)(CH3) -CH OH -Ic-c980 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-OH -Ic-c981 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-F -Ic-c982 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-OCH3 -Ic-c983 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-CF3 -Ic-c984 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CHz-CF3 -Ic-c985 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H-CHz-CF3 -Ic-c986 -CH2-N(CH2CH2CH2CH3)(CH3) N C O N H CHz 3-OH -Ic-c987 -CH2-NH-CH2CH2CH2CH3 -CH OH -Ic-c988 -CH2-NH-CH2CH2CH2CH3 N(C(O)N(H)-CH2-CH2-OH)-Ic-c989 -CH2-NH-CH2CH2CH2CH3 -N C O N H-CHz-CHz-F -Ic-c990 -CH2-NH-CH2CH2CH2CH3 -N C O N H-CHz-CHz-OCH3 -Ic-c991 -CH2-NH-CH2CH2CH2CH3 N(C(O)N(H)-CH2-CH2-CF3)-Ic-c992 -CH2-NH-CH2CH2CH2CH3 N C O N H-CHz-CHz-CF3 -Ic-c993 -CH2-NH-CH2CH2CH2CH3 -N C O N H-CHz-CF3 -Ic-c994 -CH2-NH-CH2CH2CH2CH3 -N C O N H CHz 3-OH -Ic-c995 -CH2-NH-CH2CH2-O-CH3 -CH OH -Ic-c996 -CH2-NH-CH2CH2-O-CH3 N C O N H-CHz-CHz-OH -Ic-c997 -CH2-NH-CH2CH2-O-CH3 -N C O N H-CHz-CHz-F -Ic-c998 -CH2-NH-CH2CH2-O-CH3 -N C O N H-CHz-CHz-OCH3 -Ic-c999 -CH2-NH-CH2CH2-O-CH3 N C O N H-CHz-CHz-CF3 -Ic-c1000 -CH2-NH-CH2CH2-O-CH3 N C O N H-CHz-CHz-CF3 -Ic-c1001 -CH2-NH-CH2CH2-O-CH3 -N C O N H-CHz-CF3 -Ic-c1002 -CH2-NH-CH2CH2-O-CH3 -N C O N H CHz 3-OH -Ic-cloo3 /-N/-\ N--\,oMe -CH(OH)-Ic-c1004 /-N N--,\,OMe N(C(O)N(H)-CH2-CH2-OH)-Ic-c1005 /-N N--,\,OMe N(C(O)N(H)-CH2-CH2-F)-Ic-c1006 /-N N-N\,OMe N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c1007 /-N N--\,OMe N(C(O)N(H)-CH2-CH2-CF3)-Ic-c1008 /-N N--\,OMe N(C(O)N(H)-CH2-CH2-CF3)-Ic-c1009 /-N N--\,OMe N(C(O)N(H)-CH2-CF3)-Ic-c1010 /-N/-\ N--\,OMe N(C(O)N(H)-(CH2)3-OH)-Ic-c1011 -CH(OH)-N OPO OH
Ic-c1012 N(C(O)N(H)-CHz-CHz-OH)-N OPO OH
Ic-c1013 -N(C(O)N(H)-CHz-CHz-F)-N OPO OH
Ic-c1014 N(C(O)N(H)-CH2-CH2-OCH3)-N OPO OH
Ic-c1015 N(C(O)N(H)-CH2-CH2-CF3)-N OPO OH

Ic-c1016 N(C(O)N(H)-CH2-CH2-CF3)-N OPO OH
Ic-c1017 N(C(O)N(H)-CH2-CF3)-N OPO OH
Ic-c1018 N(C(O)N(H)-(CH2)3-OH)-N OPO OH
Ic-c1019 -CH(OH)-OPO(OH)Z
Ic-c1020 N(C(O)N(H)-CHz-CHz-OH)-OPO(OH)Z
Ic-c1021 N(C(O)N(H)-CHz-CHz-F)-OPO(OH)Z
Ic-c1022 N(C(O)N(H)-CHz-CHz-OCH3)-OPO(OH)Z
Ic-c1023 N(C(O)N(H)-CHz-CHz-CF3)-OPO(OH)Z
Ic-c1024 N(C(O)N(H)-CHz-CHz-CF3)-OPO(OH)Z
Ic-c1025 N(C(O)N(H)-CHz-CF3)-OPO(OH)Z
Ic-c1026 N(C(O)N(H)-(CHz)3-OH)-OPO(OH)Z
Ic-c1O27 N OPO(OH)z -CH(OH)-Ic-c1028 N OPO(OH)z N(C(O)N(H)-CH2-CH2-OH)-Ic-c1029 N OPO(OH)z -N(C(O)N(H)-CH2-CH2-F)-Ic-c1030 N OPO(OH)z N(C(O)N(H)-CH2-CH2-OCH3)-Ic-c1031 /\N OPO(OH)z N(C(O)N(H)-CH2-CH2-CF3)-Ic-c1032 N OPO(OH)z N(C(O)N(H)-CH2-CH2-CF3)-Ic-c1033 N OPO(OH)z N(C(O)N(H)-CH2-CF3)-Ic-c1034 a OPO(OH)z N(C(O)N(H)-(CH2)3-OH)-Ic-c1035 /--NiCH3 -CH(OH)-OPO OH
Ic-c1036 /--N/CH3 N(C(O)N(H)-CHz-CHz-OH)-OPO OH
Ic-c1037 /--N/CH3 -N(C(O)N(H)-CHz-CHz-F)-OPO OH
Ic-c1038 CH3 N(C(O)N(H)-CH2-CH2 -OCH3)-OPO OH
Ic-c1039 /CH3 N(C(O)N(H)-CH2 -CH2 -CF3)-OPO OH
Ic-c1040 N/CH3 N(C(O)N(H)-CH2-CH2-CF3)-OPO OH
Ic-c1041 CH3 N(C(O)N(H)-CH2-CF3)-OPO OH
Ic-c1042 iCH3 N(C(O)N(H)-(CH2)3-OH)-OPO OH
Ic-c1043 -CH(OH)-/-N

OPO OH

Ic-c1044 N(C(O)N(H)-CHz-CHz-OH)-OPO OH
Ic-c1045 -N(C(O)N(H)-CHz-CHz-F)-OPO OH
Ic-c1046 N(C(O)N(H)-CH2-CH2-OCH3)-OPO OH
Ic-c1047 N(C(O)N(H)-CH2-CH2-CF3)-/-N

OPO OH
Ic-c1048 N(C(O)N(H)-CH2-CH2-CF3)-OPO OH
Ic-c1049 N(C(O)N(H)-CH2-CF3)-OPO OH
Ic-c1050 N(C(O)N(H)-(CH2)3-OH)-OPO OH
Ic-c1051 H -CH(OH)-N

OPO OH

Ic-c1052 N N(C(O)N(H)-CHz-CHz-OH)-OPO OH
Ic-c1053 \\__~ N(C(O)N(H)-CHz-CHz-F)-OPO OH )a, Ic-c1054 N(C(O)N(H)-CH2-CH2-OCH3)-N

OPO OH
Ic-c1055 \\--~ N(C(O)N(H)-CHz-CHz-CF3)-OPO OH )a2 Ic-c1056 \\__H N(C(O)N(H)-CH2-CH2-CF3)-N

OPO OH ~a2 Ic-c1057 N(C(O)N(H)-CH2-CF3)-N

OPO OH
Ic-c1058 \\--H -N(C(O)N(H)-(CH2)3-OH)-N

OPO OH

and pharmaceutically acceptable salts thereof.

5.5 The Indenoisoquinolinone Analogs of Formula (IIa) The present invention provides Indenoisoquinolinone Analogs according to Formula (IIa), below:

NH

X

R' (IIa) and pharmaceutically acceptable salts thereof, wherein:
X and Ri are as defined above for the compounds of Formula (IIa).
In one embodiment, X is -CHz-. In another embodiment, X is -0-. In another embodiment, X is -C(O)-. In another embodiment, X is -NH-. In another embodiment, X
is N(Ci-C4 alkyl)-. In another embodiment, X is -S-. In another embodiment, X
is -CH(OH)-.
In one embodiment, n is 1. In another embodiment, n is 2.
In one embodiment, X is -CH2- and n is 1.
In one embodiment, X is -CH2- and n is 2.
In one embodiment, X is -CH(OH)- and n is 1.
In one embodiment, X is --CH(OH)- and n is 2.
In one embodiment, R2 is -Ci-C6 alkyl and R3 is -C(O)-(C1-C6 alkylene)-(3- to membered monocyclic heterocycle).
In one embodiment, R2 is -H and R3 is -C(O)-(C1-C6 alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, n is 1 and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one -C(O)O-Ci-C6 alkyl.
In another embodiment, n is 1 and R3 is C3-C8 monocyclic cycloalkyl substituted with one hydroxy-substituted Ci-CS alkyl.
In one embodiment, n is 2 and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one -C(O)O-Ci-C6 alkyl.
In another embodiment, n is 2 and R3 is C3-C8 monocyclic cycloalkyl substituted with one hydroxy-substituted Ci-CS alkyl.

In one embodiment, N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which substituted with one of -C2-C6 alkenyl, -C(O)-C1-C6 alkyl, -(Ci-C4 alkylene)-C(O)-(C3-C8 monocyclic cycloalkyl), -C7-Cio alkyl, -(CI-C5 alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-CS alkyl, -(CI-C5 alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or -(Ci-CS alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, n is 1 and N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which substituted with one of -C2-C6 alkenyl, -C(O)-C1-C6 alkyl, -(Ci-C4 alkylene)-C(O)-(C3-Cs monocyclic cycloalkyl), -C7-C10 alkyl, -(CI-C5 alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-CS alkyl, -(Ci-CS alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or -(CI-C5 alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, X is -CH2-, n is 1 and N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which substituted with one of -Cz-C6 alkenyl, -C(O)-C1-C6 alkyl, -(Ci-C4 alkylene)-C(O)-(C3-C8 monocyclic cycloalkyl), -C7-Cio alkyl, -(CI-C5 alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-CS alkyl, -(CI-C5 alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or -(CI-C5 alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, X is -CH2-, n is 1, and R2 is C3-C8 monocyclic cycloalkyl.
In one embodiment, X is -CH2-, n is 1, and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one -C(O)O-C1-C6 alkyl.
In one embodiment, X is -CH2-, n is 1, and R3 is C3-C8 monocyclic cycloalkyl which is substituted with one hydroxy-substituted Ci-CS alkyl.
In one embodiment, X is -CH2-, n is 1, R2 is -H, and R3 is a nitrogen-containing 3-to 7-membered monocyclic heterocycle which is substituted with one -C(O)O-C1-alkyl.
In one embodiment, X is -CH2-, n is 1, R2 is -H, and R3 is C3-C8 monocyclic cycloalkyl which is substituted with one hydroxy-substituted Ci-CS alkyl.
In another embodiment, X is -CH2-, n is 1 and R3 is -C(O)-C1-C6 alkylene-(3-to 7-membered monocyclic heterocycle).
In one embodiment, X is -CH(OH)-, n is 1 and N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which substituted with one of -C2-C6 alkenyl, -C(O)-C1-C6 alkyl, -(Ci-C4 alkylene)-C(O)-(C3-C8 monocyclic cycloalkyl), -C7-Cio alkyl, -(Ci-CS alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-CS alkyl, -(Ci-CS alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or -(Ci-CS alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, X is -CH(OH)-, n is 1, and R2 is C3-C8 monocyclic cycloalkyl.
In one embodiment, X is -CH(OH)-, n is 1, and R3 is a nitrogen-containing 3-to 7-membered monocyclic heterocycle which is substituted with one -C(O)O-Ci-C6 alkyl.
In one embodiment, X is -CH(OH)-, n is 1, and R3 is C3-C8 monocyclic cycloalkyl which is substituted with one hydroxy-substituted Ci-CS alkyl.
In one embodiment, X is -CH(OH)-, n is 1, R2 is -H, and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one -C(O)O-Ci-C6 alkyl.
In one embodiment, X is -CH(OH)-, n is 1, R2 is -H, and R3 is C3-C8 monocyclic cycloalkyl which is substituted with one hydroxy-substituted Ci-CS alkyl.
In another embodiment, X is -CH(OH)-, n is 1 and R3 is -C(O)-C1-C6 alkylene-(3-to 7-membered monocyclic heterocycle).

In various embodiments, -R1 is:

H?a ON
~N~iCH2 ~ ~N N J, N J ~ N ~\O
OH

k^N

0 HN~N-tBOC
kN" v N~ ~^O
Me GO ~\
CN NBOC
O Me V-N k^N O,Me OMe N ,Z) ~, N Me O O O

A^N"'j 0 N 0 N ll OMe N N or ~/, V , =

Illustrative examples of the Indenoisoquinolinone Analogs include the compounds of Formula (IIa) in which n is 1 as set forth below:

NH
X

R' (IIa) Compound - Rl X
IIa-1 ^,,,,,CH2 -CHZ-N J
IIa-al CH2 -CH(OH)-N
J
IIa-2 J -, ,CH2 -O-N
IIa-3 ~N~~CH2 -C(O)-N
IIa-4 CH2 -NH-rJ
N
IIa-5 ^N~~CH2 -S-NrJ
IIa-6 J ^,,,,,CH2 -N(CH3)-N

IIa-7 ,CH2 -N(CH2CH3)-N J
IIa-8 ~ i~CH2 -N(CH2CH2CH3)-N
J
IIa-9 ~ ~,CH2 -N(CH2CH2CH2CH3)-N J
IIa-10 N~~CH2 -N(C(H)(CH3)(CH2CH3))-N1"
IIa-11 f Ni~CH2 -N(C(H)(CH3)2)-N
IIa-12 N,CH2 -N(CH2C(H)(CH3)2)-NN/
IIa-13 J ^2 ,,,,CH2 -N(C(CH3)3)-N
IIa-14 O~ -CHZ-O
\,N
IIa-a14 O~ -CH(OH)-\,N
IIa-15 O~ -0-\,N
IIa-16 O -C(O)-O
\,N
IIa-17 O -NH-\,N
IIa-18 O~ -S-O
\~N
IIa-19 O -N(CH3)-\~N
IIa-20 O~ -N(CH2CH3)-\~N

IIa-21 O~ -N(CH2CH2CH3)-\,N
IIa-22 O~ -N(CH2CH2CH2CH3)-\,N
IIa-23 -N(C(H)(CH3)(CH2CH3))-~0 \,N
IIa-24 -N(C(H)(CH3)2)-~0 \,N
IIa-25 -N(CH2C(H)(CH3)2)-~0 \,N
IIa-26 O~ -N(C(CH3)3)-\,N
IIa-27 N H?a CHZ
OH
IIa-a27 N H?a -CH(OH)-OH
IIa-28 H -0-N

OH
IIa-29 N H?a C(O) OH
IIa-30 H -NH-N

OH
IIa-31 H S
N

OH
IIa-32 N H?a -N(CH3)-OH
IIa-33 N H?a N(CHzCH3)-OH

IIa-34 N H?a -N(CHzCHzCH3)-OH
IIa-35 N H-P -N(CHzCHzCHzCH3)-OH
IIa-36 N -N(C(H)(CH3)(CHzCH3))-OH
IIa-37 N H?a -N(C(H)(CH3)z)-OH
IIa-38 N H-P -N(CHzC(H)(CH3)z)-OH
IIa-39 N H?a -N(C(CH3)3)-OH
IIa-40 -CHZ-ONI
C0________ IIa-a40 -,~N ~ -CH(OH)-~N

C0________ IIa-41 -O-ONI
C0________ IIa-42 -,~N ~ -C(O)-~N

C0________ IIa-43 -NH-C0________ IIa-44 -S-OI
G
IIa-45 -N(CH3)-ONI
G
IIa-46 /~N N(CHzCH3)-~N

C0________ IIa-47 -N(CHzCHzCH3)-ONI
C0________ IIa-48 /~N -N(CHzCHzCHzCH3)-~N

C0________ IIa-49 -N(C(H)(CH3)(CH2CH3))-G
IIa-50 -N(C(H)(CH3)2)-ON

C0________ IIa-51 -N(CH2C(H)(CH3)2)-O

C0________ IIa-52 -N(C(CH3)3)-C0________ IIa-53 0 -CHZ-N
Me ~O
IIa-a53 0 -CH(OH)-N--~ co Me IIa-54 0 -O-N--~ co Me IIa-55 0 -C(O)-N--~ co Me IIa-56 0 -NH-N--~ co Me IIa-57 0 -S-co Me IIa-58 0 -N(CH3)-N--V\co Me IIa-59 0 N(CHzCH3)-N--V\co Me IIa-60 0 -N(CHzCHzCH3)-N--V\co Me IIa-61 0 -N(CHzCHzCHzCH3)-N
Me ~O
IIa-62 0 -N(C(H)(CH3)(CHzCH3))-N
Me ~O
IIa-63 0 -N(C(H)(CH3)2)-N--~ co Me IIa-64 0 -N(CH2C(H)(CH3)2)-N--~ N
Me O

IIa-65 0 -N(C(CH3)3)-Me ~O
IIa-66 -~N -CHZ-~N--~CN
IIa-a66 1-1--N -CH(OH)-" N-'-~CN
IIa-67 -~N -O-~N--~CN
IIa-68 ---N -C(O)-~N--~CN
IIa-69 /~N ~ -NH-~N--~CN
IIa-70 /-N ~ -S-" N -'-~C N
IIa-71 /~N -N(CH3)-~N--~CN
IIa-72 /-N ~ N(CHzCH3)-~N --~C N
IIa-73 /-N -N(CHzCHzCH3)-" N-'-~CN
IIa-74 /-N ~ -N(CHzCHzCHzCH3)-~N--~CN
IIa-75 /~N -N(C(H)(CH3)(CHzCH3))-~N--~CN
IIa-76 -~N -N(C(H)(CH3)z)-N N --~C N
IIa-77 /-N -N(CHzC(H)(CH3)z)-" N-'-~CN
IIa-78 /~N -N(C(CH3)3)-~N--~CN
IIa-79 -CHZ-/~

N
tBOC

IIa-a79 -CH(OH)-~\N

N
tBOC
IIa-80 -O-~\N

tBOC
IIa-81 -C(O)-~\N

N
tBOC
IIa-82 ~ -NH-~\N

N
tBOC
IIa-83 -S-~\N

N
tBOC
IIa-84 -N(CH3)-/~N

N
tBOC
IIa-85 N(CH2CH3)-~\N

N
tBOC

IIa-86 -N(CH2CH2CH3)-~\N

N
tBOC
IIa-87 -N(CH2CH2CH2CH3)-~\N

tBOC
IIa-88 -N(C(H)(CH3)(CH2CH3))-~\N

N
tBOC
IIa-89 -N(C(H)(CH3)2)-N
tBOC
IIa-90 -N(CH2C(H)(CH3)2)-~\N

N
tBOC
IIa-91 -N(C(CH3)3)-/~N

N
tBOC
IIa-92 ~ -CHZ-H N-CN-tBOC

IIa-a92 -CH(OH)-H N-CN-tBOC

IIa-93 -O-~
H N N-tBOC

IIa-94 ~ -C(O)-H N-CN-tBOC

IIa-95 -NH-~
H N N-tBOC

IIa-96 -S-~
H N N-tBOC

IIa-97 ~ -N(CH3)-H N-CN-tBOC

IIa-98 ~ N(CH2CH3)-H N-CN-tBOC

IIa-99 ~ -N(CH2CH2CH3)-H N-CN-tBOC

IIa-100 ~ -N(CH2CH2CH2CH3)-H N-CN-tBOC

IIa-101 ~ -N(C(H)(CH3)(CH2CH3))-H N-CN-tBOC

IIa-102 ~ -N(C(H)(CH3)2)-H N-CN-tBOC

IIa-103 ~ -N(CH2C(H)(CH3)2)-H N-CIN-tBOC

IIa-104 ~ -N(C(CH3)3)-H N-CIN-tBOC

IIa-105 N Me -CHZ-~N~) IIa-a105 N ') Me -CH(OH)-~,, N~

IIa-106 Me -0-O

IIa-107 '~N ~ Me -C(O)-~N~
IIa-108 ',~N ") Me -NH-~, N~f) IIa-109 ',~N ~ Me -S-~N

IIa-110 N ~ Me -N(CH3)-~N

IIa-111 N Me N(CH2CH3)-~N,~
IIa-112 N Me -N(CHzCHzCH3)-~N

IIa-113 '~N ~ Me -N(CHzCHzCHzCH3)-~N~

IIa-114 ~N ~ Me -N(C(H)(CH3)(CHzCH3))-~N~

IIa-115 ~~ Me -N(C(H)(CH3)z)-N~

IIa-116 /~N ~ Me -N(CHzC(H)(CH3)z)-~N

IIa-117 N ~ Me -N(C(CH3)3)-~N

IIa-118 "^-N CHZ
~N Me IIa-a118 "^-N -CH(OH)-(DN Me IIa-119 ~N -O
(DN Me IIa-120 ~N -C(O)-(DN Me IIa-121 -NH-(DN Me IIa-122 N~ S
~N Me IIa-123 N~ -N(CH3)-N Me IIa-124 N N(CH2CH3)-(DN Me IIa-125 -N(CH2CH2CH3)-(DN Me IIa-126 N~ -N(CHzCHzCHzCH3)-~N Me IIa-127 -N(C(H)(CH3)(CH2CH3))-(DN Me IIa-128 N -N(C(H)(CH3)z)-~N Me IIa-129 N -N(CHzC(H)(CH3)z)-~N Me IIa-130 N -N(C(CH3)3)-~N Me IIa-131 ~~ -CHZ-N
IIa-a131 ll~i ~ -CH(OH)-j'~ N
IIa-132 ~~ -O-N
IIa-133 ll~i ~ -C(O)-j'~ N
IIa-134 ") -NH-N
IIa-135 ") -S-N

IIa-136 -N(CH3)-j'~ N
IIa-137 i ~ N(CHzCH3)-j'~ N
IIa-138 -N(CHzCHzCH3)-j'~ N
IIa-139 /~ -N(CHzCHzCHzCH3)-j'~ N
IIa-140 -N(C(H)(CH3)(CH2CH3))-N
IIa-141 -N(c(H)(cH3)2)-N
IIa-142 -N(CH2C(H)(CH3)2)-N
IIa-143 -N(C(CH3)3)-N

IIa-144 0-Me -CHZ-O,~, O Me IIa-a144 ---N~ 0-Me -CH(OH)-~ N ,k, 0 Me IIa-145 /--N~ 0-Me -O-~N,1, 0 Me IIa-146 /--N") 0-Me -C(O)-~,N,AO Me IIa-147 /--N~ 0-Me -NH-~ N A 0 Me IIa-148 /l-N~ 0-Me -S-~N,,,Q 0 Me IIa-149 0-Me -N(CH3)-~,N,~,kO Me IIa-150 0-Me N(CH2CH3)-N,I,O Me IIa-151 --') 0-Me -N(CH2CH2CH3)-N Me IIa-152 0-Me -N(CH2CH2CH2CH3)-O,', 0 Me IIa-153 /--N 0-Me -N(C(H)(CH3)(CHzCH3))-~NA 0 Me IIa-154 /--N ") 0-Me -N(C(H)(CH3)z)-~,N,AO Me IIa-155 0-Me -N(CHzC(H)(CH3)z)-~,N,,,,QO Me IIa-156 0-Me -N(C(CH3)3)-~,N,,,,QO Me IIa-157 '-~N 0 -CHZ-N
V
IIa-a157 '-~N 0 -CH(OH)-N
V
IIa-158 '-~N 0 -O-N
V
IIa-159 '-~N 0 -C(O)-~N~N
V
IIa-160 /~N ~ 0 -NH-N
V
IIa-161 /~N 0 -S-N
V
IIa-162 /~N 0 -N(CH3)-~N,kN
V
IIa-163 /~N 0 N(CHzCH3)-~N~N
V

IIa-164 N 0 -N(CH2CH2CH3)-N(j IIa-165 /~N 0 -N(CHzCHzCHzCH3)-~N)-N
V
IIa-166 /~N ~ 0 -N(C(H)(CH3)(CH2CH3))-N
V
IIa-167 -~N 0 -N(C(H)(CH3)2)-NV

IIa-168 /~N 0 -N(CH2C(H)(CH3)2)-N
V
IIa-169 N "I 0 -N(C(CH3)3)-N
V
IIa-170 --~-N ~ p -CHZ-~N ,K~,V

IIa-a170 --~-N p -CH(OH)-~N ,K~,V

IIa-171 --~-N ~ 0 -O-~N ,K~,V

IIa-172 --~-N ~ 0 -C(O)-~N ,K~,V

IIa-173 /~N p -NH-~N ,kV

IIa-174 /~N p -S-~N ,kV

IIa-175 /-N ~ p -N(CH3)-~N ,K~,V

IIa-176 /~N ~ p N(CHzCH3)-~N ,JtV

IIa-177 ON p -N(CHzCHzCH3) IIa-178 N ~ p -N(CH2CH2CH2CH3)-~N
IIa-179 N p -N(C(H)(CH3)(CH2CH3))-~N

IIa-180 N o N(c(H)(cH3)2) IIa-181 /~N 0 -N(CHzC(H)(CH3)z)-~N ,KV

IIa-182 /~N ~ 0 -N(C(CH3)3)-~N ,KV

IIa-183 -CHZ-~ N Me IIa-a183 -CH(OH)-N Me N
N
IIa-184 -O-~ N Me IIa-185 -C(O)-~ N Me IIa-186 -NH-~ N Me IIa-187 -S-~ N Me IIa-188 -N(CH3)-N Me N
IIa-189 N(CHzCH3)-N Me N
IIa-190 -N(CH2CH2CH3)-N Me N
IIa-191 -N(CH2CH2CH2CH3)-~ N Me N
IIa-192 -N(C(H)(CH3)(CH2CH3))-~ N Me N
IIa-193 rN Me -N(C(H)(CH3)2)-N

IIa-194 ~N Me -N(CH2C(H)(CH3)2)-N

IIa-195 -N(C(CH3)3)-N Me N
IIa-196 ~N O-Et -CHZ-~N,,,~,O Et IIa-197 ON, D- Et CH(OH) O Et IIa-198 O-Et -O-O,,,),O Et IIa-199 ON, D- Et C(O) O Et IIa-200 /-N O-Et -NH-~N,,,1,O Et IIa-201 /~N O,Et -S-~N,,,~,O Et IIa-202 O-Et -N(CH3)-O,,1,O Et IIa-203 N ~ O-Et N(CHzCH3) N~O Et IIa-204 O-Et -N(CH2CH2CH3)-O,,1,6 Et IIa-205 /-N ~ O-Et -N(CHzCHzCHzCH3)-~N Et IIa-206 ON, D ,Et N(C(H)(CH3)(CHzCH3)) O Et IIa-207 O-Et -N(C(H)(CH3)2)-O,,,1,6Et IIa-208 /~N ~ O,Et -N(CHzC(H)(CH3)z)-~N,,,~,O Et IIa-209 ON, o, Et N(c(cH3)3) O Et and pharmaceutically acceptable salts thereof.

5.6 The Indenoisoquinolinone Analogs of Formula (IIb) The present invention provides Indenoisoquinolinone Analogs according to Formula (IIb) below:

NH
X

R' (IIb) and pharmaceutically acceptable salts thereof, wherein:
X and Ri are as defined above for the compounds of Formula (IIb).
In one embodiment, X is -CHz-. In another embodiment, X is -0-. In another embodiment, X is -C(O)-. In another embodiment, X is -NH-. In another embodiment, X
is N(Ci-C4 alkyl)-. In another embodiment, X is -S-. In another embodiment, X
is -CH(OH)-.
In one embodiment, n is 1. In another embodiment, n is 2.
In one embodiment, X is -CH2- and n is 1.
In one embodiment, X is -CH2- and n is 2.
In one embodiment, X is -CH(OH)- and n is 1.
In one embodiment, X is --CH(OH)- and n is 2.
In one embodiment, R2 is -Ci-C6 alkyl and R3 is -C(0)-(C1-C6 alkylene)-(3- to membered monocyclic heterocycle).
In one embodiment, R2 is -H and R3 is -C(0)-(C1-C6 alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, n is 1 and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one -C(0)0-C1-C6 alkyl.
In another embodiment, n is 1 and R3 is C3-C8 monocyclic cycloalkyl substituted with one hydroxy-substituted Ci-CS alkyl.
In one embodiment, n is 2 and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one -C(0)0-C1-C6 alkyl.
In another embodiment, n is 2 and R3 is C3-C8 monocyclic cycloalkyl substituted with one hydroxy-substituted Ci-CS alkyl.
In one embodiment, N, W and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which substituted with one of -C2-C6 alkenyl, -C(0)-C1-C6 alkyl, -(Ci-C4 alkylene)-C(0)-(C3-C8 monocyclic cycloalkyl), -C7-Cio alkyl, -(Ci-CS alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-CS alkyl, -(Ci-CS
alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or -(Ci-C5 alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, n is 1 and N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which substituted with one of -C2-C6 alkenyl, -C(0)-C1-C6 alkyl, -(Ci-C4 alkylene)-C(0)-(C3-C8 monocyclic cycloalkyl), -C7-C10 alkyl, -(CI-C5 alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-CS alkyl, -(Ci-CS alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or -(CI-C5 alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, X is -CH2-, n is 1 and N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which substituted with one of -Cz-C6 alkenyl, -C(O)-C1-C6 alkyl, -(Ci-C4 alkylene)-C(O)-(C3-C8 monocyclic cycloalkyl), -C7-Cio alkyl, -(CI-C5 alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-CS alkyl, -(CI-C5 alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or -(CI-C5 alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, X is -CH2-, n is 1, and R2 is C3-C8 monocyclic cycloalkyl.
In one embodiment, X is -CH2-, n is 1, and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one -C(O)O-C1-C6 alkyl.
In one embodiment, X is -CH2-, n is 1, and R3 is C3-C8 monocyclic cycloalkyl which is substituted with one hydroxy-substituted Ci-CS alkyl.
In one embodiment, X is -CH2-, n is 1, R2 is -H, and R3 is a nitrogen-containing 3-to 7-membered monocyclic heterocycle which is substituted with one -C(O)O-Ci-alkyl.
In one embodiment, X is -CH2-, n is 1, R2 is -H, and R3 is C3-C8 monocyclic cycloalkyl which is substituted with one hydroxy-substituted Ci-CS alkyl.
In another embodiment, X is -CH2-, n is 1 and R3 is -C(O)-C1-C6 alkylene-(3-to 7-membered monocyclic heterocycle).
In one embodiment, X is -CH(OH)-, n is 1 and N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which substituted with one of -C2-C6 alkenyl, -C(O)-C1-C6 alkyl, -(Ci-C4 alkylene)-C(O)-(C3-C8 monocyclic cycloalkyl), -C7-Cio alkyl, -(CI-C5 alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-CS alkyl, -(CI-C5 alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or -(CI-C5 alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, X is -CH(OH)-, n is 1, and R2 is C3-C8 monocyclic cycloalkyl.
In one embodiment, X is -CH(OH)-, n is 1, and R3 is a nitrogen-containing 3-to 7-membered monocyclic heterocycle which is substituted with one -C(O)O-C1-C6 alkyl.
In one embodiment, X is -CH(OH)-, n is 1, and R3 is C3-C8 monocyclic cycloalkyl which is substituted with one hydroxy-substituted Ci-CS alkyl.
In one embodiment, X is -CH(OH)-, n is 1, R2 is -H, and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one -C(O)O-Ci-C6 alkyl.
In one embodiment, X is -CH(OH)-, n is 1, R2 is -H, and R3 is C3-C8 monocyclic cycloalkyl which is substituted with one hydroxy-substituted Ci-CS alkyl.
In another embodiment, X is -CH(OH)-, n is 1 and R3 is -C(O)-Ci-C6 alkylene-(3-to 7-membered monocyclic heterocycle).

In various embodiments, -R1 is:

O H ON
~iCH2 ~ N
N N J, ~vNJ N ~\O
OH , -N^N "L

O HN~N-tBOC
kN" v N~ ~^O
Me GO ~~
CN NBOC
NG
~~ Me ~ N Me N^3,,0 '~,^N O'Me GN/, Me 0 , 0 , O O
A'N~ 0 N N--) 0 ~ N Me N J
15 V \/ or N
N

Illustrative examples of the Indenoisoquinolinone Analogs include the compounds of Formula (IIb) in which n is 1 as set forth below:

Compound - Rl X
IIb-1 ~,CH2 -CHZ-N rJ

IIb-bl J ^2 ,,,,CH2 -CH(OH)-N
IIb-2 N CH 2 N -O
rN/
IIb-3 f NCH2 C(O) NI
IIb-4 ^ Ni~CH2 N -NH-rJ
IIb-5 ^,~,,CH2 -S-NJ
IIb-6 ~~CH2 -N(CH3)-N J
IIb-7 ~ i~CH2 N N(CHzCH3)-J
IIb-8 f ,^, ~~CH2 -N(CH2CH2CH3)-N
J
IIb-9 ~ i~CH2 N -N(CH2CH2CH2CH3)-J
IIb-10 f ,^, N,-, ~,,CH2 -N(C(H)(CH3)(CH2CH3))-NI-/
IIb-11 N^,,,,,CH2 -N(C(H)(CH3)2)-N IIb-12 N-, ,CH2 -N(CH2C(H)(CH3)2)-NN/
IIb-13 f ,^, N,-, ~,,CHz -N(C(CH3)3)-N
IIb-14 O ~ -CHZ-O
\,N

IIb-b 14 O ~ -CH(OH)-O
\,N
IIb-15 -O-O
IIb-16 -C(O)-O
\,N
IIb-17 -NH-O
IIb-18 -S-O
\,N
IIb-19 -N(CH3)-O
\,N
IIb-20 O~ N(CH2CH3)-\,N
IIb-21 O~ -N(CH2CH2CH3)-\,N
IIb-22 -N(CH2CH2CH2CH3)-\,N
IIb-23 -N(C(H)(CH3)(CH2CH3))-\~N
IIb-24 -N(C(H)(CH3)2)-'o \~N
IIb-25 -N(CH2C(H)(CH3)2)-'O
\,N
IIb-26 O~ -N(C(CH3)3)-'o \~N
IIb-27 N H?a CHZ
OH

IIb-b27 N H?a -CH(OH) OH
IIb-28 H -0-N

OH
IIb-29 N H?a C(O) OH
IIb-30 H -NH-N

OH
IIb-31 H S
N

OH
IIb-32 N H?a -N(CH3)-OH
IIb-33 N H?a N(CHzCH3)-OH
IIb-34 N H?a -N(CHzCHzCH3)-OH
IIb-35 N H-P -N(CHzCHzCHzCH3)-OH
IIb-36 N H~a -N(C(H)(CH3)(CHzCH3))-OH
IIb-37 N H?a -N(C(H)(CH3)z)-OH
IIb-38 N H-P -N(CHzC(H)(CH3)z)-OH
IIb-39 N H?a -N(C(CH3)3)-OH

IIb-40 -CHZ-OI
G
IIb-b40 -CH(OH)-ONI
G
IIb-41 ll~N -O-~N
NI
G
IIb-42 1-1-~N -C(O)-~N

IIb-43 /~N -NH-~N
NI
G
IIb-44 /~N -S-~N

C0________ IIb-45 -N(CH3)-O

C0________ IIb-46 N(CH2CH3)-O

C0________ IIb-47 -N(CH2CH2CH3)-C0________ IIb-48 -N(CHzCHzCHzCH3)-ONI
C0________ IIb-49 ") -N(C(H)(CH3)(CH2CH3))-N
NI
G
IIb-50 /~ i ~ -N(C(H)(CH3)z)-~N

C0________ IIb-51 -N(CHzC(H)(CH3)z)-ON1 C0________ IIb-52 /~N ~ -N(C(CH3)3)-~N

C0________ IIb-53 0 -CHZ-Me co IIb-b53 0 -CH(OH)-lllllN-'~co Me IIb-54 0 -O-lllllN-'~co Me IIb-55 0 -C(O)-1--l'-N--V\co Me IIb-56 0 -NH-1--l'-N--V\co Me IIb-57 0 -S-1--l'-N--V\N
Me GO

IIb-58 0 -N(CH3)-N
Me ~O
IIb-59 0 N(CH2CH3)-N--~ co Me IIb-60 0 -N(CH2CH2CH3)-N--~ co Me IIb-61 0 -N(CH2CH2CH2CH3)-N--~ co Me IIb-62 0 -N(C(H)(CH3)(CH2CH3))-N--~ co Me IIb-63 0 -N(C(H)(CH3)z)-co Me IIb-64 0 -N(CHzC(H)(CH3)z)-N--V\co Me IIb-65 0 -N(C(CH3)3)-N--V\co Me IIb-66 ,~N -CHZ-~N--~CN
IIb-b66 -~N -CH(OH)-~N --~C N
IIb-67 ,~N -O-~N--~CN
IIb-68 ---N -C(O)-~N--~CN
IIb-69 /-N -NH-" N-'-~CN
IIb-70 /~N ~ -S-~N --~C N
IIb-71 /-N -N(CH3)-" N-'-~CN

IIb-72 N(CH2CH3)-O--~CN
IIb-73 /-N ~ -N(CHzCHzCH3)-~N--~CN
IIb-74 /~N -N(CHzCHzCHzCH3)-~N--~CN
IIb-75 /-N -N(C(H)(CH3)(CHzCH3))-~N --~C N
IIb-76 ,~N -N(C(H)(CH3)z)-N--~CN
N
IIb-77 /-N -N(CHzC(H)(CH3)z)-~N --~C N
IIb-78 /'-N ~ -N(C(CH3)3)-~N--~CN
IIb-79 -CHZ-~~Nr tBOC
IIb-b79 ~ -CH(OH)-~\N

N
tBOC
IIb-80 -O-~\N

N
tBOC
IIb-81 -C(O)-~\N

N
tBOC

IIb-82 -NH-/~N

N
tBOC
IIb-83 -S-~\N

tBOC
IIb-84 ~ -N(CH3)-~\N

N
tBOC
IIb-85 N(CH2CH3)-~\N

N
tBOC
IIb-86 -N(CH2CH2CH3)-~\N

N
tBOC
IIb-87 -N(CH2CH2CH2CH3)-~\N

N
tBOC
IIb-88 -N(C(H)(CH3)(CH2CH3))-~\N

N
tBOC

IIb-89 -N(C(H)(CH3)2)-N
tBOC
IIb-90 -N(CH2C(H)(CH3)2)-~\N

tBOC
IIb-91 -N(C(CH3)3)-~\N

N
tBOC
IIb-92 ~ -CHZ-H N-CN-tBOC

IIb-b92 ~ -CH(OH)-H N-CN-tBOC

IIb-93 -O-H N N-tBOC

IIb-94 ~ -C(O)-H N-CN-tBOC

IIb-95 -NH-H N N-tBOC

IIb-96 -S-H N N-tBOC

IIb-97 -N(CH3)-H N-CIN-tBOC

IIb-98 N(CH2CH3)-H N-CIN-tBOC

IIb-99 -N(CH2CH2CH3)-H N-CIN-tBOC

IIb-100 -N(CH2CH2CH2CH3)-H N-CIN-tBOC

IIb-101 -N(C(H)(CH3)(CH2CH3))-H N-CIN-tBOC

IIb-102 -N(C(H)(CH3)2)-H N-CIN-tBOC

IIb-103 -N(CH2C(H)(CH3)2)-H N-CIN-tBOC

IIb-104 -N(C(CH3)3)-H N-CIN-tBOC

IIb-105 ll~N ~ Me -CHZ-~N~
O
IIb-b105 N Me -CH(OH)-O

IIb-106 '~N ~ Me -0-~N~
O
IIb-107 N Me -C(O)-~N,~
O
IIb-108 ll~N Me -NH-~N~
O
IIb-109 1-111-N Me -S-~N,~) O
IIb-110 '~N ') Me -N(CH3)-~, N~
O
IIb-111 ',~N Me N(CHzCH3)-~N~f) O
IIb-112 ',~N ~ Me -N(CHzCHzCH3)-~N~

O
IIb-113 ll~N ~ Me -N(CHzCHzCHzCH3)-~N~

O
IIb-114 1-111-N Me -N(C(H)(CH3)(CHzCH3))-~N~

O
IIb-115 /1-~~ Me -N(C(H)(CH3)z)-N~

O
IIb-116 '~N ~ Me -N(CHzC(H)(CH3)z)-~N~

O
IIb-117 N Me -N(C(CH3)3)-~N

O

IIb-118 N -CHZ-(DN Me IIb-b118 "'N -CH(OH)-(DN Me IIb-119 ~N -O-(DN Me IIb-120 "'N -C(O)-(DN Me IIb-121 N -NH-(DN Me IIb-122 N -S-(DN Me IIb-123 N -N(CH3)-~N Me IIb-124 N N(CHzCH3)-~N Me IIb-125 N -N(CHzCHzCH3)-~N Me IIb-126 N~ -N(CH2CH2CH2CH3)-N Me IIb-127 N~ -N(C(H)(CH3)(CH2CH3))-~'N Me IIb-128 -N(C(H)(CH3)2)-(DN Me IIb-129 N~ -N(CHzC(H)(CH3)z)-~N Me IIb-130 N -N(C(CH3)3)-~N Me IIb-131 ~ ~~ -CHZ-N
IIb-b131 , -CH(OH)-j'~ N
IIb-132 ~~ -O-N
IIb-133 ~ ~~ -C(O)-N
IIb-134 /~ ,~ -NH-j'~ N
IIb-135 ~~ -S-N
IIb-136 /~ , -N(CH3)-j'~ N
IIb-137 /~ , ~ N(CHzCH3)-j'~ N
IIb-138 /~ , -N(CHzCHzCH3)-j'~ N
IIb-139 ") -N(CH2CH2CH2CH3)-N
IIb-140 ") -N(C(H)(CH3)(CH2CH3))-N

IIb-141 ~ ~~ -N(c(H)(cH3)2)-N
IIb-142 , ~ -N(CHzC(H)(CH3)z)-j'~ N
IIb-143 , ~ -N(C(CH3)3)-j'~ N
IIb-144 0-Me -CHZ-O,1, 0 Me IIb-b144 /l-N~ 0-Me -CH(OH)-~N,', 0 Me IIb-145 /--N~ 0-Me -O-~ N A O Me IIb-146 /--N") 0-Me -C(O)-~,N,A Me IIb-147 /l-N~ 0-Me -NH-~N,,,Q O Me IIb-148 o-Me -S-O,,,Q O Me IIb-149 /--N--') o-Me -N(CH3)-~,, N ,I,O Me IIb-150 ") o-Me N(CH2CH3)-N),O Me IIb-151 N --') o-Me -N(CH2CH2CH3)-~, N~,Q Me IIb-152 o-Me -N(CHzCHzCHzCH3)-~,N,,~, Me IIb-153 N o-Me -N(C(H)(CH3)(CHzCH3))-~,N,,,,Q Me IIb-154 N o-Me -N(C(H)(CH3)2)-Me IIb-155 o-Me -N(CH2C(H)(CH3)2)-~ N ,I,O Me IIb-156 /--N--') o-Me -N(C(CH3)3)-~N Me IIb-157 N 0 -CHZ-N
V
IIb-b157 N 0 -CH(OH)-N
V
IIb-158 N 0 -O-N
V
IIb-159 N 0 -C(O)-N
V
IIb-160 N 0 -NH-~NN
V
IIb-161 N ~ 0 -S-N
V
IIb-162 N 0 -N(CH3)-~N,,,kN
V
IIb-163 N 0 N(CHzCH3)-~N,,,kN
V
IIb-164 N 0 -N(CHzCHzCH3)-~N~N
V
IIb-165 N ") 0 -N(CH2CH2CH2CH3)-N
V
IIb-166 N ") 0 -N(C(H)(CH3)(CH2CH3))-N
V
IIb-167 N 0 -N(C(H)(CH3)2)-NV

IIb-168 N ~ 0 -N(CH2C(H)(CH3)2)-N1j IIb-169 N ~ 0 -N(C(CH3)3)-~NN
V
IIb-170 p -CHZ-O,AV

IIb-b170 ,-~N ~ p -CH(OH)-~N ,AV

IIb-171 ,-~N 0 -O-~N ,AV

IIb-172 N 0 C(O) IIb-173 p -NH-O,AV

IIb-174 /~N 0 -S-~N ,AV

IIb-175 /~N p -N(CH3)-~N ,,A,V

IIb-176 /-N p N(CHzCH3)-~N ,K~,V

IIb-177 /~N ~ p -N(CHzCHzCH3)-~N ,KV

IIb-178 /~N p -N(CHzCHzCHzCH3)-~N ,,A,V

IIb-179 /~N p -N(C(H)(CH3)(CHzCH3))-~N ,,A,V

IIb-180 ~ 0 -N(C(H)(CH3)z)-N,JtV

IIb-181 N ~ p -N(CH2C(H)(CH3)2)-~N

IIb-182 N p -N(C(CH3)3)-~N

IIb-183 -CHZ-N Me N

IIb-b183 -CH(OH)-N Me N
IIb-184 O-N Me -N

IIb-185 -C(O)-0Me IIb-186 NH-N Me -N

IIb-187 0Me IIb-188 -N(CH3)-N Me N
IIb-189 N(CHzCH3)-N Me N
IIb-190 -N(CH2CH2CH3)-N Me N

IIb-191 -N(CH2CH2CH2CH3)-N Me N
IIb-192 rN Me -N(C(H)(CH3)(CH2CH3))-N

IIb-193 rN Me -N(C(H)(CH3)2)-N

IIb-194 ~N Me -N(CH2C(H)(CH3)2)-N

IIb-195 ~ N Me -N(C(CH3)3)-N

IIb-196 ~N O-Et -CHZ-~N Et IIb-197 ~N O-Et -CH(OH)-~N,,1,O Et IIb-198 -~-N ~ O-Et -O-~N Et IIb-199 ON, D, Et C(O) O Et IIb-200 O-Et -NH-O,,,),O Et IIb-201 /~N O-Et -S-~N,,,~,O Et IIb-202 /~N O-Et -N(CH3)-~N,,,1,O Et IIb-203 /-N O-Et N(CHzCH3)-~N,,,),O Et IIb-204 ON, D ,Et -N(CHzCHzCH3) O Et IIb-205 O-Et -N(CH2CH2CH2CH3)-O,,,1,6Et IIb-206 O,Et -N(C(H)(CH3)(CH2CH3))-O,,1,6 Et IIb-207 ON, o, Et N(c(H)(cH3)z) O Et IIb-208 O-Et -N(CH2C(H)(CH3)2)-O,,1,6 Et IIb-209 /-N ~ O-Et -N(C(CH3)3)-~N,,,),O Et IIb-210 -CHZ-N

N

IIb-211 CH(OH) N

N

IIb-212 -O
N

N

IIb-213 C(O) N

N

IIb-214 /~ -NH-N /I
N

IIb-215 -S-N

N

IIb-216 -N(CH3)-N

N

IIb-217 N(CHzCH3) N

N

IIb-218 0 -N(CH2CH2CH3) NN
N

IIb-219 -N(CH2CH2CH2CH3)-N

N

IIb-220 -N(C(H)(CH3)(CHzCH3))-N

N

IIb-221 -N(C(H)(CH3)z)-N

N

IIb-222 -N(CH2C(H)(CH3)2)-N

N

IIb-223 0 -N(C(CH3)3)-N

N

and pharmaceutically acceptable salts thereof.

5.7 The Indenoisoquinolinone Analogs of Formula (IIc) The present invention provides Indenoisoquinolinone Analogs according to Formula (IIc) below:

NH

R' X

(IIc) and pharmaceutically acceptable salts thereof, wherein:
X and Ri are as defined above for the compounds of Formula (IIc).
In one embodiment, X is -CHz-. In another embodiment, X is -0-. In another embodiment, X is -C(O)-. In another embodiment, X is -NH-. In another embodiment, X
is N(Ci-C4 alkyl)-. In another embodiment, X is -S-. In another embodiment, X
is -CH(OH)-.
In one embodiment, n is 1. In another embodiment, n is 2.
In one embodiment, X is -CH2- and n is 1.
In one embodiment, X is -CH2- and n is 2.
In one embodiment, X is -CH(OH)- and n is 1.
In one embodiment, X is --CH(OH)- and n is 2.
In one embodiment, R2 is -Ci-C6 alkyl and R3 is -C(0)-(C1-C6 alkylene)-(3- to membered monocyclic heterocycle).
In one embodiment, R2 is -H and R3 is -C(0)-(C1-C6 alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, n is 1 and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one -C(0)0-C1-C6 alkyl.
In another embodiment, n is 1 and R3 is C3-C8 monocyclic cycloalkyl substituted with one hydroxy-substituted Ci-CS alkyl.
In one embodiment, n is 2 and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one -C(0)0-C1-C6 alkyl.
In another embodiment, n is 2 and R3 is C3-C8 monocyclic cycloalkyl substituted with one hydroxy-substituted Ci-CS alkyl.
In one embodiment, N, W and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which substituted with one of -C2-C6 alkenyl, -C(0)-C1-C6 alkyl, -(Ci-C4 alkylene)-C(0)-(C3-C8 monocyclic cycloalkyl), -C7-Cio alkyl, -(Ci-CS alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-CS alkyl, -(Ci-CS
alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or -(Ci-C5 alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, n is 1 and N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which substituted with one of -C2-C6 alkenyl, -C(0)-C1-C6 alkyl, -(Ci-C4 alkylene)-C(0)-(C3-C8 monocyclic cycloalkyl), -C7-C10 alkyl, -(CI-C5 alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-CS alkyl, -(Ci-CS alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or -(CI-C5 alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, X is -CH2-, n is 1 and N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which substituted with one of -Cz-C6 alkenyl, -C(O)-C1-C6 alkyl, -(Ci-C4 alkylene)-C(O)-(C3-C8 monocyclic cycloalkyl), -C7-Cio alkyl, -(CI-C5 alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-CS alkyl, -(CI-C5 alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or -(CI-C5 alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, X is -CH2-, n is 1, and R2 is C3-C8 monocyclic cycloalkyl.
In one embodiment, X is -CH2-, n is 1, and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one -C(O)O-C1-C6 alkyl.
In one embodiment, X is -CH2-, n is 1, and R3 is C3-C8 monocyclic cycloalkyl which is substituted with one hydroxy-substituted Ci-CS alkyl.
In one embodiment, X is -CH2-, n is 1, R2 is -H, and R3 is a nitrogen-containing 3-to 7-membered monocyclic heterocycle which is substituted with one -C(O)O-Ci-alkyl.
In one embodiment, X is -CH2-, n is 1, R2 is -H, and R3 is C3-C8 monocyclic cycloalkyl which is substituted with one hydroxy-substituted Ci-CS alkyl.
In another embodiment, X is -CH2-, n is 1 and R3 is -C(O)-C1-C6 alkylene-(3-to 7-membered monocyclic heterocycle).
In one embodiment, X is -CH(OH)-, n is 1 and N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which substituted with one of -C2-C6 alkenyl, -C(O)-C1-C6 alkyl, -(Ci-C4 alkylene)-C(O)-(C3-C8 monocyclic cycloalkyl), -C7-Cio alkyl, -(CI-C5 alkylene)-C(H)(-O-Ci-C4 alkyl)2, -(cyano-substituted) Ci-CS alkyl, -(CI-C5 alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or -(CI-C5 alkylene)-(3- to 7-membered monocyclic heterocycle).
In one embodiment, X is -CH(OH)-, n is 1, and R2 is C3-C8 monocyclic cycloalkyl.
In one embodiment, X is -CH(OH)-, n is 1, and R3 is a nitrogen-containing 3-to 7-membered monocyclic heterocycle which is substituted with one -C(O)O-C1-C6 alkyl.
In one embodiment, X is -CH(OH)-, n is 1, and R3 is C3-C8 monocyclic cycloalkyl which is substituted with one hydroxy-substituted Ci-CS alkyl.
In one embodiment, X is -CH(OH)-, n is 1, R2 is -H, and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one -C(O)O-Ci-C6 alkyl.
In one embodiment, X is -CH(OH)-, n is 1, R2 is -H, and R3 is C3-C8 monocyclic cycloalkyl which is substituted with one hydroxy-substituted Ci-CS alkyl.
In another embodiment, X is -CH(OH)-, n is 1 and R3 is -C(O)-Ci-C6 alkylene-(3-to 7-membered monocyclic heterocycle).

In various embodiments, -R1 is:

O H ON
~iCH2 ~ N
N N J, ~vNJ N ~\O
OH , -N^N "L

O HN~N-tBOC
kN" v N~ ~^O
Me GO ~~
CN NBOC
NG
~~ Me ~ N Me N^3,,0 '~,^N O'Me GN/, Me 0 , 0 , O O
A'N") 0 N 0 ~N Me G N
N ~N ~~N
or , Illustrative examples of the Indenoisoquinolinone Analogs include the compounds of Formula (IIc) in which n is 1 as set forth below:

Compound - Rl X
IIc-1 ^,,,,CH2 -CHZ-J
N

IIc-cl ,CH2 -CH(OH)-N J
IIc-2 ^ i~CH2 -O-rJ
N
IIc-3 N,CH2 -C(O)-N
IIc-4 ^ ~~CH2 -NH-N
IIc-5 ^ i~CH2 S
rJ
N
IIc-6 ,CH2 -N(CH3)-N J
IIc-7 J ^2 ,,,,CH2 -N(CH2CH3)-N
IIc-8 ~,CH2 -N(CH2CH2CH3)-N
J
IIc-9 ~~CH2 -N(CH2CH2CH2CH3)-N
J
IIc-10 fNCH2 -N(C(H)(CH3)(CH2CH3))-N J
IIc-11 f ,^, N,-, ~,,CHz -N(C(H)(CH3)2)-NI-/
IIc-12 N^,,~,,,CH2 -N(CH2C(H)(CH3)2)-N
IIc-13 J ,CH2 -N(C(CH3)3)-N
IIc-14 O~ -CHZ-O
IIc-c14 O~ -CH(OH)-\~N

IIc-15 O~ -O-O
\,N
IIc-16 0 -C(O)-O
\,N
IIc-17 O ~ -NH-O
\,N
IIc-18 -S-O
\,N
IIc-19 O ~ -N(CH3)-O
IIc-20 O~ N(CH2CH3)-\,N
IIc-21 O~ -N(CH2CH2CH3)-\,N
IIc-22 O~ -N(CH2CH2CH2CH3)-\,N
IIc-23 -N(C(H)(CH3)(CH2CH3))-\,N
IIc-24 O -N(C(H)(CH3)2)-\~N
IIc-25 -N(CH2C(H)(CH3)2)-\~N
IIc-26 -N(C(CH3)3)-O
\,N
IIc-27 N H?a CHZ
OH
IIc-c27 N H?a -CH(OH) OH

IIc-28 H -0-N

OH
IIc-29 N H?a C(O) OH
IIc-30 H -NH-N

OH
IIc-31 H S
N

OH
IIc-32 N H?a -N(CH3)-OH
IIc-33 N H?a N(CHzCH3)-OH
IIc-34 N H?a -N(CHzCHzCH3)-OH
IIc-35 N H-P -N(CHzCHzCHzCH3)-OH
IIc-36 N H -N(C(H)(CH3)(CHzCH3))-OH
IIc-37 N H?a -N(C(H)(CH3)z)-OH
IIc-38 N H-P -N(CHzC(H)(CH3)z)-OH
IIc-39 N H?a -N(C(CH3)3)-OH

IIc-40 -CHZ-OI
G
IIc-c40 -CH(OH)-ONI
G
IIc-41 ll~N -O-~N
NI
G
IIc-42 1-1-~N -C(O)-~N

IIc-43 /~N -NH-~N
NI
G
IIc-44 /~N -S-~N

C0________ IIc-45 -N(CH3)-O

C0________ IIc-46 N(CH2CH3)-O

C0________ IIc-47 -N(CH2CH2CH3)-C0________ IIc-48 -N(CHzCHzCHzCH3)-ONI
C0________ IIc-49 ") -N(C(H)(CH3)(CH2CH3))-N
NI
G
IIc-50 /~ i ~ -N(C(H)(CH3)z)-~N

C0________ IIc-51 -N(CHzC(H)(CH3)z)-ON1 C0________ IIc-52 /~N ~ -N(C(CH3)3)-~N

C0________ IIc-53 0 -CHZ-Me co IIc-c53 0 -CH(OH)-lllllN-'~co Me IIc-54 0 -O-lllllN-'~co Me IIc-55 0 -C(O)-1--l'-N--V\co Me IIc-56 0 -NH-1--l'-N--V\co Me IIc-57 0 -S-1--l'-N--V\N
Me GO

IIc-58 0 -N(CH3)-N
Me ~O
IIc-59 0 N(CH2CH3)-N--~ co Me IIc-60 0 -N(CH2CH2CH3)-N--~ co Me IIc-61 0 -N(CH2CH2CH2CH3)-N--~ co Me IIc-62 0 -N(C(H)(CH3)(CH2CH3))-N--~ co Me IIc-63 0 -N(C(H)(CH3)z)-co Me IIc-64 0 -N(CHzC(H)(CH3)z)-N--V\co Me IIc-65 0 -N(C(CH3)3)-N--V\co Me IIc-66 ,~N -CHZ-~N--~CN
IIc-c66 -~N -CH(OH)-~N --~C N
IIc-67 ,~N -O-~N--~CN
IIc-68 ---N -C(O)-~N--~CN
IIc-69 /-N -NH-" N-'-~CN
IIc-70 /~N -S-~N --~C N
IIc-71 /-N -N(CH3)-" N-'-~CN

IIc-72 N(CH2CH3)-O--~CN
IIc-73 /-N ~ -N(CHzCHzCH3)-~N--~CN
IIc-74 /~N -N(CHzCHzCHzCH3)-~N--~CN
IIc-75 /-N -N(C(H)(CH3)(CHzCH3))-~N --~C N
IIc-76 ,~N -N(C(H)(CH3)z)-N--~CN
N
IIc-77 /-N -N(CHzC(H)(CH3)z)-~N --~C N
IIc-78 /'-N ~ -N(C(CH3)3)-~N--~CN
IIc-79 -CHZ-~\N

tBOC
IIc-c79 ~ -CH(OH)-~\N

N
tBOC
IIc-80 -O-~\N

N
tBOC
IIc-81 -C(O)-~\N

N
tBOC

IIc-82 -NH-/~N

N
tBOC
IIc-83 -S-~\N

tBOC
IIc-84 -N(CH3)-/~N

N
tBOC
IIc-85 N(CH2CH3)-~\N

N
tBOC
IIc-86 -N(CH2CH2CH3)-~\N

N
tBOC
IIc-87 -N(CH2CH2CH2CH3)-/~N

N
tBOC
IIc-88 -N(C(H)(CH3)(CH2CH3))-~\N

N
tBOC

IIc-89 -N(C(H)(CH3)2)-N
tBOC
IIc-90 -N(CH2C(H)(CH3)2)-~\N

tBOC
IIc-91 -N(C(CH3)3)-/~N

N
tBOC
IIc-92 ~ -CHZ-H N-CN-tBOC

IIc-c92 ~ -CH(OH)-H N-CN-tBOC

IIc-93 -O-H N N-tBOC

IIc-94 ~ -C(O)-H N-CN-tBOC

IIc-95 -NH-H N N-tBOC

IIc-96 -S-H N N-tBOC

IIc-97 -N(CH3)-H N-CIN-tBOC

IIc-98 N(CH2CH3)-H N-CIN-tBOC

IIc-99 -N(CH2CH2CH3)-H N-CIN-tBOC

IIc-100 -N(CH2CH2CH2CH3)-H N-CIN-tBOC

IIc-101 -N(C(H)(CH3)(CH2CH3))-H N-CIN-tBOC

IIc-102 -N(C(H)(CH3)2)-H N-CIN-tBOC

IIc-103 -N(CH2C(H)(CH3)2)-H N-CIN-tBOC

IIc-104 -N(C(CH3)3)-H N-CIN-tBOC

IIc-105 N ~ Me -CHZ-~N~
O
IIc-c105 N ~ Me -CH(OH)-O

IIc-106 '~N ~ Me -0-~N~
O
IIc-107 N Me -C(O)-~N,~
O
IIc-108 ll~N ~ Me -NH-~N~
O
IIc-109 1-111-N Me -S-~N~
O
IIc-110 '~N ") Me -N(CH3)-~, N~
O
IIc-111 ',~N Me N(CHzCH3)-~N~f) O
IIc-112 ',~N ~ Me -N(CHzCHzCH3)-~N~

O
IIc-113 ll~N ~ Me -N(CH2CH2CH2CH3)-O
IIc-114 1-111-N Me -N(C(H)(CH3)(CH2CH3))-O
IIc-115 /1-N~ Me -N(C(H)(CH3)2)-O
IIc-116 N ~ Me -N(CH2C(H)(CH3)2)-O
IIc-117 N Me -N(C(CH3)3)-~N

O

IIc-118 N -CHZ-(DN Me IIc-c118 "'N -CH(OH)-(DN Me IIc-119 ~N -O-~N Me IIc-120 "'N -C(O)-(DN Me IIc-121 N -NH-(DN Me IIc-122 N S
(DN Me IIc-123 N -N(CH3)-~N Me IIc-124 N N(CHzCH3)-~N Me IIc-125 N -N(CHzCHzCH3)-~N Me IIc-126 N~ -N(CH2CH2CH2CH3)-N Me IIc-127 N~ -N(C(H)(CH3)(CH2CH3))-~'N Me IIc-128 -N(C(H)(CH3)2)-(DN Me IIc-129 N -N(CHzC(H)(CH3)z)-~N Me IIc-130 N -N(C(CH3)3)-~N Me IIc-131 -CHZ-N
IIc-c131 ,~i -CH(OH)-j'~ N
IIc-132 -O-N
IIc-133 -C(O)-N
IIc-134 /~ , ~ -NH-j'~ N
IIc-135 -S-N
IIc-136 /~ , -N(CH3)-j'~ N
IIc-137 j" , ") N(CH2CH3)-~ N
IIc-138 /~j" , ") -N(CH2CH2CH3)-~ N
IIc-139 /~j" , ") -N(CH2CH2CH2CH3)-~ N
IIc-140 i -N(C(H)(CH3)(CHzCH3))-j' N

IIc-141 ~ ~~ -N(c(H)(cH3)2)-N
IIc-142 i ~ -N(CHzC(H)(CH3)z)-j'~ N
IIc-143 ~~ -N(C(CH3)3)-N
IIc-144 0-Me -CHZ-O,1,O Me IIc-c144 1--l-N~ 0-Me -CH(OH)-~N,', 0 Me IIc-145 /--N~ 0-Me -O-~ N A O Me IIc-146 N") 0-Me -C(O)-~,N,A Me IIc-147 /l-N~ 0-Me -NH-~N,,,Q O Me IIc-148 0-Me -S-O,,,Q O Me IIc-149 /--N--') 0-Me -N(CH3)-~,, N ,I,O Me IIc-150 ") 0-Me N(CH2CH3)-N),O Me IIc-151 N--') 0-Me -N(CH2CH2CH3)-~, N~,Q Me IIc-152 0-Me -N(CHzCHzCHzCH3)-~,N,,~, Me IIc-153 N 0-Me -N(C(H)(CH3)(CHzCH3))-~,N,,,,Q Me IIc-154 N 0-Me -N(C(H)(CH3)2)-Me IIc-155 0-Me -N(CH2C(H)(CH3)2)-~ N ,I,O Me IIc-156 --') 0-Me -N(C(CH3)3)-~N Me IIc-157 N 0 -CHZ-N
V
IIc-c157 N 0 -CH(OH)-N
V
IIc-158 N 0 -O-N
V
IIc-159 N 0 -C(O)-N
V
IIc-160 N ~ 0 -NH-~NN
V
IIc-161 N 0 -S-N
V
IIc-162 N 0 -N(CH3)-~N,,,kN
V
IIc-163 N 0 N(CHzCH3)-~N,,,kN
V
IIc-164 N 0 -N(CHzCHzCH3)-~N~N
V
IIc-165 N ") 0 -N(CH2CH2CH2CH3)-N
V
IIc-166 N 0 -N(C(H)(CH3)(CH2CH3))-N
V
IIc-167 N 0 -N(C(H)(CH3)2)-NV

IIc-168 N ~ 0 -N(CH2C(H)(CH3)2)-N1j IIc-169 0 -N(C(CH3)3)-O)-N
V
IIc-170 p -CHZ-O,,A,V

IIc-c170 ,-~N ~ p -CH(OH)-~N ,,A,V

IIc-171 ,-~N 0 -O-~N ,,A,V

IIc-172 N 0 C(O) IIc-173 p -NH-~N

IIc-174 0 -S-~N

IIc-175 p -N(CH3)-~N

IIc-176 p N(CH2CH3)-O,K~,V
IIc-177 /~N ~ p -N(CHzCHzCH3)-~N ,KV

IIc-178 /~N p -N(CHzCHzCHzCH3)-~N ,,A,V

IIc-179 /~N p -N(C(H)(CH3)(CHzCH3))-~N ,,A,V

IIc-180 ~ 0 -N(C(H)(CH3)z)-N,JtV

IIc-181 N 0 -N(CH2C(H)(CH3)2)-~N

IIc-182 N 0 -N(C(CH3)3)-~N

IIc-183 -CHZ-N Me N

IIc-c183 -CH(OH)-N Me N
IIc-184 O-N Me -N

IIc-185 -C(O)-0Me IIc-186 -NH-N Me N

IIc-187 -S-N Me N

IIc-188 -N(CH3)-N Me N
IIc-189 N(CHzCH3)-N Me N
IIc-190 -N(CH2CH2CH3)-N Me N

IIc-191 -N(CH2CH2CH2CH3)-N Me N
IIc-192 rN Me -N(C(H)(CH3)(CH2CH3))-N

IIc-193 rN Me -N(C(H)(CH3)2)-N

IIc-194 ~N Me -N(CH2C(H)(CH3)2)-N

IIc-195 ~ N Me -N(C(CH3)3)-N

IIc-196 ~N O-Et -CHZ-~N Et IIc-197 ~N O-Et -CH(OH)-~N,,1,O Et IIc-198 -~-N O-Et -O-~N Et IIc-199 ON, D- Et C(O) O Et IIc-200 N O-Et -NH-~N Et IIc-201 /~N O-Et -S-~N,,,~,O Et IIc-202 /~N O-Et -N(CH3)-~N,,,1,O Et IIc-203 /-N ~ O-Et N(CHzCH3)-~N,,,),O Et IIc-204 N ~ O-Et -N(CH2CH2CH3) ~N~O Et IIc-205 O-Et -N(CH2CH2CH2CH3)-O,,,1,6Et IIc-206 O-Et -N(C(H)(CH3)(CH2CH3))-O,,1,6 Et IIc-207 ON, o, Et N(C(H)(CH3)z) O Et IIc-208 O,Et -N(CH2C(H)(CH3)2)-O,,1,6 Et IIc-209 -~-N ~ O-Et -N(C(CH3)3)-~N,,,),O Et and pharmaceutically acceptable salts thereof.

5.8 The Indenoisoquinolinone Analogs of Formula (IIIa) The present invention provides the following Indenoisoquinolinone Analogs according to Formula (IIIa) as set forth below:

NH
R' (IIIa) Compound - Rl IIIa-1 e N Me N
IIIa-2 r NMe N
IIIa-3 r' N
N
IIIa-4 H
NH
IIIa-5 H

IIIa-6 N
~\~~ N
N

IIIa-7 N,Me H
IIIa-8 N

N\N
N
IIIa-9 rJ
N
IIIa-10 N~
~N
'-~OEt IIIa-11 No IIIa-12 N
IIIa-13 N

~N, IIIa-14 /-ON
~
IIIa-15 Na F

IIIa-16 ON, tBOC

IIIa-17 IIIa-18 "~ON Me I-lk OH
Me IIIa-19 rO
N--, N

Me IIIa-20 HN-CNH
IIIa-21 N
La CF3 IIIa-22 /--N

IIIa-23 ON, CH2 3'OH
IIIa-24 Me NH

Me (cis dimethyl) and pharmaceutically acceptable salts thereof.

5.9 The Indenoisoquinolinone Analogs of Formula (IIIb) The present invention provides the following Indenoisoquinolinone Analogs according to Formula (IIIb) as set forth below:

NH

R' (IIIb) Compound - Rl IIIb-1 e N Me N
IIIb-2 r NMe N
IIIb-3 r' N
N
IIIb-4 H
H
IIIb-5 H

IIIb-6 N
r N
NI ~~~

IIIb-7 N, Me H
IIIb-8 N

ON) IIIb-9 rJ
N
IIIb-10 N~
~N
'-~OEt IIIb-11 NU
IIIb-12 No, IIIb-13 N

~N, IIIb-14 /--ON "
IIIb-15 Na F

IIIb-16 ON, tBOC

IIIb-17 IIIb-18 '~ON Me I-lk OH
Me IIIb-19 rO
N--, N

IIIb-20 Me HN-CNH
IIIb-21 N
La CF3 IIIb-22 /--N

IIIb-23 ON, CH2 3'OH
IIIb-24 Me NH

Me (cis dimethyl) and pharmaceutically acceptable salts thereof.

5.10 The Indenoisoquinolinone Analogs of Formula (IVa) The present invention provides Indenoisoquinolinone Analogs according to Formula (IVa), below:

NH

X

R' (IV a) and pharmaceutically acceptable salts thereof, wherein X and Ri are as defined above for the Indenoisoquinolinone Analogs of Formula (IVa).
In one embodiment, X is N(CH3)-. In another embodiment, X is is -N(CH2CH3)-. In another embodiment, X is -N(CH2CH2CH3)-. In another embodiment, X is -N(CH2CH2CH2CH3)-. In another embodiment, X is -N(C(H)(CH3)(CH2CH3))-. In another embodiment, X is -N(C(H)(CH3)2)-. In another embodiment, X is -N(CH2C(H)(CH3)2)-. In another embodiment, X is -N(C(CH3)3)-.
In one embodiment, X is -0-. In one embodiment, X is -CHz-. In one embodiment, X is -C(O)-. In one embodiment, X is -NH-. In one embodiment, X is -S-.
In one embodiment, X is -CH(OH)-.
In one embodiment, each Ci-C3 alkyl is independent of the other Ci-C3 alkyl.
In one embodiment, each Ci-C3 alkyl is methyl.
In one embodiment, each Ci-C3 alkyl is methyl and X is -CHz-.
In one embodiment, each Ci-C3 alkyl is methyl and X is -CH(OH)-.
In one embodiment, each Ci-C3 alkyl is methyl, X is -CH2- and n is 1.
In one embodiment, each Ci-C3 alkyl is methyl, X is -CH(OH)- and n is 1.
In another embodiment, X is -CH(OH)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)z-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-Z)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)z-Z)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CHz)-Z)- and n is 1.

In one embodiment, X is -N((CHz)q Z)-.
In another embodiment, X is -N((CHz)-Z)-.
In another embodiment, X is -N((CHz)z-Z)-.
In another embodiment, X is -N((CHz)q Z)- and n is 1.
In yet another embodiment, X is -N((CHz)q Z)- and n is 2.
In still another embodiment, X is -N((CH2)-Z)- and n is 1.
In still another embodiment, X is -N((CH2)-Z)- and n is 2.
In one embodiment, Z is -CF3.
In another embodiment, Z is -F.
In yet another embodiment, Z is -OH.
In still another embodiment, Z is -O-CH3.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OH)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OH)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p OH)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)- and n is 1.
In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)- and n is 2.
In one embodiment, X is -N((CHz)q OH)-.
In another embodiment, X is -N((CH2)2-OH)-.
In another embodiment, X is -N((CHz)q OH)- and n is 1.
In yet another embodiment, X is -N((CHz)q OH)- and n is 2.
In still another embodiment, X is -N((CH2)2-OH)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-F)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)-F)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-F)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p F)- n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)-F)- and n is 1.
In one embodiment, X is -N((CHz)q F)-.
In another embodiment, X is -N((CH2)-F)-.
In another embodiment, X is -N((CHz)q F)- and n is 1.
In yet another embodiment, X is -N((CHz)q F)- and n is 2.
In still another embodiment, X is -N((CH2)-F)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OMe)-.

In another embodiment, X is -N(C(O)N(H)-(CH2)2-OMe)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OMe)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p OMe)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OMe)- and n is 1.
In one embodiment, X is -N((CHz)q OMe)-.
In another embodiment, X is -N((CH2)2-OMe)-.
In another embodiment, X is -N((CHz)q OMe)- and n is 1.
In yet another embodiment, X is -N((CHz)q OMe)- and n is 2.
In still another embodiment, X is -N((CH2)2-OMe)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)p-CF3)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p CF3)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)-CF3)- and n is 1.
In one embodiment, X is -N((CHz)q CF3)-.
In another embodiment, X is -N((CH2)-CF3)-.
In another embodiment, X is -N((CHz)q CF3)- and n is 1.
In yet another embodiment, X is -N((CHz)q CF3)- and n is 2.
In still another embodiment, X is -N((CH2)-CF3)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)p-CF3)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p CF3)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)-CF3)- and n is 1.
In one embodiment, X is -N((CHz)q CF3)-.
In another embodiment, X is -N((CHz)-CF3)-.
In another embodiment, X is -N((CHz)q CF3)- and n is 1.
In yet another embodiment, X is -N((CHz)q CF3)- and n is 2.
In still another embodiment, X is -N((CH2)-CF3)- and n is 1.
In one embodiment, n is 1.
In another embodiment, n is 2.
In yet another embodiment, n is 3.
In a further embodiment, n is 4, 5, or 6.

In yet a further embodiment, n is 7, 8, or 9.
In still a further embodiment, n is 10.
In one embodiment, p is 1.
In another embodiment, p is 2.
In yet another embodiment, p is an integer ranging from 2 to 5.
In one embodiment, q is 1.
In another embodiment, q is 2.
In yet another embodiment, q is an integer ranging from 2 to 5.
In one embodiment, n is 1 and X is -N(CH3)-.
In another embodiment, n is 1 and X is -N(CHzCH3).
In another embodiment, n is 1 and X is -N(CHzCHzCH3)-.
In another embodiment, n is 1 and X is -N(CHzCHzCHzCH3)-.
In another embodiment, n is 1 and X is -N(C(H)(CH3)(CHzCH3))-.
In another embodiment, n is 1 and X is -N(C(H)(CH3)2)-.
In another embodiment, n is 1 and X is -N(CHzC(H)(CH3)z)-.
In another embodiment, n is 1 and X is -N(C(CH3)3)-.
In one embodiment, one R2 is -H, and the other R2 is -Ci-C6 alkyl.
In another embodiment, each R2 is -Ci-C6 alkyl.
In another embodiment, each R2 is -methyl.
In various embodiments, -N(R2)(R2) is:

/ v / \ / \ CH3 -N 0 ~-NaOH ~-NN-CH3 ~-NN
~-N/-\ H 2-N ~-N ~N--/--N(CHs)2 I-N N~0 N N-/Ph C(O)OH C(O)OCHZCH3 H ~-N N_/ ~-N\ /N-/

~ / \N--"~NH

H3C/~CH3 where X = -H -OMe -CN -F
-Cl, -Br, or -I

N(CH3)2 OH

-N N -N N ~-N\CH3 ~-N\CH2CH3 /CH2CH2OH /CH2CH2N(CH3)2 /CH2Ph /CH2CH2OCH3 ~-N\CH2CH2OH ~-N\CH2CH2N(CH3)2 ~-N\CH3 ~-N\CH2CH2OCH3 CH3 CH2N(CH3)2 ~_N`CH3 N~CH3 I_N~CH3 ~-N' CH2N(CH3)2 ~-N\-7 I-NaOH N CH3 CH3 CH3 ~- -I-N
-CH3 ~-N

H N~/~N~ ~O N.CH3 ~O NH ~
N~ NN
~ ~~ - 482 -NN,CH3 , NN=/

/ \ I-Na OH - OP(O)(OH)2 N or I- NNCH2CH2OP(O)(OH)2 OP(O)(OH)2 In other embodiments, -N(R2)(R2) is:

/~rN ) ~\ I-N/~rN I /~
\N
~-N
~/ ~/ ~/ ~J
/ I- I-N
~ , HON O
`N OH OMe ~-N -N 0 I-No I-N`~
\~ ao N3 Hp_ ~
1 N OH I-NH ,CH2CH3 I-NH I-N I-NH

D, /-\ s I-NH CHs N ~/ ' H CH3 N

I_N ~_CH3 i-NH H3C
_O
I-NEH I-N N

OH

i-N - CH
~ NON, N Z ~~
I-N H N ' 'I-NN-\iOH
_ -1- ~~N~iCH3 -1-N~OEt , -i-NN-NIIiOMe ' -1-N

_ ~\ 0 CH3 OH
~ N~OEt ~-N~ OH ~-N CH3 ~-N CH3 H3C\
N-CH3 ' -1-N-CH2CH3 ~-N-CH2CH2CH3 -HrCH3 H3 N ~-N
O Me >--CH3 -N-CH2CH2OH , 0 , H3C -~-N ~ or \ --IQ

~-N ~N

In some embodiments, -N(R2)(R2) is AN
I V
F F
~-N\~ N Q~aF
NMe2 NMe2 F
N
-N N
or In still other embodiments, -N(R2)(R2) is -N(CH2CH3)(CH3), -N(CH2CH2CH3)(CH3), -N(CH2CH2CH2CH3)(CH3), -NH-CH2CH2CH2CH3, or -NH-CH2CH2-O-CH3.
In some embodiments, -N(R2)(R2) is aOPO(OH)2 ~-N ~-N OPO(OH)2 OPO(OH)2 , H H3 _ H

or OPO(OH)2 OPO(OH)2 OPO(OH)2 In various embodiments, -N(Z3)(Z4) is:

/ \ / \ CH3 -N 0 ~-NaOH ~-N\ N-CH3 ~-N\ N~
-N NH -N ~-N \ N_/-N(CH3)2 ~-N/ N \ / F

~-N NO N N-/Ph C(O)OH C(O)OCH2CH3 H~ ~-N / N _/ ~-N/ \N~
~

O HO
H3C CH3 where X = -H, -OMe, -CN, -F, -Cl, -Br, or -I
N(CH3)2 OH

-N N -N N / N ~-N\CH3 ~-N\CH2CH3 I-N\CH2CH2OH ~-N\CH2CH2N(CH3)2 I-N\CH2Ph I-N\CH2CH2OCH3 CH2CH2OH CH2CH2N(CH3)2 CH3 CH2CH2OCH3 ~ Hs ~-H2N(CHs)2 I_N`CH3 N~CH3 ~-NQH3 ~-N~ H2N(CH3)2 CH3 ~CH3 ~-N\-7 ~-N~
`~\OH

~- -I-N -CH3 ~-N

N~\N^ O H N.CH3 N~
~ H N,/~ N

NN,CH3 , NN=/
~OH ~-N`~
OP(O)(OH)2 ~-N or NCH2CH2OP(O)(OH)2 OP(O)(OH)2 In other embodiments, -N(Z3)(Z4) is:

õ~.
I
\ N) I-NO-Nb I-NO-Nb I N I-HO O
I-N .OH }_No OMe N
I_N Z
N
`~
~ HO_ ~ O
~
~N OH I-NH t-NH i-N, CH2CH3 ~-NH
~

I-N\_jS ' 1-NIC~-\0 H I-N

I-N OH
0 , OH

i-N CHs N~ , ~~
}-N ~ / N ~N`CH3 2 CH3CH2 }-NH N CH3 Z
-NH N I-N\_/ N--\iOH
/~
I-N~j ~iCH3 -1-N, rOEt 'i-N

N N~ O ,CH3 OH
I 'OEt ~-N~ I-N I-N_ rCH3 OH kCH3 ~/

H3C\
~-N-CH3 =}-N-CH2CH3 '~-N-CH2CH2CH3 HrCHs ~H3 ~-CH3 TNH
CH3 or v/

In some embodiments, -N(Z3)(Z4) is A N
I
F F
N\~ ~\N N
v F
NMe2 NMe2 F Q -N N
or In still other embodiments, -N(Z3)(Z4) is -N(CH2CH3)(CH3), -N(CH2CH2CH3)(CH3), -N(CH2CH2CH2CH3)(CH3), -NH-CH2CH2CH2CH3, or -NH-CHzCHz-O-CH3.
In some embodiments, -N(Z3)(Z4) is N ~-N ~- N OPO(OH)2 OPO(OH)2 OPO(OH)2 or ~

In one embodiment, X is N(CH3)- N(CHzCH3)- -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-;
n is an integer ranging from 1 to 3;
each R2 is independently -H, -Ci-C6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(Ci-C6 alkylene)-phenyl or phenyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)z, -OS(O)zOH or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -Ci-CS alkyl, or -(CI-C5 alkylene)-O-Ci-CS alkyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH or -NH2;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -Ci-CS
alkyl, -phenyl, -(CI-C5 alkylene)-phenyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(CI-C5 alkylene)-N(Ra)z, -Ci-CS alkylene-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(CI-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(CI-C5 alkylene)-OP(O)(OH)2, -(CI-C5 alkylene)-OS(O)zOH, -C(O)O-Ci-Cs alkyl, -OC(O)-Ci-Cs alkyl, -(Ci-Cs alkylene)-C(O)O-Ci-Cs alkyl, -(CI-C5 alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, or -Ci-Cio alkyl;
or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -Ci-CS alkyl, -phenyl, -(CI-C5 alkylene) -phenyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(CI-C5 alkylene)-N(Ra)z, -(CI-C5 alkylene)-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(CI-alkylene)-COOH, -OP(O)(OH)z, -OS(O)zOH, -(CI-C5 alkylene)-OP(O)(OH)2, -(CI-C5 alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)O-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, or -Ci-Cio alkyl.
In one embodiment, X is N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-;
n is an integer ranging from 1 to 3; and at least one Ci-C3 alkyl is methyl.

In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; at least one Ci-C3 alkyl is methyl; and at least one R2 is ethyl.
In yet another embodiment, X is -N(CH3)- -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; at least one Ci-C3 alkyl is methyl; and at least one R2 is propyl.
In one embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; at least one Ci-C3 alkyl is methyl; and at least one R2 is -C3-C8 monocyclic cycloalkyl.
In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; at least one Ci-C3 alkyl is methyl; and at least one R2 is cyclohexyl.
In yet another embodiment, X is -N(CH3)- -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; and at least one Ci-C3 alkyl is methyl, wherein N
and both W groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle.
In one embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; and at least one Ci-C3 alkyl is methyl, wherein N
and both W groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with a hydroxyl.
In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-; and at least one Ci-C3 alkyl is methyl, wherein N
and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with a nitrogen-containing 3- to membered monocyclic heterocycle.

Illustrative examples of the Indenoisoquinolinone Analogs include the compounds of Formula (IVa) as set forth below:

NH
X

R' (IVa) Compound - R X
IVa-1 -OC(Me)(Me)-CH2-N(Et)(Et) -0-IVa-2 -OC(Me)(Me)-CHz-N(Et)(Et) -CH2-IVa-3 -OC(Me)(Me)-CHz-N(Et)(Et) -C(O)-IVa-4 -OC(Me)(Me)-CHz-N(Et)(Et) -NH-IVa-5 -OC(Me)(Me)-CHz-N(Et)(Et) -S-IVa-6 -OC(Me)(Me)-CHz-N(Et)(Et) -N(CH3)-IVa-7 -OC(Me)(Me)-CHz-N(Et)(Et) -N(CH2CH3)-IVa-8 -OC(Me)(Me)-CHz-N(Et)(Et) N(CH2CH2CH3)-IVa-9 -OC(Me)(Me)-CHz-N(Et)(Et) -N(CH2CH2CH2CH3)-IVa-10 -OC(Me)(Me)-CHz-N(Et)(Et) -N(C(H)(CH3)(CH2CH3))-IVa-11 -OC(Me)(Me)-CHz-N(Et)(Et) -N(C(H)(CH3)2)-IVa-12 -OC(Me)(Me)-CHz-N(Et)(Et) -N(CH2C(H)(CH3)2)-IVa-13 -OC(Me)(Me)-CHz-N(Et)(Et) -N(C(CH3)3)-IVa-14 -OC(Me)(Me)-CHz-N(Et)(Et) -CH(OH)-IVa-15 -OC(Me)(Me)-CHz-N(Et)(Et) -N(C(O)N(H)-CHz-CHz-OH)-IVa-16 -OC(Me)(Me)-CH2-N(Et)(Et) -N(C(O)N(H)-CH2-CH2-F)-IVa-17 -OC(Me)(Me)-CH2-N(Et)(Et) -N(CH2-CH2-OH)-IVa-18 -OC(Me)(Me)-CH2-N(Et)(Et) -N(CH2-CH2-F)-IVa-19 -OC(Me)(Me)-CH2-N(Et)(Et) -N(CH2-CH2-OCH3)-IVa-20 -OC(Me)(Me)-CH2-N(Et)(Et) -N(CH2-CH2-CF3)-IVa-21 -OC(Me)(Me)-CH2-N(Et)(Et) -N(C(O)N(H)-CH2-CH2-OCH3)-IVa-22 -OC(Me)(Me)-CH2-N(Et)(Et) -N(C(O)N(H)-CH2-CH2-CF3)-IVa-23 -OC(Me)(Et)-CH2-N(Et)(Et) -0-IVa-24 -OC(Me)(Et)-CH2-N(Et)(Et) -CH2-IVa-25 -OC(Me)(Et)-CH2-N(Et)(Et) -C(O)-IVa-26 -OC(Me)(Et)-CHz-N(Et)(Et) -NH-IVa-27 -OC(Me)(Et)-CHz-N(Et)(Et) -S-IVa-28 -OC(Me)(Et)-CHz-N(Et)(Et) -N(CH3)-IVa-29 -OC(Me)(Et)-CHz-N(Et)(Et) -N(CH2CH3)-IVa-30 -OC(Me)(Et)-CHz-N(Et)(Et) N(CH2CH2CH3)-IVa-31 -OC(Me)(Et)-CHz-N(Et)(Et) -N(CH2CH2CH2CH3)-IVa-32 -OC(Me)(Et)-CHz-N(Et)(Et) -N(C(H)(CH3)(CH2CH3))-IVa-33 -OC(Me)(Et)-CHz-N(Et)(Et) -N(C(H)(CH3)2)-IVa-34 -OC(Me)(Et)-CHz-N(Et)(Et) -N(CH2C(H)(CH3)2)-IVa-35 -OC(Me)(Et)-CHz-N(Et)(Et) -N(C(CH3)3)-IVa-36 -OC(Me)(Et)-CHz-N(Et)(Et) -CH(OH)-IVa-37 -OC(Me)(Et)-CHz-N(Et)(Et) N(C(O)N(H)-CH2-CH2-OH)-IVa-38 -OC(Me)(Et)-CHz-N(Et)(Et) N(C(O)N(H)-CH2-CH2-F)-IVa-39 -OC(Me)(Et)-CHz-N(Et)(Et) N(CH2-CH2-OH)-IVa-40 -OC(Me)(Et)-CHz-N(Et)(Et) -N(CH2-CH2-F)-IVa-41 -OC(Me)(Et)-CHz-N(Et)(Et) -N(CH2-CH2-OCH3)-IVa-42 -OC(Me)(Et)-CHz-N(Et)(Et) -N(CH2-CH2-CF3)-IVa-43 -OC(Me)(Et)-CHz-N(Et)(Et) N(C(O)N(H)-CH2-CH2-OCH3)-IVa-44 -OC(Me)(Et)-CH2-N(Et)(Et) -N(C(O)N(H)-CH2-CH2-CF3)-IVa-45 -OC(Me)(Pr)-CH2-N(Et)(Et) -0-IVa-46 -OC(Me)(Pr)-CH2-N(Et)(Et) -CH2-IVa-47 -OC(Me)(Pr)-CH2-N(Et)(Et) -C(O)-IVa-48 -OC(Me)(Pr)-CHz-N(Et)(Et) -NH-IVa-49 -OC(Me)(Pr)-CHz-N(Et)(Et) -S-IVa-50 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(CH3)-IVa-51 -OC(Me)(Pr)-CHz-N(Et)(Et) N(CH2CH3)-IVa-52 -OC(Me)(Pr)-CHz-N(Et)(Et) N(CH2CH2CH3)-IVa-53 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(CH2CH2CH2CH3)-IVa-54 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(C(H)(CH3)(CH2CH3))-IVa-55 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(C(H)(CH3)2)-IVa-56 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(CH2C(H)(CH3)2)-IVa-57 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(C(CH3)3)-IVa-58 -OC(Me)(Pr)-CHz-N(Et)(Et) -CH(OH)-IVa-59 -OC(Me)(Pr)-CHz-N(Et)(Et) N(C(O)N(H)-CH2-CH2-OH)-IVa-60 -OC(Me)(Pr)-CHz-N(Et)(Et) N(C(O)N(H)-CH2-CH2-F)-IVa-61 -OC(Me)(Pr)-CHz-N(Et)(Et) N(CH2-CH2-OH)-IVa-62 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(CH2-CH2-F)-IVa-63 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(CH2-CH2-OCH3)-IVa-64 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(CH2-CH2-CF3)-IVa-65 -OC(Me)(Pr)-CHz-N(Et)(Et) N(C(O)N(H)-CH2-CH2-OCH3)-IVa-66 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(C(O)N(H)-CH2-CH2-CF3)-IVa-67 -OC(Me)(i-Pr)-CHz- -O-N H c clo ro 1 IVa-68 -OC(Me)(i-Pr)-CHz- -CHz-N(H)(cyclopropyl) IVa-69 -OC(Me)(i-Pr)-CHz- -C(O)-N H c clo ro 1 IVa-70 -OC(Me)(i-Pr)-CH2- -NH-N H c clo ro 1 IVa-71 -OC(Me)(i-Pr)-CHz- -S-N H c clo ro 1 IVa-72 -OC(Me)(i-Pr)-CH2- -N(CH3)-N(H)(cyclopropyl) IVa-73 -OC(Me)(i-Pr)-CH2- N(CH2CH3)-N H c clo ro 1 IVa-74 -OC(Me)(i-Pr)-CH2- N(CH2CH2CH3)-N H c clo ro 1 IVa-75 -OC(Me)(i-Pr)-CH2- -N(CH2CH2CH2CH3)-N H c clo ro 1 IVa-76 -OC(Me)(i-Pr)-CH2- -N(C(H)(CH3)(CH2CH3))-N H c clo ro 1 IVa-77 -OC(Me)(i-Pr)-CH2- -N(C(H)(CH3)2)-N H c clo ro 1 IVa-78 -OC(Me)(i-Pr)-CH2- -N(CH2C(H)(CH3)2)-N H c clo ro 1 IVa-79 -OC(Me)(i-Pr)-CH2- -N(C(CH3)3)-N(H)(cyclopropyl) IVa-80 -OC(Me)(i-Pr)-CH2- -CH(OH)-N H c clo ro 1 IVa-81 -OC(Me)(i-Pr)-CH2- N(C(O)N(H)-CHz-CHz-OH)-N H c clo ro 1 IVa-82 -OC(Me)(i-Pr)-CH2- N(C(O)N(H)-CHz-CHz-F)-N H c clo ro 1 IVa-83 -OC(Me)(i-Pr)-CH2- N(CHz-CHz-OH)-N H c clo ro 1 IVa-84 -OC(Me)(i-Pr)-CH2- -N(CHz-CHz-F)-N H c clo ro 1 IVa-85 -OC(Me)(i-Pr)-CH2- -N(CH2-CH2-OCH3)-N H c clo ro 1 IVa-86 -OC(Me)(i-Pr)-CH2- -N(CHz-CHz-CF3)-N(H)(cyclopropyl) IVa-87 -OC(Me)(i-Pr)-CH2- N(C(O)N(H)-CH2-CH2-OCH3)-N(H)(cyclopropyl) IVa-88 -OC(Me)(i-Pr)-CH2- -N(C(O)N(H)-CH2-CH2-CF3)-N H c clo ro 1 and pharmaceutically acceptable salts thereof.

5.11 The Indenoisoquinolinone Analogs of Formula (IVb) The present invention provides Indenoisoquinolinone Analogs according to Formula (IVb), below:

NH
X

R' (IVb) and pharmaceutically acceptable salts thereof, wherein X and Ri are as defined above for the Indenoisoquinolinone Analogs of Formula (IVb).
In one embodiment, X is N(CH3)-. In another embodiment, X is is -N(CH2CH3)-. In another embodiment, X is -N(CH2CH2CH3)-. In another embodiment, X is -N(CH2CH2CH2CH3)-. In another embodiment, X is -N(C(H)(CH3)(CH2CH3))-. In another embodiment, X is -N(C(H)(CH3)2)-. In another embodiment, X is -N(CH2C(H)(CH3)2)-. In another embodiment, X is -N(C(CH3)3)-.
In one embodiment, X is -0-. In one embodiment, X is -CH2-. In one embodiment, X is -C(O)-. In one embodiment, X is -NH-. In one embodiment, X is -S-.
In one embodiment, X is -CH(OH)-.
In one embodiment, each Ci-C3 alkyl is independent of the other Ci-C3 alkyl.
In one embodiment, each Ci-C3 alkyl is methyl.
In one embodiment, each Ci-C3 alkyl is methyl and X is -CHz-.
In one embodiment, each Ci-C3 alkyl is methyl and X is -CH(OH)-.
In one embodiment, each Ci-C3 alkyl is methyl, X is -CH2- and n is 1.
In one embodiment, each Ci-C3 alkyl is methyl, X is -CH(OH)- and n is 1.
In another embodiment, X is -CH(OH)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)z-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-Z)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)z-Z)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CHz)-Z)- and n is 1.

In one embodiment, X is -N((CHz)q Z)-.
In another embodiment, X is -N((CHz)-Z)-.
In another embodiment, X is -N((CHz)z-Z)-.
In another embodiment, X is -N((CHz)q Z)- and n is 1.
In yet another embodiment, X is -N((CHz)q Z)- and n is 2.
In still another embodiment, X is -N((CH2)-Z)- and n is 1.
In still another embodiment, X is -N((CH2)-Z)- and n is 2.
In one embodiment, Z is -CF3.
In another embodiment, Z is -F.
In yet another embodiment, Z is -OH.
In still another embodiment, Z is -O-CH3.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OH)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OH)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p OH)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)- and n is 1.
In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)- and n is 2.
In one embodiment, X is -N((CHz)q OH)-.
In another embodiment, X is -N((CH2)2-OH)-.
In another embodiment, X is -N((CHz)q OH)- and n is 1.
In yet another embodiment, X is -N((CHz)q OH)- and n is 2.
In still another embodiment, X is -N((CH2)2-OH)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-F)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)-F)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-F)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p F)- n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)-F)- and n is 1.
In one embodiment, X is -N((CHz)q F)-.
In another embodiment, X is -N((CH2)-F)-.
In another embodiment, X is -N((CHz)q F)- and n is 1.
In yet another embodiment, X is -N((CHz)q F)- and n is 2.
In still another embodiment, X is -N((CH2)-F)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OMe)-.

In another embodiment, X is -N(C(O)N(H)-(CH2)2-OMe)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OMe)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p OMe)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OMe)- and n is 1.
In one embodiment, X is -N((CHz)q OMe)-.
In another embodiment, X is -N((CH2)2-OMe)-.
In another embodiment, X is -N((CHz)q OMe)- and n is 1.
In yet another embodiment, X is -N((CHz)q OMe)- and n is 2.
In still another embodiment, X is -N((CH2)2-OMe)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)p-CF3)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p CF3)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)-CF3)- and n is 1.
In one embodiment, X is -N((CHz)q CF3)-.
In another embodiment, X is -N((CH2)-CF3)-.
In another embodiment, X is -N((CHz)q CF3)- and n is 1.
In yet another embodiment, X is -N((CHz)q CF3)- and n is 2.
In still another embodiment, X is -N((CH2)-CF3)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)p-CF3)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p CF3)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)-CF3)- and n is 1.
In one embodiment, X is -N((CHz)q CF3)-.
In another embodiment, X is -N((CHz)-CF3)-.
In another embodiment, X is -N((CHz)q CF3)- and n is 1.
In yet another embodiment, X is -N((CHz)q CF3)- and n is 2.
In still another embodiment, X is -N((CH2)-CF3)- and n is 1.
In one embodiment, n is 1.
In another embodiment, n is 2.
In yet another embodiment, n is 3.
In a further embodiment, n is 4, 5, or 6.

In yet a further embodiment, n is 7, 8, or 9.
In still a further embodiment, n is 10.
In one embodiment, p is 1.
In another embodiment, p is 2.
In yet another embodiment, p is an integer ranging from 2 to 5.
In one embodiment, q is 1.
In another embodiment, q is 2.
In yet another embodiment, q is an integer ranging from 2 to 5.
In one embodiment, n is 1 and X is -N(CH3)-.
In another embodiment, n is 1 and X is -N(CHzCH3).
In another embodiment, n is 1 and X is -N(CHzCHzCH3)-.
In another embodiment, n is 1 and X is -N(CHzCHzCHzCH3)-.
In another embodiment, n is 1 and X is -N(C(H)(CH3)(CHzCH3))-.
In another embodiment, n is 1 and X is -N(C(H)(CH3)2)-.
In another embodiment, n is 1 and X is -N(CHzC(H)(CH3)z)-.
In another embodiment, n is 1 and X is -N(C(CH3)3)-.
In one embodiment, one R2 is -H, and the other R2 is -Ci-C6 alkyl.
In another embodiment, each R2 is -Ci-C6 alkyl.
In another embodiment, each R2 is -methyl.
In various embodiments, -N(R2)(R2) is:

/ v / \ / \ CH3 -N 0 ~-NaOH ~-NN-CH3 ~-NN
~-N/-\ H 2-N ~-N ~N--/--N(CHs)2 I-N N~0 N N-/Ph C(O)OH C(O)OCHZCH3 H ~-N N_/ ~-N\ /N-/

~ / \N--"~NH

H3C/~CH3 where X = -H -OMe -CN -F
-Cl, -Br, or -I

N(CH3)2 OH

-N N -N N ~-N\CH3 ~-N\CH2CH3 /CH2CH2OH /CH2CH2N(CH3)2 /CH2Ph /CH2CH2OCH3 ~-N\CH2CH2OH ~-N\CH2CH2N(CH3)2 ~-N\CH3 ~-N\CH2CH2OCH3 CH3 CH2N(CH3)2 ~_N`CH3 N~CH3 I_N~CH3 ~-N' CH2N(CH3)2 ~-N\-7 I-NaOH N CH3 CH3 CH3 ~- -I-N
-CH3 ~-N

H N~/~N~ ~O N.CH3 ~O NH ~
N~ NN
~ ~~ -500-NN,CH3 , NN=/

/ \ I-Na OH - OP(O)(OH)2 N or I- NNCH2CH2OP(O)(OH)2 OP(O)(OH)2 In other embodiments, -N(R2)(R2) is:

/~rN ) ~\ I-N/~rN I /~
\N
~-N
~/ ~/ ~/ ~J
/ I- I-N
~ , HON O
`N OH OMe ~-N -N 0 I-No I-N`~
\~ ao N3 Hp_ ~
1 N OH I-NH ,CH2CH3 I-NH I-N I-NH

D, /-\ s I-NH CHs N ~/ ' H CH3 N

I_N ~_CH3 i-NH H3C
_O
I-NEH I-N N

OH

i-N - CH
~ NON, N Z ~~
I-N H N 'I-N~N-\iOH
_ -1- ~~N~iCH3 -1-N~OEt , -i-NN-NIIiOMe ' -1-N

_ ~\ 0 CH3 OH
~ N~OEt ~-N~ OH ~-N CH3 ~-N CH3 H3C\
N-CH3 ' -1-N-CH2CH3 ~-N-CH2CH2CH3 -HrCH3 H3 N ~-N
O Me >--CH3 -N-CH2CH2OH , 0 , H3C -~-N ~ or \ --IQ

~-N ~N
In some embodiments, -N(R2)(R2) is N
I
F F
~\No ~\N - N
F
;
NMe2 NMe2 F
N
N N
or In still other embodiments, -N(R2)(R2) is -N(CH2CH3)(CH3), -N(CH2CH2CH3)(CH3), -N(CH2CH2CH2CH3)(CH3), -NH-CH2CH2CH2CH3, or -NH-CH2CH2-O-CH3.
In some embodiments, -N(R2)(R2) is -aOPO(OH)2 /-N /-N OPO(OH)2 OPO(OH) , 2 _ .CH3 ~ H

N i_N i-N
or ~a OPO(OH)2 OPO(OH)2 OPO(OH)2 In various embodiments, -N(Z3)(Z4) is:

-N\ 0 ~-NaOH ~-N\ N-CH3 ~-N\ N-/

~-N NH -N ~-N ~N--//--N(CHs)2 ~-N / \ N~O N N~Ph C(O)OH C(O)OCH2CH3 H - ~-N\ N~ ~-N\ N~

~ / \N--"~NH

H3C/~CH3 where X = -H -OMe -CN -F
-Cl, -Br, or -I

N(CH3)2 OH

-N N -N N ~-N\CH3 ~-N\CH2CH3 /CH2CH2OH /CH2CH2N(CH3)2 /CH2Ph /CH2CH2OCH3 ~-N\CH2CH2OH ~-N\CH2CH2N(CH3)2 ~-N\CH3 ~-N\CH2CH2OCH3 CH3 CH2N(CH3)2 ~_N`CH3 N~CH3 I_N~CH3 ~-N' CH2N(CH3)2 ~-N\-7 I-NaOH N CH3 CH3 CH3 ~- -I-N
-CH3 ~-N

H N~/~N~ ~O N.CH3 ~O NH ~
N~ NN
~ ~~ -504-/NN,CH3 N
'~. N=/
, ~OH ~-NU
OP(O)(OH)2 N or NCH2CH2OP(O)(OH)2 OP(O)(OH)2 In other embodiments, -N(Z3)(Z4) is:
,.~,.

U N I ND-NU I ND-NU

HO O
~
P .OH }_No OMe N
I-No 2 - , N
3 HD_~ O
, ',,N OH 2-NH i-NH i-N CH2CH3 i_NH
U U
D

I-NC~-\O H ' i-N ~--~\ N

N
0 I_N
OH
OH

I-N UNU -N CHs U~N~
N ~N`CH3 N Z ~~
i-NH N i-NN-NOH

f-\ /~
I-N-j ~iCH3 -1-N, rOEt -i-N

N N~ CH3 OH
O
~ ~/ 'OEt ~-N ~-N_ rCH3 OH kCH3 ~/

H3C\
H N-CH3 N-CH2CH3 '~-N-CH2CH2CH3 -}-HrCH3 ~H3 ~CH3 -FNH
~H3 or In some embodiments, -N(Z3)(Z4) is N
I
F F
N\~ ~\N ~ N
v F
; NMe2 NMe2 F
N
N N
or In still other embodiments, -N(Z3)(Z4) is -N(CH2CH3)(CH3), -N(CH2CH2CH3)(CH3), -N(CH2CH2CH2CH3)(CH3), -NH-CH2CH2CH2CH3, or -NH-CHzCHz-O-CH3.
In some embodiments, -N(Z3)(Z4) is N ~N ~-N OPO(OH)2 OPO(OH)2 OPO(OH)2 or In one embodiment, X is N(CH3)- N(CH2CH3)- N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;
n is an integer ranging from 1 to 3;
each R2 is independently -H, -Ci-C6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(Ci-C6 alkylene)-phenyl or phenyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)z, -OS(O)zOH or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -Ci-CS alkyl, or -(CI-C5 alkylene)-O-Ci-C5 alkyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH or -NH2;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -Ci-CS
alkyl, -phenyl, -(CI-C5 alkylene)-phenyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(CI-C5 alkylene)-N(Ra)z, -Ci-C5 alkylene-C(O)O-(Ci-C5 alkylene)-N(Ra)z, -COOH, -(CI-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(CI-C5 alkylene)-OP(O)(OH)2, -(CI-C5 alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)O-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, or -Ci-Cio alkyl;
or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -Ci-CS alkyl, -phenyl, -(CI-C5 alkylene) -phenyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(CI-C5 alkylene)-N(Ra)z, -(Ci-CS alkylene)-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(Ci-CS
alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(Ci-CS alkylene)-OP(O)(OH)2, -(Ci-CS
alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(Ci-CS
alkylene)-C(O)O-Ci-CS alkyl, -(Ci-CS alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, or -Ci-Cio alkyl.
In one embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;
n is an integer ranging from 1 to 3; and at least one Ci-C3 alkyl is methyl.
In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;at least one Ci-C3 alkyl is methyl; and at least one R2 is ethyl.
In yet another embodiment, X is -N(CH3)- -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; at least one Ci-C3 alkyl is methyl; and at least one R2 is propyl.
In one embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; at least one Ci-C3 alkyl is methyl; and at least one R2 is -C3-C8 monocyclic cycloalkyl.
In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;at least one Ci-C3 alkyl is methyl; and at least one R2 is cyclohexyl.
In yet another embodiment, X is -N(CH3)- -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; and at least one Ci-C3 alkyl is methyl, wherein N
and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle.
In one embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; and at least one Ci-C3 alkyl is methyl, wherein N and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with a hydroxyl.
In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; and at least one Ci-C3 alkyl is methyl, wherein N
and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with a nitrogen-containing 3- to membered monocyclic heterocycle.
Illustrative examples of the Indenoisoquinolinone Analogs include the compounds of Formula (IVb) as set forth below:

NH
X

R' (IVb) Compound - Rl X
IVb-1 -OC(Me)(Me)-CH2-N(Et)(Et) -0-IVb-2 -OC(Me)(Me)-CHz-N(Et)(Et) -CH2-IVb-3 -OC(Me)(Me)-CHz-N(Et)(Et) -C(O)-IVb-4 -OC(Me)(Me)-CHz-N(Et)(Et) -NH-IVb-5 -OC(Me)(Me)-CHz-N(Et)(Et) -S-IVb-6 -OC(Me)(Me)-CHz-N(Et)(Et) N(CH3)-IVb-7 -OC(Me)(Me)-CH2-N(Et)(Et) N(CH2CH3)-IVb-8 -OC(Me)(Me)-CH2-N(Et)(Et) N(CH2CH2CH3)-IVb-9 -OC(Me)(Me)-CH2-N(Et)(Et) -N(CH2CH2CH2CH3)-IVb-10 -OC(Me)(Me)-CH2-N(Et)(Et) -N(C(H)(CH3)(CH2CH3))-IVb-11 -OC(Me)(Me)-CH2-N(Et)(Et) -N(C(H)(CH3)2)-IVb-12 -OC(Me)(Me)-CH2-N(Et)(Et) N(CH2C(H)(CH3)2)-IVb-13 -OC(Me)(Me)-CH2-N(Et)(Et) -N(C(CH3)3)-IVb-14 -OC(Me)(Me)-CH2-N(Et)(Et) -CH(OH)-IVb-15 -OC(Me)(Me)-CH2-N(Et)(Et) -N(C(O)N(H)-CH2-CH2-OH)-IVb-16 -OC(Me)(Me)-CH2-N(Et)(Et) N(C(O)N(H)-CH2-CH2-F)-IVb-17 -OC(Me)(Me)-CH2-N(Et)(Et) N(CH2-CH2-OH)-IVb-18 -OC(Me)(Me)-CH2-N(Et)(Et) N(CH2-CH2-F)-IVb-19 -OC(Me)(Me)-CH2-N(Et)(Et) -N(CH2-CH2-OCH3)-IVb-20 -OC(Me)(Me)-CH2-N(Et)(Et) -N(CH2-CH2-CF3)-IVb-21 -OC(Me)(Me)-CH2-N(Et)(Et) N(C(O)N(H)-CH2-CH2-OCH3)-IVb-22 -OC(Me)(Me)-CH2-N(Et)(Et) -N(C(O)N(H)-CH2-CH2-CF3)-IVb-23 -OC(Me)(Et)-CH2-N(Et)(Et) -0-IVb-24 -OC(Me)(Et)-CHz-N(Et)(Et) -CH2-IVb-25 -OC(Me)(Et)-CHz-N(Et)(Et) -C(O)-IVb-26 -OC(Me)(Et)-CHz-N(Et)(Et) -NH-IVb-27 -OC(Me)(Et)-CHz-N(Et)(Et) -S-IVb-28 -OC(Me)(Et)-CHz-N(Et)(Et) N(CH3)-IVb-29 -OC(Me)(Et)-CHz-N(Et)(Et) N(CH2CH3)-IVb-30 -OC(Me)(Et)-CHz-N(Et)(Et) N(CH2CH2CH3)-IVb-31 -OC(Me)(Et)-CHz-N(Et)(Et) -N(CH2CH2CH2CH3)-IVb-32 -OC(Me)(Et)-CHz-N(Et)(Et) -N(C(H)(CH3)(CH2CH3))-IVb-33 -OC(Me)(Et)-CHz-N(Et)(Et) -N(C(H)(CH3)2)-IVb-34 -OC(Me)(Et)-CHz-N(Et)(Et) N(CH2C(H)(CH3)2)-IVb-35 -OC(Me)(Et)-CH2-N(Et)(Et) -N(C(CH3)3)-IVb-36 -OC(Me)(Et)-CH2-N(Et)(Et) -CH(OH)-IVb-37 -OC(Me)(Et)-CH2-N(Et)(Et) N(C(O)N(H)-CH2-CH2-OH)-IVb-38 -OC(Me)(Et)-CH2-N(Et)(Et) N(C(O)N(H)-CH2-CH2-F)-IVb-39 -OC(Me)(Et)-CH2-N(Et)(Et) N(CH2-CH2-OH)-IVb-40 -OC(Me)(Et)-CH2-N(Et)(Et) N(CH2-CH2-F)-IVb-41 -OC(Me)(Et)-CH2-N(Et)(Et) -N(CH2-CH2-OCH3)-IVb-42 -OC(Me)(Et)-CH2-N(Et)(Et) -N(CH2-CH2-CF3)-IVb-43 -OC(Me)(Et)-CH2-N(Et)(Et) N(C(O)N(H)-CH2-CH2-OCH3)-IVb-44 -OC(Me)(Et)-CH2-N(Et)(Et) -N(C(O)N(H)-CH2-CH2-CF3)-IVb-45 -OC(Me)(Pr)-CH2-N(Et)(Et) -0-IVb-46 -OC(Me)(Pr)-CH2-N(Et)(Et) -CH2-IVb-47 -OC(Me)(Pr)-CH2-N(Et)(Et) -C(O)-IVb-48 -OC(Me)(Pr)-CH2-N(Et)(Et) -NH-IVb-49 -OC(Me)(Pr)-CH2-N(Et)(Et) -S-IVb-50 -OC(Me)(Pr)-CH2-N(Et)(Et) N(CH3)-IVb-51 -OC(Me)(Pr)-CH2-N(Et)(Et) N(CH2CH3)-IVb-52 -OC(Me)(Pr)-CH2-N(Et)(Et) N(CH2CH2CH3)-IVb-53 -OC(Me)(Pr)-CH2-N(Et)(Et) -N(CH2CH2CH2CH3)-IVb-54 -OC(Me)(Pr)-CH2-N(Et)(Et) -N(C(H)(CH3)(CH2CH3))-IVb-55 -OC(Me)(Pr)-CH2-N(Et)(Et) -N(C(H)(CH3)2)-IVb-56 -OC(Me)(Pr)-CH2-N(Et)(Et) N(CH2C(H)(CH3)2)-IVb-57 -OC(Me)(Pr)-CH2-N(Et)(Et) -N(C(CH3)3)-IVb-58 -OC(Me)(Pr)-CH2-N(Et)(Et) -CH(OH)-IVb-59 -OC(Me)(Pr)-CH2-N(Et)(Et) N(C(O)N(H)-CH2-CH2-OH)-IVb-60 -OC(Me)(Pr)-CH2-N(Et)(Et) N(C(O)N(H)-CH2-CH2-F)-IVb-61 -OC(Me)(Pr)-CH2-N(Et)(Et) N(CH2-CH2-OH)-IVb-62 -OC(Me)(Pr)-CH2-N(Et)(Et) N(CHz-CHz-F)-IVb-63 -OC(Me)(Pr)-CH2-N(Et)(Et) -N(CH2-CH2-OCH3)-IVb-64 -OC(Me)(Pr)-CH2-N(Et)(Et) -N(CH2-CH2-CF3)-IVb-65 -OC(Me)(Pr)-CH2-N(Et)(Et) N(C(O)N(H)-CH2-CH2-OCH3)-IVb-66 -OC(Me)(Pr)-CH2-N(Et)(Et) -N(C(O)N(H)-CH2-CH2-CF3)-IVb-67 -OC(Me)(i-Pr)-CH2- -O-N H c clo ro 1 IVb-68 -OC(Me)(i-Pr)-CHz- -CHz-N(H)(cyclopropyl) IVb-69 -OC(Me)(i-Pr)-CHz- -C(O)-N H c clo ro 1 IVb-70 -OC(Me)(i-Pr)-CH2- -NH-N H c clo ro 1 IVb-71 -OC(Me)(i-Pr)-CHz- -S-N H c clo ro 1 IVb-72 -OC(Me)(i-Pr)-CH2- -N(CH3)-N H c clo ro 1 IVb-73 -OC(Me)(i-Pr)-CH2- N(CH2CH3)-N H c clo ro 1 IVb-74 -OC(Me)(i-Pr)-CH2- N(CH2CH2CH3)-N H c clo ro 1 IVb-75 -OC(Me)(i-Pr)-CH2- -N(CHzCHzCHzCH3)-N(H)(cyclopropyl) IVb-76 -OC(Me)(i-Pr)-CH2- -N(C(H)(CH3)(CH2CH3))-N H c clo ro 1 IVb-77 -OC(Me)(i-Pr)-CH2- -N(C(H)(CH3)2)-N H c clo ro 1 IVb-78 -OC(Me)(i-Pr)-CH2- -N(CH2C(H)(CH3)2)-N H c clo ro 1 IVb-79 -OC(Me)(i-Pr)-CH2- -N(C(CH3)3)-N H c clo ro 1 IVb-80 -OC(Me)(i-Pr)-CH2- -CH(OH)-N H c clo ro 1 IVb-81 -OC(Me)(i-Pr)-CH2- N(C(O)N(H)-CHz-CHz-OH)-N H c clo ro 1 IVb-82 -OC(Me)(i-Pr)-CH2- N(C(O)N(H)-CHz-CHz-F)-N(H)(cyclopropyl) IVb-83 -OC(Me)(i-Pr)-CH2- N(CHz-CHz-OH)-N H c clo ro 1 IVb-84 -OC(Me)(i-Pr)-CH2- -N(CHz-CHz-F)-N H c clo ro 1 IVb-85 -OC(Me)(i-Pr)-CH2- -N(CH2-CH2-OCH3)-N H c clo ro 1 IVb-86 -OC(Me)(i-Pr)-CH2- -N(CH2-CH2-CF3)-N H c clo ro 1 IVb-87 -OC(Me)(i-Pr)-CH2- -N(C(O)N(H)-CH2-CH2-OCH3)-N(H)(cyclopropyl) IVb-88 -OC(Me)(i-Pr)-CH2- -N(C(O)N(H)-CH2-CH2-CF3)-N(H)(cyclopropyl) and pharmaceutically acceptable salts thereof.

5.12 The Indenoisoquinolinone Analogs of Formula (IVc) The present invention provides Indenoisoquinolinone Analogs according to Formula (IVc), below:

NH
X

R' (IVc) and pharmaceutically acceptable salts thereof, wherein X and Ri are as defined above for the Indenoisoquinolinone Analogs of Formula (IVc).
In one embodiment, X is N(CH3)-. In another embodiment, X is is -N(CH2CH3)-. In another embodiment, X is -N(CH2CH2CH3)-. In another embodiment, X is -N(CH2CH2CH2CH3)-. In another embodiment, X is -N(C(H)(CH3)(CH2CH3))-. In another embodiment, X is -N(C(H)(CH3)2)-. In another embodiment, X is -N(CH2C(H)(CH3)2)-. In another embodiment, X is -N(C(CH3)3)-.
In one embodiment, X is -0-. In one embodiment, X is -CHz-. In one embodiment, X is -C(O)-. In one embodiment, X is -NH-. In one embodiment, X is -S-.
In one embodiment, X is -CH(OH)-.
In one embodiment, each Ci-C3 alkyl is independent of the other Ci-C3 alkyl.
In one embodiment, each Ci-C3 alkyl is methyl.
In one embodiment, each Ci-C3 alkyl is methyl and X is -CHz-.
In one embodiment, each Ci-C3 alkyl is methyl and X is -CH(OH)-.

In one embodiment, each Ci-C3 alkyl is methyl, X is -CH2- and n is 1.
In one embodiment, each Ci-C3 alkyl is methyl, X is -CH(OH)- and n is 1.
In another embodiment, X is -CH(OH)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)2-Z)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-Z)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CH2)2-Z)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)-Z)- and n is 1.
In one embodiment, X is -N((CHz)q Z)-.
In another embodiment, X is -N((CHz)-Z)-.
In another embodiment, X is -N((CHz)z-Z)-.
In another embodiment, X is -N((CHz)q Z)- and n is 1.
In yet another embodiment, X is -N((CHz)q Z)- and n is 2.
In still another embodiment, X is -N((CH2)-Z)- and n is 1.
In still another embodiment, X is -N((CH2)-Z)- and n is 2.
In one embodiment, Z is -CF3.
In another embodiment, Z is -F.
In yet another embodiment, Z is -OH.
In still another embodiment, Z is -O-CH3.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OH)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OH)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p OH)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)- and n is 1.
In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OH)- and n is 2.
In one embodiment, X is -N((CHz)q OH)-.
In another embodiment, X is -N((CH2)2-OH)-.
In another embodiment, X is -N((CHz)q OH)- and n is 1.
In yet another embodiment, X is -N((CHz)q OH)- and n is 2.
In still another embodiment, X is -N((CH2)2-OH)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-F)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)-F)-.

In another embodiment, X is -N(C(O)N(H)-(CHz)p-F)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p F)- n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)-F)- and n is 1.
In one embodiment, X is -N((CHz)q F)-.
In another embodiment, X is -N((CH2)-F)-.
In another embodiment, X is -N((CHz)q F)- and n is 1.
In yet another embodiment, X is -N((CHz)q F)- and n is 2.
In still another embodiment, X is -N((CH2)-F)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OMe)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)2-OMe)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)p-OMe)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p OMe)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)2-OMe)- and n is 1.
In one embodiment, X is -N((CHz)q OMe)-.
In another embodiment, X is -N((CH2)2-OMe)-.
In another embodiment, X is -N((CHz)q OMe)- and n is 1.
In yet another embodiment, X is -N((CHz)q OMe)- and n is 2.
In still another embodiment, X is -N((CH2)2-OMe)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CH2)p-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)p-CF3)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p CF3)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)-CF3)- and n is 1.
In one embodiment, X is -N((CHz)q CF3)-.
In another embodiment, X is -N((CHz)-CF3)-.
In another embodiment, X is -N((CHz)q CF3)- and n is 1.
In yet another embodiment, X is -N((CHz)q CF3)- and n is 2.
In still another embodiment, X is -N((CH2)-CF3)- and n is 1.
In another embodiment, X is -N(C(O)N(H)-(CH2)p-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CHz)-CF3)-.
In another embodiment, X is -N(C(O)N(H)-(CH2)p-CF3)- and n is 1.
In yet another embodiment, X is -N(C(O)N(H)-(CHz)p CF3)- and n is 2.
In still another embodiment, X is -N(C(O)N(H)-(CH2)-CF3)- and n is 1.

In one embodiment, X is -N((CHz)q CF3)-.
In another embodiment, X is -N((CHz)-CF3)-.
In another embodiment, X is -N((CHz)q CF3)- and n is 1.
In yet another embodiment, X is -N((CHz)q CF3)- and n is 2.
In still another embodiment, X is -N((CH2)-CF3)- and n is 1.
In one embodiment, n is 1.
In another embodiment, n is 2.
In yet another embodiment, n is 3.
In a further embodiment, n is 4, 5, or 6.
In yet a further embodiment, n is 7, 8, or 9.
In still a further embodiment, n is 10.
In one embodiment, p is 1.
In another embodiment, p is 2.
In yet another embodiment, p is an integer ranging from 2 to 5.
In one embodiment, q is 1.
In another embodiment, q is 2.
In yet another embodiment, q is an integer ranging from 2 to 5.
In one embodiment, n is 1 and X is -N(CH3)-.
In another embodiment, n is 1 and X is -N(CH2CH3).
In another embodiment, n is 1 and X is -N(CHzCHzCH3)-.
In another embodiment, n is 1 and X is -N(CHzCHzCHzCH3)-.
In another embodiment, n is 1 and X is -N(C(H)(CH3)(CHzCH3))-.
In another embodiment, n is 1 and X is -N(C(H)(CH3)z)-.
In another embodiment, n is 1 and X is -N(CH2C(H)(CH3)2)-.
In another embodiment, n is 1 and X is -N(C(CH3)3)-.
In one embodiment, one R2 is -H, and the other R2 is -Ci-C6 alkyl.
In another embodiment, each R2 is -Ci-C6 alkyl.
In another embodiment, each R2 is -methyl.
In various embodiments, -N(R2)(R2) is:

/ \ / \ CH3 -N 0 ~-NaOH ~-N\ N-CH3 ~-N\ N~
-N NH -N ~-N \ N_/-N(CH3)2 ~-N/ N \ / F

~-N NO N N-/Ph C(O)OH C(O)OCH2CH3 H~ ~-N / N _/ ~-N/ \N~
~

O HO
H3C CH3 where X = -H, -OMe, -CN, -F, -Cl, -Br, or -I
N(CH3)2 OH

-N N -N N / N ~-N\CH3 ~-N\CH2CH3 I-N\CH2CH2OH ~-N\CH2CH2N(CH3)2 I-N\CH2Ph I-N\CH2CH2OCH3 CH2CH2OH CH2CH2N(CH3)2 CH3 CH2CH2OCH3 ~ Hs ~-H2N(CHs)2 I_N`CH3 N~CH3 ~-NQH3 ~-N~ H2N(CH3)2 CH3 ~CH3 ~-N\-7 ~-N~
`~\OH

~- -I-N -CH3 ~-N

N~\N^ O H N.CH3 N~
~ H N,/~ N

NN,CH3 , NN=/
~OH ~-N`~
OP(O)(OH)2 ~-N or NCH2CH2OP(O)(OH)2 OP(O)(OH)2 In other embodiments, -N(R2)(R2) is:

I
/~
\ N/ I-N~N ) I-N~N/~
I I-N ~-N
U ~~// ~J
HO O
`N 0 OH OMe -N
\~ N
N-~ / I-N`~

Hp_ ' O
',s'_N OH I-NH ,CH2CH3 ~-NH ~-N 1-NH
N ~~ I-NH CH3 ~ ~~ ' ~-N~OH ' CH3 N

I_N ~CH3 ~-NH 3H3C
~\
I-NEH I-N r-\ N_) ~/
OH

N~
/ N } ~N`CH3 Z
I-N H N I-N\--/ N-\iOH
_ -1- ~/ N~iCH3 -1-N~OEt , -i-NN_N\iOMe -1-N
Q , --N /-\ O CH3 D OH 1 N~OEt ~-N~ I-N ~-N rCH3 OH kCH3 H3C CH3 H3C\
I-N-CH3 ' -1-H , ~-N-CH2CH2CH3 -HrCH3 OMe >--CH3 1-N-CH2CH2OH , 0 , H3C - 519 --~-N H or ~\ ~-N N

In some embodiments, -N(R2)(R2) is 1-NO-N\ 0 AN N
I

vsF F
N\~ N Q~aF
NMe2 NMe2 F
N
N N
or L -In still other embodiments, -N(R2)(R2) is -N(CH2CH3)(CH3), -N(CH2CH2CH3)(CH3), -N(CH2CH2CH2CH3)(CH3), -NH-CH2CH2CH2CH3, or -NH-CH2CH2-O-CH3.
In some embodiments, -N(R2)(R2) is -aOPO(OH)2 N N OPO(OH)2 H or OPO(OH)2 OPO(OH)2 OPO(OH)2 In various embodiments, -N(Z3)(Z4) is:

/ v / \ CH3 -N 0 ~-NaOH ~-NN-CH3 ~-NN-/
-N/-\ NH -N ~- ~N--//--N(CHs)2 ~-N / \ N~O N N~Ph C(O)OH C(O)OCH2CH3 H - ~-N\ /N~ ~-N\ N~

O HO
HgC~CHs where X = -H -OMe -CN -F
-Cl, -Br, or -I
N(CH3)2 OH

-N -N\ \/JN -N/ N ~-N\CH3 ~-N\CH2CH3 ' F`~

/CH2CH2OH /CH2CH2N(CH3)2 /CH2Ph /CH2CH2OCH3 N\CH2CH2OH ~-N\CH2CH2N(CH3)2 ~-N\CH3 , ~-N\CH2CH2OCH3 ~ Hs ~-H2N(CHs)2 I_N`CH3 N~CH3 ~-NQH3 ~-N~ H2N(CH3)2 CH3 ~CH3 ~-N\-7 ~-N~
`~\OH

~- -I-N -CH3 ~-N

N~\N^ O H N.CH3 N~
~ H N,/~ N

NN,CH3 , NN=/
~OH ~-N`~
OP(O)(OH)2 ~-N or NCH2CH2OP(O)(OH)2 OP(O)(OH)2 In other embodiments, -N(Z3)(Z4) is:

õ~.
I
\ N) I-NO-Nb I-NO-Nb I N I-HO O
I-N .OH }_No OMe N
I_N Z
N
`~
~ HO_ ~ O
~
~N OH I-NH t-NH i-N, CH2CH3 ~-NH
~

I-N\_jS ' 1-NIC~-\0 H I-N

I-N OH
0 , OH

i-N CHs N~ , ~~
}-N ~ / N ~N`CH3 2 CH3CH2 }-NH N CH3 Z
-NH N I-N\_/ N--\iOH
/~
I-N~j ~iCH3 -1-N, rOEt 'i-N

N N~ O ,CH3 OH
I 'OEt ~-N~ I-N I-N_ rCH3 OH kCH3 ~/

H3C\
~-N-CH3 =}-N-CH2CH3 '~-N-CH2CH2CH3 HrCHs ~-CH3 TNH
CH3 or \
~/

In some embodiments, -N(Z3)(Z4) is A N
I
F F
N\~ ~\N N
v F
NMe2 NMe2 F Q -N N
or In still other embodiments, -N(Z3)(Z4) is -N(CH2CH3)(CH3), -N(CH2CH2CH3)(CH3), -N(CH2CH2CH2CH3)(CH3), -NH-CH2CH2CH2CH3, or -NH-CHzCHz-O-CH3.
In some embodiments, -N(Z3)(Z4) is N ~-N ~- N OPO(OH)2 OPO(OH)2 OPO(OH)2 or ~

In one embodiment, X is N(CH3)- N(CHzCH3)- -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;
n is an integer ranging from 1 to 3;
each R2 is independently -H, -Ci-C6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(Ci-C6 alkylene)-phenyl or phenyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)z, -OS(O)zOH or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -Ci-CS alkyl, or -(CI-C5 alkylene)-O-Ci-CS alkyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH or -NH2;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -Ci-CS
alkyl, -phenyl, -(CI-C5 alkylene)-phenyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(CI-C5 alkylene)-N(Ra)z, -Ci-CS alkylene-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(CI-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)zOH, -(CI-C5 alkylene)-OP(O)(OH)2, -(CI-C5 alkylene)-OS(O)zOH, -C(O)O-Ci-Cs alkyl, -OC(O)-Ci-Cs alkyl, -(Ci-Cs alkylene)-C(O)O-Ci-Cs alkyl, -(CI-C5 alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, or -Ci-Cio alkyl;
or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -Ci-CS alkyl, -phenyl, -(CI-C5 alkylene) -phenyl, -(hydroxy-substituted) Ci-CS alkyl, -halo, -(halo-substituted) Ci-CS alkyl, -(halo-substituted) phenyl, -phenylene-O-Ci-CS
alkyl, -(cyano-substituted) phenyl, -OH, -O-Ci-CS alkyl, -N(Ra)z, -(CI-C5 alkylene)-N(Ra)z, -(CI-C5 alkylene)-C(O)O-(Ci-CS alkylene)-N(Ra)z, -COOH, -(CI-alkylene)-COOH, -OP(O)(OH)z, -OS(O)zOH, -(CI-C5 alkylene)-OP(O)(OH)2, -(CI-C5 alkylene)-OS(O)zOH, -C(O)O-Ci-CS alkyl, -OC(O)-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)O-Ci-CS alkyl, -(CI-C5 alkylene)-C(O)NH-Ci-CS alkyl, -C(O)NH2, or -NOz, wherein each occurrence of Ra is independently -H, -benzyl, or -Ci-Cio alkyl.
In one embodiment, X is N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;
n is an integer ranging from 1 to 3; and at least one Ci-C3 alkyl is methyl.

In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;at least one Ci-C3 alkyl is methyl; and at least one R2 is ethyl.
In yet another embodiment, X is -N(CH3)- -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; at least one Ci-C3 alkyl is methyl; and at least one R2 is propyl.
In one embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; at least one Ci-C3 alkyl is methyl; and at least one R2 is -C3-C8 monocyclic cycloalkyl.
In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-;at least one Ci-C3 alkyl is methyl; and at least one R2 is cyclohexyl.
In yet another embodiment, X is -N(CH3)- -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; and at least one Ci-C3 alkyl is methyl, wherein N
and both W groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle.
In one embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; and at least one Ci-C3 alkyl is methyl, wherein N and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with a hydroxyl.
In another embodiment, X is -N(CH3)-, -N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2- or -N(C(CH3)3)-; and at least one Ci-C3 alkyl is methyl, wherein N
and both R2 groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with a nitrogen-containing 3- to membered monocyclic heterocycle.

Illustrative examples of the Indenoisoquinolinone Analogs include the compounds of Formula (IVc) as set forth below:

NH
X Rt (IVc) Compound - Rl X
IVc-1 -OC(Me)(Me)-CH2-N(Et)(Et) -0-IVc-2 -OC(Me)(Me)-CH2-N(Et)(Et) -CH2-IVc-3 -OC(Me)(Me)-CH2-N(Et)(Et) -C(O)-IVc-4 -OC(Me)(Me)-CH2-N(Et)(Et) -NH-IVc-5 -OC(Me)(Me)-CH2-N(Et)(Et) -S-IVc-6 -OC(Me)(Me)-CH2-N(Et)(Et) N(CH3)-IVc-7 -OC(Me)(Me)-CH2-N(Et)(Et) N(CH2CH3)-IVc-8 -OC(Me)(Me)-CH2-N(Et)(Et) N(CH2CH2CH3)-IVc-9 -OC(Me)(Me)-CH2-N(Et)(Et) -N(CH2CH2CH2CH3)-IVc-10 -OC(Me)(Me)-CH2-N(Et)(Et) -N(C(H)(CH3)(CH2CH3))-IVc-11 -OC(Me)(Me)-CH2-N(Et)(Et) -N(C(H)(CH3)2)-IVc-12 -OC(Me)(Me)-CH2-N(Et)(Et) N(CH2C(H)(CH3)2)-IVc-13 -OC(Me)(Me)-CH2-N(Et)(Et) -N(C(CH3)3)-IVc-14 -OC(Me)(Me)-CH2-N(Et)(Et) -CH(OH)-IVc-15 -OC(Me)(Me)-CH2-N(Et)(Et) -N(C(O)N(H)-CH2-CH2-OH)-IVc-16 -OC(Me)(Me)-CH2-N(Et)(Et) N(C(O)N(H)-CHz-CHz-F)-IVc-17 -OC(Me)(Me)-CH2-N(Et)(Et) N(CH2-CH2-OH)-IVc-18 -OC(Me)(Me)-CH2-N(Et)(Et) N(CH2-CH2-F)-IVc-19 -OC(Me)(Me)-CH2-N(Et)(Et) -N(CH2-CH2-OCH3)-IVc-20 -OC(Me)(Me)-CH2-N(Et)(Et) -N(CH2-CH2-CF3)-IVc-21 -OC(Me)(Me)-CH2-N(Et)(Et) N(C(O)N(H)-CH2-CH2-OCH3)-IVc-22 -OC(Me)(Me)-CH2-N(Et)(Et) -N(C(O)N(H)-CH2-CH2-CF3)-IVc-23 -OC(Me)(Et)-CH2-N(Et)(Et) -0-IVc-24 -OC(Me)(Et)-CHz-N(Et)(Et) -CH2-IVc-25 -OC(Me)(Et)-CHz-N(Et)(Et) -C(O)-IVc-26 -OC(Me)(Et)-CHz-N(Et)(Et) -NH-IVc-27 -OC(Me)(Et)-CHz-N(Et)(Et) -S-IVc-28 -OC(Me)(Et)-CHz-N(Et)(Et) N(CH3)-IVc-29 -OC(Me)(Et)-CHz-N(Et)(Et) N(CH2CH3)-IVc-30 -OC(Me)(Et)-CHz-N(Et)(Et) N(CH2CH2CH3)-IVc-31 -OC(Me)(Et)-CHz-N(Et)(Et) -N(CH2CH2CH2CH3)-IVc-32 -OC(Me)(Et)-CHz-N(Et)(Et) -N(C(H)(CH3)(CH2CH3))-IVc-33 -OC(Me)(Et)-CHz-N(Et)(Et) -N(C(H)(CH3)2)-IVc-34 -OC(Me)(Et)-CHz-N(Et)(Et) N(CH2C(H)(CH3)2)-IVc-35 -OC(Me)(Et)-CHz-N(Et)(Et) -N(C(CH3)3)-IVc-36 -OC(Me)(Et)-CHz-N(Et)(Et) -CH(OH)-IVc-37 -OC(Me)(Et)-CHz-N(Et)(Et) N(C(O)N(H)-CH2-CH2-OH)-IVc-38 -OC(Me)(Et)-CHz-N(Et)(Et) N(C(O)N(H)-CH2-CH2-F)-IVc-39 -OC(Me)(Et)-CHz-N(Et)(Et) N(CH2-CH2-OH)-IVc-40 -OC(Me)(Et)-CHz-N(Et)(Et) N(CH2-CH2-F)-IVc-41 -OC(Me)(Et)-CHz-N(Et)(Et) -N(CH2-CH2-OCH3)-IVc-42 -OC(Me)(Et)-CHz-N(Et)(Et) -N(CH2-CH2-CF3)-IVc-43 -OC(Me)(Et)-CHz-N(Et)(Et) N(C(O)N(H)-CH2-CH2-OCH3)-IVc-44 -OC(Me)(Et)-CHz-N(Et)(Et) -N(C(O)N(H)-CH2-CH2-CF3)-IVc-45 -OC(Me)(Pr)-CH2-N(Et)(Et) -0-IVc-46 -OC(Me)(Pr)-CH2-N(Et)(Et) -CH2-IVc-47 -OC(Me)(Pr)-CH2-N(Et)(Et) -C(O)-IVc-48 -OC(Me)(Pr)-CHz-N(Et)(Et) -NH-IVc-49 -OC(Me)(Pr)-CHz-N(Et)(Et) -S-IVc-50 -OC(Me)(Pr)-CHz-N(Et)(Et) N(CH3)-IVc-51 -OC(Me)(Pr)-CH2-N(Et)(Et) N(CH2CH3)-IVc-52 -OC(Me)(Pr)-CH2-N(Et)(Et) N(CH2CH2CH3)-IVc-53 -OC(Me)(Pr)-CH2-N(Et)(Et) -N(CH2CH2CH2CH3)-IVc-54 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(C(H)(CH3)(CH2CH3))-IVc-55 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(C(H)(CH3)2)-IVc-56 -OC(Me)(Pr)-CHz-N(Et)(Et) N(CH2C(H)(CH3)2)-IVc-57 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(C(CH3)3)-IVc-58 -OC(Me)(Pr)-CHz-N(Et)(Et) -CH(OH)-IVc-59 -OC(Me)(Pr)-CHz-N(Et)(Et) N(C(O)N(H)-CH2-CH2-OH)-IVc-60 -OC(Me)(Pr)-CHz-N(Et)(Et) N(C(O)N(H)-CH2-CH2-F)-IVc-61 -OC(Me)(Pr)-CHz-N(Et)(Et) N(CH2-CH2-OH)-IVc-62 -OC(Me)(Pr)-CHz-N(Et)(Et) N(CH2-CH2-F)-IVc-63 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(CH2-CH2-OCH3)-IVc-64 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(CH2-CH2-CF3)-IVc-65 -OC(Me)(Pr)-CHz-N(Et)(Et) N(C(O)N(H)-CH2-CH2-OCH3)-IVc-66 -OC(Me)(Pr)-CHz-N(Et)(Et) -N(C(O)N(H)-CH2-CH2-CF3)-IVc-67 -OC(Me)(i-Pr)-CHz- -O-N H c clo ro 1 IVc-68 -OC(Me)(i-Pr)-CHz- -CHz-N H c clo ro 1 IVc-69 -OC(Me)(i-Pr)-CHz- -C(O)-N H c clo ro 1 IVc-70 -OC(Me)(i-Pr)-CH2- -NH-N(H)(cyclopropyl) IVc-71 -OC(Me)(i-Pr)-CHz- -S-N(H)(cyclopropyl) IVc-72 -OC(Me)(i-Pr)-CH2- -N(CH3)-N H c clo ro 1 IVc-73 -OC(Me)(i-Pr)-CH2- N(CHzCH3)-N(H)(cyclopropyl) IVc-74 -OC(Me)(i-Pr)-CH2- N(CH2CH2CH3)-N H c clo ro 1 IVc-75 -OC(Me)(i-Pr)-CH2- -N(CH2CH2CH2CH3)-N H c clo ro 1 IVc-76 -OC(Me)(i-Pr)-CH2- -N(C(H)(CH3)(CH2CH3))-N H c clo ro 1 IVc-77 -OC(Me)(i-Pr)-CH2- -N(C(H)(CH3)2)-N H c clo ro 1 IVc-78 -OC(Me)(i-Pr)-CH2- -N(CH2C(H)(CH3)2)-N H c clo ro 1 IVc-79 -OC(Me)(i-Pr)-CH2- -N(C(CH3)3)-N H c clo ro 1 IVc-80 -OC(Me)(i-Pr)-CH2- -CH(OH)-N(H)(cyclopropyl) IVc-81 -OC(Me)(i-Pr)-CH2- N(C(O)N(H)-CHz-CHz-OH)-N H c clo ro 1 IVc-82 -OC(Me)(i-Pr)-CH2- N(C(O)N(H)-CHz-CHz-F)-N H c clo ro 1 IVc-83 -OC(Me)(i-Pr)-CH2- N(CHz-CHz-OH)-N H c clo ro 1 IVc-84 -OC(Me)(i-Pr)-CH2- -N(CHz-CHz-F)-N H c clo ro 1 IVc-85 -OC(Me)(i-Pr)-CH2- -N(CH2-CH2-OCH3)-N H c clo ro 1 IVc-86 -OC(Me)(i-Pr)-CH2- -N(CH2-CH2-CF3)-N H c clo ro 1 IVc-87 -OC(Me)(i-Pr)-CH2- N(C(O)N(H)-CH2-CH2-OCH3)-N(H)(cyclopropyl) IVc-88 -OC(Me)(i-Pr)-CH2- -N(C(O)N(H)-CH2-CH2-CF3)-N(H)(cyclopropyl) and pharmaceutically acceptable salts thereof.

5.13 The Indenoisoquinolinone Analogs of Formula (Va) The present invention provides Indenoisoquinolinone Analogs according to Formula (Va), below:

X

R' (Va) and pharmaceutically acceptable salts thereof, wherein R1, X and Y' are as defined above for the Indenoisoquinolinone Analogs of Formula (Va).
In one embodiment, Ri is -(CHz)ri NHR2 and R2 is a-C3-C8 monocyclic cycloalkyl.
In another embodiment, Ri is -(CHz)ri NHR2 and R2 is a-C3-C8 monocyclic cycloalkyl substituted with one or more of -(hydroxy-substituted) Ci-CS alkyl.
In one embodiment, Ri is -(CHz)ri NHR2, R2 is a-C3-C8 monocyclic cycloalkyl, and X is fluoro.
In one embodiment, Ri is -(CHz)ri NHR2, R2 is a-C3-C8 monocyclic cycloalkyl, and X is chloro.
In one embodiment, Ri is -(CHz)ri NHR2 and R2 is cyclopentyl.
In another embodiment, Ri is -(CHz)ri NHR2 , R2 is a-C3-C8 monocyclic cycloalkyl substituted with one or more of -(hydroxy-substituted) Ci-CS alkyl, and X is fluoro.
In another embodiment, Ri is -(CHz)ri NHR2 , R2 is cyclopentyl substituted with one ore more of -(hydroxy-substituted Ci-CS alkyl), and X is fluoro .
In one embodiment, Ri is -(CHz)ri NHR2 , R2 is a-C3-C8 monocyclic cycloalkyl, and Y' is fluoro.
In another embodiment, Ri is -(CHz)ri NHR2 , R2 is a-C3-C8 monocyclic cycloalkyl substituted with one ore more of -(hydroxy-substituted Ci-CS
alkyl), and Y' is fluoro .
In another embodiment, Ri is -(CHz)ri NHR2 , R2 is a-C3-C8 monocyclic cycloalkyl substituted with one ore more of -(hydroxy-substituted) Ci-CS
alkyl, and X
and Y' are fluoro.

In another embodiment, Ri is -(CHz)ri NHR2, R2 is a 3- to 7-membered monocyclic heterocycle, and X is fluoro.
In another embodiment, Ri is -(CHz)ri NHR2, R2 is a 3- to 7-membered monocyclic heterocycle, and Y' is fluoro.
In another embodiment, Ri is -(CHz)ri NHR2 and R2 is tetrahydropyranyl.
In one embodiment, R2 is tetrahydopyranyl, or cyclopentyl which is unsubstituted or substituted with one or more of -(hydroxy-substituted Ci-CS alkyl).
In another embodiment, one of X and Y' is fluoro.
Illustrative examples of the Indenoisoquinolinone Analogs include the compounds of Formula (Va) as set forth below:

X

1 / /Y.
\

R' (Va) Compound - Rl X Y' Va-1 ~ -Cl, at position 4 -H
NH

Va-2 ~ -F, at position 2 -H
NH

Va-3 -F, at position 3 -H
NH

Compound - Rl X Y' Va-4 ~ -F, at position 4 -H
NH

Va-5 \--F, at position 3 -H
NH

O

Va-6 \--F, at position 1 -H
NH

O

Va-7 ~ -F, at position 1 -H
NH

Va-8 \--F, at position 2 -H
NH

O

-H -F, at position 8 Va-9 \--NH oH

-F, at position 3 -F, at position 8 Va-10 \--NH oH

5.14 Methods For Making Indenoisoquinolinone Analogs Methods useful for making the Indenoisoquinolinone Analogs are set forth in the Examples below and generalized in Schemes 1-7.

Scheme 1 MeOH, H2SO4 Pd(OAc)2, DMAC K4IFe(CN)6l, 120 C CH
Br CQH3 Br s H3 reflux /
(CH2)n_1C(O)OH (CH2)n_1C(O)OMe (CH2)~~C(O)OMe NBS

O
O
~ CN
NH
CH2Br MeCN, Et3N (CH2)n_1C(O)OMe (C H2)n_1 C(O)O Me 4 LAH, THF, room temperature O 0 NHR2R2, EtOH, 0 reflux; then NH
NH 6a NH MeSO3H

(CH2)nNR2R2 (CH2)nOH (CH2)nX

wherein n and each R2 is defined above for the Indenoisoquinolinone Analogs of Formula 5 (IIa), (IIb), (IIc), (IIIa), (IIIb), (IVa), (IVb) or (IVc), and X is -Br, -I, -Cl, -0-Ts, -0-Ms, -0-Triflate, or -0-Acetate.
As shown in Scheme 1, a compound of formula 1 can be reacted with methanol in the presence of an acid, for example, sulphuric acid, to provide a compound of formula 2.
The compound of formula 2 can then be reacted with cyanide to provide a compound of formula 3. The compound of formula 3 can be brominated using, for example, N-bromosuccinimide, to provide a compound of formula 4. The compound of formula 4 can then be reacted with homophthalic anhydride to provide a compound of formula 5. The compound of formula 5 can then be reduced, for example with lithium aluminum hydride (LAH), to provide a compound of formula 6.
Scheme 2 p HX 0 eNH (X = CI or Br) NH
formaldehyde zX

As shown in Scheme 2, an indenoisoquinolinone compound of formula 8 can be reacted with hydrochloric acid or hydrobromic acid in the presence of formaldehyde to provide a halomethyl compound of fomula 9. The compound of formula 9 can then be reacted with an amine of formula NH(R2)(R3) to provide an Indenoisoquinolinone Analog of Formula (IIb), wherein Ri =-(CHz)-N(R2 )(R), wherein each R2 and R3 are as defined above. Alternatively, the compound of formula 9 can be reacted with an appropriate amine to provide an Indenoisoquinolinone Analog of Formula (IIIb) or (IVb).
A compound of formula 6 can be reacted with a reagent 6a to provide a compound of formula 7 (see, e.g., Scheme 1). Suitable reagents 6a include, but are not limited to, PBr3, HBr, HI, SOCIz, Ts-Cl, pyrene, MsC1, CF3SO2C1, acetic anhydride, acetyl chloride or NEt3. The compound of formula 7 can then be reacted with an amine of formula NH(R2)(R) to provide an Indenoisoquinolinone Analog of Formula (IIa), (IIb) or (IIc) wherein Ri =-(CHz)ri N(R2)(R3), wherein n, R2 and R3 are as defined above.
Alternatively, the compound of formula 7 can be reacted with an appropriate amine to provide an Indenoisoquinolinone Analog of Formula (IIIa) or (IIIb). Using similar methods, Indenoisoquinolinone Analogs of Formula (IVa), (IVb) or (IVc) can also be obtained using an appropriate analog of the compound of formula 1, as would be apparent to one of ordinary skill in the art.
Scheme 3 O
CN Me00C !:iF
+
X. (CH2)1_1C(O)OMe C(O)OMe X

(CH2)1_1C(O)O Me wherein n is defined above for the Indenoisoquinolinone Analogs of Formula (Ia), (Ib), (Ic), (IIa), (IIb) or (IIc) and X' is -OH, -SH, -NHC(O)OMe, or -N(Ci-C4 alkyl). As set forth in Scheme 3, a compound of formula 10 is reacted with a compound of formula 11 5 in the presence of triethylamine to provide a compound of formula 12, wherein X is -0-, -S-, -N(C(O)OMe)-, or -N(Ci-C4 alkyl)-. The compound of formula 12 can then be converted to provide an Indenoisoquinolinone Analog of Formula (Ia), (Ib), (Ic), (IIa), (IIb) or (IIc), e.g., using procedures outlined in Scheme 1 and/or 2. The compound of formula 12, wherein X is -N(C(O)OMe)-, can be deprotected, for example using 10 hydrazine, to provide a compound, wherein X is -N(H)-. Using similar methods, Indenoisoquinolinone Analogs of Formula (IVa), (IVb) or (IVc) can also be obtained using an appropriate analog of the compound of formula 1, as would be apparent to one of ordinary skill in the art.

Scheme 4 O
CN Me0()C NEt3 or K2CO3 or NaH eNH
~~ + I~ and MeCN or DMF or Me0 i/ Br / acetone or toluene C(O)OMe X

13 11 14 OMe wherein X' is -OH, -SH, or NHC(O)OMe or -N(Ci-C4 alkyl).
As set forth in Scheme 4, a compound of formula 13 is reacted with a compound of formula 11, to provide a compound of formula 14, wherein X is -0-, -S-, -N(C(O)OMe)-, or -N(Ci-C4 alkyl)-. The compound of formula 14 is then converted to provide an Indenoisoquinolinone Analog of Formula (Ia), (Ib), (Ic), wherein Ri =-O-(CHz)õ-N(R2)(R2) or an Indenoisoquinolinone Analog of Formula (IVa), (IVb) or (IVc), for example using methods described in Schemes 1 and/or 5.

Scheme 5 O O
eNH
NH BBr3X X

14 11 15 A-C(Cl-C3 alkyl)2(CH2)NR2R2 OMe O H

Base A(C H2),N R2R2 Base O
NH eNH
X X

15a O(CH2),NR2R2 15b O C(CH2)nN R2R2 Cl -C3 alkyl Cl-C3 alkyl wherein X, m, n, each R2 and each Ci-C3 alkyl is defined above for the Indenoisoquinolinone Analogs of Formula (Ia), (Ib), (Ic), (IVa), (IVb) or (IVc) and A is a halogen.
As set forth in Scheme 5, a compound of formula 14 is demethylated, for example using boron tribromide, to provide a compound of formula 15. A compound of formula is then reacted in the presence of base with A(CH2),,NR2R2 to provide the compound 10 of the general formula 15a, an Indenoisoquinolinone Analog of Formula (Ia), (Ib), or (Ic), wherein Ri =-O-(CHz)õ-N(R2)(R2). Alternatively, a compound of formula 15 is reacted in the presence of base with A-C(Ci-C3 alkyl)z(CHz)õNR2 R2 to provide the compound of the general formula 15b, an Indenoisoquinolinone Analog of Formula (IVa), (IVb), or (IVc).
Scheme 6 or NaBH4or LAH
eNH Ce(OTf)4 I~ NH C NH
then acid /

16 O -~- HO -~-R' 17 R' 18 R' wherein Ri is as defined above for the Indenoisoquinolinone Analogs of Formula (IIa), (IIb), (IIc), (IVa), (IVb) or (IVc).
As set forth in Scheme 6, compounds of the general formula 16, which can be prepared, for example, according to Schemes 1 or 2, can be oxidized to provide a compound of the general formula 17, which is an Indenoisoquinolinone Analog of Formula (IIa), (IIb), (IIc), (IVa), (IVb) or (IVc), wherein X is -C(O)-. In in one embodiment, the oxidation is achieved using 02 and dimethylsulfoxide. In one aspect, the 02 is that which is present in air. In another embodiment, the oxidation is achieved using Cerium(IV) triflate (Ce(OTf)4). Optional protecting groups can be used (Greene et al., Protective Groups in Organic Synthesis (3ra ed. 1999)). For example, where Ri is -(CHz)ri OH, protecting groups such as -SiEt3, can be used to protect the Ri hydroxyl group during the oxidation and can then be removed, for example with an acid.
The compound of the general formula 17, can be reduced, for example with sodium borohydride or lithium aluminum hydride, to provide the compound of the general formula 18, which is an Indenoisoquinolinone Analog of Formula (IIa), (IIb), (IIc), (IVa), (IVb) or (IVc), wherein X is -CH(OH)-.

Scheme 7 Br 20 0 :)q O
O
COOMe halo i\ NH
ha lo Ii O 1. NEt3, MeCN reflux M e00 C
NC \ halo 21 1. NEt3, MeCN, Br 2. LiAIH4 reflux 3. PBr3 or SOCI2 23 COOMe 4. H2NR

halo 0 NH
NH
halo (S22-halo 24 Me00 C NHR

2. LiAIH4 3. PBr3 or SOCI2 4. H2NR

halo \
I NH
wherein R = O or /
halo NHR

1. NEt3, MeCN, homophthalic 0 anhydride, reflux NH
2. LiAIH4 (2) NC halo 3. PBr3 or SOCI2 Br 4.H2NR halo R b O or OH

26 COOMe NHR
As set forth in Scheme 7, Indenoisoquinolinone Analogs of Formula (Va) can be prepared, for example, as illustrated in part (1) of the scheme by reacting compound 19 with either compounds 20 or 23 to yield compounds 21 and 24, respectively.
Compounds 21 and 24 can then be reacted with the selected amine to form compounds 22 and respectively. Compounds 22 and 25 are representative of an Indenoisoquinolinone Analog of Formula (Va). In part (2) of the scheme, reaction of compound 26 under suitable conditions and in the presence of homophthalic anhydride and the desired amine yields compound 27, which is an Indenoisoquinolinone Analog of Formula of Formula (Va).

5.15 Treatment or Prevention of a Condition In accordance with the invention, an Indenoisoquinolinone Analog is useful for treatment or prevention of a Condition as set forth below.

5.8.1 Treatment or Prevention of an Inflammatory Disease The Indenoisoquinolinone Analogs are useful for treating or preventing an inflammatory disease. An inflammatory disease can arise where there is an inflammation of the body tissue. These include local inflammatory responses and systemic inflammation. Examples of inflammatory diseases include, but are not limited to, lupus;
pancreatitis; macular degeneration; chronic obstructive pulmonary disease;
organ transplant rejection; a chronic inflammatory disease of a joint, including arthritis, rheumatoid arthritis, osteoarthritis and a bone disease associated with increased bone resorption; an inflammatory bowel disease such as ileitis, ulcerative colitis, Barrett's syndrome, and Crohn's disease; an inflammatory lung disease such as asthma, adult respiratory distress syndrome, and chronic obstructive airway disease; an inflammatory disease of the eye including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis; a chronic inflammatory disease of the gum, including gingivitis and periodontitis; tuberculosis; leprosy; an inflammatory disease of the kidney including a uremic complication, glomerulonephritis and nephrosis;
an inflammatory disease of the skin including sclerodermatitis, psoriasis and eczema; an inflammatory disease of the central nervous system, including a chronic demyelinating disease of the nervous system, multiple sclerosis, AIDS-related neurodegeneration and Alzheimer's disease, infectious meningitis, encephalomyelitis, Huntington's disease, amyotrophic lateral sclerosis and viral or autoimmune encephalitis; as well as any other disease that can have a significant inflammatory component, including preeclampsia, chronic liver failure, and brain and spinal cord trauma. The inflammatory disease can also be a systemic inflammation of the body, exemplified by gram-positive or gram negative shock, hemorrhagic or anaphylactic shock, or shock induced by cancer chemotherapy in response to pro-inflammatory cytokines, e.g., shock associated with pro-inflammatory cytokines. Such shock can be induced, e.g., by a chemotherapeutic agent that is administered as a treatment for cancer.
In one embodiment, the inflammatory disease is an inflammatory disease of a joint, a chronic inflammatory disease of the gum, an inflammatory bowel disease, an inflammatory lung disease, an inflammatory disease of the central nervous system, an inflammatory disease of the eye, gram-positive shock, gram negative shock, Rickettsial shock, fungal shock, hemorrhagic shock, anaphylactic shock, traumatic shock or chemotherapeutic shock.

5.8.2 Treatment or Prevention of a Reperfusion injury The Indenoisoquinolinone Analogs are useful for treating or preventing a reperfusion injury. Reperfusion refers to the process whereby blood-flow in the blood vessels is resumed following ischemia, such as occurs following constriction or obstruction of the vessel. Reperfusion injury can result following a naturally occurring episode, such as a myocardial infarction, stroke, or during a surgical procedure where blood flow in vessels is intentionally or unintentionally blocked. Examples of reperfusion injuries include, but are not limited to, intestinal reperfusion injury, myocardial reperfusion injury, and reperfusion injury resulting from cardiopulmonary bypass surgery, aortic aneurysm repair surgery, carotid endarterectomy surgery, and hemorrhagic shock.
In one embodiment, the reperfusion injury results from cardiopulmonary bypass surgery, aortic aneurysm repair surgery, carotid endarterectomy surgery or hemorrhagic shock.
In another embodiment, the reperfusion injury is stroke or myocardial infarction.
5.8.3 Treatment or Prevention of Reoxygenation Injury Resulting From Organ Transplantation The Indenoisoquinolinone Analogs are useful for treating or preventing reoxygenation injury resulting from organ transplantation. Examples of reoxygenation injuries include, but are not limited to, transplantation of one or more of the following:
heart, lung, liver, kidney, pancreas, intestine and cornea.
In one embodiment, reoxygenation injury resulting from organ transplantation occurs during the organ transplantation.
The Indenoisoquinolinone Analogs are also useful for treating or preventing allograph rejection. Accordingly, the invention provides methods for treating or preventing allograph rejection, comprising administering an effective amount of an Indenoisoquinolinone Analog to a subject in need thereof. In one embodiment, the methods further comprise administering an effective amount of another agent useful for treating or preventing allograph rejection. The other agent includes, but is not limited to, SK-506 and cyclosporine.

5.8.4 Treatment or Prevention of an Ischemic Condition The Indenoisoquinolinone Analogs are useful for treating or preventing an ischemic condition. Examples of ischemic conditions include, but are not limited to, stable angina, unstable angina, myocardial ischemia, hepatic ischemia, mesenteric artery ischemia, ischemic heart disease, intestinal ischemia, critical limb ischemia, chronic critical limb ischemia, cerebral ischemia, acute cardiac ischemia, and an ischemic disease of the central nervous system, such as stroke or cerebral ischemia.
In one embodiment, the ischemic condition is myocardial ischemia, stable angina, unstable angina, stroke, ischemic heart disease or cerebral ischemia.

5.8.5 Treatment or Prevention of Renal Failure The Indenoisoquinolinone Analogs are useful for treating or preventing renal failure.
In one embodiment, the renal failure is chronic renal failure.
In another embodiment, the renal failure is acute renal failure.
5.8.6 Treatment or Prevention of a Vascular Disease The Indenoisoquinolinone Analogs are useful for treating or preventing a vascular disease other than a cardiovascular disease. Examples of vascular diseases include, but are not limited to, hemorrahgic stroke, peripheral arterial occlusion, thromboangitis obliterans, Reynaud's disease and phenomenon, acrocyanosis, erythromelalgia, venous thrombosis, varicose veins, arteriovenous fistula, lymphedema, and lipedema.
In embodiment, the vascular disease is peripheral arterial occlusion, thromboangitis obliterans, Reynaud's disease and phenomenon, acrocyanosis, erythromelalgia, venous thrombosis, varicose veins, arteriovenous fistula, lymphedema or lipedema.

5.8.7 Treatment or Prevention of a Cardiovascular Disease The Indenoisoquinolinone Analogs are useful for treating or preventing a cardiovascular disease. Examples of cardiovascular diseases include, but are not limited to, congestive heart failure (such as chronic or acute heart failure), atherosclerosis, hypercholesterolemia, circulatory shock, cardiomyopathy, cardiac transplant, myocardial infarction, and a cardiac arrhythmia, such as atrial fibrillation, supraventricular tachycardia, atrial flutter, and paroxysmal atrial tachycardia.
In one embodiment, the cardiovascular disease is chronic heart failure.
In another embodiment, the cardiovascular disease is acute heart failure.
In yet another embodiment, the cardiovascular disease is cardiac arrhythmia.
In still another embodiment, the cardiac arrhythmia is atrial fibrillation, supraventricular tachycardia, atrial flutter or paroxysmal atrial tachycardia.
In one embodiment, the cardiovascular disease is chronic heart failure, atrial fibrillation, supraventricular tachycardia, atrial flutter or paroxysmal atrial tachycardia.
5.8.8 Treatment or Prevention of Diabetes Mellitus or a Diabetic Complication The Indenoisoquinolinone Analogs are useful for treating or preventing diabetes mellitus or one or more of its complications. Examples of diabetes mellitus include, but are not limited to, Type I diabetes (Insulin Dependent Diabetes Mellitus), Type II
diabetes (Non-Insulin Dependent Diabetes Mellitus), gestational diabetes, autoimmune diabetes, insulinopathies, diabetes due to pancreatic disease, diabetes associated with other endocrine diseases (such as Cushing's Syndrome, acromegaly, pheochromocytoma, glucagonoma, primary aldosteronism or somatostatinoma), Type A insulin resistance syndrome, Type B insulin resistance syndrome, lipatrophic diabetes, and diabetes induced by 0-cell toxins.
The Indenoisoquinolinone Analogs are useful for treating or preventing a complication of diabetes mellitus. Examples of complications of diabetes mellitus include, but are not limited to, diabetic cataract, glaucoma, retinopathy, nephropathy (such as microalbuminuria or progressive diabetic nephropathy), polyneuropathy, gangrene of the feet, immune-complex vasculitis, systemic lupus erythematosus (SLE), atherosclerotic coronary arterial disease, peripheral arterial disease, nonketotic hyperglycemic-hyperosmolar coma, mononeuropathies, autonomic neuropathy, foot ulcers, joint problems, and a skin or mucous membrane complication (such as an infection, a shin spot, a candidal infection or necrobiosis lipoidica diabeticorumobesity), hyperlipidemia, hypertension, syndrome of insulin resistance, coronary artery disease, retinopathy, neuropathy (such as diabetic neuropathy, polyneuropathy or mononeuropathy), autonomic neuropathy, a foot ulcer, a joint problem, a fungal infection, cardiomyopathy, and a bacterial infection.
In one embodiment diabetes mellitus is Type I diabetes mellitus or Type II
diabetes mellitus.

5.8.9 Treatment or Prevention of a Neurodegenerative Disease The Indenoisoquinolinone Analogs are useful for treating or preventing a neurodegenerative disease. Examples of neurodegenerative diseases include, but are not limited to, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
5.8.10 Treatment or Prevention of Cancer The Indenoisoquinolinone Analogs are useful for treating or preventing cancer.
Accordingly, the invention provides methods for treating or preventing cancer, comprising administering an effective amount of an Indenoisoquinolinone Analog to a subject in need thereof. In one embodiment, the methods further comprise administering an effective amount of another anticancer agent.
Examples of cancers include, but are not limited to, the cancers disclosed below in Table 1 and metastases thereo Solid tumors, including but not limited to:
fibrosarcoma myxosarcoma liposarcoma chondrosarcoma osteogenic sarcoma chordoma angiosarcoma endotheliosarcoma lymphangiosarcoma lymphangioendotheliosarcoma synovioma mesothelioma Ewing's tumor leiomyosarcoma rhabdomyosarcoma colon cancer colorectal cancer kidney cancer pancreatic cancer bone cancer breast cancer ovarian cancer prostate cancer esophagealcancer stomach cancer oralcancer nasal cancer throat cancer squamous cell carcinoma basal cell carcinoma adenocarcinoma sweat gland carcinoma sebaceous gland carcinoma papillary carcinoma papillary adenocarcinomas cystadenocarcinoma medullary carcinoma bronchogenic carcinoma renal cell carcinoma hepatoma bile duct carcinoma choriocarcinoma seminoma embryonal carcinoma Wilms' tumor cervical cancer uterine cancer testicular cancer small cell lung carcinoma bladder carcinoma lung cancer epithelial carcinoma skin cancer melanoma metastatic melanoma neuroblastoma retinoblastoma blood-borne cancers, including but not limited to:
acute lymphoblastic leukemia ("ALL") acute lymphoblastic B-cell leukemia acute lymphoblastic T-cell leukemia acute myeloblastic leukemia ("AML") acute promyelocytic leukemia ("APL") acute monoblastic leukemia acute erythroleukemic leukemia acute megakaryoblastic leukemia acute myelomonocytic leukemia acute nonlymphocyctic leukemia acute undifferentiated leukemia chronic myelocytic leukemia ("CML") chronic lymphocytic leukemia ("CLL") hairy cell leukemia multiple myeloma acute and chronic leukemias:
lymphoblastic myelogenous lymphocytic myelocytic leukemias Lymphomas:

Hodgkin's disease non-Hodgkin's Lymphoma Multiple myeloma Waldenstr6m's macroglobulinemia Heavy chain disease Polycythemia vera Central nervous system lymphomas CNS and Brain cancers:

glioma pilocytic astrocytoma astrocytoma anaplastic astrocytoma glioblastoma multiforme medulloblastoma craniopharyngioma ependymoma pinealoma hemangioblastoma acoustic neuroma oligodendroglioma meningioma vestibular schwannoma adenoma metastatic brain tumor meningioma spinal tumor medulloblastoma In one embodiment, the cancer is lung cancer, breast cancer, colorectal cancer, prostate cancer, a leukemia, a lymphoma, non-Hodgkin's lymphoma, skin cancer, a brain cancer, a cancer of the central nervous system, ovarian cancer, uterine cancer, stomach cancer, pancreatic cancer, esophageal cancer, kidney cancer, liver cancer, or a head and neck cancer.
In another embodiment, the cancer is metastatic cancer.
In yet another embodiment, the cancer is brain cancer or melanoma.
In one embodiment, the brain cancer is metastatic brain cancer or a glioma.
In one embodiment, the glioma is pilocytic astrocytoma, astrocytoma, anaplastic astrocytoma or glioblastoma multiforme.
In one embodiment, the cancer is homologous-recombination deficient, such as BRCA-1 or BRCA-2 deficient, or is deficient in one or more proteins of the Fanconi family. In one embodiment, the deficiency is caused by a genetic mutation. In another embodiment, the phenotype resulting from the deficiency is caused by abnormally low expression of BRCA-1 or BRCA-2 protein. In another embodiment, the phenotype resulting from the deficiency is caused by abnormally low expression of one or more proteins of the Fanconi family.
In still another embodiment, the subject in need of treatment has previously undergone or is presently undergoing treatment for cancer. The treatment includes, but is not limited to, chemotherapy, radiation therapy, surgery or immunotherapy, such as administration of a cancer vaccine.
The Indenoisoquinolinone Analogs are also useful for treating or preventing a cancer caused by a virus. Such viruses include human papilloma virus, which can lead to cervical cancer (see, e.g., Hernandez-Avila et al., Archives of Medical Research (1997) 28:265-271); Epstein-Barr virus (EBV), which can lead to lymphoma (see, e.g., Herrmann et al., J Pathol (2003) 199(2):140-5); hepatitis B or C virus, which can lead to liver carcinoma (see, e.g., El-Serag, J Clin Gastroenterol (2002) 35(5 Supp12):S72-8);
human T cell leukemia virus (HTLV)-I, which can lead to T-cell leukemia (see e.g., Mortreux et al., Leukemia (2003) 17(1):26-38); human herpesvirus-8 infection, which can lead to Kaposi's sarcoma (see, e.g., Kadow et al., Curr Opin Investig Drugs (2002) 3(11):1574-9); and Human Immune deficiency Virus (HIV) infection, which can lead to cancer as a consequence of immunodeficiency (see, e.g., Dal Maso et al., Lancet Oncol (2003) 4(2):110-9).
5.8.10.1 Prophylactic Methods For Cancer The Indenoisoquinolinone Analogs are also useful for preventing cancer, or preventing progression of a cancer, including but not limited to the cancers listed in Table 1. Such prophylactic use includes that in which non-neoplastic cell growth such as hyperplasia, metaplasia, or most specifically, dysplasia has occurred.
Alternatively or in addition to the presence of abnormal cell growth characterized as hyperplasia, metaplasia, or dysplasia, the presence of one or more characteristics of a transformed phenotype, or of a malignant phenotype, displayed in vivo or displayed in vitro by a cell sample from a subject, can indicate the desirability of prophylactic or therapeutic administration of an Indenoisoquinolinone Analog. Such characteristics of a transformed phenotype include morphology changes, looser substratum attachment, loss of contact inhibition, loss of anchorage dependence, protease release, increased sugar transport, decreased serum requirement, expression of fetal antigens, disappearance of the 250,000 dalton cell surface protein, etc. (see also id., at pp. 84-90 for characteristics associated with a transformed or malignant phenotype).
In a specific embodiment, leukoplakia, a benign-appearing hyperplastic or dysplastic lesion of the epithelium, or Bowen's disease, a carcinoma in situ, is treatable or preventable according to the present methods.
In another embodiment, fibrocystic disease (cystic hyperplasia, mammary dysplasia, specifically adenosis (benign epithelial hyperplasia)) is treatable or preventable according to the present methods.
In other embodiments, a subject that has one or more of the following predisposing factors for malignancy can be treated by administration of an effective amount of an Indenoisoquinolinone Analog: a chromosomal translocation associated with a malignancy (e.g., the Philadelphia chromosome for chronic myelogenous leukemia;
t(14;18) for follicular lymphoma); familial polyposis or Gardner's syndrome;
benign monoclonal gammopathy; a first degree kinship with persons having a cancer or precancerous disease showing a Mendelian (genetic) inheritance pattern (e.g., familial polyposis of the colon, Gardner's syndrome, hereditary exostosis, polyendocrine adenomatosis, medullary thyroid carcinoma with amyloid production and pheochromocytoma, Peutz-Jeghers syndrome, neurofibromatosis of Von Recklinghausen, retinoblastoma, carotid body tumor, cutaneous melanocarcinoma, intraocular melanocarcinoma, xeroderma pigmentosum, ataxia telangiectasia, Chediak-Higashi syndrome, albinism, Fanconi's aplastic anemia, and Bloom's syndrome); and exposure to carcinogens (e.g., smoking, second-hand smoke exposure, and inhalation of or contacting with certain chemicals).

5.8.10.2 Combination Chemotherapy For the Treatment of Cancer In one aspect, the present methods for treating or preventing cancer can further comprise the administration of another anticancer agent.
In one embodiment, the present invention provides methods for treating or preventing cancer, comprising the administration of an effective amount of an Indenoisoquinolinone Analog and another anticancer agent to a subject in need thereof The Indenoisoquinolinone Analog and another anticancer agent can be administered concurrently. In this embodiment, the Indenoisoquinolinone Analog and another anticancer agent can be administered within the same composition, or can be administered from different compositions, via the same or different routes of administration.
In another embodiment, the Indenoisoquinolinone Analog is administered during a time when the other anticancer agent exerts its prophylactic or therapeutic effect, or vice versa.
In another embodiment, the Indenoisoquinolinone Analog or other anticancer agent are administered in doses commonly employed when such agents are used as monotherapy for the treatment of cancer.

In one embodiment, the Indenoisoquinolinone Analog or other anticancer agent are administered in doses that are lower than the doses commonly employed when such agents are used as monotherapy for the treatment of cancer.
In another embodiment, the Indenoisoquinolinone Analog and other anticancer agent act synergistically and are administered in doses that are lower than the doses commonly employed when such agents are used as monotherapy for the treatment of cancer.
The dosage of the Indenoisoquinolinone Analog or other anticancer agent administered as well as the dosing schedule can depend on various parameters, including, but not limited to, the cancer being treated, the subject's general health, and the administering physician's discretion.
An Indenoisoquinolinone Analog can be administered prior to (e.g., 5 minutes, minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concurrently with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of the other anticancer agent, to a subject in need thereof. In various embodiments an Indenoisoquinolinone Analog and the other anticancer agent are administered 1 minute apart, 10 minutes apart, 30 minutes apart, less than 1 hour apart, 1 hour apart, 1 hour to 2 hours apart, 2 hours to 3 hours apart, 3 hours to 4 hours apart, 4 hours to 5 hours apart, 5 hours to 6 hours apart, 6 hours to 7 hours apart, 7 hours to 8 hours apart, 8 hours to 9 hours apart, 9 hours to 10 hours apart, 10 hours to 11 hours apart, 11 hours to 12 hours apart, no more than 24 hours apart or no more than 48 hours apart. In one embodiment, an Indenoisoquinolinone Analog and the other anticancer agent are administered within 3 hours. In another embodiment, an Indenoisoquinolinone Analog and the other anticancer agent are administered at 1 minute to 24 hours apart.
In one embodiment, an effective amount of an Indenoisoquinolinone Analog and an effective amount of other anticancer agent are present in the same composition. In one embodiment, this composition is useful for oral administration. In another embodiment, this composition is useful for intravenous administration.
In one embodiment, the compositions comprise an amount of an Indenoisoquinolinone Analog and the other anticancer agent which together are effective to treat or prevent cancer.
In another embodiment, the compositions comprise an effective amount of temozolomide, procarbazine, dacarbazine, interleukin-2, irinotecan, or doxorubicin, a physiologically acceptable carrier or vehicle, and an effective amount of an Indenoisoquinolinone Analog.
In one embodiment, the amount of an Indenoisoquinolinone Analog and the other anticancer agent is at least about 0.01% of the combined combination chemotherapy agents by weight of the composition. When intended for oral administration, this amount can be varied from about 0.1% to about 80% by weight of the composition. Some oral compositions can comprise from about 4% to about 50% of combined amount of an Indenoisoquinolinone Analog and the other anticancer agent by weight of the composition. Other compositions of the present invention are prepared so that a parenteral dosage unit contains from about 0.01% to about 2% by weight of the composition.
Cancers that can be treated or prevented by administering an Indenoisoquinolinone Analog and the other anticancer agent include, but are not limited to, the list of cancers set forth above in Table 1.
In one embodiment, the cancer is brain cancer.
In specific embodiments, the brain cancer is pilocytic astrocytoma, astrocytoma, anaplastic astrocytoma, glioblastoma multiforme or a metastatic brain tumor.
In one embodiment, the cancer is melanoma.
In a specific embodiment, the melanoma is metastatic melanoma.
The Indenoisoquinolinone Analog and other anticancer agent can act additively or synergistically. A synergistic combination of an Indenoisoquinolinone Analog and the other anticancer agent, might allow the use of lower dosages of one or both of these agents and/or less frequent administration of the agents to a subject with cancer. The ability to utilize lower dosages of one or both of the Indenoisoquinolinone Analog and other anticancer agent and/or to administer the agents less frequently can reduce any toxicity associated with the administration of the agents to a subject without reducing the efficacy of the agents in the treatment of cancer. In addition, a synergistic effect might result in the improved efficacy of these agents in the treatment of cancer and/or the reduction of any adverse or unwanted side effects associated with the use of either agent alone.
In one embodiment, the administration of an effective amount of an Indenoisoquinolinone Analog and an effective amount of another anticancer agent inhibits the resistance of a cancer to the other anticancer agent. In one embodiment, the cancer is a tumor.
Suitable other anticancer agents useful in the methods and compositions of the present invention include, but are not limited to temozolomide, a topoisomerase I
inhibitor, procarbazine, dacarbazine, gemcitabine, capecitabine, methotrexate, taxol, taxotere, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposide, teniposide, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, L-asparaginase, doxorubicin, epirubicin, 5-fluorouracil, taxanes such as docetaxel and paclitaxel, leucovorin, levamisole, irinotecan, estramustine, etoposide, nitrogen mustards, BCNU, nitrosoureas such as carmustine and lomustine, vinca alkaloids such as vinblastine, vincristine and vinorelbine, platinum complexes such as cisplatin, carboplatin and oxaliplatin, imatinib mesylate, hexamethylmelamine, topotecan, tyrosine kinase inhibitors, tyrphostins herbimycin A, genistein, erbstatin, and lavendustin A.
In one embodiment, the other anticancer agent is, but is not limited to, a drug listed in Table 2.

Alkylating agents Nitrogen mustards: Cyclophosphamide Ifosfamide Trofosfamide Chlorambucil Nitrosoureas: Carmustine (BCNU) Lomustine (CCNU) Alkylsulphonates: Busulfan Treosulfan Triazenes: Dacarbazine Procarbazine Temozolomide Platinum containing complexes: Cisplatin Carboplatin Aroplatin Oxaliplatin Plant Alkaloids Vinca alkaloids: Vincristine Vinblastine Vindesine Vinorelbine Taxoids: Paclitaxel Docetaxel DNA Topoisomerase Inhibitors Epipodophyllins: Etoposide Teniposide Topotecan 9-aminocamptothecin Camptothecin Crisnatol Mitomycins: Mitomycin C
Anti-metabolites Anti-folates:
DHFR inhibitors: Methotrexate Trimetrexate IMP dehydrogenase Inhibitors: Mycophenolic acid Tiazofurin Ribavirin EICAR
Ribonuclotide reductase Hydroxyurea Inhibitors:
Deferoxamine Pyrimidine Analogs:
Uracil Analogs: 5-Fluorouracil Fluoxuridine Doxifluridine Ralitrexed Cytosine Analogs: Cytarabine (ara C) Cytosine arabinoside Fludarabine Gemcitabine Capecitabine Purine Analo~4s: Mercaptopurine Thioguanine DNA Antimetabolites: 3-HP
2'-deoxy-5-fluorouridine alpha-TGDR
aphidicolin glycinate ara-C
5-aza-2'-deoxycytidine beta-TGDR
cyclocytidine guanazole inosine glycodialdehyde macebecin II
Pyrazoloimidazole Hormonal therapies:
Receptor antagonists:
Anti-estrogen: Tamoxifen Raloxifene Megestrol LHRH agonists: Goscrclin Leuprolide acetate Anti- androgens: Flutamide Bicalutamide Retinoids/Deltoids Cis-retinoic acid Vitamin A derivative: All-trans retinoic acid (ATRA-IV) Vitamin D3 Analogs: EB 1089 Photodynamic therapies: Vertoporfin (BPD-MA) Phthalocyanine Photosensitizer Pc4 Demethoxy-hypocrellin A
(2BA-2-DMHA) Cytokines: Interferon-a Interferon-0 Interferon-y Tumor necrosis factor Interleukin-2 Angiogenesis Inhibitors: Angiostatin (plasminogen fragment) antiangiogenic antithrombin III
Angiozyme Bay 12-9566 Benefin Bevacizumab cartilage-derived inhibitor (CDI) CAI
CD59 complement fragment Co13 Combretastatin A-4 Endostatin (collagen XVIII

fragment) Fibronectin fragment Gro-beta Halofuginone Heparinases Heparin hexasaccharide fragment Human chorionic gonadotropin (hCG) Interferon alpha/beta/gamma Interferon inducible protein (IP-10) Interleukin- 12 Kringle 5 (plasminogen fragment) Marimastat Metalloproteinase inhibitors (TIMPs) 2-Methoxyestradiol MMI 270 (CGS 27023A) MoAb IMC-IC11 Neovastat Panzem Placental ribonuclease inhibitor Plasminogen activator inhibitor Platelet factor-4 (PF4) Prinomastat Prolactin 16kD fragment Proliferin-related protein (PRP) Retinoids Solimastat Squalamine Tetrahydrocortisol-S
Tetrathiomolybdate Thalidomide Thrombospondin-1 (TSP-1) Transforming growth factor-beta (TGF-(3) Vasculostatin Vasostatin (calreticulin fragment) farnesyl transferase inhibitors (FTI) Bisphosphonates Antimitotic agents: Allocolchicine Halichondrin B
Colchicine colchicine derivative dolstatin 10 Maytansine Rhizoxin Thiocolchicine trityl cysteine Others:
Isoprenylation inhibitors:
Dopaminergic neurotoxins: 1-methyl-4-phenylpyridinium ion Cell cycle inhibitors: Staurosporine Actinomycins: Actinomycin D
Dactinomycin Bleomycins: Bleomycin A2 Bleomycin B2 Peplomycin Anthracyclines: Daunorubicin Doxorubicin (adriamycin) Idarubicin Epirubicin Pirarubicin Zorubicin Mitoxantrone MDR inhibitors: Verapamil Ca2+ATPase inhibitors: Thapsigargin Other additional anticancer agents that are useful in the compositions and methods of the present invention include, but are not limited to: acivicin;
aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin;
ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase;
asperlin;
azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide;
bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium;
bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer;
carboplatin;
carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil;
cirolemycin;
cisplatin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine;
dacarbazine;
dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin;
dezaguanine;
dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin hydrochloride;
droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin;
edatrexate;
eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine;
epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine;
estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine;
fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate;
fluorouracil;
flurocitabine; fosquidone; fostriecin sodium; gemcitabine hydrochloride;
hydroxyurea;

idarubicin hydrochloride; ifosfamide; ilmofosine; interleukin-2 (including recombinant interleukin-2, or rIL2), interferon alfa-2a; interferon alfa-20; interferon alfa-n1 ;
interferon alfa-n3; interferon beta-Ia; interferon gamma-I(3; iproplatin;
irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride;
lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol;
maytansine;
mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate;
melphalan;
menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine;
meturedepa;
mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin;
mitosper;
mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole;
nogalamycin;
ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine;
peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride;
plicamycin;
plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride;
puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide;
safingol;
safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin;
spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin;
streptozocin;
sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride;
temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine;
thiotepa;
tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate;
trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride;
uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate;
vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate;
vinleurosine sulfate;
vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole;
zeniplatin;
zinostatin; zorubicin hydrochloride.
Further anticancer drugs that are useful in the methods and compositions of the invention include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin;
aldesleukin;
ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine;
aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide;
angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators;
apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane;
atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin;
azatyrosine;

baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists;
benzochlorins;
benzoylstaurosporine; beta Lactam Derivatives; beta-alethine; betaclamycin B;
betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine;
bisnafide;
bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine;
calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2;
carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine;
cecropin B;
cetrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin;
cladribine;
clomifene Analogues; clotrimazole; collismycin A; collismycin B;
combretastatin A4;
combretastatin Analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8;
cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam;
cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab;
decitabine;
dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane;
dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-acytidine;
dihydrotaxol; dioxamycin; diphenyl spiromustine; docetaxel; docosanol;
dolasetron;
doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine;
edelfosine;
edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride;
estramustine Analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate;
exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride;
flavopiridol;
flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride;
forfenimex;
formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate;
galocitabine;
ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors;
hepsulfam; heregulin;
hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene;
idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod;
immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons;
interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact;
irsogladine;
isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F;
lamellarin-N
triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate;
leptolstatin; letrozole;
leukemia inhibiting factor; leukocyte alpha interferon;
leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine Analogue; lipophilic disaccharide peptide; lipophilic platinum complexes;
lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin;
loxoribine;
lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine;
mannostatin A;

marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF
inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA;
mitoguazone; mitolactol; mitomycin Analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk;
mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agents; mycaperoxide B; mycobacterial cell wall extract;
myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip;
naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin;
nemorubicin;
neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators;
nitroxide antioxidant; nitrullyn; 06-benzylguanine; octreotide; okicenone;
oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer;
ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel; paclitaxel Analogues;
paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid;
panaxytriol;
panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol;
phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum complexes; platinum-triamine complex;
porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2;
proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor;
protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated;
rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide;
rohitukine;
romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU;
sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1;
sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocaptate;
sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid;
spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors;
sulfinosine;
superactive vasoactive intestinal peptide antagonist; suradista; suramin;
swainsonine;
synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide;
tauromustine;
tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors;
temoporfin;
temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine;
thiocoraline;
thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist;
thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin;
tirapazamine;
titanocene bichloride; topsentin; toremifene; totipotent stem cell factor;
translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate;
triptorelin; tropisetron;
turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors;
ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists;
vapreotide;
variolin B; vector system, erythrocyte gene therapy; velaresol; veramine;
verdins;
verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone;
zeniplatin; zilascorb;
and zinostatin stimalamer.
In one another embodiment, the other anticancer agent is interferon-a.
In another embodiment, the other anticancer agent is interleukin-2.
In one embodiment, the other anticancer agent is an alkylating agent, such as a nitrogen mustard, a nitrosourea, an alkylsulfonate, a triazene, or a platinum-containing agent.
In one embodiment, the other anticancer agent is a triazene alkylating agent.
In another embodiment, the other anticancer agent is temozolomide, procarbazine, dacarbazine, interleukin-2, irinotecan, doxorubicin, or a combination thereof.
In a specific embodiment, the other anticancer agent is temozolomide.
Temozolomide can be administered to a subject at dosages ranging from about 60 mg/m2 (of a subject's body surface area) to about 250 mg/m2 and from about 100 mg/m2 to about 200 mg/m2. In specific embodiments, the dosages of temozolomide are about 10 mg/m2, about 1 mg/m2 , about 5 mg/m2 , about 10 mg/m2 , about 20 mg/m2 , about mg/m2, about 40 mg/m2, about 50 mg/m2 , about 60 mg/m2 , about 70 mg/m2 , about 80 mg/m2, about 90 mg/m2, about 100 mg/m2 , about 110 mg/m2 , about 120 mg/m2 , about 130 mg/m2 , about 140 mg/m2 , about 150 mg/m2 , about 160 mg/m2 , about 170 mg/m2, about 180 mg/m2 , about 190 mg/m2 , about 200 mg/m2 , about 210 mg/m2 , about mg/m2, about 230 mg/m2, about 240 mg/m2, or about 250 mg/m2.
In a specific embodiment, temozolomide is administered orally.

In one embodiment, temozolomide is administered orally to a subject at a dose ranging from about 150 mg/m2 to about 200 mg/m2.
In another embodiment, temozolomide is administered orally to a subject once per day for five consecutive days at a dose ranging from about 150 mg/m2 to about mg/m2.
In a specific embodiment, temozolomide is administered orally to a subject once per day for five consecutive days at a dose ranging from about 150 mg/m2 to about 200 mg/m2 on days 1-5, then again orally once per day for five consecutive days on days 28-32 at a dose ranging from about 150 mg/m2 to about 200 mg/m2, then again orally once per day for five consecutive days on days 55-59 at a dose ranging from about 150 mg/m2 to about 200 mg/m2.
In another embodiment, temozolomide is administered orally to a subject once per day for a week, two weeks, three weeks, a month or longer at the foregoing daily dosage.
In a specific embodiment, the other anticancer agent is procarbazine.
Procarbazine can be administered to a subject at dosages ranging from about 50 mg/m2 (of a subject's body surface area) to about 100 mg/m2 and from about 60 mg/m2 to about 100 mg/m2. In specific embodiments, the dosages of procarbazine are about 10 mg/m2, about 1 mg/m2 , about 5 mg/m2 , about 10 mg/m2 , about 20 mg/m2 , about mg/m2, about 40 mg/m2, about 50 mg/m2 , about 60 mg/m2 , about 70 mg/m2 , about 80 mg/m2, about 90 mg/m2, about 100 mg/m2 , about 110 mg/m2 , about 120 mg/m2 , about 130 mg/m2 , about 140 mg/m2 , about 150 mg/m2 , about 160 mg/m2 , about 170 mg/m2, about 180 mg/m2 , about 190 mg/m2 , about 200 mg/m2 , about 210 mg/m2 , about mg/m2 , about 230 mg/m2 , about 240 mg/m2 , about 250 mg/m2 , about 260 mg/m2 , about 270 mg/m2 , about 280 mg/m2 , about 290 mg/m2 , about 300 mg/m2 , about 310 mg/m2, about 320 mg/m2 , about 330 mg/m2 , about 340 mg/m2 , about 350 mg/m2 , about mg/m2 , about 370 mg/m2 , about 380 mg/m2 , about 390 mg/m2 , about 400 mg/m2 , about 410 mg/m2 , about 420 mg/m2 , about 430 mg/m2 , about 440 mg/m2 , about 450 mg/m2, about 460 mg/m2 , about 470 mg/m2 , about 480 mg/m2 , about 490 mg/m2, or about 500 mg/m2.
In a specific embodiment, procarbazine is administered intravenously.
In one embodiment, procarbazine is administered intravenously to a subject at a dose ranging from about 50 mg/m2 to about 100 mg/m2.

In another embodiment, procarbazine is administered intravenously to a subject once per day for five consecutive days at a dose ranging from about 50 mg/m2 to about 100 mg/m2.
In a specific embodiment, procarbazine is administered intravenously to a subject once per day for five consecutive days at a dose ranging from about 50 mg/m2 to about 100 mg/m2 on days 1-5, then again intravenously once per day for five consecutive days on days 28-32 at a dose ranging from about 50 mg/m2 to about 100 mg/m2, then again intravenously once per day for five consecutive days on days 55-59 at a dose ranging from about 50 mg/m2 to about 100 mg/m2.
In another embodiment, procarbazine is administered once intravenously to a subject at a dose ranging from about 50 mg/m2 to about 100 mg/m2.
In another embodiment, procarbazine is administered intravenously to a subject once per day for a week, two weeks, three weeks, a month or longer at the foregoing daily dosage.
In a specific embodiment, the other anticancer agent is dacarbazine.
Dacarbazine can be administered to a subject at dosages ranging from about 60 mg/m2 (of a subject's body surface area) to about 250 mg/m2 and from about 150 mg/m2 to about 250 mg/m2. In specific embodiments, the dosages of dacarbazine are about 10 mg/m2, about 1 mg/m2 , about 5 mg/m2 , about 10 mg/m2 , about 20 mg/m2 , about mg/m2, about 40 mg/m2, about 50 mg/m2 , about 60 mg/m2 , about 70 mg/m2 , about 80 mg/m2, about 90 mg/m2, about 100 mg/m2 , about 110 mg/m2 , about 120 mg/m2 , about 130 mg/m2 , about 140 mg/m2 , about 150 mg/m2 , about 160 mg/m2 , about 170 mg/m2, about 180 mg/m2 , about 190 mg/m2 , about 200 mg/m2 , about 210 mg/m2 , about mg/m2 , about 230 mg/m2 , about 240 mg/m2 , about 250 mg/m2 , about 260 mg/m2 , about 270 mg/m2 , about 280 mg/m2 , about 290 mg/m2 , about 300 mg/m2 , about 310 mg/m2, about 320 mg/m2 , about 330 mg/m2 , about 340 mg/m2 , about 350 mg/m2 , about mg/m2 , about 370 mg/m2 , about 380 mg/m2 , about 390 mg/m2 , about 400 mg/m2 , about 410 mg/m2 , about 420 mg/m2 , about 430 mg/m2 , about 440 mg/m2 , about 450 mg/m2, about 460 mg/m2 , about 470 mg/m2 , about 480 mg/m2 , about 490 mg/m2, or about 500 mg/m2.
In a specific embodiment, dacarbazine is administered intravenously.
In one embodiment, dacarbazine is administered intravenously to a subject at a dose ranging from about 150 mg/m2 to about 250 mg/m2.

In another embodiment, dacarbazine is administered intravenously to a subject once per day for five consecutive days at a dose ranging from about 150 mg/m2 to about 250 mg/m2.
In a specific embodiment, dacarbazine is administered intravenously to a subject once per day for five consecutive days at a dose ranging from about 150 mg/m2 to about 250 mg/m2 on days 1-5, then again intravenously once per day for five consecutive days on days 28-32 at a dose ranging from about 150 mg/m2 to about 250 mg/m2, then again intravenously once per day for five consecutive days on days 55-59 at a dose ranging from about 150 mg/m2 to about 250 mg/m2.
In one embodiment, dacarbazine is administered once intravenously to a subject at a dose ranging from about 150 mg/m2 to about 250 mg/m2.
In another embodiment, dacarbazine is administered intravenously to a subject once per day for a week, two weeks, three weeks, a month or longer at the foregoing daily dosage.
In a specific embodiment, the other anticancer agent is doxorubicin.
Doxorubicin can be administered to a subject at dosages ranging from about 50 mg/m2 (of a subject's body surface area) to about 100 mg/m2 and from about 60 mg/m2 to about 100 mg/m2. In specific embodiments, the dosages of doxorubicin are about mg/m2, about 1 mg/m2 , about 5 mg/m2 , about 10 mg/m2 , about 20 mg/m2 , about mg/m2, about 40 mg/m2, about 50 mg/m2 , about 60 mg/m2 , about 70 mg/m2 , about 80 mg/m2, about 90 mg/m2, about 100 mg/m2 , about 110 mg/m2 , about 120 mg/m2 , about 130 mg/m2 , about 140 mg/m2 , about 150 mg/m2 , about 160 mg/m2 , about 170 mg/m2, about 180 mg/m2 , about 190 mg/m2 , about 200 mg/m2 , about 210 mg/m2 , about mg/m2 , about 230 mg/m2 , about 240 mg/m2 , about 250 mg/m2 , about 260 mg/m2 , about 270 mg/m2 , about 280 mg/m2 , about 290 mg/m2 , about 300 mg/m2 , about 310 mg/m2, about 320 mg/m2 , about 330 mg/m2 , about 340 mg/m2 , about 350 mg/m2 , about mg/m2 , about 370 mg/m2 , about 380 mg/m2 , about 390 mg/m2 , about 400 mg/m2 , about 410 mg/m2 , about 420 mg/m2 , about 430 mg/m2 , about 440 mg/m2 , about 450 mg/m2, about 460 mg/m2 , about 470 mg/m2 , about 480 mg/m2 , about 490 mg/m2, or about 500 mg/m2.
In a specific embodiment, doxorubicin is administered intravenously.
In one embodiment, doxorubicin is administered intravenously to a subject at a dose ranging from about 50 mg/m2 to about 100 mg/m2.

In another embodiment, doxorubicin is administered intravenously to a subject once per day for five consecutive days at a dose ranging from about 50 mg/m2 to about 100 mg/m2.
In a specific embodiment, doxorubicin is administered intravenously to a subject once per day for five consecutive days at a dose ranging from about 50 mg/m2 to about 100 mg/m2 on days 1-5, then again intravenously once per day for five consecutive days on days 28-32 at a dose ranging from about 50 mg/m2 to about 100 mg/m2, then again intravenously once per day for five consecutive days on days 55-59 at a dose ranging from about 50 mg/m2 to about 100 mg/m2.
In another embodiment, doxorubicin is administered once intravenously to a subject at a dose ranging from about 50 mg/m2 to about 100 mg/m2.
In another embodiment, doxorubicin is administered intravenously to a subject once per day for a week, two weeks, three weeks, a month or longer at the foregoing daily dosage.
In one embodiment, the other anticancer agent is a Topoisomerase I inhibitor, such as etoposide, teniposide, topotecan, irinotecan, 9-aminocamptothecin, camptothecin, or crisnatol.
In a specific embodiment, the other anticancer agent is irinotecan.
Irinotecan can be administered to a subject at dosages ranging from about 50 mg/m2 (of a subject's body surface area) to about 150 mg/m2 and from about 75 mg/m2 to about 150 mg/m2. In specific embodiments, the dosages of irinotecan are about mg/m2, about 1 mg/m2 , about 5 mg/m2 , about 10 mg/m2 , about 20 mg/m2 , about mg/m2, about 40 mg/m2, about 50 mg/m2 , about 60 mg/m2 , about 70 mg/m2 , about 80 mg/m2, about 90 mg/m2, about 100 mg/m2 , about 110 mg/m2 , about 120 mg/m2 , about 130 mg/m2 , about 140 mg/m2 , about 150 mg/m2 , about 160 mg/m2 , about 170 mg/m2, about 180 mg/m2 , about 190 mg/m2 , about 200 mg/m2 , about 210 mg/m2 , about mg/m2 , about 230 mg/m2 , about 240 mg/m2 , about 250 mg/m2 , about 260 mg/m2 , about 270 mg/m2 , about 280 mg/m2 , about 290 mg/m2 , about 300 mg/m2 , about 310 mg/m2, about 320 mg/m2 , about 330 mg/m2 , about 340 mg/m2 , about 350 mg/m2 , about mg/m2 , about 370 mg/m2 , about 380 mg/m2 , about 390 mg/m2 , about 400 mg/m2 , about 410 mg/m2 , about 420 mg/m2 , about 430 mg/m2 , about 440 mg/m2 , about 450 mg/m2, about 460 mg/m2 , about 470 mg/m2 , about 480 mg/m2 , about 490 mg/m2, or about 500 mg/m2.

In a specific embodiment, irinotecan is administered intravenously.
In one embodiment, irinotecan is administered intravenously to a subject at a dose ranging from about 50 mg/m2 to about 150 mg/m2.
In another embodiment, irinotecan is administered intravenously to a subject once per day for five consecutive days at a dose ranging from about 50 mg/m~ to about 150 mg/m2.
In a specific embodiment, irinotecan is administered intravenously to a subject once per day for five consecutive days at a dose ranging from about 50 mg/m2 to about 150 mg/m2 on days 1-5, then again intravenously once per day for five consecutive days on days 28-32 at a dose ranging from about 50 mg/m2 to about 150 mg/m2, then again intravenously once per day for five consecutive days on days 55-59 at a dose ranging from about 50 mg/m2 to about 150 mg/m2.
In another embodiment, irinotecan is administered intravenously to a subject once per day for a week, two weeks, three weeks, a month or longer at the foregoing daily dosage.
In one embodiment, the other anticancer agent is O-6-benzylguanine.
In another embodiment, the other anticancer agent is O-6-benzylguanine and temozolomide.
In another embodiment, the other anticancer agent is O-6-benzylguanine and procarbazine.
In still another embodiment, the other anticancer agent is O-6-benzylguanine and dacarbazine.

5.8.10.3 Multi-Therapy For Cancer The Indenoisoquinolinone Analogs can be administered to a subject that has undergone or is currently undergoing one or more additional anticancer therapies including, but not limited to, surgery, radiation therapy, or immunotherapy, such as cancer vaccines.
In one embodiment, the invention provides methods for treating or preventing cancer comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog to treat or prevent cancer and another anticancer therapy including, but not limited to, surgery, radiation therapy, or immunotherapy, such as a cancer vaccine.

In one embodiment, the other anticancer therapy is radiation therapy.
In another embodiment, the other anticancer therapy is surgery.
In still another embodiment, the other anticancer therapy is immunotherapy.
In a specific embodiment, the present methods for treating or preventing cancer comprise administering an effective amount of an Indenoisoquinolinone Analog and radiation therapy. The radiation therapy can be administered concurrently with, prior to, or subsequent to the Indenoisoquinolinone Analog, in one embodiment at least an hour, five hours, 12 hours, a day, a week, a month, in another embodiment several months (e.g., up to three months), prior or subsequent to administration of the Indenoisoquinolinone Analog.
Where the other anticancer therapy is radiation therapy, any radiation therapy protocol can be administered depending upon the type of cancer to be treated.
For example, but not by way of limitation, X-ray radiation can be administered;
specifically, high-energy megavoltage (radiation of greater that 1 MeV energy) can be administered for deep tumors, and electron beam and orthovoltage X-ray radiation can be administered for skin cancers. Gamma-ray emitting radioisotopes, such as radioactive isotopes of radium, cobalt and other elements, can also be administered.
Additionally, the invention provides methods of treatment of cancer comprising administering an Indenoisoquinolinone Analog as an alternative to chemotherapy or radiation therapy where the chemotherapy or the radiation therapy results in a negative side effect in the subject being treated. The subject being treated can, optionally, be treated with another anticancer therapy such as surgery, radiation therapy, or immunotherapy.
The Indenoisoquinolinone Analogs can also be administered in vitro or ex vivo, such as for the treatment of certain cancers, including, but not limited to leukemias and lymphomas, such treatment involving autologous stem cell transplants. This can involve a process in which the subject's autologous hematopoietic stem cells are harvested and purged of all cancer cells, the subject's remaining bone-marrow cell population is then eradicated via the administration of an Indenoisoquinolinone Analog and/or radiation, and the resultant stem cells are infused back into the subject. Supportive care can be subsequently provided while bone marrow function is restored and the subject recovers.

5.8.11 Treatment or Prevention of Erectile Dysfunction The Indenoisoquinolinone Analogs are useful for treating or preventing erectile dysfunction. Erectile dysfunction includes an inability to achieve or maintain a full erection, specifically that which is sufficient to achieve or maintain sexual intercourse.
The inability can be a total inability, an inconsistent ability, or a tendency to maintain only a brief erection. Erectile dysfunction includes idiopathic erectile dysfunction, as well as that which can result, for example, from trauma, including mechanical trauma, specifically that resulting from surgery, to the nerves (such as during prostatectomy);
diabetes mellitus; a cardiovascular disease, including atherosclerosis;
radiation; or certain drugs. The erectile dysfunction can also be age-related.
In one embodiment, the erectile dysfunction results from prostate surgery.
In a further embodiment, the erectile dysfunction results from prostate nerve injury.
5.8.12 Treatment or Prevention of Urinary Incontinence The Indenoisoquinolinone Analogs are also useful for treating or preventing urinary incontinence. Urinary incontinence can result, for example, from trauma, including mechanical trauma, specifically during childbirth or that resulting from surgery, to the nerves (such as during prostatectomy or gynecological surgery);
diabetes mellitus;
a cardiovascular disease, including atherosclerosis; radiation; or certain drugs. The urinary incontinence can also be age-related.
In one embodiment, the subject in need of urinary incontinence treatment or prevention is male.
In one embodiment, the subject in need of urinary incontinence treatment or prevention is female.

5.8.13 Treatment or Prevention of a Complication of Prematurity The Indenoisoquinolinone Analogs are also useful for treating or preventing a complication of prematurity. Examples of complications of prematurity include, but are not limited to, retinopathy, hyaline-membrane disease and necrotizing enterocolitis.

5.8.14 Treatment or Prevention of Cardiomyopathy The Indenoisoquinolinone Analogs are also useful for treating or preventing cardiomyopathy.

5.8.15 Treatment or Prevention of Retinopathy The Indenoisoquinolinone Analogs are also useful for treating or preventing retinopathy.

5.8.16 Treatment or Prevention of Nephropathy The Indenoisoquinolinone Analogs are also useful for treating or preventing nephropathy.

5.8.17 Treatment or Prevention of Neuropathy The Indenoisoquinolinone Analogs are also useful for treating or preventing neuropathy.

5.9 Therapeutic/Prophylactic Administration and Compositions of the Invention Due to their activity, the Indenoisoquinolinone Analogs are advantageously useful in veterinary and human medicine. As described above, the Indenoisoquinolinone Analogs are useful for treating or preventing a Condition in a subject in need thereof The Indenoisoquinolinone Analogs can be administered in amounts that are effective to treat or prevent a Condition in a subject in need thereof When administered to a subject, the Indenoisoquinolinone Analogs can be administered as a component of a composition that comprises a physiologically acceptable carrier or vehicle. The present compositions, which comprise an Indenoisoquinolinone Analog, can be administered orally. The Indenoisoquinolinone Analogs can also be administered by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral, rectal, or intestinal mucosa) and can be administered together with another biologically active agent. Administration can be systemic or local. Various delivery systems are known, e.g., encapsulation in liposomes, microparticles, microcapsules and capsules.
Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation, or topical, specifically to the ears, nose, eyes, or skin. In some instances, administration will result in the release of an Indenoisoquinolinone Analog into the bloodstream.
In one embodiment, the Indenoisoquinolinone Analogs are administered orally.
In other embodiments, it can be desirable to administer the Indenoisoquinolinone Analogs locally. This can be achieved, for example, and not by way of limitation, by local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository or enema, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
In certain embodiments, it can be desirable to introduce the Indenoisoquinolinone Analogs into the central nervous system or gastrointestinal tract by any suitable route, including intraventricular, intrathecal, and epidural injection, and enema.
Intraventricular injection can be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.
Pulmonary administration can also be employed, e.g., by use of an inhaler of nebulizer, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon oar, synthetic pulmonary surfactant. In certain embodiments, the Indenoisoquinolinone Analogs can be formulated as a suppository, with traditional binders and excipients such as triglycerides.
In another embodiment Indenoisoquinolinone Analogs can be delivered in a vesicle, specifically a liposome (see Langer, Science 249:1527-1533 (1990) and Treat or prevent et al., Liposomes in Therapy ofInfectious Disease and Cancer 317-327 and 353-365 (1989)).
In yet another embodiment, the Indenoisoquinolinone Analogs can be delivered in a controlled-release system or sustained-release system (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)). Other controlled or sustained-release systems discussed in the review by Langer, Science 249:1527-1533 (1990) can be used. In one embodiment a pump can be used (Langer, Science 249:1527-1533 (1990); Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); and Saudek et al., N. Engl. JMed. 321:574 (1989)). In another embodiment polymeric materials can be used (see Medical Applications of Controlled Release (Langer and Wise eds., 1974); Controlled Drug Bioavailability, Drug Product Design and Performance (Smolen and Ball eds., 1984); Ranger and Peppas, J.
Macromol.

Sci. Rev. Macromol. Chem. 2:61 (1983); Levy et al., Science 228:190 (1935);
During et al., Ann. Neural. 25:351 (1989); and Howard et al., J. Neurosurg. 71:105 (1989)).
In yet another embodiment a controlled- or sustained-release system can be placed in proximity of a target of the Indenoisoquinolinone Analogs, e.g., the spinal column, brain, skin, lung, or gastrointestinal tract, thus requiring only a fraction of the systemic dose.
The present compositions can optionally comprise a suitable amount of a pharmaceutically acceptable excipient so as to provide the form for proper administration to the subject.
Such pharmaceutical excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical excipients can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea and the like. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used. In one embodiment, the pharmaceutically acceptable excipients are sterile when administered to a subject. Water is a useful excipient when the Indenoisoquinolinone Analog is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, specifically for injectable solutions. Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
The present compositions can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions. aerosols, sprays, suspensions, or any other form suitable for use. In one embodiment, the composition is in the form of a capsule (see e.g.
U.S. Patent No. 5,698,155). Other examples of suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds., 19th ed. 1995), incorporated herein by reference.
In one embodiment, the Indenoisoquinolinone Analog is formulated in accordance with routine procedures as a composition adapted for oral administration to human beings. Compositions for oral delivery can be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs for example.
Orally administered compositions can contain one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving an Indenoisoquinolinone Analog are also suitable for orally administered compositions. In these latter platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A
time-delay material such as glycerol monostearate or glycerol stearate can also be useful. Oral compositions can include standard excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one embodiment, the excipients are of pharmaceutical grade.
In another embodiment, the Indenoisoquinolinone Analogs can be formulated for intravenous administration. Typically, compositions for intravenous administration comprise sterile isotonic aqueous buffer. Where necessary, the compositions can also include a solubilizing agent. Compositions for intravenous administration can optionally include a local anesthetic such as lignocaine to lessen pain at the site of the injection.
Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized-powder or water-free concentrate in a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent. Where the Indenoisoquinolinone Analogs are to be administered by infusion, they can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the Indenoisoquinolinone Analogs are administered by injection, an ampule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.
Indenoisoquinolinone Analogs can be administered by controlled-release or sustained-release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533;
5,059,595;
5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; and 5,733,556, each of which is incorporated herein by reference in its entirety. Such dosage forms can be useful for providing controlled- or sustained-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled- or sustained-release formulations known to those skilled in the art, including those described herein, can be readily selected for use with the active ingredients of the invention. The invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled- or sustained-release.
In one embodiment a controlled- or sustained-release composition comprises a minimal amount of an Indenoisoquinolinone Analog to treat or prevent the Condition over a period of time. Advantages of controlled- or sustained-release compositions include extended activity of the drug, reduced dosage frequency, and increased subject compliance. In addition, controlled- or sustained-release compositions can favorably affect the time of onset of action or other characteristics, such as blood levels of the Indenoisoquinolinone Analog, and can thus reduce the occurrence of adverse side effects.
Controlled- or sustained-release compositions can initially release an amount of an Indenoisoquinolinone Analog that promptly produces the desired therapeutic or prophylactic effect, and gradually and continually release other amounts of the Indenoisoquinolinone Analog to maintain this level of therapeutic or prophylactic effect over an extended period of time. To maintain a constant level of the Indenoisoquinolinone Analog in the body, the Indenoisoquinolinone Analog can be released from the dosage form at a rate that will replace the amount of Indenoisoquinolinone Analog being metabolized and excreted from the body.
Controlled- or sustained-release of an active ingredient can be stimulated by various conditions, including but not limited to, changes in pH, changes in temperature, concentration or availability of enzymes, concentration or availability of water, or other physiological conditions or compounds.
The amount of the Indenoisoquinolinone Analog that is effective in the treatment or prevention of a Condition can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed can also depend on the route of administration, and the seriousness of the condition being treated and can be decided according to the judgment of the practitioner and each subject's circumstances in view of, e.g., published clinical studies. Suitable effective dosage amounts, however, range from about 10 micrograms to about 5 grams about every 4 hours, although they are typically about 500 mg or less per every 4 hours. In one embodiment, the effective dosage is about 0.01 mg, 0.5 mg, about 1 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1 g, about 1.2 g, about 1.4 g, about 1.6 g, about 1.8 g, about 2.0 g, about 2.2 g, about 2.4 g, about 2.6 g, about 2.8 g, about 3.0 g, about 3.2 g, about 3.4 g, about 3.6 g, about 3.8 g, about 4.0 g, about 4.2 g, about 4.4 g, about 4.6 g, about 4.8 g, and about 5.0 g, every 4 hours. Equivalent dosages can be administered over various time periods including, but not limited to, about every 2 hours, about every 6 hours, about every 8 hours, about every 12 hours, about every 24 hours, about every 36 hours, about every 48 hours, about every 72 hours, about every week, about every two weeks, about every three weeks, about every month, and about every two months. The effective dosage amounts described herein refer to total amounts administered; that is, if more than one Indenoisoquinolinone Analog is administered, the effective dosage amounts correspond to the total amount administered.
Compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present compositions can contain, in one embodiment, from about 0.1% to about 99%; and in another embodiment from about 1%
to about 70% of the Indenoisoquinolinone Analog by weight or volume.
The dosage regimen utilizing the Indenoisoquinolinone Analog can be selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the subject; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the subject; and the specific Indenoisoquinolinone Analog employed. A person skilled in the art can readily determine the effective amount of the drug useful for treating or preventing the Condition.
An Indenoisoquinolinone Analog can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three or four times daily. Furthermore, an Indenoisoquinolinone Analog can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration can be continuous rather than intermittent throughout the dosage regimen. Other illustrative topical preparations include creams, ointments, lotions, aerosol sprays and gels, wherein the concentration of Indenoisoquinolinone Analog ranges from about 0.1% to about 15%, w/w or w/v.
The Indenoisoquinolinone Analogs can be assayed in vitro or in vivo for the desired therapeutic or prophylactic activity prior to use in humans. Animal model systems can be used to demonstrate safety and efficacy.
The present methods for treating or preventing a Condition in a subject in need thereof can further comprise administering another prophylactic or therapeutic agent to the subject being administered an Indenoisoquinolinone Analog. In one embodiment, the other prophylactic or therapeutic agent is administered in an effective amount. The other prophylactic or therapeutic agent includes, but is not limited to, an anti-inflammatory agent, an anti-renal failure agent, an anti-diabetic agent, and anti-cardiovasculare disease agent, an antiemetic agent, a hematopoietic colony stimulating factor, an anxiolytic agent, and an analgesic agent.
In one embodiment, the other prophylactic or therapeutic agent is an agent useful for reducing any potential side effect of an Indenoisoquinolinone Analog. Such potential side effects include, but are not limited to, nausea, vomiting, headache, low white blood cell count, low red blood cell count, low platelet count, headache, fever, lethargy, a muscle ache, general pain, bone pain, pain at an injection site, diarrhea, neuropathy, pruritis, a mouth sore, alopecia, anxiety or depression.
In one embodiment, the Indenoisoquinolinone Analog can be administered prior to, concurrently with, or after an anti-inflammatory agent, or on the same day, or within 1 hour, 2 hours, 12 hours, 24 hours, 48 hours or 72 hours of each other.
In another embodiment, the Indenoisoquinolinone Analog can be administered prior to, concurrently with, or after an anti-renal failure agent, or on the same day, or within 1 hour, 2 hours, 12 hours, 24 hours, 48 hours or 72 hours of each other.
In still another embodiment, the Indenoisoquinolinone Analog can be administered prior to, concurrently with, or after an anti-diabetic agent, or on the same day, or within 1 hour, 2 hours, 12 hours, 24 hours, 48 hours or 72 hours of each other.

In yet another embodiment, the Indenoisoquinolinone Analog can be administered prior to, concurrently with, or after an anti-cardiovascular disease agent, or on the same day, or within 1 hour, 2 hours, 12 hours, 24 hours, 48 hours or 72 hours of each other.
In a further embodiment, the Indenoisoquinolinone Analog can be administered prior to, concurrently with, or after an antiemetic agent, or on the same day, or within 1 hour, 2 hours, 12 hours, 24 hours, 48 hours or 72 hours of each other.
In another embodiment, the Indenoisoquinolinone Analog can be administered prior to, concurrently with, or after a hematopoietic colony stimulating factor, or on the same day, or within 1 hour, 2 hours, 12 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 3 weeks or 4 weeks of each other.
In still embodiment, the Indenoisoquinolinone Analog can be administered prior to, concurrently with, or after an opioid or non-opioid analgesic agent, or on the same day, or within 1 hour, 2 hours, 12 hours, 24 hours, 48 hours or 72 hours of each other.
In yet another embodiment, the Indenoisoquinolinone Analog can be administered prior to, concurrently with, or after an anxiolytic agent, or on the same day, or within 1 hour, 2 hours, 12 hours, 24 hours, 48 hours or 72 hours of each other.
Effective amounts of the other prophylactic or therapeutic agents are well known to those skilled in the art. However, it is well within the skilled artisan's purview to determine the other prophylactic or therapeutic agent's optimal effective amount range. In one embodiment of the invention, where another prophylactic or therapeutic agent is administered to a subject, the effective amount of the Indenoisoquinolinone Analog is less than its effective amount would be where the other prophylactic or therapeutic agent is not administered. In this case, without being bound by theory, it is believed that Indenoisoquinolinone Analogs and the other prophylactic or therapeutic agent act synergistically to treat or prevent a Condition.
In one embodiment, the other therapeutic or prophylactic agent is an anti-inflammatory agent. Anti-inflammatory agents useful in the methods of the present invention include but are not limited to adrenocorticosteroids, such as cortisol, cortisone, fludrocortisone, prednisone, prednisolone, 6a-methylprednisolone, triamcinolone, betamethasone, and dexamethasone; and non-steroidal anti-inflammatory agents (NSAIDs), such as aspirin, acetaminophen, indomethacin, sulindac, tolmetin, diclofenac, ketorolac, ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen, oxaprozin, mefenamic acid, meclofenamic acid, piroxicam, meloxicam, nabumetone, rofecoxib, celecoxib, etodolac, and nimesulide.
In one embodiment, the other therapeutic or prophylactic agent is an anti-renal failure agent. Anti-renal failure agents useful in the methods of the present invention include include but are not limited to ACE (angiotensin-converting enzyme) inhibitors, such as captopril, enalaprilat, lisinopril, benazepril, fosinopril, trandolapril, quinapril, and ramipril; diuretics, such as mannitol, glycerin, furosemide, toresemide, tripamide, chlorothiazide, methyclothiazide, indapamide, amiloride, and spironolactone;
and fibric acid agents, such as clofibrate, gemfibrozil, fenofibrate, ciprofibrate, and bezafibrate.
In one embodiment, the other therapeutic or prophylactic agent is an anti-diabetic agent. Anti-diabetic agents useful in the methods of the present invention include include but are not limited to glucagons; somatostatin; diazoxide; sulfonylureas, such as tolbutamide, acetohexamide, tolazamide, chloropropamide, glybenclamide, glipizide, gliclazide, and glimepiride; insulin secretagogues, such as repaglinide, and nateglinide;
biguanides, such as metformin and phenformin; thiazolidinediones, such as pioglitazone, rosiglitazone, and troglitazone; and a-glucosidase inhibitors, such as acarbose and miglitol.
In one embodiment, the other therapeutic or prophylactic agent is an anti-cardiovascular agent. Anti-cardiovascular disease agents useful in the methods of the present invention include include but are not limited to carnitine; thiamine;
and muscarinic receptor antagonists, such as atropine, scopolamine, homatropine, tropicamide, pirenzipine, ipratropium, tiotropium, and tolterodine.
In one embodiment, the other therapeutic or prophylactic agent is an antiemetic agent. Antiemetic agents useful in the methods of the present invention include include, but are not limited to, metoclopromide, domperidone, prochlorperazine, promethazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron, hydroxyzine, acetylleucine monoethanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, clebopride, cyclizine, dimenhydrinate, diphenidol, dolasetron, meclizine, methallatal, metopimazine, nabilone, oxyperndyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol, thiethylperazine, thioproperazine, tropisetron, and mixtures thereof.
In one embodiment, the other therapeutic or prophylactic agent is a hematopoietic colony stimulating factor. Hematopoietic colony stimulating factors useful in the methods of the present invention include, but are not limited to, filgrastim, sargramostim, molgramostim and epoietin alfa.
In one embodiment, the other therapeutic or prophylactic agent is an opioid analgesic agent. Opioid analgesic agents useful in the methods of the present invention include, but are not limited to, morphine, heroin, hydromorphone, hydrocodone, oxymorphone, oxycodone, metopon, apomorphine, normorphine, etorphine, buprenorphine, meperidine, lopermide, anileridine, ethoheptazine, piminidine, betaprodine, diphenoxylate, fentanil, sufentanil, alfentanil, remifentanil, levorphanol, dextromethorphan, phenazocine, pentazocine, cyclazocine, methadone, isomethadone and propoxyphene.
In one embodiment, the other therapeutic or prophylactic agent is a non-opioid analgesic agent. Non-opioid analgesic agents useful in the methods of the present invention include, but are not limited to, aspirin, celecoxib, rofecoxib, diclofinac, diflusinal, etodolac, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, indomethacin, ketorolac, meclofenamate, mefanamic acid, nabumetone, naproxen, piroxicam and sulindac.
In one embodiment, the other therapeutic or prophylactic agent is an anxiolytic agent. Anxiolytic agents useful in the methods of the present invention include, but are not limited to, buspirone, and benzodiazepines such as diazepam, lorazepam, oxazapam, chlorazepate, clonazepam, chlordiazepoxide and alprazolam.

5.10 Kits The invention encompasses kits that can simplify the administration of an Indenoisoquinolinone Analog to a subject.
A typical kit of the invention comprises a unit dosage form of an Indenoisoquinolinone Analog. In one embodiment, the unit dosage form is a container, which can be sterile, containing an effective amount of an Indenoisoquinolinone Analog and a physiologically acceptable carrier or vehicle. The kit can further comprise a label or printed instructions instructing the use of the Indenoisoquinolinone Analog to treat or prevent a Condition. The kit can also further comprise a unit dosage form of another prophylactic or therapeutic agent, for example, a container containing an effective amount of the other prophylactic or therapeutic agent. In one embodiment, the kit comprises a container containing an effective amount of an Indenoisoquinolinone Analog and an effective amount of another prophylactic or therapeutic agent. Examples of other prophylactic or therapeutic agents include, but are not limited to, those listed above.

The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

6. EXAMPLES
Example 1 Illustrative Indenoisoquinolinone Analogs General Methods:
iH-NMR spectra were obtained using Varian 300 MHz spectrophotometer and chemical shifts (b) are reported in parts per million (ppm). iH-NMR spectra were obtained using DMSO-d6 or CDC13 as solvents. Analytical thin layer chromatography (TLC) was performed using TLC plates pre-coated with silica ge160 F-254.
Compounds were visualized with short wavelength UV light. All final compounds were characterized on the basis of iH-NMR or mass-spectrometry (MS) data. Homophthalic anhydride, methyl-3-bromobenzoic acid, benzonitrile, and 3-methyl-4-bromobenzoic acid were obtained commercially (Sigma-Aldrich Corp., St. Louis, MO).
A. Synthesis of Indenoisoguinolinone Analogs of Formula IIa and IIIa Methyl 3-bromo-2-methylbenzoate:
2 mL of concentrated sulfuric acid were added to a solution of 3-bromo-2-methylbenzoic acid (20g, 93 mmol) in methanol (150 mL). The resultant mixture was refluxed for 6 hours. Methanol was removed under reduced pressure, and the residue was dissolved in a mixture of chloroform (100 mL) and saturated solution of Na2CO3 (100 mL). The organic layer was separated and washed with brine, dried over NazSO4 and concentrated to provide methyl 3-bromo-2-methylbenzoate (21.1g). iH NMR
spectrum (in DMSO-d6): b 7.79 (d, J= 8.0 Hz, 1H); 7.69 (d, J= 7.9 Hz, 1H); 7.23 (t, 1H); 3.82 (s, 3H).

Methyl 3-cyano-2-methylbenzoate:

To a flask was added methyl 3 -bromo-2-methylbenzoate (21g, 91.7 mmol), potassium hexacyanoferrate (II) trihydrate (9.7g, 22.9 mmol), Na2CO3 (9.7g, 91.7 mmol) and Pd(OAc)z (102 mg) in N,N-dimethylacetamide (100 mL). The flask's atmosphere was evacuated and replaced with nitrogen, and the reaction mixture heated at 120 C for 10 hours. The reaction mixture was cooled to room temperature and diluted with ethyl acetate (150 mL). The resultant slurry was filtered and washed thoroughly with ethyl acetate (2 x 50 mL). The combined filtrate was washed with brine and water, dried over NazSO4 and evaporated under reduced pressure. The residue obtained after the concentration was purified using flash chromatography (ethyl acetate-hexanes (1:9) as the eluent) to provide methyl 3-cyano-2-methylbenzoate (11.2g, 70% yield). iH NMR
spectrum (in DMSO-d6): b 8.03 (d, J= 8.1 Hz, 1H); 7.98 (d, J= 7.9 Hz, 1H);
7.49 (t, 1H);
3.84 (s, 3H); 2.65 (s, 3H).

Methyl2-bromomethyl-3-cyanobenzoate:
A suspension of inethyl3-cyano-2-methylbenzoate (10.6g, 60.5 mmol), NBS
(16.2g, 90.7 mmol) and azobisisobutyronitrile (AIBN) (100 mg) in tetrachloromethane (200 mL) was refluxed under nitrogen atmosphere for 6 hours. TLC analysis indicated the complete consumption of inethyl3-cyano-2-methylbenzoate (TLC solvent: 10%
ethyl acetate in hexane). The reaction mixture was filtered and washed with chloroform (3 x 20 mL). The combined filtrate and washings were concentrated under reduced pressure.
The residue was washed through a short column of silica gel using 10% ethyl acetate in hexanes as an eluent. The eluent was concentrated and the resultant product dried under vacuum overnight to provide 15.1 g of inethyl2-bromomethyl-3-cyanobenzoate (98%
yield). iH NMR spectrum (in DMSO-d6): b 8.15 (d, J= 8.0 Hz, 1H); 8.12 (d, J=
7.9 Hz, 1H); 7.67 (t, 1H); 5.04 (s, 2H); 3.89 (s, 3H).

Methyl 5, 6-dihydro-5-oxo-1l-H-indenofl, 2-c7isoquinoline-l0-carboxylate:
A mixture of inethyl2-bromomethyl-3-cyanobenzoate (14.1g, 55.5 mmol) and homophthalic anhydride (22.5g, 138.8 mmol) in acetonitrile (150 mL) was stirred at room temperature. A solution of triethylamine (23.2 mL) in acetonitrile (100 mL) was added dropwise over the period of 1 hour. After the completion of addition, the resultant suspension was refluxed for 4 hours. The reaction mixture was then cooled to room temperature and filtered. The resultant solid was washed thoroughly with acetonitrile (100 mL) and ethanol (2 x 100 mL) and dried in vacuum oven at 50 C to provide methy15,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline-10-carboxylate was obtained in 81% yield (13.1g). iH NMR spectrum (in DMSO-d6): b 12.21 (s, 1H); 8.20 (m, 2H); 7.83 (d, J= 7.5 Hz, 1H); 7.71 (m, 2H); 7.47 (m, 2H); 4.07 (s, 2H); 3.89 (s, 3H).

10-Hydroxymethyl-5, 6-dihydro-5-oxo-11-H-indenofl, 2-c/isoquinoline Fine powder of inethy15,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline-10-carboxylate (11.3g, 28.8 mmol) was suspended in THF (150 mL) and stirred at room temperature. A 2M solution of Lithium aluminium hydride (LAH)in THF (39 mL) was added slowly to the stirred suspension. After the complete addition, the mixture was stirred at room temperature for 6 hours, then cooled to 0 C. The reaction mixture was quenched with dropwise addition of ethyl acetate (50 mL). During the quenching the reaction temperature was kept below 50 C. The reaction mixture was poured into solution (200 mL) and stirred for 1 hour. The resultant solid was collected by filtration, washed with 1N HC1 solution (20 mL) and ethyl acetate, and dried in a vacuum oven overnight to provide 10-hydroxymethyl-5,6-dihydro-5-oxo-1l-H-indeno[1,2-c]isoquinoline in 93% yield (9.5 g). iH NMR spectrum (in DMSO-d6): b 12.28 (s, 1H);
8.23 (d, J= 8.1 Hz, 1H); 7.89 (m, 1H); 7.73 (m, 2H); 7.45 (m, 1H); 7.36 (m, 2H); 5.22 (d, J= 5.1 Hz, 1H), 4.68 (d, 2H); 3.85 (s, 2H).

10-Bromomethyl-5, 6-dihydro-5-oxo-11-H-indenofl , 2-c/isoquinoline:
Fine powder of 10-hydroxymethyl-5,6-dihydro-5-oxo-1l-H-indeno[1,2-c]isoquinoline (7.3g, 27.7 mmol) was suspended in THF (150 mL). A solution of PBr3 (83 mL, 1M in dichloromethane) was added dropwise at room temperature. After the complete addition, the resultant mixture was stirred overnight and quenched by addition of water (150 mL). The suspension was stirred for 1 hour and filtered. The resultant solid was washed with water (2 x 100 mL) and ethyl acetate (2 x 100 mL) and dried in a vacuum oven to provide 10-Bromomethyl-5,6-dihydro-5-oxo-1l-H-indeno[1,2-c]isoquinoline in 81% yield. iH NMR spectrum (in DMSO-d6): b 12.31 (s, 1H);
8.23 d, J
= 7.5 Hz, 1H); 7.95 (m, 1H); 7.75 (m, 2H); 7.45 (m, 2H); 4.87 (s, 2H); 3.97 (s, 2H).
General Procedure for the Amination Reaction:
A suspension of 10-bromomethyl-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline (0.425 g, 1.3 mmol) or a higher alkylene chain bromo-derivative, an appropriate amine in ethanol or DMF and ethanol and in the presence of base is refluxed for 2 hrs to overnight. The reaction mixture is stirred at room temperature for about 30 minutes and filtered. The resultant solid is washed with ethanol (2 x 20 mL) and dried in a vacuum oven to provide an Indenoisoquinolinone Analog of Formula IIa or IIIa.
Methanesulfonate or Hydrochloride Salt Formation:
Free base of an Indenoisoquinolinone Analog of Formula IIb or IIIb is suspended in ethanol. To the stirred suspension, methanesulfonic acid or hydrochloric acid is added (2 to 10 equivalents). After some time, the resultant salt starts to precipitate from the solution. The mixture is stirred at room temperature for about 2 hours, filtered and washed with ethanol (2 x 20 mL). The filtered solid is dissolved in water (10 mL) and filtered. The filtrate is lyophilized to provide the corresponding salt of the free base of the Indenoisoquinolinone Analog of Formula IIa or IIIa.
B. Synthesis of Indenoisoguinolinone Analogs of Formula IIb and IIIb Methyl 4-cyano-3-methylbenzoate:
Methyl 4-cyano-3-methylbenzoate was obtained in 86% yield according to the procedure used to prepare methyl 3-cyano-2-methylbenzoate, except that methyl bromo-3-methylbenzoate was used in place of inethyl3-bromo-2-methylbenzoate.
iH
NMR spectrum (in DMSO-d6): b 7.96 (s, 1H); 7.85 (m, 2H); 3.85 (s, 3H); 2.46 (s, 3H).
Methyl 3-bromomethyl-4-cyanobenzoate:
Methyl 3-bromomethyl-4-cyanobenzoate was obtained in 60% yield according to the procedure used to prepare methyl 2-bromomethyl-3-cyanobenzoate (supra), except that methyl 4-cyano-3-methylbenzoate was used in place of inethyl3-cyano-2-methylbenzoate. iH NMR spectrum (in DMSO-d6): b 8.26 (s, 1H); 8.02 (s, 2H);
4.89 (s, 2H); 3.88 (s, 3H).

Methyl5,6-dihydro-5-oxo-1l-H-indenofl,2-c]isoquinoline-9-carboxylate:
Methy15,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline-9-carboxylate was obtained in 65% yield according to the procedure used to prepare methy15,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline-10-carboxylate, except that methyl3-bromomethyl-4-cyanobenzoate was used in place of inethyl2-bromomethyl-3-cyanobenzoate. iH
NMR
spectrum (in DMSO-d6): b 12.35 (s, 1H); 8.25 (d, J= 8.1 Hz, 1H); 8.11 (s, 1H);
8.06 (d, J
= 7.8 Hz, 1H); 7.98 (d, J= 8.1 Hz, 1H); 7.75 (m, 2H); 7.49 (m, 1H); 3.95 (s, 2H); 3.85 (s, 3H).
9-Hydroxymethyl-5, 6-dihydro-5-oxo-11-H-indenofl,2-c/isoquinoline 9-Hydroxymethyl-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline was obtained in 96% yield according to the procedure used to prepare 10-hydroxymethyl-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline, except that methy15,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline-9-carboxylate was used in place of inethy15,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline-10-carboxylate. iH NMR spectrum (in DMSO-d6):
b 12.26 (s, 1H); 8.22 (d, J= 8.1 Hz, 1H); 7.91 (s, J= 8.1 Hz, 1H); 7.70 (m, 2H); 7.54 (s, 1H); 7.42 (m, 1H); 7.30 (d, J= 8.1 Hz, 1H); 5.21 (d, 1H); 4.55 (d, J= 5.4 Hz, 2H); 3.89 (s, 2H).
9-Bromomethyl-5, 6-dihydro-5-oxo-11-H-indenofl,2-c/isoquinoline:
9-Bromomethyl-5,6-dihydro-5-oxo-1l-H-indeno[1,2-c]isoquinoline was obtained in 65% yield according to the procedure used to prepare 10-bromomethyl-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline, exceptthat9-hydroxymethyl-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline was used in place of 10-hydroxymethyl-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline. iH NMR spectrum (in DMSO-d6): b 12.24 (s, 1H);
8.23 (d, J= 7.5 Hz, 1H); 7.94 (d, J= 7.8 Hz, 1H); 7.72 (m, 2H); 7.65 (s, 1H); 7.45 (m, 2H);
4.79 (s, 2H); 3.89 (s, 2H).

General Procedure for the Amination Reaction:
A suspension of 9-bromomethyl-5,6-dihydro-5-oxo-1l-H-indeno[1,2-c]isoquinoline (0.425 g, 1.3 mmol) or a higher alkylene chain bromo-derivative, an appropriate amine in ethanol or DMF and ethanol and in the presence of base is refluxed for 2 hrs to overnight. The reaction mixture is stirred at room temperature for about 30 minutes and filtered. The resultant solid is washed with ethanol (2 x 20 mL) and dried in a vacuum oven to provide an Indenoisoquinolinone Analog of Formula IIb or IIIb.
Methanesulfonate or Hydrochloride Salt Formation:

Free base of an Indenoisoquinolinone Analog of Formula IIb or IIIb is suspended in ethanol. To the stirred suspension, methanesulfonic acid or hydrochloric acid is added (2 to 10 equivalents). After some time, the resultant salt starts to precipitate from the solution. The mixture is stirred at room temperature for about 2 hours, filtered and washed with ethanol (2 x 20 mL). The filtered solid is dissolved in water (10 mL) and filtered. The filtrate is lyophilized to provide the corresponding salt of the free base of the Indenoisoquinolinone Analog of Formula IIb or IIIb.

iH NMR data for illustrative Indenoisoquinolinone Analogs are presented below in Table 3.

Compound 1H NMR (DMSO-d6 or DMSO-d6 and DZO) IIa-1 10-[1-(4-Allylpiperazino)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.28 (s, 1H);
8.23 (d, J= 8.1 Hz, 1H); 7.89 (d, J= 7.2 Hz, 1H); 7.75 (m, 2H);
7.45 (m, 1H); 7.37 (t, J= 7.5 Hz, 1H); 7.28 (d, J= 7.5 Hz, 1H);
5.77 (m, 1H); 5.14 (d, J= 18.6 Hz, 1H); 5.08 (d, J= 10.8 Hz, 1H); 3.89 (s, 2H); 3.61 (s, 2H); 2.89 (d, J= 6.0 Hz, 2H); 2.40 (m, 8H). MS: m/z = 372 (M+-H) IIIa-2 10-[1-(4-Butylpiperazino)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.28 (s, 1H);
8.24 (d, J= 7.8 Hz, 1H); 7.90 (d, J= 7.2 Hz, 1H); 7.74 (m, 2H);
7.45 (m, 1H); 7.36 (t, J= 7.5 Hz, 1H); 7.27 (d, J= 7.2 Hz, 1H);
3.90 (s, 2H); 3.64 (s, 2H); 2.38 (m, 10H); 1.41 (m, 2H); 1.24 (m, 2H); 0.85 (t, J= 7.2 Hz, 3H). MS: m/z = 388 (M+-H).
Dihydrochloride 10-[1-(4-Allylpiperazino)methyl]-5,6-dihydro-5-oxo-11-H-salt of IIa-1 indeno[1,2-c]isoquinoline dihydrochloride: iH NMR (DMSO
& D20) b 12.35 (s, 1H); 8.25 (d, J= 8.1 Hz, 1H); 8.04 (d, J=
7.5 Hz, 1H); 7.78 (t, J= 7.5 Hz, 1H); 7.72 (d, J= 7.5 Hz, 1H);
7.58 (s, 1H); 7.48 (m, 2H); 5.94 (m, 1H); 5.56 (d, J= 19.2 Hz, 1H); 5.48 (d, J= 10.5 Hz, 1H); 4.15 (s, 2H); 3.73 (s, 2H); 3.51 (m, 10H).
Dihydrochloride 10-[1-(4-Butylpiperazino)methyl]-5,6-dihydro-5-oxo-11-H-salt of IIIa-2 indeno[1,2-c]isoquinoline dihydrochloride: iH NMR (DMSO
& D20) b 12.35 (s, 1H); 8.25 (d, J= 8.1 Hz, 1H); 8.04 (d, J=
7.2 Hz, 1H); 7.78 (t, J= 7.2 Hz, 1H); 7.71 (d, J= 7.2 Hz, 1H);
7.58 (s, 1H); 7.48 (m, 2H); 4.15 (s, 2H); 3.53 (m, 10H); 3.04 (s, 2H); 1.62 (m, 2H); 1.30 (m, 2H); 0.88 (t, J= 7.2 Hz, 3H). MS:
m/z = 388 (M+-H).
IIIa-3 10-[1-(4-Cyclopropylmethylpiperazino)methyl]-5,6-dihydro-5-oxo-1l-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.23 (s, 1H); 8.24 (d, J= 7.8 Hz, 1H); 7.90 (d, J= 7.2 Hz, 1H);
7.74 (m, 2H); 7.44 (m, 1H); 7.35 (t, J= 7.5 Hz, 1H); 7.27 (d, J=
7.2 Hz, 1H); 3.88 (s, 2H); 3.61 (s, 2H); 2.42 (m, 8H); 2.13 (d, J
= 5.7 Hz, 2H); 0.78 (m, 2H); 0.40 (d, J= 6.6 Hz, 2H); 0.02 (m, 2H). MS: m/z = 386 (M+-H).
IIa-14 10-[(4,4-Ethylenedioxy-piperidino)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO): b 12.28 (s, 1H); 8.24 (d, J= 7.8 Hz, 1H); 7.90 (d, J= 7.2 Hz, 1H);
7.76 (m, 2H); 7.45 (m, 1H); 7.36 (t, J= 7.5 Hz, 1H); 7.29 (d, J=
7.2 Hz, 1H); 3.90 (s, 2H); 3.84 (s, 4H); 3.64 (s, 2H); 2.45 (m, 4H); 1.61 (m, 4H). MS: m/z = 389 (M+-H).
IIIa-5 10-[N-(2-Pyrollidinoethyl)aminomethyl}-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.23 (s, 1H); 8.23 (d, J= 8.1 Hz, 1H); 7.88 (dd, J= 2.1 Hz, 6.3 Hz, 1H);
7.74 (d, J= 3.6 Hz, 2H); 7.44 (m, 1H); 7.34 (m, 2H); 3.89 (s, 2H); 3.87 (s, 2H); 2.62 (t, J= 6.3, 2H); 2.52 (m, 2H); 2.37 (m, 4H); 1.61 (m, 4H). MS: m/z = 360 (M+-H).
IIa-27 10-{N-[1-(Hydroxymethyl)cyclopentyl] aminomethyl}-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: 1H NMR
(DMSO) b 12.28 (s, 1H); 8.23 (d, J= 7.8 Hz, 1H); 7.86 (d, J=
6.9 Hz, 1H); 7.73 (m, 2H); 7.45 (m, 1H); 7.36 (m, 2H); 4.56 (s, 1H); 3.90 (s, 2H); 3.79 (s, 2H); 3.41 (s, 2H); 1.69 (m, 2H); 1.53 (m, 4H). MS: m/z = 361 (M+-H).
IIIa-6 10-{1-[4-(2-Pyrollidinoethyl)piperidino]methyl}-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.24 (s, 1H); 8.24 (d, J= 7.8 Hz, 1H); 7.89 (d, J= 7.2 Hz, 1H);
7.75 (m, 2H); 7.45 (m, 1H); 7.35 (t, J= 7.2 Hz, 1H); 7.28 (d, J=
7.2 Hz, 1H); 3.89 (s, 2H); 3.58 (s, 2H); 2.79 (d, J= 9.9 Hz, 2H);
2.35 (m, 6H); 1.95 (t, J= 10.6 Hz, 2H); 1.62 (m, 6H); 1.33 (m, 3H); 1.12 (m, 2H). MS: m/z = 428 (M+-H).
IIIa-7 10-{N-[4-(1-Methylpiperidyl)] aminomethyl}-5,6-dihydro-5-oxo-1l-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.23 (s, 1H); 8.23 (d, J= 7.8 Hz, 1H); 7.87 (m, 1H); 7.75 (m, 2H); 7.46 (m, 1H); 7.36 (m, 2H); 3.90 (s, 2H); 3.88 (s, 2H); 2.68 (d, J= 11.7 Hz, 2H); 2.40 (m, 1 H); 2.11 (s, 3H); 1.82 (m, 4H);
1.30 (m, 2H).
IIIa-9 10-[1-(4-Cyclopentylpiperazino)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.23 (s, 1H); 8.24 (d, J= 7.8 Hz, 1H); 7.90 (d, J= 7.2 Hz, 1H); 7.74 (m, 2H); 7.44 (m, 1H); 7.35 (t, J= 7.5 Hz, 1H); 7.28 (d, J= 7.2 Hz, 1H); 3.89 (s, 2H); 3.60 (s, 2H); 2.41 (m, 9H); 1.71 (m, 2H); 1.56 (m, 2H); 1.45 (m, 2H); 1.28(m, 2H). MS: m/z = 400 (M+-H).
IIIa-8 10-{1-[4-(2-Pyrimidyl)piperazino] methyl}-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.28 (s, 1H); 8.32 (d, J= 4.8, 2H); 8.24 (d, J= 7.8 Hz, 1H); 7.92 (d, J=
6.8 Hz, 1H); 7.74 (m, 2H); 7.44 (m, 1H); 7.35 (m, 2H); 6.59 (t, J
= 4.8 Hz, 1H); 3.94 (s, 2H); 3.73 (m, 4H); 3.68 (s, 2H); 2.46 (m, 4H). MS: m/z = 410 (M+-H).

IIIa-10 10-{1-[4-(2-Ethoxyethyl)piperazino] methyl}-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.28 (s, 1H); 8.23 (d, J= 7.8 Hz, 1H); 7.90 (d, J= 7.2 Hz, 1H);
7.76 (m, 2H); 7.45 (m, 1H); 7.35 (t, J= 7.5 Hz, 1H); 7.27 (d, J=
7.2 Hz, 1H); 3.89 (s, 2H); 3.60 (s, 2H); 3.38 (m, 4H); 2.40 (m, 10H); 1.06 (t, J= 6.9 Hz, 3H). MS: m/z = 404 (M+-H).

IIb-1 9-[1-(4-Allylpiperazino)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.23 (s, 1H);
8.22 (d, J= 7.8 Hz, 1H); 7.91 (d, J= 7.8 Hz, 1H); 7.71 (m, 2H);
7.51 (s, 1H); 7.44 (m, 1H); 7.28 (d, J= 7.5 Hz, 1H); 5.76 (m, 1H); 5.13 (d, J= 18.9 Hz, 1H); 5.08 (d, J= 11.2 Hz, 1H); 3.86 (s, 2H); 3.51 (s, 2H); 2.90 (d, J= 6.0 Hz, 2H); 2.37 (m, 8H). MS:
m/z = 372 (M+-H).
IIIb-1 9-[1-(4-iso-Propylpiperazino)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.22 (s, 1H); 8.23 (d, J= 7.8 Hz, 1H); 7.92 (d, J= 7.8 Hz, 1H); 7.71 (m, 2H); 7.50 (s, 1H); 7.43 (m, 1H); 7.28 (d, J= 7.8 Hz, 1H); 3.86 (s, 2H); 3.50 (s, 2H); 2.60 (m, 1H); 2.46-2.35 (m, 8H); 0.94 (d, J= 6.3 Hz, 6H). MS: m/z = 374 (M+-H).

IIIb-13 9-[1-(4-Methylhomopiperazino)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.24 (s, 1H); 8.23 (d, J= 8.1 Hz, 1H); 7.91 (d, J= 7.8 Hz, 1H); 7.71 (m, 2H); 7.53 (s, 1H); 7.43 (m, 1H); 7.31 (d, J= 7.8 Hz, 1H); 3.86 (s, 2H); 3.65 (s, 2H); 2.66-2.50 (m, 8H); 2.25 (s, 3H); 1.71 (m, 2H). m/z = 360 (M+-H).
Dihydrochloride 9-[1-(4-Cyclopropylmethylpiperazino)methyl]-5,6-dihydro-5-salt of IIIb-3 oxo-11-H-indeno[1,2-c]isoquinoline dihydrochloride: 1H
NMR (DMSO & D20) b 8.22 (d, J= 7.8 Hz, 1H); 7.98 (t, J= 7.5 Hz, 1H); 7.74 (m, 3H); 7.50 (m, 2H); 4.35 (s, 2H); 3.87 (s, 2H);
3.38 (m, 8H); 3.04 (d, J= 6.3 Hz, 2H); 1.02 (m, 1H); 0.62 (d, J=
6.3 Hz, 2H); 0.34 (m, 2H). MS: m/z = 386 (M+-H).
Dihydrochloride 9-[1-(4-iso-Propylpiperazino)methyl]-5,6-dihydro-5-oxo-11-salt of IIIb-1 H-indeno[1,2-c]isoquinoline dihydrochloride: 1H NMR
(DMSO) b 12.22 (s, 1H); 8.22 (d, J= 8.1 Hz, 1H); 7.99 (d, J=
7.8 Hz, 1 H); 7.75 (m, 3H); 7.56 (d, J= 7.8 Hz, 1 H); 7.47 (m, 1H); 4.39 (s, 2H); 3.90 (s, 2H); 3.54 (m, 9H); 1.23 (d, J= 6.0 Hz, 6H). MS: m/z = 374 (M+-H).

IIIb-2 9-[1-(4-Butylpiperazino)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.23 (s, 1H);
8.22 (d, J= 8.1 Hz, 1H); 7.91 (d, J= 7.8 Hz, 1H); 7.71 (m, 2H);
7.50 (s, 1H); 7.43 (m, 1H); 7.27 (d, J= 7.8 Hz, 1H); 3.86 (s, 2H); 3.50 (s, 2H); 2.35 (m, 8H); 2.22 (t, J= 6.9 Hz, 2H);
1.37-1.20 (m, 4H); 0.84 (t, J= 6.9 Hz, 3H). MS: m/z = 388 (M+-H).
Dihydrochloride 9-[1-(4-Butylpiperazino)methyl]-5,6-dihydro-5-oxo-11-H-salt of IIIb-2 indeno[1,2-c]isoquinoline dihydrochloride: iH NMR (DMSO) b 12.23 (s, 1H); 8.23 (d, J= 7.8 Hz, 1H); 8.00 (d, J= 8.1 Hz, 1H); 7.76 (m, 3H); 7.55 (d, J= 7.5 Hz, 1H); 7.48 (m, 1H); 4.36 (s, 2H); 3.91 (s, 2H); 3.40 (m, 8H); 3.09 (t, J= 7.5 Hz, 2H); 1.58 (m, 2H); 1.28 (m, 1H); 0.86 (t, J= 7.2 Hz, 3H). MS: m/z = 388 (M+-H).

Dihydrochloride 9-[1-(4-Allylpiperazino)methyl]-5,6-dihydro-5-oxo-11-H-salt of IIb-1 indeno[1,2-c]isoquinoline dihydrochloride: iH NMR (DMSO
& D20) b 8.22 (d, J= 8.1 Hz, 1H); 7.97 (d, J= 7.8 Hz, 1H); 7.75 (m, 3H); 7.49 (m, 2H); 5.83 (m, 1H); 5.53 (d, J= 19.5 Hz, 1H);
5.08 (d, J= 9.6 Hz, 1H); 4.29 (s, 2H); 3.91 (s, 2H); 3.71 (d, J=
6.9 Hz, 2H); 3.32 (m, 8H).
Dihydrochloride 9-[1-(4-Cyclohexylpiperazino)methyl]-5,6-dihydro-5-oxo-11-salt of IIIb-14 H-indeno[1,2-c]isoquinoline dihydrochloride: 1H NMR
(DMSO & D20) b 8.21 (d, J= 8.1 Hz, 1H); 7.94 (d, J= 7.8 Hz, 1H); 7.75 (d, J= 3.9 Hz, 2H); 7.70 (s, 1H); 7.48 (m, 2H); 3.92 (s, 2H); 3.57 (s, 3H); 3.27 (m, 8H); 2.05 (s, 2H); 1.79 (d, J=
10.8 Hz, 2H); 1.57 (d, J= 11.1 Hz, 1H); 1.43-1.05 (m, 5H).
IIIb-24 9-[1-(3,5-Dimethylpiperazino)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.22 (s, 1H); 8.22 (d, J= 7.8 Hz, 1H); 7.91 (d, J= 7.8 Hz, 1H); 7.71 (m, 2H); 7.49 (s, 1H); 7.44 (m, 1H); 7.28 (d, J= 7.8 Hz, 1H); 3.87 (s, 2H); 3.46 (s, 2H); 2.72 (m, 2H); 2.65 (d, J= 9.3 Hz, 2H);
1.49 (t, J= 10.1 Hz, 3H); 0.87 (d, J= 6.0 Hz, 6H). MS: m/z =
360 (M+-H).
IIIb-17 9-{1-[4-(2-Pyrollidinoethyl)piperidino]methyl}-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.23 (s, 1H); 8.22 (d, J= 8.1 Hz, 1H); 7.91 (d, J= 7.5 Hz, 1H);
7.73 (m, 2H); 7.50 (s, 1H); 7.44 (m, 1H); 7.28 (d, J= 7.8 Hz, 1H); 3.87 (s, 2H); 3.48 (s, 2H); 2.79 (d, J= 11.1 Hz, 2H); 2.35 (m, 6H); 1.90 (t, J= 10.6 Hz, 2H); 1.62 (m, 6H); 1.33 (m, 3H);
1.15 (m, 2H). MS: m/z = 428 (M+-H).
IIb-92 9-{N-[4-(1-Boc-piperidyl)]aminomethyl}-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.23 (s, 1H); 8.23 (d, J= 7.8 Hz, 1H); 7.90 (d, J= 7.5 Hz, 1H); 7.71 (m, 2H); 7.57 (s, 1H); 7.43 (m, 1H); 7.34 (d, J= 7.5 Hz, 1H); 3.86 (s, 2H); 3.79 (m, 4H); 2.78 (m, 2H); 2.56 (m, 1H); 1.79 (d, J=
12.0 Hz, 2H); 1.37 (s, 9H); 1.15 (m, 2H). MS: m/z = 446 (M+-H).
IIIb-9 9-[1-(4-Cyclopentylpiperazino)methyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c]isoquinoline dihydrochloride: 1H NMR
(DMSO) b 12.22 (s, 1H); 8.22 (d, J= 8.1 Hz, 1H); 7.91 (d, J=
8.1 Hz, 1H); 7.71 (m, 2H); 7.51 (s, 1H); 7.44 (m, 1H); 7.28 (d, J
= 7.5 Hz, 1H); 3.87 (s, 2H); 3.50 (s, 2H); 2.83 (m, 1H); 2.38 (m, 8H); 1.71 (m, 2H); 1.51 (m, 4H); 1.27 (m, 2H). MS: m/z = 400 (M+-H).
IIIb-10 9-{1-[4-(2-Ethoxyethyl)piperazino]methyl}-5,6-dihydro-5-oxo-1l-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.28 (s, 1H); 8.23 (d, J= 7.8 Hz, 1H); 7.91 (d, J= 7.8 Hz, 1H);
7.71 (m, 2H); 7.51 (s, 1H); 7.43 (m, 1H); 7.29 (d, J= 7.8 Hz, 1H); 3.87 (s, 2H); 3.50 (s, 2H); 3.38 (m, 4H); 2.38 (m, 10H);
1.06 (t, J= 6.9 Hz, 3H). MS: m/z = 404 (M+-H).
IIb-196 9-{1-[4-(2,2-Diethoxyethyl)piperazino]methyl}-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.29 (s, 1H); 8.22 (d, J= 7.8 Hz, 1H); 7.91 (d, J= 7.8 Hz, 1H);
7.71 (m, 2H); 7.50 (s, 1H); 7.43 (m, 1H); 7.28 (d, J= 7.8 Hz, 1H); 4.54(t, J= 4.8 Hz, 1H); 3.87 (s, 2H); 3.50 (m, 6H); 3.38 (m, 8H); 1.07 (t, J= 7.2 Hz, 3H). MS: m/z = 448 (M+-H).

IIb-53 9-[(1-N-Methyl-3-morpholinopropyonyl)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: 1H NMR
(DMSO) b 12.28 (bs, 1H); 8.25 (d, J= 7.5 Hz, 1H); 7.98 (m, 1H); 7.76 (m, 2H); 7.51 (s, 1H); 7.47 (m, 1H); 7.26 (m, 1H);
4.67 (s, 1H); 4.59 (s, 1H); 3.83 (m, 2H); 3.58-3.49 (m, 4H); 2.96 (s, 2H); 2.84 (s, 1H); 2.73-2.32 (m, 8H).
IIIb-16 9-[(4-tert-Butoxycarbonyl-piperazino)methyl]-5,6-dihydro-5-oxo-1l-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.29 (s, 1H); 8.25 (d, J= 7.5 Hz, 1H); 7.95 (d, J= 7.8 Hz, 1H);
7.74 (m, 2H); 7.48 (m, 2H); 7.32 (d, J= 7.8, 1H); 3.89 (s, 2H);
3.56 (s, 2H); 3.32 (m, 2H); 2.50 (m, 2H); 2.33 (m, 4H); 1.39 (s, 9H).
IIb-105 9-[(4-Propionyl-piperazino)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.32 (s, 1H);
8.25 (d, J= 7.5 Hz, 1H); 7.95 (d, J= 7.8 Hz, 1H); 7.75 (m, 2H);
7.55 (s, 1H); 7.47 (m, 1H); 7.33 (d, J= 8.1); 3.90 (s, 2H); 3.57 (s, 2H); 3.44 (m, 4H); 2.33 (m, 6H); 0.97 (t, J= 7.5, 3H). MS:
m/z = 388 (M+-H).
IIIb-18 9-[4-(2-Hydroxy-2-methyl-propyl-piperazino)methyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c]isoquinoline dihydrochloride: iH NMR (DMSO) b 12.37 (s, 1H); 8.27 (d, J
= 7.8 Hz, 1H); 8.05 (m, 1H); 7.78 (m, 3H); 7.50 (m, 2H); 3.96 (s, 2H); 3.72-2.73 (m, 12H); 1.20 (s, 6H). MS: m/z = 404 (M+-H).
IIb-118 9-[(4-Propionyl-homopiperazino)methyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c]isoquinoline hydrochloride:1H NMR
(DMSO) b 12.39 (s, 1H); 10.71 (bs, 1H); 8.27 (d, J= 8.1, 1H);
8.06 (d, J= 7.5 Hz, 1H); 7.81 (m, 3H); 7.64 (m, 1H); 7.51 (m, 1H); 4.42 (s, 2H); 4.15-2.99 (m, 14H); 0.99 (t, J= 7.2 Hz, 1H).
MS: m/z = 402 (M+-H).
Dihydrochloride 9-[(1-N-Methyl-2-morpholino-aminoethyl)methyl]-5,6-salt of IIIb-19 dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline dihydrochloride: iH NMR (DMSO) b 12.41 (s, 1H); 11.64 (bs, 1H); 11.35 (bs, 1H); 8.27 (d, J= 6.9, 1H); 8.07 (d, J= 6.9, 1H);
7.90 (s, 1H); 7.74 (m, 3H); 7.51 (m, 1H); 4.62 (m, 1H); 4.39 (m, 1H); 3.96 (s, 2H); 3.83-3.17 (m, 12H); 2.73 (s, 3H). MS: m/z =
390 (M+-H).

IIIa-11 10-[S-(3-Fluoropyrrolidino)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.30 (s, 1H);
8.24 (d, J= 8.1 Hz, 1H); 7.91 (d, J= 7.5); 7.75 (m, 2H); 7.48-7.30 (m, 3H); 5.30 (m, 0.5H); 5.11 (m, 0.5H); 3.89 (s, 2H); 3.78 (s, 2H); 2.87-1.86 (m, 6H). MS: m/z = 335 (M+-H).
IIIa-12 10-[(3,4-Dehydropiperidino)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.29 (s, 1H); 8.26 (d, J = 7.2 Hz, 1H); 7.93 (d, J= 6.6); 7.77 (m, 2H);
7.46-7.33 (m, 3H); 5.67 (m, 2H); 3.91 (s, 2H); 3.71 (s, 2H); 2.92 (m, 2H); 2.56 (m, 2H); 2.09 (m, 2H). MS: m/z = 329 (M+-H).
IIIa-4 10-[N-1-(3-Hydroxypropyl)aminomethyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.25 (s, 1H); 8.23 (d, J= 8.1 Hz, 1H); 7.87 (dd, J= 2.9 Hz, 5.9 Hz, 1H);
7.75 (m, 2H); 7.44 (m, 1H); 7.34 (m, 1H); 3.89 (s, 2H); 3.85 (s, 2H); 3.46 (t, J= 6.3 Hz, 2H); 2.60 (t, J= 6.9 Hz, 2H); 1.60 (m, J= 6.3 Hz, 2H). MS: m/z = 321 (M+-H).
IIIa-1 10-[1-(4-iso-Propylpiperazino)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.28 (s, 1H); 8.23 (d, J= 8.1 Hz, 1H); 7.90 (d, J= 7.5 Hz, 1H); 7.75 (m, 2H); 7.44 (m, 1H); 7.35 (t, J= 7.2 Hz, 1H); 7.27 (d, J= 7.2 Hz, 1H); 3.89 (s, 2H); 3.59 (s, 2H); 2.58 (m, 1H); 2.46-2.35 (m, 8H); 0.92 (d, J= 6.3 Hz, 6H). MS: m/z = 374 (M+-H).
IIa-40 10-{1-[4-(1-pyrrolidinocarbonylmethyl)piperazino] methyl}-5,6-dihydro-5-oxo-1l-H-indeno[1,2-c]isoquinoline: 1H NMR
(DMSO) b 12.25 (s, 1H); 8.24 (d, J= 8.1 Hz, 1H); 7.90 (d, J=
7.2 Hz, 1H); 7.76 (m, 2H); 7.45 (m, 1H); 7.36 (t, J= 7.8 Hz, 1H); 7.28 (d, J= 7.8 Hz, 1H); 3.90 (s, 2H); 3.62 (s, 2H); 3.44 (t, J= 6.6 Hz, 2H); 3.24 (t, J= 6.9 Hz, 2H); 3.04 (s, 2H); 2.43(m, 8H); 1.81 (m, 2H); 1.72 (m, 2H). MS: m/z = 443 (M+-H).
Dihydrochloride 9-[1-(4-Methylhomopiperazino)methyl]-5,6-dihydro-5-oxo-salt of IIIb-13 11-H-indeno[1,2-c]isoquinoline dihydrochloride: 1H NMR
(DMSO) b 12.35 (s, 1H); 8.23 (d, J= 7.8 Hz, 1H); 8.02 (d, J=
7.8 Hz, 1H); 7.84 (s, 1H); 7.76 (d, J= 3.3 Hz, 2H); 7.65 (d, J=
7.2 Hz, 1H); 7.47 (m, 1H); 4.42 (s, 2H); 3.92 (s, 2H); 3.32 (m, 8H); 2.76 (s, 3H); 2.19 (m, 2H). MS: m/z = 360 (M+-H).
IIb-66 9-{1-[4-(2-Cyanoethyl)piperazino]methyl}-5,6-dihydro-5-oxo-1l-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.25 (s, 1H); 8.22 (d, J= 8.1 Hz, 1H); 7.92 (d, J= 7.5 Hz, 1H);
7.71 (m, 2H); 7.51 (s, 1H); 7.44 (m, 1H); 7.29 (d, J= 7.5 Hz, 1H); 3.87 (s, 2H); 3.52 (s, 2H); 2.62 (d, J= 6.1 Hz, 2H); 2.54 (d, J= 6.1 Hz, 2H); 2.41 (m, 8H). MS: m/z = 385 (M+-H).
Methylsulfonate 9-[1-(4,4-Difluoropiperidino)methyl]-5,6-dihydro-5-oxo-11-salt of IIIb-15 H-indeno[1,2-c]isoquinoline methylsulfonate: iH NMR
(DMSO) b 12.36 (s, 1H); 9.75 (s, 1H); 8.25 (d, J= 8.1 Hz, 1H);
8.06 (d, J= 8.1 Hz, 1H); 7.77 (m, 3H); 7.51 (m, 2H); 4.47 (s, 2H); 3.96 (s, 2H); 3.42 (m, 2H); 3.19 (m, 2H); 2.32 (s, 3H); 2.29 (m, 4H). MS: m/z = 367 (M+-H).
IIb-79 9-{N-[4-(1-Boc-piperidyl)]-N-cyclopropylaminomethyl}-5,6-dihydro-5-oxo-1l-H-indeno [1,2-c]isoquinoline:1H NMR
(DMSO) b 12.28 (s, 1H); 8.22 (d, J= 8.1 Hz, 1H); 7.88 (d, J=
8.1 Hz, 1H); 7.71 (m, 2H); 7.48 (s, 1H); 7.43 (m, 1H); 7.27 (d, J
= 7.8 Hz, 1H); 3.94 (m, 2H); 3.85 (s, 2H); 3.81 (s, 2H); 2.61 (m, 3H); 2.01 (m, 1H); 1.74 (m, 2H); 1.36 (m, 11H); 0.42 (m, 2H);
0.25(m, 2H). MS: m/z = 486 (M+-H).
IIb-131 9-{ 1-[4-(2-Furyl)piperazino] methyl}-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.28 (s, 1H);
8.23 (d, J= 8.1 Hz, 1H); 7.92 (d, J= 7.8 Hz, 1H); 7.72 (m, 2H);
7.51 (s, 1H); 7.44 (m, 1H); 7.29 (d, J= 8.1 Hz, 1H); 3.88 (m, 3H); 3.68 (dt, J= 6.9 Hz, 7.5 Hz, 1H); 3.55 (dt, J= 6.9 Hz, 7.5 Hz, 1H); 3.51 (s, 2H); 2.37 (m, 10H); 1.86 (m, 1H); 1.73 (m, 2H); 1.45 (m, 1H). MS: m/z = 416 (M+-H).
IIb-157 9-{1-[4-(1-Pyrrolidinocarbonylmethyl)piperazino]methyl}-5,6-dihydro-5-oxo-11-H-indeno[1,2-c] isoquinoline: 1H NMR
(DMSO) b 12.27 (s, 1H); 8.23 (d, J= 7.8 Hz, 1H); 7.92 (d, J=
8.1 Hz, 1 H); 7.72 (m, 2H); 7.51 (s, 1 H); 7.44 (m, 1 H); 7.29 (d, J
= 7.8 Hz, 1H); 3.88 (s, 2H); 3.51 (m, 2H); 3.43 (t, J= 6.5 Hz, 2H); 3.24 (t, J= 6.6 Hz, 2H); 3.04 (s, 2H); 2.38 (m, 8H); 1.77 (m, 4H). MS: m/z = 443 (M+-H).
IIIb-20 9-(N-4-Piperidylaminomethyl)-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.35 (s, 1H);
9.67 (s, 2H); 9.04 (s, 1H); 8.90 (s, 1H); 8.25 (d, J= 7.8 Hz, 1H);
8.01 (d, J= 7.8 Hz, 1H); 7.83 (s, 1H); 7.77 (m, 2H); 7.63 (d, J=
7.5 Hz, 1H); 7.48 (m, 1H); 4.23 (s, 2H); 3.94 (s, 2H); 3.32 (m, 3H); 2.90 (m, 2H); 2.27 (m, 2H); 1.92 (m, 2H). MS: m/z = 346 (M+-H).
IIIb-8 9-{1-[4-(2-Pyrimidyl)piperazino] methyl}-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.29 (s, 1H); 8.32 (d, J= 5.1 Hz, 2H); 8.23 (d, J= 8.1 Hz, 1H); 7.94 (d, J
= 7.5 Hz, 1H); 7.72 (m, 2H); 7.57 (s, 1H); 7.45 (m, 1H); 7.34 (d, J= 7.5 Hz, 1H); 6.59 (t, J= 4.8 Hz, 1H); 3.89 (s, 2H); 3.72 (m, 4H); 3.58 (s, 2H); 2.44 (m, 4H). MS: m/z = 410 (M+-H).
IIb-170 9-{1-[4-(Cyclopropylcarbonyl)piperazino]methyl}-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: 1H NMR
(DMSO) b 12.23 (s, 1H); 8.24 (d, J= 8.1 Hz, 1H); 7.94 (d, J=
7.8 Hz, 1H); 7.72 (m, 2H); 7.55 (s, 1H); 7.45 (m, 1H); 7.33 (d, J
= 7.2 Hz, 1H); 3.89 (s, 2H); 3.66 (m, 2H); 3.57 (s, 2H); 3.46 (m, 2H); 2.40 (m, 4H); 1.93 (m, 1H); 0.68 (m, 4H). MS: m/z = 400 (M+-H).
IIIb-21 9-{1- [4-(Trifluoromethyl)piperidino] methyl}-5,6-dihydro-5-oxo-1l-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.23 (s, 1H); 8.23 (d, J= 7.8 Hz, 1H); 7.93 (d, J= 8.1 Hz, 1H);
7.72 (m, 2H); 7.52 (s, 1H); 7.44 (m, 1H); 7.30 (d, J= 7.8 Hz, 1H); 3.87 (s, 2H); 3.54 (s, 2H); 2.89 (d, J= 11.3 Hz, 2H); 2.21 (m, 1H); 1.97 (t, J= 11.5 Hz, 2H); 1.76 (d, J= 11.6 Hz, 2H);
1.45 (m, 2H). MS: m/z = 399 (M+-H).
IIIb-22 9-(1-Homopiperidinomethyl)-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.18 (s, 1H);

8.23 (d, J= 7.8 Hz, 1H); 7.90 (d, J= 7.8 Hz, 1H); 7.71 (m, 2H);
7.54 (s, 1H); 7.43 (m, 1H); 7.31 (d, J= 7.8 Hz, 1H); 3.86 (s, 2H); 3.65 (2, H); 2.57 (m, 4H), 1.57 (m, 8H). MS: m/z = 345 (M+-H).
IIb-183 9-[1-(4-Octylpiperazino)methyl]-5,6-dihydro-5-oxo-11-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.28 (s, 1H);
8.23 (d, J= 8.1 Hz, 1H); 7.93 (d, J= 7.8 Hz, 1H); 7.72 (m, 2H);
7.53 (s, 1H); 7.44 (m, 1H); 7.31 (d, J= 7.2 Hz, 1H); 3.88 (s, 2H); 3.58 (s, 2H); 2.87 (m, 4H); 2.41 (m, 6H); 1.55 (m, 2H), 1.23 (m, 10H); 0.84 (t, J= 6.9 Hz, 3H). MS: m/z = 444 (M+-H).
IIIb-23 9-{1-[4-(3-Hydroxypropyl)piperazino]methyl}-5,6-dihydro-5-oxo-1l-H-indeno[1,2-c]isoquinoline: iH NMR (DMSO) b 12.27 (s, 1H); 8.22 (d, J= 7.5 Hz, 1H); 7.92 (d, J= 7.8 Hz, 1H);
7.71 (m, 2H); 7.51 (s, 1H); 7.44 (m, 1H); 7.27 (d, J= 7.8 Hz, 1H); 3.87 (s, 2H); 3.51 (s, 2H); 3.40 (t, J= 6.3 Hz, 2H); 2.37 (m, 10H); 1.53 (t, J= 6.3 Hz, 3H). MS: m/z = 390 (M+-H).

IIb-40 9-((4-(2-oxo-2-(pyrrolidin-1-yl)ethyl)piperazin-1-yl)methyl)-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-5-one: 1H NMR
(DMSO-d6): b 12.27 (s, 1H); 8.23 (d, J= 7.8 Hz, 1H); 7.92 (d, J=
8.1 Hz, 1H); 7.72 (m, 2H); 7.51 (s, 1H); 7.43 (t, J= 7.8 Hz, 1H);
7.29 (d, J= 7.8 Hz, 1H); 3.87 (s, 2H); 3.51 (s, 2H); 3.43 (t, J= 6.6 Hz, 2H); 3.24 (t, J= 6.6 Hz, 2H); 3.04 (s, 2H); 2.38 (m, 8H); 1.80 (m, 2H); 1.72 (m, 2H).

IIb-27 9-((1-(hydroxymethyl)cyclopentylamino)methyl)-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-5-one: iH NMR (DMSO-d6): b 12.35 (s, 1H); 8.86 (s, 2H); 8.26 (d, J= 8.1 Hz, 1H); 8.03 (d, J=
7.2 Hz, 1H); 7.78 (m, 3H); 7.55 (m, 2H); 5.74 (s, 1H); 4.19 (s, 2H);
3.97 (s, 2H); 3.58 (s, 2H); 1.76 (m, 6H); 1.58 (m, 2H). MS: m/z 361 (M-H+).

IIb-210 9-((4-(2-(pyrrolidin-1-yl)ethyl)piperidin-1-yl)methyl)-6,11-dihydro-5H-indeno [1,2-c]isoquinolin-5-one: 1H NMR (DMSO-d6): b 12.24 (s, 1H); 8.22 (d, J= 8.1 Hz, 1H); 7.91 (d, J= 7.5 Hz, 1H); 7.70 (m, 2H); 7.50 (s, 1H); 7.43 (t, J= 7.8 Hz, 1H); 7.27 (d, J
= 7.8 Hz, 1H); 3.86 (s, 2H); 3.48 (s, 2H); 2.78 (d, J= 11.1 Hz, 2H);
2.35 (m, 6H); 1.89 (t, J= 10.6 Hz, 2H); 1.62 (m, 6H); 1.35 (m, 3H); 1.15 (m, 2H). MS: m/z 428 (M-H+).

IIa-28 10-((1-hydroxymethyl)cyclopentylamino)methyl)benzofuro [3,2-c]isoquinolin-5(6H)-one: iH NMR (DMSO-d6): b 12.52 (s, 1H);
9.16 (s, 2H); 8.35 (d, J= 8.1 Hz, 1H); 8.08 (m, 2H); 7.94 (t, J= 7.5 Hz, 1H); 7.69 (t, J= 7.2 Hz, 1H); 7.63 (d, J= 7.8 Hz, 1H); 7.46 (t, J= 7.5 Hz, 1H); 5.85 (s, 1H); 4.51 (s, 2H); 3.68 (s, 2H); 1.91 (m, 5H); 1.79 (m, 2H); 1.63 (m, 2H).

Va-1 4-chloro-l0-((cyclopentylamino)methyl)-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-5-one iH NMR (DMSO-d6):6 8. 94 (bs, 2H), 8.13 (m, 1H), 7.85 (m, 2H), 7.51 (m, 3H), 4.39 (m, 2H), 4.10 (s, 2H), 3.67 (m, 1H), 2.07 (m, 2H), 1.65 (m, 4H), 1.54 (m, 2H).
MS: m/z 365.2 (M-H+).
Va-2 10-((cyclopentylamino)methyl)-2-fluoro-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-5-one iH NMR (DMSO-d6):6 12.46 (bs, 1H), 8.95 (bs, 2H), 8.32 (dd, J= 6.0, 6.0 Hz, 1H), 8.07 (dd, J = 2.0, 5.0 Hz, 1H), 7.54 (m, 3H), 7.33 (dd, J= 6.0, 6.0 Hz,1H), 4.29 (m, 2H), 4.06 (s, 2H), 3.65 (m, 1H), 2.06 (m, 2H), 1.72 (m, 4H), 1.58(m, 2H). MS: m/z 349.0 (M-H+).

Va-3 10-((cyclopentylamino)methyl)-3-fluoro-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-5-one iH NMR (DMSO-d6):6 12.53 (bs, 1H); 8.95 (bs, 2H), 8.04 (dd, J= 6.0, 7.2 Hz, 1H), 7.98 (m, 1H), 7.73 (m, 1H), 7.51 (m, 2H), 4.31(dd, J= 5.2, 5.2 Hz, 2H), 4.06 (s, 2H), 3.65 (m, 1H), 2.07 (m, 2H), 1.72 (m, 4H), 1.57(m, 2H). MS:
m/z 348.9 (M-H+).

Va-4 10-((cyclopentylamino)methyl)-4-fluoro-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-5-one iH NMR (DMSO-d6):6 12.37 (bs, 1H), 8.86 (bs, 2H); 8.05 (dd, J = 2.0, 6.8 Hz, 1H), 7.77 (m, 1H), 7.54 (m, 3H); 7.23 (m, 1H); 4.30 (dd, J = 6.0, 6.0 Hz, 2H); 4.04 (s, 2H); 3.65 (m, 1H); 2.31 (m, 2H); 1.71(m, 4H); 1.57(m, 2H). MS:
m/z 348.9 (M-H) Va-5 3-fluoro-l0-((tetrahydro-2H-pyran-4-ylamino)methyl)-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-5-one 1H NMR (DMSO-d6):6 12.47 (bs, 1H), 8.85 (bs, 2H), 7.98 (d, J= 6.5 Hz, 2H), 7.67 (m, 1H), 7.44 (m, 3H), 4.38 (m, 2H), 4.27 (m, 2H), 3.99 (dd, J
3.6, 11.6 Hz, 2H), 3.53 (m, 2H), 3.42 (m, 1H), 2.01(m, 2H), 1.58(m, 2H) MS: m/z 365.30 (M-H+).

Va-6 1-fluoro-10-((tetrahydro-2H-pyran-4-ylamino)methyl)-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-5-one 1H NMR (DMSO-d6):6 12.49 (bs, 1H), 8.93 (bs, 2H). 8.65 (m, 1H), 7.95 (dd, J= 2.0, 8.9 Hz, 1H), 7.89 (dd, J= 2.5, 8.9, 1H), 7.75 (m, 2H), 7.42 (dd, J=
4.0, 8.0 Hz, 1H), 5.81 (bs, 1H), 4.28 (m, 2H), 4.07 (s, 2H), 3.65 (m, 2H), 3.49 (m, 1H), 1.84 (m, 8H). MS: m/z 379.2 (M-H) Va-7 10-((cyclopentylamino)methyl)-1-fluoro-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-5-one iH NMR (DMSO-d6):6 12.58 (bs, 1H), 8. 94 (bs, 2H), 8.13 (d, J = 2.8, 7,6 Hz, 2H), 7.65 (m, 1H), 7.51 (m, 3H), 4.34 (dd, J= 6.0, 6.0 Hz, 2H), 4.20 (s, 2H), 3.67 (m, 1H), 2.07 (m, 2H), 1.69 (m, 4H), 1.57 (m, 2H). MS: m/z 348.9 (M-H+).

Va-8 2-fluoro-10-((tetrahydro-2H-pyran-4-ylamino)methyl)-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-5-one 1H NMR (DMSO-d6):6 12.70 (bs, 1H), 9.16 (bs, 2H), 8.57 (m, 1H), 8.33 (m, 1H), 7.77 (m, 3H), 7.55 (m, 1H), 4.60 (m, 2H), 4.27 (m, 2H), 4.21 (m, 2H), 3.65 (m, 2H), 3.55 (m, 1H), 2.31 (m, 2H), 1.92 (m, 2H). MS:
m/z 365.3 (M-H+).

Va-9 8-fluoro-10-((1-(hydroxymethyl)cyclopentylamino)methyl)-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-5-one 1H NMR
(DMSO-d6):6 12.59 (bs, 1H), 8.90 (bs, 2H); 8.12 (d, J= 8.0 Hz, 2H), 7.65 (m, 1H), 7.52 (m, 3H), 4.38 (m, 2H), 4.20 (s, 2H), 3.97 (dd J= 2.0, 10 Hz, 2H),3.55 (m, 2H), 3.42 (m, 1H), 2.13(m,2H);
1.65(m, 2H). MS: m/z 365.3 (M-H+).

Va-10 3,8-difluoro-10-((1-(hydroxymethyl)cyclopentylamino)methyl)-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-5-one 1H NMR
(DMSO-d6):6 12.49 (bs, 1H); 9.12 (bs, 2H), 8.66 (m, 1H), 7.96 (m, 2H), 7.89 (m, 1H); 7.75 (m, 1H), 5.84(bs, 1H), 4.28 (m, 2H), 4.07 (s, 2H), 3.65 (m, 2H); 3.45 (m, 1H), 1.84 (m, 4H), 1.64 (m, 4H).
MS: m/z 397.2 (M-H+).
Example 2 Determination of the Effect of Indenoisoquinolinone Analogs on in vitro PARP
Activity The ability of an illustrative Indenoisoquinolinone Analog to inhibit PARP and prevent peroxynitrite induced cytotoxicity can be demonstrated using methods described in Virag et al., Br. J. Pharmacol. 1999, 126(3):769-77; and Immunology 1998, 94(3):345-55.
The potency of inhibition of purified PARP enzyme can be subsequently determined for selected Indenoisoquinolinone Analogs, and the potency is compared with that of 3-aminobenzamide, a prototypical benchmark PARP inhibitor. The assay is performed in 96 well ELISA plates according to instructions provided with a commercially available PARP inhibition assay kit (for example, from Trevigen, Gaithersburg, MD).

DEMANDE OU BREVET VOLUMINEUX

LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:

NOTE POUR LE TOME / VOLUME NOTE:

Claims (242)

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein X is N(C1-C4 alkyl)-, -CH(OH)-, -N(C(O)N(H)-(CH2)p-Z)- or -N((CH2)q-Z)-;
R1 is -(CH2)n-N(R2)(R2) or -O-(CH2)m-N(R2)(R2);
each W is independently -H, -C1-C6 alkyl, -C3-C8 monocyclic cycloalkyl, -C1-C6 alkylene phenyl, phenyl, an N-terminal alpha amino acid residue, an N-terminal alpha amino hydroxymethyl residue, a C1-C6 alkyl ester of an N-terminal alpha amino acid residue, or a nitrogen-containing 3- to 7-membered monocyclic heterocycle, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)2OH, -C1-C6 alkyl, -O-C1-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -(C1-C6 alkyl-substituted) 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -C1-C5 alkyl, -(C1-C5 alkylene)-O-C1-C5 alkyl, benzyl, or -C3-C8 monocyclic cycloalkyl, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -N(R a)2, -(C1-C5 alkylene)-O-C1-C5 alkyl, -NH2, a nitrogen-containing 3-to 7- membered monocyclic heterocycle, or a -(C1-alkyl-substituted) nitrogen-containing 3- to 7- membered monocyclic heterocycle, wherein each occurrence of R a is independently -H, benzyl, or -C1-C10 alkyl;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one or more of -C1-C5 alkyl, phenyl, -(phenyl-substituted) C1-C5 alkyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -(C1-C5 alkylene)-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R
a is independently -H, benzyl, or -C1-C10 alkyl; or N and both R a groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle or a nitrogen-containing 7- to 10-membered bicyclic heterocycle, each of which is unsubstituted or substituted with one or more of alkyl, -C3-C8 monocyclic cycloalkyl, phenyl, a nitrogen-containing 3- to 7-membered monocyclic heterocycle, -(phenyl-substituted) C1-C5 alkyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -C1-C5 alkylene-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-O-C1-C5 alkyl, -(C1-C5 alkylene)-C3-C8 monocyclic cycloalkyl, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R a is independently -H, -benzyl, -C1-C10 alkyl; or N
and both R a groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

Z is -CF3, -F, -OH or -O-CH3;
n is an integer ranging from 1 to 10;
m is an integer ranging from 2 to 10;
p is an integer ranging from 1 to 5; and q is an integer ranging from 1 to 5.
2. The compound or a pharmaceutically acceptable salt of the compound of claim 1, wherein X is N(CH3)-, N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-;
each R2 is independently -H, -C1-C6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(C1-C6 alkylene)-phenyl or phenyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)2OH or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -C1-C5 alkyl, or -(C1-C5 alkylene)-O-C1-C5 alkyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH or -NH2;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -C1-C5 alkyl, -phenyl, -(C1-C5 alkylene)-phenyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -(C1-C5 alkylene)-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R
a is independently -H, -benzyl, or -C1-C10 alkyl;
or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -C1-C5 alkyl, -phenyl, -(C1-C5 alkylene)-phenyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -(C1-C5 alkylene)-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R a is independently -H, -benzyl, or -C1-C10 alkyl;
n is an integer ranging from 1 to 10; and m is an integer ranging from 2 to 10.
3. The compound or a pharmaceutically acceptable salt of the compound of claim 1, wherein X is -N(CH3)-.
4. The compound or a pharmaceutically acceptable salt of the compound of claim 1, wherein at least one R2 is -C1-C6 alkyl or -C3-C8 monocyclic cycloalkyl.
5. The compound or a pharmaceutically acceptable salt of the compound of claim 1, wherein n is 1.
6. The compound or a pharmaceutically acceptable salt of the compound of claim 1, wherein each R2 is independently -C1-C6 alkyl.
7. The compound or a pharmaceutically acceptable salt of the compound of claim 1, wherein one R2 is -H.
8. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein X is N(C1-C4 alkyl)-, -CH(OH)-, -N(C(O)N(H)-(CH2)p-Z)- or -N((CH2)q-Z)-;
R1 is -(CH2)n-N(R2)(R2) or -O-(CH2)m-N(R2)(R2);
each R2 is independently -H, -C1-C6 alkyl, -C3-C8 monocyclic cycloalkyl, -C1-alkylene phenyl, phenyl, an N-terminal alpha amino acid residue, an N-terminal alpha amino hydroxymethyl residue, a C1-C6 alkyl ester of an N-terminal alpha amino acid residue, or a nitrogen-containing 3- to 7-membered monocyclic heterocycle, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)2OH, -C1-C6 alkyl, -O-C1-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -(C1-C6 alkyl-substituted) 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -C1-C5 alkyl, -(C1-C5 alkylene)-O-C1-C5 alkyl, benzyl, or -C3-C8 monocyclic cycloalkyl, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -N(R a)2, -(C1-C5 alkylene)-O-C1-C5 alkyl, -NH2, a nitrogen-containing 3-to 7- membered monocyclic heterocycle, or a -(C1-alkyl-substituted) nitrogen-containing 3- to 7- membered monocyclic heterocycle, wherein each occurrence of R a is independently -H, benzyl, or -C1-C10 alkyl;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one or more of -C1-C5 alkyl, phenyl, -(phenyl-substituted) C1-C5 alkyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -(C1-C5 alkylene)-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R
a is independently -H, benzyl, or -C1-C10 alkyl; or N and both R a groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle or a nitrogen-containing 7- to 10-membered bicyclic heterocycle, each of which is unsubstituted or substituted with one or more of alkyl, -C3-C8 monocyclic cycloalkyl, phenyl, a nitrogen-containing 3- to 7-membered monocyclic heterocycle, -(phenyl-substituted) C1-C5 alkyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -C1-C5 alkylene-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-O-C1-C5 alkyl, -(C1-C5 alkylene)-C3-C8 monocyclic cycloalkyl, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R a is independently -H, -benzyl, -C1-C10 alkyl; or N
and both R a groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

Z is -CF3, -F, -OH or -O-CH3;

n is an integer ranging from 1 to 10;
m is an integer ranging from 2 to 10;
p is an integer ranging from 1 to 5; and q is an integer ranging from 1 to 5.
9. The compound or a pharmaceutically acceptable salt of the compound of claim 1, wherein X is N(CH3)-, N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-;
each R2 is independently -H, -C1-C6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(C1-C6 alkylene)-phenyl or phenyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)2OH or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -C1-C5 alkyl, or -(C1-C5 alkylene)-O-C1-C5 alkyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH or -NH2;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -C1-C5 alkyl, -phenyl, -(C1-C5 alkylene)-phenyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -(C1-C5 alkylene)-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of Ra is independently -H, -benzyl, or -C1-C10 alkyl;
or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -C1-C5 alkyl, -phenyl, -(C1-C5 alkylene)-phenyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -(C1-C5 alkylene)-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R a is independently -H, -benzyl, or -C1-C10 alkyl;
n is an integer ranging from 1 to 10; and m is an integer ranging from 2 to 10.
10. The compound or a pharmaceutically acceptable salt of the compound of claim 8, wherein X is -N(CH3)-.
11. The compound or a pharmaceutically acceptable salt of the compound of claim 8, wherein at least one R2 is -C1-C6 alkyl or -C3-C8 monocyclic cycloalkyl.
12. The compound or a pharmaceutically acceptable salt of the compound of claim 8, wherein n is 1.
13. The compound or a pharmaceutically acceptable salt of the compound of claim 8, wherein each R2 is independently -C1-C6 alkyl.
14. The compound or a pharmaceutically acceptable salt of the compound of claim 8, wherein one R2 is -H.
15. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein X is N(C1-C4 alkyl)-, -CH(OH)-, -N(C(O)N(H)-(CH2)p-Z)- or -N((CH2)q Z)-;
R1 is -(CH2)n-N(R2)(R2) or -O-(CH2)m-N(R2)(R2);
each R2 is independently -H, -C1-C6 alkyl, -C3-C8 monocyclic cycloalkyl, -C1-alkylene phenyl, phenyl, an N-terminal alpha amino acid residue, an N-terminal alpha amino hydroxymethyl residue, a C1-C6 alkyl ester of an N-terminal alpha amino acid residue, or a nitrogen-containing 3- to 7-membered monocyclic heterocycle, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)2OH, -C1-C6 alkyl, -O-C1-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -(C1-C6 alkyl-substituted) 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -C1-C5 alkyl, -(C1-C5 alkylene)-O-C1-C5 alkyl, benzyl, or -C3-C8 monocyclic cycloalkyl, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -N(R a)2, -(C1-C5 alkylene)-O-C1-C5 alkyl, -NH2, a nitrogen-containing 3-to 7- membered monocyclic heterocycle, or a-(C1-alkyl-substituted) nitrogen-containing 3- to 7- membered monocyclic heterocycle, wherein each occurrence of R a is independently -H, benzyl, or -C1-C10 alkyl;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one or more of -C1-C5 alkyl, phenyl, -(phenyl-substituted) C1-C5 alkyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -(C1-C5 alkylene)-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R
a is independently -H, benzyl, or -C1-C10 alkyl; or N and both Ra groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle or a nitrogen-containing 7- to 10-membered bicyclic heterocycle, each of which is unsubstituted or substituted with one or more of alkyl, -C3-C8 monocyclic cycloalkyl, phenyl, a nitrogen-containing 3- to 7-membered monocyclic heterocycle, -(phenyl-substituted) C1-C5 alkyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -C1-C5 alkylene-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-O-C1-C5 alkyl, -(C1-C5 alkylene)-C3-C8 monocyclic cycloalkyl, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R a is independently -H, -benzyl, -C1-C10 alkyl; or N
and both R a groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

Z is -CF3, -F, -OH or -O-CH3;
n is an integer ranging from 1 to 10;
m is an integer ranging from 2 to 10;
p is an integer ranging from 1 to 5; and q is an integer ranging from 1 to 5.
16. The compound or a pharmaceutically acceptable salt of the compound of claim 15, wherein X is N(CH3)-, N(CH2CH3)-, -N(CH2CH2CH3)-, -N(CH2 CH2CH2CH3)-, -N(C(H)(CH3)(CH2CH3))-, -N(C(H)(CH3)2)-, -N(CH2C(H)(CH3)2)- or -N(C(CH3)3)-;
each R2 is independently -H, -C1-C6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(C1-C6 alkylene)-phenyl or phenyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)2OH or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -C1-C5 alkyl, or -(C1-C5 alkylene)-O-C1-C5 alkyl, each of which other than hydrogen is unsubstituted or substituted with one or more of -halo, -OH or -NH2;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -C1-C5 alkyl, -phenyl, -(C1-C5 alkylene)-phenyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -(C1-C5 alkylene)-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R
a is independently -H, -benzyl, or -C1-C10 alkyl;
or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle which is unsubstituted or substituted with one to three of -C1-C5 alkyl, -phenyl, -(C1-C5 alkylene)-phenyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -(C1-C5 alkylene)-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R a is independently -H, -benzyl, or -C1-C10 alkyl;
n is an integer ranging from 1 to 10; and m is an integer ranging from 2 to 10.
17. The compound or a pharmaceutically acceptable salt of the compound of claim 15, wherein X is -N(CH3)-.
18. The compound or a pharmaceutically acceptable salt of the compound of claim 15, wherein at least one R2 is -C1-C6 alkyl or -C3-C8 monocyclic cycloalkyl.
19. The compound or a pharmaceutically acceptable salt of the compound of claim 15, wherein n is 1.
20. The compound or a pharmaceutically acceptable salt of the compound of claim 15, wherein each R2 is independently -C1-C6 alkyl.
21. The compound or a pharmaceutically acceptable salt of the compound of claim 15, wherein one R2 is -H.
22. A compound having the formula:

(IIa) or a pharmaceutically acceptable salt thereof, wherein X is -CH2-, -O-, -C(O)-, -CH(OH)-, -NH-, -N(C1-C4 alkyl)- or -S-;
R1 is -(CH2)n-N(R2)(R3) or ;
R2 is -H, -C1-C6 alkyl, or -C3-C8 monocyclic cycloalkyl;
R3 is -C(O)-(C1-C6 alkylene)-(3- to 7-membered monocyclic heterocycle), a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one or more of -C(O)0-C1-C6 alkyl, or -C3-C8 monocyclic cycloalkyl which is substituted with one or more of (hydroxy-substituted) C1-C5 alkyl groups;

or N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with one or more of -C2-alkenyl, -C(O)-C1-C6 alkyl, -(C1-C4 alkylene)-C(O)-(C3-C8 monocyclic cycloalkyl), -C7-C10 alkyl, -(C1-C5 alkylene)-C(H)(-O-C1-C4 alkyl)2, -(cyano-substituted) C1-C5 alkyl, -(C1-C5 alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or -(C1-C5 alkylene)-(3- to 7-membered monocyclic heterocycle) groups; and an n is an integer ranging from 1 to 10.
23. The compound or a pharmaceutically acceptable salt of the compound of claim 22, wherein, X is -CH2-.
24. The compound or a pharmaceutically acceptable salt of the compound of claim 22, wherein R2 is -H, and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one or more of -C(O)O-C1-C6 alkyl groups.
25. The compound or a pharmaceutically acceptable salt of the compound of claim 22, wherein X is -CH2- and R3 is -C3-C8 monocyclic cycloalkyl which is substituted with one or more of hydroxy-substituted C1-C5 alkyl groups.
26. The compound or a pharmaceutically acceptable salt of the compound of claim 22, wherein X is -CH2- and R3 is -C(O)-C1-C6 alkylene-3- to 7-membered monocyclic heterocycle.
27. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein X is -CH2-, -O-, -C(O)-, -CH(OH)-, -NH-, -N(C1-C4 alkyl)- or -S-;
R1 is -(CH2)n-N(R2)(R3) or ;
R2 is -H, -C1-C6 alkyl, or -C3-C8 monocyclic cycloalkyl;
R3 is -C(O)-(C1-C6 alkylene)-(3- to 7-membered monocyclic heterocycle), a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one or more of -C(O)O-C1-C6 alkyl, or -C3-C8 monocyclic cycloalkyl which is substituted with one or more of (hydroxy-substituted) C1-C5 alkyl groups;

or N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with one or more of -C2-alkenyl, -C(O)-C1-C6 alkyl, -(C1-C4 alkylene)-C(O)-(C3-C8 monocyclic cycloalkyl), -C7-C10 alkyl, -(C1-C5 alkylene)-C(H)(-O-C1-C4 alkyl)2, -(cyano-substituted) C1-C5 alkyl, -(C1-C5 alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or -(C1-C5 alkylene)-(3- to 7-membered monocyclic heterocycle) groups; and an n is an integer ranging from 1 to 10.
28. The compound or a pharmaceutically acceptable salt of the compound of claim 27, wherein, X is -CH2-.
29. The compound or a pharmaceutically acceptable salt of the compound of claim 27, wherein R2 is -H, and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one or more of -C(O)O-C1-C6 alkyl groups.
30. The compound or a pharmaceutically acceptable salt of the compound of claim 27, wherein X is -CH2- and R3 is -C3-C8 monocyclic cycloalkyl which is substituted with one or more of hydroxy-substituted C1-C5 alkyl groups.
31. The compound or a pharmaceutically acceptable salt of the compound of claim 27, wherein X is -CH2- and R3 is -C(O)-C1-C6 alkylene-3- to 7-membered monocyclic heterocycle.
32. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein X is -CH2-, -O-, -C(O)-, -CH(OH)-, -NH-, -N(C1-C4 alkyl)- or -S-;
R1 is -(CH2)n-N(R2)(R3) or ;
R2 is -H, -C1-C6 alkyl, or -C3-C8 monocyclic cycloalkyl;
R3 is -C(O)-(C1-C6 alkylene)-(3- to 7-membered monocyclic heterocycle), a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one or more of -C(O)O-C1-C6 alkyl, or -C3-C8 monocyclic cycloalkyl which is substituted with one or more of (hydroxy-substituted) C1-C5 alkyl groups;

or N, R2 and R3 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle, which is substituted with one or more of -C2-alkenyl, -C(O)-C1-C6 alkyl, -(C1-C4 alkylene)-C(O)-(C3-C8 monocyclic cycloalkyl), -C7-C10 alkyl, -(C1-C5 alkylene)-C(H)(-O-C1-C4 alkyl)2, -(cyano-substituted) C1-C5 alkyl, -(C1-C5 alkylene)-C(O)-(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or -(C1-C5 alkylene)-(3- to 7-membered monocyclic heterocycle) groups; and an n is an integer ranging from 1 to 10.
33. The compound or a pharmaceutically acceptable salt of the compound of claim 32, wherein, X is -CH2-.
34. The compound or a pharmaceutically acceptable salt of the compound of claim 32, wherein R2 is -H, and R3 is a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is substituted with one or more of -C(O)O-C1-C6 alkyl groups.
35. The compound or a pharmaceutically acceptable salt of the compound of claim 32, wherein X is -CH2- and R3 is -C3-C8 monocyclic cycloalkyl which is substituted with one or more of hydroxy-substituted C1-C5 alkyl groups.
36. The compound or a pharmaceutically acceptable salt of the compound of claim 32, wherein X is -CH2- and R3 is -C(O)-C1-C6 alkylene-3- to 7-membered monocyclic heterocycle.
37. A composition comprising a physiologically acceptable carrier or vehicle and an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1.
38. A composition comprising a physiologically acceptable carrier or vehicle and an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8.
39. A composition comprising a physiologically acceptable carrier or vehicle and an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15.
40. A composition comprising a physiologically acceptable carrier or vehicle and an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22.
41. A composition comprising a physiologically acceptable carrier or vehicle and an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27.
42. A composition comprising a physiologically acceptable carrier or vehicle and an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32.
43. A method for treating cancer, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
44. A method for treating cancer, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
45. A method for treating cancer, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
46. A method for treating cancer, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
47. A method for treating cancer, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
48. A method for treating cancer, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
49. The method of claim 43, further comprising administering an effective amount of another anticancer agent.
50. The method of claim 44, further comprising administering an effective amount of another anticancer agent.
51. The method of claim 45, further comprising administering an effective amount of another anticancer agent.
52. The method of claim 46, further comprising administering an effective amount of another anticancer agent.
53. The method of claim 47, further comprising administering an effective amount of another anticancer agent.
54. The method of claim 48, further comprising administering an effective amount of another anticancer agent.
55. A method for treating renal failure, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
56. A method for treating renal failure, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
57. A method for treating renal failure, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
58. A method for treating renal failure, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
59. A method for treating renal failure, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
60. A method for treating renal failure, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
61. A method for treating a reperfusion injury, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
62. A method for treating a reperfusion injury, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
63. A method for treating a reperfusion injury, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
64. A method for treating a reperfusion injury, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
65. A method for treating a reperfusion injury, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
66. A method for treating a reperfusion injury, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
67. A method for treating an inflammatory disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
68. A method for treating an inflammatory disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
69. A method for treating an inflammatory disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
70. A method for treating an inflammatory disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
71. A method for treating an inflammatory disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
72. A method for treating an inflammatory disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
73. A method for treating diabetes mellitus, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
74. A method for treating diabetes mellitus, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
75. A method for treating diabetes mellitus, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
76. A method for treating diabetes mellitus, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
77. A method for treating diabetes mellitus, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
78. A method for treating diabetes mellitus, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
79. A method for treating an ischemic condition, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
80. A method for treating an ischemic condition, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
81. A method for treating an ischemic condition, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
82. A method for treating an ischemic condition, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
83. A method for treating an ischemic condition, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof..
84. A method for treating an ischemic condition, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
85. A method for treating reoxygenation injury resulting from organ transplantation, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
86. A method for treating reoxygenation injury resulting from organ transplantation, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
87. A method for treating reoxygenation injury resulting from organ transplantation, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
88. A method for treating reoxygenation injury resulting from organ transplantation, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
89. A method for treating reoxygenation injury resulting from organ transplantation, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
90. A method for treating reoxygenation injury resulting from organ transplantation, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
91. A method for treating a neurodegenerative disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
92. A method for treating a neurodegenerative disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
93. A method for treating a neurodegenerative disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
94. A method for treating a neurodegenerative disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
95. A method for treating a neurodegenerative disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
96. A method for treating a neurodegenerative disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
97. A method for treating a vascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
98. A method for treating a vascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
99. A method for treating a vascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
100. A method for treating a vascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
101. A method for treating a vascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
102. A method for treating a vascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
103. A method for treating a diabetic complication, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
104. A method for treating a diabetic complication, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
105. A method for treating a diabetic complication, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
106. A method for treating a diabetic complication, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
107. A method for treating a diabetic complication, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
108. A method for treating a diabetic complication, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
109. A method for treating a cardiovascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
110. A method for treating a cardiovascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
111. A method for treating a cardiovascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
112. A method for treating a cardiovascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
113. A method for treating a cardiovascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
114. A method for treating a cardiovascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
115. A method for treating erectile dysfunction, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
116. A method for treating erectile dysfunction, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
117. A method for treating erectile dysfunction, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
118. A method for treating erectile dysfunction, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
119. A method for treating erectile dysfunction, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
120. A method for treating erectile dysfunction, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
121. A method for treating urinary incontinence, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
122. A method for treating urinary incontinence, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
123. A method for treating urinary incontinence, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
124. A method for treating urinary incontinence, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
125. A method for treating urinary incontinence, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
126. A method for treating urinary incontinence, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
127. A method for treating a complication of prematurity, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
128. A method for treating a complication of prematurity, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
129. A method for treating a complication of prematurity, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
130. A method for treating a complication of prematurity, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
131. A method for treating a complication of prematurity, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
132. A method for treating a complication of prematurity, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
133. A method for treating cardiomyopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
134. A method for treating cardiomyopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
135. A method for treating cardiomyopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
136. A method for treating cardiomyopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
137. A method for treating cardiomyopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
138. A method for treating cardiomyopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
139. A method for treating retinopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
140. A method for treating retinopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
141. A method for treating retinopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
142. A method for treating retinopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
143. A method for treating retinopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
144. A method for treating retinopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
145. A method for treating nephropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
146. A method for treating nephropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
147. A method for treating nephropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
148. A method for treating nephropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
149. A method for treating nephropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
150. A method for treating nephropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
151. A method for treating neuropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 1 to a subject in need thereof.
152. A method for treating neuropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 8 to a subject in need thereof.
153. A method for treating neuropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 15 to a subject in need thereof.
154. A method for treating neuropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 22 to a subject in need thereof.
155. A method for treating neuropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 27 to a subject in need thereof.
156. A method for treating neuropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 32 to a subject in need thereof.
157. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein X is -O-, -CH2-, -C(O)-, -NH-, -S-, -N(C1-C4 alkyl)-, -CH(OH)-, -N(C(O)N(H)-(CH2)p-Z)- or -N((CH2)q-Z)-;
R1 is -O-C(C1-C3 alkyl)2-(CH2)n-N(R2)(R2);
each R2 is independently -H, -C1-C6 alkyl, -C3-C8 monocyclic cycloalkyl, -C1-alkylene phenyl, phenyl, an N-terminal alpha amino acid residue, an N-terminal alpha amino hydroxymethyl residue, a C1-C6 alkyl ester of an N-terminal alpha amino acid residue, or a nitrogen-containing 3- to 7-membered monocyclic heterocycle, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)2OH, -C1-C6 alkyl, -O-C1-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -(C1-C6 alkyl-substituted) 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -C1-C5 alkyl, -(C1-C5 alkylene)-O-C1-C5 alkyl, benzyl, or -C3-C8 monocyclic cycloalkyl, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -N(R a)2, -(C1-C5 alkylene)-O-C1-C5 alkyl, -NH2, a nitrogen-containing 3-to 7- membered monocyclic heterocycle, or a -(C1-alkyl-substituted) nitrogen-containing 3- to 7- membered monocyclic heterocycle, wherein each occurrence of R a is independently -H, benzyl, or -C1-C10 alkyl;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one or more of -C1-C5 alkyl, phenyl, -(phenyl-substituted) C1-C5 alkyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -(C1-C5 alkylene)-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R
a is independently -H, benzyl, or -C1-C10 alkyl; or N and both R a groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle or a nitrogen-containing 7- to 10-membered bicyclic heterocycle, each of which is unsubstituted or substituted with one or more of alkyl, -C3-C8 monocyclic cycloalkyl, phenyl, a nitrogen-containing 3- to 7-membered monocyclic heterocycle, -(phenyl-substituted) C1-C5 alkyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -C1-C5 alkylene-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-O-C1-C5 alkyl, -(C1-C5 alkylene)-C3-C8 monocyclic cycloalkyl, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R a is independently -H, -benzyl, -C1-C10 alkyl; or N
and both R a groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

Z is -CF3, -F, -OH or -O-CH3;
n is an integer ranging from 1 to 10;
p is an integer ranging from 1 to 5; and q is an integer ranging from 1 to 5.
158. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein X is -O-, -CH2-, -C(O)-, -NH-, -S-, -N(C1-C4 alkyl)-, -CH(OH)-, -N(C(O)N(H)-(CH2)p-Z)- or -N((CH2)q-Z)-;
R1 is -O-C(C1-C3 alkyl)2-(CH2)n-N(R2)(R2);
each R2 is independently -H, -C1-C6 alkyl, -C3-C8 monocyclic cycloalkyl, -C1-alkylene phenyl, phenyl, an N-terminal alpha amino acid residue, an N-terminal alpha amino hydroxymethyl residue, a C1-C6 alkyl ester of an N-terminal alpha amino acid residue, or a nitrogen-containing 3- to 7-membered monocyclic heterocycle, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)2OH, -C1-C6 alkyl, -O-C1-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -(C1-C6 alkyl-substituted) 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -C1-C5 alkyl, -(C1-C5 alkylene)-O-C1-C5 alkyl, benzyl, or -C3-C8 monocyclic cycloalkyl, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -N(R a)2, -(C1-C5 alkylene)-O-C1-C5 alkyl, -NH2, a nitrogen-containing 3-to 7- membered monocyclic heterocycle, or a -(C1-alkyl-substituted) nitrogen-containing 3- to 7- membered monocyclic heterocycle, wherein each occurrence of R a is independently -H, benzyl, or -C1-C10 alkyl;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one or more of -C1-C5 alkyl, phenyl, -(phenyl-substituted) C1-C5 alkyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -(C1-C5 alkylene)-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R
a is independently -H, benzyl, or -C1-C10 alkyl; or N and both R a groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle or a nitrogen-containing 7- to 10-membered bicyclic heterocycle, each of which is unsubstituted or substituted with one or more of alkyl, -C3-C8 monocyclic cycloalkyl, phenyl, a nitrogen-containing 3- to 7-membered monocyclic heterocycle, -(phenyl-substituted) C1-C5 alkyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -C1-C5 alkylene-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-O-C1-C5 alkyl, -(C1-C5 alkylene)-C3-C8 monocyclic cycloalkyl, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R a is independently -H, -benzyl, -C1-C10 alkyl; or N
and both R a groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

Z is -CF3, -F, -OH or -O-CH3;
n is an integer ranging from 1 to 10;
p is an integer ranging from 1 to 5; and q is an integer ranging from 1 to 5.
159. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein X is -O-, -CH2-, -C(O)-, -NH-, -S-, -N(C1-C4 alkyl)-, -CH(OH)-, -N(C(O)N(H)-(CH2)p-Z)- or -N((CH2)q-Z)-;
R1 is -O-C(C1-C3 alkyl)2-(CH2)n-N(R2)(R2);
each R2 is independently -H, -C1-C6 alkyl, -C3-C8 monocyclic cycloalkyl, -C1-alkylene phenyl, phenyl, an N-terminal alpha amino acid residue, an N-terminal alpha amino hydroxymethyl residue, a C1-C6 alkyl ester of an N-terminal alpha amino acid residue, or a nitrogen-containing 3- to 7-membered monocyclic heterocycle, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -OP(O)(OH)2, -OS(O)2OH, -C1-C6 alkyl, -O-C1-C6 alkyl, -C3-C8 monocyclic cycloalkyl, a 3- to 7-membered monocyclic heterocycle, -(C1-C6 alkyl-substituted) 3- to 7- membered monocyclic heterocycle, or -N(Z3)(Z4), where Z3 and Z4 are independently -H, -C1-C5 alkyl, -(C1-C5 alkylene)-O-C1-C5 alkyl, benzyl, or -C3-C8 monocyclic cycloalkyl, each of which other than hydrogen is independently unsubstituted or substituted with one or more of -halo, -OH, -N(R a)2, -(C1-C5 alkylene)-O-C1-C5 alkyl, -NH2, a nitrogen-containing 3-to 7- membered monocyclic heterocycle, or a -(C1-alkyl-substituted) nitrogen-containing 3- to 7- membered monocyclic heterocycle, wherein each occurrence of R a is independently -H, benzyl, or -C1-C10 alkyl;
or N, Z3 and Z4 are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle which is unsubstituted or substituted with one or more of -C1-C5 alkyl, phenyl, -(phenyl-substituted) C1-C5 alkyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -(C1-C5 alkylene)-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R
a is independently -H, benzyl, or -C1-C10 alkyl; or N and both R a groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

or N and both R2 groups are taken together to form a nitrogen-containing 3- to membered monocyclic heterocycle or a nitrogen-containing 7- to 10-membered bicyclic heterocycle, each of which is unsubstituted or substituted with one or more of alkyl, -C3-C8 monocyclic cycloalkyl, phenyl, a nitrogen-containing 3- to 7-membered monocyclic heterocycle, -(phenyl-substituted) C1-C5 alkyl, -(hydroxy-substituted) C1-C5 alkyl, -halo, -(halo-substituted) C1-C5 alkyl, -(halo-substituted) phenyl, -phenylene-O-C1-C5 alkyl, -(cyano-substituted) phenyl, -OH, -O-C1-C5 alkyl, -N(R a)2, -(C1-C5 alkylene)-N(R a)2, -C1-C5 alkylene-C(O)O-(C1-C5 alkylene)-N(R a)2, -COOH, -(C1-C5 alkylene)-O-C1-C5 alkyl, -(C1-C5 alkylene)-C3-C8 monocyclic cycloalkyl, -(C1-C5 alkylene)-COOH, -OP(O)(OH)2, -OS(O)2OH, -(C1-C5 alkylene)-OP(O)(OH)2, -(C1-C5 alkylene)-OS(O)2OH, -C(O)O-C1-C5 alkyl, -OC(O)-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)O-C1-C5 alkyl, -(C1-C5 alkylene)-C(O)NH-C1-C5 alkyl, -C(O)NH2, or -NO2, wherein each occurrence of R a is independently -H, -benzyl, -C1-C10 alkyl; or N
and both R a groups are taken together to form a nitrogen-containing 3- to 7-membered monocyclic heterocycle;

Z is -CF3, -F, -OH or -O-CH3;
n is an integer ranging from 1 to 10;
p is an integer ranging from 1 to 5; and q is an integer ranging from 1 to 5.
160. A composition comprising a physiologically acceptable carrier or vehicle and an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159.
161. A composition comprising a physiologically acceptable carrier or vehicle and an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157.
162. A composition comprising a physiologically acceptable carrier or vehicle and an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158.
163. A method for treating cancer, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
164. A method for treating cancer, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
165. A method for treating cancer, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
166. The method of claim 165, further comprising administering an effective amount of another anticancer agent.
167. The method of claim 163, further comprising administering an effective amount of another anticancer agent.
168. The method of claim 164, further comprising administering an effective amount of another anticancer agent.
169. A method for treating renal failure, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
170. A method for treating renal failure, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
171. A method for treating renal failure, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
172. A method for treating a reperfusion injury, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
173. A method for treating a reperfusion injury, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
174. A method for treating a reperfusion injury, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
175. A method for treating an inflammatory disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
176. A method for treating an inflammatory disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
177. A method for treating an inflammatory disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
178. A method for treating diabetes mellitus, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
179. A method for treating diabetes mellitus, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
180. A method for treating diabetes mellitus, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
181. A method for treating an ischemic condition, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
182. A method for treating an ischemic condition, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
183. A method for treating an ischemic condition, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
184. A method for treating reoxygenation injury resulting from organ transplantation, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
185. A method for treating reoxygenation injury resulting from organ transplantation, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
186. A method for treating reoxygenation injury resulting from organ transplantation, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
187. A method for treating a neurodegenerative disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
188. A method for treating a neurodegenerative disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
189. A method for treating a neurodegenerative disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
190. A method for treating a vascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
191. A method for treating a vascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
192. A method for treating a vascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
193. A method for treating a diabetic complication, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
194. A method for treating a diabetic complication, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
195. A method for treating a diabetic complication, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
196. A method for treating a cardiovascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
197. A method for treating a cardiovascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
198. A method for treating a cardiovascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
199. A method for treating erectile dysfunction, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
200. A method for treating erectile dysfunction, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
201. A method for treating erectile dysfunction, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
202. A method for treating urinary incontinence, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
203. A method for treating urinary incontinence, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
204. A method for treating urinary incontinence, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
205. A method for treating a complication of prematurity, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
206. A method for treating a complication of prematurity, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
207. A method for treating a complication of prematurity, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
208. A method for treating cardiomyopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
209. A method for treating cardiomyopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
210. A method for treating cardiomyopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
211. A method for treating retinopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
212. A method for treating retinopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
213. A method for treating retinopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
214. A method for treating nephropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
215. A method for treating nephropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
216. A method for treating nephropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
217. A method for treating neuropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 159 to a subject in need thereof.
218. A method for treating neuropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 157 to a subject in need thereof.
219. A method for treating neuropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 158 to a subject in need thereof.
220. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein R1 is -CH2NH-R2, R2 is a-C3-C8 monocyclic cycloalkyl which is unsubstituted or substituted with one or more of -(hydroxy-substituted) C1-C5 alkyl; or a 3- to 7-membered monocyclic heterocycle;
X is halo or -H; and Y' is halo or -H, wherein at least one of X and Y' is halo.
221. The compound or a pharmaceutically acceptable salt of the compound of claim 220, wherein R2 is tetrahydopyranyl; or cyclopentyl which is unsubstituted or substituted with one or more of -(hydroxy-substituted) C1-C5 alkyl.
222. The compound or a pharmaceutically acceptable salt of the compound of claim 220, wherein one of X and Y' is fluoro.
223. A composition comprising a physiologically acceptable carrier or vehicle and an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220.
224. A method for treating cancer, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
225. The method of claim 224, further comprising administering an effective amount of another anticancer agent.
226. A method for treating renal failure, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
227. A method for treating a reperfusion injury, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
228. A method for treating an inflammatory disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
229. A method for treating diabetes mellitus, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
230. A method for treating an ischemic condition, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
231. A method for treating reoxygenation injury, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
232. A method for treating a neurodegenerative disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
233. A method for treating a vascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
234. A method for treating a diabetic complication, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
235. A method for treating a cardiovascular disease, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
236. A method for treating erectile dysfunction, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
237. A method for treating urinary incontinence, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
238. A method for treating a complication of prematurity, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
239. A method for treating cardiomyopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
240. A method for treating retinopathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
241. A method for treating nephropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
242. A method for treating neuropathy, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt of a compound of claim 220 to a subject in need thereof.
CA002677046A 2007-02-28 2008-02-28 Indenoisoquinolinone analogs and methods of use thereof Abandoned CA2677046A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90439307P 2007-02-28 2007-02-28
US60/904,393 2007-02-28
PCT/US2008/055361 WO2008106619A2 (en) 2007-02-28 2008-02-28 Indenoisoquinolinone analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2677046A1 true CA2677046A1 (en) 2008-09-04

Family

ID=39721849

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002677046A Abandoned CA2677046A1 (en) 2007-02-28 2008-02-28 Indenoisoquinolinone analogs and methods of use thereof

Country Status (13)

Country Link
US (2) US20100121049A1 (en)
EP (1) EP2117545A4 (en)
JP (1) JP2010520220A (en)
KR (1) KR20090115879A (en)
CN (1) CN101674832A (en)
AU (1) AU2008221358A1 (en)
BR (1) BRPI0808054A2 (en)
CA (1) CA2677046A1 (en)
IL (1) IL200013A0 (en)
MX (1) MX2009009183A (en)
RU (1) RU2009135818A (en)
WO (1) WO2008106619A2 (en)
ZA (1) ZA200905741B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10123803B2 (en) 2007-10-17 2018-11-13 Covidien Lp Methods of managing neurovascular obstructions
AU2010331820B2 (en) * 2009-12-18 2015-03-05 Vysera Biomedical Limited A urological device
EP2804602A4 (en) 2012-01-20 2016-08-10 Dennis Brown Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
CN102977018A (en) * 2012-12-12 2013-03-20 中国药科大学 Application of indenoindene isoquinoline estrogen receptor beta adjustment agent in resisting breast cancer
JP2016519684A (en) 2013-04-08 2016-07-07 デニス エム ブラウン Methods and compositions for improving the efficacy of suboptimally administered medication and / or reducing side effects
US9993460B2 (en) 2013-07-26 2018-06-12 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
US10518003B2 (en) * 2014-07-07 2019-12-31 Meril Life Sciences Pvt. Ltd. Method to manufacture thin strut stent from bioabsorbable polymer with high fatigue and radial strength
KR102572721B1 (en) 2016-05-19 2023-09-01 삼성디스플레이 주식회사 Heterocyclic compound and organic light emitting device comprising the same
US10875860B2 (en) * 2016-12-22 2020-12-29 Purdue Research Foundation Azaindenoisoquinoline compounds and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
IT1054655B (en) * 1975-08-27 1981-11-30 Lepetit Spa CONDENSED DERIVATIVES OF L ISOKINOLINE
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
GB2025932B (en) 1978-06-13 1982-10-27 Sumitomo Chemical Co Indoloisoquinolines and processes for producing them
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
GB8828806D0 (en) * 1988-12-09 1989-01-18 Beecham Group Plc Novel compounds
CA2066728C (en) 1989-09-19 2001-12-25 Jan K. Hellstrand Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists
US5260316A (en) * 1991-07-30 1993-11-09 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
SK266991A3 (en) 1991-08-29 1998-03-04 Vufb As 2-hydroxyethylaminosubstituted derivatives of 5,11-dioxo-5,6- -dihydro-11h-indeno£1,2-c|isoquinoline, a process for manufacture thereof and pharmaceutical composition containing the same
US5597831A (en) * 1991-08-29 1997-01-28 Vufb A.S 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
TW440562B (en) * 1994-05-20 2001-06-16 Taiho Pharmaceutical Co Ltd Condensed-indan derivative and pharmaceutically acceptable salts thereof
WO1999008680A1 (en) 1997-08-15 1999-02-25 The Johns Hopkins University Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6250301B1 (en) 1997-08-28 2001-06-26 Hortal Harm B.V. Vaporizer for inhalation and method for extraction of active ingredients from a crude natural product or other matrix
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6346536B1 (en) * 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
AU9298198A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
EP1077946A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
WO1999059973A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
AU765625C (en) * 1998-08-24 2004-11-18 Maxim Pharmaceuticals, Inc. Activation and protection of T-cells (CD4+ and CD8+) using an H2 receptor agonist and other T-cell activating agents
AU765135B2 (en) 1998-10-14 2003-09-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel indenoisoquinolines as antineoplastic agents
ID28787A (en) 1998-11-03 2001-07-05 Basf Ag SUBSTITUTED 2-PHENILBENZIMIDAZOL, ITS MAKING AND USE OF IT
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US6201020B1 (en) 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
AU781711B2 (en) 1999-01-11 2005-06-09 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
US6346535B1 (en) * 1999-01-29 2002-02-12 American Cyanamid Company Fungicidal mixtures
AU779215B2 (en) * 1999-07-16 2005-01-13 Maxim Pharmaceuticals, Inc. Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6277990B1 (en) * 1999-12-07 2001-08-21 Inotek Corporation Substituted phenanthridinones and methods of use thereof
US6723733B2 (en) * 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
GB0017508D0 (en) 2000-07-17 2000-08-30 Novartis Ag Antimicrobials
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
JP2003267888A (en) 2002-03-15 2003-09-25 Seishi Yoneda Cardiac arrest fluid
US6992088B2 (en) 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
JPWO2004043959A1 (en) 2002-11-12 2006-03-09 持田製薬株式会社 Novel PARP inhibitor
PL378331A1 (en) * 2003-02-28 2006-03-20 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
JP5545690B2 (en) 2003-12-01 2014-07-09 クドス ファーマシューティカルズ リミテッド DNA damage repair inhibitors for cancer treatment
CN1964716A (en) 2004-02-26 2007-05-16 伊诺泰克制药公司 Isoquinoline derivatives and methods of use thereof
RU2006134024A (en) * 2004-02-26 2008-04-10 Инотек Фармасьютикалз Корпорейшн (Us) TETRACYCLIC DERIVATIVES OF LACTAM AND THEIR USE
AU2005264980A1 (en) * 2004-06-16 2006-01-26 Inotek Pharmaceuticals Corporation Methods for treating or preventing erectile dysfunction or urinary incontinence
WO2006039545A2 (en) * 2004-09-30 2006-04-13 Maxim Pharmaceuticals, Inc. Use of parp-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
CA2598647A1 (en) 2005-02-25 2006-09-08 Inotek Pharmaceuticals Corporation Tetracyclic amino and carboxamido compounds and methods of use thereof
CN101252930A (en) * 2005-02-25 2008-08-27 伊诺泰克制药公司 Isoquinoline compounds and methods of use thereof
WO2006093677A1 (en) 2005-02-25 2006-09-08 Inotek Pharmaceuticals Corporation Tetracyclic sulfonamide compounds and methods of use thereof
EP1937268A4 (en) * 2005-08-24 2009-07-22 Inotek Pharmaceuticals Corp Indenoisoquinolinone analogs and methods of use thereof

Also Published As

Publication number Publication date
WO2008106619A3 (en) 2008-11-27
EP2117545A2 (en) 2009-11-18
US20100004220A1 (en) 2010-01-07
US20100121049A1 (en) 2010-05-13
IL200013A0 (en) 2010-04-15
US8119654B2 (en) 2012-02-21
ZA200905741B (en) 2010-06-30
JP2010520220A (en) 2010-06-10
BRPI0808054A2 (en) 2019-09-24
KR20090115879A (en) 2009-11-09
WO2008106619A2 (en) 2008-09-04
EP2117545A4 (en) 2010-10-20
RU2009135818A (en) 2011-04-10
MX2009009183A (en) 2009-09-07
CN101674832A (en) 2010-03-17
AU2008221358A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
US7652028B2 (en) Indenoisoquinolinone analogs and methods of use thereof
US7217709B2 (en) Tetracyclic benzamide derivatives and methods of use thereof
CA2677046A1 (en) Indenoisoquinolinone analogs and methods of use thereof
EP2033645A1 (en) Isoquinoline derivatives and methods of use thereof
US20060287313A1 (en) Isoquinoline compounds and methods of use thereof
US7381722B2 (en) Tetracyclic amino and carboxamido compounds and methods of use thereof
US20060287311A1 (en) Tetracyclic Sulfonamide Compounds and methods of use thereof
US20050261288A1 (en) Tetracyclic lactam derivatives and uses thereof
US20100261706A1 (en) Substituted tetracyclic 1h-indeno [1,2-b]pyridine-2(5h)-one analogs thereof and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued